Παιδιατρική | Τόμος 71 • Τεύχος 1 • Ιανουάριος - Φεβρουάριος 2008

Pediatri Jan-Feb 08

15-02-08

10:59

¢ÈÌËÓÈ·›· ¤Î‰ÔÛË Ù˘ EÏÏËÓÈ΋˜ ¶·È‰È·ÙÚÈ΋˜ EÙ·ÈÚ›·˜ ¶Úfi‰ÚÔ˜ ∞. ∫ˆÓÛÙ·ÓÙfiÔ˘ÏÔ˜ ™˘ÓÙ·ÎÙÈ΋ EÈÙÚÔ‹ ¢È¢ı˘ÓÙ‹˜ ™‡ÓÙ·Í˘ ∫. ™ÙÂÊ·Ó›‰Ë˜ M¤ÏË ™. ∞Ó‰ÚÔÓ›ÎÔ˘ ¶. ∞˘ÁÔ˘ÛÙ›‰Ô˘-™·‚‚ÔÔ‡ÏÔ˘ A. µ·˙·›Ô˘-°ÂÚ·ÛÈÌ›‰Ë °. µ·ÚÏ¿Ì˘ ∂. °·Ï·Ó¿Î˘ §. £ˆÌ·˝‰Ô˘ ª. ∫·Ó¿ÚÈÔ˘ ∂. ∫·ÙÛ·ÚÔ‡-¶ÂÎÙ·Û›‰Ë A. K·ÙÙ¿Ì˘ ™. K›ÙÛÈÔ˘-∆˙¤ÏË ∞. ¶··‰ÔÔ‡ÏÔ˘ ¡. ¶··‰fiÔ˘ÏÔ˜ ∞. ™È·ÌÔÔ‡ÏÔ˘-ª·˘Ú›‰Ô˘ ª. ∆ÛÔÏÈ¿ ÀÔ‚ÔÏ‹ ∂ÚÁ·ÛÈÒÓ e-mail: hps@ath.forthnet.gr √‰ËÁ›Â˜ ÚÔ˜ ÙÔ˘˜ Û˘ÁÁÚ·Ê›˜: http://www.e-child.gr/Instructions_ to_Authors_GR.pdf

™ÂÏ›‰·1

¶·È‰È·ÙÚÈ΋ ∆fiÌÔ˜ 71 ñ ∆‡¯Ô˜ 1 ñ π·ÓÔ˘¿ÚÈÔ˜-ºÂ‚ÚÔ˘¿ÚÈÔ˜ 2008

¶ÂÚȯfiÌÂÓ· ∞ƒ£ƒ√ ™À¡∆∞•∏™ xviii ∫. ™ÙÂÊ·Ó›‰Ë˜ ∞¡∞™∫O¶∏™∂π™ 1 New Methods and Trends in Paediatric Education. Undergraduate Training K. Sostmann, J. Hoeffe, S. Mueller, H. Krude, G. Gaedicke 5 ¶·È‰È¿ ÌÂ Û˘¯Ó¤˜ ÏÔÈÌÒÍÂȘ: ÎÚÈÙ‹ÚÈ· ÂÍÂȉÈÎÂ˘Ì¤ÓÔ˘ ·ÓÔÛÔÏÔÁÈÎÔ‡ ÂϤÁ¯Ô˘ ¢. Ã. ∫·Û›ÌÔ˜, ª. §È¿ÙÛ˘, ∞. ™ÙÔÁÈ·ÓÓ›‰Ô˘, ª. ∫·Ó¿ÚÈÔ˘ 14 ¶ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ ª. ªÔ˘ÛÙ¿ÎË, ∞. ºÚÂÙ˙¿ÁÈ·˜

ºÈÏÔÏÔÁÈ΋ EÈ̤ÏÂÈ·

21 ¡ÂÎÚˆÙÈ΋ ÂÓÙÂÚÔÎÔÏ›Ùȉ·: ÓÂfiÙÂÚ· ‰Â‰Ô̤ӷ ÁÈ· ÙËÓ ·ıÔÊ˘ÛÈÔÏÔÁ›· Ù˘ ÓfiÛÔ˘ Ã. ∆۷ηϛ‰Ë˜, ∞. ∆Ú·ÁÈ·ÓÓ›‰Ë˜, ¡. ¡ÈÎÔÏ·˝‰Ë˜

∂È̤ÏÂÈ· ÂÏÏËÓÈÎÒÓ ÎÂÈÌ¤ÓˆÓ M. ¡·ÙÛÔ˘Ï›‰Ô˘

29 ƒÂ˘Ì·ÙÈÎfi˜ ˘ÚÂÙfi˜: Â›Ó·È ·ÎfiÌ· ‰Ò! Ã. ∆Ú¿·ÏË, ª. ¶··Ê˘Ï·ÎÙÔ‡, °. ¶··‰fiÔ˘ÏÔ˜

EÈ̤ÏÂÈ· ·ÁÁÏÈÎÒÓ ÎÂÈÌ¤ÓˆÓ ™. ¡¿ÎÔ˘ EΉfiÙ˘ K. °ÚÈ‚¤·˜ ™˘ÓÙÔÓÈÛÙ‹˜ ∂ΉfiÛˆ˜ E¶I™THMONIKE™ EK¢O™EI™ E.¶.E. ¶ÈÂÚ›·˜ 1∞ 144 51 MÂÙ·ÌfiÚʈÛË TËÏ.: 210 87 78 810 Fax: 210 87 78 822 I‰ÈÔÎÙ‹Ù˘ EÏÏËÓÈ΋ ¶·È‰È·ÙÚÈ΋ EÙ·ÈÚ›·© Mȯ·Ï·ÎÔÔ‡ÏÔ˘ 92 Aı‹Ó· 115 28 TËÏ.: 210 7771 140 210 7771 663 Fax: 210 7758 354 e-mail: hps@ath.forthnet.gr EÙ‹ÛÈ· ™˘Ó‰ÚÔÌ‹: 40 € EȉÈ΢fiÌÂÓÔÈ, ºÔÈÙËÙ¤˜: 20 € ∫ˆ‰ÈÎfi˜ ¢È‡ı˘ÓÛ˘ ∂ÔÙ›·˜ ªª∂: 3889

ISSN 0377-2551

µƒ∞µ∂Àª∂¡∏ ∂ƒ°∞™π∞ 38 ∫ÏÈÓÈ΋ Î·È ÌÔÚȷ΋ ÌÂϤÙË ÙÔ˘ ÁÔÓȉ›Ô˘ MECP2 Û ·È‰È¿ Ì ÓÔËÙÈ΋ ˘ÛÙ¤ÚËÛË ÛÙÔÓ ÂÏÏËÓÈÎfi ÏËı˘ÛÌfi ™. æÒÓË, J. Traeger-Synodinos, Ã. ™ÔÊÔÎÏ¤Ô˘˜, ™. ∫›ÙÛÈÔ˘-∆˙¤ÏË, ∞. ª·‡ÚÔ˘, ∂. ∫·Ó·‚¿Î˘, Œ. ºÚ˘Û›Ú· ∂ƒ∂À¡∏∆π∫∂™ ∂ƒ°∞™π∂™ 48 ¢È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘ Û ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ π. ∫·Ï¤ÁÈ·˜, µ. ƒÔ‡ÏË, ∞. ∫·Ú·Ù˙·Ê¤ÚË, ∫. ¢·ÎÔÚÒÓÈ·˜, ª. ¶··˚ˆ¿ÓÓÔ˘, £. ¢·Ó›‰Ë, √. ¢. ¶··ÁˆÚÁ›Ô˘, ∫. ¶·Ô˘ÙÛ‹, °. ∫ÚÔÎȉ¿˜, ¡. ¢È·Ì·ÓÙfiÔ˘ÏÔ˜

55 √È Û˘Ó¤ÂȘ Ù˘ ÁÚ›˘ ÛÙ· ·È‰È¿ ÛÙËÓ ÎÔÈÓfiÙËÙ· ª. ∆ÛÔÏÈ¿, π. §ÔÁÔı¤ÙË, ¡. ¶··‰fiÔ˘ÏÔ˜, ª. ª·˘Ú›ÎÔ˘, ¡. ™˘Ú›‰Ë˜, ¶. ¢ÚÔÛ¿ÙÔ˘, ¢. ∫·ÊÂÙ˙‹˜, ∞. ∫ˆÓÛÙ·ÓÙfiÔ˘ÏÔ˜ Î·È Ë ÔÌ¿‰· ÌÂϤÙ˘ Ù˘ ÁÚ›˘ ÛÙËÓ ÎÔÈÓfiÙËÙ· ¶ƒ∞∫∆π∫√ £∂ª∞ 62 ™˘ÁÎÔÙÈο ÂÂÈÛfi‰È· ÛÙËÓ ·È‰È΋ Î·È ÂÊË‚È΋ ËÏÈΛ·: ‰È¿ÁÓˆÛË - ·ÓÙÈÌÂÙÒÈÛË ¢. π. °ÂˆÚÁ·ÎfiÔ˘ÏÔ˜ ∂¡¢π∞º∂ƒ√À™∂™ ¶∂ƒπ¶∆ø™∂π™ 68 µÚ¤ÊÔ˜ Ì ˈÛÈÓÔÊÈÏÈ΋ ÂÓÙÂÚ›Ùȉ· Ã. ∫Ô˘ÙÛ·˘Ù›ÎË, ∂. ª¿ÓÙ˙ÈÔ˘, ¢. ÷Ù˙‹˜, ∫. ¶··ÓÙ˙›Ì·˜, ∫. ™ÙÂÊ·Ó¿ÎË, ¡. ª˘ÚÈÔÎÂÊ·ÏÈÙ¿Î˘, ∂. ƒÒÌ·-°È·ÓÓ›ÎÔ˘ 74 ƒ·‚‰ÔÌ˘fiÏ˘ÛË ÌÂÙ¿ ·fi Ïԛ̈ÍË ·fi influenza A √. ºÈÏ›Ô˘, ª. ¢ÔÏÈ·Ó›ÙË, ∫. ¢ÈÁ·Ï¿ÎË-£¤ÌÂÏË, ª. ∑‹‚·-¶ÂÙÚÔÔ‡ÏÔ˘, ™. ¶··‰¿ÎÔ˘-§·ÁÔÁÈ¿ÓÓË 79 ∫§π¡π∫√ ∫√Àπ∑ ∞. ™·‚‚›‰Ô˘, °. ªÚÈ·ÛÔ‡Ï˘, ª. ƒ·˚Û¿ÎË, Õ. ª. ™·Ó¿ÎË, ¡. º˘ÙÚÔÏ¿ÎË, ∂. °·Ï·Ó¿Î˘, ª. ∫·ÏÌ·ÓÙ‹ 80 ™À¡∆√ª∞ ¶∞π¢π∞∆ƒπ∫∞ ¡∂∞ ∂ÏÏËÓÈ΋ ·È‰È·ÙÚÈ΋ ¤Ú¢ӷ Û ‰ÈÂıÓ‹ ÂÚÈÔ‰Èο, 2007 E. °·Ï·Ó¿Î˘ 83 ¡∂∞ ∞¶√ ∆√ ¢π∞¢π∫∆À√ Ã. ™Î¢¿ÎË

Pediatri Jan-Feb 08

15-02-08

10:59

™ÂÏ›‰·3

Bimonthly Publication of the Greek Paediatric Society

Paediatriki

President A. Constantopoulos Editorial Board Editor-in-Chief C. Stefanidis Members S. Andronikou P. Augoustides-Savvopoulou A. Vazeou-Gerasimidi G. Varlamis ∂. Galanakis L. Thomaidou M. Kanariou ∂. Katsarou-Pectasides A. Kattamis S. Kitsiou-Tzeli ∞. Papadopoulou N. Papadopoulos A. Siamopoulou-Mavridou M. Tsolia Manuscript submission e-mail: hps@ath.forthnet.gr Instructions to authors: http://www.e-child.gr/paediatriki/ iae.pdf Manuscript Editing Greek Editing M. Natsoulidou English Editing S. Nakou Publisher K. Griveas Publishing Coordinator SCIENTIFIC PUBLICATIONS Ltd 1∞ Pierias St. GR - 144 51, Metamorfossi Tel.: +30 210 87 78 810 Fax: +30 210 87 78 822 Owner Greek Paediatric Society© 92 Michalakopoulou St. GR - 115 28, Athens Tel.: +30 210 7771 140 +30 210 7771 663 Fax: +30 210 7758 354 e-mail: hps@ath.forthnet.gr Annual Subscription All foreign countries: US $ 50

Volume 71 ñ Number 1 ñ January-February 2008

Contents EDITORIAL COMMENTARY xviii C. Stefanidis REVIEW ARTICLES 1 New Methods and Trends in Paediatric Education. Undergraduate Training K. Sostmann, J. Hoeffe, S. Mueller, H. Krude, G. Gaedicke 5 Children with frequent infections: criteria for specialized immunological investigations D. C. Cassimos, ª. Liatsis, ∞. Stogiannidou, ª. ∫·nariou 14 Primary ciliary dyskinesia ª. ªoustaki, ∞. Fretzayas 21 Necrotizing enterocolitis: recent evidence on the pathophysiology of the disease C. Tsakalidis, ∞. Tragiannidis, ¡. Nikolaidis 29 Rheumatic fever: it is still here!

C. Trapali, ª. Papafylaktou, G. Papadopoulos AWARD-WINNING ARTICLE 38 Clinical studies and analysis of the MECP2 gene in children with mental retardation in the Greek population S. Psoni, J. Traeger-Synodinos, C. Sofokleous, S. Kitsiou-Tzeli, ∞. ªavrou, ∂. ∫anavakis, H. Fryssira ORIGINAL ARTICLES 48 Sleep problems in school-age children J. Kaleyias, V. Rouli, ∞. Karatzaferi, ∫. Dakoronias, ª. Papaioannou, T. Danidi, U. D. Papageorgiou, ∫. Papoutsi, G. ∫rokidas, ¡. Diamantopoulos

55 The impact of influenza in children on the community ª. ∆solia, π. Logotheti, ¡. Papadopoulos, ª. Mavrikou, ¡. Spyridis, P. Drossatou, D. Kafetzis, ∞. Konstantopoulos and the outpatient flu study group PRACTICAL ISSUES 62 Syncopal episodes in childhood and adolescence: diagnosis - management D. I. Georgakopoulos CASE REPORTS 68 An infant with eosinophilic enteritis C. ∫outsaftiki, ∂. Mantziou, D. Hatzis, ∫. Papantzimas, ∫. Stefanaki, ¡. ªyriokefalitakis, ∂. Roma-Giannikou 74 Rhabdomyolysis following influenza A infection √. Filippou, ª. Dolianiti, ∫. Digalaki-Themeli, ª. Ziva-Petropoulou, S. Papadakou-Lagogianni 79 CLINICAL QUIZ ∞. Savvidou, G. Briassoulis, ª. Raisaki, A. ª. Spanaki, ¡. Fytrolaki, ∂. Galanakis, ª. Kalmandi 80 PAEDIATRIC NEWS IN BRIEF Greek paediatric research in international journals, 2007 E. Galanakis 83 NEWS FROM THE INTERNET C. Skevaki

Pediatri Jan-Feb 08

15-02-08

10:59

™ÂÏ›‰·5

™À¡∆∞∫∆π∫∏ E¶π∆ƒ√¶∏

EDITORIAL BOARD

¢È¢ı˘ÓÙ‹˜ ™‡ÓÙ·Í˘

Editor-in-Chief

∫ˆÓÛÙ·ÓÙ›ÓÔ˜ ™ÙÂÊ·Ó›‰Ë˜, ∞ı‹Ó·

Constantinos Stefanidis, Athens

∂ȉÈÎÔ› ™˘ÓÙ¿ÎÙ˜

Section Editors

™Ù¤ÏÏ· ∞Ó‰ÚfiÓÈÎÔ˘, ¡ÂÔÁÓÔÏÔÁ›·, πˆ¿ÓÓÈÓ·

Stella Andronikou, Neonatology, Ioannina

¶ÂÚÛÂÊfiÓË ∞˘ÁÔ˘ÛÙ›‰Ô˘-™·‚‚ÔÔ‡ÏÔ˘, MÂÙ·‚ÔÏÈο ÓÔÛ‹Ì·Ù·, £ÂÛÛ·ÏÔÓ›ÎË

Persefoni Avgoustides-Savvopoulou, Metabolic Disorders, Thessaloniki

∞Ó‰ÚÈ·Ó‹ µ·˙·›Ô˘-°ÂÚ·ÛÈÌ›‰Ë, ∂Ó‰ÔÎÚÈÓÔÏÔÁ›·, ∞ı‹Ó·

Andriani Vazaiou-Gerasimidi, Endocrinology, Athens

°ÂÒÚÁÈÔ˜ µ·ÚÏ¿Ì˘, ∫·Ú‰ÈÔÏÔÁ›·, £ÂÛÛ·ÏÔÓ›ÎË

George Varlamis, Cardiology, Thessaloniki

∂ÌÌ·ÓÔ˘‹Ï °·Ï·Ó¿Î˘, ∏ıÈ΋ Î·È ¢ÂÔÓÙÔÏÔÁ›·, ∏Ú¿ÎÏÂÈÔ

Emmanouil Galanakis, Ethics and Deontology, Heraklion

§ˆÚ¤ÙÙ· £ˆÌ·˚‰Ô˘, ∞Ó·Ù˘ÍȷΤ˜ ‰È·Ù·Ú·¯¤˜, ∞ı‹Ó·

Loretta Thomaidou, Developmental Pediatrics, Athens

ª·Ú›· ∫·Ó¿ÚÈÔ˘, ∞ÓÔÛÔÏÔÁ›·, ∞ı‹Ó·

Maria Kanariou, Immunology, Athens

∂˘ÛÙ·ı›· ∫·ÙÛ·ÚÔ‡-¶ÂÎÙ·Û›‰Ë, ¡Â˘ÚÔÏÔÁ›·, ∞ı‹Ó·

Eustathia Katsarou-Pektasides, Neurology, Athens

∞ÓÙÒÓ˘ ∫·ÙÙ¿Ì˘, ∞ÈÌ·ÙÔÏÔÁ›· - OÁÎÔÏÔÁ›·, ∞ı‹Ó·

Antonis Kattamis, Haematology - √ncology, Athens

™ÔÊ›· ∫›ÙÛÈÔ˘-∆˙¤ÏË, °ÂÓÂÙÈ΋, ∞ı‹Ó·

Sophia Kitsiou-Tzeli, Genetics, Athens

∞ÏÂÍ¿Ó‰Ú· ¶··‰ÔÔ‡ÏÔ˘, °·ÛÙÚÂÓÙÂÚÔÏÔÁ›· - ¢È·ÙÚÔÊ‹, ∞ı‹Ó·

Alexandra Papadopoulou, Gastroenterology - Nutrition, Athens

¡ÈÎfiÏ·Ô˜ ¶··‰fiÔ˘ÏÔ˜, ∞ÏÏÂÚÁÈÔÏÔÁ›· - ¶Ó¢ÌÔÓÔÏÔÁ›·, ∞ı‹Ó·

Nicos Papadopoulos, Allergology - Pneumonology, Athens

∞ÓÙÈÁfiÓË ™È·ÌÔÔ‡ÏÔ˘-ª·˘Ú›‰Ô˘, ƒÂ˘Ì·ÙÔÏÔÁ›·, πˆ¿ÓÓÈÓ·

Antigoni Siamopoulou-Mavridou, Rheumatology, Ioannina

ª·Ú›˙· ∆ÛÔÏÈ¿, §ÔÈ̈ÍÈÔÏÔÁ›·, ∞ı‹Ó·

Marisa Tsolia, Infectious Diseases, Athens

ª¤ÏË Ù˘ ¢ÈÂıÓÔ‡˜ ™˘ÓÙ·ÎÙÈ΋˜ ∂ÈÙÚÔ‹˜ ñ Members of the International Editorial Board Alexis Arzimanoglou, Paris, France

Peter Hoyer, Essen, Germany

Ellis D. Avner, Milwaukee, USA

Jan Janda, Prague, Czech Republic

Swati Bhave, New Delhi, India

Jan Kimpen, Ultrecht, Netherlands

Alberto Bissot, Panama, Panama

Craig B. Langman, Chicago, USA

David Branski, Jerusalem, Israel

John Manis, Boston, USA

Francesco Chiarelli, Chieti, Italy

Manuel Moya, Alicante, Spain

Chok-Wan Chan, Hong Kong, China

Hugh O'Brodovich, Toronto, Canada

Denis Daneman, Toronto, Canada

Ross Petty, Vancouver, Canada

Jochen Ehrich, Hannover, Germany

Willem Proesmans, Leuven, Belgium

Demetrius Ellis, Pittsburgh, USA

Jose Ramet, Antwerp, Belgium

Yoshikatsu Eto, Tokyo, Japan

Alan Sinaiko, Minneapolis, USA

Richard N. Fine, Stony Brook, USA

Nick J. Spencer, Coventry, UK

Margaret C. Fisher, Philadelphia, USA

Alfred Tenore, Udine, Italy

Raif Geha, Boston, USA

Alkis Togias, Bethesda, USA

Adenike Grange, Lagos, Nigeria

Eva Tsalikian, Iowa City, USA

Judith G. Hall, Vancouver, Canada

Catherine Weil-Olivier, Paris, France

Patricia Hamilton, London, UK

Max Zach, Graz, Austria

Enver Hasanoglu, Ankara, Turkey

Zheng-Yan Zhao, Hangzhou, China

Christer Holmberg, Helsinki, Finland

Johannes Zschocke, Heidelberg, Germany

v

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·11

√¢∏°π∂™ ¶ƒ√™ ∆√À™ ™À°°ƒ∞º∂π™ A. °ÂÓÈΤ˜ ¶ÏËÚÔÊÔڛ˜ ∆Ô ÂÚÈÔ‰ÈÎfi “¶·È‰È·ÙÚÈ΋” Â›Ó·È Ë ÂÈÛÙËÌÔÓÈ΋ ¤Î‰ÔÛË Î·È È‰ÈÔÎÙËÛ›· Ù˘ EÏÏËÓÈ΋˜ ¶·È‰È·ÙÚÈ΋˜ EÙ·ÈÚ›·˜, Ô˘ ‰È·Ó¤ÌÂÙ·È ÛÙ· ̤ÏË Ù˘. Œ¯ÂÈ ˆ˜ ‚·ÛÈÎÔ‡˜ ÛÙfi¯Ô˘˜ ÙËÓ ·ÔÙ‡ˆÛË ÙÔ˘ ·È‰È·ÙÚÈÎÔ‡ ÂÈÛÙËÌÔÓÈÎÔ‡ ¤ÚÁÔ˘ Î·È ÙË Û˘Ó¯‹ ÂÓË̤ڈÛË ÙˆÓ ¶·È‰È¿ÙÚˆÓ. °È· ÙÔ ÛÎÔfi ·˘Ùfi ‰¤¯ÂÙ·È ÁÈ· ‰ËÌÔÛ›Â˘ÛË ÔÈÎÈÏ›· ¿ÚıÚˆÓ Î·È Û˘ÁÎÂÎÚÈ̤ӷ: 1. ÕÚıÚ· Û‡ÓÙ·Í˘ (ÌÂÙ¿ ·fi ÚfiÛÎÏËÛË Ù˘ ™˘ÓÙ·ÎÙÈ΋˜ EÈÙÚÔ‹˜).

2. ∞Ó·ÛÎÔ‹ÛÂȘ.

3. µÚ·‚Â˘Ì¤Ó˜ ÂÚÁ·Û›Â˜.

4. ∂Ú¢ÓËÙÈΤ˜ ÌÂϤÙ˜.

5. ∫ÏÈÓÈο ∫Ô˘›˙.

6. ∂ÈÏÂÁ̤Ó˜ Û˘˙ËÙ‹ÛÂȘ ÛÙÚÔÁÁ˘ÏÒÓ ÙÚ·Â˙ÒÓ.

7. ∂›Î·ÈÚ· ı¤Ì·Ù·.

8. £¤Ì·Ù· ÂÎ·›‰Â˘Û˘ Î·È ÔÚÁ¿ÓˆÛ˘ ˘Á›·˜.

9. ∂ӉȷʤÚÔ˘Û˜ ÂÚÈÙÒÛÂȘ.

10. ™‡ÓÙÔÌ· Ó¤·.

11. µÚ·¯Â›Â˜ ‰ËÌÔÛȇÛÂȘ.

12. ∂ÈÛÙÔϤ˜ ÚÔ˜ ÙË Û‡ÓÙ·ÍË.

13. ¶ÂÚÈÏ‹„ÂȘ Ù˘ ‚È‚ÏÈÔÁÚ·Ê›·˜.

14. ∞Ó·ÎÔÈÓÒÛÂȘ ÚÔÛ¯ÒÓ Û˘Ó‰ڛˆÓ Î·È ÂÈÛÙËÌÔÓÈÎÒÓ ÂΉËÏÒÛÂˆÓ 15. ∞Ó·ÊÔÚ¤˜ Î·È ÎÚÈÙÈ΋ Ó¤ˆÓ ÂΉfiÛˆÓ, ÂÏÏËÓÈÎÒÓ Î·È Í¤ÓˆÓ, ·È‰È·ÙÚÈÎÔ‡ ÂӉȷʤÚÔÓÙÔ˜.

H ™˘ÓÙ·ÎÙÈ΋ EÈÙÚÔ‹ ‰È·ÙËÚ› ÙÔ ‰Èη›ˆÌ· Ó· ‰ËÌÔÛȇÂÈ ¿ÚıÚ· Ì ȉȷ›ÙÂÚÔ ÂÈÛÙËÌÔÓÈÎfi ÂӉȷʤÚÔÓ, ηıÒ˜ Î·È ¿ÚıÚ· Ì Â›Î·ÈÚ· ı¤Ì·Ù· ¯ˆÚ›˜ Ó· ÙËÚÂ›Ù·È Ë ÛÂÈÚ¿ ˘Ô‚ÔÏ‹˜. ∂›Û˘, ÌÔÚ› Ó· ·ÔÊ·Û›˙ÂÈ ÁÈ· ÙË ‰ËÌÔÛ›Â˘ÛË ÂÚÁ·ÛÈÒÓ Ô˘ ¤¯Ô˘Ó ·ÚÔ˘ÛÈ·ÛÙ› ÛÙÔ ÂÙ‹ÛÈÔ ¶·È‰È·ÙÚÈÎfi ™˘Ó¤‰ÚÈÔ, ÙËÓ ÔÏÈ΋ ‹ ÌÂÚÈ΋ ‰ËÌÔÛ›Â˘ÛË ·ÚÔ˘ÛÈ¿ÛÂˆÓ È‰È·›ÙÂÚÔ˘ ÂӉȷʤÚÔÓÙÔ˜ Î·È ÙËÓ ÔÏÈ΋ ‹ ÌÂÚÈ΋ ‰ËÌÔÛ›Â˘ÛË ÂÈÛÙÔÏÒÓ Ô˘ ·Ó·Ê¤ÚÔÓÙ·È Û ‰ËÌÔÛÈÂ˘Ì¤Ó· ÂÈÛÙËÌÔÓÈο ¿ÚıÚ· ÙÔ˘ ÂÚÈÔ‰ÈÎÔ‡. ™ÙȘ ÂÚÁ·Û›Â˜ Ì Â›Î·ÈÚ· ı¤Ì·Ù· Ú¤ÂÈ Ó· ·Ó·ÁÚ¿ÊÂÙ·È ÛÙËÓ ÚÒÙË ÛÂÏ›‰· Ë ÚfiıÂÛË ÙˆÓ Û˘ÁÁڷʤˆÓ ÁÈ· ÙËÓ ·Ó·ÁηÈfiÙËÙ· Ù˘ Ù·¯Â›·˜ ‰ËÌÔÛ›Â˘Û˘. ∏ ∂ÈÙÚÔ‹ ™‡ÓÙ·Í˘ ‰È·ÙËÚ› ÙÔ ‰Èη›ˆÌ· Ù˘ ·Ô‰Ô¯‹˜ Ù˘ Ù·¯Â›·˜ ‰ËÌÔÛ›Â˘Û˘. ŸÏ˜ ÔÈ ÂÚÁ·Û›Â˜ Ú¤ÂÈ Ó· ÌËÓ ¤¯Ô˘Ó ÂÓ Ì¤ÚÂÈ ‹ ÂÍ ÔÏÔÎÏ‹ÚÔ˘ ‰ËÌÔÛÈ¢ı› ‹ ˘Ô‚ÏËı› ÁÈ· ÎÚ›ÛË Û ¿ÏÏÔ ÂÚÈÔ‰ÈÎfi. ∂ÈϤÔÓ, ÛÙËÓ ÂÚÁ·Û›· ı· Ú¤ÂÈ Ó· ·Ó·Ê¤ÚÔÓÙ·È Ù˘¯fiÓ ÂȉÔÙ‹ÛÂȘ-¯ÔÚËÁ›Â˜ ‹ ¿ÏϘ ËÁ¤˜ ˘ÔÛÙ‹ÚÈ͢. ŸÏ˜ ÔÈ ÎÏÈÓÈΤ˜ ¤Ú¢Ó˜ Ú¤ÂÈ Ó· ¤¯Ô˘Ó Á›ÓÂÈ ÌÂÙ¿ ·fi ÏËÚÔÊÔÚË̤ÓË Û˘Ó·›ÓÂÛË ÙˆÓ ÌÂÙ¯fiÓÙˆÓ ‹ ÙˆÓ ÓÔÌ›ÌˆÓ ÂÎÚÔÛÒˆÓ ÙÔ˘˜, Û‡Ìʈӷ Ì ÙȘ ‰È·ÎËÚ‡ÍÂȘ ÙÔ˘ EÏÛ›ÓÎÈ Î·È ÙÔ˘ TfiÎÈÔ. E›Û˘, Ú¤ÂÈ Ó· ¤¯Ô˘Ó ÙËÚËı› ÔÈ Ô‰ËÁ›Â˜ ÁÈ· ÙË ÊÚÔÓÙ›‰· ÂÈÚ·Ì·Ùfi˙ˆˆÓ ÙÔ˘ ∂ıÓÈÎÔ‡ πÓÛÙÈÙÔ‡ÙÔ˘ ÀÁ›·˜ ÙˆÓ ∏¶∞ (DHEW Publication, NIH, 80-23). OÈ ÎÏÈÓÈΤ˜ ÌÂϤÙ˜ Ú¤ÂÈ Ó· ¤¯Ô˘Ó ÂÁÎÚÈı› ·fi ÙËÓ ÂÈÙÚÔ‹ ∏ıÈ΋˜ Î·È ¢ÂÔÓÙÔÏÔÁ›·˜ ÙÔ˘ ¡ÔÛÔÎÔÌ›Ԣ.

OÈ ·fi„ÂȘ Î·È Ù· Û˘ÌÂÚ¿ÛÌ·Ù· ÙˆÓ Û˘ÁÁڷʤˆÓ Ô˘ ‰È·Ù˘ÒÓÔÓÙ·È ÛÙȘ ‰ËÌÔÛÈÂ˘Ì¤Ó˜ ÂÚÁ·Û›Â˜ ‰ÂÓ ·ÓÙÈηÙÔÙÚ›˙Ô˘Ó ··Ú·›ÙËÙ· ·˘Ù¤˜ ÙÔ˘ ÂÚÈÔ‰ÈÎÔ‡. H ηٷ¯ÒÚÈÛË ‰È·ÊËÌ›ÛÂˆÓ ÛÙÔ ÂÚÈÔ‰ÈÎfi ‰ÂÓ ˘Ô‰ËÏÒÓÂÈ ÔˆÛ‰‹ÔÙ ¤ÁÎÚÈÛË ÙˆÓ ÂÚȯÔÌ¤ÓˆÓ ÙÔ˘˜ ·fi ÙËÓ EÏÏËÓÈ΋ ¶·È‰È·ÙÚÈ΋ EÙ·ÈÚ›·, ÙË ™˘ÓÙ·ÎÙÈ΋ EÈÙÚÔ‹ ‹ ·fi ÙÔÓ EΉfiÙË ÙÔ˘ ÂÚÈÔ‰ÈÎÔ‡. ŸÏ˜ ÔÈ ‰ËÌÔÛÈÂ˘Ì¤Ó˜ ÂÚÁ·Û›Â˜ ıˆÚÔ‡ÓÙ·È È‰ÈÔÎÙËÛ›· ÙÔ˘ ÂÚÈÔ‰ÈÎÔ‡ “¶·È‰È·ÙÚÈ΋” Î·È Ë ÔÏÈ΋ ‹ ÌÂÚÈ΋

xi

·Ó·‰ËÌÔÛ›Â˘Û‹ ÙÔ˘˜ ÂÈÙÚ¤ÂÙ·È ÌfiÓÔ ÌÂÙ¿ ·fi ¤ÁÁÚ·ÊË Û˘ÁηٿıÂÛË ÙÔ˘ ÂÚÈÔ‰ÈÎÔ‡.

µ. ™‡ÓÙ·ÍË ÙˆÓ ∂ÚÁ·ÛÈÒÓ ŸÏ˜ ÔÈ ÂÚÁ·Û›Â˜ Ú¤ÂÈ Ó· ·ÎÔÏÔ˘ıÔ‡Ó “∫ÔÈÓ¤˜ ¶ÚԉȷÁڷʤ˜ ÁÈ· ÃÂÈÚfiÁÚ·Ê· Ô˘ ˘Ô‚¿ÏÏÔÓÙ·È Û µÈÔ˚·ÙÚÈο ¶ÂÚÈÔ‰Èο” (Uniform Requirements for Manuscripts Submitted to Biomedical Journals), ÔÈ Ôԛ˜ ÙÚÔÔÔÈ‹ıËÎ·Ó ÚfiÛÊ·Ù· Î·È ‰ËÌÔÛȇÔÓÙ·È ÛÙȘ ‰È¢ı‡ÓÛÂȘ: http://www.icmje.org Î·È http://www.icmje.org/icmje.pdf TÔ Û‡ÓÔÏÔ Ù˘ ÂÚÁ·Û›·˜ (Û˘ÌÂÚÈÏ·Ì‚·ÓÔÌ¤ÓˆÓ ÙˆÓ ÈÓ¿ÎˆÓ Î·È ÙˆÓ Ù›ÙÏˆÓ ÙˆÓ ÂÈÎfiÓˆÓ) Ú¤ÂÈ Ó· Â›Ó·È Ù˘ˆÌ¤ÓÔ ÛÙË ÌÈ· fi„Ë Ï¢ÎÔ‡ ¯·ÚÙÈÔ‡ ÌÂÁ¤ıÔ˘˜ A4 (21x29,7 cm), Ì ‰ÈÏfi ‰È¿ÛÙËÌ· ÌÂٷ͇ ÙˆÓ ÁÚ·ÌÌÒÓ Î·È ÂÚÈıÒÚÈ· ÙÔ˘Ï¿¯ÈÛÙÔÓ 2,5 cm ÛÙȘ ‰‡Ô Ï¢ڤ˜.

TÔ Î›ÌÂÓÔ Ú¤ÂÈ Ó· ¤¯ÂÈ ÙËÓ ·ÎfiÏÔ˘ıË ‰È¿Ù·ÍË: ÛÂÏ›‰· Ù›ÙÏÔ˘, ‚Ú·¯‡˜ Ù›ÙÏÔ˜, ÂÚ›ÏË„Ë ÛÙ· ÂÏÏËÓÈο Î·È Ù· ·ÁÁÏÈο, ηٿÏÔÁÔ˜ Û˘ÓÙÔÌÔÁÚ·ÊÈÒÓ, ΛÌÂÓÔ, ¢¯·ÚÈÛٛ˜ ηıÒ˜ Î·È ·Ó·ÊÔÚ¿ Û ÂȉÔÙ‹ÛÂȘ-¯ÔÚËÁ›Â˜ ‹ ¿ÏϘ ËÁ¤˜ ˘ÔÛÙ‹ÚÈ͢, ‚È‚ÏÈÔÁÚ·Ê›·, ›Ó·Î˜, ÂÈÎfiÓ˜, Ù›ÙÏÔÈ ÂÈÎfiÓˆÓ. K¿ı ¤Ó· ·fi Ù· ·Ú·¿Óˆ ÛÙÔȯ›· Ú¤ÂÈ Ó· ·Ú¯›˙ÂÈ Û ¯ˆÚÈÛÙfi ʇÏÏÔ Î·È ÔÈ ÛÂÏ›‰Â˜ Ó· ·ÚÈıÌÔ‡ÓÙ·È ‰È·‰Ô¯Èο ·Ú¯›˙ÔÓÙ·˜ Ì ÙË ÛÂÏ›‰· Ù›ÙÏÔ˘.

H ¤ÎÙ·ÛË ÚÔÛ‰ÈÔÚ›˙ÂÙ·È ÁÈ·: ñ ÙȘ ·Ó·ÛÎÔ‹ÛÂȘ Û 2000-3000 ϤÍÂȘ. ñ ÙȘ ÂÚ¢ÓËÙÈΤ˜ ÂÚÁ·Û›Â˜ Û 1500-2500 ϤÍÂȘ Î·È ÙȘ ÂӉȷʤÚÔ˘Û˜ ÂÚÈÙÒÛÂȘ Û 1000-1500 ϤÍÂȘ. ñ ÙȘ ‚Ú·¯Â›Â˜ ‰ËÌÔÛȇÛÂȘ Û 1000-1500 ϤÍÂȘ. ñ ÙȘ ÂÈÛÙÔϤ˜ Û 250-500 ϤÍÂȘ.

™ÂÏ›‰· Ù›ÙÏÔ˘ ¶Ú¤ÂÈ Ó· ÂÚÈÏ·Ì‚¿ÓÂÈ: ñ ÙÔÓ Ù›ÙÏÔ (<14 ϤÍÂȘ), ηıÒ˜ Î·È ÙÔ ‚Ú·¯‡ Ù›ÙÏÔ (<5 ϤÍÂȘ) ÙÔ˘ ¿ÚıÚÔ˘. ¢ÂÓ ÂÈÙÚ¤ÔÓÙ·È Û˘ÓÙÌ‹ÛÂȘ. ñ ÙÔ fiÓÔÌ· Î·È ÙÔ ÂÒÓ˘ÌÔ Î¿ıÂ Û˘ÁÁڷʤ· ÛÙËÓ ÔÓÔÌ·ÛÙÈ΋. ñ ÙÔ ÂÈÛÙËÌÔÓÈÎfi ΤÓÙÚÔ (›‰Ú˘Ì·, ÎÏÈÓÈ΋, ÂÚÁ·ÛÙ‹ÚÈÔ) ·fi fiÔ˘ ÚÔ¤Ú¯ÂÙ·È Ë ÂÚÁ·Û›·. ™Â ÂÚ›ÙˆÛË ¤ÏÏÂȄ˘ Û˘ÓÂÚÁ·Û›·˜ ÌÂ Û˘ÁÎÂÎÚÈ̤ӷ ΤÓÙÚ·, Ú¤ÂÈ Ó· ·Ó·Ê¤ÚÂÙ·È Ë È‰ÈfiÙËÙ· ÙÔ˘/ÙˆÓ Û˘ÁÁڷʤ·/ˆÓ (.¯. ȉÈÒÙ˘ ·È‰›·ÙÚÔ˜) Î·È Ô ÙfiÔ˜ ‰È·ÌÔÓ‹˜ ÙÔ˘/ÙÔ˘˜. ñ ÙËÓ Ï‹ÚË ‰È‡ı˘ÓÛË, e-mail Î·È ÙÔ ÙËϤʈÓÔ ÙÔ˘ Û˘ÁÁڷʤ· Ì ÙÔÓ ÔÔ›Ô Á›ÓÂÙ·È Ë ·ÏÏËÏÔÁÚ·Ê›·.

¶ÂÚÈÏ‹„ÂȘ H ÂÚ›ÏË„Ë Ú¤ÂÈ Ó· ·Ó·ÎÂÊ·Ï·ÈÒÓÂÈ ÙÔ˘˜ ÛÙfi¯Ô˘˜ Ù˘ ÂÚÁ·Û›·˜, ÙË ÌÂıÔ‰ÔÏÔÁ›·, Ù· ΢ÚÈfiÙÂÚ· ·ÔÙÂϤÛÌ·Ù· Î·È Ù· Û˘ÌÂÚ¿ÛÌ·Ù· Ù˘ ÌÂϤÙ˘. ñ £· Ú¤ÂÈ Ó· ÂÚÈÏ·Ì‚¿ÓÂÈ ÙÔ˘Ï¿¯ÈÛÙÔÓ 200 ϤÍÂȘ, fï˜ ‰ÂÓ ı· Ú¤ÂÈ Ó· ˘ÂÚ‚·›ÓÂÈ ÙȘ 250 ϤÍÂȘ. ñ ∏ ÂÚ›ÏË„Ë ÙˆÓ ÂÚÁ·ÛÈÒÓ Ú¤ÂÈ Ó· Â›Ó·È ‰ÔÌË̤ÓË ÛÙȘ ÂÍ‹˜ ·Ú·ÁÚ¿ÊÔ˘˜: ÂÈÛ·ÁˆÁ‹, ̤ıÔ‰ÔÈ, ·ÔÙÂϤÛÌ·Ù· Î·È Û˘ÌÂÚ¿ÛÌ·Ù·. ™ÙËÓ ÂÚ›ÏË„Ë ÛÙ· ·ÁÁÏÈο Ú¤ÂÈ Ó· ·Ó·ÁÚ¿ÊÔÓÙ·È ÛÙËÓ ·Ú¯‹ ÙÔ˘ ÎÂÈ̤ÓÔ˘ Ô Ù›ÙÏÔ˜ Ù˘ ÂÚÁ·Û›·˜ Î·È Ù· ÔÓfiÌ·Ù· ÙˆÓ Û˘ÁÁڷʤˆÓ ÛÙ· ·ÁÁÏÈο. TÔ ÂÚȯfiÌÂÓÔ ÙÔ˘ ·ÁÁÏÈÎÔ‡ ÎÂÈ̤ÓÔ˘ Ú¤ÂÈ Ó· Â›Ó·È ‰ÔÌË̤ÓÔ ÛÂ: ÂÈÛ·ÁˆÁ‹ (background), ̤ıÔ‰ÔÈ (methods), ·ÔÙÂϤÛÌ·Ù· (results) Î·È Û˘ÌÂÚ¿ÛÌ·Ù· (conclusions). H ÂÚ›ÏË„Ë ÛÙ· ·ÁÁÏÈο ‰ÂÓ Ú¤ÂÈ Ó· ‰È·Ê¤ÚÂÈ ·fi ÙËÓ ·ÓÙ›ÛÙÔÈ¯Ë ÛÙ· ÂÏÏËÓÈο.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·12

xii

K¿Ùˆ ·fi ÙËÓ ÂÏÏËÓÈ΋ Î·È ÙËÓ ·ÁÁÏÈ΋ ÂÚ›ÏË„Ë ÛËÌÂÈÒÓÔÓÙ·È ÙÚÂȘ ¤ˆ˜ ¤ÓÙ ϤÍÂȘ ÎÏÂȉȿ Ô˘ ı· ¯ÚËÛÈÌÔÔÈËıÔ‡Ó ÁÈ· ÙÔ ıÂÌ·ÙÈÎfi ¢ÚÂÙ‹ÚÈÔ.

K›ÌÂÓÔ OÈ ÂÚ¢ÓËÙÈΤ˜ ÂÚÁ·Û›Â˜ ÂÚÈÏ·Ì‚¿ÓÔ˘Ó: ÂÈÛ·ÁˆÁ‹, ÌÂıfi‰Ô˘˜, ·ÔÙÂϤÛÌ·Ù· Î·È Û˘˙‹ÙËÛË. H ÂÈÛ·ÁˆÁ‹ ÂÚÈÏ·Ì‚¿ÓÂÈ Ù· ÙÂÏÂ˘Ù·›· ‰Â‰Ô̤ӷ Ù˘ ¤Ú¢ӷ˜ ÛÙÔ Û˘ÁÎÂÎÚÈ̤ÓÔ ı¤Ì· Ì ÙȘ ΢ÚÈfiÙÂÚ˜ ‚È‚ÏÈÔÁÚ·ÊÈΤ˜ ·Ú·ÔÌ¤˜ Î·È ÙÔ ÛÎÔfi Ù˘ ÂÚÁ·Û›·˜. H ÂÚÈÁÚ·Ê‹ ÙˆÓ ÌÂıfi‰ˆÓ Ú¤ÂÈ Ó· Â›Ó·È ·ÎÚÈ‚‹˜ Î·È ·ÚÎÂÙ¿ ÏÂÙÔÌÂÚ‹˜, ÒÛÙ ӷ ÂÈÙÚ¤ÂÈ ÙËÓ ·Ó··Ú·ÁˆÁ‹ ÙÔ˘˜ ·fi ¿ÏÏÔ˘˜ ÂÚ¢ÓËÙ¤˜. ∂›Û˘, Ú¤ÂÈ Ó· ·Ó·Ê¤ÚÔÓÙ·È Ì ÏÂÙÔ̤ÚÂȘ ÔÈ ÛÙ·ÙÈÛÙÈΤ˜ ̤ıÔ‰ÔÈ ·Ó¿Ï˘Û˘ Î·È ·ÍÈÔÏfiÁËÛ˘ ÙˆÓ ·ÔÙÂÏÂÛÌ¿ÙˆÓ. T· ·ÔÙÂϤÛÌ·Ù· Ú¤ÂÈ Ó· ·ÚÔ˘ÛÈ¿˙ÔÓÙ·È Ì ۷ʋÓÂÈ· Î·È Ó· Û˘Óԉ‡ÔÓÙ·È ·fi ÙËÓ ··Ú·›ÙËÙË ÛÙ·ÙÈÛÙÈ΋ ·Ó¿Ï˘ÛË. H Û˘˙‹ÙËÛË Ú¤ÂÈ Ó· ÂÚÈÏ·Ì‚¿ÓÂÈ Ù· Û˘ÌÂÚ¿ÛÌ·Ù· Ô˘ ÚÔ·ÙÔ˘Ó ·fi ÙËÓ ÂÚÁ·Û›·, ÙË ÛËÌ·Û›· Ô˘ ÌÔÚ› Ó· ¤¯Ô˘Ó Î·È ÙËÓ Èı·Ó‹ Û˘Û¯¤ÙÈÛ‹ ÙÔ˘˜ Ì ·Ú·ÙËÚ‹ÛÂȘ ¿ÏÏˆÓ ÂÚ¢ÓËÙÒÓ.

OÈ ÂӉȷʤÚÔ˘Û˜ ÂÚÈÙÒÛÂȘ ÂÚÈÏ·Ì‚¿ÓÔ˘Ó Û‡ÓÙÔÌË ÂÈÛ·ÁˆÁ‹, ÂÚÈÁÚ·Ê‹ Ù˘ ÂÚ›ÙˆÛ˘ Î·È ‚Ú·¯Â›· Û˘˙‹ÙËÛË, Ì ¤ÌÊ·ÛË ÛÙË ‰È·ÊÔÚÈ΋ ‰È¿ÁÓˆÛË.

T· ˘fiÏÔÈ· ı¤Ì·Ù· ¤¯Ô˘Ó ÂχıÂÚË ‰ÔÌ‹ ηٿ ÙËÓ ÎÚ›ÛË ÙˆÓ Û˘ÁÁڷʤˆÓ ÙÔ˘˜. ∂˘¯·ÚÈÛٛ˜ ‹ ·Ó·ÁÓˆÚ›ÛÂȘ (·Ó·ÊÔÚ¿ Û ÂȉÔÙ‹ÛÂȘ-¯ÔÚËÁ›Â˜ ‹ ¿ÏϘ ËÁ¤˜ ˘ÔÛÙ‹ÚÈ͢) ı· Ú¤ÂÈ Ó· ·Ó·Ê¤ÚÔÓÙ·È ÛÙÔ Ù¤ÏÔ˜ ÙÔ˘ ÎÂÈ̤ÓÔ˘ Î·È ÚÈÓ ·fi ÙȘ ‚È‚ÏÈÔÁÚ·ÊÈΤ˜ ·Ú·ÔÌ¤˜.

TÈ̤˜ ÂÚÁ·ÛÙËÚÈ·ÎÒÓ ÂÍÂÙ¿ÛÂˆÓ OÈ ÙÈ̤˜ ÙˆÓ ÂÚÁ·ÛÙËÚÈ·ÎÒÓ ÂÍÂÙ¿ÛÂˆÓ Ú¤ÂÈ Ó· ÂÎÊÚ¿˙ÔÓÙ·È ÛÙÔ ¢ÈÂıÓ¤˜ ™‡ÛÙËÌ· MÔÓ¿‰ˆÓ (SI Units) Î·È ÛÙÔ MÂÙÚÈÎfi (Conventional-™˘Ì‚·ÙÈÎfi) ™‡ÛÙËÌ· ̤۷ Û ·Ú¤ÓıÂÛË. ¶›Ó·Î˜ ÌÂÙ·ÙÚÔ‹˜ ÂÚÈÏ·Ì‚¿ÓÔÓÙ·È ÛÙȘ ‰È¢ı‡ÓÛÂȘ: http://www.icmje.org Î·È http://www.icmje.org/icmje.pdf

™˘ÓÙÔÌÔÁڷʛ˜ OÈ Û˘ÓÙÔÌÔÁڷʛ˜ Ô˘ ¤¯Ô˘Ó ÂÈ‚ÏËı› ‰ÈÂıÓÒ˜, ‰ËÌÔÛȇÔÓÙ·È Û οı Ù‡¯Ô˜ ÙÔ˘ ÂÚÈÔ‰ÈÎÔ‡. ™‡ÓıÂÙÔÈ Î·È Ì·ÎÚÔÛÎÂÏ›˜ fiÚÔÈ Ô˘ Â·Ó·Ï·Ì‚¿ÓÔÓÙ·È Û˘¯Ó¿ ÛÙÔ Î›ÌÂÓÔ ÌÔÚÔ‡Ó Ó· ·ÓÙÈηı›ÛÙ·ÓÙ·È ·fi Û˘ÓÙÔÌÔÁڷʛ˜ Ô˘ ÂÂÍËÁÔ‡ÓÙ·È ·fi ÙÔ˘˜ Û˘ÁÁÚ·Ê›˜ Û ÂȉÈÎfi ηٿÏÔÁÔ, Ô ÔÔ›Ô˜ ˘Ô‚¿ÏÏÂÙ·È Ì·˙› Ì ÙËÓ ÂÚÁ·Û›·. OÈ Û˘ÓÙÔÌÔÁڷʛ˜ ·Ó·Ê¤ÚÔÓÙ·È Û ·Ú¤ÓıÂÛË ÌfiÓÔ ÛÙȘ ÂÚÈÏ‹„ÂȘ.

BÈ‚ÏÈÔÁÚ·ÊÈΤ˜ ·Ú·ÔÌ¤˜ ™ÙÔ ÙÌ‹Ì· Ù˘ ‚È‚ÏÈÔÁÚ·Ê›·˜ ηٷ¯ˆÚÔ‡ÓÙ·È fiϘ ÔÈ ‚È‚ÏÈÔÁÚ·ÊÈΤ˜ ·Ú·ÔÌ¤˜ Ì ÙË ÛÂÈÚ¿ Ô˘ ·Ó·Ê¤ÚÔÓÙ·È ÛÙÔ Î›ÌÂÓÔ. ™ÙÔ Î›ÌÂÓÔ, ÔÈ ‚È‚ÏÈÔÁÚ·ÊÈΤ˜ ·Ú·ÔÌ¤˜ ·Ó·Ê¤ÚÔÓÙ·È Ì ·Ú·‚ÈÎÔ‡˜ ·ÚÈıÌÔ‡˜ Û ·Ú¤ÓıÂÛË. OÈ ‚È‚ÏÈÔÁÚ·ÊÈΤ˜ ·Ú·ÔÌ¤˜ ‰ÂÓ Ú¤ÂÈ Ó· ˘ÂÚ‚·›ÓÔ˘Ó: ñ ÙȘ 70 ÛÙȘ ·Ó·ÛÎÔ‹ÛÂȘ. ñ ÙȘ 30 ÛÙȘ ÂÚ¢ÓËÙÈΤ˜ ÂÚÁ·Û›Â˜. ñ ÙȘ 12 ÛÙ· Â›Î·ÈÚ· ı¤Ì·Ù· Î·È ÙȘ ÂӉȷʤÚÔ˘Û˜ ÂÚÈÙÒÛÂȘ. ñ ÙȘ 5 ÛÙȘ ‚Ú·¯Â›Â˜ ‰ËÌÔÛȇÛÂȘ Î·È ÙȘ ÂÈÛÙÔϤ˜.

H Û‡ÓÙ·ÍË ÙˆÓ ‚È‚ÏÈÔÁÚ·ÊÈÎÒÓ ·Ú·ÔÌÒÓ Á›ÓÂÙ·È Û‡Ìʈӷ Ì ÙȘ ÚfiÛÊ·Ù· ÙÚÔÔÔÈË̤Ó˜ ÚԉȷÁڷʤ˜ Ù˘ International Committee of Medical Journal Editors/Uniform Requirements for Manuscripts Submitted to Biomedical Journals, (http://www.icmje.org Î·È http://www.icmje.org/icmje.pdf). OÈ Û˘ÓÙÌ‹ÛÂȘ ÙˆÓ Ù›ÙÏˆÓ ÙˆÓ ÂÚÈÔ‰ÈÎÒÓ Á›ÓÔÓÙ·È Ì ‚¿ÛË ÙÔ Cumulated Index Medicus [List of Journals Indexed in Index Medicus (http://www.nlm.nih.gov/bsd/uniform_requirements.html)].

¶·Ú·‰Â›ÁÌ·Ù· ‚È‚ÏÈÔÁÚ·ÊÈÎÒÓ ·Ú·ÔÌÒÓ I. ¶∂ƒπO¢π∫∞ AÓ ÔÈ Û˘ÁÁÚ·Ê›˜ Â›Ó·È ¤ˆ˜ ¤ÍÈ, ·Ó·ÁÚ¿ÊÔÓÙ·È fiÏÔÈ, ÂÓÒ ·Ó Â›Ó·È ÂÙ¿ ‹ ÂÚÈÛÛfiÙÂÚÔÈ, ·Ó·ÁÚ¿ÊÔÓÙ·È ÔÈ ÚÒÙÔÈ ¤ÍÈ Î·È ÚÔÛÙ›ıÂÙ·È “et al” ‹ “Î·È Û˘Ó”.

T·ÎÙÈ΋ ¤Î‰ÔÛË ÂÚÈÔ‰ÈÎÔ‡: ∞ÓÙˆÓ›Ô˘ ¢, ª¿Ú· Ã, °È·ÓÓ¿ÙÔ˘ Ã. ∂Ì‚fiÏÈ·: Â›‰Ú·ÛË ÛÙËÓ ÂȉËÌÈÔÏÔÁ›· ÙˆÓ ÏÔÈ̈‰ÒÓ ÓÔÛËÌ¿ÙˆÓ Î·È ÙËÓ ·È‰È·ÙÚÈ΋ Ú¿ÍË. ¶·È‰È·ÙÚÈ΋ 1999;59:272-279.

Proesmans W. Bartter syndrome and its neonatal variant. Eur J Pediatr 1997;156:669-679. ™˘ÌÏËڈ̷ÙÈÎfi Ù‡¯Ô˜ ÂÚÈÔ‰ÈÎÔ‡: Flyvbjerg A. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int 1997;52 (60 Suppl):S12-S19. Èڛ˜ Û˘ÁÁڷʤ·: National Institutes of Health Consensus Development Conference. Neurofibromatosis conference statement. Arch Neurol 1988;45:575-578. ¶ÚÔÛ‰ÈÔÚÈÛÌfi˜ Ù‡Ô˘ ¿ÚıÚÔ˘: Schreiner GF, Lange L. Ethanol modulation of macrophage influx in glomerulonephritis [Abstract]. J Am Soc Nephrol 1991;2:562.

Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? [Editorial]. Am J Respir Crit Care Med 1998;158:1697-1701.

Laux-End R, Inaebnit D, Gerber HA, Bianchetti MG. Vasculitis associated with levamisole and circulating autoantibodies [Letter]. Arch Dis Child 1996;75:355-356.

II. µπµ§π∞ ∫ÂÊ¿Ï·ÈÔ Û ‚È‚Ï›Ô: Clark AG, Barratt TM. Steroid-responsive nephrotic syndrome. In: Barratt TM, Arner ED, Harmon WE, editors. Pediatric Nephrology. 4th ed. Baltimore: Lippincott William Wilkins; 1999. p. 742. ™‡ÁÁÚ·ÌÌ· ‹ ÌÔÓÔÁÚ·Ê›·: Gorlin RJ, Cohen MM, Levin LS. Syndromes of the head and neck. 3rd ed. New York: Oxford University Press; 1990. ¢ËÌÔÛ›Â˘ÛË Û ÙfiÌÔ Ú·ÎÙÈÎÒÓ: Bauer AW. The two definitions of bacterial resistance. In: Smith AJ, Rogers CA, eds. Proceedings of the Third International Congress of Chemotherapy; 1962 May 29-31; New York: International Society of Chemotherapy; 1963. p. 484-500. ¢È‰·ÎÙÔÚÈ΋ ‰È·ÙÚÈ‚‹: ¶··‰fiÔ˘ÏÔ˜ Ã. ∏ ıÂÚ·›· ÙÔ˘ ÛÙÚ·‚ÈÛÌÔ‡ [‰È‰·ÎÙÔÚÈ΋ ‰È·ÙÚÈ‚‹]. ∞ı‹Ó·: ¶·ÓÂÈÛÙ‹ÌÈÔ ∞ıËÓÒÓ; 1979.

Kaplan SJ. Post hospital home health care: the elderly’s access and utilization [dissertation]. St. Louis (Mo): Washington Univ.; 1995. πππ. CD-ROM Anderson SC, Poulsen KB. Anderson’s electronic atlas of hematology [CD-ROM]. Philadelphia: Lippincott Williams & Wilkins; 2002.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·13

xiii

IV. ™∆O ¢π∞¢π∫∆ÀO ÕÚıÚÔ Û ÂÚÈÔ‰ÈÎfi: Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. Am J Nurs [Internet]. 2002 Jun: Webpage: http://www.nursingworld.org/AJN/2002/june/Wawatch.htm ªÔÓÔÁÚ·Ê›·: Foley KM, Gelband H, editors. Improving palliative care for cancer [Monograph, Internet]. Washington: National Academy Press; 2001. Webpage: http://www.nap.edu/books/0309074029/html πÛÙÔÛÂÏ›‰Â˜: Cancer-Pain.org [Webpage, Internet]. New York: Association of Cancer Online Resources, Inc.; 2002: http://www.cancerpain.org/

°. ÀÔ‚ÔÏ‹ Î·È ¢ËÌÔÛ›Â˘ÛË ÙˆÓ ∂ÚÁ·ÛÈÒÓ ŸÏ˜ ÔÈ ÂÚÁ·Û›Â˜ Ú¤ÂÈ Ó· ˘Ô‚¿ÏÏÔÓÙ·È ÂȘ ÙÚÈÏÔ‡Ó Î·È Ó· Û˘Óԉ‡ÔÓÙ·È ·fi ‰ÈÛΤٷ ‹ CD, ηıÒ˜ Î·È ·fi ÂÈÛÙÔÏ‹, Ë ÔÔ›· ı· Û˘Ó˘ÔÁÚ¿ÊÂÙ·È ·fi fiÏÔ˘˜ ÙÔ˘˜ Û˘ÁÁÚ·Ê›˜, ÛÙËÓ ÔÔ›· ı· ‰ËÏÒÓÂÙ·È fiÙÈ Ë ÂÚÁ·Û›· ‰ÂÓ ¤¯ÂÈ ÂÓ Ì¤ÚÂÈ ‹ ÂÍ ÔÏÔÎÏ‹ÚÔ˘ ‰ËÌÔÛÈ¢ı› ‹ ˘Ô‚ÏËı› ÁÈ· ÎÚ›ÛË Û ¿ÏÏÔ ÂÚÈÔ‰ÈÎfi Î·È fiÙÈ ÔÈ Û˘ÁÁÚ·Ê›˜ ÂÁÎÚ›ÓÔ˘Ó ÙË ‰ËÌÔÛ›Â˘Û‹ Ù˘ ÛÙÔ ÂÚÈÔ‰ÈÎfi “¶·È‰È·ÙÚÈ΋”. ∂ÈϤÔÓ, ı· Ú¤ÂÈ Ó· ·Ó·Ê¤ÚÔÓÙ·È Ù˘¯fiÓ ÂȉÔÙ‹ÛÂȘ-¯ÔÚËÁ›Â˜ ‹ ¿ÏϘ ËÁ¤˜ ˘ÔÛÙ‹ÚÈ͢.

EÊfiÛÔÓ Ë ÂÚÁ·Û›· Á›ÓÂÈ ·Ô‰ÂÎÙ‹, ÙÔ ‰ÈÔÚıˆÌ¤ÓÔ Û‡Ìʈӷ Ì ÙȘ ˘ԉ›ÍÂȘ ÙˆÓ ÎÚÈÙÒÓ Î·È ÂÎ Ó¤Ô˘ ‰·ÎÙ˘ÏÔÁÚ·ÊË̤ÓÔ Î›ÌÂÓÔ Ú¤ÂÈ Ó· ˘Ô‚¿ÏÂÙ·È ÛÙË ™˘ÓÙ·ÎÙÈ΋ EÈÙÚÔ‹, Û˘Óԉ¢fiÌÂÓÔ ·fi ‰ÈÛΤٷ ‹ CD Ô˘ Ó· ÂÚÈÏ·Ì‚¿ÓÂÈ ÙËÓ ÂÚÁ·Û›· Û ÚfiÁÚ·ÌÌ· Word, ηıÒ˜ Î·È ÂÈÛÙÔÏ‹ fiÔ˘ Ó· ·Ó·Ê¤ÚÔÓÙ·È ·Ó·Ï˘ÙÈο ÔÈ ÙÚÔÔÔÈ‹ÛÂȘ ‹ ÔÈ ·ÓÙÈÚÚ‹ÛÂȘ ÛÙȘ ÚÔÙ¿ÛÂȘ ÙˆÓ ÎÚÈÙÒÓ.

H ηı˘ÛÙ¤ÚËÛË Ù˘ Â·Ó˘Ô‚ÔÏ‹˜ ÙÔ˘ ÙÚÔÔÔÈË̤ÓÔ˘ ÎÂÈ̤ÓÔ˘ ¤Ú·Ó ÙˆÓ 30 ËÌÂÚÒÓ Û˘ÓÂ¿ÁÂÙ·È Ó¤· ˘Ô‚ÔÏ‹.

T· ¤ÍÔ‰· ÙˆÓ ÊÈÏÌ Î·È ÙˆÓ ·Ó·Ù‡ˆÓ ‚·Ú‡ÓÔ˘Ó ÙÔ˘˜ Û˘ÁÁÚ·Ê›˜ Î·È Ú¤ÂÈ Ó· ÏËÚÒÓÔÓÙ·È Ì ÙËÓ ·ÔÛÙÔÏ‹ ÙÔ˘ ÚÒÙÔ˘ ‰ÔÎÈÌ›Ô˘ ηÙ¢ı›·Ó ÛÙÔÓ Ù˘ÔÁÚ¿ÊÔ.

T· ΛÌÂÓ· ÙˆÓ ÂÚÁ·ÛÈÒÓ Ô˘ ‰ÂÓ Á›ÓÔÓÙ·È ·Ô‰ÂÎÙ¤˜ ÁÈ· ‰ËÌÔÛ›Â˘ÛË, ‰ÂÓ ÂÈÛÙÚ¤ÊÔÓÙ·È. MÔÚ› Ó· ÂÈÛÙÚ·ÊÔ‡Ó, ÂÊfiÛÔÓ ˙ËÙËı› ÂÓÙfi˜ ÂÍ·Ì‹ÓÔ˘, Ù· Û¯‹Ì·Ù· Î·È ÔÈ ÊˆÙÔÁڷʛ˜ Ô˘ Ù· Û˘Óԉ‡ԢÓ.

OÈ ÂÚÁ·Û›Â˜ Ô˘ ˘Ô‚¿ÏÏÔÓÙ·È ÚÔ˜ ÎÚ›ÛË ÁÈ· ‰ËÌÔÛ›Â˘ÛË ÛÙÔ ÂÚÈÔ‰ÈÎfi “¶·È‰È·ÙÚÈ΋” ·ÔÛÙ¤ÏÏÔÓÙ·È ÂȘ ÙÚÈÏÔ‡Ó ÛÙË ‰È‡ı˘ÓÛË: ™˘ÓÙ·ÎÙÈ΋ EÈÙÚÔ‹, EÏÏËÓÈ΋ ¶·È‰È·ÙÚÈ΋ EÙ·ÈÚ›· Mȯ·Ï·ÎÔÔ‡ÏÔ˘ 92, 115 28 Aı‹Ó·

¶›Ó·Î˜ Î·È EÈÎfiÓ˜ AÔÛÙ¤ÏÏÔÓÙ·È ÂȘ ÙÚÈÏÔ‡Ó (¤Ó· ÚˆÙfiÙ˘Ô Î·È ‰‡Ô ʈÙÔ·ÓÙ›ÁÚ·Ê·). ¶Ú¤ÂÈ Ó· ¤¯Ô˘Ó Ï¿ÙÔ˜ ›ÛÔ Ì ÙÔ Ï¿ÙÔ˜ ÙÔ˘ ÌÔÓfiÛÙËÏÔ˘ (7,5 cm) ‹ Ì ÙÔ Ï¿ÙÔ˜ fiÏ˘ Ù˘ ÛÂÏ›‰·˜ (15,5 cm).

TÔ Ì¤ÁÈÛÙÔ Ì‹ÎÔ˜ ÙÔ˘˜, Ì·˙› Ì ÙÔ˘˜ Ù›ÙÏÔ˘˜, ‰ÂÓ Ú¤ÂÈ Ó· Â›Ó·È ÂÚÈÛÛfiÙÂÚÔ ·fi 22 cm.

OÈ ›Ó·Î˜ ·ÚÈıÌÔ‡ÓÙ·È Ì ·Ú·‚ÈÎÔ‡˜ ·ÚÈıÌÔ‡˜ Ì ÙË ÛÂÈÚ¿ Ô˘ ÂÌÊ·Ó›˙ÔÓÙ·È ÛÙÔ Î›ÌÂÓÔ. ¶ÂÚÈÏ·Ì‚¿ÓÔ˘Ó ‚Ú·¯‡ Ù›ÙÏÔ Î·È ÂÂÍ‹ÁËÛË ÙˆÓ Û˘ÓÙÌ‹ÛÂˆÓ ÛÙÔ Î¿Ùˆ ̤ÚÔ˜. ™ÙÔ˘˜ ›Ó·Î˜ Ú¤ÂÈ Ó· ·ÔʇÁÔÓÙ·È ÔÈ Î¿ıÂÙ˜ ÁÚ·Ì̤˜. ŸÏÔ ÙÔ ·ÂÈÎÔÓÈÛÙÈÎfi ˘ÏÈÎfi (Û¯‹Ì·Ù·, ‰È·ÁÚ¿ÌÌ·Ù·, ʈÙÔÁڷʛ˜, Î.Ï.) ¯·Ú·ÎÙËÚ›˙ÂÙ·È ˆ˜ ÂÈÎfiÓ˜ Î·È ı· Ú¤ÂÈ Ó· Â›Ó·È ¿ÚÈÛÙ˘ ÔÈfiÙËÙ·˜. ™ÙÔ ›Ûˆ ̤ÚÔ˜ ÙˆÓ ÂÈÎfiÓˆÓ Ú¤ÂÈ Ó· ÛËÌÂÈÒÓÂÙ·È Ì ÌÔχ‚È Ô ·ÚÈıÌfi˜ Ù˘ ÂÈÎfiÓ·˜ Î·È ÙÔ fiÓÔÌ· ÙÔ˘ ÚÒÙÔ˘ Û˘ÁÁڷʤ·, ηıÒ˜ Î·È ¤Ó· ‚¤ÏÔ˜, ÙÔ ÔÔ›Ô Ó· ‰Â›¯ÓÂÈ ÙÔ ¿Óˆ ̤ÚÔ˜ Ù˘ ÂÈÎfiÓ·˜. ™ÙȘ ʈÙÔÁڷʛ˜ ·ÛıÂÓÒÓ ‰ÂÓ Ú¤ÂÈ Ó· ·Ó·ÁÓˆÚ›˙ÂÙ·È Ë Ù·˘ÙfiÙËÙ¿ ÙÔ˘˜. OÈ ·ÛıÂÓ›˜ ‰ÂÓ Ú¤ÂÈ Ó· ·Ó·Ê¤ÚÔÓÙ·È ÔÓÔÌ·ÛÙÈο.

¶ÚÈÓ ·ÔÛÙ›ÏÂÙ ÙËÓ ÂÚÁ·Û›· Û·˜, ‚‚·Èˆı›Ù fiÙÈ ÂÚÈÏ·Ì‚¿ÓÂÈ: 1. 3 ·ÓÙ›ÁÚ·Ê· ÙÔ˘ ÎÂÈ̤ÓÔ˘ Ù˘ ÂÚÁ·Û›·˜, Ù˘ˆÌ¤Ó· Û‡Ìʈӷ Ì ÙȘ Ô‰ËÁ›Â˜.

2. ¢ÈÛΤٷ ‹ CD Ì fiÏÔ ÙÔ ˘ÏÈÎfi Ù˘ ÂÚÁ·Û›·˜ (ΛÌÂÓÔ, ›Ó·Î˜, ÂÈÎfiÓ˜).

3. ∂ÈÛÙÔÏ‹ ˘Ô‚ÔÏ‹˜ Î·È ‰‹ÏˆÛË ÌË ÚÔÁÂÓ¤ÛÙÂÚ˘ ‰ËÌÔÛ›Â˘Û˘ Ù˘ ÂÚÁ·Û›·˜.

4. ™ÂÏ›‰· Ù›ÙÏÔ˘ (¯ˆÚÈÛÙ‹ ÛÂÏ›‰·) ÂÚÈÏ·Ì‚¿ÓÂÈ: ·.Ù›ÙÏÔ Î·È ‚Ú·¯‡ Ù›ÙÏÔ ÂÚÁ·Û›·˜ ‚.fiÓÔÌ· Î·È ÂÒÓ˘ÌÔ Û˘ÁÁڷʤˆÓ (ÔÏÔÁڿʈ˜) Á. ÂÈÛÙËÌÔÓÈÎfi/¿ ΤÓÙÚÔ/· fiÔ˘ ¤ÁÈÓÂ Ë ÂÚÁ·Û›· ‰.fiÓÔÌ·, ‰È‡ı˘ÓÛË Î·È ÙËϤʈÓÔ Û˘ÁÁڷʤ· ÁÈ· ·ÏÏËÏÔÁÚ·Ê›·.

5. ¶ÂÚ›ÏË„Ë ÂÏÏËÓÈ΋-·ÁÁÏÈ΋, ‰ÔÌË̤ÓË ÛÙȘ ÂÍ‹˜ ·Ú·ÁÚ¿ÊÔ˘˜: ÂÈÛ·ÁˆÁ‹, ̤ıÔ‰ÔÈ, ·ÔÙÂϤÛÌ·Ù· Î·È Û˘ÌÂÚ¿ÛÌ·Ù·, ηıÒ˜ Î·È Ï¤ÍÂȘ ÎÏÂȉȿ (‰ÈÏfi ‰È¿ÛÙËÌ· - ¯ˆÚÈÛÙ‹ ÛÂÏ›‰·).

6. ∫·Ù¿ÏÔÁÔ Û˘ÓÙÔÌÔÁÚ·ÊÈÒÓ (‰ÈÏfi ‰È¿ÛÙËÌ· - ¯ˆÚÈÛÙ‹ ÛÂÏ›‰·).

7. ∫›ÌÂÓÔ (‰ÈÏfi ‰È¿ÛÙËÌ· - ¯ˆÚÈÛÙ‹ ÛÂÏ›‰·).

8. ∂˘¯·ÚÈÛٛ˜ ‹ ·Ó·ÁÓˆÚ›ÛÂȘ (·Ó·ÊÔÚ¿ Û ÂȉÔÙ‹ÛÂȘ-¯ÔÚËÁ›Â˜ ‹ ¿ÏϘ ËÁ¤˜ ˘ÔÛÙ‹ÚÈ͢).

9. µÈ‚ÏÈÔÁÚ·Ê›· (‰ÈÏfi ‰È¿ÛÙËÌ· - ¯ˆÚÈÛÙ‹ ÛÂÏ›‰·).

10. ¶›Ó·Î˜ (Ô Î·ı¤Ó·˜ Û ¯ˆÚÈÛÙ‹ ÛÂÏ›‰·) ÂȘ ÙÚÈÏÔ‡Ó.

11. ∂ÈÎfiÓ˜, Ì ‚¤ÏÔ˜ ÛÙÔ ›Ûˆ ̤ÚÔ˜, ÙÔ ÔÔ›Ô Ó· ‰Â›¯ÓÂÈ ÚÔ˜ Ù· Â¿Óˆ, ·ÚÈıÌË̤Ó˜, ÂȘ ÙÚÈÏÔ‡Ó.

12. ∆›ÙÏÔ˘˜ ÂÈÎfiÓˆÓ (‰ÈÏfi ‰È¿ÛÙËÌ· - Ô Î·ı¤Ó·˜ Û ¯ˆÚÈÛÙ‹ ÛÂÏ›‰·) ÂȘ ÙÚÈÏÔ‡Ó.

Pediatri Jan-Feb 08

xiv

15-02-08

11:00

™ÂÏ›‰·14

™À¡∆√ª√°ƒ∞ºπ∂™ o

A cal cm cm2 cm3 o C g h IU kg l m mg min mm mol n NS ‹ ª™ osm p SD SE sec U

angstrom ıÂÚÌ›‰· ÂηÙÔÛÙfi ÙÂÙÚ·ÁˆÓÈÎfi ÂηÙÔÛÙfi ΢‚ÈÎfi ÂηÙÔÛÙfi ‚·ıÌfi˜ ∫ÂÏÛ›Ô˘ ÁÚ·ÌÌ¿ÚÈÔ ÒÚ· ‰ÈÂıÓ‹˜ ÌÔÓ¿‰· ¯ÈÏÈfiÁÚ·ÌÌÔ Ï›ÙÚÔ Ì¤ÙÚÔ ¯ÈÏÈfiÁÚ·ÌÌÔ ÏÂÙfi ¯ÈÏÈÔÛÙfiÌÂÙÚÔ ÁÚ·ÌÌÔÌfiÚÈÔ ·ÚÈıÌfi˜ ÌË ÛËÌ·ÓÙÈÎfi ÔÛÌÒÏÈÔ Èı·ÓfiÙËÙ· ÛÙ·ıÂÚ‹ ·fiÎÏÈÛË ÛÙ·ıÂÚfi ÛÊ¿ÏÌ· ‰Â˘ÙÂÚfiÏÂÙÔ ÌÔÓ¿‰·

™˘Ó‰˘·˙fiÌÂÓ· ÚÔı¤Ì·Ù· 12

tera- (10 ) giga- (109) mega- (106) kilo- (103) hector- (102) deca- (101) deci- (10-1) centi- (10-2) milli- (10-3) micro- (10-6) nano- (10-9) pico- (10-12) femto- (10-15) atto- (10-18)

ABBREVIATIONS

Combining prefixes T G M k h da d c m Ì n p f a

angstrom calorie centimeter square centimeter cubic centimeter degree Celsius gram hour international unit kilogram liter meter milligram minute millimeter mole number not significant osmole probability standard deviation standard error second unit

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·15

INSTRUCTIONS TO AUTHORS A. General Information The Greek Paediatric Society is the owner of “Paediatriki”, its official scientific journal, which is distributed to its members. Its objectives are the publication of paediatric scientific work and the continuing education of paediatricians. For this purpose, it publishes a variety of articles, and in particular: 1. Editorials (upon invitation by the Editorial Board).

2. Review articles.

3. Award-winning articles.

4. Original articles.

5. Clinical Quiz.

6. Round tables.

7. Current issues.

8. Issues of healthcare management and education.

9. Case reports.

10. News.

11. Brief reports.

12. Letters to the editor.

13. Abstracts.

14. Future congresses and events.

15. Book reviews.

The Editorial Board reserves the right to publish articles of special scientific interest and articles on current issues without observing submission order. In addition, it publishes upon decision original papers presented at the Annual Paediatric Conference, presentations of special interest - in whole or in part, and letters - in whole or in part - referring to scientific articles published in the journal.

Regarding papers on current issues, the author’s request for immediate publication should be quoted on the first page. The Editorial Board reserves the right to accept such papers for immediate publication.

All manuscripts should not have been published previously, in whole or in part, and not be under consideration by another publication. Manuscripts should acknowledge any funding, sponsorship or other financial support. All clinical research should have been conducted following informed consent of participants or of their legal representatives according to the Declarations of Helsinki and Tokyo.

In addition, the US National Institute of Health guide for the care and use of laboratory animals (DHEW Publication, NIH, 80-23) should have been observed. Clinical trials should have been approved by the Ethics Committee of the Hospital.

Authors’ opinions and conclusions expressed in the published papers do not necessarily reflect those of the journal.

The Greek Paediatric Society, the Editorial Board and the Publisher of the journal do not necessarily approve the content of the advertisements appearing in the journal.

The copyright of all published papers is held by “Paediatriki” and their reproduction in whole or in part is authorized only following written consent of the journal.

B. Manuscript Preparation “Paediatriki” suggests compliance with the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals”, recently modified and published on the websites: http://www.icmje.org and http://www.icmje.org/icmje.pdf The entire paper (including figure legends and tables)

xv

should be typed on one side of blank paper format A4 (21x29.7 cm), double line spacing and minimum indent 2.5 cm on both sides.

The paper should have the following structure: title page, short title, abstract in Greek and English, list of abbreviations, text, acknowledgements and quoting of grants, sponsorships or other financial support sources, references, tables, figures, figure legends. Each of these sections should be started on a new page. Pages should be numbered consecutively, beginning with the title page.

Text length shall be: ñ review articles 2000-3000 words; ñ original articles 1500-2500 words and case reports 1000-1500 words; ñ brief reports 1000-1500 words; ñ letters 250-500 words.

The title page should include: ñ the title (<14 words) and the short title (<5 words) of the article. No abbreviations are permitted in the title; ñ the name and surname of all authors; ñ the centre (institution, clinic, laboratory) of origin of the paper. If there is no affiliation with a specific centre, the status of the author(s) should be cited (e.g., private paediatrician) and home address; ñ the complete address, e-mail and telephone number of the author to whom correspondence should be addressed.

Abstracts The abstract should summarize the objectives, methodology, main results and conclusions of the study. ñ It should contain at least 200 words, and not exceed 250 words. ñ It should consist of the following paragraphs: background, methods, results and conclusions.

The English abstract should cite at the beginning the title of the paper and the authors’ names in English. The content of the text should consist of the following paragraphs: background, methods, results and conclusions. The abstract in English should not differ in content from the corresponding Greek abstract.

Beneath the Greek and English abstracts, three to five key words in the respective language should be supplied, to be used in the thematic index.

Text Original articles include: introduction, methods, results and discussion. The introduction includes the latest research data on the subject and the main references and the objectives of the paper. The description of the methods should be precise and detailed so as to enable reproduction by other researchers. In addition, the statistical methods of analysis and evaluation of the results should be described. Results should be presented clearly, together with the appropriate statistical analysis. Discussion should cover the results ensuing from the research, their significance and possible associations with the observations of other researchers.

Case reports comprise a short introduction, case description and brief discussion, with emphasis on differential diagnosis.

The structure of all other articles is free, according to the judgment of the authors.

Thanks or acknowledgements (reference to grants, sponsorships or other sources of financial support) should be quoted at the end of the text, before references.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·16

xvi

Units of measures of laboratory analyses Laboratory analyses should be expressed in the Système International (SI) units and in the metric (Conventional) system in parentheses. See conversion tables on the websites: http://www.icmje.org and http://www.icmje.org/icmje.pdf Abbreviations All issues of the journal contain internationally established abbreviations. Complex or long terms often repeated in the text may be replaced by abbreviations explained by the authors in a list submitted with the paper. Abbreviations are reported in parentheses only in abstracts.

References The reference section contains all references numbered in the order in which they appear in the text. In the text, references are to be indicated by Arabic numerals in parentheses. References should be no more than: ñ 70 in review articles; ñ 30 in original articles; ñ 12 in current issues and case reports; ñ 5 in brief reports and letters.

In listing references follow the recently modified standards of the International Committee of Medical Journal Editors/Uniform Requirements for Manuscripts Submitted to Biomedical Journals, (http://www.icmje.org and http:// www.icmje.org/icmje.pdf). Abbreviated names of journals should conform to the Cumulated Index Medicus [List of Journals Indexed in Index Medicus (http://www.nlm.nih.gov/bsd/uniform_requirements.html)].

Examples of reference style I. JOURNALS All authors are cited if they are six or less; if they are 7 or more, the first six are cited, followed by “et al”.

Regular edition: Proesmans W. Bartter syndrome and its neonatal variant. Eur J Pediatr 1997;156:669-679.

Supplement issue: Flyvbjerg A. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int 1997;52 (60 Suppl):S12-S19.

No author: National Institutes of Health Consensus Development Conference. Neurofibromatosis conference statement. Arch Neurol 1988;45:575-578.

Article type specification: Schreiner GF, Lange L. Ethanol modulation of macrophage influx in glomerulonephritis [Abstract]. J Am Soc Nephrol 1991;2:562.

Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? [Editorial]. Am J Respir Crit Care Med 1998;158:1697-1701.

Laux-End R, Inaebnit D, Gerber HA, Bianchetti MG. Vasculitis associated with levamisole and circulating autoantibodies [Letter]. Arch Dis Child 1996;75:355-356.

II. BOOKS Chapter in book: Clark AG, Barratt TM. Steroid-responsive nephrotic syndrome.

In: Barratt TM, Arner ED, Harmon WE, editors. Pediatric Nephrology. 4th ed. Baltimore: Lippincott William Wilkins; 1999. p. 742.

Book or monograph: Gorlin RJ, Cohen MM, Levin LS. Syndromes of the head and neck. 3rd ed. New York: Oxford University Press; 1990.

Publication in a volume of proceedings: Bauer AW. The two definitions of bacterial resistance. In: Smith AJ, Rogers CA, eds. Proceedings of the Third International Congress of Chemotherapy; 1962 May 29-31; New York: International Society of Chemotherapy; 1963. p. 484-500.

Doctoral dissertation: Kaplan SJ. Post hospital home health care: the elderly’s access and utilization [dissertation]. St. Louis (Mo): Washington Univ.; 1995. πππ. CD-ROM Anderson SC, Poulsen KB. Anderson’s electronic atlas of hematology [CD-ROM]. Philadelphia: Lippincott Williams & Wilkins; 2002.

IV. ON THE INTERNET Article in journal Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. Am J Nurs [Internet]. 2002 Jun: Webpage: http://www.nursingworld.org/ AJN/2002/june/Wawatch.htm Monograph Foley KM, Gelband H, editors. Improving palliative care for cancer [Monograph, Internet]. Washington: National Academy Press; 2001. Webpage: http://www.nap.edu/books/0309074029/html Websites Cancer-Pain.org [Webpage, Internet]. New York: Association of Cancer Online Resources, Inc.; 2002: http://www.cancerpain.org/ Tables and Figures Three copies should be submitted (original plus 2 copies).

Their width should either be equal to the width of one column (7.5 cm) or to the width of the page (15.5 cm). Their maximum length, titles included, should not exceed 22 cm.

Tables are numbered with Arabic numerals in the order in which they appear in the text. They should have a short title and abbreviations should be listed at the bottom. Vertical lines in tables should be avoided.

All illustration material is considered as figures (graphs, pictures, etc.). They should be of excellent quality. Also, at the back of every picture, the number of the picture and the name of the first author should be noted in pencil, with an arrow showing the top of the picture. The identity of patients should not be recognizable from their pictures nor should their names be stated.

C. Manuscript Submission and Publication All manuscripts should be accompanied by a floppy disk or CD, as well as by a letter, signed by all the authors, in which it is stated that the paper has not been published in part or in whole, or is not under consideration by another journal and that the authors accept its publication in “Paediatriki”. Any funding, sponsorship or other financial support should be acknowledged.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·17

xvii

Once the manuscript has been accepted, the corrected version, rewritten according to the reviewers’ recommendations, should be submitted to the Editorial Board accompanied by a floppy disk or CD, containing the paper in Word format, along with a covering letter specifying in detail the modifications or objections to the reviewers’ suggestions.

Delay in submission of the modified paper exceeding 30 days entails new submission.

Authors will be charged film and reprint expenses, paid upon dispatch of the first proof directly to the printer.

Manuscripts of papers, which have not been approved for publication, are not returned to the author. The accompanying figures and photographs can be returned upon request within six months.

Manuscripts submitted for review and publication in “Paediatriki” should be sent in three copies to the following address: Editorial Board, Greek Paediatric Society 92, Michalakopoulou Street, 115 28 Athens, Greece Before submitting your paper, make sure it contains: 1. 3 copies of the text of the paper, printed according to instructions.

2. A floppy disk or CD with the entire material of the paper (text, tables, pictures).

3. A covering letter and a statement that the paper has not been previously published.

4. The title page (on a separate page), which includes: a. the title and short title of the paper; b. the name and surname (full name) of the author(s); c. the academic centre(s) of origin; d. the corresponding authors’ name, address and telephone number; 5. English and Greek abstracts, with the following structure: background, methods, results and conclusions (double space, separate page) and keywords.

6. List of abbreviations (double space, separate page).

7. Text (double space, separate page).

8. Acknowledgements and reference to funding, sponsorships or other financial sources.

9. References (double space, separate page).

10. Tables (one per page) in three copies.

11. Figures with an arrow at the back showing the top, numbered, in two copies.

12. Figure titles (double space - on separate pages) in three copies.

Pediatri Jan-Feb 08

15-02-08

xviii

11:00

™ÂÏ›‰·18

∂¶π™∆√§∏ ∞¶√ ∆∏ ™À¡∆∞•∏

EDITORIAL

∞Á·ËÙÔ› Û˘Ó¿‰ÂÏÊÔÈ, ∂Π̤ÚÔ˘˜ Ù˘ ™˘ÓÙ·ÎÙÈ΋˜ ∂ÈÙÚÔ‹˜ Ù˘ “¶·È‰È·ÙÚÈ΋˜” Û·˜ ‡¯ÔÌ·È Â˘Ù˘¯ÈṲ̂ÓÔ, ‰ËÌÈÔ˘ÚÁÈÎfi Î·È Ì ˘Á›· ÙÔ 2008. ªÂ ÙËÓ Â˘Î·ÈÚ›· ·˘Ù‹, ı· ı¤Ï·Ì ӷ ¢¯·ÚÈÛÙ‹ÛÔ˘Ì fiÛÔ˘˜ Û˘ÓÂÈÛ¤ÊÂÚ·Ó ÛÙËÓ ÂÈÙ˘¯›· ÙÔ˘ ÂÚÈÔ‰ÈÎÔ‡. ∆ÔÓ ÙÂÏÂ˘Ù·›Ô ¯ÚfiÓÔ, Ô ·ÚÈıÌfi˜ ÙˆÓ ÂÚÁ·ÛÈÒÓ Ô˘ ˘Ô‚Ï‹ıËÎ·Ó ÛÙËÓ “¶·È‰È·ÙÚÈ΋” ·˘Í‹ıËΠÛËÌ·ÓÙÈο Û ۯ¤ÛË Ì ٷ ÚÔËÁÔ‡ÌÂÓ· ¯ÚfiÓÈ·. ∞˘Ùfi Ì·˜ ¤‰ˆÛ ÙËÓ Â˘Î·ÈÚ›· Ó· ‚ÂÏÙÈÒÛÔ˘Ì ٷ ÔÈÔÙÈο ÎÚÈÙ‹ÚÈ· Î·È ÔÈ ‰ËÌÔÛȇÛÂȘ Ó· Â›Ó·È ‰ÈÂıÓÔ‡˜ ·ÚÔ˘˜. ∏ ËÏÂÎÙÚÔÓÈ΋ ˘Ô‚ÔÏ‹ Î·È Ë ÂΉÔÙÈ΋ ‰ÈÂÎÂÚ·›ˆÛË ÙˆÓ ÂÚÁ·ÛÈÒÓ Â›¯·Ó ˆ˜ ·ÔÙ¤ÏÂÛÌ· ÙËÓ ÂÈÙ¿¯˘ÓÛË Ù˘ ÎÚ›Û˘ Î·È Ù˘ ‰ËÌÔÛ›Â˘Û‹˜ ÙÔ˘˜. §ÂÙÔ̤ÚÂȘ ÁÈ· ÙËÓ ËÏÂÎÙÚÔÓÈ΋ ˘Ô‚ÔÏ‹ ÂÚÁ·ÛÈÒÓ ı· ‚Ú›Ù ÛÙȘ “√‰ËÁ›Â˜ ÚÔ˜ ÙÔ˘˜ Û˘ÁÁÚ·Ê›˜”. °È· Ó· ÂÍÔÈÎÔÓÔÌËı› ¯ÒÚÔ˜ ÛÙÔ ÂÚÈÔ‰ÈÎfi, ÔÈ Ô‰ËÁ›Â˜ ·˘Ù¤˜ ÂÚÈÏ·Ì‚¿ÓÔÓÙ·È ÌfiÓÔ ÛÙÔ ÚÒÙÔ Ù‡¯Ô˜ οı ¯ÚfiÓÔ˘ Î·È ÛÙËÓ ÈÛÙÔÛÂÏ›‰· Ù˘ “¶·È‰È·ÙÚÈ΋˜”. ™·˜ ˘ÂÓı˘Ì›˙Ô˘Ì fiÙÈ ÌÔÚ›Ù ӷ ‚Ú›Ù ÙȘ ‰ËÌÔÛȇÛÂȘ Ù˘ “¶·È‰È·ÙÚÈ΋˜” ¯ˆÚ›˜ ¯Ú¤ˆÛË ÛÙËÓ ÈÛÙÔÛÂÏ›‰· ÙÔ˘ ÂÚÈÔ‰ÈÎÔ‡ (http://www.paediatriki.edu.gr). ™Ù· ÂfiÌÂÓ· Ù‡¯Ë ı· Û˘Ó¯›ÛÔ˘ÌÂ, ·Ú¿ÏÏËÏ· Ì ÙË ‰ËÌÔÛ›Â˘ÛË ÂÚ¢ÓËÙÈÎÒÓ ÂÚÁ·ÛÈÒÓ, ÙË ‰ËÌÔÛ›Â˘ÛË ·Ó·ÛÎÔ‹ÛÂˆÓ Ì ÂÚˆÙ‹ÛÂȘ ÔÏÏ·ÏÒÓ ··ÓÙ‹ÛˆÓ, ÙˆÓ “™‡ÓÙÔÌˆÓ ·È‰È·ÙÚÈÎÒÓ Ó¤ˆÓ” Ì ۯÔÏÈ·ÛÌfi ÚfiÛÊ·ÙˆÓ ÂÚÁ·ÛÈÒÓ ∂ÏÏ‹ÓˆÓ ÂÚ¢ÓËÙÒÓ ÛÙË ‰ÈÂıÓ‹ ‚È‚ÏÈÔÁÚ·Ê›·, ηıÒ˜ Î·È ÓÂfiÙÂÚˆÓ ·fi ·È‰È·ÙÚÈο Û˘Ó¤‰ÚÈ· Î·È ·fi ÙÔ ‰È·‰›ÎÙ˘Ô. ¶ÂÚÈ̤ÓÔ˘Ì ÂÚˆÙ‹Ì·Ù· Ô˘ Û·˜ ··Û¯ÔÏÔ‡Ó ÛÙËÓ Î·ıËÌÂÚÈÓ‹ ÎÏÈÓÈ΋ Ú¿ÍË. ∆· ÂÚˆÙ‹Ì·Ù· ·˘Ù¿ ı· ·ÔÙÂϤÛÔ˘Ó Ù· ı¤Ì·Ù· ÁÈ· ÙË Ó¤· ÛÂÈÚ¿ ¿ÚıÚˆÓ: “ƒˆÙ‹ÛÙ ÙÔÓ ÂȉÈÎfi”. ∆¤ÏÔ˜, Û·˜ ˘ÂÓı˘Ì›˙Ô˘Ì fiÙÈ ı· Ú¤ÂÈ Ó· ‰ËÏÒÓÂÙ·È ÛÙȘ ÂÚÁ·Û›Â˜ Ô˘ ˘Ô‚¿ÏÏÂÙ οı Èı·Ófi ·ÓÙÈÎÚÔ˘fiÌÂÓÔ Û˘ÌʤÚÔÓ, fiˆ˜ ¤¯ÂÈ ‰ÈÂıÓÒ˜ ηıÈÂÚˆı›. ªÂ ıÂÚÌÔ‡˜ ¯·ÈÚÂÙÈÛÌÔ‡˜,

∫ˆÓÛÙ·ÓÙ›ÓÔ˜ I. ™ÙÂÊ·Ó›‰Ë˜ ¢È¢ı˘ÓÙ‹˜ ™‡ÓÙ·Í˘

Dear colleagues, On behalf of the Editorial Board of “Paediatriki”, I wish you a happy, creative and healthy 2008.

On this occasion, we would like to thank all who have contributed to the success of the journal.

Submissions to the journal increased significantly during the past year. This gave us the opportunity to further improve the quality standards to achieve a world-class level.

The submission of papers by e-mail and the electronic handling of the editorial process contributed so as to shorten the time to access the important information our articles provide.

Detailed information about the submission of articles is included in the “Instructions to authors” of this issue. To save space, you will find the “Instructions to authors” only in the first issue of each year and at the web page of the journal. In addition, we would like to remind you that you can find the past publications free of charge at the web page of the journal (http://www.paediatriki.edu.gr).

In the next issues we will continue, additionally to the original research studies, the publication of Continuing Medical Education papers with multiple choice questions, the “Paediatric news in brief” with comments on recent pediatric articles of Greek researchers, as well as brief information on news from Congresses, Seminars and from the Internet. Also, we would like to invite you to send us questions that arise from your every day practice. These questions will become the topics of the new section: “Ask the expert”.

Finally, we remind that authors are required to declare any possible conflict of interest.

Warm greetings, Constantinos J. Stefanidis, M.D., Ph.D. Editor-in-Chief Paediatriki 2007;70:18-000

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·1

REVIEW ARTICLE

∞¡∞™∫√¶∏™∏

1

New Methods and Trends in Paediatric Education.

Undergraduate Training K. Sostmann, J. Hoeffe, S. Mueller, H. Krude, G. Gaedicke Abstract: According to the most recent amendment to medical training in Germany, lessons in the form of lectures have been reduced considerably in favour of practical instruction and bedside teaching in small groups. Because of these changes, it became necessary to develop a new concept for paediatric undergraduate training. The faculty introduced the learning management system Blackboard© as a platform for providing scripts, videos, slides, and podcasts of all paediatric lectures. The students use this material to prepare for their practical training. A blended learning scenario was chosen to support bedside teaching with E-learning-elements under the supervision of tutors. During their self-study time students are provided with paediatric virtual patients for learning about cases that cannot be shown during ward rounds. E-tutors are available at the disposal of the students. In addition, the students have the opportunity to attend regular lectures during which case studies derived from the most important clinical paediatric fields are discussed. An audience response system, Mobi-Ted©, is used, which allows students to input questions into an auditory monitor and to get back the individual answer electronically. The results are immediately evaluated and presented on the screen to the audience, and can thus be interpreted and discussed interactively. This makes learning easy and discussions more fruitful. Making European Higher Education a “world quality reference” is a very ambitious goal for the year 2010. The Bologna process is an exciting development for undergraduate medical training and the widespread use of modern computer-based technologies will become mandatory for academic teaching.

Charité-Universitaetsmedizin Berlin, Campus VirchowKlinikum Correspondence: Prof. Dr. Gerhard Gaedicke gerhard.gaedicke@charite.de Klinik für Allgemeine Paediatrie und Arbeitsbereich/Projekt ELWIS-MED Charité Universitaetsmedizin Berlin, Campus Virchow Augustenburgerplatz 1, 133 53 Berlin

Key words: Paediatric undergraduate training, blended learning, E-learning, trends in medical education, education technology, interactive learning.

Introduction “I hear - I forget I see - I remember I do - I understand” This 4000 year-old Chinese proverb has been translated into English but never into German. It contains information that has been demonstrated by recent studies. A lecture alone is not a very effective method for transferring knowledge. To learn effectively we need to open other channels for information transfer (ears, eyes, senses) as well. This is particularly necessary because modern medical curricula are no longer knowledge-based alone, but also demand development of the students’ competence and skills. At present the Charité, Medical Faculty of Berlin (Figure 1), is in a state of transition. It runs a conventional curriculum (600 students per year), which has recently been amended by law, and a reformed curriculum (63 students per year), which represents a field of experimentation and development of new methodologies in teaching, learning and assessment.

Lectures: Past and present situations The process of teaching medicine by lectures has largely remained unchanged during the last hundred years. In clinical lectures for students,

the live demonstration of patients is still a key element. Although the methods of presenting data have been considerably refined by the introduction of computer programmes, it is easy to see that the mediation of knowledge in lectures follows the same pattern as if data and facts had been written on a blackboard. One advantage of lectures is the instruction of a large number of students by a single lecturer (Figure 2). Proponents of this method say this would make a lecture economically attractive. But is this really the case? Of course a skilled teacher can act as a role model for

Figure 1. Charité, Medical Faculty of Berlin. ¶·È‰È·ÙÚÈ΋ 2008;71:1-4

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·2

2

K. Sostmann et al.

Figure 3. Portable digital audio player (MP3-Player).

Figure 2. A clinical lecture.

the students. These examples, however, are rare. We all have been taught by such leaders in their field, but find that most lecturers do not meet up our expectations (1).

The popularity of clinical lectures has steadily decreased during the last two decades among students in Germany. They would describe this type of learning clinical medicine as being outdated. This fact is reflected by the very low attendance, with less than 10% of students in a class attending clinical lectures regularly. The reasons given for this phenomenon vary: 1. Lectures are unsuitable for teaching clinical skills and knowledge 2. Exercises, seminars and examinations require a significant time investment 3. Students must work to earn a living 4. Students have family obligations A description follows of the ways being introduced for dealing with the new requirements of teaching clinical medicine to undergraduate medical students.

Reinvention of lectures This mode of pedagogical practice seeks to bridge the gap between theory-based instruction on the one hand and practical application on the other. It requires the development of a new way of thinking for medical faculties. The expansion of the space of learning crosses traditional borders. Educators must accept that their role will change from that of providing owner-based knowledge to becoming knowledge managers who must stimulate students to acquire that knowledge and skills. The students need to achieve an understanding of the conceptual and propositional knowledge that educators would formerly have transferred in the classroom setting. Now students from different universities can visit online course modules and collect their own electronic portfolios from the material in the learning environments of the universities.

Podcasts as a teaching tool There is already extensive experience in the use of audio and videorecordings of teaching sessions (2).

Podcasts represent a new and easy way of producing digital recordings from teaching units, which comPaediatriki 2008;71:1-4

bine the spoken word with the visual slides in one data-package (Figure 3). Podcasts also represent a new way of storing and distributing these files through the Internet to different kinds of players (computers, MP3-players). The user can subscribe to the files and his/her computer will automatically receive new transmissions. Production and distribution of podcasts have become much easier through the widespread use of portable MP3-Players.

Students are able to use the podcasts at their own pace. They can access the files whenever they wish and use them. Digital storage of their data allows students to search the content and to select and include their collected and preferred data in their lifelong-learning tracks.

Teachers are able to provide life-data from their class sessions and combine these with additional teaching material for their students simply by uploading the files to a server. They can edit and delete the files at any time and secure entry to the site by passwords.

Bedside teaching with virtual patients (Case based teaching) Contextual learning plays an important role in the development of expert knowledge. During the current renewal of the paediatric curriculum at German universities in general and at the Charité in particular, the focus on face-to-face teaching has shifted from theoretical systematic learning to bedside teaching with real patients. Bedside teaching as a method focuses on the conveying of practical clinical skills to students in an authentic environment (3). It aims to foster clinical decision-making skills, which correlate with the development of clinical expertise. The new German licensing rules for doctors obligate teaching of a maximum of three students at the patient’s bedside (4). Clinical case presentations can be held with a maximum of six students. Therefore, by the predefinition of learning goals, clinical learning in paediatrics is placed in the context of typical paediatric patients and clinical cases.

Students can start to integrate their theoretical knowledge and earlier understanding of basic clinical sciences with practical demands. The challenge consists in the case mix of a university hospital, where the typical cases cannot be provided as standard to all of the 1,000 students who rotate through the wards each year. The

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·3

3

Methods in paediatric undergraduate education

Table 1. Virtual paediatric cases Six common or severe paediatric problems as virtual learning patients Gastroenteritis Febrile seizure Intussusception Pseudocroup Meningococcal meningitis Osteomyelitis

Figure 4. E-learning module (CAMPUS© Case based teaching software).

duration of stay of the patients in the hospital is usually very short and the typical initial symptoms that led to the first diagnostic steps disappear very quickly. To resolve these problems, a blended learning scenario was chosen, where the traditional bedside teaching is supplemented (blended) with eLearning modules (Figure 4), on which the students are required to work before and after they visit the paediatric ward.

Didactics Blended learning represents a shift in instructional strategy. The most useful parts of each teaching method are combined to reach the maximum teaching effort. This system merges the advantages of technology-based teaching methods, e.g. e-Learning, with traditional teaching (face-to-face), and small-group teaching methods such as problem-based learning.

Blended learning makes possible self-directed learning by shifting the choice of teaching methods and materials used from the teacher to the student. It helps students choose the learning materials that match their learning types and needs (5). The additional use of virtual communication tools stresses the learner-centred role of these scenarios. The introduction of new communication tools helps partners to access teaching from multiple perspectives.

Blended learning is achieved through the following steps: Students rotate through ten paediatric subspecialities during their paediatric semester in the 5th clinical semester. They receive four hours of bedside teaching time. Every 14 days they visit a new paediatric specialty with a new teacher. In order to provide continuity for the students, the e-Tutor was introduced. E-Tutors are physicians on the hospital staff who are trained to operate the different communication tools offered by the Blackboard© learning management system. Their role is to moderate the online discussions students are required to participate in during the semester. Online discussions can be held asynchronously which allows students and physicians

to participate in accordance with their daily commitments and at a distance.

Learning goals for each ward are predefined, to ensure that the students get standardized teaching from all the different 60 teachers in the departments. Casebased interactive learning software called CAMPUS (6) is used, which enables the authors to represent digitally complete clinical cases in the form of virtual patient, with all kinds of multimedia materials (video, audio, photographs, hyperlinks) that are useful from the didactic perspective, and to distribute them as CDs or through the Internet to their teaching and learning community. Learners approach the cases from a constructivist point of view, and they have to accomplish the same steps as they would in an outpatient department or on a clinical ward. As a constructivist learning intervention this provides learners with an opportunity to discover information and to make meaningful decisions collaboratively. The students are respected in this setting as unique individuals and the physicians act as facilitators rather than teachers.

Thus the software offers the possibility of approaching the virtual patient from individual perspectives.

E-Learning Six learning cases, so called virtual patients, were provided for the students (Table 1).

Students can reach the learning cases online through the learning management system Blackboard©. The cases were passed through a peer review process and were chosen to represent typical and common problems of paediatric patients. The cases were supplemented with videos and sound materials that reproduce the patients’ major problems and symptoms even at an acute stage of their illness. For example, one video shows a patient with severe dehydration with ketoacidosis and Kussmaul-breathing.

This method generates a surplus of information for the students using the learning cases. It should be realized in this context that additional information will put an additional study load on the students (7), but the key advantages of eLearning are flexibility and the possibility for the students to work in any place ¶·È‰È·ÙÚÈ΋ 2008;71:1-4

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·4

4

K. Sostmann et al.

where an Internet connection is available. A further advantage is the fact that teachers can use the learning cases to present the acute clinical situations with symptoms not available at the moment of teaching. Patients themselves are relieved of stress because the students are better prepared when attending the bedside teaching sessions.

Assessment A variety of elements are considered in assessing the students: Recent studies have shown the advantages for student motivation and have proved positive learning effects from the use of formative tests during a clinical rotation (8). When completing study of the virtual cases, the students have to complete 12 formative tests (case-related multiple-choice tests with three to six questions, at the end of each case). After finishing the tests, the students receive direct online feedback and hints about how to complete their knowledge gaps.

They can do the tests as often as they wish, and they do not have to pass them. These tests are provided to offer the students a tool of self-assessment, and as a preparation for the final multiple-choice test at the end of the rotation, which consists of 40 questions.

Students are asked to complete case-related tasks, e.g., discuss the differential diagnoses or therapeutic options of the virtual cases online with their tutors and colleagues.

During the interdisciplinary course on pain management students are faced with an objective structured clinical examination (OSCE) where they are tested in practical tasks. In the future, it could prove useful to expand the use of the OSCE to assess further aspects of the students’ practical competence.

The introduction of different test methods aims at assessing not only cognitive but also contextual knowledge, and thus to test in a more reliable way the students’ development of clinical reasoning skills (9).

New methods are being developed at present for assessing students’ clinical decision-making skills.

Outlook Triggered by the recent advances in technical teaching infrastructure and by the introduction of new teaching methods, the structure of medical education has changed. These changes have to be adopted by both teachers and students. Blended learning can overcome some of the constraints caused by the compression of workflow in the wards for staff and the reduction of hospitalization for the patients. The emphasis on clinical bedside teaching means that more students meet fewer patients with acute illnesses and see more patients with chronic diseases. Blended learning can help Paediatriki 2008;71:1-4

to disburden the patients and allow questions to be answered, from the audiovisual point of view, which cannot be discussed at the bedside. Students are better prepared in this way for the clinical ward round. The adoption of the new didactic concepts is essential to develop a surplus of learning material by means of the eLearning environment for students and teaching staff.

The learner-centred design of eLearning environments can help students to choose the right media for their learning types and the particular learning situations, but it demands more initial preparation time from the teacher. New distributional technologies, such as podcasts and audience response systems, can help to make traditional classroom sessions more attractive. By introducing the new technologies as extensions of the operating learning environment, curriculum integration should be assured.

Finally, eLearning materials demand a higher effort in the area of technical support for teaching staff from their faculties. It must be taken into account that a higher learning load is an extra burden for the students, when new eLearning materials are integrated into a curriculum.

References 1. Brown G, Manogue M. AMEE Medical Education Guide No. 22: Refreshing lecturing: a guide for lecturers. Med Teach 2001;23:231-244.

2. Tomlinson DR. Independent learning packages (audio tape/pamphlet) for a course in cell excitation: evidence that they can be at least as effective as conventional lectures.

Med Educ 1979;13:257-262.

3. Lacombe MA. On bedside teaching. Ann Intern Med 1997;126:217-220.

4. German licensing order for medical doctors: Approbationsordnung für Aerzte - Bundesministerium für Gesundheit.

Gesetztestext: htpp://www.bmg.bund.de/cln_040/nn_ 603274/SharedDocs/Gesetzestexte/Gesundheitsberufe/ 5. Gordon DL, Issenberg SB, Gordon MS, LaCombe D, McGaghie WC, Petrusa ER. Stroke training of prehospital providers: an example of simulation-enhanced blended learning and evaluation. Med Teach 2005;27:114-121.

6. Garde S, Heid J, Haag M, Bauch M, Weires T, Leven FJ. Can design principles of traditional learning theories be fulfilled by computer-based training systems in medicine: the example of CAMPUS. Int J Med Inform 2007;76:124129. (doi:10.1016/j.ijmedinf.2006.07.009) 7. De Leng B, Dolmans D, van de Wiel M, Muijtjens A, van der Vleuten C. How video cases should be used as authentic stimuli in problem-based medical education. Med Educ 2007;41:181-188.

8. Lewis DJ, Sewell RD. Providing formative feedback from a summative computer-aided assessment. Am J Pharm Educ 2007;71:33.

9. Wass V, McGibbon D, Van der Vleuten C. Composite undergraduate clinical examinations: how should the components be combined to maximize reliability? Med Educ 2001;35:326-330.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·5

∞¡∞™∫√¶∏™∏

REVIEW ARTICLE

5

¶·È‰È¿ ÌÂ Û˘¯Ó¤˜ ÏÔÈÌÒÍÂȘ: ÎÚÈÙ‹ÚÈ· ÂÍÂȉÈÎÂ˘Ì¤ÓÔ˘ ·ÓÔÛÔÏÔÁÈÎÔ‡ ÂϤÁ¯Ô˘ ¢. X. ∫·Û›ÌÔ˜1, ª. §È¿ÙÛ˘2, ∞. ™ÙÔÁÈ·ÓÓ›‰Ô˘1, ª. ∫·Ó¿ÚÈÔ˘2 ¶ÂÚ›ÏË„Ë: ¶ÔÏÏ¿ ·È‰È¿ ÂÌÊ·Ó›˙Ô˘Ó Û˘¯Ó¤˜ ÏÔÈÌÒÍÂȘ, ·ÏÏ¿ Ï›Á· Â›Ó·È ÂΛӷ Ô˘ ¤¯Ô˘Ó ‰È·Ù·Ú·¯‹ ÙˆÓ ·Ì˘ÓÙÈÎÒÓ ÙÔ˘˜ Ì˯·ÓÈÛÌÒÓ. ™˘¯Ó¤˜, ˘ÔÙÚÔÈ¿˙Ô˘Û˜, Â›ÌÔÓ˜, ‚·ÚȤ˜ ‹ ·Û˘Ó‹ıÈÛÙ˜ ÏÔÈÌÒÍÂȘ ·Ó·Ù‡ÛÛÔÓÙ·È Û ·È‰È¿ Ì ·ÓÂ¿ÚÎÂÈ· ÙÔ˘ ·Ì˘ÓÙÈÎÔ‡ Î·È ÂȉÈÎfiÙÂÚ· ÙÔ˘ ·ÓÔÛÔÔÈËÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜. ∆Ô ÈÛÙÔÚÈÎfi Î·È Ë Ê˘ÛÈ΋ ÂͤٷÛË ı¤ÙÔ˘Ó ÙËÓ ˘Ô„›· οÔÈ·˜ ˘ÔΛÌÂÓ˘ ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ·˜. ™Â ‰Â‡ÙÂÚÔ ¯ÚfiÓÔ, Á›ÓÂÙ·È ‚·ÛÈÎfi˜, ÂÚÁ·ÛÙËÚÈ·Îfi˜, ·ÓÔÛÔÏÔÁÈÎfi˜ ¤ÏÂÁ¯Ô˜ ηÈ, ·Ó οÙÈ Â›Ó·È ·ıÔÏÔÁÈÎfi ‹ ÙÂı› ˘Ô„›· ÁÈ· οÔÈÔ ·ÓÔÛÔÏÔÁÈÎfi ¤ÏÏÂÈÌÌ·, Á›ÓÂÙ·È ÂÚ·ÈÙ¤Úˆ ¤ÏÂÁ¯Ô˜ Ì ÂÍÂȉÈÎÂ˘Ì¤Ó˜ ·ÓÔÛÔÏÔÁÈΤ˜ ÂÍÂÙ¿ÛÂȘ, ÔÈÔÙÈΤ˜ Î·È ÏÂÈÙÔ˘ÚÁÈΤ˜ ‰ÔÎÈ̷ۛ˜. ™ÎÔfi˜ Ù˘ ·ÚÔ‡Û·˜ ·Ó·ÛÎfiËÛ˘ Â›Ó·È Ó· ‰ÒÛÔ˘Ì ٷ ÂÊfi‰È· ÛÙÔÓ ÎÏÈÓÈÎfi ÁÈ·ÙÚfi ÁÈ· ÙË ÌÂıÔ‰È΋ ÚÔÛ¤ÁÁÈÛË ÂÓfi˜ ÔÏ˘Û‡ÓıÂÙÔ˘ ÚÔ‚Ï‹Ì·ÙÔ˜ Î·È ÙËÓ ÔÚıÔÏÔÁÈ΋ ‰ÈÂÚ‡ÓËÛË ÙˆÓ ·È‰ÈÒÓ Ô˘ ¤¯Ô˘Ó ¤Ó‰ÂÈÍË ˘ÔΛÌÂÓ˘ ·ÓÔÛÔÏÔÁÈ΋˜ ‰È·Ù·Ú·¯‹˜.

§¤ÍÂȘ ÎÏÂȉȿ: ∞ÓÔÛÔ·ÓÂ¿ÚÎÂÈ·, ·ÓÔÛ›·, ¤ÏÂÁ¯Ô˜, ÏÔÈÌÒÍÂȘ, ·È‰È¿, ·Ó·ÛÎfiËÛË.

1 ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋, ¢ËÌÔÎÚ›ÙÂÈÔ ¶·ÓÂÈÛÙ‹ÌÈÔ £Ú¿Î˘ 2 ∆Ì‹Ì· ∞ÓÔÛÔÏÔÁ›·˜πÛÙÔÛ˘Ì‚·ÙfiÙËÙ·˜, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ “∞Á›· ™ÔÊ›·” AÏÏËÏÔÁÚ·Ê›·: ª·Ú›· °. ∫·Ó¿ÚÈÔ˘ mkanariou@hol.gr ∆Ì‹Ì· ∞ÓÔÛÔÏÔÁ›·˜πÛÙÔÛ˘Ì‚·ÙfiÙËÙ·˜, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ “∞Á›· ™ÔÊ›·” £Ë‚ÒÓ Î·È ¶··‰È·Ì·ÓÙÔÔ‡ÏÔ˘, ∆.∫. 115 27, °Ô˘‰‹, ∞ı‹Ó·

Children with frequent infections: criteria for specialized immunological investigations D. C. Cassimos1, M. Liatsis2, A. Stogiannidou1, M. Kanariou2 Abstract: Although many children develop frequent infections, only a few have an underlying immune disorder. Children with dysfunction of the defense mechanisms of the immune system develop not only frequent infections but also recurrent, persistent, severe and rare infections. The medical history and physical examination provide a hint and should give rise to suspicion of an immune disorder. The approach to these patients starts with a primary diagnostic work up which, in relation to the clinical picture and the initial findings, should be extended to include more specialized investigations (qualitative and functional). The aim of this review is to provide paediatricians with the tools for approaching this problem and to propose an optimal method for investigating children with possible immune dysfunction.

Key words: Immunodeficiency, immunity, investigation, infections, children, review.

™˘ÓÙÔÌÔÁڷʛ˜ BMAA µ·ÚÈ¿ ªÈÎÙ‹ ∞ÓÔÛÔ·ÓÂ¿ÚÎÂÈ· C Complement / ™˘Ìϋڈ̷ CD Cluster Differentiation / ¢Â›ÎÙ˘ ¢È·ÊÔÚÔÔ›ËÛ˘ CMV Cytomegalovirus / ∫˘ÙÙ·ÚÔÌÂÁ·ÏÔ˚fi˜ DHR Dihydrorodamine / ¢È˘‰ÚÔÚÔ‰·Ì›ÓË HPV Human Papilloma Virus / πfi˜ ·ÓıÚˆ›ÓˆÓ ıËÏˆÌ¿ÙˆÓ Ig Immunoglobulin / ∞ÓÔÛÔÛÊ·ÈÚ›ÓË MHC Major Histocompatibility Complex / ªÂ›˙ÔÓ ™‡ÛÙËÌ· πÛÙÔÛ˘Ì‚·ÙfiÙËÙ·˜ NBT Nitro Blue Tetrazolium / ¢ÔÎÈÌ·Û›· ¯ÚÒÛ˘ ÙÔ˘ ΢·ÓÔ‡ ÙÔ˘ ÙÂÙÚ·˙ÔÏ›Ô˘ NK Natural Killer / º˘ÛÈο ∫˘ÙÙ·ÚÔÎÙfiÓ· ¶∞∞ ¶ÚˆÙÔ·ı›˜ ∞ÓÔÛÔ·ÓÂ¿ÚÎÂȘ

∂ÈÛ·ÁˆÁ‹ µ·ÛÈÎfi ¯·Ú·ÎÙËÚÈÛÙÈÎfi ÙÔ˘ Ê˘ÛÈÔÏÔÁÈÎÔ‡ ·ÓÔÛÈ·ÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ Â›Ó·È Ë ·Ó·ÁÓÒÚÈÛË Î·È ‰È¿ÎÚÈÛË ÙˆÓ ‰ÈÎÒÓ ÙÔ˘ ȉ›ˆÓ ÛÙÔȯ›ˆÓ ·fi Ù·

1 Department of Paediatrics, Democritus University of Thrace 2 Department of Immunology and Histocompatibility, “Aghia Sophia” Children’s Hospital, Athens, Greece Correspondence: Maria G. Kanariou mkanariou@hol.gr Department of Immunology and Histocompatibility, “Aghia Sofia” Children’s Hospital Thivon & Papadiamantopoulou St., 115 27, Goudi, Athens, Greece

ͤӷ, Ì ÛÎÔfi Ó· ·Ó¤¯ÂÙ·È Ù· ‰Èο ÙÔ˘ Î·È Ó· ÂÈÙ›ıÂÙ·È ‹ ·ÔÚÚ›ÙÂÈ Ù· ͤӷ, ÒÛÙ ӷ ÚÔÛٷهÂÈ ÙËÓ ÔÌÔÈÔÛÙ·Û›· Î·È ÙËÓ ·ÎÂÚ·ÈfiÙËÙ· ÙÔ˘ ÔÚÁ·ÓÈÛÌÔ‡. ∆· ÈÔ Û˘Ó‹ıË Í¤Ó·, ÂÈÙÈı¤ÌÂÓ· ÛÙÔÓ ·ÓıÚÒÈÓÔ ÔÚÁ·ÓÈÛÌfi ÛÙÔȯ›· Â›Ó·È ÔÈ ÏÔÈÌÔÁfiÓÔÈ ·Ú¿ÁÔÓÙ˜. √È ÏÔÈÌÒÍÂȘ Â›Ó·È ÓÔÛ‹Ì·Ù· Ô˘ Û˘Ó‰¤ÔÓÙ·È ÙfiÛÔ ÛÙÂÓ¿ Ì ÙÔ ·ÓÔÛÔÔÈËÙÈÎfi Û‡ÛÙËÌ·, ÒÛÙÂ Â›Ó·È ‰˘Ó·Ùfi Ì ‚¿ÛË ÙË Ïԛ̈ÍË Î·È ÙÔ˘˜ ÙÔÈÎÔ‡˜ ‹ Û˘ÛÙËÌ·ÙÈÎÔ‡˜, ÂȉÈÎÔ‡˜ ‹ ÌË ÂȉÈÎÔ‡˜ Î·È Î˘ÙÙ·ÚÈÎÔ‡˜ ‹ ¯˘ÌÈÎÔ‡˜ ·ÓÔÛÈ·ÎÔ‡˜ Ì˯·ÓÈÛÌÔ‡˜ Ó· ·Ó·ÁÓˆÚÈÛı› ÙÔ ¤ÏÏÂÈÌÌ· Î·È Ó· Ù·ÍÈÓÔÌËı› Ë Ù˘¯fiÓ ·ÓÂ¿ÚÎÂÈ·. √ÔÈÔÛ‰‹ÔÙ ÏÔÈÌÔÁfiÓÔ˜ ·Ú¿ÁÔÓÙ·˜ ÁÈ· Ó· ÂΉËÏÒÛÂÈ ÓfiÛÔ ÚÔ¸Ôı¤ÙÂÈ ÙËÓ ÂÈÙ˘¯Ë̤ÓË ‰È¿Û·ÛË ÙÔ˘ ·ÓÔÛÈ·ÎÔ‡ ·Ì˘ÓÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜. ∞fi ÙË ÛÙÈÁÌ‹ Ô˘ ÙÔ ÓÂÔÁÓfi ÂÁηٷÏ›ÂÈ ÙÔ ÛÙ›ÚÔ ÂÚÈ‚¿ÏÏÔÓ Ù˘ Ì‹ÙÚ·˜ ·ÔÈΛ˙ÂÙ·È Ì ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ‡˜. ∏ ÌÈÎÚԂȷ΋ ¯ÏˆÚ›‰· Ô˘ ¶·È‰È·ÙÚÈ΋ 2008;71:5-13

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·6

6

¢. X. ∫·Û›ÌÔ˜ Î·È Û˘Ó.

ª˘ÂÏfi˜ ÙˆÓ ÔÛÙÒÓ

√˘‰ÂÙÂÚfiÊÈÏÔ ¶ÔÏ˘‰‡Ó·ÌÔ ·Ú¯¤ÁÔÓÔ Î‡ÙÙ·ÚÔ

¡∫ ·ÙÙ·ÚÔ

∞Ú¯¤ÁÔÓÔ Ì˘ÂÏÔÂȉ¤˜

∞Ú¯¤ÁÔÓÔ ÏÂÌÊÔÂȉ¤˜ ¶ÚÔ ∆ ·ÙÙ·ÚÔ

ªÔÓÔ·ÙÙ·ÚÔ

¶ÚÔ µ ·ÙÙ·ÚÔ ∏ˆÛÈÓfiÊÈÏÔ ª˘ÂÏfi˜ ÙˆÓ ÔÛÙÒÓ

£‡ÌÔ˜

µ·ÛÂfiÊÈÏÔ

flÚÈÌÔ ∆ ·ÙÙ·ÚÔ

flÚÈÌÔ µ ·ÙÙ·ÚÔ

¶Ï·ÛÌ·ÙÔ·ÙÙ·ÚÔ

∞ÓÔÛÔÛÊ·ÈÚ›Ó˜ ∂ÈÎfiÓ· 1. ™¯ËÌ·ÙÈ΋ ·ÂÈÎfiÓÈÛË ÙÔ˘ ·ÓÔÛÔÔÈËÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜.

·Ó·Ù‡ÛÛÂÙ·È fi¯È ÌfiÓÔ ‰ÂÓ Â›Ó·È ·ıÔÁfiÓÔ˜, ·ÏÏ¿ ÏÂÈÙÔ˘ÚÁ› Û˘Ì‚ÈÔÙÈο ˆ˜ ·Û›‰· ÌË ÂÈÙÚ¤ÔÓÙ·˜ Û ͤÓÔ˘˜ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ‡˜ Ó· ·Ó·Ù˘¯ıÔ‡Ó. ŸÙ·Ó ÙÔ ·È‰› ÚˆÙÔÛ˘Ó·ÓÙ‹ÛÂÈ Î¿ÔÈÔ ·ıÔÁfiÓÔ ÌÈÎÚÔÔÚÁ·ÓÈÛÌfi Â›Ó·È ‰˘Ó·ÙfiÓ Ó· ÓÔÛ‹ÛÂÈ. ªÂ ÙËÓ ÂͤÏÈÍË Ù˘ ÓfiÛÔ˘ ·Ó·Ù‡ÛÛÔÓÙ·È ·Ú¿ÏÏËÏ· ·ÓÔÛÔÏÔÁÈÎÔ› ·Ì˘ÓÙÈÎÔ› Ì˯·ÓÈÛÌÔ› Ô˘ ηıÈÛÙÔ‡Ó ÙÔ ¿ÙÔÌÔ ÈηÓfi Ó· ÂÈ˙‹ÛÂÈ Î·È Ó· ·ÔÎÙ‹ÛÂÈ ÌÓËÌÔÓÈ΋ ·ÓÔÛ›· ηٿ ÙÔ˘ ·ıÔÁfiÓÔ˘ ÏÔÈÌÔÁfiÓÔ˘ ·Ú¿ÁÔÓÙ·. §ÔÈÌÒÍÂȘ ·fi Û˘ÁÎÂÎÚÈ̤ÓÔ˘˜ ÔÚÁ·ÓÈÛÌÔ‡˜, fiˆ˜ Ë §ÈÛÙ¤ÚÈ· Ë ÌÔÓÔ΢ÙÙ·ÚÈ΋ (Listeria monocytogenes) Î·È Ë ¶Ó¢ÌÔ·ÛÙË jiroveci (carinii), ‰ÂÓ Û˘Ó·ÓÙÒÓÙ·È ·Ú¿ ÌfiÓÔ Û ¿ÙÔÌ· Ì ˘ÔΛÌÂÓË ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ·, ÂÓÒ ÌÂÚÈÎÔ› ÏÔÈÌÔÁfiÓÔÈ ·Ú¿ÁÔÓÙ˜, fiˆ˜ Ô ÌÂÁ·ÏÔ΢ÙÙ·ÚÔ˚fi˜ (CMV), ÚÔηÏÔ‡Ó ·ÓÔÛÔηٷÛÙÔÏ‹. ∆Ô Â›Â‰Ô ıÚ¤„˘ ÂËÚ¿˙ÂÈ Û ÌÂÁ¿ÏÔ ‚·ıÌfi ÙËÓ ·Ì˘ÓÙÈ΋ ÈηÓfiÙËÙ· ÙÔ˘ ·È‰ÈÔ‡, ÂÓÒ ÙÔ ÂÚÈ‚¿ÏÏÔÓ ÛÙÔ ÔÔ›Ô ÌÂÁ·ÏÒÓÂÈ Î·ıÔÚ›˙ÂÈ ÙÔ˘˜ ÏÔÈÌÔÁfiÓÔ˘˜ ·Ú¿ÁÔÓÙ˜ ÛÙÔ˘˜ ÔÔ›Ô˘˜ ÂÎÙ›ıÂÙ·È. º˘ÛÈÔÏÔÁÈο, fiÏ· Ù· ·È‰È¿ ÂÌÊ·Ó›˙Ô˘Ó ÏÔÈÌÒPaediatriki 2008;71:5-13

ÍÂȘ. ∫·Ù¿ ÙË ÓËȷ΋ ËÏÈΛ· ÛÙË ‰È¿ÚÎÂÈ· ÂÓfi˜ ¯ÚfiÓÔ˘ Â›Ó·È ‰˘Ó·ÙfiÓ Ó· ÂÌÊ·Ó›ÛÔ˘Ó 8-10 ÏÔÈÌÒÍÂȘ ÙÔ˘ ·ÓÒÙÂÚÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Î·È 1-2 ÙÔ˘ Á·ÛÙÚÂÓÙÂÚÈÎÔ‡. øÛÙfiÛÔ, ··ÈÙÂ›Ù·È Ë ¿ÚÔ‰Ô˜ ÔÏÏÒÓ ÂÙÒÓ ÁÈ· Ó· ‰ËÌÈÔ˘ÚÁ‹ÛÂÈ ÈηÓÔÔÈËÙÈ΋ ·ÓÔÛȷ΋ ÌÓ‹ÌË Î·È Ó· ÌÂȈı› Ë Û˘¯ÓfiÙËÙ· ÙˆÓ ÏÔÈÌÒ͈Ó. √ ·ÚÈıÌfi˜ ÙˆÓ ÏÔÈÌÒÍÂˆÓ ÌÂÈÒÓÂÙ·È ÌÂÙ¿ Ù· ÙÚ›· ÚÒÙ· ¯ÚfiÓÈ· ˙ˆ‹˜, ÂÊfiÛÔÓ ÙÔ ·È‰› ‰ÂÓ ·Ú·ÎÔÏÔ˘ı› ·È‰ÈÎfi ÛÙ·ıÌfi Î·È ‰ÂÓ ˘¿Ú¯ÂÈ ¿ÏÏÔ ·È‰› ÛÙÔ ÂÚÈ‚¿ÏÏÔÓ ÙÔ˘ Ô˘ Ó· ËÁ·›ÓÂÈ Û¯ÔÏÂ›Ô (1). ∆Ô ÂÚÒÙËÌ· Ô˘ ÚÔ·ÙÂÈ Â›Ó·È ÔÈfi˜ ·ÚÈıÌfi˜ ÏÔÈÌÒÍÂˆÓ ı· ıˆÚËı› ÛËÌ·ÓÙÈÎfi˜ Î·È Û ÔÈ¿ ·È‰È¿ ı· ˘ÔÙ¢ıԇ̠‰È·Ù·Ú·¯‹ Ù˘ ¿Ì˘Ó·˜ Î·È Û ÙÈ ÂÚÁ·ÛÙËÚÈ·Îfi ¤ÏÂÁ¯Ô ı· ÚÔ¯ˆÚ‹ÛÔ˘ÌÂ. °È· Ó· ··ÓÙ‹ÛÔ˘Ì ے ·˘Ù¿ Ù· ÂÚˆÙ‹Ì·Ù· ı· Ú¤ÂÈ Ó· ˘ÂÓı˘Ì›ÛÔ˘Ì ÙÔ˘˜ Ê˘ÛÈÔÏÔÁÈÎÔ‡˜ ·Ì˘ÓÙÈÎÔ‡˜ Ì˯·ÓÈÛÌÔ‡˜. ∆Ô ‰¤ÚÌ·, ÔÈ ‚ÏÂÓÓÔÁfiÓÔÈ Î·È Ù· ÚÔ˚fiÓÙ· Ô˘ ·˘ÙÔ› ÂÎÎÚ›ÓÔ˘Ó Â›Ó·È ÔÈ ÚÒÙÔÈ ÊÚ·ÁÌÔ› ÛÙË Ïԛ̈ÍË.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·7

7

∞ÓÔÛÔÏÔÁÈÎfi˜ ¤ÏÂÁ¯Ô˜ Û ÏÔÈÌÒÍÂȘ

∞ÓÙÈÁfiÓÔ

∞ÓÙÈÁÔÓÔ·ÚÔ˘ÛÈ·ÛÙÈÎfi ·ÙÙ·ÚÔ (APC)

AÓ·ÁÓÒÚÈÛË, ÂÂÍÂÚÁ·Û›· ·ÚÔ˘Û›·ÛË ·ÓÙÈÁfiÓÔ˘

¶Úfi‰ÚÔÌÔ ·ÈÌÔÔÈËÙÈÎfi ·ÙÙ·ÚÔ

∫‡ÙÙ·ÚÔ ¡∫ TH (T4) CD4

µ ·ÙÙ·ÚÔ

Tc (T8) CD8 Ts (T8) CD8

flÚÈÌÔ µ ∫‡ÙÙ·ÚÔ

IgM, IgD, IgG, IgA, IgE ∂ÈÎfiÓ· 2. ™¯ËÌ·ÙÈ΋ ·ÂÈÎfiÓÈÛË Ù˘ ·ÏÏËÏÂ›‰Ú·Û˘ ÙˆÓ ·ÓÙÈÁÔÓÔ·ÚÔ˘ÛÈ·ÛÙÈÎÒÓ, ∆, µ, Î·È NK ΢ÙÙ¿ÚˆÓ Ì ÎÂÓÙÚÈÎfi ÚfiÏÔ ÙÔ˘ ‚ÔËıËÙÈÎÔ‡ ∆ ΢ÙÙ¿ÚÔ˘ (CD4) ÛÙËÓ ·ÓÔÛȷ΋ ·¿ÓÙËÛË (ÙÚÔÔÔÈË̤ÓÔ ·fi Ã. ∫·Û›ÌÔ˜, °ÂÓÈ΋ ¶·È‰È·ÙÚÈ΋, 1995).

ŸÙ·Ó ÔÈ ÏÔÈÌÔÁfiÓÔÈ ·Ú¿ÁÔÓÙ˜ ˘ÂÚÈÛ¯‡ÛÔ˘Ó Î·È ÂÈÛ¤ÏıÔ˘Ó ÛÙËÓ Î˘ÎÏÔÊÔÚ›·, ÌË ÂȉÈÎÔ› Î·È ÂȉÈÎÔ› ·ÓÔÛÔÏÔÁÈÎÔ› ·Ú¿ÁÔÓÙ˜ Î·È Ì˯·ÓÈÛÌÔ› ÎÈÓËÙÔÔÈÔ‡ÓÙ·È ÁÈ· Ó· ÂÌÔ‰›ÛÔ˘Ó ÙËÓ ·Ó¿Ù˘Í‹ ÙÔ˘˜. ∞Ó Î·È Ô Î¿ı ·ÓÔÛÔÏÔÁÈÎfi˜ ·Ú¿ÁÔÓÙ·˜ ¤¯ÂÈ Í¯ˆÚÈÛÙ¤˜ ÏÂÈÙÔ˘ÚÁ›Â˜, ˘¿Ú¯ÂÈ Î·È ·ÍÈfiÏÔÁË ·ÏÏËÏÂ›‰Ú·ÛË Î·È ·ÏÏËÏÂÍ¿ÚÙËÛË ÁÈ· Ó· ÙÂÏÂÛÊÔÚ‹ÛÂÈ Ë ¿Ì˘Ó· ÙÔ˘ ÍÂÓÈÛÙ‹. °È· ÏfiÁÔ˘˜ ÌÂϤÙ˘ Î·È Î·Ù·ÓfiËÛ˘, ÙÔ ·ÓÔÛÔÔÈËÙÈÎfi Û‡ÛÙËÌ· ‰È·ÈÚÂ›Ù·È ÛÙ· “Û˘ÛÙ·ÙÈο” ÙÔ˘ (∂ÈÎfiÓ· 1), ÙÔ ÏÂÌÊÈÎfi Û‡ÛÙËÌ·, ÙÔ Ê·ÁÔ΢ÙÙ·ÚÈÎfi Î·È ÙÔ Û‡ÛÙËÌ· ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜ (2,3,4).

∆Ô ∞ÓÔÛÔÔÈËÙÈÎfi ™‡ÛÙËÌ· §ÂÌÊÔ·ÙÙ·Ú·: ∆· ÏÂÌÊÔ·ÙÙ·Ú· ‰È·ÎÚ›ÓÔÓÙ·È Û ‰‡Ô ‚·ÛÈΤ˜ ÔÌ¿‰Â˜, Ù· ∆ Î·È Ù· µ, Ì ‚¿ÛË ÙËÓ ·ÓÔÛÔÏÔÁÈ΋ ÙÔ˘˜ ÏÂÈÙÔ˘ÚÁ›· Î·È Ù· Ê·ÈÓÔÙ˘Èο ÙÔ˘˜ ¯·Ú·ÎÙËÚÈÛÙÈο. √ Ê·ÈÓfiÙ˘fi˜ ÙÔ˘˜ ÚÔÛ‰ÈÔÚ›˙ÂÙ·È Ì ‚¿ÛË ÂȉÈÎÔ‡˜ ‰Â›ÎÙ˜ (ÁÏ˘ÎÔÚˆÙ½Ó˜) Ô˘ ÂÎÊÚ¿˙Ô˘Ó ÛÙËÓ ÂÈÊ¿ÓÂÈ¿ ÙÔ˘˜ ·Ó¿ÏÔÁ· Ì ÙÔ ÛÙ¿-

‰ÈÔ ˆÚ›Ì·ÓÛ˘ Î·È ‰È·ÊÔÚÔÔ›ËÛ‹˜ ÙÔ˘˜ Î·È Ô˘ ·ÓȯÓ‡ÔÓÙ·È Ì ٷ ÌÔÓÔÎψÓÈο ·ÓÙÈÛÒÌ·Ù·. ∆· ∆ ÏÂÌÊÔ·ÙÙ·Ú· ÂÍÂÏ›ÛÛÔÓÙ·È ÛÙÔ ı‡ÌÔ Û ÒÚÈÌ· ∆ ÏÂÌÊÔ·ÙÙ·Ú·. ∞ÔÙÂÏÔ‡Ó ÙËÓ ÏÂÈÔ„ËÊ›· ÙÔ˘ ÏÂÌÊÔ΢ÙÙ·ÚÈÎÔ‡ ÏËı˘ÛÌÔ‡ ÙÔ˘ ÂÚÈÊÂÚÈÎÔ‡ ·›Ì·ÙÔ˜ Î·È Â›Ó·È ‰˘Ó·Ù‹ Ë ·ÓÔÛÔÊ·ÈÓÔÙ˘È΋ ÙÔ˘˜ ‰È¿ÎÚÈÛË ÛÙÔ˘˜ ˘ÔÏËı˘ÛÌÔ‡˜ ÙÔ˘˜. ∆Ô 70% ÙˆÓ ∆ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ Ê¤ÚÂÈ ÛÙËÓ ÂÈÊ¿ÓÂÈ¿ ÙÔ˘ ÙË CD4 ÁÏ˘ÎÔÚˆÙ›ÓË Î·È Ë ÏÂÈÔ„ËÊ›· ÙÔ˘˜ ¤¯ÂÈ ‚ÔËıËÙÈ΋/Â·ÁˆÁÈ΋ ÏÂÈÙÔ˘ÚÁ›·. ∆Ô ˘fiÏÔÈÔ 30% Â›Ó·È CD8+ ·ÙÙ·Ú· Î·È ¤¯Ô˘Ó ηٷÛÙ·ÏÙÈ΋/΢ÙÙ·ÚÔÙÔÍÈ΋ ÏÂÈÙÔ˘ÚÁ›·. √ ∆ ‚ÔËıËÙÈÎfi˜ ÏËı˘ÛÌfi˜ ÌÂÙ¿ ÙÔÓ ·ÓÙÈÁÔÓÈÎfi ÂÚÂıÈÛÌfi ·Ú¿ÁÂÈ Û˘ÁÎÂÎÚÈ̤Ó˜ ‰È·Ï˘Ù¤˜ Ô˘Û›Â˜, ÙȘ ÏÂÌÊÔΛÓ˜. ∞˘Ù¤˜ ·ÊÂÓfi˜ Â¿ÁÔ˘Ó ÙËÓ ·Ó¿Ù˘ÍË Î·È ‰È·ÊÔÚÔÔ›ËÛË ÙˆÓ µ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ ÁÈ· ·Ú·ÁˆÁ‹ ÂȉÈÎÒÓ ·ÓÙÈۈ̿وÓ, ·ÊÂÙ¤ÚÔ˘ ¢ԉÒÓÔ˘Ó ÌË ÂȉÈÎÔ‡˜ ÁÈ· ÙÔ ·ÓÙÈÁfiÓÔ Ì˯·ÓÈÛÌÔ‡˜, ÂÓÂÚÁÔÔÈÒÓÙ·˜ Ù· Ì·ÎÚÔÊ¿Á·, Ù· ÔÏ˘ÌÔÚÊÔ‡ÚËÓ· Î·È ¿ÏÏ· Ï¢ÎÔ·ÙÙ·Ú·. ∆Ô ∆ ‚ÔËıËÙÈÎfi ·ÙÙ·ÚÔ ¶·È‰È·ÙÚÈ΋ 2008;71:5-13

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·8

8

¢. X. ∫·Û›ÌÔ˜ Î·È Û˘Ó.

¶›Ó·Î·˜ 1. ™ÙÔȯ›· ·fi ÙÔ ÈÛÙÔÚÈÎfi Û ·È‰È¿ Ì Èı·Ó‹ ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ· ∞ÙÔÌÈÎfi πÛÙÔÚÈÎfi §ÔÈÌÒÍÂȘ: ‚·ÚȤ˜ (.¯. ÌËÓÈÁÁ›Ùȉ·, ÔÛÙÂÔÌ˘ÂÏ›Ùȉ·) ˘ÔÙÚÔÈ¿˙Ô˘Û˜ Ì ÔÏÏ·Ϥ˜ ÂÓÙÔ›ÛÂȘ Ì ÂÈÏÔΤ˜ Ì ·Ú·ÙÂٷ̤ÓË ‰È¿ÚÎÂÈ· Ì Ùˆ¯‹ ·ÓÙ·fiÎÚÈÛË ÛÙË ıÂÚ·›· ·ÔÛÙ‹Ì·Ù· §ÔÈÌÔÁfiÓÔÈ ·Ú¿ÁÔÓÙ˜: ¢ηÈÚÈ·ÎÔ› ∂Ì‚ÔÏÈ·ÛÌÔ›: Ì ÂÈÏÔ΋/Ïԛ̈ÍË ∞ÏÏÂÚÁ›·: Â›ÌÔÓË µÚÔÁ¯ÈÎfi ¿ÛıÌ·: ‚·Ú‡, ·ÓıÂÎÙÈÎfi ‹ ÎÔÚÙÈÎÔÂÍ·ÚÙÒÌÂÓÔ Ã∞¶, ‚ÚÔÁ¯ÔÂÎٷۛ˜ ∞˘ÙÔ¿ÓÔÛ˜ ÂΉËÏÒÛÂȘ: ΢ÙÙ·ÚÔÂӛ˜, ·ÁÁÂÈ›Ùȉ· ∫·ı˘ÛÙÂÚË̤ÓË ·fiÙˆÛË ÔÌÊ¿ÏÈÔ˘ ÏÒÚÔ˘ ∫·ı˘ÛÙ¤ÚËÛË ÛˆÌ·ÙÈ΋˜ ·Ó¿Ù˘Í˘ ¢˘ÛÌÔÚÊ›·, ÌÈÎÚÔÎÂÊ·Ï›· ÃÚfiÓÈ· ‰È¿ÚÚÔÈ· √ÈÎÔÁÂÓÂÈ·Îfi πÛÙÔÚÈÎfi ¡ÂÔÁÓÈÎfi˜/µÚÂÊÈÎfi˜ ı¿Ó·ÙÔ˜ ·ÁÓÒÛÙÔ˘ ·ÈÙÈÔÏÔÁ›·˜ °ÓˆÛÙ‹/¶Èı·Ó‹ ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ· ™˘ÁÁ¤ÓÂÈ· ÁÔÓ¤ˆÓ §ÔÈÌÒÍÂȘ ÛÙÔ ÔÈÎÔÁÂÓÂÈ·Îfi ÂÚÈ‚¿ÏÏÔÓ (HIV)

η٤¯ÂÈ ÎÂÓÙÚÈÎfi ÚfiÏÔ ÛÙËÓ Â˘fi‰ˆÛË Î·È ÔÏÔÎÏ‹ÚˆÛË Ù˘ ·ÓÔÛÔ·¿ÓÙËÛ˘. ™Â ·ÓÙ›ıÂÛË, Ô ∆ ηٷÛÙ·ÏÙÈÎfi˜ ˘ÔÏËı˘ÛÌfi˜ ¯·ÏÈÓ·ÁˆÁ› ÙËÓ ·ÓÔÛÔ·¿ÓÙËÛË. ∆ÔÓ CD4 ‰Â›ÎÙË ¤¯Ô˘Ó Î·È Ù· ∆ ÏÂÌÊÔ·ÙÙ·Ú· Ô˘ Û˘ÌÌÂÙ¤¯Ô˘Ó ÛÙȘ ÏÂÈÙÔ˘ÚÁ›Â˜ ÂÈ‚Ú·‰˘ÓfiÌÂÓ˘ ˘ÂÚ¢·ÈÛıËÛ›·˜, ÂÓÒ ÙÔÓ CD8 ¤¯Ô˘Ó Ù· ∆ ·ÙÙ·Ú· Ô˘ ÌÂÙ¤¯Ô˘Ó ÛÙËÓ ·fiÚÚÈ„Ë ÌÔۯ‡̷ÙÔ˜, ÙËÓ “ÂÈÙ‹ÚËÛË” ÙˆÓ Î·ÚÎÈÓÈÎÒÓ Î˘ÙÙ¿ÚˆÓ Î·È ÙËÓ Î·Ù·ÛÙÚÔÊ‹ ÙˆÓ ÌÔÏ˘ÛÌ¤ÓˆÓ ·fi ÙÔ˘˜ ÈÔ‡˜ ΢ÙÙ¿ÚˆÓ (5,6). ∆· µ ÏÂÌÊÔ·ÙÙ·Ú· Â›Ó·È Ô ¿ÏÏÔ˜ ÌÂÁ¿ÏÔ˜ ÏÂÌÊÔ¶›Ó·Î·˜ 2. ∫ÏÈÓÈο ÛËÌ›· ·È‰ÈÒÓ Ì Èı·Ó‹ ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ· ¢˘ÛÙÚÔÊ›· ¢˘ÛÌÔÚÊ›· ÕÎÚ·: ÏËÎÙÚÔ‰·ÎÙ˘Ï›·, ˆ¯ÚfiÙ˘ ™ÙÔÌ·ÙÔÊ¿Ú˘ÁÁ·˜: Ô˘Ï›ÙȘ, Â›ÌÔÓË Ô˘ÏÔÛÙÔÌ·Ù›Ùȉ·, ÂÚÈÔ‰ÔÓÙ›Ùȉ·, ηı˘ÛÙÂÚË̤ÓË ·fiÙˆÛË ÓÂÔÁÈÏÒÓ Ô‰fiÓÙˆÓ ∫·Ú‰È·ÁÁÂÈ·Îfi: Û˘ÁÁÂÓ‹˜ ηډÈÔ¿ıÂÈ· ∞Ó·Ó¢ÛÙÈÎfi: ¯ÚfiÓÈ· Ó¢ÌÔÓÔ¿ıÂÈ·, ‚ÚÔÁ¯ÂÎٷۛ˜, ÓÂ˘Ì·ÙÔ΋Ϙ °·ÛÙÚÂÓÙÂÚÈÎfi: Ë·ÙÔÛÏËÓÔÌÂÁ·Ï›· §ÂÌÊÈÎfi˜ ÈÛÙfi˜ (·Ì˘Á‰·Ï¤˜, ÏÂÌÊ·‰¤Ó˜, ı‡ÌÔ˜): ·Ô˘Û›· ‹ ÏÂÌÊ·‰ÂÓÔ¿ıÂÈ·, ı‡ÌˆÌ· ¢¤ÚÌ·-ÙÚ›¯Â˜: ¤Î˙ÂÌ·, ÂÙ¤¯ÂȘ, Ô˘Ï¤˜, ÎÔÎÎÈÒÌ·Ù·, ·ÁÁÂÈÔÔ›‰ËÌ·, ·ÏÊÈÛÌfi˜, ·ÏˆÂΛ· √Êı·ÏÌÔ›: ·ÓˆÌ·Ï›Â˜ ·ÌÊÈ‚ÏËÛÙÚÔÂȉԇ˜, ÙËÏ·ÁÁÂÈÂÎٷۛ˜ ¡Â˘ÚÈÎfi Û‡ÛÙËÌ·: ·Ù·Í›·

Paediatriki 2008;71:5-13

΢ÙÙ·ÚÈÎfi˜ ÏËı˘ÛÌfi˜, Ô ÔÔ›Ô˜ ‰È·ÊÔÚÔÔÈÂ›Ù·È Î·È ˆÚÈÌ¿˙ÂÈ ÛÙÔ ÂÚÈ‚¿ÏÏÔÓ ÙÔ˘ Ì˘ÂÏÔ‡ ÙˆÓ ÔÛÙÒÓ. ∆· ÂÚÈÛÛfiÙÂÚ· ·fi ·˘Ù¿, ÌÂÙ¿ ·fi οÔÈÔ ·ÓÙÈÁÔÓÈÎfi ÂÚÂıÈÛÌfi, ÂÍÂÏ›ÛÛÔÓÙ·È Û Ï·ÛÌ·ÙÔ·ÙÙ·Ú·, Ù· ÔÔ›· Û˘Óı¤ÙÔ˘Ó Î·È ÂÎÎÚ›ÓÔ˘Ó ·ÓÔÛÔÛÊ·ÈÚ›Ó˜. ∫¿ı ¿ÙÔÌÔ ¤¯ÂÈ ÙËÓ ÈηÓfiÙËÙ· Ó· ·Ú¿ÁÂÈ ÂηÙÔÌ̇ÚÈ· µ ΢ÙÙ·ÚÈÎÒÓ ÎÏÒÓˆÓ, ηı¤Ó·˜ ·fi ÙÔ˘˜ ÔÔ›Ô˘˜ Û˘Óı¤ÙÂÈ ¤Ó· ÂȉÈÎfi ·Óٛۈ̷. ªÂ ·˘Ùfi ÙÔÓ ÙÚfiÔ, ÙÔ ¿ÙÔÌÔ Â›Ó·È ¤ÙÔÈÌÔ Ó· ·ÓÙÈÌÂÙˆ›ÛÂÈ ÙËÓ ÔÈÎÈÏ›· ÙˆÓ ·ÓÙÈÁÔÓÈÎÒÓ ÂÚÂıÈÛÌ¿ÙˆÓ Ô˘ ı· Û˘Ó·ÓÙ‹ÛÂÈ ÛÙË ‰È¿ÚÎÂÈ· Ù˘ ˙ˆ‹˜ ÙÔ˘. ªÂÚÈο ·fi Ù· ÂÓÂÚÁÔÔÈË̤ӷ µ ·ÙÙ·Ú· ‰ÂÓ ‰È·ÊÔÚÔÔÈÔ‡ÓÙ·È Û Ï·ÛÌ·ÙÔ·ÙÙ·Ú·, ·ÏÏ¿ ·Ú·Ì¤ÓÔ˘Ó ÁÈ· Ì·ÎÚfi ¯ÚÔÓÈÎfi ‰È¿ÛÙËÌ· ˆ˜ ÌÓËÌÔÓÈο ·ÙÙ·Ú·. ∂›Ó·È ·˘Ù¿ Ô˘ ı· ‰ÒÛÔ˘Ó ÙË ÁÚ‹ÁÔÚË ·ÓÙÈۈ̷ÙÈ΋ ·¿ÓÙËÛË Û ÂÚ›ÙˆÛË ·Ó·ÌfiÏ˘ÓÛ˘. Ÿˆ˜ Ù· ∆, ¤ÙÛÈ Î·È Ù· µ ·ÙÙ·Ú· ¤¯Ô˘Ó ÂÈÊ·ÓÂÈ·ÎÔ‡˜ ‰Â›ÎÙ˜, ‚¿ÛÂÈ ÙˆÓ ÔÔ›ˆÓ Ù·˘ÙÔÔÈÔ‡ÓÙ·È. √È ÏÂÌÊÔ΢ÙÙ·ÚÈΤ˜ ÏÂÈÙÔ˘ÚÁ›Â˜ ‰È·ÎÚ›ÓÔÓÙ·È ·‰Ú¿ Û ÂΛӘ ÙˆÓ ∆ ΢ÙÙ¿ÚˆÓ (΢ÙÙ·ÚÈΤ˜) Î·È Û ÂΛӘ ÙˆÓ µ (·ÓÙÈۈ̷ÙÈΤ˜), ·ÚfiÏÔ Ô˘ ˘¿Ú¯ÂÈ Î·È ÌÂÁ¿ÏË ·ÏÏËÏÂ›‰Ú·ÛË ÌÂٷ͇ ÙˆÓ ‰‡Ô ·˘ÙÒÓ Î˘ÙÙ·ÚÈÎÒÓ ÏËı˘ÛÌÒÓ (∂ÈÎfiÓ· 2). ™ÙËÓ ÎÏÈÓÈ΋ Ú¿ÍË ·˘Ù‹ Ë ÂÈÎ¿Ï˘„Ë Î·È ·ÏÏËÏÂ›‰Ú·ÛË ‰ÂÓ Ú¤ÂÈ Ó· ˘ÔÙÈÌ¿Ù·È. ∂ÓÙÔ‡ÙÔȘ, ˆ˜ ÁÂÓÈÎfi ηÓfiÓ· ÌÔÚԇ̠ӷ ıˆڋÛÔ˘Ì fiÙÈ Ù· ∆ ·ÙÙ·Ú· Â›Ó·È ÈÔ ÛËÌ·ÓÙÈο ÛÙËÓ ¿Ì˘Ó· ¤Ó·ÓÙÈ ÙˆÓ ÈÒÓ, ÙˆÓ Ì˘Î‹ÙˆÓ, ÙˆÓ ·Ú·Û›ÙˆÓ, fiˆ˜ Î·È ¤Ó·ÓÙÈ ÙˆÓ fiÁÎˆÓ Î·È ÙˆÓ Í¤ÓˆÓ ÈÛÙÈÎÒÓ ÌÔÛ¯Â˘Ì¿ÙˆÓ, ÂÓÒ Ù· µ ·ÙÙ·Ú· ¤¯Ô˘Ó ηıÔÚÈÛÙÈÎfi ÚfiÏÔ ÛÙËÓ ¿Ì˘Ó· ηٿ ÙˆÓ ‚·ÎÙËÚȉ›ˆÓ. ∆¤ÏÔ˜, ÌÈ· ÙÚ›ÙË ÔÌ¿‰· ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ Â›Ó·È Ù· Ê˘ÛÈο ΢ÙÙ·ÚÔÎÙfiÓ· (NK) ·ÙÙ·Ú·. ∆· Ê˘ÛÈο ΢ÙÙ·ÚÔÎÙfiÓ· ÚÔ¤Ú¯ÔÓÙ·È ·fi Úfi‰ÚÔÌ· ·ÙÙ·Ú· ÙÔ˘ Ì˘ÂÏÔ‡ ÙˆÓ ÔÛÙÒÓ, Ù· ÂÚÈÛÛfiÙÂÚ· ÙˆÓ ÔÔ›ˆÓ ÌÂÙ·Ó·ÛÙÂ‡Ô˘Ó ÛÙÔÓ ÛÏ‹Ó· ‹ ΢ÎÏÔÊÔÚÔ‡Ó ÛÙÔ ÂÚÈÊÂÚÈÎfi ·›Ì· Î·È ·ÔÙÂÏÔ‡Ó ¤Ó· ÌÈÎÚfi ÔÛÔÛÙfi ÙˆÓ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ (ÂÚ›Ô˘ 10%). ∆· ¡∫ ÏÂÌÊÔ·ÙÙ·Ú· ‰ÂÓ ¤¯Ô˘Ó ÂȉÈÎÔ‡˜ ˘ԉԯ›˜ Î·È ÛÙÂÚÔ‡ÓÙ·È ·ÓÔÛÔÏÔÁÈ΋˜ ÂȉÈÎfiÙËÙ·˜ Î·È ÌÓ‹Ì˘. ∆· NK ·ÙÙ·Ú· Ï‡Ô˘Ó Ù· ÌÔÏ˘Ṳ̂ӷ Ì ÈÔ‡˜ Î·È Î·ÚÎÈÓÈο ·ÙÙ·Ú·. ¢ÂÓ ··ÈÙÂ›Ù·È ÚÔËÁÔ‡ÌÂÓË Â˘·ÈÛıËÙÔÔ›ËÛ‹ ÙÔ˘˜ Î·È ‰ÂÓ ÂÚÈÔÚ›˙ÔÓÙ·È ·fi Ù· ·ÓÙÈÁfiÓ· ÙÔ˘ MHC, ¤ÙÛÈ Ë ÎÈÓËÙÔÔ›ËÛË Î·È Ë ‰Ú¿ÛË ÙÔ˘˜ Â›Ó·È ¿ÌÂÛË. ∆Ô Ê·ÁÔ΢ÙÙ·ÚÈÎfi Û‡ÛÙËÌ·: ∆Ô Ê·ÁÔ΢ÙÙ·ÚÈÎfi ÛΤÏÔ˜ ÙÔ˘ ·ÓÔÛÔÏÔÁÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ ÂÚÈÏ·Ì‚¿ÓÂÈ ÔÈÎÈÏ›· ΢ÙÙ¿ÚˆÓ, Ô˘ ¤¯Ô˘Ó ÙËÓ ÈηÓfiÙËÙ· Ù˘ ÚfiÛÏ˄˘ Î·È Î·Ù·ÛÙÚÔÊ‹˜ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÒÓ. ∆¤ÙÔÈ· ·ÙÙ·Ú· Â›Ó·È Ù· ÔÏ˘ÌÔÚÊÔ‡ÚËÓ·, Ù· ˈÛÈÓfiÊÈÏ· Î·È Ù· ÌÔÓÔ·ÙÙ·Ú·, Ù· ÔÔ›·, ˘fi ÙËÓ Â›‰Ú·ÛË ¯ËÌÂÈÔÙ·ÎÙÈÎÒÓ ·Ú·ÁfiÓÙˆÓ, ÌÂÙ·Ó·ÛÙÂ‡Ô˘Ó ÛÙÔ˘˜ ÈÛÙÔ‡˜. ∂Λ Ù· ÌÔÓÔ·ÙÙ·Ú· ÂÍÂÏ›ÛÛÔÓÙ·È ÛÂ

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·9

9

∞ÓÔÛÔÏÔÁÈÎfi˜ ¤ÏÂÁ¯Ô˜ Û ÏÔÈÌÒÍÂȘ

¶›Ó·Î·˜ 3. ™˘Ó‹ıË ·ıÔÁfiÓ· ˘‡ı˘Ó· ÁÈ· ÏÔÈÌÒÍÂȘ ·Ó¿ÏÔÁ· Ì ÙÔ ·ÓÔÛÈ·Îfi ¤ÏÏÂÈÌÌ· ∞ÓÔÛÈ·Îfi ŒÏÏÂÈÌÌ· ∞ÓÙÈۈ̷ÙÈ΋ ·ÓÂ¿ÚÎÂÈ·

™˘Ó‹ıË ¶·ıÔÁfiÓ· µ·ÎÙËÚ›‰È·:

¯Ú˘Û›˙ˆÓ ÛÙ·Ê˘ÏfiÎÔÎÎÔ˜, ·ÈÌfiÊÈÏÔ˜ ÈÓÊÏÔ˘¤ÓÙÛ· Ù‡Ô˘ b, ÛÙÚÂÙfiÎÔÎÎÔ˜ ÔÏÈÔÌ˘ÂÏ›Ùȉ·˜, echo

∂ÓÙÂÚÔÈÔ›: ∞ÓÂ¿ÚÎÂÈ· ∆ ΢ÙÙ¿ÚˆÓ

ªÈÎÙ‹ ·ÓÂ¿ÚÎÂÈ· ∆ & µ ΢ÙÙ¿ÚˆÓ (¯˘ÌÈ΋ & ΢ÙÙ·ÚÈ΋)

∂Ó‰Ô΢ÙÙ·ÚÈο ‚·ÎÙËÚ›‰È·:

Ì˘ÎÔ‚·ÎÙËÚ›‰È·, ÏÈÛÙ¤ÚÈ·

πÔ› ª‡ÎËÙ˜:

Candida, ·Û¤ÚÁÈÏÏÔ˜

µ·ÎÙËÚ›‰È· ª‡ÎËÙ˜ πÔ›: ¶·Ú¿ÛÈÙ·: ¶ÚˆÙfi˙ˆ·:

CMV, ¤Ú˘, ÈÏ·Ú¿˜ ÎÚ˘ÙfiÎÔÎÎÔ˜, ÎÚ˘ÙÔÛÔÚ›‰ÈÔ pneumocystis carinii

∞ÓÂ¿ÚÎÂȘ Ê·ÁÔ΢ÙÙ¿ÚˆÓ

µ·ÎÙËÚ›‰È·: ª‡ÎËÙ˜: ÕÙ˘· Ì˘ÎÔ‚·ÎÙËÚ›‰È·

∞ÓÂ¿ÚÎÂȘ Ê˘ÛÈ΋˜ ·ÓÔÛ›·˜

µ·ÎÙËÚ›‰È· (˘ÔÁfiÓ·) ª˘ÎÔ‚·ÎÙËÚ›‰È· πfi˜ ·ÓıÚˆ›ÓˆÓ ıËÏˆÌ¿ÙˆÓ (HPV)

∞ÓÂ¿ÚÎÂȘ ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜

µ·ÎÙËÚ›‰È·:

Ì·ÎÚÔÊ¿Á· ÁÓˆÛÙ¿ Î·È ˆ˜ ÈÛÙÈÔ·ÙÙ·Ú·. ∞ÚÎÂÙ¿ fiÚÁ·Ó· ¤¯Ô˘Ó ·Ó·Ù‡ÍÂÈ ÂȉÈÎÔ‡˜ ˘ÔÏËı˘ÛÌÔ‡˜ Ì·ÎÚÔÊ¿ÁˆÓ. ∆· ·ÙÙ·Ú· ÙÔ˘ Kupffer ÛÙÔ ‹·Ú, ÙÔ˘ Langerhans ÛÙÔ ‰¤ÚÌ·, Ù˘ ÌÈÎÚÔÁÏÔ›·˜ ÛÙÔÓ ÂÁΤʷÏÔ Î·È Ù· ÌÂÛ·ÁÁÂȷο ·ÙÙ·Ú· ÙˆÓ ÓÂÊÚÒÓ. ∆Ô ·Ú¯ÈÎfi ÁÂÁÔÓfi˜ Ù˘ Ê·ÁÔ΢ÙÙ¿ÚˆÛ˘ Â›Ó·È Ë ¯ËÌÂÈÔÙ·Í›·, ÏÂÈÙÔ˘ÚÁ›· Ì ÙËÓ ÔÔ›· ÚÔÛÂÏ·ÔÓÙ·È Ù· Ô˘‰ÂÙÂÚfiÊÈÏ· ÛÙÔÓ ÙfiÔ Ù˘ ÊÏÂÁÌÔÓ‹˜. ∞˘Ùfi ÂÈÙ˘Á¯¿ÓÂÙ·È Ì ‰È¿ÊÔÚÔ˘˜ ¯ËÌÂÈÔÙ·ÎÙÈÎÔ‡˜ ·Ú¿ÁÔÓÙ˜, Ì ΢ÚÈfiÙÂÚÔ ÙÔ ÎÏ¿ÛÌ· C5· ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜. ∆· Ê·ÁÔ·ٷڷ ·Ó·ÁÓˆÚ›˙Ô˘Ó Î·È ÚÔÛÎÔÏÏÒÓÙ·È Û ÔÏÏÔ‡˜ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ‡˜. ªÂ ÙËÓ Ô„ˆÓÈÓÔÔ›ËÛË ÙˆÓ ·ÓÙÈÁfiÓˆÓ, ÙË Û‡Ó‰ÂÛË ‰ËÏ·‰‹ ÙÔ˘ ·ÓÙÈÁfiÓÔ˘ Ì ٷ ‹‰Ë Û¯ËÌ·ÙÈṲ̂ӷ ·ÓÙÈÛÒÌ·Ù· ‹/Î·È ÙÔ C3, Î·È Ì¤Ûˆ ·˘ÙÒÓ Î·È ÙˆÓ ˘Ô‰Ô¯¤ˆÓ ÙÔ˘˜ Ì ÙÔ Ê·ÁÔ·ÙÙ·ÚÔ, Â·˘Í¿ÓÂÙ·È Ë ·Ó·ÁÓÒÚÈÛË Î·È Ë ÚÔÛÎfiÏÏËÛË ÙˆÓ Ê·ÁÔ΢ÙÙ¿ÚˆÓ ÛÙÔ˘˜ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ‡˜, ÒÛÙ ӷ Ê·ÁÔ΢ÙÙ·ÚˆıÔ‡Ó Î·È Ó· Á›ÓÂÈ Ë ‚·ÎÙËÚÈÔÎÙÔÓ›·. ªÂ ·˘Ùfi ÙÔÓ ÙÚfiÔ, ÙÔ Ê·ÁÔ΢ÙÙ·ÚÈÎfi Û‡ÛÙËÌ· ·›˙ÂÈ ÛËÌ·ÓÙÈÎfi ÚfiÏÔ ÛÙËÓ ¿Ì˘Ó·, ȉȷÈÙ¤Úˆ˜ ηٿ ‚·ÎÙËÚȉȷÎÒÓ ÏÔÈÌÒÍÂˆÓ (7,8). ∆Ô Û‡ÛÙËÌ· ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜: ∆Ô Û‡ÛÙËÌ· ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜ Û˘ÌÌÂÙ¤¯ÂÈ Î·È ÂÓÈÛ¯‡ÂÈ ÙËÓ ÔÈÎÈÏ›· ÂȉÈÎÒÓ Î·È ÌË ÂȉÈÎÒÓ ·Ì˘ÓÙÈÎÒÓ ÏÂÈÙÔ˘ÚÁÈÒÓ, fiˆ˜ Ë ¯ËÌÂÈÔÙ·Í›· Î·È Ë Ô„ˆÓÈÓÔÔ›ËÛË. ∞ÔÙÂÏÂ›Ù·È ·fi ÂÚÈÛÛfiÙÂÚ˜ ·fi 20 ÚˆÙ½Ó˜, Ô˘ ÌÂÙ¿ ·fi ÂÓÂÚÁÔÔ›ËÛË, ·ÏÏËÏÂȉÚÔ‡Ó Ì ηıÔÚÈṲ̂ÓË ÛÂÈÚ¿ ÁÈ· Ó· ·Ú¿ÁÔ˘Ó ÂÓÂÚÁ¿ ÚÔ˚fiÓÙ·. ∆·

ÛÙ·Ê˘ÏfiÎÔÎÎÔ˜ ¯Ú˘Û›˙ˆÓ, Gram (-) ·Û¤ÚÁÈÏÏÔ˜

Ó·˚ÛÛ¤ÚÈ· ÌËÓÈÁÁ›Ùȉ·˜

ÎÏ¿ÛÌ·Ù· ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜ ÂÓÂÚÁÔÔÈÔ‡Ó Ù· Ô˘‰ÂÙÂÚfiÊÈÏ· Î·È Ù· Ì·ÎÚÔÊ¿Á·, Ù· ÔÔ›· Ï‡Ô˘Ó ·¢ı›·˜ Ù· ‚·ÎÙËÚ›‰È· Î·È Ù· ·ÙÙ·Ú· ÛÙfi¯Ô˘˜ Î·È ·˘Í¿ÓÔ˘Ó ÙË ‰È·‚·ÙfiÙËÙ· ÙˆÓ ·ÁÁ›ˆÓ. ∏ ÂÓÂÚÁÔÔ›ËÛË Î·È ÙˆÓ ‰‡Ô Ô‰ÒÓ ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜, Ù˘ ÎÏ·ÛÈ΋˜ Î·È Ù˘ ÂÓ·ÏÏ·ÎÙÈ΋˜, Ô‰ËÁ› ÙÂÏÈο ÛÙË ‰Ú·ÛÙËÚÈÔÔ›ËÛË ÙÔ˘ C3 Î·È ÙËÓ ·Ú·ÁˆÁ‹ ÙˆÓ ›‰ÈˆÓ ÂÓÂÚÁÒÓ ‚ÈÔÏÔÁÈÎÒÓ ÎÏ·ÛÌ¿ÙˆÓ. ™ÙÔÓ ¿ÓıÚˆÔ, ÔÈ ·ÓÂ¿ÚÎÂȘ ÙˆÓ ÎÏ·ÛÌ¿ÙˆÓ ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜ Û˘Ó‰¤ÔÓÙ·È Ì ¯·Ú·ÎÙËÚÈÛÙÈο ÎÏÈÓÈο Û‡Ó‰ÚÔÌ·. ∞ÛıÂÓ›˜ Ì ·ÓÂ¿ÚÎÂÈ· ÙÔ˘ C1, C4 ‹ C2 Û˘Ó‹ıˆ˜ ·ÚÔ˘ÛÈ¿˙Ô˘Ó ÎÏÈÓÈ΋ ÂÈÎfiÓ· Û˘Ó‰ÚfiÌÔ˘ Ô˘ ÌÔÈ¿˙ÂÈ Ì ÂÚ˘ıËÌ·ÙÒ‰Ë Ï‡ÎÔ (ÂÍ¿ÓıËÌ· ·ÚÂÈÒÓ, ·ÚıÚ·ÏÁ›·, ÛÂÈÚ·Ì·ÙÔÓÂÊÚ›Ùȉ·, ˘ÚÂÙfi ‹ ¯ÚfiÓÈ· ·ÁÁÂÈ›Ùȉ·) Î·È Û·Ó›ˆ˜ Ì ˘ÔÙÚÔÈ¿˙Ô˘Û˜ ˘ÔÁÂÓ›˜ ÏÔÈÌÒÍÂȘ. ∞ÛıÂÓ›˜ Ì ·ÓÂ¿ÚÎÂÈ· ÙÔ˘ C3 ˘ÔʤÚÔ˘Ó ·fi ‚·ÚȤ˜, ˘ÔÙÚÔÈ¿˙Ô˘Û˜, ˘ÔÁfiÓÔ˘˜ ÏÔÈÌÒÍÂȘ, ÂÓÒ ·Ú·ÙËÚÂ›Ù·È ÂÓÙ˘ˆÛȷ΋ Û˘Û¯¤ÙÈÛË ÙˆÓ ·ÓÂ·ÚÎÂÈÒÓ ÙˆÓ ÎÏ·ÛÌ¿ÙˆÓ ÙÔ˘ ÙÂÏÈÎÔ‡ ÛΤÏÔ˘˜ (C5, C6, C7, C8) Ì ˘ÔÙÚÔÈ¿˙Ô˘Û˜ ÏÔÈÌÒÍÂȘ ·fi Ó·˚ÛÛ¤ÚȘ (ÁÔÓfiÎÎÔÎÔ, ÌËÓÈÁÁÈÙȉfiÎÔÎÎÔ) (3,8,9).

∞ÓÔÛÔ·ÓÂ¿ÚÎÂȘ Î·È ÏÔÈÌÒÍÂȘ √ˆ˜ ‹‰Ë ·Ó·Ê¤ÚıËÎÂ, fiÏ· Ù· ·È‰È¿ ¤¯Ô˘Ó ÙËÓ ÂÌÂÈÚ›· ÙˆÓ ÏÔÈÌÒ͈Ó. ∆Ô ¯·Ú·ÎÙËÚÈÛÙÈÎfi Ô˘ ı· ·ÔÙÂϤÛÂÈ ÎÚÈÙ‹ÚÈÔ ÂÍÂȉÈÎÂ˘Ì¤ÓÔ˘ ÂϤÁ¯Ô˘ ÁÈ· ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ· Â›Ó·È Ë ·˘ÍË̤ÓË Â˘·ÈÛıËÛ›· ÛÙȘ ÏÔÈÌÒÍÂȘ. ∞˘Ùfi ÌÔÚ› Ó· ÛËÌ·›ÓÂÈ ·˘ÍË̤ÓË ¶·È‰È·ÙÚÈ΋ 2008;71:5-13

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·10

10

¢. X. ∫·Û›ÌÔ˜ Î·È Û˘Ó.

¶›Ó·Î·˜ 4. ¢ÈÂÚ‡ÓËÛË ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ·˜ Û ·È‰È¿ ÌÂ Û˘¯Ó¤˜ ÏÔÈÌÒÍÂȘ ∞Ú¯ÈÎfi˜ ∂ÚÁ·ÛÙËÚÈ·Îfi˜ ŒÏÂÁ¯Ô˜ °ÂÓÈ΋ ·›Ì·ÙÔ˜ ∞ÓÔÛÔÛÊ·ÈÚ›Ó˜ ÔÚÔ‡: IgG, IgA, IgM, IgE πÛÔ·ÈÌÔÛ˘ÁÎÔÏÏËÙ›Ó˜ ™˘Ìϋڈ̷ C3, C4 ∂ȉÈÎfi˜ ∂ÚÁ·ÛÙËÚÈ·Îfi˜ ŒÏÂÁ¯Ô˜ ÀÔÙ¿ÍÂȘ ·ÓÔÛÔÛÊ·ÈÚÈÓÒÓ ŒÏÂÁ¯Ô˜ Û˘ÌÏËÚÒÌ·ÙÔ˜ ŒÏÂÁ¯Ô˜ Ê·ÁÔ΢ÙÙ¿Úˆv ÀÔÏËı˘ÛÌÔ› ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ ŒÏÂÁ¯Ô˜ ÁÈ· HIV

ÛÂ Û˘¯Ó¤˜ ‚·ÎÙËÚȉȷΤ˜ ÏÔÈÌÒÍÂȘ Û ‚·ÚȤ˜ ‚·ÎÙËÚȉȷΤ˜ ÏÔÈÌÒÍÂȘ, fiˆ˜ ·fi Ó·˚ÛÛ¤ÚÈ· ÌËÓÈÁÁ›Ùȉ·˜ Û ÏÔÈÌÒÍÂȘ ·fi ¯Ú˘Û›˙ÔÓÙ· ÛÙ·Ê˘ÏfiÎÔÎÎÔ, Gram (-) ‚·ÎÙËÚ›‰È·, ̇ÎËÙ˜ Û ‚·ÚȤ˜ ÈÔÁÂÓ›˜ ‹ ¢ηÈÚȷΤ˜ ÏÔÈÌÒÍÂȘ Û ¢ηÈÚȷΤ˜ ÏÔÈÌÒÍÂȘ, TBC, ‚·ÚȤ˜ ÏÔÈÌÒÍÂȘ

∂ÍÂȉÈÎÂ˘Ì¤ÓÔ˜ ŒÏÂÁ¯Ô˜ (‚Ϥ ¶›Ó·Î· 5)

Û˘¯ÓfiÙËÙ· (ÂÚÈÛÛfiÙÂÚ˜ ·fi 8-10 ·Ó¿ ¤ÙÔ˜), ·˘ÍË̤ÓË ÛÔ‚·ÚfiÙËÙ· ηÈ/‹ ·Ú·ÙÂٷ̤ÓË ‰È¿ÚÎÂÈ· ÙˆÓ ÏÔÈÌÒ͈Ó, ‚·ÚȤ˜ ÂÈÏÔΤ˜, ÏÔÈÌÒÍÂȘ ·fi ·Û˘Ó‹ıÂȘ ‹ ¢ηÈÚÈ·ÎÔ‡˜ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ‡˜ (¯ˆÚ›˜ Ï‹ÚË ·ÔηٿÛÙ·ÛË), Ì ·˘ÍË̤ÓË ÂÍ¿ÚÙËÛË ·fi Ù· ·ÓÙÈ‚ÈÔÙÈο Î·È Ù¤ÏÔ˜ Ì Ùˆ¯‹ ·ÓÙ·fiÎÚÈÛË ÛÙË ıÂÚ·¢ÙÈ΋ ·ÁˆÁ‹ (10). ÀÔ„›· ·ıÔÏÔÁÈÎÔ‡ ·ÓÔÛÔÏÔÁÈÎÔ‡ ˘ÔÛÙÚÒÌ·ÙÔ˜ Ù›ıÂÙ·È Â›Û˘ ÛÂ: ÔÚÈṲ̂Ó˜ ‰ÂÚÌ·ÙÈΤ˜ ÂΉËÏÒÛÂȘ (ÂÙ¤¯ÂȘ, ‚·Ú‡ ¤Î˙ÂÌ·, ηÓÙÈÓÙ›·ÛË), ¯ÚfiÓÈ· ‰È¿ÚÚÔÈ·, ÌÂȈ̤ÓË ·Ó¿Ù˘ÍË, ‡·ÚÍË Ë·ÙÔÛÏËÓÔÌÂÁ·Ï›·˜, ˘ÔÙÚÔÈ¿˙ÔÓÙ· ·ÔÛÙ‹Ì·Ù·, ˘ÔÙÚÔÈ¿˙Ô˘Û· ÔÛÙÂÔÌ˘ÂÏ›Ùȉ· Î·È ‚·ÚÈ¿ ·ÏÏÂÚÁÈο ‹ ·˘ÙÔ¿ÓÔÛ· ÓÔÛ‹Ì·Ù·. ∞ÎfiÌË, ¤ÏÂÁ¯Ô˜ ··ÈÙÂ›Ù·È ÛÂ Û˘ÁÎÂÎÚÈ̤Ó˜ ÎÏÈÓÈΤ˜ ÂΉËÏÒÛÂȘ (·Ù·Í›·, ÙËÏ·ÁÁÂÈÂÎÙ·Û›·, ıÚÔÌ‚ÔÂÓ›·, ¤Î˙ÂÌ·, ÙÂÙ·Ó›·), ÔÈ Ôԛ˜ Î·È Û˘Ó‰¤ÔÓÙ·È ÌÂ Û˘ÁÎÂÎÚÈ̤ӷ Û‡Ó‰ÚÔÌ·. ¶·Ú¿ÏÏËÏ· Ì ÙÔ ÂÓ‰Âϯ¤˜ ÈÛÙÔÚÈÎfi, Î·È Ë ÚÔÛÂÎÙÈ΋ Ê˘ÛÈ΋ ÂͤٷÛË ‚ÔËı¿ÂÈ ÛÙËÓ ÂÎÙ›ÌËÛË ÙÔ˘ ÚÔ‚Ï‹Ì·ÙÔ˜. ªÂÁ¿ÏË ÛËÌ·Û›· ÛÙËÓ ·ÍÈÔÏfiÁËÛË ÙÔ˘ ·ÚÚÒÛÙÔ˘ ¤¯ÂÈ Ë Ù˘¯fiÓ ÛÔ‚·Ú‹ ·ÓÙ›‰Ú·ÛË ÛÙ· ÂÌ‚fiÏÈ·, ȉ›ˆ˜ Ì ˙ÒÓÙ˜ ÈÔ‡˜, Ë ‡·ÚÍË ı·Ó¿ÙÔ˘ Û ÓËȷ΋ ËÏÈΛ· ÛÙËÓ ÔÈÎÔÁ¤ÓÂÈ· ‹ Ë ‡·ÚÍË Û˘ÁÁÂÓÒÓ Ì ·˘ÙÔ¿ÓÔÛ· ÓÔÛ‹Ì·Ù·, ·ÏÏÂÚÁ›Â˜ ‹ ηÎÔ‹ıÂȘ ÙÔ˘ ÏÂÌÊÈÎÔ‡ ÈÛÙÔ‡ (¶›Ó·Î˜ 1 Î·È 2). ¡ÔÛÔÏÔÁÈ΋ ÔÓÙfiÙËÙ· - ™˘¯ÓfiÙËÙ·: √È ·ÓÔÛÔ·ÓÂ¿ÚÎÂȘ ‰È·ÎÚ›ÓÔÓÙ·È ·ÊÂÓfi˜ Û ÚˆÙÔ·ı›˜ ‹ ‰Â˘ÙÂÚÔ·ı›˜, ·ÊÂÙ¤ÚÔ˘ Û ·˘Ù¤˜ Ô˘ ÂÌϤÎÔÓÙ·È Ì˯·ÓÈÛÌÔ› Ù˘ ÂȉÈ΋˜ (¯˘ÌÈ΋˜, ΢ÙÙ·ÚÈ΋˜) ‹ ÌË ÂȉÈ΋˜ (.¯. Ê·ÁÔ·ÙÙ·Ú·, Û˘Ìϋڈ̷) ·ÓÔÛ›·˜. ™ÙËÓ ·È‰È΋ ËÏÈΛ· ΢ÚÈ·Ú¯Ô‡Ó ÔÈ ÚˆÙÔ·ı›˜ ·ÓÔÛÔ·ÓÂ¿ÚÎÂȘ (¶∞∞), ÂÓÒ ÛÙËÓ ÂÓ‹ÏÈÎË ˙ˆ‹ ÔÈ ‰Â˘ÙÂÚÔ·ı›˜ (11). √È ¶∞∞ Â›Ó·È Û¿ÓÈ· ÓÔÛ‹Ì·Ù·. ∏ Û˘¯ÓfiÙËÙ¿ ÙÔ˘˜ Â›Ó·È 1:10.000 ¿ÙÔÌ· ÛÙÔÓ ÁÂÓÈÎfi ÏËı˘ÛÌfi, ·Ó ÂÍ·ÈÚ¤ÛÂÈ Î·Ó›˜ ÙËÓ ·ÓÙÈۈ̷ÙÈ΋ ·ÓÂ¿ÚÎÂÈ· Ù˘ ·ÓÔÛÔÛÊ·ÈÚ›Ó˘ ∞ (IgA), Ô˘ ¤¯ÂÈ ÂÚ›Ô˘ 20Ï¿ÛÈ· Û˘¯ÓfiÙËÙ·. À¿Ú¯ÂÈ ÌÂÁ¿ÏË ÂÙÂÚÔÁ¤ÓÂÈ· ˆ˜ Paediatriki 2008;71:5-13

ÚÔ˜ ÙËÓ ·ÈÙÈÔ·ıÔÁ¤ÓÂÈ· Î·È ÙË ÁÂÓÂÙÈ΋ ‰È·Ù·Ú·¯‹. ª¤¯ÚÈ Û‹ÌÂÚ· ¤¯Ô˘Ó ÂÚÈÁÚ·Ê› ÂÚÈÛÛfiÙÂÚ˜ ·fi 150 ¶∞∞ Ì ‰È·ÊÔÚÂÙÈÎfi Ë Î·ıÂÌ›· ·ÓÔÛÔÏÔÁÈÎfi ˘fiÛÙڈ̷, ·ÏÏ¿ Î·È Ì ÌÂÁ¿ÏË ÔÈÎÈÏÔÌÔÚÊ›· fiÛÔÓ ·ÊÔÚ¿ ÛÙËÓ ÎÏÈÓÈ΋ ÂÈÎfiÓ· Î·È ÙË ‚·Ú‡ÙËÙ· ÙˆÓ ÂΉËÏÒÛÂˆÓ (12-14).

∂ÚÁ·ÛÙËÚȷ΋ ‰ÈÂÚ‡ÓËÛË ∆Ô ·È‰› ÌÂ Û˘¯Ó¤˜ ÏÔÈÌÒÍÂȘ ÌÔÚ› Ó· ηٷٷ¯ı› Û ÂΛÓÔ Ô˘ ¯ÚÂÈ¿˙ÂÙ·È Ï‹ÚË ·ÓÔÛÔÏÔÁÈ΋ ÂÎÙ›ÌËÛË, ÂΛÓo Ô˘ ‰ÈηÈÔ‡Ù·È ‚·ÛÈÎfi ¤ÏÂÁ¯Ô Î·È ÛÙË ÌÂÁ¿ÏË ÏÂÈÔ„ËÊ›· ÙˆÓ ·È‰ÈÒÓ Ô˘ ·ÏÒ˜ ¯ÚÂÈ¿˙ÔÓÙ·È ·Ú·ÎÔÏÔ‡ıËÛË. ∏ ηı˘ÛÙ¤ÚËÛË Ù˘ ‰È¿ÁÓˆÛ˘ ¤¯ÂÈ ÛÔ‚·Úfiٷ٘ Û˘Ó¤ÂȘ ÁÈ· ÙÔÓ ·ÛıÂÓ‹, ÂÓÒ Ë ‰È¿ÁÓˆÛË ÛÙË ÌÈÎÚfiÙÂÚË ‰˘Ó·Ù‹ ËÏÈΛ· ‚ÔËı¿ ÛÙËÓ “·ÈÙÈÔÏÔÁÈ΋” ıÂÚ·›· Î·È ÙËÓ ÚfiÏË„Ë ÙˆÓ ÂÈÏÔÎÒÓ, Ì ÙËÓ ¿ÌÂÛË Î·È ÛˆÛÙ‹ Û˘Ìو̷ÙÈ΋ ·ÁˆÁ‹. ∂ÈϤÔÓ, Ë ‰È·Ù‹ÚËÛË ÙÔ˘ ¿Û¯ÔÓÙÔ˜ Û ηϋ ηٿÛÙ·ÛË ı· ÂÈÙÚ¤„ÂÈ ÌÂÏÏÔÓÙÈο ÙËÓ ÂÊ·ÚÌÔÁ‹ Èı·ÓÒÓ ÚÈ˙ÈÎÒÓ ·ÈÙÈÔÏÔÁÈÎÒÓ ıÂÚ·ÂÈÒÓ. Œ¯ÔÓÙ·˜ ÁÓÒÛË ÙˆÓ ·ÓÔÛÔÏÔÁÈÎÒÓ Ì˯·ÓÈÛÌÒÓ Î·È ÙÔ˘ ÙÚfiÔ˘ ¿Ì˘Ó·˜ ¤Ó·ÓÙÈ ÙˆÓ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÒÓ, ηÙ¢ı˘ÓfiÌ·ÛÙ ÛÙÔ˘˜ ÏÔÈÌÔÁfiÓÔ˘˜ ·Ú¿ÁÔÓÙ˜, ·fi ÙÔ˘˜ ÔÔ›Ô˘˜ ÎÈÓ‰˘Ó‡ÂÈ Ô ¿ÚÚˆÛÙÔ˜ Ì ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ· (¶›Ó·Î·˜ 3) (3,11). ∞ÎÔÏÔ˘ıÒÓÙ·˜ ·Ó¿ÏÔÁÔ ÙÚfiÔ ÛΤ„˘ Î·È ·ÓÙ›ÛÙÚÔÊË Ô‰fi, ÚÔÛ·Ó·ÙÔÏÈ˙fiÌ·ÛÙ ÛÙÔ Èı·Ófi, ¿Û¯ÔÓ, ·ÓÔÛÔÏÔÁÈÎfi ÛΤÏÔ˜. “¶˘Í›‰·” Â›Ó·È ÙÔ Â›‰Ô˜ Ù˘ Ïԛ̈͢ Î·È Ë ÎÏÈÓÈ΋ ÚÔ‚ÔÏ‹ Ù˘. ∏ ÂÌÊ¿ÓÈÛË ·ÔÛÙËÌ¿ÙˆÓ Î·È “ÂÓ Ùˆ ‚¿ıÂÈ” ÏÔÈÌÒÍÂˆÓ ·fi ÛÙ·Ê˘ÏfiÎÔÎÎÔ, ÛÂÚÚ¿ÙÈ· ‹ ·Û¤ÚÁÈÏÏÔ Î·Ù¢ı‡ÓÔ˘Ó ÙË ÛΤ„Ë Ì·˜ Û ·ÓÂ¿ÚÎÂÈ· ÙˆÓ ÔÏ˘ÌÔÚÊÔ˘Ú‹ÓˆÓ. √È ˘ÔÙÚÔÈ¿˙Ô˘Û˜ ÏÔÈÌÒÍÂȘ ·fi Ó·˚ÛÛ¤ÚÈ· (ÁÔÓfiÎÔÎÎÔ ‹ ÌËÓÈÁÁÈÙȉfiÎÔÎÎÔ) ÂÌÊ·Ó›˙ÔÓÙ·È Û ¿ÙÔÌ· Ì ·ÓÂ¿ÚÎÂÈ· ÙˆÓ ÎÏ·ÛÌ¿ÙˆÓ ÙÔ˘ ÙÂÏÈÎÔ‡ ÛΤÏÔ˘˜ ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜, ÂÓÒ Ù· ˘ÔÁfiÓ· ‚·ÎÙËÚ›‰È· (·ÈÌfiÊÈÏÔ˜, Ó¢ÌÔÓÈfiÎÔÎÎÔ˜, „¢‰ÔÌÔÓ¿‰·) ·Ó·Ù‡ÛÛÔ˘Ó ÓfiÛÔ Û ˘fiÛÙڈ̷ ·ÓÙÈۈ̷ÙÈ΋˜ ·ÓÂ¿ÚÎÂÈ·˜ (1).

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·11

11

∞ÓÔÛÔÏÔÁÈÎfi˜ ¤ÏÂÁ¯Ô˜ Û ÏÔÈÌÒÍÂȘ

¶›Ó·Î·˜ 5. ∞ÏÁfiÚÈıÌÔ˜ ·ÓÔÛÔÏÔÁÈÎÔ‡ ÂϤÁ¯Ô˘ ·È‰ÈÒÓ Ì ‚¿ÛË ÙȘ ÏÔÈÌÒÍÂȘ ¶·ıÔÁfiÓ·

µ·ÎÙËÚ›‰È·

™Ù·Ê˘ÏfiÎÔÎÎÔ˜

¡·˚ÛÛ¤ÚÈ· ÌËÓÈÁÁ›Ùȉ·˜

∂Ó‰Ô΢ÙÙ¿ÚÈ·: ª˘ÎÔ‚·ÎÙËÚ›‰È·, ÏÈÛÙ¤ÚÈ·, ÈÔ›, ÚˆÙfi˙ˆ·, ̇ÎËÙ˜

∫ÏÈÓÈ΋ ÂÈÎfiÓ·

ÀÔÙÚÔÈ¿˙Ô˘Û˜ ÏÔÈÌÒÍÂȘ .¯. ·Ó·Ó¢ÛÙÈÎÔ‡

ÀÔÙÚÔÈ¿˙Ô˘Û˜ ‹ ‚·ÚȤ˜ ÏÔÈÌÒÍÂȘ, ·ÔÛÙ‹Ì·Ù·

¶ÔÏÏ·Ϥ˜ ÌËÓÈÁÁ›Ùȉ˜

¶ÔÈΛÏÏÂÈ

¶Èı·Ó¤˜ ‰È·ÁÓÒÛÂȘ

∞Á·ÌÌ·ÛÊ·ÈÚÈÓ·ÈÌ›·

∞ÓÂ¿ÚÎÂÈ· Ô˘‰ÂÙÂÚÔʛψÓ

∞ÓÂ¿ÚÎÂÈ· Û˘ÌÏËÚÒÌ·ÙÔ˜

¢È·Ù·Ú·¯‹ ΢ÙÙ·ÚÈ΋˜ ·ÓÔÛ›·˜

¢È·Ù·Ú·¯‹ ·ÓÙÈۈ̷ÙÈ΋˜ ·¿ÓÙËÛ˘

¢È·Ù·Ú·¯‹ ·ÓÙÈۈ̷ÙÈ΋˜ ·¿ÓÙËÛ˘

™˘Ó‰˘·Ṳ̂ÓË ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ·

ÀÂÚ IgM ∞ÓÂ¿ÚÎÂÈ· ˘ÔÙ¿ÍÂˆÓ IgG ∞ÓÂ¿ÚÎÂÈ· ·ÓÙÈۈ̷ÙÈ΋˜ ·¿ÓÙËÛ˘

∞Ú¯ÈÎfi˜ ÂÚÁ·ÛÙËÚÈ·Îfi˜ ¤ÏÂÁ¯Ô˜ (¶›Ó·Î·˜ 4) ∞ÓÔÛÔÏÔÁÈÎfi˜ ¤ÏÂÁ¯Ô˜ ∂ȉÈÎfi˜ ÂÚÁ·ÛÙËÚÈ·Îfi˜ ¤ÏÂÁ¯Ô˜ (¶›Ó·Î·˜ 4)

¶¿Û¯ÔÓ ·ÓÔÛÈ·Îfi ÛΤÏÔ˜

ŒÏÏÂÈÌÌ· ·ÓÙÈۈ̷ÙÈ΋˜ ·¿ÓÙËÛ˘

ŒÏÏÂÈÌÌ· Ô˘‰ÂÙÂÚÔʛψÓ

¢È·Ù·Ú·¯‹ Û˘ÌÏËÚÒÌ·ÙÔ˜

∞ÓÂ¿ÚÎÂȘ ÙÔ˘ ∆ ΢ÙÙ¿ÚÔ˘ ªÈÎÙ¤˜ ·ÓÂ¿ÚÎÂȘ

∂ÍÂȉÈÎÂ˘Ì¤ÓÔ˜ ÂÚÁ·ÛÙËÚÈ·Îfi˜ ¤ÏÂÁ¯Ô˜ §ÂÈÙÔ˘ÚÁ›Â˜ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ, ·ÓÔÛÔ΢ÙÙ¿ÚˆÓ ÌÔÚÈ·Îfi˜ Î·È ÁÂÓÂÙÈÎfi˜ ¤ÏÂÁ¯Ô˜

¶·Ú·‰Â›ÁÌ·Ù· ÂÍÂȉÈÎÂ˘Ì¤ÓÔ˘ ÂϤÁ¯Ô˘

Btk ÛÂ Ê˘ÏÔÛ‡Ó‰ÂÙË ·-Á-ÛÊ·ÈÚÈÓ·ÈÌ›· CD40L Û ˘ÂÚ IgM I

πÛÔ¤Ó˙˘ÌÔ Î˘ÙÙÔ¯ÚÒÌ·ÙÔ˜ °ÔÓ›‰ÈÔ gp 91 phox

™˘¯ÓfiÙÂÚ˜ ‰È·ÁÓÒÛÂȘ

º˘ÏÔÛ‡Ó‰ÂÙË ·Á·ÌÌ·ÛÊ·ÈÚÈÓ·ÈÌ›·

ÃÚfiÓÈ· ÎÔÎÎȈ̷Ù҉˘ ÓfiÛÔ˜

∞ÓÂ¿ÚÎÂÈ· ˘ÔÙ¿ÍÂˆÓ IgG ÀÂÚ πgM Û‡Ó‰ÚÔÌ·

∞ÓÂ¿ÚÎÂÈ· ÌÔÚ›ˆÓ ÚÔÛÎfiÏÏËÛ˘ (LAD)

∂ȉÈÎfi ·ÓÙÈۈ̷ÙÈÎfi ¤ÏÏÂÈÌÌ· ∫ÔÈÓ‹ ÔÈΛÏË ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ·

∞ÓÙ›ıÂÙ·, Ë ·Ó¿Ù˘ÍË ÂÓ‰Ô΢ÙÙ¿ÚÈˆÓ ÔÚÁ·ÓÈÛÌÒÓ ÂÓÔ¯ÔÔÈ› ¤ÏÏÂÈÌÌ· ÛÙÔ Î˘ÙÙ·ÚÈÎfi ÛΤÏÔ˜ Ù˘ ·ÓÔÛ›·˜ Î·È È‰È·›ÙÂÚ· ÛÙ· ∆ ÏÂÌÊÔ·ÙÙ·Ú·. ¶ÔÈfiÓ ¤ÏÂÁ¯Ô ı· ·ÎÔÏÔ˘ı‹ÛÂÈ Ô ·È‰›·ÙÚÔ˜ ÛÙÔ ¿ÚÚˆÛÙÔ ·È‰› Ô˘ ı· ÙÂı› Ë ˘Ô„›· Ù˘ ·ÓÔÛÔ·ÓÂ-

Ác ·Ï˘Û›‰· ÁÈ· µª∞∞ ¶ÚˆÙ½ÓË/ÁÔÓ›‰ÈÔ Û˘Ó‰ÚfiÌÔ˘ Wiskott-Aldrich (WASP) ∞ÓÂ¿ÚÎÂÈ· ·Ú·ÁfiÓÙˆÓ Û˘ÌÏËÚÒÌ·ÙÔ˜ (c)

ªÈÎÙ‹ ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ· ¢È·Ù·Ú·¯‹ ΢ÙÙ·ÚÈ΋˜ ·ÓÔÛ›·˜ ™‡Ó‰ÚÔÌÔ Di George ∞Ù·Í›· ÙËÏ·ÁÁÂÈÂÎÙ·Û›· ™‡Ó‰ÚÔÌÔ Wiskott-Aldrich AIDS

¿ÚÎÂÈ·˜ (9,11,15-17); √ ·Ú¯ÈÎfi˜ ¤ÏÂÁ¯Ô˜ ÂÚÈÏ·Ì‚¿ÓÂÈ: ÁÂÓÈ΋ ·›Ì·ÙÔ˜, ·ÓÔÛÔÛÊ·ÈÚ›Ó˜ ÔÚÔ‡, Û˘Ìϋڈ̷ Î·È ÂȉÈÎfiÙÂÚ· ÛÙ· ‚Ú¤ÊË ÈÛÔ·ÈÌÔÛ˘ÁÎÔÏÏËÙ›Ó˜ (¶›Ó·Î·˜ 4). √ ÚÔÛ‰ÈÔÚÈÛÌfi˜ ÙÔ˘ ·ÚÈıÌÔ‡ ÙˆÓ Ï¢ÎÒÓ Î·È ÙÔ˘ Ù‡Ô˘ ÙÔ˘˜ ·ÔÎÏ›ÂÈ ¶·È‰È·ÙÚÈ΋ 2008;71:5-13

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·12

12

¢. X. ∫·Û›ÌÔ˜ Î·È Û˘Ó.

Ù˘¯fiÓ Ô˘‰ÂÙÂÚÔÂÓ›· ‹ ÏÂÌÊÔÂÓ›· Î·È Ë ÌÔÚÊÔÏÔÁ›· ÙÔ˘˜ ÌÔÚ› Ó· Ì·˜ ηÙ¢ı‡ÓÂÈ ÛÙË ‰È¿ÁÓˆÛË (.¯. Û‡Ó‰ÚÔÌÔ Chediak-Higashi). H ·ÈÌÔÛÊ·ÈÚ›ÓË, Ô ·ÈÌ·ÙÔÎÚ›Ù˘ Î·È Ë ÌÔÚÊÔÏÔÁ›· ÙˆÓ ÂÚ˘ıÚÒÓ Â›Ó·È Î·ÏÔ› ‰Â›ÎÙ˜ ÁÈ· ˘ÔΛÌÂÓÔ ¯ÚfiÓÈÔ ÓfiÛËÌ·. ∆· ·ÈÌÔÂÙ¿ÏÈ·, Ô˘ Â›Ó·È ¤Ó·˜ ·ÎfiÌË Î·Ïfi˜ ‰Â›ÎÙ˘ Ù˘ ÏÂÈÙÔ˘ÚÁ›·˜ ÙÔ˘ Ì˘ÂÏÔ‡, ÌÔÚ› Ó· Â›Ó·È ÌÂȈ̤ӷ Û ·˘ÙÔ¿ÓÔÛ· ÓÔÛ‹Ì·Ù· Î·È ÛÙÔ Û‡Ó‰ÚÔÌÔ WiskottAldrich. √ ‚·ÛÈÎfi˜ ¤ÏÂÁ¯Ô˜ Ù˘ ÏÂÈÙÔ˘ÚÁ›·˜ ÙˆÓ µ ΢ÙÙ¿ÚˆÓ ÂÚÈÏ·Ì‚¿ÓÂÈ ÚÔÛ‰ÈÔÚÈÛÌfi ÙˆÓ ÂÈ¤‰ˆÓ ÙˆÓ ·ÓÔÛÔÛÊ·ÈÚÈÓÒÓ. ∞Ó¿ÏÔÁ· Ì ÙËÓ ÎÏÈÓÈ΋ ÂÈÎfiÓ· Î·È ÙÔ˘˜ ·ıÔÁfiÓÔ˘˜ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ‡˜, Ô ÂÚÁ·ÛÙËÚÈ·Îfi˜ ¤ÏÂÁ¯Ô˜ ÂÂÎÙ›ÓÂÙ·È (¶›Ó·Î˜ 4 Î·È 5). °È· ÙËÓ ÂÎÙ›ÌËÛË Ù˘ ·ÓÙÈۈ̷ÙÈ΋˜ ÏÂÈÙÔ˘ÚÁ›·˜, Ô ÈÔ ÂȉÈÎfi˜ ¤ÏÂÁ¯Ô˜ ÂÚÈÏ·Ì‚¿ÓÂÈ ÚÔÛ‰ÈÔÚÈÛÌfi ÔÚÈṲ̂ӈÓ, Û˘ÁÎÂÎÚÈ̤ӈÓ, ÂȉÈÎÒÓ ·ÓÙÈÛˆÌ¿ÙˆÓ Î·È ÂÈ¤‰ˆÓ ÙˆÓ ˘ÔÙ¿ÍÂˆÓ Ù˘ ·ÓÔÛÔÛÊ·ÈÚ›Ó˘ G (IgG) Î·È Ù›ÙÏÔ˘ ÈÛÔ·ÈÌÔÛ˘ÁÎÔÏÏËÙÈÓÒÓ (·ÓÙÈ-∞, ·ÓÙÈ-µ) ÁÈ· ÙÔÓ ¤ÏÂÁ¯Ô Ù˘ ·ÓÔÛÔÛÊ·ÈÚ›Ó˘ ª (IgM) (8,18). ∞Í›˙ÂÈ Ó· ˘ÂÓı˘Ì›ÛÔ˘Ì fiÙÈ Ù· ‚Ú¤ÊË ÙˆÓ 6-8 ÌËÓÒÓ Û˘¯Ó¿ ÂÌÊ·Ó›˙Ô˘Ó ÙË ÁÓˆÛÙ‹ ·ÚÔ‰È΋ ˘ÔÁ·ÌÌ·ÛÊ·ÈÚÈÓ·ÈÌ›· Î·È Ú¤ÂÈ Ó· ÙÔÓÈÛÙ› fiÙÈ ‰ÂÓ ÂÚÈ̤ÓÔ˘Ì ·ÓÙÈۈ̷ÙÈ΋ ·¿ÓÙËÛË Û ÔÏ˘Û·Î¯·ÚȉÈο ·ÓÙÈÁfiÓ·, .¯. ·ÈÌfiÊÈÏÔ˜ Ù˘ influenza-b Û ӋÈ· οو ÙˆÓ 24 ÌËÓÒÓ (19). °È· ÙÔ ÏfiÁÔ ·˘Ùfi, ÁÈ· Ù· Û˘ÁÎÂÎÚÈ̤ӷ ÓÔÛ‹Ì·Ù· Î·È ÁÈ’ ·˘Ù¤˜ ÙȘ ËÏÈ˘, ‰ËÌÈÔ˘ÚÁÔ‡ÓÙ·È ÂÌ‚fiÏÈ· Û˘Ó‰Â‰Â̤ӷ Ì ÚˆÙÂ˚ÓÈο ·ÓÙÈÁfiÓ·, Ù· ÔÔ›· ¢ԉÒÓÔ˘Ó ÈηÓÔÔÈËÙÈ΋ ·ÓÔÛÔ·¿ÓÙËÛË (·-Ó¢ÌÔÓÈÔÎÔÎÎÈÎfi, ·-·ÈÌÔÊ›ÏÔ˘, ·-ÌËÓÈÁÁÈÙȉÔÎfiÎÎÔ˘) (20). ∏ ΢ÙÙ·ÚÈ΋ ·ÓÔÛ›· ÂÎÙÈÌ¿Ù·È ·ÊÂÓfi˜ Ì ÙË Ì¤ÙÚËÛË ÙˆÓ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ Î·È ÙˆÓ ˘ÔÏËı˘ÛÌÒÓ ÙÔ˘˜, ·ÊÂÙ¤ÚÔ˘ Ì ÙËÓ ·ÍÈÔÏfiÁËÛË ÙˆÓ ‰ÂÚÌ·ÙÈÎÒÓ ‰ÔÎÈÌ·ÛÈÒÓ ÂÈ‚Ú·‰˘ÓÔ̤Ó˘ ˘ÂÚ¢·ÈÛıËÛ›·˜ Û ÎÔÈÓ¿ ·ÓÙÈÁfiÓ·. ∆¤ÙÔÈ· ·ÓÙÈÁfiÓ· Â›Ó·È ·˘Ù¿ ÙˆÓ ÂÌ‚ÔÏ›ˆÓ (ÙÂÙ¿ÓÔ˘ Î·È ‰ÈÊıÂÚ›Ùȉ·˜) Î·È Ù· ÎÔÈÓ¿ ·ÓÙÈÁfiÓ· ÙÔ˘ ÂÚÈ‚¿ÏÏÔÓÙÔ˜, fiˆ˜ ÙÚȯfiÊ˘Ù·, candida, ÚˆÙ¤·˜. °È· ÙËÓ ÂÎÙ›ÌËÛË Ù˘ Ê·ÁÔ΢ÙÙ·ÚÈ΋˜ ÏÂÈÙÔ˘ÚÁ›·˜, ηÙ' ·Ú¯‹Ó ·ÚΛ Ô ÚÔÛ‰ÈÔÚÈÛÌfi˜ ÙˆÓ Ï¢ÎÔ΢ÙÙ¿ÚˆÓ Î·È Ù˘ ÌÔÚÊÔÏÔÁ›·˜ ÙÔ˘˜. °È· ÙÔÓ ÔÏÔÎÏËڈ̤ÓÔ ¤ÏÂÁ¯Ô ÙˆÓ Ê·ÁÔ΢ÙÙ¿ÚˆÓ, ‚ÔËı¿ÂÈ Ô ¤ÏÂÁ¯Ô˜ Ù˘ ÔÍÂȉˆÙÈ΋˜ ÈηÓfiÙËÙ·˜ ÙˆÓ Ô˘‰ÂÙÂÚÔÊ›ÏˆÓ Ì ÙËÓ ÎÏ·ÛÈ΋ ‰ÔÎÈÌ·Û›· ¯ÚÒÛ˘ ÙÔ˘ ΢·ÓÔ‡ ÙÔ˘ ÙÂÙÚ·˙ÔÏ›Ô˘ (NBT) ‹ Ì ÙËÓ Î˘ÙÙ·ÚÔÌÂÙÚ›· ÚÔ‹˜ (DHR), ηıÒ˜ Î·È Ô ¤ÏÂÁ¯Ô˜ Ù˘ ¯ËÌÂÈÔÙ·Í›·˜ Î·È Ù˘ Ê·ÁÔ΢ÙÙ¿ÚˆÛ˘. °È· ÙÔ Û˘ÓÔÏÈÎfi ¤ÏÂÁ¯Ô Ù˘ ÏÂÈÙÔ˘ÚÁ›·˜ ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜, Ë ÈÔ ÚÔÛÈÙ‹ ̤ıÔ‰Ô˜ Â›Ó·È Ë Ì¤ÙÚËÛË ÙˆÓ ÎÏ·ÛÌ¿ÙˆÓ C3, C4. ¶ÈÔ ¯Ú‹ÛÈÌÔ˜, ˆÛÙfiÛÔ, Â›Ó·È Ô ÚÔÛ‰ÈÔÚÈÛÌfi˜ ÙÔ˘ ÔÏÈÎÔ‡ ·ÈÌÔÏ˘ÙÈÎÔ‡ Û˘ÌÏËÚÒÌ·ÙÔ˜ (CH50), ̤ıÔ‰Ô˜ Ô˘ ··ÈÙ› ÙËÓ ·ÚÔ˘Û›· fiÏˆÓ ÙˆÓ ÎÏ·ÛÌ¿ÙˆÓ ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜. ∂¿Ó οÔÈ· ·fi ÙȘ ‚·ÛÈΤ˜ ‰ÔÎÈ̷ۛ˜ Â›Ó·È ·Paediatriki 2008;71:5-13

ıÔÏÔÁÈ΋, Ú¤ÂÈ Ó· ÚÔ¯ˆÚ‹ÛÔ˘Ì Û ÈÔ ÂȉÈÎfi ¤ÏÂÁ¯Ô. √È ÂÍÂȉÈÎÂ˘Ì¤Ó˜ ̤ıÔ‰ÔÈ ÂÚÈÏ·Ì‚¿ÓÔ˘Ó ÙÔÓ ÚÔÛ‰ÈÔÚÈÛÌfi ÙÔ˘ ·ÓÔÛÔÊ·ÈÓÔÙ‡Ô˘ ÙˆÓ ∆ Î·È µ ÏÂÌÊÔ΢ÙÙ·ÚÈÎÒÓ ÏËı˘ÛÌÒÓ, ÙËÓ ÈηÓfiÙËÙ· ·ÓÙÈÁÔÓÈ΋˜ ‰È¤ÁÂÚÛ˘, ηÏÏȤÚÁÂȘ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ, ÂȉÈÎfiÙÂÚ˜ ‰ÔÎÈ̷ۛ˜ ÁÈ· Ù· ÔÏ˘ÌÔÚÊÔ‡ÚËÓ· Î·È Ì¤ÙÚËÛË fiÏˆÓ ÙˆÓ ÎÏ·ÛÌ¿ÙˆÓ ÙÔ˘ Û˘ÌÏËÚÒÌ·ÙÔ˜. ™Â Ôχ ÂÍÂȉÈÎÂ˘Ì¤Ó˜ ÂÚÈÙÒÛÂȘ ··ÈÙÔ‡ÓÙ·È ÂȉÈΤ˜ ηÏÏȤÚÁÂȘ, ÂȉÈÎÔ› ÂÓ˙˘ÌÈÎÔ› ÚÔÛ‰ÈÔÚÈÛÌÔ›, ·Ó¿Ï˘ÛË ÙˆÓ ÁÏ˘ÎÔÚˆÙ½ÓÒÓ ÙˆÓ Ï¢ÎÔ΢ÙÙ¿ÚˆÓ Î·È ÁÔÓȉȷÎfi˜ ¤ÏÂÁ¯Ô˜ Ì DNA ‹ RNA ·Ó·Ï‡ÛÂȘ. ∂¿Ó ˆ˜ ·ÈÙ›· ÙˆÓ ÎÏÈÓÈÎÒÓ ÂΉËÏÒÛÂˆÓ Èı·ÓÔÏÔÁÂ›Ù·È ·ÏÏÂÚÁÈÎfi ÓfiÛËÌ·, ÚÔÛ‰ÈÔÚ›˙ÔÓÙ·È Ù· Â›‰· Ù˘ ÔÏÈ΋˜ ·ÓÔÛÔÛÊ·ÈÚ›Ó˘ ∂ (IgE) ÛÙÔÓ ÔÚfi Î·È ÙˆÓ ÂȉÈÎÒÓ IgE (RAST) ¤Ó·ÓÙÈ Û˘ÁÎÂÎÚÈÌ¤ÓˆÓ ·ÏÏÂÚÁÈÔÁfiÓˆÓ.

¶ÚfiÁÓˆÛË ∏ ÚfiÁÓˆÛË ÙˆÓ ·È‰ÈÒÓ Ì ·ÓÔÛÔ·ÓÂ¿ÚÎÂÈ· Â›Ó·È Î·Ù¿ Ôχ ηχÙÂÚË ÙËÓ ÙÂÏÂ˘Ù·›· ‰ÂηÂÓÙ·ÂÙ›· Î·È Ë ÚfiÔ‰Ô˜ ·˘Ù‹ Â›Ó·È ‚¤‚·ÈÔ fiÙÈ ı· Û˘Ó¯ÈÛÙ›, ·ÊÔ‡ ÔÈ ÏÂÙÔ̤ÚÂȘ ÙˆÓ ·ÓÔÛÔÏÔÁÈÎÒÓ Ì˯·ÓÈÛÌÒÓ Î·È Ù˘ ÁÂÓÂÙÈ΋˜ ÙÔ˘˜ ‚¿Û˘ ηıËÌÂÚÈÓ¿ ‰È¢ÎÚÈÓ›˙ÔÓÙ·È Î·È ÚÔÔÙÈο Ë ıÂÚ·¢ÙÈ΋ ·Ú¤Ì‚·ÛË Á›ÓÂÙ·È ÈÔ ·ÔÙÂÏÂÛÌ·ÙÈ΋. øÛÙfiÛÔ, ηıÔÚÈÛÙÈ΋ ·Ú·Ì¤ÓÂÈ Ë ¤ÁηÈÚË ‰È¿ÁÓˆÛË ·˘ÙÒÓ ÙˆÓ ·ÚÚÒÛÙˆÓ Î·È Ë ¤ÁηÈÚË, ¿ÌÂÛË Î·È “ÂÈıÂÙÈ΋” ıÂÚ·›· ¤Ó·ÓÙÈ ÙÔ˘ ÓÔÛ‹Ì·ÙÔ˜ Ô˘ ı· ÂΉËψı› ÛÙÔ ·È‰› Ì ·ÓÔÛÔ·ÓÂ·ÚÎÔ‡Ó ˘fiÛÙڈ̷. ™Ùfi¯Ô˜ Â›Ó·È Ó· ÌËÓ ÂÁηٷÛÙ·ıÔ‡Ó ÌfiÓÈ̘ ‚Ï¿‚˜ ‹ ·ÂÈÏËı› Ë ˙ˆ‹ ÙÔ˘, Û˘Ó‹ıˆ˜ ·fi οÔÈ· ÛÔ‚·Ú‹ Ïԛ̈ÍË. √È ¶∞∞ ·ÔÙÂÏÔ‡Ó ¤Ó· ÔÏ˘Û‡ÓıÂÙÔ ÎÏÈÓÈÎfi Úfi‚ÏËÌ· Ì ÔÈΛϘ ÂΉËÏÒÛÂȘ Î·È ÌÈ· ‰È·ÁÓˆÛÙÈ΋ ÚfiÎÏËÛË ÁÈ· ÙÔÓ ÎÏÈÓÈÎfi È·ÙÚfi. ∂›ÏÔÁÔ˜ ∏ ÌÂıÔ‰È΋, ·Ó·Ï˘ÙÈ΋ Î·È Û˘ÓıÂÙÈ΋ ÚÔÛ¤ÁÁÈÛË ÙˆÓ ·È‰ÈÒÓ Ì Èı·Ó‹ ¶∞∞ ı· ‚ÔËı‹ÛÂÈ ÛÙË ÛˆÛÙ‹ ‰È·ÁÓˆÛÙÈ΋ ÚÔÛ¤Ï·ÛË, ·ÔÎÏ›ÔÓÙ·˜ ¿ÏϘ ·ıÔÏÔÁÈΤ˜ ηٷÛÙ¿ÛÂȘ Î·È ı· Ô‰ËÁ‹ÛÂÈ ÛÙËÓ ÔÚı‹ ‰È¿ÁÓˆÛË, ÙËÓ Î·Ù¿ÏÏËÏË ıÂÚ·›· Î·È ·ÓÙÈÌÂÙÒÈÛË (21). ∂˘¯·ÚÈÛٛ˜ ∂˘¯·ÚÈÛÙԇ̠ÙÔÓ ∫·ıËÁËÙ‹ ∆¿ÎË ¶·Ó·ÁȈÙfiÔ˘ÏÔ ÁÈ· ÙËÓ Î·ıÔÚÈÛÙÈ΋ Û˘Ì‚ÔÏ‹ ÙÔ˘ ÛÙË Û˘ÁÁÚ·Ê‹ Ù˘ ÂÚÁ·Û›·˜.

µÈ‚ÏÈÔÁÚ·Ê›· 1. Bird AG. Diagnosis of antibody deficiency states. In: Levinsky RJ, editor. IgG subclass deficiencies. London: Royal Society of Medicine Services; 1989. p. 3-12.

2. °ÂÚÌÂÓ‹˜ ∞. §ÂÈÙÔ˘ÚÁÈ΋ ‰ÔÌ‹ ÙÔ˘ ·ÓÔÛÈ·ÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜. ™ÙÔ: °ÂÚÌÂÓ‹˜ ∞, ÂΉfiÙ˘. π·ÙÚÈ΋ ∞ÓÔÛÔÏÔÁ›·. ∞ı‹Ó·: ∂ΉfiÛÂȘ ¶··˙‹ÛË; 2000. Û. 13-21.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·13

13

∞ÓÔÛÔÏÔÁÈÎfi˜ ¤ÏÂÁ¯Ô˜ Û ÏÔÈÌÒÍÂȘ

3. Chapel H, Haeney M, Misbah S and Snowden N. Basic Components: structure and function. In: Chapel H, Haeney M, Misbah S and Snowden N, editors. Essentials of Clinical Immunology. 5th ed. Oxford: Blackwell Publishing; 2006. p. 1-32.

4. ∫·Ó¿ÚÈÔ˘ M. ¢È·Ù·Ú·¯¤˜ ·ÓÔÛÈ·ÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜. ™ÙÔ: ∫ˆÓÛÙ·ÓÙfiÔ˘ÏÔ˜ A., ÂΉfiÙ˘. ∫ÏÈÓÈ΋ ¶·È‰È·ÙÚÈ΋.

Aı‹Ó·: ∂ΉfiÛÂȘ ∑‹Ù·; 2006-2007. Û. 199-211.

5. Report of a WHO scientific group. Primary immunodeficiency diseases. Clin Exp Immunol 1997;109 Suppl 1:1-28.

6. De Vries E, Noordzij JG, Kuijpers TW, van Dongen JJ. Flow cytometric immunophenotyping in the diagnosis and follow-up of immunodeficient children. Eur J Pediatr 2001; 160:583-591.

7. Golub ES. Immunity, infections and tumors. In: Golub ES, editor. Immunology: A Synthesis. Sunderland, Massachussets: Sinauer Associates, Inc.; 1987. p. 439-460.

8. Wood RA, Sampson HA. The child with frequent infections.

Curr Probl Pediatr 1989;19:229-284.

9. Fleisher TA. Immune function. Pediatr Rev 1997;18:351-356.

10. Stiehm ER. Clinical and laboratory evaluation of the child with suspected immunodeficiency. Pediatr Rev 1985;7:53-61.

11. De Vries E; Clinical Working Party of the European Society for Immunodeficiencies (ESID). Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists. Clin Exp Immunol 2006;145:204-214.

12. Bonilla FA, Geha RS. 12. Primary immunodeficiency diseases. J Allergy Clin Immunol 2003;111:S571-581.

13. Notarangelo L, Casanova JL, Conley ME, Chapel H, Fischer A, Puck J, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 2006;117:883-896.

14. Smith CIE, Ochs HD, Puck JM. Genetically determined immunodeficiency diseases: a perspective. In: Ochs HD, Smith CIE, Puck JM, editors. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. 2nd ed. Oxford: Oxford Universiry Press; 2007. p. 3-15.

15. Pacheco SE, Shearer WT. Laboratory aspects of immunology.

Pediatr Clin North Am 1994;41:623-655.

16. Sewell WA, Khan S, Doré PC. Early indicators of immunodeficiency in adults and children: protocols for screening for primary immunological defects. Clin Exp Immunol 2006;145:201-203.

17. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94:S1-63.

18. Pachman LM, Lynch PA, Silver RK, Ozog DL, Poznanski AK. Primary immunodeficiency disease in children: an update.

Curr Probl Pediatr 1989;19:1-64.

19. Umetsu DT, Ambrosino DM, Quinti I, Siber GR, Geha RS. Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency. N Engl J Med 1985;313:1247-1251.

20. Sorensen RU, Moore C. Immunology in the pediatrician’s office. Pediatr Clin North Am 1994;41:691-714.

21. Buckley RH. Primary immunodeficiency or not? Making the correct diagnosis. J Allergy Clin Immunol 2006;117:756-8.

¶·È‰È·ÙÚÈ΋ 2008;71:5-13

Pediatri Jan-Feb 08

14

15-02-08

11:00

™ÂÏ›‰·14

∞¡∞™∫√¶∏™∏

REVIEW ARTICLE

¶ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ 1 µ’ ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋ ¶·ÓÂÈÛÙËÌ›Ô˘ ∞ıËÓÒÓ 2 °’ ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋ ¶·ÓÂÈÛÙËÌ›Ô˘ ∞ıËÓÒÓ AÏÏËÏÔÁÚ·Ê›·: ª·Ú›· ªÔ˘ÛÙ¿ÎË maria-m@otenet.gr µ’ ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋, ¶·ÓÂÈÛÙ‹ÌÈÔ ∞ıËÓÒÓ

ª. ªÔ˘ÛÙ¿ÎË1, ∞. ºÚÂÙ˙¿ÁÈ·˜2 ¶ÂÚ›ÏË„Ë: H ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ Â›Ó·È ÔÏ˘Û˘ÛÙËÌ·ÙÈ΋ ÓfiÛÔ˜. ∂ΉËÏÒÓÂÙ·È ·fi ÙÔ ·Ó·Ó¢ÛÙÈÎfi Î·È ÙȘ ·Ú·ÚÚ›ÓȘ ÎÔÈÏfiÙËÙ˜, fiÔ˘ ·Ú·ÙËÚÔ‡ÓÙ·È ˘ÔÙÚÔÈ¿˙Ô˘Û˜ ·Ó·Ó¢ÛÙÈΤ˜ ÏÔÈÌÒÍÂȘ, ‚ÚÔÁ¯ÂÎٷۛ˜ Î·È ÂÂÈÛfi‰È· ˆÙ›Ùȉ·˜ Î·È ÈÁÌÔÚ›Ùȉ·˜. ∞fi ÙÔ ÁÂÓÓËÙÈÎfi Û‡ÛÙËÌ· ·ÌÊÔÙ¤ÚˆÓ ÙˆÓ Ê‡ÏˆÓ ·Ú·ÙËÚÂ›Ù·È ˘ÔÁÔÓÈÌfiÙËÙ·. ∆Ô Û‡Ó‰ÚÔÌÔ Û˘Ó‰¤ÂÙ·È Û 50% ÂÚ›Ô˘ ÙˆÓ ·ÛıÂÓÒÓ Ì ·Ó·ÛÙÚÔÊ‹ ÙˆÓ ÛÏ¿Á¯ÓˆÓ (Û‡Ó‰ÚÔÌÔ Kartagener). ∏ ‰È¿ÁÓˆÛË Á›ÓÂÙ·È Ì ÌÈ· ÛÂÈÚ¿ ÌË ÂȉÈÎÒÓ ÂÍÂÙ¿ÛˆÓ, fiˆ˜ ‰ÔÎÈÌ·Û›· ۷ί·Ú›Ó˘, ̤ÙÚËÛË Ù˘ Û˘¯ÓfiÙËÙ·˜ ΛÓËÛ˘ ÙˆÓ ÎÚÔÛÛÒÓ Î·È ·ÂÈÎfiÓÈÛË Ù˘ ÌÔÚÊÔÏÔÁ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ Î·È ÙÔ˘ ÚÔÛ·Ó·ÙÔÏÈÛÌÔ‡ ÙÔ˘˜ Ì ÙÔ ËÏÂÎÙÚÔÓÈÎfi ÌÈÎÚÔÛÎfiÈÔ. ∞Ó Î·È Î¿ı ÂÚÁ·ÛÙ‹ÚÈÔ ¤¯ÂÈ ÙȘ ‰ÈΤ˜ ÙÔ˘ Ê˘ÛÈÔÏÔÁÈΤ˜ ÙÈ̤˜, ÔÈ Î·Ù¿ ÚÔÛ¤ÁÁÈÛË Ê˘ÛÈÔÏÔÁÈΤ˜ ÙÈ̤˜ ÁÈ· ÙË Û˘¯ÓfiÙËÙ· ΛÓËÛ˘ ÙˆÓ ÎÚÔÛÛÒÓ Â›Ó·È 11-16 Hz. ∆Ô ËÏÂÎÙÚÔÓÈÎfi ÌÈÎÚÔÛÎfiÈÔ Â›Ó·È ÛËÌ·ÓÙÈÎfi ÙÌ‹Ì· ÙˆÓ ‰È·ÁÓˆÛÙÈÎÒÓ ‰ÔÎÈÌ·ÛÈÒÓ. ÃÚÂÈ¿˙ÂÙ·È ÁÈ· ÙËÓ ·ÔÙ‡ˆÛË Ù˘ ‰ÔÌ‹˜ ÙˆÓ ÎÚÔÛÛÒÓ Î·È ÙÔ˘ ÚÔÛ·Ó·ÙÔÏÈÛÌÔ‡ ÙÔ˘˜. ∞ӈ̷ϛ˜ Û 10% ÙˆÓ ÎÚÔÛÛÒÓ ·Ú·ÙËÚÔ‡ÓÙ·È Î·È ÛÂ Ê˘ÛÈÔÏÔÁÈο ‰Â›ÁÌ·Ù·. ™ËÌÂÈÒÓÂÙ·È fiÙÈ ÙÔ ÚÈÓÈÎfi ÂÎÓÂfiÌÂÓÔ ÔÍ›‰ÈÔ ÙÔ˘ ·˙ÒÙÔ˘ (¡√) Â›Ó·È ¯·ÌËÏfi Î·È ÌÔÚ› ÛÙÔ Ì¤ÏÏÔÓ Ó· ·ÔÙÂϤÛÂÈ ÂͤٷÛË ‰ÂÈÁÌ·ÙÔÏË„›·˜ ÁÈ· ÙË ‰È¿ÁÓˆÛË Ù˘ ÓfiÛÔ˘, ·ÏÏ¿ ÚÔ˜ ÙÔ ·ÚfiÓ ‰ÂÓ ˘¿Ú¯ÂÈ Â›ÛËÌË Û‡ÛÙ·ÛË ÁÈ· ÙË ¯Ú‹ÛË ÙÔ˘. ¢ÂÓ ˘¿Ú¯ÂÈ ÂȉÈ΋ ıÂÚ·›· ·ÔηٿÛÙ·Û˘ Ù˘ ‰ÔÌ‹˜ ‹ Ù˘ ÏÂÈÙÔ˘ÚÁ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ. ÃÚËÛÈÌÔÔÈÂ›Ù·È ·Ó·Ó¢ÛÙÈ΋ Ê˘ÛÈÔıÂÚ·›· Î·È Û˘ÛÙËÌ·ÙÈ΋ ¯ÔÚ‹ÁËÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ fiÙ·Ó ÂӉ›ÎÓ˘Ù·È.

§¤ÍÂȘ ÎÏÂȉȿ: ¢˘ÛÎÈÓËÛ›· ÎÚÔÛÛÒÓ, ·Ó·Ó¢ÛÙÈΤ˜ ÏÔÈÌÒÍÂȘ, ˘ÔÁÔÓÈÌfiÙËÙ·, ·Ó·ÛÙÚÔÊ‹ ÛÏ¿Á¯ÓˆÓ.

Primary ciliary dyskinesia 1 2nd Paediatric Clinic, University of Athens 2 3rd Paediatric Clinic, University of Athens Correspondence: Maria Moustaki maria-m@otenet.gr 2nd Paediatric Clinic, University of Athens

M. Moustaki1, A. Fretzayas2 Abstract: Primary ciliary dyskinesia is a multisystem disease characterized by recurrent respiratory tract infections, bronchiectasis, otitis, sinusitis and subfertility in both sexes. It is associated in about 50% of patients with situs inversus (Kartagener syndrome). It is a genetic disorder characterized by abnormalities in ciliary structural function. Diagnosis is made by a series of investigations, starting with the saccharin test, ciliary beat frequency, and electron microscopy, in order to reveal ciliary morphology and orientation.

Although it is recommended that each laboratory has its own normal range, the approximate normal range for beat frequency is 11-16 Hz. Electron microscopy is an essential part of diagnostic testing, necessary for the assessment of cilia structure and possible disorientation. Abnormalities in up to 10% of cilia may be seen in normal samples. Nasal nitric oxide (NO) is low and this measurement may be used in future as a screening tool but at present a definite clinical role for NO measurement in the diagnosis of primary ciliary dyskinesia is not recommended. There is no specific treatment. And the cornerstone of management is physiotherapy, with administration of systematic antibiotics when appropriate.

Key words: Ciliary dyskinesia, respiratory tract infections, subfertility, situs inversus.

∂ÈÛ·ÁˆÁ‹ ∆Ô Û‡Ó‰ÚÔÌÔ Ù˘ ÚˆÙÔ·ıÔ‡˜ ‰˘ÛÎÈÓËÛ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ ÂÚÈÁÚ¿ÊËΠÁÈ· ÚÒÙË ÊÔÚ¿ ÙÔ 1904 ·fi ÙÔÓ Siewert Î·È ·ÚÁfiÙÂÚ· ÙÔ 1935 ·fi ÙÔÓ Kartagener ˆ˜ Ë ÙÚÈ¿‰· ·Ó·ÛÙÚÔÊ‹˜ ÙˆÓ ÛÏ¿Á¯ÓˆÓ, ÈÁÌÔÚ›Ùȉ·˜ Î·È ‚ÚÔÁ¯ÂÎÙ·Û›·˜ (1). ŒÎÙÔÙÂ, Ë ·ıÔÏÔÁ›· Ù˘ ÚˆÙÔ·ıÔ‡˜ ‰˘ÛÎÈÓËÛ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ ¤¯ÂÈ ÂÚÈÁÚ·Ê› ÏÂÙÔÌÂÚ¤ÛÙÂÚ· Î·È Û‹ÌÂÚ· Ë ‰È¿ÁÓˆÛË Ù›ıÂÙ·È ·ÎfiÌË Î·È Â› ·Ô˘Û›·˜ ·Ó·ÛÙÚÔÊ‹˜ ÙˆÓ ÛÏ¿Á¯ÓˆÓ (1-3). ∏ ı¤ÛË ÙˆÓ ÛÏ¿Á¯ÓˆÓ ηٿ ÙÔ ÛÙ¿‰ÈÔ Ù˘ ÂÌ‚Ú˘ÔÁ¤ÓÂÛ˘ ηıÔPaediatriki 2008;71:14-20

Ú›˙ÂÙ·È ·fi ÙË Ê˘ÛÈÔÏÔÁÈ΋ ΛÓËÛË ÙˆÓ ÎÚÔÛÛÒÓ Î·È Â› ‰˘ÛÎÈÓËÛ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ ·fiÏÏ˘Ù·È Ô ¯ˆÚÔÙ·ÍÈÎfi˜ ÚÔÛ·Ó·ÙÔÏÈÛÌfi˜ Î·È ˘¿Ú¯ÂÈ Èı·ÓfiÙËÙ· 50% ·Ó·ÛÙÚÔÊ‹˜ ÙˆÓ ÛÏ¿Á¯ÓˆÓ (1,4,5). ∞Ó Î·È Û¿ÓÈ· ÁÂÓÂÙÈο ηıÔÚÈ˙fiÌÂÓË ÓfiÛÔ˜, Ë ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ ·ÔÙÂÏ› ¯ÚfiÓÈÔ ÛÔ‚·Úfi ÓfiÛËÌ·, ÂÓÒ Ô ·È‰›·ÙÚÔ˜ ¯ÚÂÈ¿˙ÂÙ·È Ó· Â›Ó·È ÂÍÔÈÎÂȈ̤ÓÔ˜ Ì ÙËÓ ÚÒÈÌË ‰È¿ÁÓˆÛË Î·È ÙËÓ ·Ú·ÎÔÏÔ‡ıËÛË ·˘ÙÔ‡ ÙÔ˘ ÓÔÛ‹Ì·ÙÔ˜. ™ÎÔfi˜ Ù˘ ·ÚÔ‡Û·˜ ·Ó·ÛÎfiËÛ˘ Â›Ó·È Ë ·ÚÔ˘Û›·ÛË ÙˆÓ

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·15

15

¶ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ

ÎÏÈÓÈÎÒÓ Î·È ÂÚÁ·ÛÙËÚÈ·ÎÒÓ ‰Â‰ÔÌ¤ÓˆÓ Ô˘ ·ÊÔÚÔ‡Ó ÙËÓ ÚˆÙÔ·ı‹ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ, Ù· ÔÔ›· ¤¯Ô˘Ó ÂÌÏÔ˘ÙÈÛÙ› Ì ٷ ÛÙÔȯ›· Ù˘ ÚfiÛÊ·Ù˘ ‚È‚ÏÈÔÁÚ·Ê›·˜.

∫ÚÔÛÛˆÙfi ÂÈı‹ÏÈÔ ∞fi ÎÚÔÛÛˆÙfi ÂÈı‹ÏÈÔ Î·Ï‡ÙÔÓÙ·È ÔÈ ‚ÏÂÓÓÔÁfiÓÔÈ ÙˆÓ ·Ú·ÚÚÈÓ›ˆÓ ÎfiÏˆÓ, ÔÈ ·ÓÒÙÂÚÔÈ Î·È Î·ÙÒÙÂÚÔÈ ·ÂÚ·ÁˆÁÔ›, ÔÈ ÛÂÚÌ·ÙÈΤ˜ Ô‰Ô› Ì ٷ ÛÂÚÌ·ÙÔ˙ˆ¿ÚÈ·, ÔÈ Û¿ÏÈÁÁ˜ Î·È ÙÔ Â¤Ó‰˘Ì· ÙˆÓ ÎÔÈÏÈÒÓ ÙÔ˘ ÂÁÎÂÊ¿ÏÔ˘ (4,5). ∫¿ı ÎÚÔÛÛfi˜ ·ÔÙÂÏÂ›Ù·È ·fi ÙË Ú›˙·, ÙÔ ‚·ÛÈÎfi ۈ̿ÙÈÔ Î·È ÙÔ ÂχıÂÚÔ Û٤ϯԘ. ∆Ô Ì¤ÁÂıfi˜ ÙÔ˘˜ Â›Ó·È 5-15 nm Î·È Ë ‰È¿ÌÂÙÚfi˜ ÙÔ˘˜ 0,2 nm. ∆Ô Û٤ϯԘ ·ÔÙÂÏÂ›Ù·È ·fi 9 ÂÚÈÊÂÚÈο ˙‡ÁË ÌÈÎÚÔÛˆÏËÓ›ÛÎˆÓ Î·È ‰‡Ô ÎÂÓÙÚÈÎÔ‡˜ ÌÈÎÚÔÛˆÏËÓ›ÛÎÔ˘˜ (1) (∂ÈÎfiÓ˜ 1, 2, 3). ¢‡Ô ‚Ú·¯›ÔÓ˜ ·ÔÙÂÏÔ‡ÌÂÓÔÈ ·fi ÚˆÙ½ÓË (‰˘Ó½ÓË) ÂÎÙ›ÓÔÓÙ·È ·fi ÙÔÓ ∞ ÌÈÎÚÔÛˆÏËÓ›ÛÎÔ Î¿ı ÂÚÈÊÂÚÈÎÔ‡ ˙‡ÁÔ˘˜ ÚÔ˜ ÙÔ µ ÌÈÎÚÔÛˆÏËÓ›ÛÎÔ ÙÔ˘ ·Ú·Î›ÌÂÓÔ˘ ˙‡ÁÔ˘˜ (1,6). √ ¤Ó·˜ ‚Ú·¯›ÔÓ·˜ ÂÎÙ›ÓÂÙ·È ÂÛˆÙÂÚÈο Î·È Ô ¿ÏÏÔ˜ Â͈ÙÂÚÈο. ÕÏÏÔÈ, ·ÎÙÈÓÔÂȉҘ ÊÂÚfiÌÂÓÔÈ, ‚Ú·¯›ÔÓ˜ (·ÎÙÈÓÔÂȉ¤˜ ÓËÌ¿ÙÈÔ) ÂÂÎÙ›ÓÔÓÙ·È ·fi ÙÔ˘˜ ÂÚÈÊÂÚÈÎÔ‡˜ ÌÈÎÚÔÛˆÏËÓ›ÛÎÔ˘˜ ÚÔ˜ ÙÔ ÎÂÓÙÚÈÎfi ˙‡ÁÔ˜, ÂÓÒ Ô ‚Ú·¯›ÔÓ·˜ Ù˘ ÓÂ͛Ӣ ÂÓÒÓÂÈ ÌÂٷ͇ ÙÔ˘˜ Ù· ˙‡ÁË ÙˆÓ ÂÚÈÊÂÚÈÎÒÓ ÌÈÎÚÔÛˆÏËÓ›ÛÎˆÓ (∂ÈÎfiÓ˜ 1, 2, 3). √È ÎÈÓ‹ÛÂȘ ÙˆÓ ÎÚÔÛÛÒÓ ¯·Ú·ÎÙËÚ›˙ÔÓÙ·È ·fi ¤Ó· ·Ú¯Èο Ù·¯‡ ÎÙ‡ËÌ·, ηٿ ÙÔ ÔÔ›Ô ·Ú·Ì¤ÓÔ˘Ó ¿Î·ÌÙÔÈ, Î·È ·fi ·ÎfiÏÔ˘ıË ‚Ú·‰Â›· Â¿ÓÔ‰Ô ÛÙË ı¤ÛË ÙÔ˘˜, fiÔ˘ fiÏÔ ÙÔ Û٤ϯԘ οÌÙÂÙ·È ¯·Ï·Úfi. √È ÎÈÓ‹ÛÂȘ ÙˆÓ ÎÚÔÛÛÒÓ ÛÙËÓ ÂÈıËÏȷ΋ ÂÈÊ¿ÓÂÈ· Â›Ó·È Û˘Á¯ÚÔÓÈṲ̂Ó˜, ÌÂÙ·ÎÈÓÒÓÙ·˜ ¤ÙÛÈ ÙË ‚ϤÓÓ· ·fi ÙËÓ ÂÈÊ¿ÓÂÈ· ÙˆÓ Î˘ÙÙ¿ÚˆÓ (1). ∂ȉËÌÈÔÏÔÁ›· ¶ÚfiÎÂÈÙ·È ÁÈ· Û¿ÓÈ· ÁÂÓÂÙÈ΋ ÓfiÛÔ ÌÂ Û˘¯ÓfiÙËÙ· 1:20.000 (1,2). ÀÔÏÔÁ›˙ÂÙ·È fiÙÈ Ë Û˘¯ÓfiÙËÙ· Ù˘ ·Ï‹˜ ·Ó·ÛÙÚÔÊ‹˜ ÙˆÓ ÛÏ¿Á¯ÓˆÓ Â›Ó·È 1:10.000 Î·È ÙÔ˘ Û˘Ó‰ÚfiÌÔ˘ Kartagener 1:40.000 (1,2). ∂Âȉ‹ ·˘Ù‹ Ë Û˘¯ÓfiÙËÙ· ÙˆÓ 1:20.000 ÛÙËÚ›˙ÂÙ·È ÛÙËÓ

∂ÈÎfiÓ· 2. º˘ÛÈÔÏÔÁÈÎfi˜ ÎÚÔÛÛfi˜ fiˆ˜ Ê·›ÓÂÙ·È ÛÙÔ ËÏÂÎÙÚÔÓÈÎfi ÌÈÎÚÔÛÎfiÈÔ.

˘fiıÂÛË fiÙÈ fiÏÔÈ ÔÈ ·ÛıÂÓ›˜ Ì ÙÔ Û‡Ó‰ÚÔÌÔ ı· ·Ó·Ù‡ÍÔ˘Ó ‚ÚÔÁ¯ÂÎÙ·Û›·, Â›Ó·È Û·Ê¤˜ fiÙÈ Ë Û˘¯ÓfiÙËÙ· ·˘Ù‹ ˘ÔÂÎÙÈÌ¿ ÙÔÓ Ú·ÁÌ·ÙÈÎfi ÂÈÔÏ·ÛÌfi Ù˘ ÓfiÛÔ˘. ªÂ ‚¿ÛË ·˘ÙÔ‡˜ ÙÔ˘˜ ˘ÔÏÔÁÈÛÌÔ‡˜, 3.000 ¿ÙÔÌ· ÛÙË ª. µÚÂÙ·Ó›· Ú¤ÂÈ Ó· ¿Û¯Ô˘Ó ·fi ÙÔ Û‡Ó‰ÚÔÌÔ. ™Â ÌÈ· ÔÌ¿‰·, fï˜, ÛÙ‹ÚÈ͢ ÙˆÓ ·ÛıÂÓÒÓ Ì ÙË ÓfiÛÔ Â›Ó·È ÂÁÁÂÁÚ·Ì̤ӷ 130-150 ¿ÙÔÌ· (1) ‰ËÏÒÓÔÓÙ·˜ ÙË ‰˘ÛÎÔÏ›· Ó· ÙÂı› Ë ‰È¿ÁÓˆÛË, ηıÒ˜ ÂÏ¿¯ÈÛÙ· ΤÓÙÚ· ¤¯Ô˘Ó ÙË ‰˘Ó·ÙfiÙËÙ· Ó· ı¤ÛÔ˘Ó ÙË ‰È¿ÁÓˆÛË Ì ÂÓ‰Âϯ‹ ¤ÏÂÁ¯Ô Ù˘ ·Ó·ÙÔÌ›·˜ Î·È Ù˘ ÏÂÈÙÔ˘ÚÁÈÎfiÙËÙ·˜ ÙˆÓ ÎÚÔÛÛÒÓ.

∫ÏÈÓÈ΋ ÂÈÎfiÓ· ∏ ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ ‰ÂÓ ¯·Ú·ÎÙËÚ›˙ÂÙ·È ·fi ηıÔÚÈÛÙÈο ÁÈ· ÙË ‰È¿ÁÓˆÛË Û˘ÌÙÒÌ·Ù·. ∞Ó¿ÏÔÁ· Ì ÙËÓ ËÏÈΛ·, ÚÔÂÍ¿Ú¯Ô˘Ó Î¿ÔÈ· Û˘ÌÙÒÌ·Ù· Î·È ÛËÌ›· Ô˘ ı¤ÙÔ˘Ó ÙËÓ ˘Ô„›· Ù˘ ÓfiÛÔ˘, fiˆ˜ Â›Ó·È ÛÙË ÓÂÔÁÓÈ΋ ËÏÈΛ· Ë Â›ÌÔÓË ÚÈÓ›Ùȉ· ·fi ÙËÓ ÚÒÙË Ë̤ڷ Ù˘ ˙ˆ‹˜ (711), ÙÔ Û‡Ó‰ÚÔÌÔ ·ÚÔ‰È΋˜ Ù·¯‡ÓÔÈ·˜ Û ·Ô˘Û›·

∞ÎÙÈÓˆÙ‹ Û‡Ó‰ÂÛË ∂͈ÙÂÚÈ΋ ‰˘Ó½ÓË ∂ÛˆÙÂÚÈ΋ ‰˘Ó½ÓË ™‡Ó‰ÂÛÌÔÈ ÓÂ͛Ӣ ™ˆÏËÓ¿ÚÈÔ ∞ ™ˆÏËÓ¿ÚÈÔ µ ∂ÈÎfiÓ· 1. ∂ÁοÚÛÈ· Û¯ËÌ·ÙÈ΋ ÙÔÌ‹ ÎÚÔÛÛÔ‡ fiˆ˜ Ê·›ÓÂÙ·È ÛÙÔ ËÏÂÎÙÚÔÓÈÎfi ÌÈÎÚÔÛÎfiÈÔ.

∂ÈÎfiÓ· 3. ∫ÚÔÛÛfi˜ ·fi ·ÛıÂÓ‹ Ì ÚˆÙÔ·ı‹ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ, fiÔ˘ ·Ô˘ÛÈ¿˙Ô˘Ó ÔÈ ÎÏ¿‰ÔÈ Ù˘ ‰˘Ó½Ó˘. ¶·È‰È·ÙÚÈ΋ 2008;71:14-20

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·16

16

ª. ªÔ˘ÛÙ¿ÎË, ∞. ºÚÂÙ˙¿ÁÈ·˜

ÚԉȷıÂÛÈÎÒÓ ·Ú·ÁfiÓÙˆÓ (7,8) Î·È Ë ÓÂÔÁÓÈ΋ Ó¢ÌÔÓ›· (7,8) ¯ˆÚ›˜ ÈÛÙÔÚÈÎfi ÓfiÛÔ˘ Ù˘ ÌËÙ¤Ú·˜ ‹ ·Ú·ÙÂٷ̤Ó˘ ڋ͢ ÙÔ˘ ı˘Ï·Î›Ô˘. ∏ Â›ÌÔÓË ÚÈÓ›Ùȉ· ·fi ÙËÓ ÚÒÙË Ë̤ڷ Ù˘ ˙ˆ‹˜ ‰È·Ê¤ÚÂÈ ·fi ÙË ‰È·Ï›Ô˘Û· ÚÈÓ›Ùȉ· Ô˘ ÂÌÊ·Ó›˙ÂÙ·È ÌÂÙ¿ ÙȘ ÚÒÙ˜ ‚‰ÔÌ¿‰Â˜ Ù˘ ˙ˆ‹˜ ÂÍ·ÈÙ›·˜ ÈÔÁÂÓÒÓ ÏÔÈÌÒÍÂˆÓ (10,11). ™Â ÌÈ· ÛÂÈÚ¿ 30 ·ÛıÂÓÒÓ Ì ÚˆÙÔ·ı‹ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ, ÔÈ 13 ÂÌÊ¿ÓÈÛ·Ó Û˘ÌÙÒÌ·Ù· ·fi ÙË ÓÂÔÁÓÈ΋ ÂÚ›Ô‰Ô (9). ¢ÂÍÈÔηډ›· ·Ú·ÙËÚÂ›Ù·È ÛÙÔ 50% ÙˆÓ ÓÂÔÁÓÒÓ, ÂÓÒ ÛÙÔ 23% ·˘ÙÒÓ Ì ‰ÂÍÈÔηډ›· ˘¿Ú¯ÂÈ Û‡Ó‰ÚÔÌÔ ‰˘ÛÎÈÓ‹ÙˆÓ ÎÚÔÛÛÒÓ (12). ™ÙË ‰ÂÍÈÔηډ›· Î·È ÛÙË Û˘ÓÔ‰fi ·Ó·ÛÙÚÔÊ‹ ÙˆÓ ÛÏ¿Á¯ÓˆÓ Ë Î·Ú‰È¿ ·Ó·ÙÔÌÈο Â›Ó·È Ê˘ÛÈÔÏÔÁÈ΋. Œ¯Ô˘Ó ·Ú·ÙËÚËı› ÌÂÌÔӈ̤Ó˜ ÂÚÈÙÒÛÂȘ ÓÂÔÁÓÒÓ ÌÂ Û˘ÁÁÂÓ‹ ηډÈÔ¿ıÂÈ·, ·ÙÚËÛ›· ÙÔ˘ ÔÈÛÔÊ¿ÁÔ˘ ‹ ÙˆÓ ¯ÔÏËÊfiÚˆÓ, ˘‰ÚÔΤʷÏÔ Î·È ıÂÙÈÎfi ÔÈÎÔÁÂÓÂÈ·Îfi ÈÛÙÔÚÈÎfi (13-15). ™ÙËÓ ·È‰È΋ ËÏÈΛ·, ¤Ú· ·fi ÙËÓ Èı·ÓfiÙËÙ· Ù˘ ‰ÂÍÈÔηډ›·˜, ·Ú·ÙËÚÔ‡ÓÙ·È ‚ÚÔÁ¯ÂÎٷۛ˜, ÂÈÎfiÓ· ÛÔ‚·ÚÔ‡ ‹ ¿Ù˘Ô˘ ¿ÛıÌ·ÙÔ˜ ÌË ·ÓÙ·ÔÎÚÈÓfiÌÂÓÔ˘ ÈηÓÔÔÈËÙÈο ÛÙËÓ ·ÁˆÁ‹, ˆÙ›Ùȉ· ÂÎÎÚÈÙÈ΋, ÈÁÌÔÚ›Ùȉ· Ì ‹ ¯ˆÚ›˜ Û˘ÓÔ‰Ô‡˜ Ôχԉ˜ (1,10). øÙ›Ùȉ· Ì ÔÏÏ·Ϥ˜ ÂÂÌ‚¿ÛÂȘ ·Ú·ÙËÚ‹ıËΠÛÙÔ 95% ÌÈ·˜ ÔÌ¿‰·˜ 110 ·ÛıÂÓÒÓ Ì ۇӉÚÔÌÔ ‰˘ÛÎÈÓ‹ÙˆÓ ÎÚÔÛÛÒÓ (16). ∏ ÂÌÊ¿ÓÈÛË ÙˆÓ ‚ÚÔÁ¯ÂÎÙ·ÛÈÒÓ ·˘Í¿ÓÂÈ Ì ÙËÓ ËÏÈΛ· ÏfiÁˆ Ù˘ ·ıÔÏÔÁ›·˜ ·fi ÙÔÓ Ó‡ÌÔÓ·. ¶·Ú·ÙËÚ‹ıËΠfiÙÈ Ë Ì¤ÛË ËÏÈΛ· ÂÌÊ¿ÓÈÛ˘ ‚ÚÔÁ¯ÂÎÙ·ÛÈÒÓ ‹Ù·Ó 30±2,2 ¤ÙË Û ·ÓÙ›ıÂÛË ÙȘ ËÏÈ˘ 10±4,4 ¤ÙË (16), Ô˘ ‹Ù·Ó Ë Ì¤ÛË ËÏÈΛ· ηٿ ÙËÓ ÔÔ›· ‰ÂÓ Â›¯·Ó ·Ú·ÙËÚËı› ·ÎfiÌË ‚ÚÔÁ¯ÂÎٷۛ˜. ¶ÏËÎÙÚÔ‰·ÎÙ˘Ï›· ·Ú·ÙËÚÂ›Ù·È Û˘Ó‹ıˆ˜ ÌÂÙ¿ ÙËÓ ËÏÈΛ· ÙˆÓ 18 ÂÙÒÓ (16). ∏ Ó¢ÌÔÓÈ΋ ÏÂÈÙÔ˘ÚÁ›· Â›Ó·È ·ÔÊÚ·ÎÙÈÎÔ‡ Ù‡Ô˘ ¯ˆÚ›˜ ‹ Ì ÌÂÚÈ΋ ·Ó·ÛÙÚ„ÈÌfiÙËÙ· ÌÂÙ¿ ·fi ¯ÔÚ‹ÁËÛË ‚2 ‰ÈÂÁ¤ÚÙË. ™Â ÚÔ¯ˆÚË̤ӷ ÛÙ¿‰È· ·Ú·ÙËÚÂ›Ù·È ˘ÔÍ›· Î·È ˘ÂÚηÓ›·. ™ÙÔ˘˜ ÂÓ‹ÏÈΘ, ÂÎÙfi˜ ·fi Ù· Û˘ÌÙÒÌ·Ù· ·fi ÙÔ ·Ó·Ó¢ÛÙÈÎfi, ˘Ô„›· Ù˘ ÓfiÛÔ˘ Ù›ıÂÙ·È Û ÂÚÈÙÒÛÂȘ ·Ó‰ÚÈ΋˜ ÛÙÂÈÚfiÙËÙ·˜, fiÙ·Ó Ù· ÛÂÚÌ·ÙÔ˙ˆ¿ÚÈ· Â›Ó·È ·Î›ÓËÙ· ‹ ¤¯Ô˘Ó ÌÂȈ̤ÓË ÎÈÓËÙÈÎfiÙËÙ· (17), ¯ˆÚ›˜ Ë ÁÔÓÈÌfiÙËÙ· Ó· ·ÔÎÏ›ÂÈ ÙË ‰È¿ÁÓˆÛË ÛÙÔ˘˜ ¿ÚÚÂÓ˜. ∞Ó¿ÏÔÁ· ÈÛ¯‡Ô˘Ó ÁÈ· ÙË ÛÙÂÈÚfiÙËÙ· ÙˆÓ Á˘Ó·ÈÎÒÓ, fiÙ·Ó ‰ÂÓ ˘¿Ú¯Ô˘Ó ·Ó·ÙÔÌÈÎÔ› ‹ ÔÚÌÔÓÈÎÔ› ÏfiÁÔÈ Ù˘ ˘ÔÁÔÓÈÌfiÙËÙ·˜ (4).

¢È·ÊÔÚÈ΋ ‰È¿ÁÓˆÛË ¢È·ÊÔÚÈ΋ ‰È¿ÁÓˆÛË Ù˘ ÓfiÛÔ˘ Á›ÓÂÙ·È ·fi ÙËÓ ÈÓÔ΢ÛÙÈ΋ ÓfiÛÔ, ÙÔ ¿ÛıÌ·, ÙȘ ·ÓÔÛÔ·ÓÂ¿ÚÎÂȘ Î·È ¿ÏϘ ¯ÚfiÓȘ Ó¢ÌÔÓÈΤ˜ ÓfiÛÔ˘˜. °È· ÙÔ ÏfiÁÔ ·˘Ùfi, Ë ÚÒÙË ÛÂÈÚ¿ ÂÍÂÙ¿ÛÂˆÓ ÂÚÈÏ·Ì‚¿ÓÂÈ ‰ÔÎÈÌ·Û›· ȉÚÒÙ·, ·ÓÔÛÔÛÊ·ÈÚ›Ó˜, Û˘ÌÂÚÈÏ·Ì‚·ÓfiÌÂÓ˘ Ù˘ IgE, ˘ÔÔÌ¿‰Â˜ ·ÓÔÛÔÛÊ·ÈÚÈÓÒÓ, ÚÔÛ‰ÈÔÚÈÛÌfi ·ÓÙÈۈ̷ÙÈÎÒÓ ··ÓÙ‹ÛÂˆÓ Û ÚÔËÁËı¤Paediatriki 2008;71:14-20

ÓÙ˜ ÂÌ‚ÔÏÈ·ÛÌÔ‡˜ ‹ Ïԛ̈ÍË Ì ·‰ÂÓÔ˚fi ‹ Ì˘ÎfiÏ·ÛÌ·, ·˘ÙÔ·ÓÙÈÛÒÌ·Ù· Î·È Â›‰· ·1-·ÓÙÈıÚ˘„›Ó˘. ™Â ·È‰È¿ Ì ¿ÛıÌ· Ô˘ ‰ÂÓ ··ÓÙÔ‡Ó ÛÙËÓ Î·Ù¿ÏÏËÏË ·ÁˆÁ‹ Ú¤ÂÈ Ó· Á›ÓÔÓÙ·È ÂÍÂÙ¿ÛÂȘ Ô˘ ÂȂ‚·ÈÒÓÔ˘Ó ÙË ‰È¿ÁÓˆÛË ÙÔ˘ Û˘Ó‰ÚfiÌÔ˘ ‰˘ÛÎÈÓ‹ÙˆÓ ÎÚÔÛÛÒÓ.

¢È·ÁÓˆÛÙÈΤ˜ ÂÍÂÙ¿ÛÂȘ ¢ÔÎÈÌ·Û›· ۷ί·Ú›Ó˘ ™Â ·È‰È¿ Ô˘ ÌÔÚÔ‡Ó Ó· Û˘ÓÂÚÁ·ÛÙÔ‡Ó, ËÏÈΛ·˜ Û˘Ó‹ıˆ˜ ÌÂÁ·Ï‡ÙÂÚ˘ ÙˆÓ 12 ÂÙÒÓ, ÙÂÌ¿¯ÈÔ 12 mm ۷ί·Ú›Ó˘ Ù›ıÂÙ·È ÛÙÔ ÚfiÛıÈÔ ¿ÎÚÔ Ù˘ οو ÚÈÓÈ΋˜ ÎfiÁ¯Ë˜ (18,19). √ ·ÛıÂÓ‹˜ οıÂÙ·È ‹ÚÂÌÔ˜ Ì ÙÔ ÎÂÊ¿ÏÈ ÁÂṲ́ÓÔ ÚÔ˜ Ù· ÂÌÚfi˜ ¯ˆÚ›˜ Ó· ‚‹¯ÂÈ, Ó· ÙÚÒÂÈ ‹ Ó· ›ÓÂÈ Î·Ù¿ ÙË ‰È¿ÚÎÂÈ· Ù˘ ‰ÔÎÈÌ·Û›·˜. ∂¿Ó ÌÂÙ¿ ÙËÓ ¿ÚÔ‰Ô Ì›·˜ ÒÚ·˜ ‰ÂÓ ·ÈÛı·Óı› ÙË Á‡ÛË Ù˘ ۷ί·Ú›Ó˘ ÛËÌ·›ÓÂÈ fiÙÈ ÚfiÎÂÈÙ·È ÁÈ· ·ıÔÏÔÁÈ΋ οı·ÚÛË Ù˘ ‚ϤÓÓ·˜ ·fi ÙÔ˘˜ ÎÚÔÛÛÔ‡˜. ™ÙÔÓ ·ÛıÂÓ‹ ÙÔÔıÂÙÂ›Ù·È Û·Î¯·Ú›ÓË Î·Ù¢ı›·Ó ÛÙË ÁÏÒÛÛ· ÁÈ· Ó· ÂȂ‚·Èˆı› fiÙÈ ÌÔÚ› Ó· ·ÈÛı·Óı› ÙË Á‡ÛË Ù˘. ª¤ÙÚËÛË Ù˘ Û˘¯ÓfiÙËÙ·˜ ΛÓËÛ˘ ÙˆÓ ÎÚÔÛÛÒÓ ∂¿Ó Ë ‰ÔÎÈÌ·Û›· ۷ί·Ú›Ó˘ Â›Ó·È Ê˘ÛÈÔÏÔÁÈ΋ (<Ì›· ÒÚ·), ÙfiÙ ‰ÂÓ ¯ÚÂÈ¿˙ÂÙ·È ÂÚ·ÈÙ¤Úˆ ÂͤٷÛË. ∞Ó fï˜ Â›Ó·È ·ıÔÏÔÁÈ΋, ··ÈÙÂ›Ù·È Ó· Á›ÓÂÈ Ì¤ÙÚËÛË Ù˘ Û˘¯ÓfiÙËÙ·˜ Ù˘ ΛÓËÛ˘ ÙˆÓ ÎÚÔÛÛÒÓ Î·È ·ÂÈÎfiÓÈÛË Ù˘ ÌÔÚÊÔÏÔÁ›·˜ Ù˘ ΛÓËÛ˘. °È· ÙÔ ÏfiÁÔ ·˘Ùfi, Ï·Ì‚¿ÓÂÙ·È ÂÈı‹ÏÈÔ ·fi ÙÔ ÚÈÓÔÊ¿Ú˘ÁÁ· Ì ΢ÙÙ·ÚÔÏÔÁÈ΋ ‚Ô‡ÚÙÛ· ·ÔÛÙÂÈڈ̤ÓË ‹ ÌÈ·˜ ¯Ú‹Ûˆ˜ (20). ∆Ô ‰Â›ÁÌ· Ô˘ Ï·Ì‚¿ÓÂÙ·È Ì ·˘Ùfi ÙÔÓ ÙÚfiÔ, ·ÎfiÌË Î·È fiÙ·Ó ÙÔ ·È‰› ‰ÂÓ Û˘ÓÂÚÁ¿˙ÂÙ·È, Â›Ó·È ÈηÓÔÔÈËÙÈÎfi ÛÙÔ 80% ÙˆÓ ÂÚÈÙÒÛÂˆÓ (21). ∂¿Ó Á›ÓÂÈ ‚ÚÔÁ¯ÔÛÎfiËÛË ÁÈ· ¿ÏÏÔ ÏfiÁÔ, ηÏfi Â›Ó·È Ó· ÏËÊı› Î·È ·fi ÙÔ˘˜ ‚ÚfiÁ¯Ô˘˜ ‰Â›ÁÌ·, ÁÓˆÚ›˙ÔÓÙ·˜ fiÙÈ ·Ó·ÈÛıËÙÈο, fiˆ˜ Ë ·ÏÔı¿ÓË Î·È Ë ÏȉÔη˝ÓË, ÌÂÈÒÓÔ˘Ó ÙË Û˘¯ÓfiÙËÙ· ΛÓËÛ˘ ÙˆÓ ÎÚÔÛÛÒÓ (22). ∆Ô ‰Â›ÁÌ· ηÓÔÓÈο Ú¤ÂÈ Ó· ÌÂÙ·ÊÂÚı› ÂÓÙfi˜ 2 ˆÚÒÓ ÛÙÔ Î¤ÓÙÚÔ Ô˘ ı· οÓÂÈ ÙË Ì¤ÙÚËÛË, ·ÏÏ¿ Î·È ‰Â›ÁÌ·Ù· ÌÂÙ·ÊÂÚfiÌÂÓ· ÂÓÙfi˜ 24 ˆÚÒÓ ÌÂÙÚÒÓÙ·È Û˘Ó‹ıˆ˜ ¯ˆÚ›˜ Úfi‚ÏËÌ· (7). ¶ÔÏÏÔ› ÚÔÛı¤ÙÔ˘Ó ÛÙÔ ‰Â›ÁÌ· Ô˘ ÚfiÎÂÈÙ·È Ó· ηı˘ÛÙÂÚ‹ÛÂÈ ¤Ú·Ó ÙˆÓ ‰‡Ô ˆÚÒÓ Î·È ÂÓÈÎÈÏÏ›ÓË ‹ ÛÙÚÂÙÔÌ˘Î›ÓË ÁÈ· Ó· ηٷȤÛÔ˘Ó ÙËÓ ·Ó¿Ù˘ÍË Ù˘ ¯ÏˆÚ›‰·˜ ÙÔ˘ ÂÈıËÏ›Ô˘. ∫¿ı ΤÓÙÚÔ Ú¤ÂÈ Ó· ÚÔÛ‰ÈÔÚ›˙ÂÈ ÙȘ ‰ÈΤ˜ ÙÔ˘ Ê˘ÛÈÔÏÔÁÈΤ˜ ÙÈ̤˜ ‰ÈfiÙÈ ÂÍ·ÚÙÒÓÙ·È ·fi ÙËÓ ËÏÈΛ· Î·È ·fi ÙË Ì¤ıÔ‰Ô. √È Û˘Ó‹ıÂȘ Ê˘ÛÈÔÏÔÁÈΤ˜ ÙÈ̤˜ Â›Ó·È 11-16 Hz (7). ∂Âȉ‹ Ë Û˘¯ÓfiÙËÙ· Ù˘ ΛÓËÛ˘ ÂËÚ¿˙ÂÙ·È ·ÎfiÌË Î·È ·fi Û˘Ó‹ıÂȘ ÏÔÈÌÒÍÂȘ, ÙÔ ‰Â›ÁÌ· ı· Ú¤ÂÈ Ó· Ï·Ì‚¿ÓÂÙ·È 4-6 ‚‰ÔÌ¿‰Â˜ ÌÂÙ¿ ·fi ·Ó¿ÏÔÁÔ ÂÂÈÛfi‰ÈÔ Ô˘ ÂÈÓ¤ÌÂÙ·È ÙÔ ·Ó·Ó¢ÛÙÈÎfi (1,23,24). °È· ÙË Ì¤ÙÚËÛË Ù˘ Û˘¯ÓfiÙËÙ·˜ ¯ÚËÛÈÌÔÔÈ›ٷÈ

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·17

17

¶ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ

Û˘Ó‹ıˆ˜ Ë ÊˆÙÔ‰ÈÔ‰È΋ ̤ıÔ‰Ô˜, Ì ÙËÓ ÔÔ›· ‰ÂÓ ÂϤÁ¯ÂÙ·È Ô ÙÚfiÔ˜ Ù˘ ΛÓËÛ˘ ÙˆÓ ÎÚÔÛÛÒÓ. °È· ÙËÓ ·ÂÈÎfiÓÈÛË ÙÔ˘ ÙÚfiÔ˘ Ù˘ ΛÓËÛ˘, ··ÈÙÂ›Ù·È Ë ·Ó¿Ï˘ÛË Ì video ˘„ËÏ‹˜ ¢ÎÚ›ÓÂÈ·˜ Î·È ˘„ËÏ‹˜ Ù·¯‡ÙËÙ·˜. ∏ ηٷÁÚ·Ê‹ ÙÔ˘ ÙÚfiÔ˘ ΛÓËÛ˘ Â›Ó·È ··Ú·›ÙËÙË, ÁÈ·Ù› ·Ó¿ÏÔÁ· Ì ÙÔ ‰ÔÌÈÎfi ÂÏ¿Ùو̷ ÌÔÚ› Ë Û˘¯ÓfiÙËÙ· ΛÓËÛ˘ Ó· Â›Ó·È Ê˘ÛÈÔÏÔÁÈ΋, ·ÏÏ¿ Ë ÌÔÚÊ‹ Ù˘ ΛÓËÛ˘ ·ıÔÏÔÁÈ΋ (1,4,7). √ ÙÂÏÂ˘Ù·›Ô˜ Û˘Ó‰˘·ÛÌfi˜ ·Ú·ÙËÚÂ›Ù·È Û ·ÛıÂÓ›˜ Ì ÌÂÙ·ÙfiÈÛË ÙˆÓ ÎÚÔÛÛÒÓ ‹ Ì ·ÁÂÓÂÛ›· ÙˆÓ ÎÂÓÙÚÈÎÒÓ ÌÈÎÚÔÛˆÏËÓ·Ú›ˆÓ. ™ÙȘ ˘fiÏÔÈ˜ ÂÚÈÙÒÛÂȘ ‚Ï¿‚˘ Ù˘ Â͈ÙÂÚÈ΋˜ ‹ Ù˘ ÂÛˆÙÂÚÈ΋˜ ‰˘Ó½Ó˘ ‹ ÙÔ˘ ·ÎÙÈÓÔÂȉԇ˜ ÓËÌ·Ù›Ô˘ (radial spoke), ÂËÚ¿˙ÂÙ·È ¿ÓÙÔÙÂ Î·È Ë Û˘¯ÓfiÙËÙ·, ÂÓÒ Ë Î›ÓËÛË Î·Ù¿ ÙËÓ ·Ó¿Ï˘ÛË Ì video Â›Ó·È ·ıÔÏÔÁÈ΋. ∞Ó Ë Î›ÓËÛË Î·È Ë Û˘¯ÓfiÙËÙ· Â›Ó·È Ê˘ÛÈÔÏÔÁÈΤ˜, ‰ÂÓ ˘¿Ú¯ÂÈ ÓfiÛÔ˜ ‰˘ÛÎÈÓ‹ÙˆÓ ÎÚÔÛÛÒÓ Î·È Ë ‰ÈÂÚ‡ÓËÛË ÛÙ·Ì·Ù¿ ‰Ò. ∞Ó Â›Ó·È ·ıÔÏÔÁÈ΋ ÌÈ· ·fi ÙȘ ‰‡Ô ‹ ·Ó Ë Û˘¯ÓfiÙËÙ· Â›Ó·È ÌÂÓ Ê˘ÛÈÔÏÔÁÈ΋, ·ÏÏ¿ ¯ˆÚ›˜ Ó· ¤¯ÂÈ Á›ÓÂÈ Î·È ·Ó¿Ï˘ÛË Ù˘ ΛÓËÛ˘, Ë ÂͤٷÛË Û˘Ó¯›˙ÂÙ·È Ì ËÏÂÎÙÚÔÓÈ΋ ÌÈÎÚÔÛÎfiËÛË (∂ÈÎfiÓ· 4). ∏ÏÂÎÙÚÔÓÈÎfi ÌÈÎÚÔÛÎfiÈÔ °È· ÙËÓ ÂͤٷÛË Ù˘ ‰ÔÌ‹˜ ÙˆÓ ÎÚÔÛÛÒÓ Ì ËÏÂÎÙÚÔÓÈÎfi ÌÈÎÚÔÛÎfiÈÔ Â›Ó·È ÚÔÙÈÌËÙ¤· Ë Ï‹„Ë ‰Â›ÁÌ·ÙÔ˜ Ì ‚ÈÔ„›· ·fi ‰‡Ô ‰È·ÊÔÚÂÙÈΤ˜ ÂÚÈÔ¯¤˜, ÒÛÙ ӷ ·ÔÎÏÂÈÛÙ› Î·È Ë ÂÚ›ÙˆÛË ‰Â˘ÙÂÚÔÁÂÓÒÓ ‚Ï·‚ÒÓ ÂÍ·ÈÙ›·˜ Ïԛ̈͢ ‹ ÊÏÂÁÌÔÓ‹˜. ∆· ÙÂÏÂ˘Ù·›· ¯ÚfiÓÈ· ÁÈ· ÙÔÓ ·ÔÎÏÂÈÛÌfi Ù˘ Ïԛ̈͢ ¯ÚËÛÈÌÔÔÈÔ‡ÓÙ·È ÎÚÔÛÛÔ› ÌÂÙ¿ ·fi ÂȉÈΤ˜ ηÏÏȤÚÁÂȘ ÛÂ Û˘Óı‹Î˜ ·ÂÚ›Ô˘-˘ÁÚ¿˜ Ê¿Ûˆ˜ (25), ·ÏÏ¿ ·˘Ù¤˜ ÔÈ Î·ÏÏȤÚÁÂȘ ¯ÚËÛÈÌÔÔÈÔ‡ÓÙ·È Û ÂÚÈÔÚÈṲ̂ÓÔ ·ÚÈıÌfi ΤÓÙÚˆÓ. ™˘ÓÔÏÈο, Ú¤ÂÈ Ó· ÌÂÏÂÙËıÔ‡Ó ÙÔ˘Ï¿¯ÈÛÙÔÓ 50 ÎÚÔÛÛÔ› (26). ∞ӈ̷ϛ˜ ÌÔÚ› Ó· ·Ú·ÙËıÔ‡Ó ÛÙÔ 10% Î·È ÛÂ Ê˘ÛÈÔÏÔÁÈÎfi ÂÈı‹ÏÈÔ Î·È ÁÈ· ÙÔ ÏfiÁÔ ·˘Ùfi ÔÈ ·ÓˆÌ·Ï›Â˜ Ú¤ÂÈ Ó· ÂÎÊÚ·ÛÙÔ‡Ó Î·È ÔÛÔÙÈο (26,27). √È Û˘¯ÓfiÙÂÚ˜ ‰È·Ù·Ú·¯¤˜ (28) Â›Ó·È Ë ‰˘ÛÌÔÚÊ›· ‹ ·Ô˘Û›· ÙˆÓ ÂÛˆÙÂÚÈÎÒÓ ‹ ÙˆÓ Â͈ÙÂÚÈÎÒÓ ‚Ú·¯ÈfiÓˆÓ Ù˘ ‰˘Ó½Ó˘ (80%), ÌÂÙ·ÙfiÈÛË ÙˆÓ ÎÂÓÙÚÈÎÒÓ ÌÈÎÚÔÛˆÏËÓ·Ú›ˆÓ (10%) Î·È ‚Ï¿‚Ë ÙÔ˘ ·ÎÙÈÓÔÂȉԇ˜ ÓËÌ·Ù›Ô˘ (6%). ÕÏϘ, ÏÈÁfiÙÂÚÔ Û˘¯Ó¤˜ ·ÓˆÌ·Ï›Â˜ Â›Ó·È Ë ·Ï·Û›· ÙˆÓ ÎÚÔÛÛÒÓ, ‰È·ÊÔÚÔÔÈ‹ÛÂȘ ÙÔ˘ ‚·ÛÈÎÔ‡ ÛˆÌ·Ù›Ô˘, ¤ÏÏÂÈ„Ë ÙÔ˘ ·ÍÔÓÈÎÔ‡ ÛˆÌ·Ù›Ô˘ ‹ ÎÚÔÛÛÔ› ÌÂÁ¿ÏÔ˘ Ì‹ÎÔ˘˜. √ÚÈṲ̂Ó˜ ·fi ÙȘ ‚Ï¿‚˜, fiˆ˜ Ë ÌÂÙ·ÙfiÈÛË ÙˆÓ ÎÂÓÙÚÈÎÒÓ ÌÈÎÚÔÛˆÏËÓ·Ú›ˆÓ, ÌÔÚ› Ó· ·Ú·ÙËÚËıÔ‡Ó ÌÂÙ¿ ·fi ‰Â˘ÙÂÚÔÁÂÓ›˜ ÌÂÙ·‚ÔϤ˜ ÏfiÁˆ Ïԛ̈͢ ‹ ÊÏÂÁÌÔÓ‹˜. ™ÙÔ 3% ÙˆÓ ÂÚÈÙÒÛÂˆÓ ‰ÂÓ ·Ú·ÙËÚÂ›Ù·È ·ÓˆÌ·Ï›· (28), ÔfiÙÂ Ë ‰È¿ÁÓˆÛË ÌÔÚ› Ó· ÛÙÔȯÂÈÔıÂÙËı› ÌfiÓÔ Ì ÙËÓ ·ıÔÏÔÁÈ΋ ΛÓËÛË ÙˆÓ ÎÚÔÛÛÒÓ. °È· ÙÔ ÏfiÁÔ ·˘Ùfi Â›Ó·È ÛËÌ·ÓÙÈÎfi Ó·

¢ÔÎÈÌ·Û›· ۷ί·Ú›Ó˘ ‹ ÚÈÓÈÎÔ‡ ¡√ (Û ·È‰È¿ ÌÂÁ·Ï‡ÙÂÚ· ÙˆÓ 12 Î·È 6 ÂÙÒÓ, ·ÓÙ›ÛÙÔȯ·)

º˘ÛÈÔÏÔÁÈ΋

¶·ıÔÏÔÁÈ΋

ª¤ÙÚËÛË Ù˘ Û˘¯ÓfiÙËÙ·˜ Î·È ·Ó¿Ï˘ÛË Î›ÓËÛ˘

º˘ÛÈÔÏÔÁÈ΋

¶·ıÔÏÔÁÈ΋

∏ÏÂÎÙÚÔÓÈÎfi ÌÈÎÚÔÛÎfiÈÔ ∂ÈÎfiÓ· 4. ∞ÏÁfiÚÈıÌÔ˜ ‰È·ÁÓˆÛÙÈ΋˜ ÚÔÛ¤ÁÁÈÛ˘ ·ÛıÂÓÔ‡˜ Ì ˘Ô„›· ÚˆÙÔ·ıÔ‡˜ ‰˘ÛÎÈÓËÛ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ.

Á›ÓÂÙ·È Î·È ÌÂϤÙË ÚÔÛ·Ó·ÙÔÏÈÛÌÔ‡ ÙˆÓ ÎÚÔÛÛÒÓ (29,30), ‰ÈfiÙÈ ¤¯Ô˘Ó ·Ú·ÙËÚËı› ÂÚÈÙÒÛÂȘ ÌÂ Ê˘ÛÈÔÏÔÁÈÎÔ‡˜ ·Ó·ÙÔÌÈο ÎÚÔÛÛÔ‡˜, ·ÏÏ¿ Ì ·ıÔÏÔÁÈÎfi ÚÔÛ·Ó·ÙÔÏÈÛÌfi ηٿ ÙËÓ Î›ÓËÛË, fiÔ˘ Ë Ì¤ÛË ·fiÎÏÈÛË ÙˆÓ Û¯ËÌ·ÙÈ˙fiÌÂÓˆÓ ÁˆÓÈÒÓ (7) Â›Ó·È ÌÂÁ·Ï‡ÙÂÚË ÙˆÓ 20Æ. ¢ÔÎÈÌ·Û›· ÚÈÓÈÎÔ‡ ÂÎÓÂfiÌÂÓÔ˘ ¡√ √È ÙÈ̤˜ ÙÔ˘ ÚÈÓÈÎÔ‡ ÂÎÓÂfiÌÂÓÔ˘ ¡√ Û ·ÛıÂÓ›˜ Ì ÚˆÙÔ·ı‹ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ Â›Ó·È Ôχ ¯·ÌËϤ˜ (14,31) Î·È ‰ÂÓ Û¯ÂÙ›˙ÔÓÙ·È Ì ÙËÓ ËÏÈΛ·. ™Â ÌÈ· ÔÌ¿‰· 64 ·ÛıÂÓÒÓ Ì ÂȂ‚·ÈˆÌ¤ÓË ‰È¿ÁÓˆÛË ‹Ù·Ó 19±17 nl/minute Û ۯ¤ÛË Ì 376±124 nl/minute ÛÙ· Ê˘ÛÈÔÏÔÁÈο ¿ÙÔÌ· Î·È 184±109 nl/minute ÛÙÔ˘˜ ·ÛıÂÓ›˜ Ì ÈÓÔ΢ÛÙÈ΋ ÓfiÛÔ (16). √È ÙÈ̤˜ ÙÔ˘ ¡√ Û ·ÛıÂÓ›˜ Ì ‚·Ú‡ ¿ÛıÌ· ‹ Ì ‚ÚÔÁ¯ÂÎٷۛ˜ ¿ÏÏ˘ ·ÈÙÈÔÏÔÁ›·˜ Â›Ó·È ˘„ËϤ˜ (7,16,32)Î·È ÁÈ· ÙÔ ÏfiÁÔ ·˘Ùfi ¯·ÌËÏfi ¡√ Û ·ÛıÂÓ‹ Ì ¿ÛıÌ· Ô˘ ‰ÂÓ ·ÓÙ·ÔÎÚ›ÓÂÙ·È ÛÙËÓ ·ÁˆÁ‹ ı¤ÙÂÈ ÙËÓ ˘Ô„›· Ù˘ ÚˆÙÔ·ıÔ‡˜ ‰˘ÛÎÈÓËÛ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ. ÷ÌËÏfi, ˆÛÙfiÛÔ, Â›Ó·È ÙÔ ¡√ Î·È Û ·ÛıÂÓ›˜ Ì ÈÓÔ΢ÛÙÈ΋ ÓfiÛÔ Î·È Û ·ÛıÂÓ›˜ Ì ÚÈÓÈÎÔ‡˜ Ôχԉ˜ ¿ÏÏ˘ ·ÈÙÈÔÏÔÁ›·˜ (33). µ¤‚·È·, ÔÈ ÙÈ̤˜ Û ÚˆÙÔ·ı‹ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ Â›Ó·È Ôχ ÈÔ ¯·ÌËϤ˜, ·ÏÏ¿ ˘¿Ú¯ÂÈ ÌÈÎÚÔ‡ ‚·ıÌÔ‡ ·ÏÏËÏÔÂÈÎ¿Ï˘„Ë Ì ÙËÓ ÈÓÔ΢ÛÙÈ΋ ÓfiÛÔ (33). °È’ ·˘Ùfi ÙÔ ÏfiÁÔ, ··ÈÙÂ›Ù·È Ô ·ÔÎÏÂÈÛÌfi˜ Ù˘ ‰È¿ÁÓˆÛ˘ Ù˘ ÈÓÔ΢ÛÙÈ΋˜ Û ·ÛıÂÓ›˜ Ì ¯·ÌËÏfi ¡√. ¢ÂÓ ¤¯ÂÈ ·Ú·ÙËÚËı› Û˘Û¯¤ÙÈÛË ÙˆÓ ÙÈÌÒÓ ÙÔ˘ ¡√ Ì ÙÔ Â›‰Ô˜ Ù˘ ÈÛÙÔÏÔÁÈ΋˜ ‚Ï¿‚˘ Ô‡ÙÂ Â›Ó·È ÁÓˆÛÙfi˜ Ô ·ıÔÊ˘ÛÈÔÏÔÁÈÎfi˜ Ì˯·ÓÈÛÌfi˜ Ù˘ ÂÎÓÔ‹˜ ÙfiÛÔ ¯·ÌËÏÒÓ ÂÈ¤‰ˆÓ ¡√. ™ËÌÂÈÒÓÂÙ·È fiÙÈ ÔÈ ÙÈ̤˜ ÙˆÓ ˘Ô¯ÚˆÙÈÎÒÓ ÂÙÂÚÔ˙˘ÁˆÙÒÓ, ÁÔÓ¤ˆÓ ÙˆÓ ¶·È‰È·ÙÚÈ΋ 2008;71:14-20

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·18

18

ª. ªÔ˘ÛÙ¿ÎË, ∞. ºÚÂÙ˙¿ÁÈ·˜

·È‰ÈÒÓ Ì ÂȂ‚·ÈˆÌ¤ÓË ‰È¿ÁÓˆÛË, Â›Ó·È ÂӉȿÌÂÛ˜ 285±101 nl/minute, Ì ‡ÚÔ˜ 37-613 nl/minute, ˘Ô‰ËÏÒÓÔÓÙ·˜ fiÙÈ ˘¿Ú¯ÂÈ Î¿ÔÈ· Û¯¤ÛË ÌÂٷ͇ ÙˆÓ ÂÙÂÚÔ˙˘ÁˆÙÒÓ Î·È Ù˘ ·Ú·ÁˆÁ‹˜ ¡√ (14). ∞Ó Î·È ‰ÂÓ ¤¯ÂÈ Â›ÛËÌ· ηıÈÂÚˆı› ˆ˜ ÂͤٷÛË ‰È·ÏÔÁ‹˜ ÁÈ· ·ÛıÂÓ›˜ Ì ˘Ô„›· ÁÈ· ÚˆÙÔ·ı‹ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ, ÚÔÙ›ÓÂÙ·È ·fi ÔÚÈṲ̂ÓÔ˘˜ ÂÚ¢ÓËÙ¤˜ (34,35) ˆ˜ ¯Ú‹ÛÈÌÔ ÂÚÁ·ÏÂ›Ô ÁÈ· ÙËÓ ·Ó›¯Ó¢ÛË ·ÛıÂÓÒÓ Ì ÚˆÙÔ·ı‹ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ. °ÂÓÂÙÈ΋ ·Ó¿Ï˘ÛË ∏ ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ Â›Ó·È ÁÂÓÂÙÈο ÎÏËÚÔÓÔÌÔ‡ÌÂÓË ÓfiÛÔ˜ Ì ·˘ÙfiÛˆÌÔ ˘ÔÏÂÈfiÌÂÓÔ Ù‡Ô, ·Ó Î·È ¤¯Ô˘Ó ÂÚÈÁÚ·Ê› Î·È Û¿ÓȘ ÂÚÈÙÒÛÂȘ ÎÏËÚÔÓÔÌÈÎfiÙËÙ·˜ Ì ·˘ÙfiÛˆÌÔ ÂÈÎÚ·ÙËÙÈÎfi ‹ Î·È ÌÂ Ê˘ÏÔÛ‡Ó‰ÂÙÔ (7,36,37). ∂Âȉ‹ ÔÈ ÈÛÙÔÏÔÁÈΤ˜ ‚Ï¿‚˜ Â›Ó·È ÔÈΛÏÔ˘ Ù‡Ô˘, ‰ÂÓ ¤¯ÂÈ ‚ÚÂı› ¤Ó·˜ Â›ÙÔÔ˜ ÁÂÓÂÙÈο ˘‡ı˘ÓÔ˜ ÁÈ· ÙË ÓfiÛÔ. ÕÏψÛÙÂ, Î·È Û ·ÛıÂÓ›˜ Ì ÙȘ ›‰È˜ ÈÛÙÔÏÔÁÈΤ˜ ‚Ï¿‚˜ ·Ú·ÙËÚÂ›Ù·È ÁÂÓÂÙÈ΋ ÂÙÂÚÔÁ¤ÓÂÈ·. ª¤¯ÚÈ Û‹ÌÂÚ·, ÔÈ Î˘ÚÈfiÙÂÚ˜ ÌÂÙ·ÏÏ¿ÍÂȘ Ô˘ ¤¯Ô˘Ó Ù·˘ÙÔÔÈËı› Â›Ó·È ÔÈ ·ÎfiÏÔ˘ı˜. ªÂÙ¿ÏÏ·ÍË Ô˘ Έ‰ÈÎÔÔÈ› ÙËÓ ÚˆÙ½ÓË (4,38) DNAI1 (dynein axonemal intermediate chain 1) Ô˘ ‰ڿ˙ÂÙ·È ÛÙÔ ¯ÚˆÌfiۈ̷ 9p13-21, ·˘Ù‹ Ô˘ Έ‰ÈÎÔÔÈ› ÙËÓ ÚˆÙ½ÓË (4,37) DNAH5 (dynein axonemal heavy chain 5) Ô˘ ‰ڿ˙ÂÙ·È ÛÙÔ ¯ÚˆÌfiۈ̷ 5p155p14 Î·È ·˘Ù‹ Ô˘ Έ‰ÈÎÔÔÈ› ÙËÓ ÚˆÙ½ÓË (4,37) DNAH11 Ô˘ Έ‰ÈÎÔÔÈ› Â›Û˘ ÙË ‚·Ú›· ¿Ï˘ÛÔ Ù˘ ‰˘Ó½Ó˘ Î·È ÂÓÙÔ›˙ÂÙ·È ÛÙÔ ¯ÚˆÌfiۈ̷ 17p21. ∏ ÙÂÏÂ˘Ù·›· ÌÂÙ¿ÏÏ·ÍË ¤¯ÂÈ Û˘Ó‰Âı› ΢ڛˆ˜ Ì ÙÔ Û‡Ó‰ÚÔÌÔ ·Ó·ÛÙÚÔÊ‹˜ ÙˆÓ ÛÏ¿Á¯ÓˆÓ. ∂›Û˘, ÌÂÙ¿ÏÏ·ÍË ¤¯ÂÈ ·Ú·ÙËÚËı› Î·È ÁÈ· ÙË ‚·Ú›· ¿Ï˘ÛÔ Ù˘ ÂÛˆÙÂÚÈ΋˜ ‰˘Ó½Ó˘ (4,38) DNAH7 Ô˘ ‰ڿ˙ÂÙ·È ÛÙÔ ¯ÚˆÌfiۈ̷ 2q32. ™Â ÌÂÌÔӈ̤ӷ ÂÚÈÛÙ·ÙÈο ¤¯ÂÈ ·Ú·ÙËÚËı› ÌÂÙ¿ÏÏ·ÍË Ù˘ ÚˆÙ½Ó˘ RPGR (37,39) Ô˘ ‰ڿ˙ÂÙ·È ÛÙÔ ¯ÚˆÌfiۈ̷ Ãp21 Î·È Ù˘ ÚˆÙ½Ó˘ √FD1 Ô˘ ‰ڿ˙ÂÙ·È ÛÙÔ ¯ÚˆÌfiۈ̷ Ãp22 (40). ¶ÂÚ·ÈÙ¤Úˆ ÁÂÓÂÙÈΤ˜ ÌÂϤÙ˜ ··ÈÙÔ‡ÓÙ·È ÁÈ· Ó· ·Ô‰Âȯı› Â¿Ó Ë ·Ó·ÛÙÚÔÊ‹ ÙˆÓ ÛÏ¿Á¯ÓˆÓ Û˘ÓÙÂÏÂ›Ù·È Ù˘¯·›· ÛÙÔ˘˜ ÌÈÛÔ‡˜ ·ÛıÂÓ›˜ Ì ÙË ÓfiÛÔ ÏfiÁˆ ¤ÏÏÂȄ˘ ÙÔ˘ ÚÔÛ·Ó·ÙÔÏÈÛÌÔ‡ ÙˆÓ ÎÚÔÛÛÒÓ ‹ ÔÚÈṲ̂ӷ ÁÔÓ›‰È· Â›Ó·È ÈÔ ÛÙÂÓ¿ Û˘Ó‰Â‰Â̤ӷ Ì ÙËÓ ·Ó·ÛÙÚÔÊ‹ ÙˆÓ ÛÏ¿Á¯ÓˆÓ.

£ÂÚ·›· ∏ ıÂÚ·¢ÙÈ΋ ·ÓÙÈÌÂÙÒÈÛË ÙˆÓ ÚÔ‚ÏËÌ¿ÙˆÓ, Ù· ÔÔ›· Û˘ÓÂ¿ÁÂÙ·È Ë ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ, ÏfiÁˆ ¤ÏÏÂȄ˘ ÌÂÏÂÙÒÓ, Á›ÓÂÙ·È ·fi ÎÏÈÓÈΤ˜ ÌÂϤÙ˜ Î·È ·fi ÙËÓ ÂÌÂÈÚ›· Ô˘ ˘¿Ú¯ÂÈ Û ·ÛıÂÓ›˜ Ì ÈÓÔ΢ÛÙÈ΋ ÓfiÛÔ Î·È ‚ÚÔÁ¯ÂÎٷۛ˜ ¿ÏPaediatriki 2008;71:14-20

Ï˘ ·ÈÙÈÔÏÔÁ›·˜. ∏ ıÂÚ·¢ÙÈ΋ ÙÔ˘˜ ·ÓÙÈÌÂÙÒÈÛË ÚÔÙ›ÓÂÙ·È Ó· Á›ÓÂÙ·È Û ÂȉÈο ΤÓÙÚ·, ÛÙ· ÔÔ›· ÙÔ ·È‰› ÌÔÚ› Ó· ·Ú·ÎÔÏÔ˘ıÂ›Ù·È Û ٷÎÙ¿ ÌÂÛԉȷÛÙ‹Ì·Ù·, ÂÊfiÛÔÓ Ì¤ÓÂÈ Ì·ÎÚÈ¿, Î·È Ë ÂӉȿÌÂÛË ·Ú·ÎÔÏÔ‡ıËÛË Ó· Á›ÓÂÙ·È ÛÂ Û˘ÓÂÓÓfiËÛË Ì ÙÔ ıÂÚ¿ÔÓÙ· ·È‰›·ÙÚÔ (11). ™ËÌÂÈÒÓÂÙ·È fiÙÈ ÛÙË ¯ÒÚ· Ì·˜ ˘¿Ú¯ÂÈ ·Ó¿ÁÎË ÔÚÁ·ÓˆÌ¤ÓˆÓ ΤÓÙÚˆÓ ‰È¿ÁÓˆÛ˘, ·Ú·ÎÔÏÔ‡ıËÛ˘ Î·È ·ÓÙÈÌÂÙÒÈÛ˘ ÙˆÓ ·È‰ÈÒÓ Ì ÚˆÙÔ·ı‹ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ. ∏ ÚÒÙÈÛÙË ÊÚÔÓÙ›‰· ÁÈ· ÙË ‰È·Ù‹ÚËÛË ÈηÓÔÔÈËÙÈ΋˜ ·Ó·Ó¢ÛÙÈ΋˜ ÏÂÈÙÔ˘ÚÁ›·˜ Â›Ó·È Ë ·Ó·Ó¢ÛÙÈ΋ Ê˘ÛÈÎÔıÂÚ·›· (1,7). ¶Ú¤ÂÈ Ó· Á›ÓÂÙ·È ‰‡Ô ÊÔÚ¤˜ ÙËÓ Ë̤ڷ Â› ›ÎÔÛÈ ÙÔ˘Ï¿¯ÈÛÙÔÓ ÏÂÙ¿. ∏ Ê˘ÛÈÎÔıÂÚ·›· Ú¤ÂÈ Ó· Û˘Ó‰˘¿˙ÂÙ·È Ì ¯Ú‹ÛË ‚2 ‰ÈÂÁ¤ÚÙË, ÂÊfiÛÔÓ Â›Ó·È ıÂÙÈ΋ Ë ‰ÔÎÈÌ·Û›· ·ÓÙÈÛÙÚ„ÈÌfiÙËÙ·˜, ηıÒ˜ Î·È Ì ¿ÛÎËÛË. √ ‚‹¯·˜ ¯ÚÂÈ¿˙ÂÙ·È Ó· ÂÓı·ÚÚ‡ÓÂÙ·È Î·È fi¯È Ó· ηٷȤ˙ÂÙ·È, ‰ÈfiÙÈ ‚ÔËı¿ ÛÙË ‚ÏÂÓÓÒ‰Ë Î¿ı·ÚÛË. ™Â ÂÚ›ÙˆÛË ÏÔÈÌÒÍÂˆÓ ·fi ÙÔ ·Ó·Ó¢ÛÙÈÎfi, ··ÈÙÂ›Ù·È Ë ¯ÔÚ‹ÁËÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ, ·Ó¿ÏÔÁ· Ì ÙÔ˘˜ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ‡˜ Ô˘ ·ÔÌÔÓÒÓÔÓÙ·È. ¶ÚÔÏËÙÈο ¯ÔÚËÁÂ›Ù·È ÂÙËÛ›ˆ˜ ÙÔ ·ÓÙÈÁÚÈÈÎfi ÂÌ‚fiÏÈÔ Î·È Á›ÓÂÙ·È ÂÌ‚ÔÏÈ·ÛÌfi˜ ηٿ ÙÔ˘ Ó¢ÌÔÓÈÔÎfiÎÎÔ˘ ÙfiÛÔ Ì ÙÔ Û˘ÓÂ˙¢Á̤ÓÔ 7‰‡Ó·ÌÔ fiÛÔ Î·È Ì ÙÔ ÔÏ˘Û·Î¯·ÚȉÈÎfi 23‰‡Ó·ÌÔ ÂÌ‚fiÏÈÔ, ÒÛÙ ӷ ·Ú¤¯ÂÙ·È Î¿Ï˘„Ë ÁÈ· ηٿ ÙÔ ‰˘Ó·ÙfiÓ ÂÚÈÛÛfiÙÂÚ· ÛÙÂϤ¯Ë ÙÔ˘ Ó¢ÌÔÓÈÔÎfiÎÎÔ˘ (10). ∞ÓÙÈ‚›ˆÛË ·Ó¿ÏÔÁ· Ì ÙÔ ÛÙ¿‰ÈÔ Ù˘ Ïԛ̈͢ ‰›‰ÂÙ·È ·fi ÙÔ ÛÙfiÌ· ‹ ÂÓ‰ÔÊϤ‚È·. ∏ ·ÔÌfiÓˆÛË ÙˆÓ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÒÓ Á›ÓÂÙ·È Â›Ù Ì ηÏÏȤÚÁÂÈ· ÂÎÎÚ›ÛÂˆÓ ·fi ÙÔ ‚‹¯· ‹ Ì ηÏÏȤÚÁÂÈ· ÙÔ˘ Ê·Ú˘ÁÁÈÎÔ‡ ÂȯڛÛÌ·ÙÔ˜, ·Ó¿ÏÔÁ· Ì ÙËÓ ËÏÈΛ·. √È ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ› Ô˘ Û˘Ó‹ıˆ˜ ·ÔÌÔÓÒÓÔÓÙ·È Â›Ó·È ·ÈÌfiÊÈÏÔ˜ Ù˘ ÁÚ›˘, ¯Ú˘Û›˙ÔÓÙ·˜ ÛÙ·Ê˘ÏfiÎÔÎÎÔ˜ Î·È Ó¢ÌÔÓÈfiÎÔÎÎÔ˜ (41,42). 梉ÔÌÔÓ¿‰· ·ÂÚÈÔÁÂÓ‹˜ ·ÔÌÔÓÒÓÂÙ·È Û˘Ó‹ıˆ˜ ÛÙËÓ ÂÓ‹ÏÈÎË ˙ˆ‹ ¯ˆÚ›˜ Ó· ·ÔÎÏ›ÂÙ·È Ë Î·ÏÏȤÚÁÂÈ¿ Ù˘ Î·È ÛÙËÓ ·È‰È΋ ‹ ÂÊË‚È΋ ËÏÈΛ· (14,41). ™ÙÔ˘˜ ÂÓ‹ÏÈΘ Ì ÚˆÙÔ·ı‹ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ ¤¯Ô˘Ó ·ÔÌÔÓˆı› ¿Ù˘· Ì˘ÎÔ‚·ÎÙËÚ›‰È·. ∞ÓÙÈ‚ÈÔÙÈο ¯ÚËÛÈÌÔÔÈÔ‡ÓÙ·È Â›Û˘ Î·È ÁÈ· ÙËÓ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ÔÍ›·˜ ̤Û˘ ˆÙ›Ùȉ·˜. ∏ Ì˘ÚÈÁÁÔÙÔÌ‹ Î·È Ë ÙÔÔı¤ÙËÛË ÛˆÏËÓ›ÛÎˆÓ ·ÂÚÈÛÌÔ‡ ·Ú·Ì¤ÓÂÈ ı¤Ì· ˘fi Û˘˙‹ÙËÛË, ÁÈ·Ù›, ·Ó Î·È ·ÔÙÂÏ› ̤ıÔ‰Ô ·ÓÙÈÌÂÙÒÈÛ˘ Ù˘ ¯ÚfiÓÈ·˜ ̤Û˘ ˆÙ›Ùȉ·˜ Ì ˘ÁÚfi, ÌÔÚ› Ó· ·Ú·ÙËÚËı› ¯ÚfiÓÈ· ¤ÎÎÚÈÛË ‹ Î·È Ù˘Ì·ÓÔÛÎÏ‹Ú˘ÓÛË (4). ∂›Ó·È ·ÌÊ›‚ÔÏÔ Î·Ù¿ fiÛÔ Ë ¯Ú‹ÛË ÙÔ˘˜ ‚ÔËı¿ ÛÙÔ ÙÂÏÈÎfi ·ÔÙ¤ÏÂÛÌ· Ù˘ ·ÎÔ‹˜, Ë ÔÔ›· fiÙ·Ó ÂËÚ¿˙ÂÙ·È Ú¤ÂÈ Ó· ˘Ô‚ÔËıÂ›Ù·È Ì ·ÎÔ˘ÛÙÈο ‚·ÚËÎÔ˝·˜ (4). ™ÙȘ ÂÚÈÙÒÛÂȘ Ô˘ ¯ÚÂÈ·ÛÙ› Ù˘Ì·ÓÔÏ·ÛÙÈ΋, fiÙ·Ó ÂӉ›ÎÓ˘Ù·È, ÌÔÚ› Ó· Û˘Ì‚Â›, ηıÒ˜ ¤¯ÂÈ ¯ÚËÛÈÌÔÔÈËı› Ì ÂÈÙ˘¯›· (43).

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·19

19

¶ÚˆÙÔ·ı‹˜ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ

∏ ¯ÚfiÓÈ· ·Ú·ÚÈÓÔÎÔÏ›Ùȉ· ·ÓÙÈÌÂÙˆ›˙ÂÙ·È Ì χÛÂȘ ÙˆÓ ÎfiÏˆÓ, ÚÈÓÈο ÛÙÂÚÔÂȉ‹ Î·È Û˘ÛÙËÌ·ÙÈ΋ ¯ÔÚ‹ÁËÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ. ¢ÂÓ ˘¿Ú¯Ô˘Ó ÂȉÈο Ê¿Ú̷η ÁÈ· ÙËÓ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ÚˆÙÔ·ıÔ‡˜ ‰˘ÛÎÈÓËÛ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ Î·È Ë ¯ÂÈÚÔ˘ÚÁÈ΋ ·ÓÙÈÌÂÙÒÈÛË ÙˆÓ ‚ÚÔÁ¯ÂÎÙ·ÛÈÒÓ ‰ÂÓ Û˘ÓÈÛÙ¿Ù·È ÁÈ·Ù› Â›Ó·È ÂÓ ‰˘Ó¿ÌÂÈ ÁÂÓÈÎÂ˘Ì¤ÓÔ Úfi‚ÏËÌ· ÁÈ· ÙË ÓfiÛÔ Î·È Û˘˙ËÙÂ›Ù·È ÌfiÓÔ Û ÂÚÈÙÒÛÂȘ ÌÔÓ‹ÚÔ˘˜ ‚ÚÔÁ¯ÂÎÙ·Û›·˜ ÌË ·ÓÙÈÌÂÙˆÈ˙fiÌÂÓ˘ ÈηÓÔÔÈËÙÈο Û˘ÓÙËÚËÙÈο (44). ∂›Û˘, Û ·ÛıÂÓ›˜ Ì ÙÂÏÈÎÔ‡ ÛÙ·‰›Ô˘ ·Ó·Ó¢ÛÙÈ΋ ·ÓÂ¿ÚÎÂÈ· ¤¯ÂÈ Á›ÓÂÈ ÌÂÙ·ÌfiÛ¯Â˘ÛË Î·Ú‰È¿˜-Ó¢ÌfiÓˆÓ ‹ ÌÂÙ·ÌfiÛ¯Â˘ÛË Ó¢ÌfiÓˆÓ (45). ∆Ô ÚÔÛ‰fiÎÈÌÔ ÂÈ‚›ˆÛ˘ ·˘ÙÒÓ ÙˆÓ ·ÛıÂÓÒÓ Â›Ó·È ·Ó¿ÏÔÁÔ Ì ·˘Ùfi ÙˆÓ ÌÂÙ·ÌÔÛ¯Â˘ı¤ÓÙˆÓ ÁÈ· ¿ÏϘ ·Èٛ˜.

µÈ‚ÏÈÔÁÚ·Ê›· 1.Meeks M, Bush A. Primary ciliary dyskinesia (PCD). Pediatr Pulmonol 2000;29:307-316.

2.Afzelius BA. Genetics and pulmonary medicine. 6. Immotile cilia syndrome: past, present, and prospects for the future. Thorax 1998;53:894-897.

3.De Iongh RU, Rutland J. Ciliary defects in healthy subjects, bronchiectasis, and primary ciliary dyskinesia. Am J Respir Crit Care Med 1995;151:1559-1567.

4.Ferkol T, Mitchison HM, O’Callaghan C, Leigh M, Carson J, Lie H, et al. Current issues in the basic mechanisms, pathophysiology, diagnosis and management of primary ciliary dyskinesia. Eur Respir Mon 2006;37:291-313.

5.Nonaka S, Tanaka Y, Okada Y, Takeda S, Harada A, Kanai Y, et al. Randomization of left-right asymmetry due to loss of nodal cilia generating leftward flow of extraembryonic fluid in mice lacking KIF3B motor protein. Cell 1998; 95:829-837.

6.Porter ME, Johnson KA. Dynein structure and function.

Annu Rev Cell Biol 1989;5:119-151.

7.Bush A, Cole P, Hariri M, Mackay I, Phillips G, O’Callaghan C, et al. Primary ciliary dyskinesia: diagnosis and standards of care. Eur Respir J 1998;12:982-988.

8.Whitelaw A, Evans A, Corrin B. Immotile cilia syndrome: a new cause of neonatal respiratory distress. Arch Dis Child 1981;56:432-435.

9.Greenstone M, Rutman A, Dewar A, Mackay I, Cole PJ. Primary ciliary dyskinesia: cytological and clinical features.

Q J Med 1988;67: 405-423.

10.∫˘Ú‚·Û›Ï˘ ºµ, ∆۷ӿη˜ π¡. ∫ÏÈÓÈΤ˜ ÂΉËÏÒÛÂȘ Î·È ·ÓÙÈÌÂÙÒÈÛË ÚˆÙÔ·ıÔ‡˜ ‰˘ÛÎÈÓËÛ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ. ªÔÓÔÁÚ·Ê›· ·È‰È·ÙÚÈ΋˜ Ó¢ÌÔÓÔÏÔÁ›·˜. ™ÙÔ: ∞ÓıÚ·ÎfiÔ˘ÏÔ˜ ª, ¶Ú›ÊÙ˘ ∫, ÂÈ̤ÏÂÈ· ¤Î‰ÔÛ˘. ™˘ÛÙËÌ·ÙÈο ÓÔÛ‹Ì·Ù· Ì Ó¢ÌÔÓÈ΋ Û˘ÌÌÂÙÔ¯‹ (ππ). ∞ı‹Ó·:2006. Û. 95-100.

11.µush ∞, Chodhari R, Collins N, Copeland F, Hall P, Harcourt J, et al. Primary ciliary dyskinesia: current state of the art. Arch Dis Child 2007;92:1136-1140.

12.Holzmann D, Ott PM, Felix H. Diagnostic approach to primary ciliary dyskinesia: a review. Eur J Pediatr 2000;159: 95-98.

13.Engesaeth VG, Warner JO, Bush A. New associations of primary ciliary dyskinesia syndrome. Pediatr Pulmonol 1993;16:9-12.

14.Gershoni-Baruch R, Gottfried E, Pery M, Sahin A, Etzioni A. Immotile cilia syndrome including polysplenia, situs inversus, and extrahepatic biliary atresia. Am J Med Genet 1989;33:390-393.

15.Greenstone MA, Jones RW, Dewar A, Neville BG, Cole PJ. Hydrocephalus and primary ciliary dyskinesia. Arch Dis Child 1984;59:481-482.

16.Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL, Hazucha M, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004;169:459-467.

17.Munro NC, Currie DC, Lindsay KS, Ryder TA, Rutman A, Dewar A, et al. Fertility in men with primary ciliary dyskinesia presenting with respiratory infection. Thorax 1994;49:684-687.

18.Stanley P, MacWilliam L, Greenstone M, Mackay I, Cole P. Efficacy of a saccharin test for screening to detect abnormal mucociliary clearance. Br J Dis Chest 1984;78:62-65.

19.Greenstone M, Cole PJ. Ciliary function in health and disease. Br J Dis Chest 1985;79:9-26.

20.Rutland J, Griffin W, Cole P. Nasal brushing and measurement of ciliary beat frequency. An in vitro method for evaluating pharmacologic effects on human cilia. Chest 1981;80:865-867.

21.Stillwell PC, Abell-Aleff P, Scheithauer BW. Electron microscopy of cilia obtained by nasal brushing. Am Rev Respir Dis 1990;141:A626.

22.Gyi A, O’Callaghan C, Langton JA. Effect of halothane on cilia beat frequency of ciliated human respiratory epithelium in vitro. Br J Anaesth 1994;73:507-510.

23.Afzelius BA. Immotile cilia syndrome and ciliary abnormalities induced by infection and injury. Am Rev Respir Dis 1981;124:107-109.

24.Wilson R. Secondary ciliary dysfunction. Clin Sci (Lond) 1988;75:113-120.

25.Jorissen M, Willems T. Success rates of respiratory epithelial cell culture techniques with ciliogenesis for diagnosing primary ciliary dyskinesia. Acta Otorhinolaryngol Belg 2000;54:357-365.

26.Carlén B, Stenram U. Primary ciliary dyskinesia: a review.

Ultrastruct Pathol 2005;29:217-220.

27.Rossman CM, Lee RM, Forrest JB, Newhouse MT. Nasal ciliary ultrastructure and function in patients with primary ciliary dyskinesia compared with that in normal subjects and in subjects with various respiratory diseases. Am Rev Respir Dis 1984;129:161-167.

28.Van’s Gravesande KS, Omran H. Primary ciliary dyskinesia: clinical presentation, diagnosis and genetics. Ann Med 2005;37:439-449.

29.Rutland J, de Iongh RU. Random ciliary orientation. A cause of respiratory tract disease. N Engl J Med 1990;323:1681-1684.

30.Rutman A, Cullinan P, Woodhead M, Cole PJ, Wilson R. Ciliary disorientation: a possible variant of primary ciliary dyskinesia. Thorax 1993;48:770-771.

31.Narang I, Ersu R, Wilson NM, Bush A. Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance. Thorax 2002;57:586-589.

32.Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133-135.

33.Balfour-Lynn IM, Laverty A, Dinwiddie R. Reduced upper ¶·È‰È·ÙÚÈ΋ 2008;71:14-20

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·20

20

ª. ªÔ˘ÛÙ¿ÎË, ∞. ºÚÂÙ˙¿ÁÈ·˜

airway nitric oxide in cystic fibrosis. Arch Dis Child 1996;75:319-322.

34.µ·Ú‚·Ú¤ÛÔ˘ ∞, °È¿ÏÔ˘ÚÔ˜ ¶. ¢È¿ÁÓˆÛË ÚˆÙÔ·ıÔ‡˜ ‰˘ÛÎÈÓËÛ›·˜ ÙˆÓ ÎÚÔÛÛÒÓ. ªÔÓÔÁÚ·Ê›· ¶·È‰È·ÙÚÈ΋˜ ¶Ó¢ÌÔÓÔÏÔÁ›·˜. ™ÙÔ: ∞ÓıÚ·ÎfiÔ˘ÏÔ˜ ª, ¶Ú›ÊÙ˘ ∫, ÂÈ̤ÏÂÈ· ¤Î‰ÔÛ˘. ™˘ÛÙËÌ·ÙÈο ÓÔÛ‹Ì·Ù· Ì Ó¢ÌÔÓÈ΋ Û˘ÌÌÂÙÔ¯‹ (ππ). ∞ı‹Ó·:2006. Û. 88-94.

35.Corbelli R, Bringolf-Isler B, Amacher A, Sasse B, Spycher M, Hammer J. Nasal nitric oxide measurements to screen children for primary ciliary dyskinesia. Chest 2004;126: 1054-1059.

36.Perraudeau M, Scott J, Walport M, Oakley C, Bloom S, Brooks D. Late presentation of Kartagener’s syndrome. Consequences of ciliary dysfunction. BMJ 1994;308:519-521.

37.ªÈ¯·ËÏ›‰Ô˘ ∂, ¶·Û·Ï¿ÎË ¶. ∏ ‚·ÛÈ΋ ‰È·Ù·Ú·¯‹ ÛÙË ‚·ÛÈ΋ ‰˘ÛÎÈÓËÛ›· ÙˆÓ ÎÚÔÛÛÒÓ. ªÔÓÔÁÚ·Ê›· ¶·È‰È·ÙÚÈ΋˜ ¶Ó¢ÌÔÓÔÏÔÁ›·˜. ™ÙÔ: ∞ÓıÚ·ÎfiÔ˘ÏÔ˜ ª, ¶Ú›ÊÙ˘ ∫, ÂÈ̤ÏÂÈ· ¤Î‰ÔÛ˘. ™˘ÛÙËÌ·ÙÈο ÓÔÛ‹Ì·Ù· Ì Ó¢ÌÔÓÈ΋ Û˘ÌÌÂÙÔ¯‹ (ππ). ∞ı‹Ó·:2006. Û. 77-87.

38.Geremek M, Witt M. Primary ciliary dyskinesia: genes, candidate genes and chromosomal regions. J Appl Genet.

2004;45:347-361.

39.Pedersen M, Stafanger G. Bronchopulmonary symptoms

Paediatriki 2008;71:14-20

in primary ciliary dyskinesia. A clinical study of 27 patients.

Eur J Respir Dis Suppl 1983;127:118-128.

40.Moore A, Escudier E, Roger G, Tamalet A, Pelosse B, Marlin S, et al. RPGR is mutated in patients with a complex X linked phenotype combining primary ciliary dyskinesia and retinitis pigmentosa. J Med Genet 2006;43:326-333.

41.Budny B, Chen W, Omran H, Fliegauf M, Tzschach A, Wisniewska M, et al. A novel X-linked recessive mental retardation syndrome comprising macrocephaly and ciliary dysfunction is allelic to oral-facial-digital type I syndrome.

Hum Genet 2006;120:171-178.

42.Schidlow DV. Primary ciliary dyskinesia (the immotile cilia syndrome). Ann Allergy 1994;73:457-468.

43.Denoyelle F, Roger G, Ducroz V, Escudier E, Fauroux B, Garabedian EN. Results of tympanoplasty in children with primary ciliary dyskinesia. Arch Otolaryngol Head Neck Surg 1998;124:177-179.

44.Smit HJ, Schreurs AJ, Van den Bosch JM, Westermann CJ. Is resection of bronchiectasis beneficial in patients with primary ciliary dyskinesia? Chest 1996;109:1541-1544.

45.Raã bago G, Copeland JG 3rd, Rosapepe F, Tsen AC, Arzouman DA, Arabia FA, et al. Heart-lung transplantation in situs inversus. Ann Thorac Surg 1996;62:296-298.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·21

∞¡∞™∫√¶∏™∏

REVIEW ARTICLE

21

¡ÂÎÚˆÙÈ΋ ÂÓÙÂÚÔÎÔÏ›Ùȉ·: ÓÂfiÙÂÚ· ‰Â‰Ô̤ӷ ÁÈ· ÙËÓ ·ıÔÊ˘ÛÈÔÏÔÁ›· Ù˘ ÓfiÛÔ˘ Ã. ∆۷ηϛ‰Ë˜1, ∞. ∆Ú·ÁÈ·ÓÓ›‰Ë˜2, ¡. ¡ÈÎÔÏ·˝‰Ë˜1 ¶ÂÚ›ÏË„Ë: ∏ ÓÂÎÚˆÙÈ΋ ÂÓÙÂÚÔÎÔÏ›Ùȉ· (¡∂∫) ·ÔÙÂÏ› ÓfiÛÔ Î˘Ú›ˆ˜ ÙˆÓ ÚfiˆÚˆÓ ÓÂÔÁÓÒÓ Î·È Û˘¯Ó¿ ¯·Ú·ÎÙËÚ›˙ÂÙ·È ·fi ‚·ÚÈ¿ ÎÏÈÓÈ΋ ÂÈÎfiÓ·, ÛÔ‚·Ú¤˜ ÂÈÏÔΤ˜ Î·È ˘„ËÏ‹ ıÓËÙfiÙËÙ·. ∞Ó Î·È ·ÚÎÂÙÔ› ÚԉȷıÂÛÈÎÔ› ·Ú¿ÁÔÓÙ˜ ¤¯Ô˘Ó ÂÓÔ¯ÔÔÈËı› ÁÈ· ÙËÓ ÂΉ‹ÏˆÛ‹ Ù˘, Ì ΢ÚÈfiÙÂÚÔ˘˜ ÙËÓ ÚÔˆÚfiÙËÙ·, ÙËÓ ÚÒÈÌË ¤Ó·ÚÍË Ù˘ ÂÓÙÂÚÈ΋˜ Û›ÙÈÛ˘ Î·È ÙË Ïԛ̈ÍË, ÂÓÙÔ‡ÙÔȘ, ̤¯ÚÈ Û‹ÌÂÚ· ‰ÂÓ ¤¯ÂÈ Ï‹Úˆ˜ ‰È¢ÎÚÈÓÈÛÙ› Ë ·ıÔÁ¤ÓÂÛ‹ Ù˘. ∆· ÙÂÏÂ˘Ù·›· 20 ¯ÚfiÓÈ·, ¤¯ÂÈ ÂÎÙÂÓÒ˜ ÌÂÏÂÙËı›, ΢ڛˆ˜ Û ÂÈÚ·Ì·ÙÈο ÌÔÓ٤Ϸ, Ë Â›‰Ú·ÛË Ù˘ ˘ÔÍ›·˜ Î·È Ù˘ ÌÈÎÚԂȷ΋˜ ÚÔÛ‚ÔÏ‹˜ ÛÙËÓ ÚfiÎÏËÛË ‚Ï¿‚˘ ÙÔ˘ ‚ÏÂÓÓÔÁfiÓÔ˘ ÙÔ˘ Á·ÛÙÚÂÓÙÂÚÈÎÔ‡. ∞˘Ù¤˜, Î·È ÛÂ Û˘Ó‰˘·ÛÌfi Ì ÙËÓ ·Ô˘Û›· ÚÔÛٷ٢ÙÈÎÒÓ Ì˯·ÓÈÛÌÒÓ ÛÙÔ ÌÈÎÚÔ·ÁÁÂÈ·Îfi ÂÓÙÂÚÈÎfi ÂÓ‰Ôı‹ÏÈÔ, fiˆ˜ ÙÔ ÌÔÓÔÍ›‰ÈÔ ÙÔ˘ ·˙ÒÙÔ˘ (NO) Î·È Ë ·ÓˆÚÈÌfiÙËÙ· ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÊÚ·ÁÌÔ‡, ÚÔηÏÔ‡Ó ‰È·Ù·Ú·¯‹ Ù˘ ·Ì˘ÓÙÈ΋˜ ÈÛÔÚÚÔ›·˜ Î·È Û˘ÓÂ·ÎfiÏÔ˘ıË ‚Ï¿‚Ë. ∂ÈϤÔÓ, Û‹ÌÂÚ· Â›Ó·È ÁÓˆÛÙ‹ Ë ‰Ú¿ÛË ÙˆÓ ÚÔÊÏÂÁÌÔÓˆ‰ÒÓ ÌÂÛÔÏ·‚ËÙÒÓ, fiˆ˜ Ô ·Ú¿ÁÔÓÙ·˜ ‰È¤ÁÂÚÛ˘ ÙˆÓ ·ÈÌÔÂÙ·Ï›ˆÓ (platelet activating factor - PAF) Î·È ÔÈ Î˘ÙÔΛÓ˜, ÛÙËÓ ÚfiÎÏËÛË ÈÛ¯·ÈÌ›·˜ Î·È ·ÎÔÏÔ‡ıˆ˜ Ó¤ÎÚˆÛ˘ ÙÔ˘ ÂÓÙ¤ÚÔ˘. ™ÙÔ ¿ÚıÚÔ ·˘Ùfi, ·Ó·ÛÎÔÔ‡ÓÙ·È ÔÈ ÛËÌ·ÓÙÈÎfiÙÂÚÔÈ ·Ú¿ÁÔÓÙ˜ Ô˘ Û˘Ì‚¿ÏÏÔ˘Ó ÛÙËÓ ÂΉ‹ÏˆÛË Ù˘ ÓfiÛÔ˘ Î·È Ù· ÓÂfiÙÂÚ· ‰Â‰Ô̤ӷ ÁÈ· ÙËÓ ·ıÔÁ¤ÓÂÛ‹ Ù˘.

1 µ’ ¡ÂÔÁÓÔÏÔÁÈ΋ ∫ÏÈÓÈ΋ ∞¶£, ¡ÔÛÔÎÔÌÂ›Ô ¶··ÁˆÚÁ›Ô˘, £ÂÛÛ·ÏÔÓ›ÎË 2 µ’ ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋ ∞¶£, ¡ÔÛÔÎÔÌÂ›Ô ∞Ã∂¶∞, £ÂÛÛ·ÏÔÓ›ÎË AÏÏËÏÔÁÚ·Ê›·: ∞ı·Ó¿ÛÈÔ˜ ∆Ú·ÁÈ·ÓÓ›‰Ë˜ atragian@hotmail.com & atriagia@auth.gr µ’ ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋ ∞¶£, ¡ÔÛÔÎÔÌÂ›Ô ∞Ã∂¶∞, £ÂÛÛ·ÏÔÓ›ÎË

§¤ÍÂȘ ÎÏÂȉȿ: ¡ÂÎÚˆÙÈ΋ ÂÓÙÂÚÔÎÔÏ›Ùȉ·, ÚÔˆÚfiÙËÙ·, ·Ú¿ÁÔÓÙ·˜ ‰È¤ÁÂÚÛ˘ ÙˆÓ ·ÈÌÔÂÙ·Ï›ˆÓ, ÂÓÙÂÚÈ΋ Û›ÙÈÛË, Ïԛ̈ÍË.

Necrotizing enterocolitis: recent evidence on the pathophysiology of the disease C. Tsakalidis1, A. Tragiannidis2, N. Nikolaidis1 Abstract: Necrotizing enterocolitis (NEC) is a disease affecting predominantly premature infants. It has a severe clinical presentation and many complications and is a leading cause of mortality in preterm neonates. Although many predisposing factors have been identified, such as prematurity, enteral feeding and infection, its pathogenesis is not fully understood. In the past 20 years, the role of hypoxia and infection in causing damage to the intestinal mucosa has been studied, mainly in animals. The lack of protective mechanisms in the vascular enteric endothelium, such as nitric oxide, and the immaturity of the intestinal epithelial barrier in premature infants affect the balance between protective and injurious mechanisms. It is now known that proinflammatory mediators play an important role in intestinal ischaemia and necrosis. This review focuses on the main contributing factors in NEC and recent data on its pathogenesis.

Key words: Necrotizing enterocolitis, prematurity, platelet activating factor, enteral feeding, infection.

∂ÈÛ·ÁˆÁ‹ ∏ ÓÂÎÚˆÙÈ΋ ÂÓÙÂÚÔÎÔÏ›Ùȉ· (¡∂∫) Â›Ó·È ÊÏÂÁÌÔÓ҉˘ ÓfiÛÔ˜ ÙÔ˘ ·ÓÒÚÈÌÔ˘ ÂÓÙ¤ÚÔ˘ ÙˆÓ ÓÂÔÁÓÒÓ Î·È ·ÔÙÂÏ› ÙÔ Û˘¯ÓfiÙÂÚÔ ·›ÙÈÔ ıÓËÛÈÌfiÙËÙ·˜ Î·È ÓÔÛËÚfiÙËÙ·˜ ·fi ÙÔ Á·ÛÙÚÂÓÙÂÚÈÎfi ÙÔ˘˜ Û‡ÛÙËÌ·. ¶ÚÒÙÔ˜ Ô Paltauf ÂÚȤÁÚ·„ ÎÏÈÓÈΤ˜ ÂÚÈÙÒÛÂȘ ÓÂÔÁÓÒÓ Ì ¡∂∫ ÙÔ 1888, fï˜ Ô fiÚÔ˜ “ÓÂÎÚˆÙÈ΋ ÂÓÙÂÚÔÎÔÏ›Ùȉ·” ¯ÚËÛÈÌÔÔÈ‹ıËΠÁÈ· ÚÒÙË ÊÔÚ¿ ·fi ÙÔ˘˜ Schmid Î·È Quaiser ÙÔ 1953 (1,2). ™ÙË Û˘Ó¤¯ÂÈ· ÔÈ Mizrahi Î·È Û˘Ó. ÂÚȤÁÚ·„·Ó ÙÔ 1965 ÙË Û˘ÁÎÂÎÚÈ̤ÓË ÎÏÈÓÈ΋ ÔÓÙfiÙËÙ· ˆ˜ “Û‡Ó‰ÚÔÌÔ Ô˘ ¯·Ú·ÎÙËÚ›˙ÂÙ·È ·fi Â̤ÙÔ˘˜, ‰È¿Ù·ÛË ÎÔÈ-

1 2nd Department of Neonatology, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece 2 2nd Department of Paediatrics, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece Correspondence: Athanassios Tragiannidis atragian@hotmail.com & atriagia@auth.gr 2nd Department of Paediatrics, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece

Ï›·˜, ·ÈÌÔÚÚ·Á›· ·fi ÙÔ ÂÙÈÎfi Î·È shock Û ÚfiˆÚ· ÓÂÔÁÓ¿” (3). ∆Ô ÚÔÂͤ¯ÔÓ ¯·Ú·ÎÙËÚÈÛÙÈÎfi Ù˘ ¡∂∫ Â›Ó·È Ë ÊÏÂÁÌÔÓ‹ ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÙÔȯÒÌ·ÙÔ˜ Û˘Óԉ¢fiÌÂÓË ·fi Ó¤ÎÚˆÛË, Ô˘ Û˘¯Ó¿ Ô‰ËÁ› Û ·ÂÈÏËÙÈΤ˜ ÁÈ· ÙË ˙ˆ‹ ÙÔ˘ ÓÂÔÁÓÔ‡ ÂÈÏÔΤ˜, fiˆ˜ Ë ‰È¿ÙÚËÛË. ∏ ¡∂∫ ÚÔÛ‚¿ÏÏÂÈ Î˘Ú›ˆ˜ ÓÂÔÁÓ¿ Ô˘ ÓÔÛËχÔÓÙ·È Û ª∂¡¡ Î·È Ë Â›ÙˆÛ‹ Ù˘ ÔÈΛÏÏÂÈ Û‡Ìʈӷ Ì ٷ Â˘Ú‹Ì·Ù· ÌÂÏÂÙÒÓ. ™˘ÁÎÂÎÚÈ̤ӷ, Ë Â›ÙˆÛ‹ Ù˘ ÛÙÔ ÁÂÓÈÎfi ÏËı˘ÛÌfi ·ÁÁ›˙ÂÈ ÙȘ 1-2,4 ÂÚÈÙÒÛÂȘ ÛÙ· 1.000 ˙ÒÓÙ· ÓÂÔÁÓ¿ (4,5). ¶ÚfiÛÊ·Ù· ‚È‚ÏÈÔÁÚ·ÊÈο ‰Â‰Ô̤ӷ ·Ó·Ê¤ÚÔ˘Ó fiÙÈ ÔÛÔÛÙfi 1-7,7% ÙˆÓ ÓÂÔÁÓÒÓ Ô˘ ¶·È‰È·ÙÚÈ΋ 2008;71:21-28

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·22

22

Ã. ∆۷ηϛ‰Ë˜ Î·È Û˘Ó.

ÂÈÛ¿ÁÔÓÙ·È Û ª∂¡¡ Î·È 10% ÂÎÂ›ÓˆÓ Ì ¯·ÌËÏfi ‚¿ÚÔ˜ Á¤ÓÓËÛ˘ (VLBW) ı· ÂΉËÏÒÛÔ˘Ó ¡∂∫ (4-6). ∂ÈϤÔÓ, fiÛÔÓ ·ÊÔÚ¿ Ù· ÙÂÏÂÈfiÌËÓ· ÓÂÔÁÓ¿, Ë Â›ÙˆÛË Ù˘ ÓfiÛÔ˘ ·Ó¤Ú¯ÂÙ·È ÛÙÔ 5-25ò Î·È Û˘Ó‹ıˆ˜ ÂΉËÏÒÓÂÙ·È ÌÂٷ͇ Ù˘ 2˘ Î·È 3˘ Ë̤ڷ˜ ˙ˆ‹˜ Û ·ÓÙ›ıÂÛË Ì ٷ ÚfiˆÚ· ÛÙ· ÔÔ›· ·Ú¯›˙ÂÈ ÌÂٷ͇ Ù˘ 10˘ Î·È Ù˘ 15˘ Ë̤ڷ˜ ˙ˆ‹˜ (7). ¶ÔÏϤ˜ ÂÚ¢ÓËÙÈΤ˜ ÔÌ¿‰Â˜ ¤¯Ô˘Ó ÂÈÎÂÓÙÚÒÛÂÈ Û‹ÌÂÚ· ÙÔ ÂӉȷʤÚÔÓ ÙÔ˘˜ ÛÙËÓ ÂȉËÌÈÔÏÔÁ›·, ÙËÓ ·ıÔÊ˘ÛÈÔÏÔÁ›· Î·È ÙȘ ıÂÚ·¢ÙÈΤ˜ ÚÔÛÂÁÁ›ÛÂȘ Ù˘. ∞Ú¯Èο, Ë ¡∂∫ ›¯Â ·Ô‰Ôı› Û ÔÈÎÈÏ›· ·Ú·ÁfiÓÙˆÓ Ô˘ ÚÔηÏÔ‡Ó ÂÚÈÁÂÓÓËÙÈÎfi stress, ÂÓÒ ·ÚÎÂÙ¤˜ ÂȉËÌÈÔÏÔÁÈΤ˜ ÌÂϤÙ˜ ¤¯Ô˘Ó Û˘Û¯ÂÙ›ÛÂÈ ÙËÓ ÂΉ‹ÏˆÛ‹ Ù˘ Ì Â͈ÁÂÓ›˜ ·Ú¿ÁÔÓÙ˜, fiˆ˜ Ô ¯ÚfiÓÔ˜ ηÈ/‹ Ë Ù·¯‡ÙËÙ· ¯ÔÚ‹ÁËÛ˘ ÙÔ˘ Á¿Ï·ÎÙÔ˜, Ô Ù‡Ô˜ ÙÔ˘ Á¿Ï·ÎÙÔ˜ (ÌËÙÚÈÎfi ¤Ó·ÓÙÈ ÙÚÔÔÔÈË̤ÓÔ˘ Á¿Ï·ÎÙÔ˜ ·ÁÂÏ¿‰·˜) (8-12). ™‹ÌÂÚ·, ·ÚfiÏÔ Ô˘ Ô ·ÎÚÈ‚‹˜ ·ıÔÁÂÓÂÙÈÎfi˜ Ì˯·ÓÈÛÌfi˜ ÚfiÎÏËÛ‹˜ Ù˘ ‰ÂÓ ¤¯ÂÈ Ï‹Úˆ˜ ‰È¢ÎÚÈÓÈÛÙ›, ¤¯ÂÈ ÔÌÔÊÒÓˆ˜ ηٷÛÙ› ·Ô‰ÂÎÙ‹ Ë Û˘Ó¤ÚÁÂÈ· Î·È Ë Û˘ÌÌÂÙÔ¯‹ ÔÏÏÒÓ ·Ú·ÁfiÓÙˆÓ (13). ™ËÌ·ÓÙÈ΋ ı¤ÛË ÌÂٷ͇ ·˘ÙÒÓ Î·Ù¤¯Ô˘Ó Ë ÚÔˆÚfiÙËÙ·, Ë ÈÛ¯·ÈÌ›· ÙÔ˘ ÂÓÙ¤ÚÔ˘, Ô ·ÔÈÎÈÛÌfi˜ ÙÔ˘ Ì ·ıÔÁfiÓ· ÌÈÎÚfi‚È· Î·È Ë ÚÒÈÌË ¤Ó·ÚÍË Ù˘ ÂÓÙÂÚÈ΋˜ Û›ÙÈÛ˘ (14,15). ∆· ¯·Ú·ÎÙËÚÈÛÙÈο ·ıÔÏÔÁÔ·Ó·ÙÔÌÈο Â˘Ú‹Ì·Ù· Ù˘ ¡∂∫ ÂÚÈÏ·Ì‚¿ÓÔ˘Ó ÙË ÊÏÂÁÌÔÓ‹ ÙÔ˘ ÂÓÙ¤ÚÔ˘, ÙËÓ ÈÛ¯·ÈÌÈ΋ Ó¤ÎÚˆÛË, ÙÔÓ ·ÔÈÎÈÛÌfi Î·È ÔÏÏ·Ï·ÛÈ·ÛÌfi ÙˆÓ ‚·ÎÙËÚ›ˆÓ Î·È Ù¤ÏÔ˜, ÙËÓ ·Ó·‰fiÌËÛË ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÂÈıËÏ›Ô˘ Û˘Óԉ¢fiÌÂÓË Û˘Ó‹ıˆ˜ ·fi ›ÓˆÛË. ™ÙÔ ¿ÚıÚÔ ·˘Ùfi ·Ó·ÛÎÔÔ‡ÓÙ·È Ô Èı·Ófi˜ ·ıÔÁÂÓÂÙÈÎfi˜ Ì˯·ÓÈÛÌfi˜ Î·È ÙÔ ÚÔÙÂÈÓfiÌÂÓÔ ÌÔÓÙ¤ÏÔ Û˘ÌÌÂÙÔ¯‹˜ Î·È ‰Ú¿Û˘ ÙˆÓ ·ÈÙÈÔÏÔÁÈÎÒÓ ·Ú·ÁfiÓÙˆÓ ÛÙËÓ ÂΉ‹ÏˆÛË Ù˘ ¡∂∫.

ÎÔÈÏ›·˜ Î·È ¯ÔÏÒ‰Ë ˘fiÏÔÈ· ÌÂÙ¿ ÙËÓ ¤Ó·ÚÍË Ù˘ ÂÓÙÂÚÈ΋˜ Û›ÙÈÛ˘ (16). √È ·ÛıÂÓ›˜ ·˘ÙÔ› ·ÔÙ¤ÏÂÛ·Ó ÙË ‚¿ÛË ÁÈ· ÙÔÓ ÔÚÈÛÌfi Ù˘ ¡∂∫, Ô˘ ¯·Ú·ÎÙËÚ›˙ÂÙ·È ·fi ÙÔÓ ·ÔÈÎÈÛÌfi Î·È ÔÏÏ·Ï·ÛÈ·ÛÌfi ÌÈÎÚÔ‚›ˆÓ, ÙËÓ ÈÛ¯·ÈÌ›· Î·È ÙËÓ ·ÚÔ˘Û›· ÚԉȷıÂÛÈÎÒÓ ·Ú·ÁfiÓÙˆÓ (.¯. ¤Ó·ÚÍË ÂÓÙÂÚÈ΋˜ Û›ÙÈÛ˘). ™‹ÌÂÚ·, ¯¿ÚË ÛÙËÓ ÚfiÔ‰Ô Ô˘ ¤¯ÂÈ ÂÈÙ¢¯ı› ÛÙË ÓÂÔÁÓÔÏÔÁ›· ¤¯ÂÈ ·ÊÂÓfi˜ ÌÂȈı› Ô ·ÚÈıÌfi˜ ÙˆÓ ·ÛÊ˘ÎÙÈÎÒÓ ÚfiˆÚˆÓ ÓÂÔÁÓÒÓ Î·È Ë ·Ú·ÌÔÓ‹ ÙÔ˘˜ Û Ì˯·ÓÈÎfi ·ÂÚÈÛÌfi Î·È ·ÊÂÙ¤ÚÔ˘ ÂÚÈÔÚÈÛÙ› Ë Ú·ÎÙÈ΋ ηıÂÙËÚÈ·ÛÌÔ‡ ÙˆÓ ÔÌÊ·ÏÈÎÒÓ ·ÁÁ›ˆÓ. ∂ÈϤÔÓ, Â›Ó·È Â˘Ú¤ˆ˜ ·Ô‰ÂÎÙfi fiÙÈ Ù· ÚfiˆÚ· ÓÂÔÁÓ¿ ÂÎÙ›ıÂÓÙ·È ÔÏÔ¤Ó· Î·È ÏÈÁfiÙÂÚÔ Û ·Ú¿ÁÔÓÙ˜ Ô˘ ÚÔηÏÔ‡Ó ÂÚÈÁÂÓÓËÙÈÎfi stress, fiˆ˜ ˘fiÙ·ÛË, ˘ÔıÂÚÌ›·, ˘ÔÍ›· Î·È ·Ó·ÈÌ›·, ÔÈ ÔÔ›ÔÈ Ì ÙË ÛÂÈÚ¿ ÙÔ˘˜ ¢ı‡ÓÔÓÙ·È ÁÈ· ÙËÓ ÚfiÎÏËÛË ÈÛ¯·ÈÌÈ΋˜ ‚Ï¿‚˘ ÙÔ˘ ÂÓÙ¤ÚÔ˘. ∏ ¤Ú¢ӷ ¤¯ÂÈ, ÂÔ̤ӈ˜, ÂÈÎÂÓÙÚˆı› ÛÙÔ ÚfiÏÔ ÙÔ˘ ·ÓÒÚÈÌÔ˘ ÂÓÙÂÚÈÎÔ‡ ‚ÏÂÓÓÔÁfiÓÔ˘ ÛÂ Û˘Ó‰˘·ÛÌfi Ì ÙËÓ Ùˆ¯‹ ·ÓÔÛÔÏÔÁÈ΋ ·¿ÓÙËÛË ÛÙËÓ ÂÈÛ‚ÔÏ‹ ÂÓÙÂÚÈÎÒÓ ·ıÔÁfiÓˆÓ. ∞Ó Î·È Ë ÂÎÎÚÈÙÈ΋ ·ÓÔÛÔÛÊ·ÈÚ›ÓË ∞ (sIgA) ‰ÂÓ Û˘ÌÌÂÙ¤¯ÂÈ ÛÙË ÊÏÂÁÌÔÓÒ‰Ë ‰ÈÂÚÁ·Û›·, Ë ¤ÏÏÂÈ„‹ Ù˘ ¢ÓÔ› ÙË ÌÂÙ·Ó¿ÛÙ¢ÛË Î·È ÙÔÓ ·ÔÈÎÈÛÌfi ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ‚ÏÂÓÓÔÁfiÓÔ˘ ·fi ‚·ÎÙ‹ÚÈ·. ™˘ÁÎÂÎÚÈ̤ӷ, Ë sIgA ‰È·‰Ú·Ì·Ù›˙ÂÈ ÛËÌ·ÓÙÈÎfi ÚfiÏÔ ÛÙËÓ ¿Ì˘Ó· ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÂÈıËÏ›Ô˘, ·ÊÔ‡ Û˘Ó‰¤ÂÙ·È Ì ٷ ÂÈÊ·ÓÂȷο ·ÓÙÈÁfiÓ· ÙˆÓ ·ıÔÁfiÓˆÓ, ÚÔˆıÒÓÙ·˜ ÙËÓ ·ÔÚÚfiÊËÛ‹ ÙÔ˘˜ ·fi Ù· ÂÓÙÂÚÔ·ÙÙ·Ú· (17,18). ŒÓ·˜ ‰Â‡ÙÂÚÔ˜ Èı·ÓÔÏÔÁÔ‡ÌÂÓÔ˜ Ì˯·ÓÈÛÌfi˜ ÂÓÔ¯ÔÔÈ› ÙË ÌÂȈ̤ÓË ‰Ú·ÛÙËÚÈfiÙËÙ· ÙˆÓ ∆ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ, Î·È Î·Ù¿ Û˘Ó¤ÂÈ· ÙËÓ ·‰˘Ó·Ì›· ·Ó·ÁÓÒÚÈÛ˘ Ù˘ ‚Ï¿‚˘ ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ‚ÏÂÓÓÔÁfiÓÔ˘ Ô˘ ÚÔηÏÂ›Ù·È ·fi ·ıÔÁfiÓÔ˘˜ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ‡˜ (17).

¶ÚÔˆÚfiÙËÙ· ∏ ÚÔˆÚfiÙËÙ· ·ÔÙÂÏ› ÙÔ ÛËÌ·ÓÙÈÎfiÙÂÚÔ ÚԉȷıÂÛÈÎfi ·Ú¿ÁÔÓÙ· Ô˘ Û¯ÂÙ›˙ÂÙ·È Ì ÙËÓ ÂΉ‹ÏˆÛË ¡∂∫, ·Ó Î·È Â›Ó·È Â˘Ú¤ˆ˜ ÁÓˆÛÙfi fiÙÈ Ë Û˘ÁÎÂÎÚÈ̤ÓË ÎÏÈÓÈ΋ ÔÓÙfiÙËÙ· ÌÔÚ› Ó· ÂΉËψı› Î·È Û ÙÂÏÂÈfiÌËÓ· ÓÂÔÁÓ¿ (4,6,7). ¶ÂÚ›Ô˘ 5-10% ÙˆÓ ÓÂÔÁÓÒÓ Ì ‚¿ÚÔ˜ Á¤ÓÓËÛ˘ <1.500g ı· ÂΉËÏÒÛÂÈ ¡∂∫ Î·È Ë Â›ÙˆÛË ·˘Í¿ÓÂÈ ·ÓÙÈÛÙÚfiʈ˜ ·Ó¿ÏÔÁ· Ì ÙËÓ ËÏÈΛ· ·ËÛ˘ (4-6). ™ÙȘ ·Ú¯¤˜ Ù˘ ‰ÂηÂÙ›·˜ ÙÔ˘ ’60, Ô Santulli ÂÚȤÁÚ·„ ÛÙË ‰ÈÂıÓ‹ ‚È‚ÏÈÔÁÚ·Ê›· ÙË Û˘ÁÎÂÎÚÈ̤ÓË ÎÏÈÓÈ΋ ÔÓÙfiÙËÙ· Û ÚfiˆÚ· ÓÂÔÁÓ¿ Ì ¯·ÌËÏ‹ ‚·ıÌÔÏfiÁËÛË Apgar ηٿ ÙË Á¤ÓÓËÛË Î·È ÓfiÛÔ Ù˘ ˘·ÏÔÂȉԇ˜ ÌÂÌ‚Ú¿Ó˘ (16). ™Ù· ÓÂÔÁÓ¿ Ù˘ Û˘ÁÎÂÎÚÈ̤Ó˘ ÌÂϤÙ˘ Û˘Ó˘‹Ú¯·Ó ÂÈϤÔÓ Ù· ÂÍ‹˜ ¯·Ú·ÎÙËÚÈÛÙÈο: ¯Ú‹ÛË Ì˯·ÓÈÎÔ‡ ·ÂÚÈÛÌÔ‡, ηıÂÙËÚÈ·ÛÌfi˜ ÙˆÓ ÔÌÊ·ÏÈÎÒÓ ·ÁÁ›ˆÓ, ÂÌÊ¿ÓÈÛË ÛËÌ›ˆÓ Î·È Û˘ÌÙˆÌ¿ÙˆÓ ·fi ÙÔ Á·ÛÙÚÂÓÙÂÚÈÎfi Û‡ÛÙËÌ·, fiˆ˜ ÌÂÙˆÚÈÛÌfi˜

™›ÙÈÛË ∏ ¡∂∫ ¤¯ÂÈ Û˘Û¯ÂÙÈÛı› Ì ÙËÓ ÚÒÈÌË ¤Ó·ÚÍË Ù˘ ÂÓÙÂÚÈ΋˜ Û›ÙÈÛ˘ Î·È ÙȘ ÂÚÈÛÛfiÙÂÚ˜ ÊÔÚ¤˜ ÂΉËÏÒÓÂÙ·È ÌÂÙ¿ ·fi ÚfiÛÊ·ÙË ·‡ÍËÛË ‹ Â·Ó¤Ó·ÚÍ‹ Ù˘ ÌÂÙ¿ ·fi ‰È·ÎÔ‹ (19-21). ∏ ¯ÔÚ‹ÁËÛË ÌËÙÚÈÎÔ‡ Á¿Ï·ÎÙÔ˜ ÂÏ·ÙÙÒÓÂÈ ÙËÓ Â›ÙˆÛ‹ Ù˘, ·ÏÏ¿ ‰ÂÓ ÚÔÏ·Ì‚¿ÓÂÈ ÂÓÙÂÏÒ˜ ÙËÓ ÂΉ‹ÏˆÛ‹ Ù˘. ¶ÚÒÙÔ˜ Ô Barlow ‰ËÌÔÛ›Â˘Û ÙÔ 1974 ÌÂϤÙË ·Ó·‰ÂÈÎÓ‡ÔÓÙ·˜ ÙË ÛËÌ·Û›· ÙÔ˘ ÌËÙÚÈÎÔ‡ Á¿Ï·ÎÙÔ˜ ÛÙË Ì›ˆÛË ÙÔ˘ ÎÈÓ‰‡ÓÔ˘ ÂΉ‹ÏˆÛ˘ ¡∂∫ Î·È ÙÔÓ ÚÔÛٷ٢ÙÈÎfi ÚfiÏÔ Ù˘ sIgA (8). ÕÏϘ ÌÂϤÙ˜ ÂÈÎÂÓÙÚÒıËÎ·Ó ÛÙËÓ Â›‰Ú·ÛË Ù˘ ˆÛ̈ÙÈÎfiÙËÙ·˜ ÙÔ˘ Á¿Ï·ÎÙÔ˜ ÛÙËÓ ÚfiÎÏËÛË ‚Ï¿‚˘ ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÂÈıËÏ›Ô˘, ¯ˆÚ›˜ fï˜ Ó· Â·ÏËı¢ÙÔ‡Ó Ù· ·ÔÙÂϤÛÌ·Ù¿ ÙÔ˘˜. ™‹ÌÂÚ·, ·Ó Î·È ˘¿Ú¯ÂÈ ‰È¯ÔÁӈ̛·, fiÛÔÓ ·ÊÔÚ¿ ÙËÓ “·ÛÊ·Ï‹” ·‡ÍËÛË Ù˘ ÂÓÙÂÚÈ΋˜ Û›ÙÈÛ˘, ÔÈ ÂÚÈÛÛfiÙÂÚÔÈ ÌÂÏÂÙËÙ¤˜ ÙËÓ ·Ô‰¤¯ÔÓÙ·È (22-24).

Paediatriki 2008;71:21-28

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·23

23

¡ÂÎÚˆÙÈ΋ ÂÓÙÂÚÔÎÔÏ›Ùȉ·

™˘ÁÎÂÎÚÈ̤ӷ, Ë ·‡ÍËÛË Î·Ù¿ 20 ml/kg/ËÌÂÚËÛ›ˆ˜ ·ÔÙÂÏ› ·ÛÊ·Ï‹ Ú·ÎÙÈ΋ ÛÙȘ ª∂¡¡ (22,31). ∆ËÓ ÙÂÏÂ˘Ù·›· ‰ÂηÂÙ›· ¤¯ÂÈ ·Ó·ÁÓˆÚÈÛÙ› Ô ÛËÌ·ÓÙÈÎfi˜ ÚfiÏÔ˜ ÙfiÛÔ ÙˆÓ Úo‚ÈÔÙÈÎÒÓ fiÛÔ Î·È ÙˆÓ Ú‚ÈÔÙÈÎÒÓ ÛÙË Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ Ù˘ ¡∂∫ Û ÂÈÚ·Ì·ÙÈο ÌÔÓ٤Ϸ, ·ÏÏ¿ Î·È Û ÎÏÈÓÈΤ˜ ÌÂϤÙ˜. ∆· ÚÔ‚ÈÔÙÈο ·ÔÙÂÏÔ‡Ó ÌÈ· ÂÙÂÚÔÁÂÓ‹ ηÙËÁÔÚ›· ‚·ÎÙËÚ›ˆÓ Î·È ÔÊ›ÏÔ˘Ó ÙËÓ ÔÓÔÌ·Û›· ÙÔ˘˜ ÛÙËÓ ·Ú·ÁˆÁ‹ ÙÔ˘ Á·Ï·ÎÙÈÎÔ‡ ÔͤԘ ˆ˜ ÙÔ˘ ÙÂÏÈÎÔ‡ ÚÔ˚fiÓÙÔ˜ ˙‡ÌˆÛ˘. ™ËÌ·ÓÙÈ΋ ı¤ÛË ÌÂٷ͇ ·˘ÙÒÓ Î·Ù¤¯Ô˘Ó Ù· Bifidobacterium Î·È ÔÈ Lactobacillus Ô˘ ·ÔÙÂÏÔ‡Ó Ê˘ÛÈÔÏÔÁÈ΋ ¯ÏˆÚ›‰· ÙˆÓ ˘ÁÈÒÓ ÓÂÔÁÓÒÓ. ∆· Ú‚ÈÔÙÈο Â›Ó·È ÔÏÈÁÔ۷ί·Ú›Ù˜ Ô˘ ‰ÂÓ ¤ÙÔÓÙ·È Î·È Â˘ÓÔÔ‡Ó ÙËÓ ·Ó¿Ù˘ÍË Ù˘ Ê˘ÛÈÔÏÔÁÈ΋˜ ÌÈÎÚԂȷ΋˜ ¯ÏˆÚ›‰·˜ Î·È Û˘ÁÎÂÎÚÈ̤ӷ ÙÔ˘ Bifidobacterium Î·È ÙÔ˘ Lactobacillus. ™‡Ìʈӷ Ì ٷ Â˘Ú‹Ì·Ù· ÙˆÓ ÌÂÏÂÙÒÓ ·˘ÙÒÓ, Â›Ó·È Èı·Ófi Ó· ·›˙Ô˘Ó ÚfiÏÔ ÛÙËÓ ÚfiÏË„Ë Ù˘ ÓfiÛÔ˘, ·ÊÔ‡ ·Ú·ÙËÚ‹ıËΠÛËÌ·ÓÙÈ΋ Ì›ˆÛË Ù˘ Â›ÙˆÛ˘, ·ÏÏ¿ Î·È Ù˘ ‚·Ú‡ÙËÙ·˜ Ù˘ ‹‰Ë ÂÁηÙÂÛÙË̤Ó˘ ¡∂∫, ·Ó¿ÏÔÁ· ‚¤‚·È· Ì ÙÔ ¯ÚfiÓÔ ¯ÔÚ‹ÁËÛ‹˜ ÙÔ˘˜ (27-31).

§Ô›ÌˆÍË ∂›Ó·È ¢ڤˆ˜ ÁÓˆÛÙ‹ Ë ÛËÌ·Û›· ÙÔ˘ ·Ú¿ÁÔÓÙ· Ïԛ̈ÍË ÛÙËÓ ÂΉ‹ÏˆÛË Ù˘ ¡∂∫ (14,15). ∏ ÌÈÎÚԂȷ΋ ‰È‹ıËÛË ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ‚ÏÂÓÓÔÁfiÓÔ˘ ·ÔÙÂÏ› ·Ó·ÌÊ›‚ÔÏ· ‰Â˘ÙÂÚÔ·ı‹ ·Ú¿ÁÔÓÙ· ÛÙËÓ ·ıÔÁ¤ÓÂÈ¿ Ù˘. ª¤¯ÚÈ Û‹ÌÂÚ· ¤¯Ô˘Ó ÂÓÔ¯ÔÔÈËı› ·ÚÎÂÙÔ› ÌÈÎÚÔÔÚÁ·ÓÈÛÌÔ›, ÌÂٷ͇ ÙˆÓ ÔÔ›ˆÓ ÙËÓ ÚÒÙË ı¤ÛË Î·Ù¤¯Ô˘Ó Ù· Gram ·ÚÓËÙÈο ‚·ÎÙ‹ÚÈ· (΢ڛˆ˜ ÂÓÙÂÚÔ‚·ÎÙËÚÈÔÂȉ‹) Î·È ·ÎÔÏÔ˘ıÔ‡Ó ÔÈ Gram ıÂÙÈÎÔ› ÎfiÎÎÔÈ, Ù· ·Ú¿ÛÈÙ· Î·È ÔÈ ÈÔ›. ¶ÔÈΛϷ ‚·ÎÙ‹ÚÈ· ¤¯Ô˘Ó ·ÔÌÔÓˆı› ·fi ηÏÏȤÚÁÂȘ ÎÔÚ¿ÓˆÓ ÓÂÔÁÓÒÓ Ì ¡∂∫ fiˆ˜: Escherichia coli, Klebsiella, Enterobacter, Pseudomonas, Salmonella, Clostridium difficile, Coagulase-negative staphylococci Î·È ¿ÏÏ·. ∆· ÂÚÈÛÙ·ÙÈο ÓÂÔÁÓÒÓ Ô˘ ÂΉËÏÒÓÔ˘Ó ¡∂∫ Â›Ó·È Û˘Ó‹ıˆ˜ ÛÔÚ·‰Èο, ÂÓÙÔ‡ÙÔȘ, ÔÏϤ˜ ÌÂϤÙ˜ ·Ó·Ê¤ÚÔ˘Ó fiÙÈ Ô ·ÔÈÎÈÛÌfi˜ ª∂¡¡ Ì ‚·ÎÙ‹ÚÈ· ¢ı‡ÓÂÙ·È ÁÈ· ÙËÓ ÂΉ‹ÏˆÛË ÌÈÎÚÔÂȉËÌÈÒÓ. ∞Ó Î·È ÌfiÓÔ ÛÙÔ 1/3 ÙˆÓ ÓÂÔÁÓÒÓ Ì ¡∂∫ ı· Û˘Ó˘¿Ú¯ÂÈ ıÂÙÈ΋ ηÏÏȤÚÁÂÈ· ·›Ì·ÙÔ˜, Ë ÌÈÎÚÔ‚È·ÈÌ›· ¤¯ÂÈ Û˘Û¯ÂÙÈÛÙ› Ì ‚·Ú‡ÙÂÚË ÎÏÈÓÈ΋ ÂÈÎfiÓ· Î·È ÚÔ¯ˆÚË̤ÓË ÓfiÛÔ. πÛ¯·ÈÌ›· ∆Ô ˘ÔÍ·ÈÌÈÎfi-ÈÛ¯·ÈÌÈÎfi ÙÚ·‡Ì· ‰È·‰Ú·Ì·Ù›˙ÂÈ ÛËÌ·ÓÙÈÎfi ÚfiÏÔ ÛÙËÓ ·ıÔÁ¤ÓÂÛË Ù˘ ¡∂∫ (32-34). ∞Ó Î·È ÚÔÛ‚¿ÏÏÂÈ Î˘Ú›ˆ˜ ÚfiˆÚ· ÓÂÔÁÓ¿, ÂÓÙÔ‡ÙÔȘ, Î·È Ù· ÙÂÏÂÈfiÌËÓ· ÂÌÊ·Ó›˙Ô˘Ó ·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ ÂΉ‹ÏˆÛ˘ ¡∂∫, fiÙ·Ó Û˘Ó˘¿Ú¯Ô˘Ó Î·È ¿ÏϘ ·ıÔÏÔÁÈΤ˜ ηٷÛÙ¿ÛÂȘ Ô˘ ÚÔηÏÔ‡Ó ÈÛ¯·ÈÌ›· ÙÔ˘ ÂÓÙ¤ÚÔ˘, fiˆ˜ ÔÈ Î˘·ÓˆÙÈΤ˜ Û˘ÁÁÂÓ›˜ ηډÈÔ¿ıÂȘ, Ë ÔÏ˘Î˘ÙÙ·Ú·ÈÌ›·, Ë ˘fiÙ·ÛË Î·È Ë ¯ÔÚ‹-

ÁËÛË ÈÓ‰ÔÌÂı·Î›Ó˘ (10,12,34). ∆Ô ˘ÔÍ·ÈÌÈÎfiÈÛ¯·ÈÌÈÎfi stress Â›Ó·È ÁÓˆÛÙfi fiÙÈ ÚÔηÏ› ‚Ï¿‚Ë ÙÔ˘ ÂÓÙ¤ÚÔ˘, ·ÏÏ¿ Ë ˘fiıÂÛË fiÙÈ ·˘Ùfi ·ÔÙÂÏ› ÙÔ ÁÂÁÔÓfi˜ Ô˘ “˘ÚÔ‰ÔÙ›” ÙËÓ ÚfiÎÏËÛË Ù˘ ÓfiÛÔ˘ ¤¯ÂÈ ÂÓÙfiÓˆ˜ ·ÌÊÈÛ‚ËÙËı›. ™‹ÌÂÚ·, Ë ÂÈÎÚ·ÙÔ‡Û· ¿Ô„Ë ÁÈ· ÙËÓ ·ıÔÁ¤ÓÂÛË Ù˘ ÓfiÛÔ˘ ÂÓÔ¯ÔÔÈ› Û ÌÂÁ·Ï‡ÙÂÚÔ ‚·ıÌfi ÙËÓ ÚÔˆÚfiÙËÙ·, ÙËÓ ÚÒÈÌË Î·È “ÂÈıÂÙÈ΋” ¤Ó·ÚÍË Ù˘ ÂÓÙÂÚÈ΋˜ Û›ÙÈÛ˘ Î·È ÙË ÊÏÂÁÌÔÓÒ‰Ë ‰ÈÂÚÁ·Û›· Û ۯ¤ÛË Ì ÙËÓ ÈÛ¯·ÈÌ›·. ™˘ÁÎÂÎÚÈ̤ӷ, Èı·ÓÔÏÔÁÂ›Ù·È fiÙÈ Ë ·ÓÒÚÈÌË Ú‡ıÌÈÛË Ù˘ ÂÓÙÂÚÈ΋˜ ΢ÎÏÔÊÔÚ›·˜ Ô‰ËÁ› Û ˘ÔÍ›·ÈÛ¯·ÈÌ›· ˆ˜ ·¿ÓÙËÛË ÛÙËÓ ÂÓÙÂÚÈ΋ Û›ÙÈÛË ‹ ÛÙÔÓ ·ÔÈÎÈÛÌfi Ì ·ıÔÁfiÓ· ‚·ÎÙ‹ÚÈ·. √ÚÈṲ̂Ó˜ ÌÂϤÙ˜ Û ·ÓÒÚÈÌ· ÂÈÚ·Ì·Ùfi˙ˆ· ‰Â›¯ÓÔ˘Ó Î¿ÔÈ· ‰È·Ù·Ú·¯‹ Ù˘ Ú‡ıÌÈÛ˘ Ù˘ ÂÓÙÂÚÈ΋˜ ΢ÎÏÔÊÔÚ›·˜ ÌÂÙ¿ ·fi ˘ÔÍ›· ‹ ÈÛ¯·ÈÌ›·, Â˘Ú‹Ì·Ù· Ô˘ ‰ÂÓ ÂȂ‚·ÈÒÓÔÓÙ·È ·fi ¿ÏϘ ÌÂϤÙ˜. ÕÏÏÔÈ ÂÚ¢ÓËÙ¤˜ ÂÓÔ¯ÔÔÈÔ‡Ó ÙË ÌÂȈ̤ÓË ·Ú·ÁˆÁ‹ ÓÈÙÚÈÎÔ‡ ÔÍÂȉ›Ô˘ (NO) ·fi ÙÔ ·ÁÁÂÈ·Îfi ÂÓ‰Ôı‹ÏÈÔ ˆ˜ ÚԉȷıÂÛÈÎfi ·Ú¿ÁÔÓÙ· ÁÈ· ÙËÓ ÚfiÎÏËÛË ÈÛ¯·ÈÌÈ΋˜ ‚Ï¿‚˘ (32,35,36). ∆Ô NO ·ÔÙÂÏ› ÂχıÂÚË Ú›˙· Ô˘ ·Ú¿ÁÂÙ·È ·fi ÙÔ ·Î¤Ú·ÈÔ ÂÓ‰Ôı‹ÏÈÔ Î·È ÚÔ¿ÁÂÈ ÙËÓ ·ÁÁÂÈԉȷÛÙÔÏ‹ (32). ∂Ô̤ӈ˜, ˘fi Ê˘ÛÈÔÏÔÁÈΤ˜ Û˘Óı‹Î˜, ΢Úȷگ› ÛÙÔ ÌÈÎÚÔ·ÁÁÂÈ·Îfi ÂÓ‰Ôı‹ÏÈÔ Ë ·ÁÁÂÈԉȷÛÙÔÏ‹. °ÂÁÔÓfiÙ· Ô˘ ‰È·Ù·Ú¿ÛÛÔ˘Ó ÙË Û˘ÁÎÂÎÚÈ̤ÓË ÈÛÔÚÚÔ›·, fiˆ˜ Ë ÂÚÈÁÂÓÓËÙÈ΋ ·ÛÊ˘Í›· ‹ Ë ·Ú·ÙÂٷ̤ÓË ¯·ÌËÏ‹ ·ÈÌ·ÙÈ΋ ÚÔ‹ Û ÓÂÔÁÓ¿ Ì ÂÓ‰ÔÌ‹ÙÚÈ· ηı˘ÛÙ¤ÚËÛË ·Ó¿Ù˘Í˘, ¢ı‡ÓÔÓÙ·È ÁÈ· ÙË ÌÂȈ̤ÓË ·Ú·ÁˆÁ‹ ÙÔ˘ ¡√, Ì ·ÔÙ¤ÏÂÛÌ· ÙËÓ ·‡ÍËÛË ÙˆÓ ·ÁÁÂÈ·ÎÒÓ ·ÓÙÈÛÙ¿ÛÂˆÓ Î·È, ÂÔ̤ӈ˜, ÙË Ì›ˆÛË Ù˘ ·ÈÌ·ÙÈ΋˜ ÚÔ‹˜ Î·È Ù˘ ·ÚÔ¯‹˜ Ô͢ÁfiÓÔ˘. (35,36). ªÂϤÙ˜ ˘ÔÛÙËÚ›˙Ô˘Ó ÙÔ ÚfiÏÔ ÙÔ˘ ¡√ ÛÙË ‰˘ÛÏÂÈÙÔ˘ÚÁ›· Ù˘ ÂÓÙÂÚÈ΋˜ ΢ÎÏÔÊÔÚ›·˜, ̤ۈ ‰È·Ù·Ú·¯‹˜ Ù˘ ·Ú·ÁˆÁ‹˜ ÙÔ˘. ¶ÂÚ·ÈÙ¤Úˆ ÌÂϤÙ˜ ··ÈÙÔ‡ÓÙ·È, ÒÛÙ ӷ ‰È¢ÎÚÈÓÈÛÙ› Ô Â·ÎÚÈ‚‹˜ ÚfiÏÔ˜ Ù˘ ÈÛ¯·ÈÌ›·˜ ˆ˜ ÚÒÈÌÔ ‹ ·ÒÙÂÚÔ ·ÔÙ¤ÏÂÛÌ· Ù˘ ‰È·Ù·Ú·¯‹˜ Ù˘ ÂÓÙÂÚÈ΋˜ ΢ÎÏÔÊÔÚ›·˜.

ºÏÂÁÌÔÓ҉˘ ‰ÈÂÚÁ·Û›· ∆· ÙÂÏÂ˘Ù·›· ¯ÚfiÓÈ·, Ô ÚfiÏÔ˜ Ù˘ ÂÓÂÚÁÔÔ›ËÛ˘ Ù˘ ÊÏÂÁÌÔÓÒ‰Ô˘˜ ‰ÈÂÚÁ·Û›·˜ Î·È Ù˘ ·ÓÂ·ÚÎÔ‡˜ ·ÓÙÈÊÏÂÁÌÔÓÒ‰Ô˘˜ ·¿ÓÙËÛ˘ ÛÙË ‰È·Ù·Ú·¯‹ Ù˘ ·ÎÂÚ·ÈfiÙËÙ·˜ ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÊÚ·ÁÌÔ‡ ¤¯Ô˘Ó ·ÔÙÂϤÛÂÈ ÛËÌ·ÓÙÈÎfi ‰›Ô ¤Ú¢ӷ˜ ÛÙËÓ ·ıÔÁ¤ÓÂÛË Ù˘ ¡∂∫. ™Â ÔÏϤ˜ ÎÏÈÓÈΤ˜ ÌÂϤÙ˜ ¤¯ÂÈ Î·Ù·ÁÚ·Ê› ·‡ÍËÛË ÊÏÂÁÌÔÓˆ‰ÒÓ ÌÂÛÔÏ·‚ËÙÒÓ Î·È ¤¯ÂÈ Á›ÓÂÈ ÚÔÛ¿ıÂÈ· Û˘Û¯ÂÙÈÛÌÔ‡ ÙÔ˘˜ Ì ÙËÓ ÂΉ‹ÏˆÛË Î·È ÙËÓ ÔÚ›· Ù˘ ÓfiÛÔ˘ (37-42). ∆· ÂÓÙÂÚÈο ÂÈıËÏȷο ·ÙÙ·Ú· ·Ú¿ÁÔ˘Ó ÔÏϤ˜ ΢ÙÙÔΛÓ˜ Ô˘ ÂÌϤÎÔÓÙ·È ÛÙË Ïԛ̈ÍË Î·È ÙË ‚Ï¿‚Ë ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÊÚ·ÁÌÔ‡. ªÂٷ͇ ·˘ÙÒÓ, ÛËÌ·ÓÙÈÎfi˜ Â›Ó·È Ô ÚfiÏÔ˜ Ù˘ IL-6 ÛÙËÓ ·Ú·ÁˆÁ‹ ¶·È‰È·ÙÚÈ΋ 2008;71:21-28

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·24

24

Ã. ∆۷ηϛ‰Ë˜ Î·È Û˘Ó.

ÚˆÙÂ˚ÓÒÓ ÔÍ›·˜ Ê¿Û˘, ÛÙËÓ ÚÔ·ÁˆÁ‹ ÙˆÓ ∆ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ Î·È ÛÙËÓ ·Ú·ÁˆÁ‹ ·ÓÙÈÛˆÌ¿ÙˆÓ ·fi Ù· µ ÏÂÌÊÔ·ÙÙ·Ú· (37). ∏ ·Ú·ÁˆÁ‹ ÙÔ˘ TNF-a Â¿ÁÂÙ·È ·fi ÙÔ˘˜ ÌÈÎÚÔ‚È·ÎÔ‡˜ ·Ú¿ÁÔÓÙ˜ Î·È ¿ÏϘ ΢ÙÙÔΛÓ˜, ÂÓÒ Ì ÙË ÛÂÈÚ¿ ÙÔ˘ ÚÔ¿ÁÂÈ ÙËÓ Î˘ÙÙ·ÚÔÙÔÍÈ΋ ·¿ÓÙËÛË Î·È ÙÔÓ ÚÔÁÚ·ÌÌ·ÙÈṲ̂ÓÔ Î˘ÙÙ·ÚÈÎfi ı¿Ó·ÙÔ (41). √ ·Ú¿ÁÔÓÙ·˜ ÂÓÂÚÁÔÔ›ËÛ˘ ÙˆÓ ·ÈÌÔÂÙ·Ï›ˆÓ (platelet activating factor - PAF) ·ÔÙÂÏ› ¤Ó·Ó ·fi ÙÔ˘˜ ÛËÌ·ÓÙÈÎfiÙÂÚÔ˘˜ Î·È ÂÚÈÛÛfiÙÂÚÔ ÌÂÏÂÙË̤ÓÔ˘˜ ÌÂÛÔÏ·‚ËÙ¤˜ Ù˘ ÊÏÂÁÌÔÓ‹˜ Ô˘ ÂÌϤÎÔÓÙ·È ÛÙËÓ ·ıÔÁ¤ÓÂÛË Ù˘ ¡∂∫ (41,43). ∞ÔÙÂÏ› ¤Ó·Ó ʈÛÊÔÏÈȉÈÎfi ·Ú¿ÁÔÓÙ· Ô˘ ·Ú¿ÁÂÙ·È ·fi Ù· ÊÏÂÁÌÔÓÒ‰Ë, Ù· ÂÓ‰ÔıËÏȷο ·ÙÙ·Ú·, Ù· ·ÈÌÔÂÙ¿ÏÈ· Î·È Ù· ‚·ÎÙ‹ÚÈ· Î·È ‰È·‰Ú·Ì·Ù›˙ÂÈ ÛËÌ·ÓÙÈÎfi ÚfiÏÔ ÛÙËÓ ·ıÔÊ˘ÛÈÔÏÔÁ›· Ù˘ ÓfiÛÔ˘. ™˘ÓÙ›ıÂÙ·È ÌÂÙ¿ ·fi ÂÓÂÚÁÔÔ›ËÛË Ù˘ ʈÛÊÔÏÈ¿Û˘ ∞2ππ (PLA2) Î·È ‰È·Û¿Ù·È ·fi ÙÔ ¤Ó˙˘ÌÔ PAF-·ÎÂÙ˘ÏÔ¸‰ÚÔÏ¿ÛË. Àԉԯ›˜ ÁÈ· ÙÔÓ PAF ˘¿Ú¯Ô˘Ó Û ÔÏÏ¿ ·ÙÙ·Ú· Î·È Ë ‰Ú¿ÛË ÙÔ˘ ·ÛÎÂ›Ù·È Ì¤Ûˆ Ù˘ ÂÓÂÚÁÔÔ›ËÛ˘ ÙÔ˘ ˘Ô‰Ô¯¤· G-ÚˆÙ½ÓË-˙‡ÁÔ˜ PAF Ô˘ ‚Ú›ÛÎÂÙ·È Û ˘„ËϤ˜ Û˘ÁÎÂÓÙÚÒÛÂȘ, ΢ڛˆ˜ ÛÙ· ·ÙÙ·Ú· ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÂÈıËÏ›Ô˘ Î·È Û˘ÁÎÂÎÚÈ̤ӷ ÛÙÔÓ ÂÈÏÂfi, Ô˘ ·ÔÙÂÏ› Î·È ÙË Û˘¯ÓfiÙÂÚË ı¤ÛË ÚÔÛ‚ÔÏ‹˜ Ù˘ ¡∂∫. ∏ ÂÓÂÚÁÔÔ›ËÛË ÙˆÓ ˘Ô‰Ô¯¤ˆÓ ÙÔ˘ PAF ÚÔ¿ÁÂÈ ÙËÓ ·Ú·ÁˆÁ‹ ¿ÏÏˆÓ Î˘ÙÙÔÎÈÓÒÓ Î·È ‰Â˘ÙÂÚ¢fiÓÙˆÓ ÌÂÛÔÏ·‚ËÙÒÓ, fiˆ˜ Ô TNF-a, Ë IL-6, Ë IL-8, Ë IL-1, ÙÔ ¡√ Î·È ÔÈ Ï¢ÎÔÙÚȤÓ˜. ∂ÈϤÔÓ, Û‡Ìʈӷ Ì ÌÂϤÙ˜, Ë ‰Ú¿ÛË ÙÔ˘ ·ÛÎÂ›Ù·È Î·È Ì¤Ûˆ Ù˘ ·fiÙˆÛ˘ ÙˆÓ ÂÓÙÂÚÈÎÒÓ ÂÈıËÏÈ·ÎÒÓ Î˘ÙÙ¿ÚˆÓ. ªÂ ‚¿ÛË ÙËÓ ˘fiıÂÛË ·˘Ù‹, Ë ·fiÙˆÛË ÙˆÓ Î˘ÙÙ¿ÚˆÓ ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÂÈıËÏ›Ô˘ ¤¯ÂÈ ˆ˜ ·ÔÙ¤ÏÂÛÌ· ÙËÓ ·ÒÏÂÈ· Ù˘ ·ÎÂÚ·ÈfiÙËÙ·˜ ÙÔ˘ ÂÈıËÏ›Ô˘, ÙËÓ ·‡ÍËÛË Ù˘ ‰È·ÂÚ·ÙfiÙËÙ·˜ ÙÔ˘ ‚ÏÂÓÓÔÁfiÓÔ˘ Î·È ÙËÓ Â›ÛÔ‰Ô ÙˆÓ ‚·ÎÙËÚ›ˆÓ ÛÙÔ ÂÓÙÂÚÈÎfi ÙÔ›¯ˆÌ·. ™Â ÂÈÚ·Ì·ÙÈο ÌÔÓ٤Ϸ ¤¯ÂÈ ·Ô‰Âȯı› fiÙÈ Ô PAF ÚÔηÏ› ‚Ï¿‚Ë ÛÙ· ÙÚȯÔÂȉ‹, ‰˘ÛÏÂÈÙÔ˘ÚÁ›· ÙÔ˘ Ì˘Ôηډ›Ô˘ Î·È ÙˆÓ ÓÂÊÚÒÓ, Ô˘‰ÂÙÂÚÔÂÓ›·, ıÚÔÌ‚ÔÂÓ›· Î·È ˘fiÙ·ÛË (41,43). ∆Ô ¤Ó˙˘ÌÔ PAF-·ÎÂÙ˘ÏÔ¸‰ÚÔÏ¿ÛË, Ô˘ ÙÔÓ ·‰Ú·ÓÔÔÈ›, ‚Ú›ÛÎÂÙ·È Û ¯·ÌËÏ‹ Û˘ÁΤÓÙÚˆÛË ÛÙ· ÚfiˆÚ· ΢ڛˆ˜ ÓÂÔÁÓ¿ Î·È ÛÙÔ ÙÚÔÔÔÈË̤ÓÔ Á¿Ï· Ì ÙÔ ÔÔ›Ô ÛÈÙ›˙ÔÓÙ·È, Û ·ÓÙ›ıÂÛË Ì ÙÔ ÌËÙÚÈÎfi, Ô˘ ¤¯ÂÈ ·Ô‰Âȯı› fiÙÈ ÂÚȤ¯ÂÈ ˘„ËÏ‹ Û˘ÁΤÓÙÚˆÛË (41,43). ∆¤ÏÔ˜, Û ÓÂÔÁÓ¿ Ô˘ ÂΉ‹ÏˆÛ·Ó ¡∂∫ ‰È·ÈÛÙÒıËÎ·Ó ·˘ÍË̤ӷ Â›‰· ÙÔ˘ PAF ÛÙÔ Ï¿ÛÌ· Î·È Ù· ÎfiÚ·Ó·, Â˘Ú‹Ì·Ù· Ô˘ ÂÓÈÛ¯‡Ô˘Ó ¤ÌÌÂÛ· ÙÔ ÛËÌ·ÓÙÈÎfi ÚfiÏÔ ÙÔ˘ ÛÙËÓ ·ıÔÁ¤ÓÂÛË Ù˘ ÓfiÛÔ˘ (41).

Toll-like receptors (TLRs) √È TLRs ‚Ú›ÛÎÔÓÙ·È ÛÙËÓ Î˘ÙÙ·ÚÈ΋ ÂÈÊ¿ÓÂÈ· Î·È ‰ÚÔ˘Ó ˆ˜ ·ÈÛıËÙ‹Ú˜ Ù˘ ÌÈÎÚԂȷ΋˜ Ïԛ̈͢, ‰È·‰Ú·Ì·Ù›˙ÔÓÙ·˜ Û˘Á¯ÚfiÓˆ˜ ÛËÌ·ÓÙÈÎfi ÚfiÏÔ Paediatriki 2008;71:21-28

ÛÙËÓ ¤Ó·ÚÍË Ù˘ ÊÏÂÁÌÔÓ‹˜ Î·È Ù˘ ·ÓÔÛȷ΋˜ ·¿ÓÙËÛ˘. ∆· ÌÈÎÚfi‚È· ÂÎÎÚ›ÓÔ˘Ó ÌfiÚÈ· Ô˘ ‰ÚÔ˘Ó ˆ˜ ˘ԉԯ›˜ ÛÙÔ˘˜ TLRs, fiˆ˜ ÔÈ ÏÈÔÔÏ˘Û·Î¯·Ú›Ù˜ (LPS) Î·È ÙÔ ÏÈÔÙ¯Ô˚Îfi Ô͇ (LTA). ™˘ÁÎÂÎÚÈ̤ӷ, ÔÈ LPS ·ÓÙȉÚÔ‡Ó Ì ÙȘ TLR4 Î·È ÙÔ LTA Ì ÙȘ TLR2. ¶ÂÈÚ·Ì·ÙÈΤ˜ ÌÂϤÙ˜ ÙˆÓ RakoffNahoum Î·È Û˘Ó. ‰Â›¯ÓÔ˘Ó fiÙÈ Ë ÂÓÂÚÁÔÔ›ËÛË ÙˆÓ TLRs ·fi ÙË Ê˘ÛÈÔÏÔÁÈ΋ ÂÓÙÂÚÈ΋ ÌÈÎÚԂȷ΋ ¯ÏˆÚ›‰· Û˘Ì‚¿ÏÏÂÈ ÛÙËÓ ·ÎÂÚ·ÈfiÙËÙ· ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÂÈıËÏ›Ô˘, ÂÓÒ Û˘Á¯ÚfiÓˆ˜ ÙÔ ÚÔÛٷهÂÈ ·fi ÙÔ ÙÚ·‡Ì· Î·È Î·Ù·Ï‹ÁÔ˘Ó ÛÙÔ Û˘Ì¤Ú·ÛÌ· fiÙÈ ÔÈ TLRs Â›Ó·È ··Ú·›ÙËÙÔÈ ÁÈ· ÙËÓ ÔÌÔÈfiÛÙ·ÛË ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÂÈıËÏ›Ô˘ ÌÂÙ¿ ·fi ‚Ï¿‚Ë ‹ ÙÚ·˘Ì·ÙÈÛÌfi (44). ∂ÈϤÔÓ, Û‡Ìʈӷ Ì ÌÈ· ¿ÏÏË ˘fiıÂÛË, Ë ˘ÂÚ¤ÎÊÚ·ÛË ÔÚÈÛÌ¤ÓˆÓ TLRs, fiˆ˜ ÔÈ TLR4, ¢ı‡ÓÂÙ·È ÁÈ· ÙËÓ ÚfiÎÏËÛË ÚÔÊÏÂÁÌÔÓÒ‰Ô˘˜ ·¿ÓÙËÛ˘ ÛÙÔ ÂÓÙÂÚÈÎfi ÂÈı‹ÏÈÔ ÚfiˆÚˆÓ ÓÂÔÁÓÒÓ, Ì ·Ô˘Û›· Ê˘ÛÈÔÏÔÁÈ΋˜ ÌÈÎÚԂȷ΋˜ ¯ÏˆÚ›‰·˜ (33).

∞ÓˆÚÈÌfiÙËÙ· ÂÓÙÂÚÈÎÔ‡ ÊÚ·ÁÌÔ‡ ∏ ·ÎÂÚ·ÈfiÙËÙ· Î·È ÌË ‰È·ÂÚ·ÙfiÙËÙ· ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÊÚ·ÁÌÔ‡ ‰È·ÙËÚÂ›Ù·È Ì¤Ûˆ ÛÂÈÚ¿˜ Ì˯·ÓÈÎÒÓ Î·È ÌË ·Ú·ÁfiÓÙˆÓ, Ô˘ ‰ÚÔ˘Ó Û˘ÓÂÚÁÈο, Ì ·ÒÙÂÚÔ ÛÎÔfi ÙËÓ ÚÔÛÙ·Û›· ÙÔ˘ ·fi ÙËÓ ÂÈÛ‚ÔÏ‹ ·ıÔÁfiÓˆÓ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÒÓ (17,45,46). √È ·Ú¿ÁÔÓÙ˜ ·˘ÙÔ› ›ӷÈ: ·. ÔÈ ÛÙ·ıÂÚ¤˜ Û˘Ó‰¤ÛÂȘ, ‚. Ô ÂÚÈÛÙ·ÏÙÈÛÌfi˜ Î·È Á. Ù· Û˘ÛÙ·ÙÈο ÙÔ˘ ÛÙÚÒÌ·ÙÔ˜ Ù˘ ‚ϤÓÓ·˜, Û˘ÌÂÚÈÏ·Ì‚·ÓÔ̤Ó˘ Ù˘ ÂÎÎÚÈÙÈ΋˜ sIgA. ¶ÔÏÏÔ› ·fi ÙÔ˘˜ Ì˯·ÓÈÛÌÔ‡˜ ·˘ÙÔ‡˜ Â›Ó·È ·ÓÒÚÈÌÔÈ ÛÙ· ÚfiˆÚ· ÓÂÔÁÓ¿ ηıÈÛÙÒÓÙ·˜ Ù· ÂÚÈÛÛfiÙÂÚÔ Â˘¿ÏˆÙ· ÛÙËÓ ÂΉ‹ÏˆÛË ¡∂∫. ∏ ·ÓÒÚÈÌË ÂÓÙÂÚÈ΋ ÎÈÓËÙÈÎfiÙËÙ· Î·È ¤„Ë ·ÔÙÂÏÔ‡Ó ÂÈϤÔÓ ÚԉȷıÂÛÈÎÔ‡˜ ·Ú¿ÁÔÓÙ˜ ÁÈ· ÙËÓ ÂΉ‹ÏˆÛË ¡∂∫ Û ÚfiˆÚ· ÓÂÔÁÓ¿. ªÂϤÙ˜ ÙfiÛÔ Û ÓÂÔÁÓ¿ fiÛÔ Î·È Û ÂÈÚ·Ì·ÙÈο ÌÔÓ٤Ϸ ¤¯Ô˘Ó ·ԉ›ÍÂÈ fiÙÈ Ë ÂÓÙÂÚÈ΋ ÎÈÓËÙÈÎfiÙËÙ· ·Ú¯›˙ÂÈ ÛÙÔ ‰Â‡ÙÂÚÔ Î·È ˆÚÈÌ¿˙ÂÈ ÛÙÔ ÙÚ›ÙÔ ÙÚ›ÌËÓÔ Ù˘ ÂÁ΢ÌÔÛ‡Ó˘ (4749). ™‡Ìʈӷ Ì ٷ Â˘Ú‹Ì·Ù· Û˘ÁÎÚÈÙÈÎÒÓ ÌÂÏÂÙÒÓ ÌÂٷ͇ ÚfiˆÚˆÓ Î·È ÙÂÏÂÈfiÌËÓˆÓ ÓÂÔÁÓÒÓ, ÚԤ΢„ fiÙÈ Ë ÂÓÙÂÚÈ΋ ÎÈÓËÙÈÎfiÙËÙ· ÙˆÓ ÚfiˆÚˆÓ Â›Ó·È ·ÓÒÚÈÌË, fï˜ Ë ¤Ó·ÚÍË Ù˘ ÂÓÙÂÚÈ΋˜ Û›ÙÈÛ˘ ÚÔ¿ÁÂÈ ÙËÓ ˆÚ›Ì·ÓÛ‹ Ù˘ (50-53). ¶·Ú¿ÁÔÓÙ˜, fiˆ˜ Ë ÂÓ‰ÔÌ‹ÙÚÈ· ηı˘ÛÙ¤ÚËÛË Ù˘ ·Ó¿Ù˘Í˘, Û˘Ì‚¿ÏÏÔ˘Ó ÛÙËÓ ·ÓˆÚÈÌfiÙËÙ· Ù˘ ÂÓÙÂÚÈ΋˜ ÎÈÓËÙÈÎfiÙËÙ·˜, ÂÓÒ ‰Â‰Ô̤ӷ ÌÂÏÂÙÒÓ Û ·ÓıÚÒÔ˘˜ Î·È ˙Ò· ·¤‰ÂÈÍ·Ó fiÙÈ Ë ÂÌ‚Ú˘˚΋ ˘ÔÍ›· ‹ Ë ÂÚÈÁÂÓÓËÙÈ΋ ·ÛÊ˘Í›· ÂÏ·ÙÙÒÓÔ˘Ó ÙË ÌÂÙ·ÁÂÓÓËÙÈ΋ ÂÓÙÂÚÈ΋ ÎÈÓËÙÈÎfiÙËÙ· (53,55). ∆¤ÏÔ˜, Ù· ÚfiˆÚ· ÓÂÔÁÓ¿ ‰ÂÓ ¤¯Ô˘Ó ·Ó·Ù‡ÍÂÈ Ï‹Úˆ˜ ÙËÓ ÈηÓfiÙËÙ· ¤„˘ Î·È ·ÔÚÚfiÊËÛ˘ ÙˆÓ ıÚÂÙÈÎÒÓ Û˘ÛÙ·ÙÈÎÒÓ ÙÔ˘ Á¿Ï·ÎÙÔ˜, Ì ·ÔÙ¤ÏÂÛÌ· ¿ÂÙ· ÌfiÚÈ¿ ÙÔ˘ Ó· ÚÔηÏÔ‡Ó ÙÚ·˘Ì·ÙÈÛÌfi ÛÙÔ ¤ÓÙÂÚÔ, Û˘Ì‚¿ÏÏÔÓÙ·˜ ÛÙËÓ ÚfiÎÏËÛË Ù˘ ¡∂∫ (56,57).

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·25

25

¡ÂÎÚˆÙÈ΋ ÂÓÙÂÚÔÎÔÏ›Ùȉ·

¶ÚÔ·ÙÂÈ, ÂÔ̤ӈ˜, fiÙÈ Ë ÂÏ·Ùو̤ÓË ¤„Ë/ ·ÔÚÚfiÊËÛË Î·È Ë ·Ú¿Ù·ÛË ÙÔ˘ ¯ÚfiÓÔ˘ ·Ú·ÌÔÓ‹˜ Ù˘ ÙÚÔÊ‹˜ ÛÙÔ ¤ÓÙÂÚÔ Û˘Ì‚¿ÏÏÂÈ ÛÙËÓ ÚfiÎÏËÛË ÙÚ·‡Ì·ÙÔ˜, ÛÂ Û˘Ó‰˘·ÛÌfi Ì ÙËÓ ·ÓÒÚÈÌË ¿Ì˘Ó· Î·È ÙÔ˘˜ ÌÂȈ̤ÓÔ˘˜ ÂÓÙÂÚÈÎÔ‡˜ ÊÚ·ÁÌÔ‡˜. ∞. Tight junctions (™Ù·ıÂÚ¤˜ Û˘Ó‰¤ÛÂȘ) ™ÎÔfi˜ ÙÔ˘˜ Â›Ó·È Ë ‰ËÌÈÔ˘ÚÁ›· ÊÚ·ÁÌÔ‡, ̤ۈ Û‡Ó‰ÂÛ˘ ÙˆÓ Ï·Á›ˆÓ ÂÈÊ·ÓÂÈÒÓ ÙˆÓ ÂÓÙÂÚÔ΢ÙÙ¿ÚˆÓ. √È tight junctions ‹ ÛÙ·ıÂÚ¤˜ Û˘Ó‰¤ÛÂȘ ·ÔÙÂÏÔ‡ÓÙ·È ·fi ÔÏÏ·Ϥ˜ ÔÈÎÔÁ¤ÓÂȘ ÚˆÙÂ˚ÓÒÓ (‰È·ÌÂÌ‚Ú·ÓÈΤ˜ ÚˆÙ½Ó˜, fiˆ˜ Ë ÔÎÏÔ˘‰›ÓË, Ë ÎÏ·Ô˘‰›ÓË Î·È ÔÈ ÚˆÙ½Ó˜ ÚÔÛÎfiÏÏËÛ˘) (58). ¶ÚfiÛÊ·Ù· ‰Â‰Ô̤ӷ ·Ó·Ê¤ÚÔ˘Ó fiÙÈ ÔÈ ÛÙ·ıÂÚ¤˜ Û˘Ó‰¤ÛÂȘ ‰ÂÓ Â›Ó·È ÛÙ·ÙÈΤ˜ ‰Ô̤˜, ·ÏÏ¿ ÌÂÙ·‚¿ÏÏÔÓÙ·È Î·Ù¿ ÙË ‰È·‰ÚÔÌ‹ ‰È·ÊfiÚˆÓ ÎÏÈÓÈÎÒÓ Î·Ù·ÛÙ¿ÛÂˆÓ (45). ∆fiÛÔ in vivo fiÛÔ Î·È in vitro ÌÂϤÙ˜ ¤¯Ô˘Ó ·ԉ›ÍÂÈ fiÙÈ Ë ÂÓ‰ÔÙÔÍÈÓ·ÈÌ›· ÚÔηÏ› Ì›ˆÛË ÛÙËÓ ¤ÎÊÚ·ÛË ÚˆÙÂ˚ÓÒÓ ÙˆÓ ÛÙÂÚÂÒÓ ÂÓÒÛˆÓ, fiˆ˜ ÔÈ ZO-1, ZO-2, ZO-3 Î·È Ë ÔÎÏÔ˘‰›ÓË, ̤ۈ Ù˘ ‰Ú¿Û˘ ÙÔ˘ ¡√, Ì ·ÔÙ¤ÏÂÛÌ· ÙË ‰È¿Û·ÛË Ù˘ ·ÎÂÚ·ÈfiÙËÙ·˜ ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÊÚ·ÁÌÔ‡ (56,58). µ. ∂ÓÙÂÚÈÎfi˜ ÂÚÈÛÙ·ÏÙÈÛÌfi˜ √ ÂÚÈÛÙ·ÏÙÈÛÌfi˜ Î·È ÔÈ ÎÈÓ‹ÛÂȘ ÙÔ˘ ÂÓÙ¤ÚÔ˘ ÚÔηÏÔ‡Ó ÌÂٷΛÓËÛË ÙÔ˘ ÂÚȯÔ̤ÓÔ˘ ÌÂ Î˘Ì·ÙÔÂȉ›˜ Û˘Û¿ÛÂȘ (59). ™ÎÔfi˜ ÙÔ˘˜ Â›Ó·È Ë ¤„Ë ÙˆÓ ÙÚÔÊÒÓ, ÂÓÒ, ÂÈϤÔÓ, ‰ÚÔ‡Ó Û˘ÓÂÚÁÈο ÛÙË ‰È·Ù‹ÚËÛË Ù˘ ÂÈıËÏȷ΋˜ ·ÎÂÚ·ÈfiÙËÙ·˜. √ ÂÚÈÛÙ·ÏÙÈÛÌfi˜ ÌÂÈÒÓÂÈ Û˘Á¯ÚfiÓˆ˜ ÙÔ ¯ÚfiÓÔ Ì ÙÔÓ ÔÔ›Ô Ù· ·ÓÙÈÁfiÓ· ÙˆÓ ·ıÔÁfiÓˆÓ ÌÈÎÚÔÔÚÁ·ÓÈÛÌÒÓ ‚Ú›ÛÎÔÓÙ·È Û Â·Ê‹ Ì ÙÔ ÎÔÚ˘Ê·›Ô ÙÌ‹Ì· ÙˆÓ ÂÓÙÂÚÔ΢ÙÙ¿ÚˆÓ, ÌË ÂÈÙÚ¤ÔÓÙ·˜ ÙËÓ ·ÓÙ›‰Ú·ÛË ·ÓÙÈÁfiÓÔ˘-·ÓÙÈÛÒÌ·ÙÔ˜ (59). ∆· ÚfiˆÚ· ÓÂÔÁÓ¿ ‰ÂÓ ¤¯Ô˘Ó Ï‹Úˆ˜ ·Ó·Ù˘Á̤ÓÔ ÂÚÈÛÙ·ÏÙÈÛÌfi, ·ÊÔ‡ Ô Ì˯·ÓÈÛÌfi˜ ÏÂÈÙÔ˘ÚÁ›·˜ ÙÔ˘ ‰ÂÓ ˆÚÈÌ¿˙ÂÈ ÚÈÓ ·fi ÙÔÓ 8Ô Ì‹Ó· Ù˘ ·ËÛ˘ (60). ∆¤ÏÔ˜, ÙÔ ÚÔÙÂÈÓfiÌÂÓÔ ÌÔÓÙ¤ÏÔ Û‹ÌÂÚ· ÂÓÔ¯ÔÔÈ› ÙËÓ ¤ÏÏÂÈ„Ë ÂÚÈÛÙ·ÏÙÈÛÌÔ‡ ÁÈ· ÙËÓ ÚfiÎÏËÛË stress ÛÙÔÓ ÂÓÙÂÚÈÎfi ÊÚ·ÁÌfi Î·È ‰Â˘ÙÂÚÔ·ı‹ ÌÈÎÚԂȷ΋ ÚÔÛ‚ÔÏ‹ Î·È ÊÏÂÁÌÔÓÒ‰Ë ·¿ÓÙËÛË. °. ™‡ÛÙ·ÛË ÙÔ˘ ÛÙÚÒÌ·ÙÔ˜ ‚ϤÓÓ·˜ ∆Ô ÛÙÚÒÌ· Ù˘ ‚ϤÓÓ·˜ Ô˘ ÂÈηχÙÂÈ Ù· ÂÓÙÂÚÔ·ÙÙ·Ú· ‰È·‰Ú·Ì·Ù›˙ÂÈ ÛËÌ·ÓÙÈÎfi ÚfiÏÔ ÛÙËÓ ·ÎÂÚ·ÈfiÙËÙ· Î·È ÚÔÛÙ·Û›· ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÊÚ·ÁÌÔ‡ (61). √È ÂÈÊ¿ÓÂȘ ÙÔ˘ ÂÈıËÏ›Ô˘ ÙÔ˘ Á·ÛÙÚÂÓÙÂÚÈÎÔ‡, ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Î·È ÙÔ˘ ·Ó··Ú·ÁˆÁÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ ÙˆÓ ıËÏ·ÛÙÈÎÒÓ ·ÔÙÂÏÂ›Ù·È ·fi ÓÂÚfi, ‚ÏÂÓÓ›ÓË Î·È ÏÈ›‰È· (46). ∏ ‚ÏÂÓÓ›ÓË ·ÔÙÂÏ› ÁÏ˘ÎÔÚˆÙ½ÓË ˘„ËÏÔ‡ ÌÔÚÈ·ÎÔ‡ ‚¿ÚÔ˘˜ Ô˘ ¤¯ÂÈ ÙËÓ ÈηÓfiÙËÙ· Ó· Û¯ËÌ·Ù›˙ÂÈ ·¯‡ÚÚ¢ÛÙË Á¤ÏË ÛÙËÓ ÂÈÊ¿ÓÂÈ· ÙˆÓ ÂÓÙÂÚÔ΢ÙÙ¿ÚˆÓ. √ ‚·ıÌfi˜ ÚÔÛÙ·-

Û›·˜ ÙÔ˘ Á·ÛÙÚÂÓÙÂÚÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ ·fi ÙȘ ‚ÏÂÓÓ›Ó˜ Û¯ÂÙ›˙ÂÙ·È Ì ÙÔ ‚·ıÌfi ˆÚ›Ì·ÓÛ‹˜ ÙÔ˘˜, Ë ÔÔ›· ÂÍ·ÚÙ¿Ù·È Î˘Ú›ˆ˜ ·fi ÙËÓ ËÏÈΛ· ·ËÛ˘ (62). ™˘ÁÎÂÎÚÈ̤ӷ, ÔÈ ˆÚÈÌfiÙÂÚ˜ Â›Ó·È ÈÔ ·¯‡ÚÚ¢ÛÙ˜, Ô͇ÙÂÚ˜ Î·È ÂÚÈÛÛfiÙÂÚÔ ·ÓıÂÎÙÈΤ˜ ÛÙË ‰Ú¿ÛË ÙˆÓ ‚·ÎÙËÚÈ·ÎÒÓ ÂÓ˙‡ÌˆÓ, Û ·ÓÙ›ıÂÛË Ì ÂΛӘ Ô˘ ··ÓÙÒÓÙ·È ÛÙ· ÚfiˆÚ· (63-65). ¶ÔÏϤ˜ ÌÂϤÙ˜ ¤¯Ô˘Ó ‰Â›ÍÂÈ fiÙÈ Ë ¤ÏÏÂÈ„Ë ‚ϤÓÓ˘ ‰È·‰Ú·Ì·Ù›˙ÂÈ ÚfiÏÔ Û ÓÔÛ‹Ì·Ù· ÙÔ˘ Á·ÛÙÚÂÓÙÂÚÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ Ô˘ ÌÈÌÔ‡ÓÙ·È ÙË ¡∂∫, fiˆ˜ Ë ÌÂÙ·Ï·Û›· ÙÔ˘ ÂÓÙ¤ÚÔ˘, Ë Á·ÛÙÚ›Ùȉ·, Ô˘ Ô‰ËÁ› Û ¤ÏÎÔ˜, Î·È ÔÈ ÊÏÂÁÌÔÓÒ‰ÂȘ ÓfiÛÔÈ ÙÔ˘ ÂÓÙ¤ÚÔ˘ (61-62). ∏ IgA ·ÔÙÂÏ› ÙËÓ ·ÓÔÛÔÛÊ·ÈÚ›ÓË Ô˘ ·Ú¿ÁÂÙ·È Û ÌÂÁ·Ï‡ÙÂÚË ÔÛfiÙËÙ· ÛÙÔÓ ·ÓıÚÒÈÓÔ ÔÚÁ·ÓÈÛÌfi (66). ™ÙÔ ¤ÓÙÂÚÔ, Ë sIgA ‰Ú· ·ÊÂÓfi˜ ̤ۈ Ù˘ Û‡Ó‰ÂÛ‹˜ Ù˘ Ì ٷ ‚·ÎÙ‹ÚÈ· Î·È ·ÊÂÙ¤ÚÔ˘ ̤ۈ Ù˘ ÂÍÔ˘‰ÂÙ¤ÚˆÛ˘ ÙˆÓ ‚·ÎÙËÚÈ·ÎÒÓ ÂÓ‰ÔÙÔÍÈÓÒÓ, ÙˆÓ ÚÔÙ·˚ÒÓ Î·È ÙÔ˘ ÈÔ‡ Ù˘ ÁÚ›˘, Ô˘ ÂÓÔ¯ÔÔÈÔ‡ÓÙ·È ÛÙËÓ ·ıÔÁ¤ÓÂÛË Ù˘ ¡∂∫ (67). ¶·Ú¿ ÙÔÓ ·Ú¯ÈÎfi ÂÓıÔ˘ÛÈ·ÛÌfi ÁÈ· ÙËÓ Èı·Ó‹ ÚÔÛٷ٢ÙÈ΋ Ù˘ ‰Ú¿ÛË, ÚfiÛÊ·ÙË ÌÂÙ·Ó¿Ï˘ÛË 3 ÎÏÈÓÈÎÒÓ ÌÂÏÂÙÒÓ Ì 2.095 ÂÓÙ·¯ı¤ÓÙ· ÓÂÔÁÓ¿ ‰ÂÓ ·¤‰ÂÈÍ Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ Ù˘ ¡∂∫ ÌÂÙ¿ ÙËÓ ÚÔÊ˘Ï·ÎÙÈ΋ ¯ÔÚ‹ÁËÛË Û˘Ó‰˘·ÛÌÔ‡ IgG/IgA ‹ ÌfiÓÔ IgG (68).

¶ÚfiÏË„Ë - ∞ÓÙÈÌÂÙÒÈÛË ∏ ıÂÚ·¢ÙÈ΋ ·ÓÙÈÌÂÙÒÈÛË ÙˆÓ ÓÂÔÁÓÒÓ Ì ¡∂∫ ‚·Û›˙ÂÙ·È ÛÙË Û˘Ó¯‹ ·ÔÛ˘ÌÊfiÚËÛË ÙÔ˘ ÂÙÈÎÔ‡ ۈϋӷ, ÛÙËÓ ·Ú·ÎÔÏÔ‡ıËÛË ÙˆÓ ˙ˆÙÈÎÒÓ ÛËÌ›ˆÓ Î·È ‰È·Ù‹ÚËÛË ÙÔ˘ ÈÛÔ˙˘Á›Ô˘ ÙˆÓ ˘ÁÚÒÓ Î·È, Ù¤ÏÔ˜, ÛÙË ¯ÔÚ‹ÁËÛË ·ÓÙÈÌÈÎÚÔ‚È·ÎÒÓ. ∏ Û‡Á¯ÚÔÓË ÛÙÚ·ÙËÁÈ΋ ÚfiÏ˄˘ Î·È ·ÓÙÈÌÂÙÒÈÛ˘ ¤¯ÂÈ Û˘Ì‚¿ÏÏÂÈ ÛËÌ·ÓÙÈο ÛÙË ‚ÂÏÙ›ˆÛË ÙˆÓ ÚÒÈÌˆÓ Î·È ·ÒÙÂÚˆÓ ÂÈÏÔÎÒÓ ÙˆÓ Ôχ ¯·ÌËÏÔ‡ ‚¿ÚÔ˘˜ Á¤ÓÓËÛ˘ ÓÂÔÁÓÒÓ (¶Ãµ¡) Ì ¡∂∫. ∏ Û›ÙÈÛË Ì ÌËÙÚÈÎfi Á¿Ï·, ΢ڛˆ˜ ÛÙ· ÓÂÔÁÓ¿ ˘„ËÏÔ‡ ÎÈÓ‰‡ÓÔ˘, ¤¯ÂÈ ·Ô‰Âȯı› fiÙÈ Û˘Ì‚¿ÏÏÂÈ ÛËÌ·ÓÙÈο ÛÙË Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ (69-71). ¶·ÚfiÏ· ·˘Ù¿, ˘¿Ú¯ÂÈ ·ÎfiÌË ‰È¯ÔÁӈ̛· ÛÙË ‰ÈÂıÓ‹ ‚È‚ÏÈÔÁÚ·Ê›·, fiÛÔÓ ·ÊÔÚ¿ ÙËÓ ÚÔÛÙ·Û›· Ô˘ ÚÔÛʤÚÂÈ Ë ¯ÔÚ‹ÁËÛË Í¤ÓÔ˘ ÌËÙÚÈÎÔ‡ Á¿Ï·ÎÙÔ˜ (72). ∏ ÚÔÁÂÓÂÙÈ΋ ¯ÔÚ‹ÁËÛË ÎÔÚÙÈÎÔÛÙÂÚÔÂȉÒÓ, Ë Û˘ÌÏËڈ̷ÙÈ΋ ¯ÔÚ‹ÁËÛË IgA, ·ÓıÚÒÈÓ˘ ·Ó·Û˘Ó‰˘·Ṳ̂Ó˘ ÂÚ˘ıÚÔÔÈËÙ›Ó˘ (rhEPO), ·ÚÁÈÓ›Ó˘ ηÈ, Ù¤ÏÔ˜, Ë ÚÔÊ˘Ï·ÎÙÈ΋ ·ÓÙÈÌÂÙÒÈÛË Ì ·ÓÙÈ‚ÈÔÙÈο ·fi ÙÔ˘ ÛÙfiÌ·ÙÔ˜ Û˘Ì‚¿ÏÏÔ˘Ó ÛÙË Ì›ˆÛË Ù˘ Â›ÙˆÛ‹˜ Ù˘, ¯ˆÚ›˜ fï˜ Ó· ¤¯Ô˘Ó ̤¯ÚÈ Û‹ÌÂÚ· ‰Ôı› Û·Ê›˜ Û˘ÛÙ¿ÛÂȘ ÁÈ· ÙȘ Û˘ÁÎÂÎÚÈ̤Ó˜ Ú·ÎÙÈΤ˜ ·ÓÙÈÌÂÙÒÈÛ˘ (68,73-76). ∏ ¢ÂÚÁÂÙÈ΋ ‰Ú¿ÛË Ù˘ EPO ÛÙË Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ Ù˘ ¡∂∫ ¤¯ÂÈ ·Ô‰Âȯı› ÙfiÛÔ Û ÂÈÚ·Ì·ÙÈο fiÛÔ Î·È Û ÌË ÌÔÓ٤Ϸ (75,77). √ ÚfiÏÔ˜ Ù˘ ÛÙËÓ ·Ó¿Ù˘ÍË ÙÔ˘ Á·ÛÙÚÂÓÙÂÚÈÎÔ‡ ¶·È‰È·ÙÚÈ΋ 2008;71:21-28

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·26

26

Ã. ∆۷ηϛ‰Ë˜ Î·È Û˘Ó.

Û˘ÛÙ‹Ì·ÙÔ˜ ‚·Û›ÛÙËΠÛÙËÓ ·Ó‡ÚÂÛ‹ Ù˘ ÛÙÔ ·ÓıÚÒÈÓÔ Á¿Ï· Î·È ÛÙËÓ ¤ÎÊÚ·ÛË ˘Ô‰Ô¯¤ˆÓ Ù˘ ÛÙ· ÂÓÙÂÚÔ·ÙÙ·Ú·. ŸÛÔÓ ·ÊÔÚ¿ ÙËÓ ÂÈÛ·ÁˆÁ‹ Ù˘ ÙÚÔÊ‹˜, Â›Ó·È ÁÓˆÛÙfi fiÙÈ ·Ó ‰Ôı› ÚÒÈÌ· Û¯ÂÙ›˙ÂÙ·È Ì ˘„ËÏfiÙÂÚË ·ÓÔ¯‹, ηχÙÂÚË ·Ó¿Ù˘ÍË, ÌÈÎÚfiÙÂÚÔ ‰È¿ÛÙËÌ· ÂÓ‰ÔÓÔÛÔÎÔÌÂȷ΋˜ ÓÔÛËÏ›·˜ Î·È ÌÂȈ̤ÓÔ ÔÛÔÛÙfi ÛË„·ÈÌ›·˜ (78,79). ∂ÈϤÔÓ, Ë ÚÒÈÌË ¤Ó·ÚÍË Ù˘ Û›ÙÈÛ˘ ‰ÂÓ ·˘Í¿ÓÂÈ ÙËÓ Èı·ÓfiÙËÙ· ÂΉ‹ÏˆÛ˘ ¡∂∫ (78,79). ∂ÓÙÔ‡ÙÔȘ, ̤¯ÚÈ Û‹ÌÂÚ· ‰ÂÓ ¤¯ÂÈ ‰È¢ÎÚÈÓÈÛÙ› Ï‹Úˆ˜ ·fi ÙȘ ÌÂϤÙ˜ Ë ÔÚı‹ ÛÙÚ·ÙËÁÈ΋ Û›ÙÈÛ˘ ÙˆÓ ÚfiˆÚˆÓ ÓÂÔÁÓÒÓ. ∂›Ó·È ÁÓˆÛÙfi fiÙÈ Ô ‚·ÎÙËÚÈ·Îfi˜ ·ÔÈÎÈÛÌfi˜ Ì ÚÔ‚ÈÔÙÈο Û˘Ì‚¿ÏÏÂÈ ÛÙËÓ ÚfiÏË„Ë ÔÏÏÒÓ Á·ÛÙÚÂÓÙÂÚÈÎÒÓ ÓÔÛËÌ¿ÙˆÓ Î·È, ÂÔ̤ӈ˜, ·ÔÙÂÏÔ‡Ó ÌÈ· ÔÏÏ¿ ˘ÔÛ¯fiÌÂÓË ·Ú¤Ì‚·ÛË ÛÙËÓ ÚfiÏË„Ë Î·È ıÂÚ·›· Ù˘ ÓfiÛÔ˘. √È ÌÂϤÙ˜ ¤¯Ô˘Ó ÂȂ‚·ÈÒÛÂÈ fiÙÈ Ë ¯ÔÚ‹ÁËÛË ÚÔ‚ÈÔÙÈÎÒÓ Û¯ÂÙ›˙ÂÙ·È Ì Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ Î·È Ù˘ ‚·Ú‡ÙËÙ·˜ Ù˘ ¡∂∫ (80,81). ∂Ó·ÏÏ·ÎÙÈΤ˜ ‹ Û˘ÌÏËڈ̷ÙÈΤ˜ ÛÙÚ·ÙËÁÈΤ˜ ÚfiÏ˄˘ ·ÔÙÂÏÔ‡Ó Ë ¯ÔÚ‹ÁËÛË ÙˆÓ Ú‚ÈÔÙÈÎÒÓ Ô˘, fiˆ˜ Â›Ó·È ÁÓˆÛÙfi, ÚÔ¿ÁÔ˘Ó ÙËÓ ·Ó¿Ù˘ÍË Ù˘ Ê˘ÛÈÔÏÔÁÈ΋˜ ÌÈÎÚԂȷ΋˜ ¯ÏˆÚ›‰·˜, ηıÒ˜ Î·È ÙˆÓ ÌÂÙ·‚ÈÔÙÈÎÒÓ (postbiotics), fiˆ˜ ÙÔ ‚Ô˘Ù˘ÚÈÎfi Ô͇ Ô˘ ¤¯ÂÈ Û˘Û¯ÂÙÈÛÙ› Û ÂÈÚ·Ì·ÙÈο ÌÔÓ٤Ϸ Ì ÙËÓ ·Ó¿Ù˘ÍË Î·È ‰È·ÊÔÚÔÔ›ËÛË ÙÔ˘ ÂÓÙ¤ÚÔ˘, ÙËÓ Î·Ù·ÛÙÔÏ‹ Ù˘ ÊÏÂÁÌÔÓÒ‰Ô˘˜ ‰ÈÂÚÁ·Û›·˜ Î·È ÙËÓ ·fiÙˆÛË (82-86). ∏ ¯ÔÚ‹ÁËÛ‹ ÙÔ˘ ¤¯ÂÈ ÌÂÏÂÙËı› Û ·È‰È¿ Ì ÊÏÂÁÌÔÓÒ‰Ë ÓÔÛ‹Ì·Ù· ÙÔ˘ ÂÓÙ¤ÚÔ˘, fï˜ ‰ÂÓ ¤¯ÂÈ Ì¤¯ÚÈ Û‹ÌÂÚ· ¯ÔÚËÁËı› Û ÓÂÔÁÓ¿ (87). ∆¤ÏÔ˜, fiÛÔÓ ·ÊÔÚ¿ Ù· ¶Ãµ¡ Ô˘ ÂÈ˙Ô‡Ó ·fi ¡∂∫, ¤¯ÂÈ ‰È·ÈÛÙˆı› fiÙÈ ÂÌÊ·Ó›˙Ô˘Ó ·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ Ó¢ÚÔ·Ó·Ù˘ÍÈ·ÎÒÓ, ΢ڛˆ˜, ‰È·Ù·Ú·¯ÒÓ (88,89). ™‡Ìʈӷ Ì ٷ Â˘Ú‹Ì·Ù· Ù˘ ÌÂϤÙ˘ ÙˆÓ Stoll Î·È Û˘Ó., ÚԤ΢„ fiÙÈ Ù· ·È‰È¿ Ì ¡∂∫ ÂÌÊ¿ÓÈ˙·Ó Û ˘„ËÏfiÙÂÚ· ÔÛÔÛÙ¿ ηı˘ÛÙ¤ÚËÛË ·Ó¿Ù˘Í˘, ÂÁÎÂÊ·ÏÈ΋ ·Ú¿Ï˘ÛË, ÚÔ‚Ï‹Ì·Ù· fiÚ·Û˘ Î·È ·ÎÔ‹˜ (90). ™Â ÌÂϤÙË 3.000 ¶Ãµ¡ (<1.000g) ÂÎ ÙˆÓ ÔÔ›ˆÓ Â¤˙ËÛ·Ó 245 ÌÂÙ¿ ·fi ¡∂∫, ‰È·ÈÛÙÒıËΠfiÙÈ fiÛ· ·ÓÙÈÌÂÙˆ›ÛÙËÎ·Ó ¯ÂÈÚÔ˘ÚÁÈο ÂÌÊ¿ÓÈ˙·Ó Û ˘„ËÏfiÙÂÚ· ÔÛÔÛÙ¿ ηı˘ÛÙ¤ÚËÛË Ù˘ ۈ̷ÙÈ΋˜ ·Ó¿Ù˘Í˘ Î·È Ó¢ÚÔ·Ó·Ù˘ÍȷΤ˜ ‰È·Ù·Ú·¯¤˜ Û ۇÁÎÚÈÛË Ì ÂΛӷ Ô˘ ·ÓÙÈÌÂÙˆ›ÛÙËÎ·Ó Û˘ÓÙËÚËÙÈο (91).

¶ÚfiÔ‰ÔÈ, ÂÚˆÙ‹Ì·Ù· Î·È ÌÂÏÏÔÓÙÈÎÔ› ÛÙfi¯ÔÈ ™‡Ìʈӷ Ì ٷ ÚÔ·Ó·ÊÂÚfiÌÂÓ·, ÚÔ·ÙÂÈ fiÙÈ Ë ÂΉ‹ÏˆÛË ¡∂∫ ·ÓÙ·Ó·ÎÏ¿ ÙÔ Û˘Ó‰˘·ÛÌfi Î·È ÙË Û˘ÓÂÚÁÈ΋ ‰Ú¿ÛË ÔÏÏÒÓ ·Ú·ÁfiÓÙˆÓ Ô˘ Ô‰ËÁÔ‡Ó ÛÙËÓ Î·Ù·ÛÙÚÔÊ‹ Ù˘ ·ÎÂÚ·ÈfiÙËÙ·˜ ÙÔ˘ ÂÓÙÂÚÈÎÔ‡ ÊÚ·ÁÌÔ‡, ÛÙËÓ ÂÓÂÚÁÔÔ›ËÛË ÙˆÓ ·Ì˘ÓÙÈÎÒÓ Ì˯·ÓÈÛÌÒÓ Î·È Ù˘ Û˘ÛÙËÌ·ÙÈ΋˜ ÊÏÂÁÌÔÓÒ‰Ô˘˜ ·¿ÓÙËÛ˘.

Paediatriki 2008;71:21-28

∏ Ï‹Ú˘ ηٷÓfiËÛË ÙˆÓ ÌÔÚÈ·ÎÒÓ Ì˯·ÓÈÛÌÒÓ Ô˘ ¢ı‡ÓÔÓÙ·È ÁÈ· ÙË ‚Ï¿‚Ë Î·È ÙËÓ ÈÛ¯·ÈÌ›· ÙÔ˘ ÂÓÙ¤ÚÔ˘, ÛÂ Û˘Ó‰˘·ÛÌfi Ì Ӥ˜ ıÂÚ·¢ÙÈΤ˜ ÛÙÚ·ÙËÁÈΤ˜ Ô˘ ı· ¤¯Ô˘Ó ˆ˜ ÛÙfi¯Ô ÙËÓ ·ÔηٿÛÙ·Û‹ Ù˘, ı· Û˘Ì‚¿ÏÏÔ˘Ó ÛËÌ·ÓÙÈο ÛÙËÓ ·‡ÍËÛË Ù˘ ÂÈ‚›ˆÛ˘ ÙˆÓ ÓÂÔÁÓÒÓ Ô˘ ÂΉËÏÒÓÔ˘Ó ¡∂∫. ∆¤ÏÔ˜, Ë ÂÈΤÓÙÚˆÛË Ù˘ ÌÂÏÏÔÓÙÈ΋˜ ¤Ú¢ӷ˜ ÛÙÔ˘˜ ·Ú¿ÁÔÓÙ˜ Ô˘ Èı·ÓÒ˜ Ó· Û¯ÂÙ›˙ÔÓÙ·È Ì ÙË ÁÂÓÂÙÈ΋ ÚԉȿıÂÛË ÂΉ‹ÏˆÛ˘ ¡∂∫ ı· ÌÔÚÔ‡Û ӷ Û˘Ì‚¿ÏÏÂÈ ÛÙËÓ ÂÍ·ÙƠ̂΢ÛË Ù˘ ıÂÚ·›·˜ Î·È ÛÙËÓ ÚÒÈÌË ÂÊ·ÚÌÔÁ‹ ÚÔÏËÙÈÎÒÓ Ì¤ÙÚˆÓ ÛÙ· ÓÂÔÁÓ¿ Ì ·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ ÂΉ‹ÏˆÛ‹˜ Ù˘.

µÈ‚ÏÈÔÁÚ·Ê›· 1. Paltauf A. Die spontane dickdarm Ruptur der Neugeborenen. Virchows Arch Path Anat 1888;111:461.

2. Schmid O, Quaiser K. Uer eine besondere schwere verlaufende Form von Enteritis beim saugling. Oesterr Z Kinderh 1953;8:114.

3. Mizrahi A, Barlow O, Berdon W, Blanc WA, Silverman WA. Necrotizing Enterocolitis in premature infants. J Pediatr 1965;66:697-705.

4. Kosloske AM. Epidemiology of necrotizing enterocolitis.

Acta Paediatr Suppl 1994;396:2-7.

5. Stoll BJ. Epidemiology of necrotizing enterocolitis. Clin Perinatol 1994;21:205-218.

6. Rowe MI, Reblock KK, Kurkchubasche AG, Healey PJ. Necrotizing enterocolitis in the extremely low birth weight infant. J Pediatr Surg 1994;29:987-990.

7. Ng S. Necrotizing enterocolitis in the full-term neonate. J Paediatr Child Health 2001;37:1-4.

8. Barlow B, Santulli TV, Heird WC, Pitt J, Blanc WA, Schullinger JN. An experimental study of acute neonatal enterocolitis-the importance of breast milk. J Pediatr Surg 1974;9:587-595.

9. Kennedy KA, Tyson JE, Chamnanvanakij S. Rapid versus slow rate of advancement of feedings for promoting growth and preventing necrotizing enterocolitis in parenterally fed low-birth-weight infants. Cochrane Database Syst Rev 2000;(2):CD001241.

10. Hällström M, Koivisto AM, Janas M, Tammela O. Frequency of and risk factors for necrotizing enterocolitis in infants born before 33 weeks of gestation. Acta Paediatr 2003;92:111-113.

11. Kamitsuka MD, Horton MK, Williams MA. The incidence of necrotizing enterocolitis after introducing standardized feeding schedules for infants between 1250 and 2500 grams and less than 35 weeks of gestation. Pediatrics 2000;105: 379-384.

12. Grosfeld JL, Chaet M, Molinari F, Engle W, Engum SA, West KW, et al. Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Ann Surg 1996;224:350-355.

13. Kafetzis DA, Skevaki C, Costalos C. Neonatal necrotizing enterocolitis: an overview. Curr Opin Infect Dis 2003;16: 349-355.

14. Hsueh W, Caplan MS, Qu XW, Tan XD, De Plaen IG, Gonzalez-Crussi F. Neonatal necrotizing enterocolitis: clinical considerations and pathogenetic concepts. Pediatr Dev Pathol 2003;6:6-23.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·27

27

¡ÂÎÚˆÙÈ΋ ÂÓÙÂÚÔÎÔÏ›Ùȉ·

15. Neu J, Weiss MD. Necrotizing enterocolitis: pathophysiology and prevention. JPEN J Parenter Enteral Nutr 1999;23:S13-17.

16. Saãntulli TV, Schullinger JN, Heird WC, Congaware RD, Wigger J, Barlow B, et al. Acute necrotizing enterocolitis in infancy: a review of 64 cases. Pediatrics 1975;55:376-387.

17. Neu J, Chen M, Beierle E. Intestinal innate immunity: how does it relate to the pathogenesis of necrotizing enterocolitis. Semin Pediatr Surg 2005;14:137-144.

18. Eibl MM, Wolf HM, Fürnkranz H, Rosenkranz A. Prevention of necrotizing enterocolitis in low-birth-weight infants

by IgA-IgG feeding. N Engl J Med. 1988;319:1-7.

19. Tyson JE, Kennedy KA, Lucke JF, Pedroza C. Dilemmas initiating enteral feedings in high risk infants: how can they be resolved? Semin Perinatol 2007;31:61-73.

20. Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O'Shea TM. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J Perinatol 2007;27:428-433.

21. Thureen PJ. Early aggressive nutrition in very preterm infants. Nestle Nutr Workshop Ser Pediatr Program 2007;59:193-204; discussion 204-8.

22. Pietz J, Achanti B, Lilien L, Stepka EC, Mehta SK. Prevention of necrotizing enterocolitis in preterm infants: a 20year experience. Pediatrics 2007;119:e164-170.

23. Smith JR. Early enteral feeding for the very low birth weight infant: the development and impact of a research-based guideline. Neonatal Netw 2005;24:9-19.

24. LaGamma EF, Ostertag SG, Birenbaum H. Failure of delayed oral feedings to prevent necrotizing enterocolitis. Results of study in very-low-birth-weight neonates. Am J Dis Child 1985;139:385-389.

25. Eyal F, Sagi E, Arad I, Avital A: Necrotising enterocolitis in the very low birthweight infant: expressed breast milk feeding compared with parenteral feeding. Arch Dis Child 1982;57:274-276.

26. Hackam DJ, Upperman JS, Grishin A, Ford HR. Disordered enterocyte signaling and intestinal barrier dysfunction in the pathogenesis of necrotizing enterocolitis. Semin Pediatr Surg 2005;14:49-57.

27. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 1999;3:197-202.

28. Caplan MS, Miller-Catchpole R, Kaup S, Russell T, Lickerman M, Amer M, et al. Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Gastroenterology 1999;117:577-583.

29. Schanler RJ. Probiotics and necrotising enterocolitis in premature infants. Arch Dis Child Fetal Neonatal Ed 2006;91: F395-397.

30. Rautava S. Potential uses of probiotics in the neonate.

Semin Fetal Neonatal Med 2007;12:45-53.

31. Salminen S, Isolauri E. Intestinal colonization, microbiota and probiotics. J Pediatr 2006;149:S115-120.

32. Nowicki PT. Ischemia and necrotizing enterocolitis: where, when, and how. Semin Pediatr Surg 2005;14:152-158.

33. Gibbs K, Lin J, Holzman IR. Necrotising enterocolitis: the state of the science. Indian J Pediatr 2007;74:67-72.

34. Wilson R, del Portillo M, Schmidt E, Feldman RA, Kanto WP Jr. Risk factors for necrotizing enterocolitis in infants weighing more than 2,000 grams at birth: a case-control study. Pediatrics 1983;71:19-22.

35. Payne D, Kubes P. Nitric oxide donors reduce the rise in reperfusion-induced intestinal mucosal permeability. Am J Physiol 1993;265:G189-195.

36. Kubes P. Ischemia-reperfusion in feline small intestine: a role for nitric oxide. Am J Physiol 1993;264:G143-149.

37. Edelson MB, Bagwell CE, Rozycki HJ. Circulating pro- and counterinflammatory cytokine levels and severity in necrotizing enterocolitis. Pediatrics 1999;103:766-771.

38. Ledbetter DJ, Juul SE. Necrotizing enterocolitis and hematopoietic cytokines. Clin Perinatol 2000;27:697-716.

39. Morecroft JA, Spitz L, Hamilton PA, Holmes SJ. Plasma cytokine levels in necrotizing enterocolitis. Acta Paediatr Suppl 1994;396:18-20.

40. Harris MC, D'Angio CT, Gallagher PR, Kaufman D, Evans J, Kilpatrick L. Cytokine elaboration in critically ill infants with bacterial sepsis, necrotizing enterocolitis, or sepsis syndrome: correlation with clinical parameters of inflammation and mortality. J Pediatr 2005;147:462-468.

41. Caplan MS, Simon D, Jilling T. The role of PAF, TLR, and the inflammatory response in neonatal necrotizing enterocolitis. Semin Pediatr Surg 2005;14:145-151.

42. Caplan MS, Lickerman M, Adler L, Dietsch GN, Yu A. The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis. Pediatr Res 1997;42:779-783.

43. Caplan MS, Sun XM, Hseuh W, Hageman JR. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr 1990;116:960-964.

44. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis.

Cell 2004;118:229-241.

45. Han X, Fink MP, Delude RL: Proinflammatory cytokines cause NO*-dependent and -independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock 2003;19:229-237.

46. Müller CA, Autenrieth IB, Peschel A. Innate defenses of the intestinal epithelial barrier. Cell Mol Life Sci 2005;62:1297-1307.

47. Sase M, Lee JJ, Park JY, Thakur A, Ross MG, BuchmillerCrair TL. Ontogeny of fetal rabbit upper gastrointestinal motility. J Surg Res 2001;101:68-72.

48. Sase M, Miwa I, Sumie M, Nakata M, Sugino N, Okada K. Gastric emptying cycles in the human fetus. Am J Obstet Gynecol 2005;193:1000-1004.

49. Sase M, Miwa I, Sumie M, Nakata M, Sugino N, Ross MG. Ontogeny of gastric emptying patterns in the human fetus.

J Matern Fetal Neonatal Med 2005;17:213-217.

50. Berseth CL. Gestational evolution of small intestine motility in preterm and term infants. J Pediatr 1989;115:646-651.

51. Berseth CL. Neonatal small intestinal motility: motor responses to feeding in term and preterm infants. J Pediatr 1990;117:777-782.

52. Berseth CL, Ittmann PI. Antral and duodenal motor responses to duodenal feeding in preterm and term infants. J Pediatr Gastroenterol Nutr 1992;14:182-186.

53. Al Tawil Y, Berseth CL. Gestational and postnatal maturation of duodenal motor responses to intragastric feeding. J Pediatr 1996;129:374-381.

54. Sase M, Lee JJ, Ross MG, Buchmiller-Crair TL. Effect of hypoxia on fetal rabbit gastrointestinal motility. J Surg Res 2001;99:347-351.

55. Berseth CL, McCoy HH. Birth asphyxia alters neonatal ¶·È‰È·ÙÚÈ΋ 2008;71:21-28

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·28

28

Ã. ∆۷ηϛ‰Ë˜ Î·È Û˘Ó.

intestinal motility in term neonates. Pediatrics 1992;90: 669-673.

56. Di Lorenzo M, Bass J, Krantis A. An intraluminal model of necrotizing enterocolitis in the developing neonatal piglet.

J Pediatr Surg 1995;30:1138-1142.

57. Lin J. Too much short chain fatty acids cause neonatal necrotizing enterocolitis. Med Hypotheses 2004;62:291293.

58. Liu Z, Li N, Neu J: Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr 2005;94:386-393.

59. Sarna SK. Cyclic motor activity; migrating motor complex: 1985. Gastro-enterology 1985;89:894-913.

60. Berseth CL. Gestational evolution of small intestine motility in preterm and term infants. J Pediatr 1989;115:646-651.

61. Corfield AP, Myerscough N, Longman R, Sylvester P, Arul S, Pignatelli M. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut 2000;47:589-594.

62. Einerhand AW, Renes IB, Makkink MK, van der Sluis M, Büller HA, Dekker J: Role of mucins in inflammatory bowel disease: important lessons from experimental models.

Eur J Gastroenterol Hepatol 2002;14:757-765.

63. Allen A, Bell A, Mantle M, Pearson JP: The structure and physiology of gastrointestinal mucus. Adv Exp Med Biol 1982;144:115-133.

64. Montagne L, Piel C, Lallès JP. Effect of diet on mucin kinetics and composition: nutrition and health implications.

Nutr Rev 2004;62:105-114.

65. Rhodes JM. Colonic mucus and mucosal glycoproteins: the key to colitis and cancer? Gut 1989;30:1660-1666.

66. Fagarasan S, Honjo T: Regulation of IgA synthesis at mucosal surfaces. Curr Opin Immunol 2004;16:277-283.

67. Van der Waaij LA, Mesander G, Limburg PC, van der Waaij D. Direct flow cytometry of anaerobic bacteria in human feces. Cytometry 1994;16:270-279.

68. Foster J, Cole M. Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth-weight neonates. Cochrane Database Syst Rev 2001;(3):CD001816.

69. Berseth CL. Feeding strategies and necrotizing enterocolitis. Curr Opin Pediatr 2005;17:170-173.

70. Lucas A, Cole TJ. Breast milk and neonatal necrotizing enterocolitis. Lancet 1990;336:1519-1523.

71. Patole S. Strategies for prevention of feed intolerance in preterm neonates: a systematic review. J Matern Fetal Neonatal Med 2005;18:67-76.

72. Schanler RJ, Lau C, Hurst NM, Smith EO. Randomized trial of donor human milk versus preterm formula as substitutes for mothers' own milk in the feeding of extremely premature infants. Pediatrics 2005;116:400-406.

73. Eibl MM, Wolf HM, Fürnkranz H, Rosenkranz A. Prevention of necrotizing enterocolitis in low-birth-weight infants

by IgA-IgG feeding. N Engl J Med 1988;319:1-7.

74. Shah P, Shah V. Arginine supplementation for prevention of necrotising enterocolitis in preterm infants. Cochrane Database Syst Rev 2004;(4):CD004339.

75. Ledbetter DJ, Juul SE. Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J Pediatr Surg 2000;35:178-181; discussion 182.

76. Siu YK, Ng PC, Fung SC, Lee CH, Wong MY, Fok TF, et al.

Double blind, randomised, placebo controlled study of oral vancomycin in prevention of necrotising enterocolitis in preterm, very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1998;79:F105-109.

Paediatriki 2008;71:21-28

77. Kumral A, Baskin H, Duman N, Yilmaz O, Tatli M, Ozer E, et al. Erythropoietin protects against necrotizing enterocolitis of newborn rats by the inhibiting nitric oxide formation. Biol Neonate 2003;84:325-329.

78. McClure RJ. Trophic feeding of the preterm infant. Acta Paediatr Suppl 2001;90:19-21.

79. Newell SJ. Enteral feeding of the micropremie. Clin Perinatol 2000;27:221-234, viii.

80. Bin-Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005;147:192-196.

81. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, et al.

Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005;115:1-4.

82. Ouwehand AC, Derrien M, de Vos W, Tiihonen K, Rautonen N. Prebiotics and other microbial substrates for gut functionality. Curr Opin Biotechnol 2005;16:212-217.

83. Tsukahara T, Iwasaki Y, Nakayama K, Ushida K. Stimulation of butyrate production in the large intestine of weaning piglets by dietary fructooligosaccharides and its influence on the histological variables of the large intestinal mucosa. J Nutr Sci Vitaminol (Tokyo) 2003;49:414-421.

84. Bartholome AL, Albin DM, Baker DH, Holst JJ, Tappenden KA. Supplementation of total parenteral nutrition with butyrate acutely increases structural aspects of intestinal adaptation after an 80% jejunoileal resection in neonatal piglets. JPEN J Parenter Enteral Nutr 2004;28:210-222; discussion 222-223.

85. Kanauchi O, Andoh A, Iwanaga T, Fujiyama Y, Mitsuyama K, Toyonaga A, et al. Germinated barley foodstuffs attenuate colonic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model. J Gastroenterol Hepatol 1999;14:1173-1179.

86. Avivi-Green C, Polak-Charcon S, Madar Z, Schwartz B. Apoptosis cascade proteins are regulated in vivo by high intracolonic butyrate concentration: correlation with colon cancer inhibition. Oncol Res 2000;12:83-95.

87. Scheppach W, Weiler F. The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care 2004:7:563-567.

88. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics 2000;105:1216-1226.

89. Salhab WA, Perlman JM, Silver L, Sue Broyles R. Necrotizing enterocolitis and neurodevelopmental outcome in extremely low birth weight infants <1000 g. J Perinatol 2004;24:534-540.

90. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004;292:2357-2365.

91. Hintz SR, Kendrick DE, Stoll BJ, Vohr BR, Fanaroff AA, Donovan EF, et al. Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. Pediatrics 2005;115:696-703.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·29

∞¡∞™∫√¶∏™∏

REVIEW ARTICLE

29

ƒÂ˘Ì·ÙÈÎfi˜ ˘ÚÂÙfi˜: Â›Ó·È ·ÎfiÌ· ‰Ò! ∫·Ú‰ÈÔÏÔÁÈÎfi ∆Ì‹Ì·, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ∞ıËÓÒÓ “¶. & ∞. ∫˘ÚÈ·ÎÔ‡”

Ã. ∆Ú¿·ÏË, ª. ¶··Ê˘Ï·ÎÙÔ‡, °. ¶··‰fiÔ˘ÏÔ˜ ¶ÂÚ›ÏË„Ë: √ ÚÂ˘Ì·ÙÈÎfi˜ ˘ÚÂÙfi˜ (ƒ¶), ·Ó Î·È Û˘Û¯ÂÙ›˙ÂÙ·È Ì ÌÈÎÚԂȷ΋ Ïԛ̈ÍË, ·Ú·Ì¤ÓÂÈ ¤Ó· ÛËÌ·ÓÙÈÎfi Úfi‚ÏËÌ· 2500 ¯ÚfiÓÈ· ·fi ÙËÓ ÂÚÈÁÚ·Ê‹ ÙÔ˘ ·fi ÙÔÓ πÔÎÚ¿ÙË. ∆Ô Úfi‚ÏËÌ· ·˘Ùfi ÔÊ›ÏÂÙ·È ÛÙȘ ÂÈÏÔΤ˜ Ù˘ ÚÂ˘Ì·ÙÈ΋˜ ηډ›Ùȉ·˜ (ƒ∫) Ô˘ ÚÔηÏ› ÛËÌ·ÓÙÈ΋ ÓÔÛËÚfiÙËÙ· Î·È ıÓËÙfiÙËÙ·. ™Â οı ÏËı˘ÛÌfi ÂÎÙÈÌ¿Ù·È fiÙÈ ˘¿Ú¯Ô˘Ó ¿ÙÔÌ· ¢¿ÏˆÙ· Û ƒ¶. ∆· ÂÌ‚fiÏÈ· Â›Ó·È ·ÎfiÌ· Ì·ÎÚÈ¿ ·fi ÙÔ Ó· Ù‡¯Ô˘Ó ÂÊ·ÚÌÔÁ‹˜ ÛÙËÓ ÎÏÈÓÈ΋ Ú¿ÍË Î·È Ë ıÂÚ·›· ÙˆÓ ÏÔÈÌÒÍÂˆÓ ÙÔ˘ Ê¿Ú˘ÁÁ· ·fi ‚-·ÈÌÔÏ˘ÙÈÎfi ÛÙÚÂÙfiÎÔÎÎÔ ÔÌ¿‰·˜ ∞ ·Ú·Ì¤ÓÂÈ Ë ‚¿ÛË Ù˘ ÚˆÙÔÁÂÓÔ‡˜ ÚfiÏ˄˘. ∏ ‰È¿ÁÓˆÛË ÂÍ·ÎÔÏÔ˘ı› Ó· ‚·Û›˙ÂÙ·È ÛÙ· ÎÏ·ÛÈο ÎÚÈÙ‹ÚÈ· Jones Ì ÙÚÔÔÔÈ‹ÛÂȘ Î·È ÂÈÛËÌ¿ÓÛÂȘ. ∏ ıÂÚ·›· ÙÔ˘ ÔͤԘ ƒ¶ ÂÍ·ÎÔÏÔ˘ı› Ó· ‚·Û›˙ÂÙ·È Û ÎÏ·ÛÈΤ˜ Ú·ÎÙÈΤ˜, ·Ú¿ Û ÙÂÎÌËÚȈ̤Ó˜ Ô‰ËÁ›Â˜ ·fi Ù· ·ÔÙÂϤÛÌ·Ù· ÌÂÁ¿ÏˆÓ Ù˘¯·ÈÔÔÈËÌ¤ÓˆÓ ÌÂÏÂÙÒÓ. ∏ ‰Â˘ÙÂÚÔÁÂÓ‹˜ ÚfiÏË„Ë Ì ̷ÎÚÔ¯ÚfiÓÈ· ¯ÔÚ‹ÁËÛË Î·Ù¿ÏÏËÏ˘ ·ÓÙÈÌÈÎÚԂȷ΋˜ ·ÁˆÁ‹˜ Â›Ó·È Ô ·ÎÚÔÁˆÓÈ·›Ô˜ Ï›ıÔ˜ ÁÈ· ÙËÓ ·ÔÊ˘Á‹ Ù˘ ƒ∫. ∫·ÈÓÔ‡ÚÁÈ· ÂȉËÌÈÔÏÔÁÈο ‰Â‰Ô̤ӷ, Èı·ÓÔ› ·ıÔÁÂÓÂÙÈÎÔ› Ì˯·ÓÈÛÌÔ› Î·È ÓÂfiÙÂÚ· ÛÙÔȯ›· ÁÈ· ÙËÓ ÚfiÏË„Ë, ÙË ‰È¿ÁÓˆÛË Î·È ÙË ıÂÚ·›· Ù˘ ÓfiÛÔ˘ Û˘ÓÔ„›˙ÔÓÙ·È, Ì ¤ÌÊ·ÛË ÛÙËÓ Èı·Ó‹ ÎÏÈÓÈ΋ ÙÔ˘˜ ·ÍÈÔÔ›ËÛË.

AÏÏËÏÔÁÚ·Ê›·: ÃÚÈÛÙ›Ó· ∆Ú¿·ÏË trapali_chr@yahoo.gr ∫·Ú‰ÈÔÏÔÁÈÎfi ∆Ì‹Ì·, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ∞ıËÓÒÓ «¶. & ∞. ∫˘ÚÈ·ÎÔ‡»

§¤ÍÂȘ ÎÏÂȉȿ: ƒÂ˘Ì·ÙÈÎfi˜ ˘ÚÂÙfi˜, ÚÂ˘Ì·ÙÈ΋ ηډ›Ùȉ·, ıÂÚ·›·, ÚfiÏË„Ë.

Rheumatic fever: it is still here!

C. Trapali, M. Papafylaktou, G. Papadopoulos Abstract: Acute rheumatic fever (RF), although related to infection, remains a major health problem 2500 years since it was first described by Hippocrates. Its main problem derives from the chronic sequelae of rheumatic heart disease, which causes considerable morbidity and mortality. It is estimated that in any population some individuals are more susceptible to RF. Vaccines are still far away from being available and the effective treatment of group A beta-haemolytic streptococcal pharyngitis remains the cornerstone of primary prevention. The Jones criteria modified and revised are still the main diagnostic tool for RF. The treatment of acute RF is still based more on traditional practice than on the use of optimal agents tested in randomized controlled trials. Secondary prevention of RF is essential and is focused on the long-term administration of the appropriate antibiotic agent. New epidemiological findings, pathogenetic mechanisms and current views on prevention, diagnosis and treatment of RF are reviewed, with special consideration given to their potential clinical application.

Cardiology Department, “P. & A. Kyriakou” Children’s Hospital, Athens, Greece Correspondence: Christina Trapali trapali_chr@yahoo.gr Cardiology Department, “P. & A. Kyriakou” Children’s Hospital, Athens, Greece

Key words: Rheumatic fever, rheumatic heart disease, treatment, prevention.

™˘ÓÙÔÌÔÁڷʛ˜ ƒ¶ ƒ∫ ∏Ã∫ ASTO ∆∫∂ CRP i.m. i.v. p.os µ™ ¶√À RF ª∫ ∂∫

ƒÂ˘Ì·ÙÈÎfi˜ ¶˘ÚÂÙfi˜ ƒÂ˘Ì·ÙÈ΋ ∫·Ú‰›Ùȉ· ∏¯ÔηډÈÔÁÚ¿ÊËÌ· ∆›ÙÏÔ˜ ∞ÓÙÈÛÙÚÂÙÔÏ˘Û›Ó˘ ∆·¯‡ÙËÙ· ∫·ı›˙ËÛ˘ ∂Ú˘ıÚÒÓ C-∞ÓÙȉÚÒÛ· ¶ÚˆÙ½ÓË ÂÓ‰ÔÌ˘Èο ÂÓ‰ÔÊϤ‚È· ·fi ÙÔ ÛÙfiÌ· µ¿ÚÔ˜ ™ÒÌ·ÙÔ˜ ¶·ÁÎfiÛÌÈÔ˜ √ÚÁ·ÓÈÛÌfi˜ ÀÁ›·˜ Rheumatic Fever ªÂ›˙ÔÓ· ∫ÚÈÙ‹ÚÈ· ∂Ï¿ÛÛÔÓ· ∫ÚÈÙ‹ÚÈ·

∂ÈÛ·ÁˆÁ‹ √ ƒ¶ ·Ú·Ì¤ÓÂÈ ÛÙÔ Â›ÎÂÓÙÚÔ ÙÔ˘ ÂӉȷʤÚÔÓÙÔ˜, ΢ڛˆ˜ ÏfiÁˆ ÙˆÓ Ì·ÎÚÔ¯ÚfiÓÈˆÓ ÂÈ-

ÙÒÛÂˆÓ Ù˘ ƒ∫. ∆Ș ÙÂÏÂ˘Ù·›Â˜ ‰ÂηÂٛ˜, Ë ‚ÂÏÙ›ˆÛË ÙˆÓ Û˘ÓıËÎÒÓ ‰È·‚›ˆÛ˘ Î·È ˘ÁÈÂÈÓ‹˜, Ë ‰˘Ó·ÙfiÙËÙ· ÚfiÛ‚·Û˘ ÛÙȘ ˘ËÚÂۛ˜ ˘Á›·˜, ·ÏÏ¿ Î·È Ë ¯Ú‹ÛË ÙˆÓ ·ÓÙÈ‚ÈÔÙÈÎÒÓ Û˘Ó¤‚·Ï·Ó ÛÙË ÛËÌ·ÓÙÈ΋ Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ Ù˘ ÓfiÛÔ˘, Ô˘ ÛÙȘ ·Ó·Ù˘Á̤Ó˜ ÎÔÈӈӛ˜ ˘ÔÏÔÁ›˙ÂÙ·È Û ÏÈÁfiÙÂÚÔ ·fi 0,05% (1). ∞ÓÙ›ıÂÙ·, Ô ƒ¶ ·ÔÙÂÏ› ÛËÌ·ÓÙÈÎfi Úfi‚ÏËÌ· ‰ËÌfiÛÈ·˜ ˘Á›·˜ ÛÙȘ ·Ó·Ù˘ÛÛfiÌÂÓ˜ ¯ÒÚ˜, ηıÒ˜ Î·È Û ÏËı˘ÛÌÔ‡˜ Èı·ÁÂÓÒÓ ÛÙȘ ·Ó·Ù˘Á̤Ó˜ ¯ÒÚ˜ (.¯. ∞˘ÛÙÚ·Ï›·, ¡¤· ∑ËÏ·Ó‰›·). ÀÔÏÔÁ›˙ÂÙ·È, fiÙÈ ÂÚ›Ô˘ 3-6% οı ÏËı˘ÛÌÔ‡ Â›Ó·È ÂÈÚÚÂ¤˜ ÛÙËÓ ·Ó¿Ù˘ÍË ƒ¶ (1). ™˘ÓÂÒ˜, Â›Ó·È ÛËÌ·ÓÙÈÎfi Ô È·ÙÚÈÎfi˜ ÎfiÛÌÔ˜ Ó· ‰È·ÙËÚ› ÙËÓ ÂÙÔÈÌfiÙËÙ· ÙÔ˘ ÁÈ· ÙËÓ ¤ÁηÈÚË ‰È¿ÁÓˆÛË Ù˘ ÓfiÛÔ˘. ∞Í›˙ÂÈ Ó· ÛËÌÂȈı› fiÙÈ ‰ËÌÔÛȇÙËΠÚfiÛÊ·Ù· ÛÙÔ Lancet Ë ¶·È‰È·ÙÚÈ΋ 2008;71:29-37

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·30

30

Ã. ∆Ú¿·ÏË Î·È Û˘Ó.

ı·Ó·ÙËÊfiÚÔ˜ ηٿÏËÍË ÂÊÙ¿¯ÚÔÓ˘ Ì ƒ¶, ÛÙËÓ ÔÔ›· ÁÈ· ‰‡Ô ¯ÚfiÓÈ· ‰ÂÓ Î·Ù¤ÛÙË ‰˘Ó·Ùfi Ó· ÙÂı› Ë ‰È¿ÁÓˆÛË Ù˘ ÓfiÛÔ˘ (2). ™ÙËÓ ·Ó·ÛÎfiËÛË ·˘Ù‹ ·Ó·Ê¤ÚÔÓÙ·È ÓÂÒÙÂÚ· ‰Â‰Ô̤ӷ Û¯ÂÙÈο Ì ÙË ‰È¿ÁÓˆÛË Î·È ÙËÓ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ÓfiÛÔ˘, Û‡Ìʈӷ Ì ÙȘ ˘¿Ú¯Ô˘Û˜ ηÙ¢ı˘ÓÙ‹ÚȘ Ô‰ËÁ›Â˜. ∂›Û˘, ÙÔÓ›˙ÔÓÙ·È Ù· ·ÌÊÈÏÂÁfiÌÂÓ· ‰›· Î·È ÔÈ ÌÂÏÏÔÓÙÈΤ˜ ÚÔÔÙÈΤ˜.

∂ȉËÌÈÔÏÔÁ›· √ ¶·ÁÎfiÛÌÈÔ˜ √ÚÁ·ÓÈÛÌfi˜ ÀÁ›·˜ (¶√À) ·Ó·Ê¤ÚÂÈ fiÙÈ ÙÔ 2004 ÂÚÈÛÛfiÙÂÚÔÈ ·fi 15,6 ÂηÙÔÌ̇ÚÈ· ¿ÓıÚˆÔÈ ¤·Û¯·Ó ·fi ƒ¶ Î·È ¿Óˆ ·fi 230.000 ¿ÓıÚˆÔÈ Î¿ı ¯ÚfiÓÔ Âı·›ÓÔ˘Ó ·fi ƒ¶. ∫¿ı ¯ÚfiÓÔ ˘ÔÏÔÁ›˙ÔÓÙ·È 500.000 Ӥ˜ ÂÚÈÙÒÛÂȘ ƒ¶ Î·È ÂÚ›Ô˘ ÔÈ 300.000 ηٷϋÁÔ˘Ó Û ƒ∫. ∏ ÛËÌ·ÓÙÈ΋ ÓÔÛËÚfiÙËÙ· Ù˘ ƒ∫ ·ÊÔÚ¿ ΢ڛˆ˜ ÙÔ˘˜ Ó¤Ô˘˜ ·ÓıÚÒÔ˘˜ Ì ÙÂÚ¿ÛÙȘ ÎÔÈÓˆÓÈÎÔÔÈÎÔÓÔÌÈΤ˜ ÂÈÙÒÛÂȘ. ∏ Â›ÙˆÛË Î·È ıÓËÙfiÙËÙ· ÙÔ˘ ƒ¶ ·ÚÔ˘ÛÈ¿˙Ô˘Ó ÙÂÚ¿ÛÙȘ ‰È·ÊÔÚ¤˜ ÌÂٷ͇ ·Ó·Ù˘ÁÌ¤ÓˆÓ Î·È ˘·Ó¿Ù˘ÎÙˆÓ ¯ˆÚÒÓ (1). ™ÙȘ ·Ó·Ù˘Á̤Ó˜ ¯ÒÚ˜, Ë Â›ÙˆÛË Û ·È‰È¿ ËÏÈΛ·˜ 514 ÂÙÒÓ ˘ÔÏÔÁ›˙ÂÙ·È Û ÏÈÁfiÙÂÚÔ ·fi 0,5ò, ÂÓÒ ÛÙȘ ˘·Ó¿Ù˘ÎÙ˜ ¯ÒÚ˜ Â›Ó·È È‰È·›ÙÂÚ· ·˘ÍË̤ÓË, ÂÎÙÈÌÒÌÂÓË ÛÙÔ˘˜ ·˘Ùfi¯ıÔÓ˜ Ù˘ ∞˘ÛÙÚ·Ï›·˜ Û 5ò (1). ∆Ô ¯·ÌËÏfi ÎÔÈÓˆÓÈÎÔÔÈÎÔÓÔÌÈÎfi Â›Â‰Ô Î·È Ù· Â·ÎfiÏÔ˘ı¿ ÙÔ˘ (ηΤ˜ Û˘Óı‹Î˜ ‰È·‚›ˆÛ˘, Û˘ÓˆÛÙÈÛÌfi˜, ˘ÔÛÈÙÈÛÌfi˜, ‰˘Û¯ÂÚ‹˜ ÚfiÛ‚·ÛË Û ˘ËÚÂۛ˜ ˘Á›·˜) ÔÏÏ·Ï·ÛÈ¿˙Ô˘Ó ÙËÓ Èı·ÓfiÙËÙ· ƒ¶, fiˆ˜ Ê·›ÓÂÙ·È ÛÙËÓ ∂ÈÎfiÓ· 1. ∏ ÓfiÛÔ˜ Â›Ó·È Û¯Â‰fiÓ ·Ó‡·ÚÎÙË ÚÈÓ ·fi ÙÔ 2Ô ¤ÙÔ˜ Ù˘ ˙ˆ‹˜, ÂÓÒ ÌfiÓÔ ÙÔ 5% ÙÔ˘ ÚÒÙÔ˘ ÂÂÈÛÔ-

‰›Ô˘ ƒ¶ ·Ú·ÙËÚÂ›Ù·È Û ·È‰È¿ ÌÈÎÚfiÙÂÚ· ÙˆÓ 5 ÂÙÒÓ (3). ∏ ˘„ËÏfiÙÂÚË Â›ÙˆÛË Ù˘ ÓfiÛÔ˘ ·Ú·ÙËÚÂ›Ù·È ÚÔ Ù˘ ÂÊ˂›·˜ Î·È ·ÎÔÏÔ˘ı› ÚÔԉ¢ÙÈ΋ Ì›ˆÛË Ì¤¯ÚÈ ÙËÓ ËÏÈΛ· ÙˆÓ 20 ÂÙÒÓ. ∏ ÓfiÛÔ˜ Â›Ó·È Û¿ÓÈ· ÌÂÙ¿ ÙËÓ ËÏÈΛ· ÙˆÓ 35 ÂÙÒÓ (1). √ ÂÈÔÏ·ÛÌfi˜ Ù˘ ƒ∫ ·˘Í¿ÓÂÈ Ì ÙËÓ ËÏÈΛ·, Êı¿ÓÔÓÙ·˜ ÛÙË Ì¤ÁÈÛÙË ÙÈÌ‹ Û ËÏÈΛ· 25-35 ÂÙÒÓ, ·ÓÙÈηÙÔÙÚ›˙ÔÓÙ·˜ ÙËÓ ÚÔÛ‚ÔÏ‹ ·fi ƒ¶ Û ÓÂfiÙÂÚË ËÏÈΛ·. ∞ÎfiÌ· ÎÈ ¤Ó· ÌÂÌÔӈ̤ÓÔ ÂÂÈÛfi‰ÈÔ ƒ¶ ÌÔÚ› Ó· Ô‰ËÁ‹ÛÂÈ Û ƒ∫ (4), ÂÓÙÔ‡ÙÔȘ, ηٿ ηÓfiÓ· ··ÈÙÔ‡ÓÙ·È ÂÚÈÛÛfiÙÂÚ· ÂÂÈÛfi‰È·. ™ÙÔ˘˜ Ó·ÚÔ‡˜ ·ÛıÂÓ›˜, Ë ·ÓÂ¿ÚÎÂÈ· Ù˘ ÌÈÙÚÔÂȉԇ˜ ‚·Ï‚›‰·˜ Â›Ó·È Ë Û˘ÓËı¤ÛÙÂÚË ‚Ï¿‚Ë. ¶ÚÔ˚Ô‡Û˘ Ù˘ ËÏÈΛ·˜, Ë ‚Ï¿‚Ë Û˘Ó‹ıˆ˜ ÂÍÂÏ›ÛÛÂÙ·È ÚÔ˜ ÛÙ¤ÓˆÛË.

¶·ıÔÁ¤ÓÂÈ· √ ƒ¶ ıˆÚÂ›Ù·È ·ÔÙ¤ÏÂÛÌ· ηı˘ÛÙÂÚË̤Ó˘ ·ÓÔÛÔ·¿ÓÙËÛ˘ ÛÂ Ê·Ú˘ÁÁÈΤ˜ ÏÔÈÌÒÍÂȘ ·fi ‚·ÈÌÔÏ˘ÙÈÎfi ÛÙÚÂÙfiÎÔÎÎÔ ÔÌ¿‰·˜ ∞, ·Ó Î·È Ô ·ÎÚÈ‚‹˜ Ì˯·ÓÈÛÌfi˜ ‰ÂÓ Â›Ó·È ÁÓˆÛÙfi˜. √È ‚-·ÈÌÔÏ˘ÙÈÎÔ› ÛÙÚÂÙfiÎÔÎÎÔÈ ¯ˆÚ›˙ÔÓÙ·È Û ÔÌ¿‰Â˜ Ì ‚¿ÛË ÙÔ ÔÏ˘Û·Î¯·ÚȉÈÎfi ·ÓÙÈÁfiÓÔ ÙÔ˘ ÙÔȯÒÌ·Ùfi˜ ÙÔ˘˜ Î·È ÔÈ ÛÙÚÂÙfiÎÔÎÎÔÈ Ù˘ ÔÌ¿‰·˜ ∞ Â›Ó·È ˘‡ı˘ÓÔÈ ÁÈ· ÙË Û˘ÓÙÚÈÙÈ΋ ÏÂÈÔ„ËÊ›· ÙˆÓ ÛÙÚÂÙÔÎÔÎÎÈÎÒÓ ÏÔÈÌÒÍÂˆÓ ÛÙÔÓ ¿ÓıÚˆÔ (5). ∞fi ÙËÓ ÏËıÒÚ· ÙˆÓ ÏÔÈÌÒÍÂˆÓ ·˘ÙÒÓ, ÌfiÓÔ Ë Ê·Ú˘ÁÁ›Ùȉ· ¤¯ÂÈ Û˘Ó‰Âı› ·ÈÙÈÔ·ıÔÏÔÁÈο Ì ƒ¶ (6). ŸÌˆ˜, ˘¿Ú¯Ô˘Ó ÂӉ›ÍÂȘ fiÙÈ Î·È ÏÔÈÌÒÍÂȘ ÙÔ˘ ‰¤ÚÌ·ÙÔ˜ ·fi ÛÙÚÂÙfiÎÔÎÎÔ ÔÌ¿‰·˜ ∞ ›Ù ·¢ı›·˜ ›Ù ̤ۈ ÚfiÎÏËÛ˘ Ê·Ú˘ÁÁÈ΋˜ Ïԛ̈͢ ¢ı‡ÓÔÓÙ·È ÁÈ· ÙËÓ ÚfiÎÏËÛË ƒ¶ (7). ∂›Ó·È Èı·Ófi Î·È ÔÈ ÛÙÚÂÙfiÎÔÎÎÔÈ ÙˆÓ ÔÌ¿‰ˆÓ C Î·È G Ó· ¤¯Ô˘Ó ·ıÔÁÂÓÂÙÈÎfi

¶ÂÚÈ‚·ÏÏÔÓÙÈÎÔ› ·Ú¿ÁÔÓÙ˜ ∂·ÓÂÈÏËÌ̤Ó˜ ÏÔÈÌÒÍÂȘ

∂·ÓÂÈÏËÌ̤Ó˜ ÏÔÈÌÒÍÂȘ ∂˘·ı‹˜ ÔÚÁ·ÓÈÛÌfi˜ ∞¡√™√∞¶∞¡∆∏™∏

ƒÂ˘Ì·ÙÈ΋ ηډ›Ùȉ·

1Ô ÂÂÈÛfi‰ÈÔ ƒ¶ ∫·ÈÓÔ‡ÚÁÈ· ÂÂÈÛfi‰È· ƒ¶

ªÔÚȷ΋ ÔÌÔÈfiÙËÙ· ·ÓÙÈÁfiÓÔ˘ -ÈÛÙÒÓ ÍÂÓÈÛÙ‹

∂ÓÂÚÁÔÔ›ËÛË ·˘ÙÔ¿ÓÔÛÔ˘ Ì˯·ÓÈÛÌÔ‡ °ÂÓÂÙÈ΋ ÚԉȿıÂÛË

∂ÈÎfiÓ· 1. ¶·ıÔÁÂÓÂÙÈÎfi˜ Ì˯·ÓÈÛÌfi˜ ÚÂ˘Ì·ÙÈÎÔ‡ ˘ÚÂÙÔ‡ Î·È ÚÂ˘Ì·ÙÈ΋˜ ηډ›Ùȉ·˜.

Paediatriki 2008;71:29-37

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·31

31

ƒÂ˘Ì·ÙÈÎfi˜ ˘ÚÂÙfi˜

ÚfiÏÔ ÛÙÔ ƒ¶ (8), ηıÒ˜ Û˘¯Ó¿ ¤¯Ô˘Ó ·ÔÌÔÓˆı› Û ηÏÏȤÚÁÂȘ Ê·Ú˘ÁÁÈÎÔ‡ ÂȯڛÛÌ·ÙÔ˜ ·fi ÏËı˘ÛÌÔ‡˜ Ì ˘„ËÏ‹ Â›ÙˆÛË ƒ¶. ¶Èı·ÓÔÏÔÁÂ›Ù·È fiÙÈ ÔÈ ÛÙÚÂÙfiÎÔÎÎÔÈ C Î·È G ·ÔÎÙÔ‡Ó ÏÔÈÌÔÁfiÓÔ ‰Ú¿ÛË (9,10). ™˘ÓÂÒ˜, Â›Ó·È ÛÎfiÈÌÔ Ó· ˘¿Ú¯ÂÈ ÂÁÚ‹ÁÔÚÛË Î·È ÁÈ· ÙȘ ÂÚÈÙÒÛÂȘ Ì ÈÛÙÔÚÈÎfi ‰ÂÚÌ·ÙÈ΋˜ Ïԛ̈͢ ‹ Ê·Ú˘ÁÁ›Ùȉ·˜ Ì ηÏÏȤÚÁÂÈ· ıÂÙÈ΋ ÁÈ· ÛÙÚÂÙfiÎÔÎÎÔ ÔÌ¿‰·˜ C ‹ G. ™ÙËÓ EÈÎfiÓ· 1, Û˘ÓÔ„›˙ÂÙ·È Ô ·ıÔÁÂÓÂÙÈÎfi˜ Ì˯·ÓÈÛÌfi˜ ƒ¶ Î·È ƒ∫. ¶Ú¤ÂÈ Ó· ÚÔËÁËıÔ‡Ó Â·ÓÂÈÏËÌ̤Ó˜ ÏÔÈÌÒÍÂȘ ÚÈÓ ·fi ÌÈ· Ê·Ú˘ÁÁ›Ùȉ· ·fi ÛÙÚÂÙfiÎÎÔ ÔÌ¿‰·˜ ∞ Ô˘ ı· ÂÓÂÚÁÔÔÈ‹ÛÂÈ ÙËÓ ·ÓÔÛÔ·¿ÓÙËÛË Û ¢·›ÛıËÙÔ ÍÂÓÈÛÙ‹, Ô‰ËÁÒÓÙ·˜ ÛÙÔ ÚÒÙÔ ÂÂÈÛfi‰ÈÔ ƒ¶ (11). ∏ ·ÈÙ›· Ù˘ ÂÓÂÚÁÔÔ›ËÛ˘ Ù˘ ·ÓÔÛÔ·¿ÓÙËÛ˘ ·Ô‰›‰ÂÙ·È Û ‰ÔÌÈΤ˜ Î·È ·ÓÔÛÔÏÔÁÈΤ˜ ÔÌÔÈfiÙËÙ˜ ÌÂٷ͇ ·ÓıÚÒÈÓˆÓ ÈÛÙÒÓ Î·È Û˘ÁÎÂÎÚÈÌ¤ÓˆÓ ÂÈÙfiˆÓ Ù˘ ÛÙÚÂÙÔÎÔÎÎÈ΋˜ ÚˆÙ½Ó˘ ª. ™˘ÁÎÂÎÚÈ̤ӷ, Ë ÔÌÔÈfiÙËÙ· Ù˘ ÚˆÙ½Ó˘ ª Ì ÙË Ì˘Ôηډȷ΋ Ì˘ÔÛ›ÓË ıˆÚÂ›Ù·È ˘‡ı˘ÓË ÁÈ· ·˘Ù‹ ÙËÓ ÂÓÂÚÁÔÔ›ËÛË (12). ∂Ó·ÓÙ›ÔÓ ·˘Ù‹˜ Ù˘ ¿Ԅ˘ Â›Ó·È ÙÔ ÁÂÁÔÓfi˜ fiÙÈ Ë Î·Ú‰›Ùȉ· ÙÔ˘ ÔͤԘ ƒ¶ Â›Ó·È ‚·Ï‚ȉ›Ùȉ· ÎÈ fi¯È Ì˘Ôηډ›Ùȉ·. ∞Ó Ë Ì˘ÔÛ›ÓË ÂÌÏÂÎfiÙ·Ó ÛÙÔÓ Ì˯·ÓÈÛÌfi, ı· ·Ó·ÌÂÓfiÙ·Ó Ì˘Ôηډ›Ùȉ· Ì ·‡ÍËÛË ÙˆÓ ÂÓ˙‡ÌˆÓ Î·È fi¯È ‚·Ï‚ȉ›Ùȉ·, ·ÊÔ‡ ÔÈ ‚·Ï‚›‰Â˜ ‰ÂÓ ¤¯Ô˘Ó Ì˘ÔÛ›ÓË (13). ∞fi ¿ÏÏÔ˘˜ ÂÚ¢ÓËÙ¤˜ ¤¯ÂÈ ˘ÔÛÙËÚȯı› fiÙÈ Ë ·ÈÙ›· Ù˘ ‚·Ï‚ȉ›Ùȉ·˜ Â›Ó·È Ë Â˘·ÈÛıËÙÔÔ›ËÛË ÙˆÓ ∆ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ ¤Ó·ÓÙÈ Ù˘ ÛÙÚÂÙÔÎÔÎÎÈ΋˜ ÚˆÙ½Ó˘ ª. ™Â Ì›· ÂfiÌÂÓË Ê¿ÛË ÚÔηÏÂ›Ù·È ·ÓÔÛÔ·ÓÙ›‰Ú·ÛË ·fi ÙËÓ ·Ó·ÁÓÒÚÈÛË Ù˘ Ï·ÌÈÓ›Ó˘ ÙˆÓ ‚·Ï‚›‰ˆÓ ·fi Ù· ¢·ÈÛıËÙÔÔÈË̤ӷ ∆ ÏÂÌÊÔ·ÙÙ·Ú· (14). ∆¤ÏÔ˜,

˘¿Ú¯Ô˘Ó ÓÂÒÙÂÚ· ‰Â‰Ô̤ӷ Ô˘ ˘ÔÛÙËÚ›˙Ô˘Ó ÙËÓ ¿Ô„Ë ‰È·ÛÙ·˘ÚÔ‡ÌÂÓ˘ ·ÓÙ›‰Ú·Û˘ Ì ÙË ¡·ÎÂÙ˘ÏÔÁÏ˘ÎÔ˙·Ì›ÓË (15). ŸÔÈÔ˜ ÎÈ ·Ó Â›Ó·È Ô ·Ú¿ÁÔÓÙ·˜ Ô˘ ÂÓÂÚÁÔÔÈ› ÙËÓ ·ÓÔÛÔ·ÓÙ›‰Ú·ÛË, ·˘Ùfi Ô˘ ¤¯ÂÈ È‰È·›ÙÂÚË ÎÏÈÓÈ΋ ÛËÌ·Û›· Â›Ó·È Ë ÚfiÎÏËÛË ‚·Ï‚›Ùȉ·˜. ªÂÙ¿ ÙËÓ ·Ú¯È΋ Ú‹ÍË Ù˘ ·ÎÂÚ·ÈfiÙËÙ·˜ ÙÔ˘ ÂÓ‰ÔıËÏ›Ô˘, ÚÔηÏÂ›Ù·È ‚·Ï‚›Ùȉ· ·fi Ì›· ·Ï˘ÛȉˆÙ‹ ·ÓÙ›‰Ú·ÛË Ì ÂÓÂÚÁÔÔ›ËÛË ÙˆÓ ∆ ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ, ‰È‹ıËÛË ·fi Ì·ÎÚÔÊ¿Á· Î·È ÓÂÔ·ÁÁ›ˆÛË (16,17).

¶ÚfiÏË„Ë ™ÙËÓ ∂ÈÎfiÓ· 2, ·ÂÈÎÔÓ›˙ÔÓÙ·È ÔÈ ıˆÚËÙÈΤ˜ ‰˘Ó·ÙfiÙËÙ˜ ·Ú¤Ì‚·Û˘, Ì ÛÎÔfi ÙËÓ ÚfiÏË„Ë ÙÔ˘ ƒ¶. √È ÎÔÈÓˆÓÈÎÔÔÈÎÔÓÔÌÈΤ˜ ·ÚÂÌ‚¿ÛÂȘ ·ÊÔÚÔ‡Ó Î˘Ú›ˆ˜ ÙËÓ ÔÏÈÙ›·. ∏ ¯Ú‹ÛË ÙÔ˘ ·ÓÙÈÛÙÚÂÙÔÎÔÎÎÈÎÔ‡ ÂÌ‚ÔÏ›Ô˘ ÛÙÂÚÂ›Ù·È Ú·ÎÙÈ΋˜ ÛËÌ·Û›·˜, ·ÊÔ‡ ·Ú·Ì¤ÓÔ˘Ó ·Ó·¿ÓÙËÙ· ÔÏÏ¿ ÂÚˆÙ‹Ì·Ù· Û¯ÂÙÈο Ì ÙÔ Ì˯·ÓÈÛÌfi, ÙËÓ ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ·, ÙËÓ ·ÛÊ¿ÏÂÈ· Î·È ÙÔ ÎfiÛÙÔ˜ ÙÔ˘ (18). ÕÏψÛÙÂ, ıˆÚÂ›Ù·È ·›ı·ÓÔ Ó· Â›Ó·È ‰È·ı¤ÛÈÌÔ ÚÈÓ ·fi ÙÔ 2015 (19). ∏ ÚˆÙÔÁÂÓ‹˜ ÚfiÏË„Ë ÂÛÙÈ¿˙ÂÙ·È ÛÙË ıÂÚ·›· Ì ·ÓÙÈ‚ÈÔÙÈο Ù˘ Û˘Ìو̷ÙÈ΋˜ Ê·Ú˘ÁÁ›Ùȉ·˜ ·fi ÛÙÚÂÙfiÎÔÎÎÔ ÔÌ¿‰·˜ ∞. ∆· ÂÚÈÛÛfiÙÂÚ· ÂÂÈÛfi‰È· ƒ¶ Â›Ó·È ‰˘Ó·Ùfi Ó· ÚÔÏËÊıÔ‡Ó, fiÙ·Ó Ë ·ÁˆÁ‹ ‰Ôı› ÂÓÙfi˜ 9 ËÌÂÚÒÓ ·fi ÙËÓ ¤Ó·ÚÍË Û˘ÌÙˆÌ¿ÙˆÓ Ê·Ú˘ÁÁ›Ùȉ·˜ (20). ¶ÚÔÙ›ÓÂÙ·È Ë ‰ÈÂÓ¤ÚÁÂÈ· Ù·¯Â›·˜ ÂͤٷÛ˘ ·Ó›¯Ó¢Û˘ ÙÔ˘ ·ÓÙÈÁfiÓÔ˘ ηÈ, Â› ·ÌÊÈ‚ÔÏ›·˜, ηÏÏȤÚÁÂÈ· Ê·Ú˘ÁÁÈÎÔ‡ ÂȯڛÛÌ·ÙÔ˜ ÚÈÓ ·fi ÙËÓ ¤Ó·ÚÍË Ù˘ ıÂÚ·›·˜, ‰Â‰Ô̤ÓÔ˘ fiÙÈ ÌfiÓÔ ÙÔ 20% ÙˆÓ Ê·Ú˘ÁÁ›ÙȉˆÓ ÔÊ›ÏÂÙ·È ÛÂ

¶ÂÚÈ‚·ÏÏÔÓÙÈÎÔ› ·Ú¿ÁÔÓÙ˜

1 ∂·ÓÂÈÏËÌ̤Ó˜ ÏÔÈÌÒÍÂȘ

∂·ÓÂÈÏËÌ̤Ó˜ ÏÔÈÌÒÍÂȘ

3 3

∂˘·ı‹˜ ÔÚÁ·ÓÈÛÌfi˜ ∞¡√™√∞¶∞¡∆∏™∏

ƒÂ˘Ì·ÙÈ΋ ηډ›Ùȉ·

1Ô ÂÂÈÛfi‰ÈÔ ƒ¶ ∫·ÈÓÔ‡ÚÁÈ· ÂÂÈÛfi‰È· ƒ¶

2

4

6 ªÔÚȷ΋ ÔÌÔÈfiÙËÙ· ·ÓÙÈÁfiÓÔ˘ -ÈÛÙÒÓ ÍÂÓÈÛÙ‹

5

∂ÓÂÚÁÔÔ›ËÛË ·˘ÙÔ¿ÓÔÛÔ˘ Ì˯·ÓÈÛÌÔ‡

1) µÂÏÙ›ˆÛË Û˘ÓıËÎÒÓ ‰È·‚›ˆÛ˘-ÂÚ›ı·Ï„˘ (ÎÔÈÓˆÓÈÎÔÔÈÎÔÓÔÌÈΤ˜ ·ÚÂÌ‚¿ÛÂȘ).

2) ∞ÓÔÛÔÔ›ËÛË-ÂÌ‚fiÏÈ·.

3) £ÂÚ·›· ÛÙÚÂÙÔÎÔÎÎÈÎÒÓ ÏÔÈÌÒÍÂˆÓ Ì ·ÓÙÈ‚ÈÔÙÈο.

4) ª·ÎÚÔ¯ÚfiÓÈ· ‰Â˘ÙÂÚÔÁÂÓ‹˜ ÚfiÏË„Ë Ì ·ÓÙÈ‚ÈÔÙÈο.

5) °ÂÓÂÙÈ΋ ·Ú¤Ì‚·ÛË.

6) ∫·Ù·ÛÙÔÏ‹ Ù˘ ÂÓÂÚÁÔÔ›ËÛ˘ ÙÔ˘ ·˘ÙÔ¿ÓÔÛÔ˘ Ì˯·ÓÈÛÌÔ‡.

°ÂÓÂÙÈ΋ ÚԉȿıÂÛË ∂ÈÎfiÓ· 2. £ÂˆÚËÙÈο ÛËÌ›· ·Ú¤Ì‚·Û˘ ÁÈ· ·ÔÙÚÔ‹ ÚÂ˘Ì·ÙÈÎÔ‡ ˘ÚÂÙÔ‡ Î·È ÚÂ˘Ì·ÙÈ΋˜ ηډ›Ùȉ·˜. ¶·È‰È·ÙÚÈ΋ 2008;71:29-37

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·32

32

Ã. ∆Ú¿·ÏË Î·È Û˘Ó.

¶›Ó·Î·˜ 1. ¶ÚˆÙÔÁÂÓ‹˜ ÚfiÏË„Ë ÚÂ˘Ì·ÙÈÎÔ‡ ˘ÚÂÙÔ‡: ÚÔÙÂÈÓfiÌÂÓË ıÂÚ·›· ÁÈ· ÙË ÛÙÚÂÙÔÎÔÎÎÈ΋ Ê·Ú˘ÁÁ›Ùȉ· (22) ∞ÓÙÈ‚ÈÔÙÈÎfi

ÃÔÚ‹ÁËÛË

¢ÔÛÔÏÔÁ›·

™¯fiÏÈ·

µÂÓ˙·ıÈÓÈ΋ ÂÓÈÎÈÏ›ÓË G

i.m. ÂÊ¿·Í

™˘ÓÈÛÙ¿Ù·È Û ·ÛıÂÓ›˜ Ì Èı·ÓfiÙËÙ· ÌË Û˘ÌÌfiÚʈÛ˘ ÛÙÔ 10‹ÌÂÚÔ Û¯‹Ì·

º·ÈÓÔ͢ÌÂı˘ÏÔ ÂÓÈÎÈÏ›ÓË (¶ÂÓÈÎÈÏ›ÓË V)

p.os ÁÈ· 10 ̤Ú˜

∞ÌÔ͢ÎÈÏÏ›ÓË

p.os ÁÈ· 10 ̤Ú˜

¶ÚÒÙ˘ ÁÂÓÈ¿˜ ÎÂÊ·ÏÔÛÔÚ›Ó˜* ∂Ú˘ıÚÔÌ˘Î›ÓË

p.os ÁÈ· 10 Ë̤Ú˜ p.os ÁÈ· 10 Ë̤Ú˜

1.200.000 IU 600.000 IU ÁÈ· µ™ < 27 kg ¶·È‰È¿: 250 mg 2-3 ÊÔÚ¤˜/24ˆÚÔ ∂Ó‹ÏÈΘ: 250 mg 3-4 ÊÔÚ¤˜/24ˆÚÔ ‹ 500 mg 2 ÊÔÚ¤˜/24ˆÚÔ 25-50mg/kg/24ˆÚÔ Û 3 ‰fiÛÂȘ (̤ÁÈÛÙË ‰fiÛË: 750-1500 mg/24ˆÚÔ) ¶ÔÈΛÏÏÂÈ ·Ó¿ÏÔÁ· Ì ÙÔ Û··ÛÌ· ¶ÔÈΛÏÏÂÈ ·Ó¿ÏÔÁ· Ì ÙÔ Û··ÛÌ·

¢ÂÓ ¤¯ÂÈ ·Ó·ÊÂÚı› ·ÓÙÔ¯‹ ÛÙËÓ ÂÓÈÎÈÏ›ÓË ·fi ÛÙÚÂÙfiÎÔÎÎÔ ÔÌ¿‰·˜ ∞

∂Ó·ÏÏ·ÎÙÈο Ù˘ p.os ÂÓÈÎÈÏ›Ó˘, ÏfiÁˆ Á‡Û˘

∂Ó·ÏÏ·ÎÙÈο Ù˘ p.os ÂÓÈÎÈÏ›Ó˘** ∂Ó·ÏÏ·ÎÙÈο Û ·ÛıÂÓ›˜ Ì ·ÏÏÂÚÁ›· ÛÙËÓ ÂÓÈÎÈÏ›ÓË

*¢ÂÓ Ú¤ÂÈ Ó· ¯ÔÚËÁÔ‡ÓÙ·È Û ·ÛıÂÓ›˜ Ô˘ ÂÌÊ¿ÓÈÛ·Ó ¿ÌÂÛÔ˘ Ù‡Ô˘ ˘ÂÚ¢·ÈÛıËÛ›· ÛÙ· ‚-Ï·ÎÙ·ÌÈο ·ÓÙÈ‚ÈÔÙÈο **5% ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ÂÌÊ¿ÓÈÛ ¤ÛÙˆ Î·È ‹È· ·ÏÏÂÚÁÈ΋ ·ÓÙ›‰Ú·ÛË ÛÙËÓ ÂÓÈÎÈÏ›ÓË, ÌÔÚ› Ó· ÂÌÊ·Ó›ÛÂÈ Î·È ÛÙȘ ÎÂÊ·ÏÔÛÔÚ›Ó˜

ÛÙÚÂÙfiÎÔÎÎÔ ÔÌ¿‰·˜ ∞ (21). √ ¤ÏÂÁ¯Ô˜ Ù›ÙÏÔ˘ ·ÓÙÈۈ̿وÓ, fiˆ˜ ASTO Î·È anti-DNase µ, ‰ÂÓ Û˘Ì‚¿ÏÏÂÈ ÛÙËÓ ¤ÁηÈÚË ‰È¿ÁÓˆÛË, ‰Â‰Ô̤ÓÔ˘ fiÙÈ ÔÈ Ì¤ÁÈÛÙ˜ ÙÈ̤˜ ·Ú·ÙËÚÔ‡ÓÙ·È 3-4 ‚‰ÔÌ¿‰Â˜ ÌÂÙ¿ ÙË Ïԛ̈ÍË. ∆Ô Â›‰Ô˜, Ë ‰fiÛË, Ô ·ÚÈıÌfi˜ ‰fiÛÂˆÓ ÙÔ˘ ηٿÏÏËÏÔ˘ ÁÈ· ÙË ıÂÚ·›· Ù˘ Ê·Ú˘ÁÁ›Ùȉ·˜ ·ÓÙÈ‚ÈÔÙÈÎÔ‡ ¤¯Ô˘Ó Á›ÓÂÈ ·ÓÙÈΛÌÂÓÔ ÌÂÏÂÙÒÓ. ™ÙÔÓ ¶›Ó·Î· 1 ηٷÁÚ¿ÊÂÙ·È Ë ÚfiÙ·ÛË ÙÔ˘ ¶√À (22). °È· ÙÔ˘˜ ·ÛıÂÓ›˜ Ì ÔÍ›· Ê·Ú˘ÁÁ›Ùȉ· Î·È ÈÛÙÔÚÈÎfi ƒ¶ ÔÈ Ô‰ËÁ›Â˜ Â›Ó·È ›‰È˜. ŸÌˆ˜, ÛÙËÓ ÂÚ›ÙˆÛË ·˘Ù‹, fiˆ˜ Î·È Â› ˘ÔÙÚÔ‹˜ Ù˘ Ê·Ú˘ÁÁ›Ùȉ·˜, Û˘ÛÙ‹ÓÂÙ·È Î·ÏÏȤÚÁÂÈ· Ê·Ú˘ÁÁÈÎÔ‡ ÂȯڛÛÌ·ÙÔ˜ Î·È ÌÂÙ¿ ÙËÓ ÔÏÔÎÏ‹ÚˆÛË Ù˘ 10‹ÌÂÚ˘ ·ÁˆÁ‹˜ (22). ∂› ˘ÔÙÚÔ‹˜, ¯ÔÚËÁÔ‡ÓÙ·È 1.200.000 IU ‚ÂÓ˙·ıÈÓÈ΋˜ ‚ÂÓ˙˘ÏÔÂÓÈÎÈÏÏ›Ó˘ (i.m.) Û ÌÈ· ‰fiÛË Î·È, ·Ó ˘¿Ú¯Ô˘Ó ˘Ô„›Â˜ ÁÈ· ·Ú·ÁˆÁ‹ ÂÓÈÎÈÏÏÈÓ¿Û˘ ·fi ÙÔ ÛÙÚÂÙfiÎÔÎÎÔ, ÚÔÙ›ÓÂÙ·È Ë ¯ÔÚ‹ÁËÛË ÎÏÈÓ‰·Ì˘Î›Ó˘ ‹ ·ÌÔ͢ÎÈÏÏ›Ó˘-ÎÏ·‚Ô˘Ï·ÓÈÎÔ‡ ÔͤԘ (22). ø˜ ‰Â˘ÙÂÚÔÁÂÓ‹˜ ÚfiÏË„Ë ÔÚ›˙ÂÙ·È Ë Ù·ÎÙÈ΋ ¯ÔÚ‹ÁËÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ Û ·ÛıÂÓ›˜ Ì ÈÛÙÔÚÈÎfi ƒ¶, ÚÔÎÂÈ̤ÓÔ˘ Ó· ·ÔÊ¢¯ı› ÛÙÚÂÙÔÎÔÎÎÈ΋ Ê·Ú˘ÁÁ›Ùȉ· Î·È ˘ÔÙÚÔ‹ ÂÂÈÛÔ‰›Ô˘ ÔͤԘ ƒ¶. ◊‰Ë ·fi ÙË ‰ÂηÂÙ›· ÙÔ˘ ã60 ‹Ù·Ó ÁÓˆÛÙfi fiÙÈ ÂÚ›Ô˘ ÙÔ 60% ÙˆÓ ÚÂ˘Ì·ÙÈÎÒÓ ‚·Ï‚ȉÈÎÒÓ ‚Ï·‚ÒÓ ˘ÔÛÙÚ¤ÊÔÓÙ·È ÛÙË 10ÂÙ›·, ·Ó ‰ÂÓ ˘¿ÚÍÂÈ ˘ÔÙÚÔ‹ ƒ¶ (23). ¡ÂfiÙÂÚ· ‰Â‰Ô̤ӷ Ì ∏Ã∫ ‰Â›¯ÓÔ˘Ó ‚ÂÏÙ›ˆÛË ÌÂÙ¿ ÙÔ ÚÒÙÔ ÂÂÈÛfi‰ÈÔ ƒ¶ ·ÎfiÌ· Î·È ÛÙÔ 24% ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ›¯·Ó ÛÔ‚·Ú‹ ηډ›Ùȉ· (24). ∏ ·ÔÊ˘Á‹, ÂÔ̤ӈ˜, Ó¤Ô˘ ÂÂÈÛÔ‰›Ô˘ ƒ¶ Â›Ó·È ÌÂPaediatriki 2008;71:29-37

Á¿Ï˘ ÛËÌ·Û›·˜, ‰Â‰Ô̤ÓÔ˘ fiÙÈ, ηٿ ηÓfiÓ·, Ë ¯ÚfiÓÈ· ƒ∫ Â›Ó·È ·ÔÙ¤ÏÂÛÌ· ÔÏÏÒÓ ÂÂÈÛÔ‰›ˆÓ ƒ¶ (4). ∏ ÚfiÙ·ÛË ÙÔ˘ ¶√À (22) ÁÈ· ‰Â˘ÙÂÚÔÁÂÓ‹ ÚfiÏË„Ë Î·Ù·ÁÚ¿ÊÂÙ·È ÛÙÔÓ ¶›Ó·Î· 2. ∏ ¯ÔÚ‹ÁËÛË ÂÓÈÎÈÏ›Ó˘ ÂÓ‰ÔÌ˘˚ο ¤¯ÂÈ Ê·Ó› ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙÂÚË Ù˘ ·ÁˆÁ‹˜ ·fi ÙÔ ÛÙfiÌ·, ÂÓÒ ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙÂÚË, Â›Û˘, Â›Ó·È Î·È Ë ¯ÔÚ‹ÁËÛË Î¿ı 3 ‚‰ÔÌ¿‰Â˜ (25). ¶·Ú¿ Ù·‡Ù·, ÙÔ ·Ó¿ 3 ‚‰ÔÌ¿‰Â˜ Û¯‹Ì· ÚÔÙ›ÓÂÙ·È Î˘Ú›ˆ˜ ÁÈ· ÙÔ˘˜ ·ÛıÂÓ›˜ Ì ÛÔ‚·Ú‹ ƒ∫, ÂÓÒ ÁÈ· ÙÔ˘˜ ˘fiÏÔÈÔ˘˜ ÚÔÙÈÌ¿Ù·È Ë ¯ÔÚ‹ÁËÛË Î¿ı 4 ‚‰ÔÌ¿‰Â˜ (19). ∂›Ó·È ÛÎfiÈÌÔ Ó· ÂÊ·ÚÌfi˙ÔÓÙ·È ÔÈ ·Ϥ˜ Ô‰ËÁ›Â˜ ÁÈ· Ì›ˆÛË ÙÔ˘ fiÓÔ˘, fiˆ˜ Ë ı¤ÚÌ·ÓÛË ÙÔ˘ Ê·ÚÌ¿ÎÔ˘ Û ıÂÚÌÔÎÚ·Û›· ÂÚÈ‚¿ÏÏÔÓÙÔ˜, ÙÔ ÛÙ¤Áӈ̷ ÙÔ˘ ‰¤ÚÌ·ÙÔ˜ ÚÈÓ ·fi ÙË ¯ÔÚ‹ÁËÛË Î·È Ë ·ÚÁ‹ ¯ÔÚ‹ÁËÛË (ÁÈ· ÂÚÈÛÛfiÙÂÚÔ ·fi 3 ÏÂÙ¿) (19). ∂›Û˘, ¤¯ÂÈ ÚÔÙ·ı› Û˘Á¯ÔÚ‹ÁËÛË Ì ÏȉÔη˝ÓË (26), ÂÓÒ Ê·›ÓÂÙ·È Ó· ‚ÔËı¿ Ë ÁÓˆÛÙ‹ ÛÙË ¯ÒÚ· Ì·˜ Ú·ÎÙÈ΋ Ì ÂÈı¤Ì·Ù· ÙÔÈÎÔ‡ ·Ó·ÈÛıËÙÈÎÔ‡, Ô˘ ÚÔËÁÂ›Ù·È Ù˘ ¯ÔÚ‹ÁËÛ˘. ¶Ú¤ÂÈ Ó· ÂÈÛËÌ·Óı› fiÙÈ Ë ¯ÚfiÓÈ· ¯ÔÚ‹ÁËÛË ÂÓÈÎÈÏ›Ó˘ ‰ÂÓ ·ÔÙÚ¤ÂÈ ÙÔÓ Î›Ó‰˘ÓÔ ‚·ÎÙËÚȉȷ΋˜ ÂÓ‰Ôηډ›Ùȉ·˜, ÁÈ· ÙËÓ ·ÔÊ˘Á‹ Ù˘ ÔÔ›·˜ ÈÛ¯‡Ô˘Ó Ù· ÁÓˆÛÙ¿ ÁÈ· Ô‰ÔÓÙÈ·ÙÚÈΤ˜ Î·È ¯ÂÈÚÔ˘ÚÁÈΤ˜ ÂÂÌ‚¿ÛÂȘ.

¢È¿ÁÓˆÛË °È· ÙË ‰È¿ÁÓˆÛË ÙÔ˘ ƒ¶ ‰ÂÓ ˘¿Ú¯ÂÈ ÂȉÈ΋ ÂͤٷÛË. ∆Ô 1944 ıÂÛ›ÛÙËÎ·Ó Ù· ÁÓˆÛÙ¿ ÎÚÈÙ‹ÚÈ· Jones (27), Ô˘ ¤ÎÙÔÙ ÙÚÔÔÔÈ‹ıËÎ·Ó ¤ÓÙ ÊÔÚ¤˜. √È ÙÂÏÂ˘Ù·›Â˜ ÙÚÔÔÔÈ‹ÛÂȘ ·fi ÙËÓ American

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·33

33

ƒÂ˘Ì·ÙÈÎfi˜ ˘ÚÂÙfi˜

¶›Ó·Î·˜ 2. ¢Â˘ÙÂÚÔÁÂÓ‹˜ ÚfiÏË„Ë: Ì·ÎÚÔ¯ÚfiÓÈ· ıÂÚ·›· Û ·ÛıÂÓ›˜ Ì ÈÛÙÔÚÈÎfi ÚÂ˘Ì·ÙÈÎÔ‡ ˘ÚÂÙÔ‡ ‹ ÚÂ˘Ì·ÙÈ΋˜ ηډ›Ùȉ·˜ (22) ∞ÓÙÈ‚ÈÔÙÈÎfi

ÃÔÚ‹ÁËÛË ¢ÔÛÔÏÔÁ›·

™¯fiÏÈ·

µÂÓ˙·ıÈÓÈ΋ ÂÓÈÎÈÏ›ÓË G

i.m.

- ™Â ƒ¶ ¯ˆÚ›˜ ηډ›Ùȉ·: 5 ¯ÚfiÓÈ· ·fi ÙÂÏÂ˘Ù·›Ô ÂÂÈÛfi‰ÈÔ ƒ¶ ‹ ̤¯ÚÈ 18 ¯ÚÔÓÒÓ - ™Â ‹È· ‹ ıÂÚ·¢ı›۷ ηډ›Ùȉ·: 10 ¯ÚfiÓÈ· ·fi ÙÔ ÙÂÏÂ˘Ù·›Ô ÂÂÈÛfi‰ÈÔ ƒ¶ ‹ ̤¯ÚÈ 25 ¯ÚÔÓÒÓ** - ™Â ÈÔ ÛÔ‚·Ú‹ ηډ›Ùȉ· ‹ ¯ÂÈÚÔ˘ÚÁÈ΋ ·ÔηٿÛÙ·ÛË ‚·Ï‚›‰·˜: ÂÊ' fiÚÔ˘ ˙ˆ‹˜

º·ÈÓÔ͢ÌÂı˘ÏÔ p.os ÂÓÈÎÈÏ›ÓË (¶ÂÓÈÎÈÏ›ÓË V) ∂Ú˘ıÚÔÌ˘Î›ÓË p.os

1-2 ÂηÙÔÌ̇ÚÈ· IU οı 3-4 ‚‰ÔÌ¿‰Â˜ 600.000 IU οı 3-4 ‚‰ÔÌ¿‰Â˜ ÁÈ· µ™ < 27 kg* 250 mg 2 ÊÔÚ¤˜/24ˆÚÔ 250 mg 2 ÊÔÚ¤˜/24ˆÚÔ

* º·ÚÌ·ÎÔÎÈÓËÙÈΤ˜ ÌÂϤÙ˜ ¤‰ÂÈÍ·Ó fiÙÈ Èı·ÓÒ˜ Ë ‰fiÛË Â›Ó·È ·ÓÂ·Ú΋˜ ÁÈ· οÔÈ· ·È‰È¿ Î·È ÚÔÙ›ÓÂÙ·È Ë ÌÈÎÚ‹ ‰fiÛË ÌfiÓÔ ·Ó ÙÔ µ™ <20 kg (19) ** ◊ fiÛÔ ˘¿Ú¯Ô˘Ó ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ ÛÙÔ ÔÈÎÔÁÂÓÂÈ·Îfi ÂÚÈ‚¿ÏÏÔÓ (52)

Heart Association (AHA) ¤ÁÈÓ·Ó ÙÔ 1992 (28) Î·È ·fi ÙÔÓ ¶√À ÙÔ 2003, Ô˘ ‰È·ÊÔÚÔÔÈ› Ù· ÎÚÈÙ‹ÚÈ· ÙÔ˘ 1992 ÌfiÓÔ ÁÈ· ˘ÔÙÚÔ‹ ƒ¶, ı¤ÙÔÓÙ·˜ ÏÈÁfiÙÂÚÔ “·˘ÛÙËÚ¿” ÎÚÈÙ‹ÚÈ·, Ì ·ÔÙ¤ÏÂÛÌ· Ó· ·˘Í¿ÓÔ˘Ó ÙËÓ Â˘·ÈÛıËÛ›· Û ‚¿ÚÔ˜ Ù˘ ÂȉÈÎfiÙËÙ·˜. ∆· ÎÚÈÙ‹ÚÈ· ‰È·ÎÚ›ÓÔÓÙ·È Û Ì›˙ÔÓ· (ª∫) Î·È ÂÏ¿ÛÛÔÓ· (∂∫) Î·È ·Ó·Ê¤ÚÔÓÙ·È ÛÙÔÓ ¶›Ó·Î· 3. °È· ÙË ‰È¿ÁÓˆÛË ÙÔ˘ ÚÒÙÔ˘ ÂÂÈÛÔ‰›Ô˘ ˘¿Ú¯ÂÈ ÔÌÔʈӛ· AHA Î·È ¶√À. ∞·ÈÙÔ‡ÓÙ·È 2 ª∫ ‹ 1 ª∫ Î·È 2 ∂∫ Î·È ÂÈÚfiÛıÂÙ· ·fi‰ÂÈÍË ÚÔËÁËı›۷˜ ÛÙÚÂÙÔÎÔÎÎÈ΋˜ ∞ Ïԛ̈͢ (ÚfiÛÊ·ÙË ÔÛÙÚ·ÎÈ¿, ÙÂÎÌËÚȈ̤ÓË ÛÙÚÂÙÔÎÔÎÎÈ΋ Ê·Ú˘ÁÁ›Ùȉ·, ˘„ËÏfi˜ Ù›ÙÏÔ˜ ·ÓÙÈÛÙÚÂÙÔÎÔÎÎÈÎÒÓ ·ÓÙÈۈ̿وÓ). ÀÂÓı˘Ì›˙ÂÙ·È fiÙÈ ÛÙÔ 20% ÙˆÓ ÂÚÈÙÒÛÂˆÓ ÚÒÙÔ˘ ÂÂÈÛÔ‰›Ô˘ ƒ¶ Î·È ÛÙÔ˘˜ ÂÚÈÛÛfiÙÂÚÔ˘˜ ·ÛıÂÓ›˜ Ì ¯ÔÚ›· ·Ú·ÙËÚÂ›Ù·È ¯·ÌËÏfi˜ Ù›ÙÏÔ˜ ASTO. ∂È‚¿ÏÏÂÙ·È ÏÔÈfiÓ ¤ÏÂÁ¯Ô˜ Î·È ÙÔ˘ Ù›ÙÏÔ˘ antiDNase µ. ¶Ú¤ÂÈ Ó· ÙÔÓÈÛÙ› fiÙÈ Ô Û˘Ó‰˘·ÛÌfi˜ ¯ÔÚ›·˜ Î·È ˘ÔÎÏÈÓÈ΋˜ ηډ›Ùȉ·˜, Û‡Ìʈӷ Ì ÙËÓ ∞∏∞ (28) Î·È Ì ÙÔÓ ¶√À (22), ‰ÂÓ ··ÈÙ› ·fi‰ÂÈÍË ÚÔËÁËı›۷˜ ÛÙÚÂÙÔÎÔÎÎÈ΋˜ Ïԛ̈͢ ÁÈ· ÙËÓ ÙÂÎÌËÚ›ˆÛË ƒ¶. °È· ˘ÔÙÚÔ‹ ƒ¶, Ô ¶√À ·ÚÎÂ›Ù·È Û 2 ∂∫ ÎÚÈÙ‹ÚÈ· Î·È ÂÈÚfiÛıÂÙ· ·fi‰ÂÈÍË ÚÔËÁËı›۷˜ ÛÙÚÂÙÔÎÔÎÎÈ΋˜ Ïԛ̈͢, ÂÓÒ Ë ∞∏∞ ··ÈÙ› ÂÚÈÛÛfiÙÂÚ· ∂∫ ÎÚÈÙ‹ÚÈ· (·‡ÍËÛË ÂȉÈÎfiÙËÙ·˜, Ì›ˆÛË Â˘·ÈÛıËÛ›·˜) (28). ∂Ӊ¯Ô̤ӈ˜, ·˘Ù‹ Ë Ú·ÎÙÈ΋ Ó· Â›Ó·È ÚÔÙÈÌfiÙÂÚË ÛÙË ¯ÒÚ· Ì·˜. ™ÎfiÈÌÔ Â›Ó·È Ó· ÂÈÛËÌ·Óı› fiÙÈ Ù· ÎÚÈÙ‹ÚÈ· Jones Â›Ó·È ‰È·ÁÓˆÛÙÈο ÂÚÁ·Ï›· ÎÈ fi¯È ·fiÏ˘ÙÔÈ Ô‰ËÁÔ› ÎÈ fiˆ˜ ۯ‰fiÓ Û οı ÂÚ›ÙˆÛË ÛÙËÓ È·ÙÚÈ΋ Û˘ÓÈÛÙ¿Ù·È ÂÍ·ÙƠ̂΢ÛË. √ ÔÚÈÛÌfi˜ Ù˘ ηډ›Ùȉ·˜ Â› ƒ¶ ·ÔÙÂÏ› ÛËÌÂ›Ô ÙÚÈ‚‹˜ ÛÙËÓ ÚfiÛÊ·ÙË ‚È‚ÏÈÔÁÚ·Ê›·. ∂›ÛËÌ·, ··ÈÙÂ›Ù·È Ë ·ÚÔ˘Û›· Ê˘Û‹Ì·ÙÔ˜ ÁÈ· ÙÂÎÌËÚ›ˆÛË ‚·Ï‚ȉ›Ùȉ·˜ (22,28), ·ÏÏ¿ fiÏÔ Î·È ÂÚÈÛÛfiÙÂÚÔ ˘ÔÛÙËÚ›˙ÂÙ·È fiÙÈ Ë ∏Ã∫ÊÈ΋ ‰È·›ÛÙˆÛË ‚·Ï‚ȉ›-

Ùȉ·˜, ¤ÛÙˆ Î·È ¯ˆÚ›˜ ʇÛËÌ·, Ú¤ÂÈ Ó· ıˆÚÂ›Ù·È ·Ô‰ÂÈÎÙÈ΋ ηډ›Ùȉ·˜. ∆· ÛÙÔȯ›· Ô˘ ‚·Û›˙ÂÙ·È Ë ¿Ô„Ë ·˘Ù‹ ›ӷÈ: (1) ∞ÛıÂÓ›˜ Ì ƒ¶ ¯ˆÚ›˜ ηډ›Ùȉ· (¯ˆÚ›˜ ʇÛËÌ·) ·Ó¤Ù˘Í·Ó ÛÙËÓ ·Ú·ÎÔÏÔ‡ıËÛË ƒ∫ (29,30), Ô˘ ÛËÌ·›ÓÂÈ fiÙÈ Î·È Ì “¯Ú˘Û¿ ·˘ÙÈ¿” οÔȘ ‚·Ï‚ȉ›Ùȉ˜ ¯¿ÓÔÓÙ·È.

(2) ¢È·ÈÛÙÒıËÎ·Ó ‚·Ï‚ȉÈΤ˜ ‚Ï¿‚˜ 6 Ì‹Ó˜ ˆ˜ 8 ¯ÚfiÓÈ· ÌÂÙ¿ ·fi ˘ÔÎÏÈÓÈ΋ ƒ∫ (31-33).

(3) ™Â 452 ·ÛıÂÓ›˜ Ì ƒ¶, ‰È·ÁÓˆṲ̂ÓÔ Ì ‚¿ÛË Ù· Â›ÛËÌ· ÎÚÈÙ‹ÚÈ·, ‰È·ÈÛÙÒıËΠ̠∏Ã∫ fiÙÈ Û οÔÈÔ˘˜ ·ÛıÂÓ›˜ ÙÔ Ê‡ÛËÌ· Ô˘ ›¯Â ·Ô‰Ôı› Û ηډ›Ùȉ· ÔÊÂÈÏfiÙ·Ó Û ¿ÏÏË ·ÈÙ›· (.¯. ÌÂÛÔÎÔÈÏȷ΋ ÂÈÎÔÈÓˆÓ›·) Î·È ÔÈ ·ÛıÂÓ›˜ ·˘ÙÔ› ‰ÂÓ Â›¯·Ó ƒ¶. ¶·Ú¿ÏÏËÏ·, Û οÔÈÔ˘˜ ¿ÏÏÔ˘˜ ·ÛıÂÓ›˜, ¯ˆÚ›˜ ÎÏÈÓÈ΋ ¤Ó‰ÂÈÍË Î·Ú‰›Ùȉ·˜, Ì ∏Ã∫ ‰È·ÈÛÙÒıËΠ‚·Ï‚ȉ›Ùȉ·, ÁÂÁÔÓfi˜ Ô˘ ¿ÏÏ·Í ÙËÓ ÚÔÛ¤ÁÁÈÛ‹ ÙÔ˘˜ (34). Œ¯ÂÈ ‰È·Ù˘ˆı› Î·È Ô ·ÓÙ›ıÂÙÔ˜ ÚÔ‚ÏËÌ·ÙÈÛÌfi˜, Ì‹ˆ˜ ‰ËÏ·‰‹, ÏfiÁˆ Ù˘ Û˘¯Ó‹˜ ·Ó›¯Ó¢Û˘ ‹È·˜ ‰È·Ê˘Á‹˜ ÌÈÙÚÔÂȉԇ˜ ‚·Ï‚›‰·˜ ÛÂ Ê˘ÛÈÔÏÔÁÈÎfi ÏËı˘ÛÌfi, Ë ı¤ÛÈÛË ÛÙ· ÎÚÈÙ‹ÚÈ· Ù˘ ∏Ã∫ÊÈ΋˜ ·Ó›¯Ó¢Û˘ ·ÓÂ¿ÚÎÂÈ·˜ ı· Ô‰ËÁ‹ÛÂÈ Û ˘ÂډȿÁÓˆÛË ƒ¶. ÀÔÛÙËÚ›˙ÂÙ·È fiÙÈ ˘¿Ú¯Ô˘Ó ÈÛ¯˘Ú¿ ÎÚÈÙ‹ÚÈ· ∏Ã∫ ‰È·ÊÔÚÔÔ›ËÛ˘ Ê˘ÛÈÔÏÔÁÈ΋˜ ·fi ·ıÔÏÔÁÈ΋ “ÛȈËÏ‹” ·ÓÂ¿ÚÎÂÈ· ÌÈÙÚÔÂȉԇ˜ ‚·Ï‚›‰·˜ (35), fï˜ ·˘Ùfi ‰ÂÓ Â›Ó·È Î·ıÔÏÈο ·Ô‰ÂÎÙfi. ¶Ú¤ÂÈ Ó· ÙÔÓÈÛı› fiÙÈ fiÙ·Ó Ô ·È‰›·ÙÚÔ˜ ˘ÔÙ‡ÂÙ·È ƒ¶ Î·È ‰ÂÓ ·ÎÔ‡ÂÈ Ê‡ÛËÌ· Ú¤ÂÈ Ó· Û˘ÓÂÎÙÈÌ‹ÛÂÈ Ù· ‰Â‰Ô̤ӷ Ì ÙÔÓ ·È‰ÔηډÈÔÏfiÁÔ. ∏ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ˘ÔÎÏÈÓÈ΋˜ ‚·Ï‚ȉ›Ùȉ·˜ ·Ú·Ì¤ÓÂÈ ÌÈ· ÚfiÎÏËÛË Î·È, fiˆ˜ ÚfiÛÊ·Ù· ‰ËÌÔÛȇıËÎÂ: “fiÔ˘ Ô Î›Ó‰˘ÓÔ˜ ƒ¶ Â›Ó·È ÌÂÁ¿ÏÔ˜, Ë ˘ÔÎÏÈÓÈ΋ ηډ›Ùȉ· ı· Ú¤ÂÈ Ó· ˘ÔÏÔÁ›˙ÂÙ·È Ì¤ÚÔ˜ ÙÔ˘ Ê¿ÛÌ·ÙÔ˜ ÙÔ˘ ƒ¶” (19). ™Â ÚfiÛÊ·ÙË ÌÂϤÙË ‰È·ÈÛÙÒıËΠfiÙÈ ÛËÌ·ÓÙÈÎfi˜ ·ÚÈıÌfi˜ ‚·Ï‚›‰ˆÓ, Ô˘ ·Ê·ÈÚ¤ıËÎ·Ó ·fi ¶·È‰È·ÙÚÈ΋ 2008;71:29-37

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·34

34

Ã. ∆Ú¿·ÏË Î·È Û˘Ó.

¶›Ó·Î·˜ 3. ∫ÚÈÙ‹ÚÈ· Jones ÁÈ· ÙË ‰È¿ÁÓˆÛË ÙÔ˘ ÚÂ˘Ì·ÙÈÎÔ‡ ˘ÚÂÙÔ‡ (27) ªÂ›˙ÔÓ· ÎÚÈÙ‹ÚÈ· 1. ∫·Ú‰›Ùȉ· (ÚÔÊ·Ó‹˜ ÎÏÈÓÈο) 2. ¶ÔÏ˘·ÚıÚ›Ùȉ· 3. ÃÔÚ›· 4. ¶ÔχÌÔÚÊÔ ÂÚ‡ıËÌ· 5. ÀÔ‰fiÚÈ· Ô˙›‰È· ∂Ï¿ÛÛÔÓ· ÎÚÈÙ‹ÚÈ·: 1. ∫ÏÈÓÈο (˘ÚÂÙfi˜, ·ÚıÚ·ÏÁ›·) 2. ∂ÚÁ·ÛÙËÚȷο (Ï¢ÎÔ΢ÙÙ¿ÚˆÛË, ·Ú¿Ù·ÛË ÙÔ˘ ‰È·ÛÙ‹Ì·ÙÔ˜ PR, ·˘ÍË̤ÓË ∆∫∂, ·˘ÍË̤ÓË CRP)

Ó·ÚÔ‡˜ ·ÛıÂÓ›˜ (ËÏÈΛ· <40 ÂÙÒÓ) ÏfiÁˆ ƒ¶, ›¯·Ó ·˘ÍË̤ÓÔ Ì˘ÍˆÌ·ÙÒ‰Ë ÈÛÙfi (36). √È Ì˘ÍˆÌ·ÙÒ‰ÂȘ ‚·Ï‚›‰Â˜ ¤¯Ô˘Ó ·˘ÍË̤ÓÔ ˘·ÏÔ˘ÚÔÓÈÎfi. ™ÙÂϤ¯Ë ÛÙÚÂÙÔÎfiÎÎˆÓ ˘„ËÏ‹˜ ÏÔÈÌÔÁfiÓÔ˘ ‰‡Ó·Ì˘, Â›Û˘, ¤¯Ô˘Ó ·˘ÍË̤ÓÔ ˘·ÏÔ˘ÚÔÓÈÎfi Î·È ·˘Ùfi Èı·Ó¿ Ô‰ËÁ› Û ‰È·ÛÙ·˘ÚÔ‡ÌÂÓË ·ÓÙ›‰Ú·ÛË. ∫·Ù¿ Û˘Ó¤ÂÈ·, ı· Ú¤ÂÈ Ó· ‰›ÓÂÙ·È È‰È·›ÙÂÚË ÚÔÛÔ¯‹ Û ·È‰È¿ ÌÂ Ê·Ú˘ÁÁ›Ùȉ· Î·È ÚfiÙˆÛË ÌÈÙÚÔÂȉԇ˜ (ÌÂ Ì˘ÍˆÌ·ÙÒ‰ÂȘ ‚·Ï‚›‰Â˜).

£ÂÚ·›· √È ÂÚÈÛÛfiÙÂÚ˜ ıÂÚ·¢ÙÈΤ˜ Ú·ÎÙÈΤ˜ ÁÈ· ÙÔ ƒ¶ ‰ÂÓ ‚·Û›˙ÔÓÙ·È ÛÂ Ù˘¯·ÈÔÔÈË̤Ó˜ ÌÂϤÙ˜, ·ÏÏ¿ Û ÎÔÈÓ‹ ÎÏÈÓÈ΋ ·›ÛıËÛË ÁÈ· ÙËÓ Î·Ù·ÏÏËÏfiÙËÙ· Ù˘ ·ÁˆÁ‹˜, Ì ·Ú¿ÏÏËÏË ‰È·Ù‹ÚËÛË ˘„ËÏÔ‡ ÂÈ¤‰Ô˘ ·ÛÊ¿ÏÂÈ·˜. ÷ڷÎÙËÚÈÛÙÈο ÙÔÓ›˙ÂÙ·È Û ÚfiÛÊ·ÙË ‰ËÌÔÛ›Â˘ÛË ÛÙÔ British Medical Journal fiÙÈ “ÙfiÛ· ¯ÚfiÓÈ· ÎÈ ·ÎfiÌ· ‰ÂÓ Í¤ÚÔ˘ÌÂ, ·Ó Ú¤ÂÈ ÛÙÔ ƒ¶ Ó· ¯ÚËÛÈÌÔÔÈԇ̠ÛÙÂÚÔÂȉ‹” (37). ™Â ÌÂÙ··Ó·Ï‡ÛÂȘ ‰ÂÓ ‰È·ÈÛÙÒıËΠ˘ÂÚÔ¯‹ οÔÈ·˜ ıÂÚ·›·˜, fiÛÔÓ ·ÊÔÚ¿ ÙËÓ Â›ÙˆÛË ƒ∫ 1-10 ¯ÚfiÓÈ· ÌÂÙ¿ ·fi ƒ¶ (23). ∂›Û˘, ‰ÂÓ ‰È·ÈÛÙÒıËΠ˘ÂÚÔ¯‹ Ù˘ ıÂÚ·›·˜ Ì ·ÎÂÙ˘ÏÔÛ·ÏÈ΢ÏÈÎfi Û ۇÁÎÚÈÛË Ì ÙÔÓ ÎÏÈÓÔÛÙ·ÙÈÛÌfi (38-40), fiÛÔÓ ·ÊÔÚ¿ ÙËÓ Â›ÙˆÛË ˘ÔÏÂÈfiÌÂÓ˘ ƒ∫, Ô‡Ù ‰È·ÈÛÙÒıËΠ˘ÂÚÔ¯‹ Ù˘ ·ÛÈÚ›Ó˘ ¤Ó·ÓÙÈ ÙˆÓ ÎÔÚÙÈÎÔÂȉÒÓ Ô‡ÙÂ Î·È ÙÔ ·ÓÙ›ıÂÙÔ (41,42). ∆¤ÏÔ˜, Û ÚfiÛÊ·ÙË ÌÂϤÙË ‰ÂÓ ‰È·ÈÛÙÒıËΠ‰È·ÊÔÚ¿ ÛÙË ‚·Ú‡ÙËÙ· ÙˆÓ ÂΉËÏÒÛÂˆÓ Ù˘ ÔÍ›·˜ ‚·Ï‚ȉ›Ùȉ·˜ Ô‡Ù ÛÙËÓ Â›ÙˆÛË ¯ÚfiÓÈ·˜ ƒ∫ Û ·Ú·ÎÔÏÔ‡ıËÛË ÂÓfi˜ ¤ÙÔ˘˜ ÌÂÙ¿ ·fi ÙËÓ ÂÓ‰ÔÊϤ‚ÈÔ ¯ÔÚ‹ÁËÛË ·ÓÔÛÔÛÊ·ÈÚ›Ó˘ ¤Ó·ÓÙÈ placebo (43). ¶Ú¤ÂÈ Ó· Á›ÓÔ˘Ó ÌÂÁ¿Ï˜, ÔÏ˘ÎÂÓÙÚÈΤ˜, Ù˘¯·ÈÔÔÈË̤Ó˜ ÌÂϤÙ˜ ÁÈ· Ó· ηٷ‰ÂȯıÔ‡Ó Ù· Èı·Ó¿ ÔʤÏË ÎÔÚÙÈÎÔÂȉÒÓ Î·È ÙˆÓ Î·ÈÓÔ‡ÚÁÈˆÓ ·ÓÙÈÊÏÂÁÌÔÓˆ‰ÒÓ ·Ú·ÁfiÓÙˆÓ ÛÙËÓ ÔÍ›· Î·È ¯ÚfiÓÈ· ƒ∫ (19). ∏ ·ÏÈ¿ Ô‰ËÁ›· ÁÈ· ÎÏÈÓÔÛÙ·ÙÈÛÌfi “ʈٛ˙ÂÙ·È” ·fi Ó¤· ‰Â‰Ô̤ӷ, Û‡Ìʈӷ Ì ٷ ÔÔ›·, Ë ·Ú¯È΋ ‚Ï¿‚Ë ÛÙÔÓ ƒ¶ ·ÊÔÚ¿ ÙÔ ‰·ÎÙ‡ÏÈÔ Î·È ÙȘ ¯ÔÚ‰¤˜, Ë ‰Â Ù¿ÛË ÛÙȘ ¯ÔÚ‰¤˜ Â›Ó·È ·Ó¿ÏÔÁË Ù˘ ›ÂÛ˘ ÛÙËÓ Paediatriki 2008;71:29-37

¶›Ó·Î·˜ 4. ∞ÓÙÈÌÂÙÒÈÛË ·ÛıÂÓÒÓ Ì Ô͇ ÚÂ˘Ì·ÙÈÎfi ˘ÚÂÙfi (22) 1. ∞ÔÊ˘Á‹ ¯ÔÚ‹ÁËÛ˘ ÎÔÚÙÈÎÔÂȉÒÓ ‹ Û·ÏÈ΢ÏÈÎÒÓ Ì¤¯ÚÈ ÙËÓ ÂȂ‚·›ˆÛË Ù˘ ‰È¿ÁÓˆÛ˘ ƒ¶ 2. ∫ÏÈÓÔÛÙ·ÙÈÛÌfi˜, Ô˘ ·Ó ˘¿Ú¯ÂÈ Î·Ú‰›Ùȉ·, ·Ú·Ù›ÓÂÙ·È ÁÈ· ÂÚÈÛÛfiÙÂÚÔ ·fi 4 ‚‰ÔÌ¿‰Â˜ 3. ∞ÓÙÈ‚›ˆÛË ÁÈ· ÂÎÚ›˙ˆÛË ÙÔ˘ ÛÙÚÂÙÔÎfiÎÎÔ˘ 4. ∞ÓÙÈÊÏÂÁÌÔÓÒ‰Ë: ·) ∞ÛÈÚ›ÓË 100 mg/kg/24ˆÚÔ Û 4-5 ‰fiÛÂȘ ÁÈ· 2 ‚‰ÔÌ¿‰Â˜, Ì›ˆÛË Û 60-70 mg/kg/24ˆÚÔ ÁÈ· ¿ÏϘ 3-6 ‚‰ÔÌ¿‰Â˜ ™ËÌ›ˆÛË: π. ™˘¯Ófi˜ ¤ÏÂÁ¯Ô˜ ÂÈ¤‰ˆÓ ÒÛÙ ӷ ÂÍ·ÛÊ·Ï›˙ÔÓÙ·È ıÂÚ·¢ÙÈο Â›‰· Î·È Ó· ·ÔʇÁÂÙ·È Ë ÙÔÍÈÎfiÙËÙ· ππ. ∂› ·ÏÏÂÚÁ›·˜, Ó·ÚÔͤÓË 10-20 mg/kg/24ˆÚÔ ‚) ¶Ú‰ÓÈ˙fiÓË 1-2 mg/kg/24ˆÚÔ (̤ÁÈÛÙË: 80 mg) ÁÈ· 2-3 ‚‰ÔÌ¿‰Â˜, Ì›ˆÛË 20-25% οı ‚‰ÔÌ¿‰· ˘fi Û˘Á¯ÔÚ‹ÁËÛË ·ÛÈÚ›Ó˘ ™ËÌ›ˆÛË: ∏ Ú‰ÓÈ˙fiÓË ¤¯ÂÈ ¤Ó‰ÂÈÍË Û ÂÚÈÙÒÛÂȘ ηډȷ΋˜ ·ÓÂ¿ÚÎÂÈ·˜ ‹ ÌË ·ÓÙ·fiÎÚÈÛ˘ ÛÙ· Û·ÏÈ΢ÏÈο Á) ªÂı˘ÏÚ‰ÓÈ˙ÔÏfiÓË ÂÓ‰ÔÊÏ‚›ˆ˜ ™ËÌ›ˆÛË: ∏ ÌÂı˘ÏÚ‰ÓÈ˙ÔÏfiÓË ÂӉ›ÎÓ˘Ù·È Û ηٷÛÙ¿ÛÂȘ ÂÈΛӉ˘Ó˜ ÁÈ· ÙË ˙ˆ‹ 5. ÃÂÈÚÔ˘ÚÁÈ΋ ·ÔηٿÛÙ·ÛË Û ·ÛıÂÓ›˜ Ì ÂÌ̤ÓÔ˘Û· ÔÍ›· ηډ›Ùȉ· Ì ÛÔ‚·Ú‹ ηډȷ΋ ·ÓÂ¿ÚÎÂÈ·

·ÚÈÛÙÂÚ‹ ÎÔÈÏ›· (44). ™˘ÓÂÒ˜, ÂÏ·ÙÙÒÓÔÓÙ·˜ ÙËÓ ›ÂÛË ›Ûˆ˜ ·ÏÏ¿˙ÂÈ Ë ÔÚ›· ÙÔ˘ ƒ¶ ÏfiÁˆ Ù˘ Û˘Ó·ÎfiÏÔ˘ı˘ ÂÏ¿ÙÙˆÛ˘ Ù˘ Ù¿Û˘ ÛÙȘ ¯ÔÚ‰¤˜. ∏ ÁÓˆÛÙ‹ Ì·˜ Ô‰ËÁ›· ÁÈ· ÎÏÈÓÔÛÙ·ÙÈÛÌfi Â› ƒ¶, ›Ûˆ˜ ‚ÔËı¿, ÁÈ·Ù› Ë ›ÂÛË Î·È Û˘ÓÂÒ˜ Î·È Ë Ù¿ÛË Â›Ó·È ¯·ÌËÏfiÙÂÚË Û ÎÏÈÓÔÛÙ·ÙÈÛÌfi ·’ fiÙÈ Û ‰Ú·ÛÙËÚÈfiÙËÙ·. ÀÂÓı˘Ì›˙ÂÙ·È, Â›Û˘, fiÙÈ Ù· ·È‰È¿ Ì ƒ¶ Î·È ÛÔ‚·Ú‹ ·ÚıÚ›Ùȉ· ÛÙ·ÙÈÛÙÈο ¤¯Ô˘Ó ÏÈÁfiÙÂÚÔ ÛÔ‚·Ú‹ ηډ›Ùȉ·, ÂÂȉ‹, Èı·ÓfiÓ, ηıÒ˜ ÂÚÈÔÚ›˙ÂÙ·È Ë ‰Ú·ÛÙËÚÈfiÙËÙ¿ ÙÔ˘˜, ÂÍ·ÈÙ›·˜ ÙÔ˘ ¿ÏÁÔ˘˜ Ù˘ ·ÚıÚ›Ùȉ·˜, ÂÏ·ÙÙÒÓÂÙ·È Ë ›ÂÛË ÛÙËÓ ·ÚÈÛÙÂÚ‹ ÎÔÈÏ›· Î·È ÙÂÏÈο Ë Ù¿ÛË ÛÙȘ ¯ÔÚ‰¤˜. ŸÏ· Ù· ·Ú·¿Óˆ Ô‰ËÁÔ‡Ó ÛÙÔ Ú·ÎÙÈÎfi ÂÚÒÙËÌ· Ì‹ˆ˜ ¯ÔÚËÁÒÓÙ·˜ Ê¿Ú̷η Ô˘ ÂÏ·ÙÙÒÓÔ˘Ó ÙÔ ÌÂÙ·ÊfiÚÙÈÔ, ¿Ú· ÙËÓ ›ÂÛË Î·È ÙÂÏÈο Î·È ÙËÓ Ù¿ÛË, ÙÚÔÔÔÈËı› Ë ÂͤÏÈÍË Ù˘ ‚·Ï‚ȉ›Ùȉ·˜. √È Û˘ÛÙ¿ÛÂȘ ÙÔ˘ ¶√À ÁÈ· ÙÔ˘˜ ·ÛıÂÓ›˜ Ì Ô͇ ƒ¶ Û˘ÓÔ„›˙ÔÓÙ·È ÛÙÔÓ ¶›Ó·Î· 4. ¶Ú¤ÂÈ Ó· ÛËÌÂȈı› fiÙÈ Ë ¯ÔÚ‹ÁËÛË ÌÂı˘ÏÚ‰ÓÈ˙ÔÏfiÓ˘ ÂÓ‰ÔÊÏ‚›ˆ˜ ÂӉ›ÎÓ˘Ù·È Û ÂÈΛӉ˘Ó˜ ηٷÛÙ¿ÛÂȘ ÁÈ· ÙË ˙ˆ‹ ÙÔ˘ ·ÛıÂÓÔ‡˜, fï˜ Û ÚfiÛÊ·ÙË ÌÂϤÙË ‰È·ÈÛÙÒıËΠfiÙÈ ‹Ù·Ó ÏÈÁfiÙÂÚÔ ·ÔÙÂÏÂÛÌ·ÙÈ΋ Û˘ÁÎÚÈÙÈο Ì ÙËÓ p.os ¯ÔÚ‹ÁËÛË Ú‰ÓÈ˙fiÓ˘ (45). ∆¤ÏÔ˜, Û ·ÛıÂÓ›˜ Ì ÂÌ̤ÓÔ˘Û· ÔÍ›· ηډ›Ùȉ· Ì ÛÔ‚·Ú‹ ηډȷ΋ ·ÓÂ¿ÚÎÂÈ· Ë ¯ÂÈÚÔ˘ÚÁÈ΋ ·ÔηٿÛÙ·ÛË ˘ÂÚ¤¯ÂÈ ¤Ó·ÓÙÈ Ù˘ Ì·ÎÚÔ¯ÚfiÓÈ·˜ ¯ÔÚ‹ÁËÛ˘ ÎÔÚÙÈÎÔÂȉÒÓ. ∏ ·ÓÙÈÌÂÙÒÈÛË ÙÔ˘ ·È‰ÈÔ‡ Ì ¯ÚfiÓÈ· ƒ∫ ÂÍ·ÚÙ¿Ù·È ·fi ÙÔ ÔÈ· ‹ ÔȘ ‚·Ï‚›‰Â˜ ¿Û¯Ô˘Ó (ÌÈÙÚÔÂȉ‹˜, ·ÔÚÙ‹ ‹ Î·È ÔÈ ‰‡Ô), ·fi ÙÔÓ Ù‡Ô Ù˘

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·35

35

ƒÂ˘Ì·ÙÈÎfi˜ ˘ÚÂÙfi˜

‚·Ï‚ȉÔ¿ıÂÈ·˜ (ÛÙ¤ÓˆÛË, ·ÓÂ¿ÚÎÂÈ· ‹ ÌÈÎÙ‹ ÓfiÛÔ˜), ·fi ÙË ÛÔ‚·ÚfiÙËÙ· Ù˘ ‚Ï¿‚˘ Î·È ÙȘ ÂÈÙÒÛÂȘ Ù˘ ÛÙË Ì˘Ôηډȷ΋ ÏÂÈÙÔ˘ÚÁ›·. ∏ ·ÓÙÈÌÂÙÒÈÛË Ú¤ÂÈ Ó· Á›ÓÂÙ·È ·fi ·È‰ÔηډÈÔÏfiÁÔ.

ÃÔÚ›· ∞Ó·ÊÔÚÈο Ì ÙË ıÂÚ·›· Ù˘ ¯ÔÚ›·˜, Ô ¶√À (22) ÙÔÓ›˙ÂÈ fiÙÈ ‰ÂÓ ˘¿Ú¯Ô˘Ó ÂӉ›ÍÂȘ fiÙÈ Ù· ÎÔÚÙÈÎÔÂȉ‹ ˆÊÂÏÔ‡Ó, ÂÓÒ Û ÌÈÎÚ¤˜ ÛÂÈÚ¤˜ ηٷÁÚ¿ÊÔÓÙ·È ‰Â‰Ô̤ӷ ÁÈ· ÙÔ ·ÓÙ›ıÂÙÔ (46). ∏ ¯ÔÚ‹ÁËÛË ‚·ÏÚÔ˚ÎÔ‡, ηڂ·Ì·˙Â›Ó˘, ·ÏÔÂÚȉfiÏ˘, ·ÔÙÂÏ› Â›Û˘ ·ÓÙÈΛÌÂÓÔ ‰È·ÊˆÓÈÒÓ (47,48). ∂ÈϤÔÓ, ·ÌÊÈÛ‚ËÙÂ›Ù·È Î·È Ë ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ· Ù˘ ¯ÔÚ‹ÁËÛ˘ ·ÓÔÛÔÛÊ·ÈÚ›Ó˘ (49,50). ∏ ÂÍ·ÛÊ¿ÏÈÛË ‹Û˘¯Ô˘ Î·È ‹ÚÂÌÔ˘ ÂÚÈ‚¿ÏÏÔÓÙÔ˜ ıˆÚÂ›Ù·È fiÙÈ ‚ÔËı¿ ÙÔ˘Ï¿¯ÈÛÙÔÓ ÛÙȘ ‹Ș ÂÚÈÙÒÛÂȘ ¯ÔÚ›·˜ (19). ∞fi Ú·ÎÙÈ΋˜ ÏÂ˘Ú¿˜, Ì ‰Â‰Ô̤Ó˜ fiϘ ÙȘ ·Ú·¿Óˆ ·ÓÙÈÊ¿ÛÂȘ, Ë Û˘ÓÂÚÁ·Û›· Ó¢ÚÔÏfiÁÔ˘ Ì ÙÔÓ ·È‰›·ÙÚÔ Â›Ó·È ··Ú·›ÙËÙË ÁÈ· ÙËÓ ÂÈÏÔÁ‹ ÙÔ˘ ηٿÏÏËÏÔ˘ ıÂÚ·¢ÙÈÎÔ‡ Û¯‹Ì·ÙÔ˜. ªÂÙ·ÛÙÚÂÙÔÎÔÎÎÈ΋ ·ÚıÚ›Ùȉ· (ª™∞) ∆· ¯·Ú·ÎÙËÚÈÛÙÈο Ù˘ ª™∞, Ô˘ ÙË ‰È·ÊÔÚÔÔÈÔ‡Ó ·fi ÙÔÓ ÎÏ·ÛÈÎfi ƒ¶, ›ӷÈ: Ë ·Ú·ÌÔÓ‹ Ù˘ ·ÚıÚ›Ùȉ·˜ ÁÈ· ÌÂÚÈÎÔ‡˜ Ì‹Ó˜, Ô ÌË ÌÂÙ·Ó·ÛÙ¢ÙÈÎfi˜ ¯·Ú·ÎÙ‹Ú·˜, Ë ÂÓȯڋ ·ÓÙ·fiÎÚÈÛË ÛÙ· ÌË ÛÙÂÚÈÓÔÂȉ‹ ·ÓÙÈÊÏÂÁÌÔÓÒ‰Ë, ηıÒ˜ Î·È Ë ˘ÂÚÔ¯‹ ÙÔ˘ Á˘Ó·ÈΛԢ ʇÏÔ˘ ÌÂٷ͇ ÙˆÓ ÂÓ‹ÏÈÎˆÓ ·ÛıÂÓÒÓ. ¢ÂÓ Û˘Óԉ‡ÂÙ·È ·fi ΛӉ˘ÓÔ ÁÈ· ηډ›Ùȉ·, ·Ú¿ Ù·‡Ù·, ·Ó·Ê¤ÚÔÓÙ·È ·ÛıÂÓ›˜ Ô˘ ·ÚÔ˘Û›·Û·Ó ƒ∫ ηٿ ÙËÓ ÂÚ›Ô‰Ô ·Ú·ÎÔÏÔ‡ıËÛ˘. ¶ÚÔÊ·ÓÒ˜ ÛÙÔ˘˜ ·ÛıÂÓ›˜ ·˘ÙÔ‡˜ ˘‹ÚÍ ‰È·ÁÓˆÛÙÈ΋ ·ÛÙÔ¯›· Î·È ÂÚfiÎÂÈÙÔ ÁÈ· ƒ¶ Î·È fi¯È ª™∞ (51). ¶ÚÔÙ›ÓÂÙ·È ÁÈ· ÙË ª™∞ ÚÔʇϷÍË Ì i.m ÂÓÈÎÈÏ›ÓË ÁÈ· ¤Ó· ¯ÚfiÓÔ Û ÏËı˘ÛÌÔ‡˜ Ì ¯·ÌËÏfi ΛӉ˘ÓÔ ÁÈ· ƒ¶ Î·È ÁÈ· ¤ÓÙ ¯ÚfiÓÈ· Û ÏËı˘ÛÌÔ‡˜ Ì ˘„ËÏfi ΛӉ˘ÓÔ ÁÈ· ƒ¶ (19,22). ∫·Ù·Ï‹ÁÔÓÙ·˜, ÛËÌÂÈÒÓÔ˘Ì fiÙÈ, ·ÚfiÙÈ Û¯ÂÙÈ˙fiÌÂÓÔ˜ Ì ÌÈÎÚԂȷ΋ Ïԛ̈ÍË, Ô ƒ¶ 2.500 ¯ÚfiÓÈ· ·fi ÙËÓ ÂÚÈÁÚ·Ê‹ ÙÔ˘ ·fi ÙÔÓ πÔÎÚ¿ÙË (53) ÂÍ·ÎÔÏÔ˘ı› Ó· ·ÊÔÚ¿ ÙËÓ ·ÁÎfiÛÌÈ· ÎÔÈÓfiÙËÙ· Ì ÛÔ‚·Ú¤˜ ÂÈÙÒÛÂȘ. ª¤¯ÚÈ Ó· ‰ÔıÔ‡Ó ÔÚÈÛÙÈÎfiÙÂÚ˜ χÛÂȘ ̤ۈ ÂÌ‚ÔÏÈ·ÛÌÒÓ ‹ ¿ÏÏ˘ ·Ú¤Ì‚·Û˘, ÂÈ‚¿ÏÏÂÙ·È Ë Â·ÁÚ‡ÓËÛË ÙˆÓ ÁÈ·ÙÚÒÓ, ÒÛÙÂ Ë ÓfiÛÔ˜ Ó· ·ÔʇÁÂÙ·È Î·Ù¿ ÙÔ ‰˘Ó·ÙfiÓ ‹ ¤ÛÙˆ Ó· ·Ó·ÁÓˆÚ›˙ÂÙ·È Î·È Ó· ·ÓÙÈÌÂÙˆ›˙ÂÙ·È Î·Ù¿ ÙÔÓ ÚÔÛÊÔÚfiÙÂÚÔ ÙÚfiÔ. µÈ‚ÏÈÔÁÚ·Ê›· 1. Carapetis JR, Currie BJ, Mathews JD. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? Epidemiol Infect 2000; 124:239-244.

2. Steer AC, Kado J, Colquhoun S, Noonan S, Babitu T. Awareness of rheumatic heart disease. Lancet 2006;367: 2118.

3. Tani LY, Veasy LG, Minich LL, Shaddy RE. Rheumatic fever in children younger than 5 years: is the presentation different? Pediatrics 2003;112:1065-1068.

4. Majeed HA, Batnager S, Yousof AM, Khuffash F, Yusuf AR. Acute rheumatic fever and the evolution of rheumatic heart disease: a prospective 12 year follow-up report. J Clin Epidemiol 1992;45:871-875.

5. Shulman ST. Streptococcal infections. In: Stevens D, Kaplan E, editors. Clinical aspects, microbiology and molecular pathogenesis. New York: Oxford University Press; 2000. p. 76-101.

6. Stollerman GH. Rheumatic fever in the 21st century. Clin Infect Dis 2001;33:806-14.

7. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat?

Lancet Infect Dis 2004;4:240-245.

8. Haidan A, Talay SR, Rohde M, Sriprakash KS, Currie BJ, Chhatwal GS. Pharyngeal carriage of group C and group G streptococci and acute rheumatic fever in an Aboriginal population. Lancet 2000;356:1167-1169.

9. Kalia A, Bessen DE. Presence of streptococcal pyrogenic exotoxin A and C genes in human isolates of group G streptococci. FEMS Microbiol Lett 2003;219:291-295.

10. Kalia A, Enright MC, Spratt BG, Bessen DE. Directional gene movement from human-pathogenic to commensallike streptococci. Infect Immun 2001;69:4858-4869.

11. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470-511.

12. Lymbury RS, Olive C, Powell KA, Good MF, Hirst RG, LaBrooy JT, et al. Induction of autoimmune valvulitis in Lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein. J Autoimmun 2003;20:211-217.

13. Kamblock J, Payot L, Iung B, Costes P, Gillet T, Le Goanvic C, et al. Does rheumatic myocarditis really exists? Systematic study with echocardiography and cardiac troponin I blood levels. Eur Heart J 2003;24:855-862.

14. Galvin JE, Hemric ME, Ward K, Cunningham MW. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest 2000;106:217-224.

15. Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease.

Front Biosci 2003;8:s533-543.

16. Roberts S, Kosanke S, Terrence Dunn S, Jankelow D, Duran CM, Cunningham MW. Pathogenic mechanisms in rheumatic carditis: focus on valvular endothelium. J Infect Dis 2001;183:507-511.

17. Guilherme L, Kalil J. Rheumatic fever: from sore throat to autoimmune heart lesions. Int Arch Allergy Immunol 2004;134:56-64.

18. Pichichero ME. Group A streptococcal vaccines. JAMA 2004;292:738-739.

19. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005;366:155-168.

20. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a metaanalysis. Eur Heart J 2004;25:527.

21. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group ¶·È‰È·ÙÚÈ΋ 2008;71:29-37

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·36

36

Ã. ∆Ú¿·ÏË Î·È Û˘Ó.

A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002;35:113-125.

22. Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation. World Health Organ Tech Rep Ser 2004;923:1-122.

23. Anon. United Kingdom and United States joint report: the natural history of rheumatic fever and rheumatic heart disease - ten-year report of a cooperative clinical trial of ACTH, cortisone, and aspirin. Circulation 1965;32:457-76.

24. Veasy LG, Tani LY, Hill HR. Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr 1994;124:9-16.

25. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev 2002;(3):CD002227.

26. Amir J, Ginat S, Cohen YH, Marcus TE, Keller N, Varsano I. Lidocaine as a diluent for administration of benzathine penicillin G. Pediatr Infect Dis J 1998;17:890-893.

27. Jones TD. The diagnosis of rheumatic fever. JAMA 1944;126:481-484.

28. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA 1992;268:2069-2073.

29. Taranta A. Factors influencing recurrent rheumatic fever.

Annu Rev Med 1967;18:159-172.

30. Feinstein AR, Spagnuolo M, Wood HF, Taranta A, Tursky E, Kleinberg E. Rheumatic fever in children and adolescents. A long-term epidemiologic study of subsequent prophylaxis, streptococcal infections, and clinical sequelae. VI. Clinical features of streptococcal infections and rheumatic recurrences. Ann Intern Med 1964;60:Suppl 5:68-86.

31. Hilaãrio MO, Andrade JL, Gasparian AB, Carvalho AC, Andrade CT, Len CA. The value of echocardiography in the diagnosis and followup of rheumatic carditis in children and adolescents: a 2 year prospective study. J Rheumatol 2000;27:1082-1086.

32. Figueroa FE, Fernaãndez MS, Valdés P, Wilson C, Lanas F, Carrifin F, et al. Prospective comparison of clinical and echocardiographic diagnosis of rheumatic carditis: long term follow up of patients with subclinical disease. Heart 2001;85:407-410.

33. Lanna CC, Tonelli E, Barros MV, Goulart EM, Mota CC. Subclinical rheumatic valvitis: a long-term follow-up. Cardiol Young 2003;13:431-438.

34. Vijayalakshmi IB, Mithravinda J, Deva AN. The role of echocardiography in diagnosing carditis in the setting of acute rheumatic fever. Cardiol Young 2005;15:583-588.

35. Minich LL, Tani LY, Pagotto LT, Shaddy RE, Veasy LG. Doppler echocardiography distinguishes between physiologic and pathologic “silent” mitral regurgitation in patients with rheumatic fever. Clin Cardiol 1997;20:924-926.

Paediatriki 2008;71:29-37

36. Nayar S, Nayar PG, Cherian KM. Heart valve structure: a predisposing factor for rheumatic heart disease. Heart 2006;92:1151-1152.

37. Cilliers A. Treating acute rheumatic fever. BMJ 2003;327: 631-632.

38. Illingworth RS, Lorber J, Holt KS, Rendle-Short J. Acute rheumatic fever in children; a comparison of six forms of treatment in 200 cases. Lancet 1957;273:653-659.

39. Bywaters EG, Thomas GT. Bed rest, salicylates, and steroid in rheumatic fever. Br Med J 1961;1:1628-1634.

40. Dorfman A, Gross JI, Lorincz AE. The treatment of acute rheumatic fever. Pediatrics 1961;27:692-706.

41. Albert DA, Harel L, Karrison T. The treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore) 1995;74:1-12.

42. Cilliers AM, Manyemba J, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev 2003;(2):CD003176.

43. Voss LM, Wilson NJ, Neutze JM, Whitlock RM, Ameratunga RV, Cairns LM, et al. Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial.

Circulation 2001;103:401-406.

44. Veasy LG, Tani LY. A new look at acute rheumatic mitral regurgitation. Cardiol Young 2005;15:568-577.

45. Câmara EJ, Braga JC, Alves-Silva LS, Câmara GF, da Silva Lopes AA. Comparison of an intravenous pulse of methylprednisolone versus oral corticosteroid in severe acute rheumatic carditis: a randomized clinical trial. Cardiol Young 2002;12:119-124.

46. Barash J, Margalith D, Matitiau A. Corticosteroid treatment in patients with Sydenham’s chorea. Pediatr Neurol 2005;32:205-207. ~ a J, Mora E, Cardozo J, Molina O, Montiel C. Compar47. Pen ison of the efficacy of carbamazepine, haloperidol and valproic acid in the treatment of children with Sydenham’s chorea: clinical follow-up of 18 patients. Arq Neuropsiquiatr 2002;60:374-377.

48. Walker K, Wilmshurst J. Acute rheumatic fever. Lancet 2005;366:1354-1355.

49. Swedo SE. Sydenham’s chorea. A model for childhood autoimmune neuropsychiatric disorders. JAMA 1994;272: 1788-1791.

50. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005;366:1355; author reply 1355-1356.

51. Shulman ST, Ayoub EM. Poststreptococcal reactive arthritis. Curr Opin Rheumatol 2002;14:562-565.

52. Taranta A, Markowitz M. Rheumatic fever and rheumatic heart disease. Cardiovascular problem in everyday practice. Switzerland: CIBA-GEIGY. 53. Hippocrates. The Genuine Works of Hippocrates. Vol. 2 Translated by Francis Adams. New York: William Wood and Co; 1986. p. 192-273.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·37

37

ƒÂ˘Ì·ÙÈÎfi˜ ˘ÚÂÙfi˜

Quiz 1. ∏ ˘„ËÏfiÙÂÚË Â›ÙˆÛË ÙÔ˘ ƒ¶ ·Ú·ÙËÚ›ٷÈ: ·. ™Ù· ·È‰È¿ ÚÈÓ ·fi ÙËÓ ÂÊ˂›· ‚. ™Â ÚÔÛ¯ÔÏÈ΋ ËÏÈΛ· Á. ™Â Ó·ÚÔ‡˜ ÂÓ‹ÏÈΘ 2. √ ÂÈÔÏ·ÛÌfi˜ Ù˘ ƒ∫ Â›Ó·È ÌÂÁ·Ï‡ÙÂÚÔ˜: ·. ™Ù· ·È‰È¿ ‚. ™ÙÔ˘˜ ÂÊ‹‚Ô˘˜ Á. ™ÙÔ˘˜ ÂÓ‹ÏÈΘ 3. ∏ ‰È¿ÚÎÂÈ· ıÂÚ·›·˜ Ù˘ ÛÙÚÂÙÔÎÔÎÎÈ΋˜ Ê·Ú˘ÁÁ›Ùȉ·˜ ›ӷÈ: ·. 10 Ë̤Ú˜ ‚. 1 ‚‰ÔÌ¿‰· Á. 2-3 Ë̤Ú˜ ÌÂÙ¿ ÙËÓ ˘Ô¯ÒÚËÛË ÙˆÓ Û˘ÌÙˆÌ¿ÙˆÓ 4. ŒÊË‚Ô˜ 17 ÂÙÒÓ Ì ‹È· ·ÓÂ¿ÚÎÂÈ· ÌÈÙÚÔÂȉԇ˜, ÏfiÁˆ ÔͤԘ ƒ¶, ÂÊfiÛÔÓ ‰ÂÓ ·ÚÔ˘ÛÈ¿ÛÂÈ ¿ÏÏÔ ÂÂÈÛfi‰ÈÔ, ı· Ú¤ÂÈ Ó· ¿ÚÂÈ ÚfiÏË„Ë: ·. °È· ÌÈ· 5ÂÙ›· ‚. °È· ÌÈ· 10ÂÙ›· Á. ø˜ ÙÔ 25Ô ¤ÙÔ˜ ‰. ∂Ê’ fiÚÔ˘ ˙ˆ‹˜ 5. ¶ÔÈfi˜ ·fi ÙÔ˘˜ ·Ú·Î¿Ùˆ ¤¯ÂÈ ÙÂÎÌËÚȈ̤ÓÔ ƒ¶: ·. 9¯ÚÔÓÔ˜ Ì ÈÛÙÔÚÈÎfi ÔÛÙÚ·ÎÈ¿˜, Ô˘ ¤¯ÂÈ ¯ÔÚ›· Î·È Ì¤ÙÚÈ· ·ÓÂ¿ÚÎÂÈ· ÌÈÙÚÔÂȉԇ˜ ‚. 9¯ÚÔÓÔ˜ Ì ¯ÔÚ›· Î·È ‹È· ·ÓÂ¿ÚÎÂÈ· ÌÈÙÚÔÂȉԇ˜ Á. ∫·È ÔÈ ‰‡Ô ‰. ∫·Ó¤Ó·˜ 6. 10¯ÚÔÓÔ˜ Ì ˘ÚÂÙfi, ·ÚıÚ·ÏÁ›·, Û˘Ìو̷ÙÔÏÔÁ›· ηډȷ΋˜ ·ÓÂ¿ÚÎÂÈ·˜ Î·È Û˘ÛÙÔÏÈÎfi ʇÛËÌ· 3/6 ÛÙËÓ ÎÔÚ˘Ê‹ Ì Â¤ÎÙ·ÛË ÛÙË Ì·Û¯¿ÏË ¤¯ÂÈ ÙÂÎÌËÚȈ̤ӷ ƒ¶, ÂÊfiÛÔÓ Û˘Ó˘¿Ú¯ÂÈ: ·. ∞˘ÍË̤ÓË ∆∫∂ ‚. ™ÙÚÂÙÔÎÔÎÎÈ΋ Ê·Ú˘ÁÁ›Ùȉ· ÚÔ 2-3 ‚‰ÔÌ¿‰ˆÓ Á. ∞˘ÍË̤ÓË CRP ‰. ¶·Ú¿Ù·ÛË ÙÔ˘ ‰È·ÛÙ‹Ì·ÙÔ˜ PR ÛÙÔ ∏∫° √È ÛˆÛÙ¤˜ ··ÓÙ‹ÛÂȘ ÛÙË ÛÂÏ›‰· 61

¶·È‰È·ÙÚÈ΋ 2008;71:29-37

Pediatri Jan-Feb 08

15-02-08

38

11:00

™ÂÏ›‰·38

µƒ∞µ∂Àª∂¡∏ ∂ƒ°∞™π∞

AWARD-WINNING ARTICLE

∫ÏÈÓÈ΋ Î·È ÌÔÚȷ΋ ÌÂϤÙË ÙÔ˘ ÁÔÓȉ›Ô˘ MECP2 Û ·È‰È¿ Ì ÓÔËÙÈ΋ ˘ÛÙ¤ÚËÛË ÛÙÔÓ ÂÏÏËÓÈÎfi ÏËı˘ÛÌfi ∆Ì‹Ì· π·ÙÚÈ΋˜ °ÂÓÂÙÈ΋˜ ¶·ÓÂÈÛÙËÌ›Ô˘ ∞ıËÓÒÓ, ÈڤÌÂÈÔ ∂Ú¢ÓËÙÈÎfi ∂ÚÁ·ÛÙ‹ÚÈÔ, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ “∞Á›· ™ÔÊ›·” AÏÏËÏÔÁÚ·Ê›·: ™Ù·˘ÚԇϷ æÒÓË psonistavroula@gmail.com ∆Ì‹Ì· π·ÙÚÈ΋˜ °ÂÓÂÙÈ΋˜ ¶·ÓÂÈÛÙËÌ›Ô˘ ∞ıËÓÒÓ, ÈڤÌÂÈÔ ∂Ú¢ÓËÙÈÎfi ∂ÚÁ·ÛÙ‹ÚÈÔ, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ “∞Á›· ™ÔÊ›·” £Ë‚ÒÓ Î·È §Â‚·‰Â›·˜, ∆.∫. 115 27, ∞ı‹Ó·

™. æÒÓË, J. Traeger-Synodinos, Ã. ™ÔÊÔÎÏ¤Ô˘˜, ™. ∫›ÙÛÈÔ˘-∆˙¤ÏË, ∞. ª·‡ÚÔ˘, ∂. ∫·Ó·‚¿Î˘, Œ. ºÚ˘Û›Ú· ¶ÂÚ›ÏË„Ë ∂ÈÛ·ÁˆÁ‹: ªÂÙ·ÏÏ¿ÍÂȘ ÛÙÔ ÁÔÓ›‰ÈÔ MECP2 ¢ı‡ÓÔÓÙ·È ÁÈ· ÙÔ 60-95% ÙˆÓ ÂÚÈÙÒÛÂˆÓ Û˘Ó‰ÚfiÌÔ˘ Rett (RS), ÌÈ·˜ Ê˘ÏÔÛ‡Ó‰ÂÙ˘, ÂÈÎÚ·ÙËÙÈ΋˜, Ó¢ÚÔ·Ó·Ù˘Íȷ΋˜ ‰È·Ù·Ú·¯‹˜ Ô˘ ÂËÚ¿˙ÂÈ Î˘Ú›ˆ˜ ÎÔÚ›ÙÛÈ·. ∆Ô ÎÏ·ÛÈÎfi RS ¯·Ú·ÎÙËÚ›˙ÂÙ·È ·fi Ê˘ÛÈÔÏÔÁÈ΋ ÚÒÈÌË ·Ó¿Ù˘ÍË, ·ÎÔÏÔ˘ıÔ‡ÌÂÓË ·fi „˘¯ÔÎÈÓËÙÈ΋ ·ÏÈÓ‰ÚfiÌËÛË Î·È ÛÙ·‰È·Î‹ ¤Ó·ÚÍË ÌÈÎÚÔÎÂÊ·Ï›·˜, ÂÓÒ ·Ú·ÙËÚÔ‡ÓÙ·È ·ÚÎÂÙ¤˜ ¿Ù˘˜ ÌÔÚʤ˜. ∆Ô MECP2 ÂÌϤÎÂÙ·È Â›Û˘ Û ÌÈ· ÔÈÎÈÏ›· Ê·ÈÓÔÙ‡ˆÓ Ì „˘¯ÔÎÈÓËÙÈ΋ ηı˘ÛÙ¤ÚËÛË (æ∫∫), fiˆ˜ Ê˘ÏÔÛ‡Ó‰ÂÙË ÔÈÎÔÁÂÓ‹ æ∫∫ Î·È ÂÈÎfiÓ˜ ÔÌÔÈ¿˙Ô˘Û˜ Ì ۇӉÚÔÌÔ Â‡ıÚ·˘ÛÙÔ˘-à (FXS) Î·È Û‡Ó‰ÚÔÌÔ Angelman (AS). ™ÎÔfi˜ Ù˘ ÌÂϤÙ˘ Â›Ó·È Ë ‰ÈÂÚ‡ÓËÛË Ù˘ Û˘¯ÓfiÙËÙ·˜ Î·È ÙÔ˘ Ê¿ÛÌ·ÙÔ˜ ÙˆÓ MECP2 ÌÂÙ·ÏÏ¿ÍÂˆÓ ÛÙÔÓ ÂÏÏËÓÈÎfi ÏËı˘ÛÌfi Î·È Ë Û˘Û¯¤ÙÈÛË ÁÔÓÔÙ‡Ô˘-Ê·ÈÓÔÙ‡Ô˘. ª¤ıÔ‰ÔÈ: ∞ӷχıËÎ·Ó Ù· ÂÍfiÓÈ· 3 Î·È 4 Ì ËÏÂÎÙÚÔÊfiÚËÛË Û ‹Îو̷ Ì ÎÏ›ÛË ·ԉȷٷÎÙÈÎÔ‡ (DGGE - Denaturant Gradient Gel Electrophoresis), ¿ÌÂÛÔ ÚÔÛ‰ÈÔÚÈÛÌfi ·ÏÏËÏÔ˘¯›·˜ DNA Î·È GAPPCR ÛÂ: ∞. 124 ·È‰È¿ (102 ·ÁfiÚÈ·-22 ÎÔÚ›ÙÛÈ·) Î·È 41 ·È‰È¿ (14 ·ÁfiÚÈ·-27 ÎÔÚ›ÙÛÈ·) Ì ʷÈÓfiÙ˘Ô ·ÚfiÌÔÈÔ Ì FXS Î·È AS ·ÓÙ›ÛÙÔȯ·, ·ÏÏ¿ ·ÚÓËÙÈÎfi ÌÔÚÈ·Îfi ¤ÏÂÁ¯Ô, µ. 23 Î·È 25 ÎÔÚ›ÙÛÈ· Ì ÎÏ·ÛÈÎfi Î·È ¿Ù˘Ô RS, ·ÓÙ›ÛÙÔȯ· Î·È °. 11 ·ÁfiÚÈ· Ô˘ ÚÔÛ‹Ïı·Ó Ì Èı·Ófi RS. ŒÁÈÓ ÛÙ·ÙÈÛÙÈ΋ ·Ó¿Ï˘ÛË ÁÈ· Û˘Û¯¤ÙÈÛË ÙÔ˘ ÎÏÈÓÈÎÔ‡ score ‚·Ú‡ÙËÙ·˜ (Kerr, 2001) Ì ÙÔÓ Ù‡Ô ÙˆÓ MECP2 ÌÂÙ·ÏϿ͈Ó. ∞ÔÙÂϤÛÌ·Ù·: ªÂÙ·ÏÏ¿ÍÂȘ ·ÓȯÓ‡ıËÎ·Ó Û 78,3% Î·È 20% ÂÚÈÙÒÛÂȘ ÎÏ·ÛÈÎÔ‡ Î·È ¿Ù˘Ô˘ RS, ·ÓÙ›ÛÙÔȯ·. ŒÓ· ·ÁfiÚÈ ·ÚÔ˘Û›·Û ÙË ÌÂÙ¿ÏÏ·ÍË p.R106W Î·È ¤Ó· ¿ÏÏÔ ÌÂÁ¿ÏË ÁÔÓȉȷ΋ ·Ó·Î·Ù¿Ù·ÍË Ô˘ ··ÈÙ› ÂÚ·ÈÙ¤Úˆ ‰ÈÂÚ‡ÓËÛË. 7,3% Î·È 2,4% ÙˆÓ FXS Î·È AS ÔÌ¿‰ˆÓ, ·ÓÙ›ÛÙÔȯ·, ›¯·Ó ÌÂÙ·ÏÏ¿ÍÂȘ, ÂÚÈÏ·Ì‚¿ÓÔÓÙ·˜ Î·È Ì›· ÂÚ›ÙˆÛË Ê˘ÏÔÛ‡Ó‰ÂÙ˘ ÔÈÎÔÁÂÓÔ‡˜ æ∫∫. ™˘ÌÂÚ¿ÛÌ·Ù·: ∏ ·Ó¿Ï˘ÛË ÙÔ˘ ÁÔÓȉ›Ô˘ MECP2 ·Ú¤¯ÂÈ ¤Ó· ηٿÏÏËÏÔ ‰È·ÁÓˆÛÙÈÎfi ÂÚÁ·ÏÂ›Ô ÁÈ· ÙÔ RS Î·È Û˘ÓÂÈÛʤÚÂÈ ÛÙËÓ ¤Ú¢ӷ Ù˘ ÓÔËÙÈ΋˜ ˘ÛÙ¤ÚËÛ˘.

§¤ÍÂȘ ÎÏÂȉȿ: MECP2, Û‡Ó‰ÚÔÌÔ Rett, ÓÔËÙÈ΋ ˘ÛÙ¤ÚËÛË.

Clinical studies and analysis of the MECP2 gene in children with mental retardation in the Greek population Medical Genetics, University of Athens, Choremio Research Laboratory, “Aghia Sophia” Children’s Hospital, Athens, Greece Correspondence: Stavroula Psoni psonistavroula@gmail.com Medical Genetics, University of Athens, Choremio Research Laboratory, “Aghia Sophia” Children’s Hospital Thivon & Levadias St., 115 27, Athens, Greece

S. Psoni, J. Traeger-Synodinos, C. Sofokleous, S. Kitsiou-Tzeli, A. Mavrou, E. Kanavakis, H. Fryssira Abstract Background: Mutations in the MECP2 gene (methyl-CpG-binding protein 2) are responsible for 70-95% of cases of Rett syndrome (RS), an X-linked dominant neurodevelopmental disorder, affecting mostly girls.

Classical RS is characterized by normal early development, followed by psychomotor regression and gradual onset of microcephaly, although variable atypical forms are also observed. MECP2 has also been implicated in a variety of other mental retardation (MR) phenotypes, including X-linked Mental Retardation (XLMR), Fragile-X Syndrome (FXS) -like and Angelman Syndrome (AS) -like phenotypes. The aim of the study was: a) To evaluate the incidence and spectrum of MECP2 mutations in children with RS and atypical MR; b) ∆o make phenotype-genotype correlation.

Methods: Exons 3 and 4 were analysed using Denaturant Gradient Gel Electrophoresis, sequencing and GAP-PCR in: A. 124 FXS-like children (102 males-22 females) and 41 AS-like children (14 males-27 females) negative for gene variation at FXS and AS loci, respectively; B. 23 classic and 25 atypical RS girls; C. 11 boys referred with possible RS. Statistical analysis included correlation of the RS clinical severity score (Kerr, 2001) with MECP2 mutations, and frequency of MECP2 mutations in the various patient categories.

Results: Mutations were detected in 78.3% of classic and 20% of atypical RS cases respectively. One boy carried the p.R106W mutation, and another boy showed a large rearrangement requiring further characterization. Amongst AS- and FXS-like cases, 7.3% and 2.4% had MECP2 mutations respectively, including an XLMR case.

Conclusions: MECP2 gene analysis provides an appropriate diagnostic tool for RS and contributes further information for research into MR.

Key words: MECP2, Rett syndrome, mental retardation.

Paediatriki 2008;71:38-47

∞’ ÈڤÌÂÈÔ Œ·ıÏÔ, 45Ô ¶·ÓÂÏÏ‹ÓÈÔ ¶·È‰È·ÙÚÈÎfi ™˘Ó¤‰ÚÈÔ, 25-27 ª·˝Ô˘ 2007, ÷ÏÎȉÈ΋

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·39

39

∫ÏÈÓÈ΋ Î·È ÌÔÚȷ΋ ÌÂϤÙË ÙÔ˘ ÁÔÓȉ›Ô˘ MECP2

¶›Ó·Î·˜ 1·. ∞Ó·Óˆ̤ӷ ÎÏÈÓÈο ÎÚÈÙ‹ÚÈ· ÁÈ· ÙÔ ÎÏ·ÛÈÎfi RS (3)

™˘ÓÙÔÌÔÁڷʛ˜ RS ª∂CP2 Kb ªµP MBD TRD NLS æ∫∫ AS FXS PCR DGGE CDKL5 HDAC Ac æ∫∂ ¶∫ πVF EEG SMA II XLMR ··

Rett Syndrome ªethyl-CpG-Binding-Protein 2 Kilobases Methyl-Binding-Proteins Methyl-Binding-Domain Transcription-Repression-Domain Nuclear-Localization-Signal æ˘¯ÔÎÈÓËÙÈ΋ ∫·ı˘ÛÙ¤ÚËÛË Angelman Syndrome Fragile-X Syndrome Polymerase Chain Reaction Denaturant Gradient Gel Electrophoresis Cyclin Dependent Kinase-Like 5 Histone Deacetylase Acetyl æ˘¯ÔÎÈÓËÙÈ΋ ∂ͤÏÈÍË ¶ÂÚ›ÌÂÙÚÔ˜ ∫ÂÊ·Ï‹˜ In Vitro Fertilization ∂lectroencephalogram Spinal Muscular ∞trophy II X-Linked Mental Retardation ·ÌÈÓÔͤ·

∂ÈÛ·ÁˆÁ‹ ∆Ô Û‡Ó‰ÚÔÌÔ Rett (RS) Â›Ó·È Ê˘ÏÔÛ‡Ó‰ÂÙË, ÂÈÎÚ·ÙËÙÈ΋, ÎÏËÚÔÓÔÌÈ΋, Ó¢ÚÔ·Ó·Ù˘Íȷ΋ ‰È·Ù·Ú·¯‹ Î·È ·ÔÙÂÏ› ÙË ‰Â‡ÙÂÚË ·ÈÙ›· ÓÔËÙÈ΋˜ ˘ÛÙ¤ÚËÛ˘ ÛÙ· ÎÔÚ›ÙÛÈ· ÌÂÙ¿ ÙÔ Û‡Ó‰ÚÔÌÔ Down (1). ∂ÌÊ·Ó›˙ÂÙ·È ÛÔÚ·‰Èο ÌÂ Û˘¯ÓfiÙËÙ· 1/10.00015.000 ÁÂÓÓ‹ÛÂȘ ·ÁÎÔÛÌ›ˆ˜ (2). ÷ڷÎÙËÚ›˙ÂÙ·È ·fi ÔÌ·Ï‹ „˘¯ÔÎÈÓËÙÈ΋ ÂͤÏÈÍË Ì¤¯ÚÈ ÙÔ˘˜ 6-12 Ì‹Ó˜ ˙ˆ‹˜, ÂÓ Û˘Ó¯›· ÛÙ·‰È·Î‹ ÌÈÎÚÔÎÂÊ·Ï›·, ·ÏÈÓ‰ÚfiÌËÛË ÙˆÓ ·ÔÎÙËıÂÈÛÒÓ ÁÓˆÛÙÈÎÒÓ Î·È ÎÈÓËÙÈÎÒÓ ÈηÓÔÙ‹ÙˆÓ Ì ÂÁηٿÛÙ·ÛË Ù˘ÈÎÒÓ ÛÙÂÚÂÔÙ˘ÈÎÒÓ ÎÈÓ‹ÛÂˆÓ ÙˆÓ ¯ÂÚÈÒÓ, ·˘ÙÈÛÙÈÎÒÓ Ù¿ÛÂˆÓ Î·È ‰˘ÛÚ·Í›·˜ ‚¿‰ÈÛ˘. ªÂÙ¿ ÙÔ ÛÙ¿‰ÈÔ Ù˘ ·ÏÈÓ‰ÚfiÌËÛ˘, Û˘Ó‹ıˆ˜ ·Ú·ÙËÚÂ›Ù·È ÂÚ›Ô‰Ô˜ ÛÙ·ÛÈÌfiÙËÙ·˜. ™˘ÓÔ‰¤˜ ÂΉËÏÒÛÂȘ Â›Ó·È ÂÂÈÛfi‰È· ¿ÓÔÈ·˜-˘¤ÚÓÔÈ·˜, ËÏÂÎÙÚÔÂÁÎÂÊ·ÏÔÁÚ·ÊÈΤ˜ ·ÓˆÌ·Ï›Â˜, Û·ÛÌÔ›, ˘ÂÚÙÔÓ›·-·ÙÚÔÊ›· ¿ÎÚˆÓ Î·È ÛÎÔÏ›ˆÛË (3) (¶›Ó·Î·˜ 1·). ∏ ÌÔÚȷ΋ ‚Ï¿‚Ë ÔÊ›ÏÂÙ·È Û ÌÂÙ·ÏÏ¿ÍÂȘ ÙÔ˘

∫Ï·ÛÈÎfi RS ªÂ›˙ÔÓ· ∫ÚÈÙ‹ÚÈ· 1. º˘ÛÈÔÏÔÁÈ΋ ÚÔÁÂÓÓËÙÈ΋ Î·È ÂÚÈÁÂÓÓËÙÈ΋ ÂÚ›Ô‰Ô˜ 2. º˘ÛÈÔÏÔÁÈ΋ æ∫∂ ÙÔ˘˜ ÚÒÙÔ˘˜ 6 Ì‹Ó˜ 3. º˘ÛÈÔÏÔÁÈ΋ ¶∫ ÛÙË Á¤ÓÓËÛË 4. ∂È‚Ú¿‰˘ÓÛË ÙÔ˘ Ú˘ıÌÔ‡ ·Ó¿Ù˘Í˘ Ù˘ ¶∫ 5. ∞ÒÏÂÈ· ÛÎfiÈÌˆÓ ÎÈÓ‹ÛÂˆÓ ¯ÂÚÈÒÓ ÌÂٷ͇ 6 ÌËÓÒÓ Î·È 2 1/2 ÂÙÒÓ 6. ™ÙÂÚÂÔÙ˘›Â˜ ¯ÂÚÈÒÓ 7. ∂ÍÂÏÈÛÛfiÌÂÓË ÎÈÓËÙÈ΋ ·fiÛ˘ÚÛË, ‰˘ÛÎÔÏ›· ÂÈÎÔÈÓˆÓ›·˜, ·ÒÏÂÈ· ·ÔÎÙËı¤ÓÙÔ˜ ÏfiÁÔ˘ Î·È ÁÓˆÛÙÈο ÂÏÏ›ÌÌ·Ù· ∂Ï¿ÛÛÔÓ· ÎÚÈÙ‹ÚÈ· 1. ¢È·Ù·Ú·¯‹ ·Ó·ÓÔ‹˜ ηٿ ÙËÓ ÂÁÚ‹ÁÔÚÛË 2. ∆ÚÈÛÌfi˜ Ô‰fiÓÙˆÓ 3. ∞ÓÒÌ·ÏÔ ÚfiÙ˘Ô ‡ÓÔ˘ ·fi ÙË ÓÂÔÁÓÈ΋ ÂÚ›Ô‰Ô 4. ∞ÓÒÌ·ÏÔ˜ Ì˘˚Îfi˜ ÙfiÓÔ˜ Û˘Ó‰ÂfiÌÂÓÔ˜ Ì ·ÙÚÔÊ›· Î·È ‰˘ÛÙÔÓ›· 5. ¶ÂÚÈÊÂÚÈΤ˜ ·ÁÁÂÈÔÎÈÓËÙÈΤ˜ ‰È·Ù·Ú·¯¤˜ 6. ¶ÚÔԉ¢ÙÈ΋ ·ʈÛË-ÛÎÔÏ›ˆÛË 7. ∫·ı˘ÛÙ¤ÚËÛË ·Ó¿Ù˘Í˘ 8. ÀÔÙÚÔÊÈο ÌÈÎÚ¿ Î·È ÎÚ‡· ¿ÎÚ· ∫ÚÈÙ‹ÚÈ· ·ÔÎÏÂÈÛÌÔ‡ 1. ŒÓ‰ÂÈÍË ·ÔıËÛ·˘ÚÈÛÙÈ΋˜ ÓfiÛÔ˘ Î·È ÔÚÁ·ÓÔÌÂÁ·Ï›· 2. ∫·Ù·ÚÚ¿ÎÙ˘, ·ÌÊÈ‚ÏËÛÙÚÔÂȉÔ¿ıÂÈ· ‹ Î·È ·ÙÚÔÊ›· ÔÙÈÎÔ‡ Ó‡ÚÔ˘ 3. πÛÙÔÚÈÎfi ÂÁÎÂÊ·ÏÈ΋˜ ‚Ï¿‚˘ ÚÔ- ‹ Î·È ÌÂÙ·ÁÂÓÓËÙÈο 4. ∂Ȃ‚·ÈˆÌ¤ÓË ÌÂÙ·‚ÔÏÈ΋ ‰È·Ù·Ú·¯‹ ‹ Ó¢ÚÔÂÎÊ˘ÏÈÛÙÈ΋ ÓfiÛÔ˜ 5. ∂›ÎÙËÙË Ó¢ÚÔÏÔÁÈ΋ ‰È·Ù·Ú·¯‹ ÏfiÁˆ ÂÁÎÂÊ·ÏÈÎÔ‡ ÙÚ·‡Ì·ÙÔ˜ ‹ Ïԛ̈͢ ∞·ÈÙÔ‡ÓÙ·È Î·È Ù· 6 Ì›˙ÔÓ· ÎÚÈÙ‹ÚÈ· ‹ 4/6 Ì›˙ÔÓ· Î·È ÙÔ˘Ï¿¯ÈÛÙÔÓ 2 ÂÏ¿ÛÛÔÓ·

ÁÔÓȉ›Ô˘ MECP2 (ªethyl-CpG-Binding-Protein 2), ÙÔ ÔÔ›Ô ¤¯ÂÈ ¯·ÚÙÔÁÚ·ÊËı› ÛÙÔ ÁÂÓÂÙÈÎfi ÙfiÔ Ãq28 (4). Œ¯ÂÈ Ì¤ÁÂıÔ˜ 76 kb Î·È ·ÔÙÂÏÂ›Ù·È ·fi 4 ÂÍfiÓÈ·, Ù· ÔÔ›· ˘fiÎÂÈÓÙ·È Û ÂÓ·ÏÏ·ÎÙÈÎfi Ì¿ÙÈÛÌ·, ‰›‰ÔÓÙ·˜ Á¤ÓÂÛË Û ‰‡Ô ÚˆÙÂ˚ÓÈΤ˜ ÈÛÔÌÔÚʤ˜ (ªeCP2∞-486 ··, ªeCP2B-449 ··) (∂ÈÎfiÓ· 1). ∏ ªeCP2B ΢Úȷگ› ÛÙÔ˘˜ ÂÁÎÂÊ·ÏÈÎÔ‡˜ ÈÛÙÔ‡˜ Î·È Â˘ı‡ÓÂÙ·È ÂÚÈÛÛfiÙÂÚÔ ÁÈ· ÙÔ Ê·ÈÓfiÙ˘Ô (5). ¡LS (·· 255-271)

ªBD TRD (·· 78-162) (·· 207-310)

5'

1

2

3

C-terminus (·· 311-486)

∂ÍfiÓÈÔ 4

3'

∂ÈÎfiÓ· 1. To ÁÔÓ›‰ÈÔ MECP2 Î·È ÔÈ ÏÂÈÙÔ˘ÚÁÈÎÔ› ÙÔÌ›˜ ÙÔ˘. MBD: ªethyl-Binding-Domain, TRD: Transcription-Repression-Domain, NLS: Nuclear-Localisation-Signal, C-Terminus: ηڂÔ͢ÙÂÏÈÎfi ¿ÎÚÔ, ··: ·ÌÈÓÔͤ·. ¶·È‰È·ÙÚÈ΋ 2008;71:38-47

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·40

40

™. æÒÓË Î·È Û˘Ó.

∆Ô MECP2 ·Ó‹ÎÂÈ ÛÙËÓ ÔÈÎÔÁ¤ÓÂÈ· ªBP (Methyl-Binding Proteins), Û˘Ó‰¤ÂÙ·È Û ÌÂı˘ÏȈ̤Ó˜ ·ÏÏËÏÔ˘¯›Â˜ DNA Î·È Î·Ù·ÛÙ¤ÏÏÂÈ ÙË ÁÔÓȉȷ΋ ÌÂÙ·ÁÚ·Ê‹ (6). ¶ÂÚȤ¯ÂÈ ÙÔ˘˜ ÏÂÈÙÔ˘ÚÁÈÎÔ‡˜ ÙÔÌ›˜ ªBD, ∆RD Î·È ¡LS (EÈÎfiÓ· 2). ∞Ú¯Èο ıˆڋıËΠÁÂÓÈÎfi˜ ÌÂÙ·ÁÚ·ÊÈÎfi˜ ηٷÛÙÔϤ·˜. øÛÙfiÛÔ, ÂÚ¢ÓËÙÈο ‰Â‰Ô̤ӷ ˘Ô‰ÂÈÎÓ‡Ô˘Ó fiÙÈ Û˘Ó‰¤ÂÙ·È ÌÂ Û˘ÁÎÂÎÚÈ̤ӷ ÁÔÓ›‰È·-ÛÙfi¯Ô˘˜ ÛÙÔÓ ÂÁΤʷÏÔ, Ú˘ıÌ›˙ÔÓÙ·˜ ÙËÓ ¤ÎÊÚ·Û‹ ÙÔ˘˜ (7,8). ™Â ÎÏÈÓÈÎfi Â›‰Ô, oÈ ÂΉËÏÒÛÂȘ ÙÔ˘ RS Û¯ÂÙ›˙ÔÓÙ·È Ì ÙË Û˘Ó·ÙÈ΋ ÏÂÈÙÔ˘ÚÁ›· ÛÙÔÓ ·Ó·Ù˘ÛÛfiÌÂÓÔ ÂÁΤʷÏÔ Î·È ÙËÓ ˆÚ›Ì·ÓÛË ÙˆÓ Ó¢ÚÒÓˆÓ (9). ∞Ô̤ÓÂÈ Ó· ·Ô‰Âȯı› ÔÈ· Â›Ó·È ·ÎÚÈ‚Ò˜ Ù· ÁÔÓ›‰È·-ÛÙfi¯ÔÈ Î·È Ò˜ ηıÔÚ›˙Ô˘Ó ÙËÓ ·Ó¿Ù˘ÍË Î·È ‰È·Ù‹ÚËÛË ÙˆÓ ÂÁÎÂÊ·ÏÈÎÒÓ Û˘Ó¿„ˆÓ. ªÂÙ¿ÏÏ·ÍË ÙÔ˘ MECP2 ‰ÂÓ ÈÛÔ‰˘Ó·Ì› ¿ÓÙ· Ì ‰È¿ÁÓˆÛË RS. Œ¯Ô˘Ó ·Ó·ÁÓˆÚÈÛı› ·ÚÎÂÙ¤˜ ¿Ù˘˜ ÌÔÚʤ˜ RS: ·. ÓÂÔÁÓÈÎfi˜ Ù‡Ô˜ Ì Û·ÛÌÔ‡˜, ‚. Û˘ÁÁÂÓ‹˜ Ù‡Ô˜, Á. ÂÎÙÚˆÙÈ΋ ÌÔÚÊ‹, ‰. ‰È·Ù‹ÚËÛ˘ ÛÙÔȯ›ˆÓ ÏfiÁÔ˘ Î·È Â. fi„ÈÌ˘ ·ÏÈÓ‰ÚfiÌËÛ˘ (10) (¶›Ó·Î·˜ 1‚). ªÂÙ·ÏÏ¿ÍÂȘ ¤¯Ô˘Ó ·Ú·ÙËÚËı› Î·È Û ÏËıÒÚ· Ê·ÈÓÔÙ‡ˆÓ Ì „˘¯ÔÎÈÓËÙÈ΋ ηı˘ÛÙ¤ÚËÛË (æ∫∫) Ô˘ ‰ÂÓ Û¯ÂÙ›˙ÔÓÙ·È Ì RS, fiˆ˜ Û ·ÛıÂÓ›˜ Ì ÂÈÎfiÓ· Û˘Ó‰ÚfiÌÔ˘ Angelman (∞S), ÌË Û˘Ó‰ÚÔÌÈ΋ Ê˘ÏÔÛ‡Ó‰ÂÙË æ∫∫ Î·È ·˘ÙÈÛÙÈο ÛÙÔȯ›· (11-13). MECP2 ÌÂÙ·ÏÏ¿ÍÂȘ Û ·ÁfiÚÈ· ıˆÚÔ‡ÓÙ·Ó ¤ˆ˜ ÚfiÛÊ·Ù· ı·Ó·ÙËÊfiÚ˜. øÛÙfiÛÔ, ¤¯Ô˘Ó ÂÚÈÁÚ·Ê› ÂÚÈÙÒÛÂȘ ·ÁÔÚÈÒÓ ÌÂ: i) ÛÔ‚·-

Sin3A

¶›Ó·Î·˜ 1‚. ∞Ó·Óˆ̤ӷ ÎÏÈÓÈο ÎÚÈÙ‹ÚÈ· ÁÈ· ÙÔ ¿Ù˘Ô RS (3) ÕÙ˘Ô RS ∫‡ÚÈ· ÎÚÈÙ‹ÚÈ· 1. ªÂ›ˆÛË ‹ ·ÒÏÂÈ· ÙˆÓ ÈηÓÔÙ‹ÙˆÓ ÙˆÓ ¯ÂÚÈÒÓ 2. ªÂ›ˆÛË ‹ ·ÒÏÂÈ· ÙˆÓ ÏÂÎÙÈÎÒÓ ÈηÓÔÙ‹ÙˆÓ 3. ™ÙÂÚÂÔÙ˘›Â˜ ¯ÂÚÈÒÓ 4. ªÂ›ˆÛË ‹ ·ÒÏÂÈ· ÙˆÓ ÈηÓÔÙ‹ÙˆÓ ÂÈÎÔÈÓˆÓ›·˜ 5. ∂È‚Ú¿‰˘ÓÛË ÙÔ˘ Ú˘ıÌÔ‡ ·Ó¿Ù˘Í˘ Ù˘ ¶∫ ·fi ÙËÓ ÚÒÈÌË ·È‰È΋ ËÏÈΛ· 6. ¶·ÏÈÓ‰ÚfiÌËÛË ·ÎÔÏÔ˘ıÔ‡ÌÂÓË ·fi ÌÂÚÈ΋ ‚ÂÏÙ›ˆÛË ÀÔÛÙËÚÈÎÙÈο ÎÚÈÙ‹ÚÈ· 1. ∞ӈ̷ϛ˜ ·Ó·ÓÔ‹˜ 2. ªÂÙˆÚÈÛÌfi˜ ÎÔÈÏ›·˜ ‹ Î·È Î·Ù¿ÔÛË ·¤Ú· 3. ∆ÚÈÛÌfi˜ Ô‰fiÓÙˆÓ 4. ∞ÓÒÌ·ÏË ÎÈÓËÙÈÎfiÙËÙ· 5. ∫‡ÊˆÛË ‹ Î·È ÛÎÔÏ›ˆÛË 6. ∞ÙÚÔÊ›· οو ¿ÎÚˆÓ 7. ∫Ú‡·, ·ԯڈ̷ÙÈṲ̂ӷ Î·È Û˘Ó‹ıˆ˜ ˘ÔÙÚÔÊÈο fi‰È· 8. ¢È·Ù·Ú·¯¤˜ ‡ÓÔ˘ 9. ∞ÓÂÍ‹ÁËÙ· ÂÂÈÛfi‰È· ÎÚ·˘ÁÒÓ ‹ Á¤ÏˆÙÔ˜ 10. ∂ÌÊ·ÓÒ˜ ÌÂȈ̤ÓË Â˘·ÈÛıËÛ›· ÛÙÔÓ fiÓÔ 11. ŒÓÙÔÓË ‚ÏÂÌÌ·ÙÈ΋ Â·Ê‹ ‹ Î·È ÚÔۋψÛË ∞·ÈÙÔ‡ÓÙ·È 3 ·fi Ù· 6 ·ÚÈ· Î·È ÙÔ˘Ï¿¯ÈÛÙÔÓ 5 ˘ÔÛÙËÚÈÎÙÈο ÎÚÈÙ‹ÚÈ·

Ú‹ ÓÂÔÁÓÈ΋ ÂÁÎÂÊ·ÏÔ¿ıÂÈ·, ii) ÂÈÎfiÓ· ·ÚfiÌÔÈ· Ì RS, ÔÊÂÈÏfiÌÂÓË Û ̈۷˚ÎÈÛÌfi ‹ ˘ÂÚ¿ÚÈıÌÔ X ¯ÚˆÌfiۈ̷ Î·È iii) ÌË ÂȉÈ΋, ÌË ÂÍÂÏÈÛÛfiÌÂÓË æ∫∫ (14,15).

HDAC1 HDAC2

MeCP2 ∞c

¡ËÛ›‰Â˜ CpG

∞c ∞c ∞c

∞c

ÃÚˆÌfiۈ̷ Ã

HDAC1 Sin3A HDAC2 MeCP2

¡ËÛ›‰Â˜ CpG

ÃÚˆÌfiۈ̷ Ã

∂ÈÎfiÓ· 2. H MeCP2 Û˘Ó‰¤ÂÙ·È Ì¤Ûˆ ÙÔ˘ ÙÔ̤· MBD Û ÂȉÈΤ˜ ÌÂı˘ÏȈ̤Ó˜ ÓËÛ›‰Â˜ ÙÔ˘ DNA (CpG-ÓËÛ›‰Â˜), ÂÓÂÚÁÔÔÈÒÓÙ·˜ ¤Ó· ‚ÔËıËÙÈÎfi ηٷÛÙ·ÏÙÈÎfi ÌfiÚÈÔ, ÙÔ mSin3A, ÙÔ ÔÔ›Ô Û˘Ó‰¤ÂÙ·È Î·ÙfiÈÓ Ì ÙÔÓ ÙÔ̤· TRD. ∆Ô Û‡ÌÏÂÁÌ· ·˘Ùfi ÂÓÂÚÁÔÔÈ› ÙȘ ·Ô·ÎÂÙ˘Ï¿Û˜ ÙˆÓ ÈÛÙÔÓÒÓ 2 Î·È 2 (HDAC1, HDAC2), Ì ·ÔÙ¤ÏÂÛÌ· ÙËÓ ·Ô·ÎÂÙ˘Ï›ˆÛË ÙˆÓ ˘ÚËÓÈÎÒÓ ÈÛÙÔÓÒÓ Î·È ÙË Û˘Ì›ÂÛË ÙÔ˘ DNA Û ·ÓÂÓÂÚÁ‹ ÂÙÂÚԯڈ̷ٛÓË, ÌÂ Û˘Ó¤ÂÈ· ÙË ‰È·ÎÔ‹ Ù˘ ÌÂÙ·ÁÚ·Ê‹˜. Ac: ∞ÎÂÙ˘ÏÔÌ¿‰Â˜.

Paediatriki 2008;71:38-47

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·41

41

∫ÏÈÓÈ΋ Î·È ÌÔÚȷ΋ ÌÂϤÙË ÙÔ˘ ÁÔÓȉ›Ô˘ MECP2

¶›Ó·Î·˜ 2. ¶·Ú¿ÌÂÙÚÔÈ Ô˘ ÂÍÂÙ¿˙ÔÓÙ·È ÛÙËÓ Îϛ̷η ÎÏÈÓÈ΋˜ ·ÍÈÔÏfiÁËÛ˘ RS 1. ¶ÂÚ›ÌÂÙÚÔ˜ ÎÂÊ·Ï‹˜ (¶∫) ηٿ ÙË Á¤ÓÓËÛË 2. ¶ÚÒÈÌË ·Ó·Ù˘Íȷ΋ ÂͤÏÈÍË (0-12 ÌËÓÒÓ) 3. ¶·ÚÔ‡Û· (¶∫) 4. µ¿ÚÔ˜ 5. ⁄„Ô˜ 6. ª˘˚Îfi˜ ÙfiÓÔ˜ 7. ∫·Ù¿ÛÙ·ÛË ÛÔÓ‰˘ÏÈ΋˜ ÛÙ‹Ï˘ 8. ™˘Áο̄ÂȘ ·ÚıÚÒÛÂˆÓ 9. ∞‰Ú‹ ÎÈÓËÙÈÎfiÙËÙ· - µ¿‰ÈÛË 10. ™ÙÂÚÂfiÙ˘˜ ÎÈÓ‹ÛÂȘ ¯ÂÚÈÒÓ 11. ÕÏϘ ·ÎÔ‡ÛȘ ÎÈÓ‹ÛÂȘ (ÙÚfiÌÔ˜, ‰˘ÛÙÔÓ›·, ¯ÔÚ›·, ·ı¤ÙˆÛË) 12. ∂ÎÔ‡ÛÈ· ¯Ú‹ÛË ÙˆÓ ¯ÂÚÈÒÓ 13. ¢˘ÛÎÔÏ›· ÛÙËÓ ÎÈÓËÙÈÎfiÙËÙ· ÙˆÓ Ì˘ÒÓ Ù˘ ÛÙÔÌ·ÙÔÊ·Ú˘ÁÁÈ΋˜ ÂÚÈÔ¯‹˜ - ™›ÙÈÛË 14. ¢È·ÓÔËÙÈ΋ ÈηÓfiÙËÙ· - πηÓfiÙËÙ· Ì¿ıËÛ˘ 15. §fiÁÔ˜ 16. ∂ÈÏË„›· - ™·ÛÌÔ› 17. ¢È·Ù·Ú·Á̤ÓÔ˜ ·Ó·Ó¢ÛÙÈÎfi˜ Ú˘ıÌfi˜ (˘ÂÚ·ÂÚÈÛÌÔ›-¿ÓÔȘ) 18. ¶ÂÚÈÊÂÚÈ΋ ΢ÎÏÔÊÔÚ›· ¿ÎÚˆÓ 19. ¢È·Ù·Ú·¯¤˜ Û˘Ó·ÈÛı‹Ì·ÙÔ˜ (·Ó·›ÙÈ· Á¤ÏÈ·, ÎÚ·˘Á¤˜, ÎÏ¿Ì·Ù·) 20. ¢È·Ù·Ú·¯‹ ÚÔÙ‡Ô˘ ‡ÓÔ˘

ÓÔÙ‡Ô˘˜ Î·È ‰. ÌÂϤÙ˘ ÙˆÓ ·ÁÔÚÈÒÓ Ì ÌÂÙ·ÏÏ¿ÍÂȘ. ∏ ÛËÌ·Û›· Ù˘ ÌÂϤÙ˘ ¤ÁÎÂÈÙ·È, Â›Û˘, ÛÙËÓ ÚÔÛ¿ıÂÈ· ÁÈ· ηٷÓfiËÛË Î¿ÔÈˆÓ ·fi Ù· ·›ÙÈ· Ù˘ ÎÏÈÓÈο ·‰È¢ÎÚ›ÓÈÛÙ˘ æ∫∫.

ÀÏÈÎfi Î·È Ì¤ıÔ‰ÔÈ ∆Ô ˘ÏÈÎfi ·ÔÙ¤ÏÂÛ·Ó ‰‡Ô ÔÌ¿‰Â˜ ·È‰ÈÒÓ, ηÙfiÈÓ ¤ÁÁÚ·Ê˘ Û˘ÁηٿıÂÛ˘ ÙˆÓ ÁÔÓ¤ˆÓ ÙÔ˘˜. ™ÙËÓ ÚÒÙË ÔÌ¿‰· ÂÈϤÁËÛ·Ó ·Ó·‰ÚÔÌÈο 180 ‰Â›ÁÌ·Ù· ·›Ì·ÙÔ˜ ·fi ·È‰È¿ Ô˘ ›¯·Ó ÂÏÂÁ¯ı› ÌÔÚȷο ÙËÓ ÙÂÏÂ˘Ù·›· ‰ÂηÂÙ›· ÛÙÔ ∆Ì‹Ì· °ÂÓÂÙÈ΋˜ ÁÈ· Û‡Ó‰ÚÔÌÔ Fragile-X (FÃS) (n=137) Î·È AS (n=43) Ì ·ÚÓËÙÈο ·ÔÙÂϤÛÌ·Ù·. ∂ÎÙfi˜ ·fi ÙËÓ æ∫∫, ¤ÚÂ ӷ ˘¿Ú¯ÂÈ ÙÔ˘Ï¿¯ÈÛÙÔÓ ¤Ó· ·fi Ù· ·Ú·Î¿Ùˆ ÎÚÈÙ‹ÚÈ·: ·. Ê·ÈÓfiÙ˘Ô˜ ·ÚfiÌÔÈÔ˜ Ì FÃS ‹ AS, ‚. Ó¢ÚÔÏÔÁÈο ÚÔ‚Ï‹Ì·Ù· ¯ˆÚ›˜ ‰ÔÌÈΤ˜ ·ÓˆÌ·Ï›Â˜ ÂÁÎÂÊ¿ÏÔ˘ ÛÙÔ Ó¢ÚÔ·ÂÈÎÔÓÈÛÙÈÎfi ¤ÏÂÁ¯Ô, Á. ËÏÂÎÙÚÔÂÁÎÂÊ·ÏÔÁÚ·ÊÈΤ˜ ·ÓˆÌ·Ï›Â˜ Ì ‹ ¯ˆÚ›˜ Û·ÛÌÔ‡˜, ‰. ·Ô˘Û›· ÌÂÈ˙fiÓˆÓ ÌÔÚÊÔÏÔÁÈÎÒÓ ·ÓˆÌ·ÏÈÒÓ Î·È Â. ÔÈÎÔÁÂÓÂÈ·Îfi ÈÛÙÔÚÈÎfi æ∫∫. ªÔÚȷ΋ ·Ó¿Ï˘ÛË Î·Ù¤ÛÙË ‰˘Ó·Ù‹ Û 124 ·È‰È¿ (102 ·ÁfiÚÈ·-22 ÎÔÚ›ÙÛÈ·) Ù˘ FÃS-ÔÌ¿‰·˜. 16/124 ·È‰È¿ ›¯·Ó ·‰¤ÏÊÈ· Ì æ∫∫, Ù· ÔÔ›· ÂϤÁ¯ıËηÓ. ™ÙËÓ AS-ÔÌ¿‰· ÌÔÚȷ΋ ·Ó¿Ï˘ÛË ¤ÁÈÓ Û 41 ·È‰È¿ (14 ·ÁfiÚÈ·-27 ÎÔÚ›ÙÛÈ·). ™˘ÓÔÏÈο, ÂϤÁ¯ıËÎ·Ó 165 ·ÛıÂÓ›˜, ËÏÈΛ·˜ 1-27 ÂÙÒÓ. ™ÙË ‰Â‡ÙÂÚË ÔÌ¿‰· ÂÍÂÙ¿ÛıËÎ·Ó ·È‰È¿ ÚÔÛÂÚ¯fiÌÂÓ· Ì ‰È¿ÁÓˆÛË RS ÙÔ ‰È¿ÛÙËÌ· 2000-2006 (n=69). §fiÁÔ˘˜

µ·ıÌÔÏÔÁ›·: 3 ‚·ıÌ›‰Â˜ ‚·Ú‡ÙËÙ·˜ (2, 1, 0) Score: 0-40

H ÂÎÙÂÓ‹˜ ·Ó¿Ï˘ÛË ÙÔ˘ ÁÔÓȉ›Ô˘ MECP2 ·fi ÙÔ 1999 ¤ˆ˜ Û‹ÌÂÚ· ¤¯ÂÈ ·Ôηχ„ÂÈ ÂÚÈÛÛfiÙÂÚ˜ ·fi 255 ÌÂÙ·ÏÏ¿ÍÂȘ (16). √È ÔÎÙÒ Û˘¯ÓfiÙÂÚ˜ ηχÙÔ˘Ó ÙÔ 65% fiÏˆÓ ÙˆÓ ÌÂÙ·ÏÏ¿ÍÂˆÓ (17). 10% Â›Ó·È ÌÈÎÚ¿ ÂÏÏ›ÌÌ·Ù· (20-150 bp) ÛÙÔ Î·Ú‚Ô͢ÙÂÏÈÎfi ¿ÎÚÔ, Û ÌÈ· ÂÚÈÔ¯‹ Ì ÔÏÏ¿ Â·Ó·ÏËÙÈο ÛÙÔȯ›· ÌÂٷ͇ ÙˆÓ Îˆ‰ÈÎÔÓ›ˆÓ 1040-1200 Î·È ÂÈÚÚ¤ÂÈ· ÁÈ· ıÚ·‡ÛË ÙÔ˘ DNA (18). ªÔÚȷ΋ ‰È¿ÁÓˆÛË, Ì Ù¯ÓÈΤ˜ ‚·ÛÈṲ̂Ó˜ ÛÙËÓ PCR, ÚÔÛʤÚÂÙ·È ÛÙÔ 60-85% ÙˆÓ ÂÚÈÙÒÛÂˆÓ ÙÔ˘ ÎÏ·ÛÈÎÔ‡ Î·È ÛÙÔ 30-45% ÙÔ˘ ¿Ù˘Ô˘ RS (16). ∏ ¯ÚËÛÈÌÔÔ›ËÛË ÓÂfiÙÂÚˆÓ ÌÂıfi‰ˆÓ ÁÈ· ·Ó›¯Ó¢ÛË ÌÂÁ¿ÏˆÓ ·Ó·Î·Ù·Ù¿ÍÂˆÓ ·Ó‚¿˙ÂÈ ÙÔ ÔÛÔÛÙfi ‰È¿ÁÓˆÛ˘ ÛÙÔ 95% (19). ∆Ô ÂÍfiÓÈÔ 1 ¤¯ÂÈ ·Ú¯›ÛÂÈ Ó· ÌÂÏÂÙ¿Ù·È ÚfiÛÊ·Ù· Î·È Ê·›ÓÂÙ·È Ó· Û˘Ì‚¿ÏÏÂÈ ÌfiÓÔ Î·Ù¿ 0,5%, ÂÓÒ ÛÙÔ ÂÍfiÓÈÔ 2 ‰ÂÓ ¤¯Ô˘Ó ·Ú·ÙËÚËı› ÌÂÙ·ÏÏ¿ÍÂȘ (16). ™ÎÔfi˜ Ù˘ ·ÚÔ‡Û·˜ ÌÂϤÙ˘ ‹Ù·Ó Ë ‰ÈÂÚ‡ÓËÛË ÛÙÔÓ ÂÏÏËÓÈÎfi ÏËı˘ÛÌfi ÙÔ˘ ›‰Ô˘˜ Î·È ÙÔ˘ ·ÚÈıÌÔ‡ ÙˆÓ ÌÂÙ·ÏÏ¿ÍÂˆÓ ÛÙÔ ÁÔÓ›‰ÈÔ MECP2, Û ·ÛıÂÓ›˜ Ì RS, ·ÏÏ¿ Î·È ¿ÏÏÔ˘˜ Ê·ÈÓÔÙ‡Ô˘˜. ŒÁÈÓ ÚÔÛ¿ıÂÈ·: ·. ηٷÁÚ·Ê‹˜ Ù˘ Û˘¯ÓfiÙËÙ·˜ Î·È Û‡ÁÎÚÈÛ˘ ÙÔ˘ ÚÔÙ‡Ô˘ ÙˆÓ ÌÂÙ·ÏÏ¿ÍÂˆÓ Û ۯ¤ÛË Ì ÙȘ ·Ó·ÊÔÚ¤˜ ·ÁÎÔÛÌ›ˆ˜, ‚. Û˘Û¯¤ÙÈÛ˘ ÁÔÓÔÙ‡Ô˘-Ê·ÈÓÔÙ‡Ô˘, Á. ‰ÈÂÚ‡ÓËÛ˘ Ù˘ ÛËÌ·Û›·˜ ÙˆÓ ÌÂÙ·ÏÏ¿ÍÂˆÓ Û ·È‰È¿ Ì ‰È¿ÊÔÚÔ˘˜ æ∫∫ Ê·È-

º˘ÛÈÔÏÔÁÈÎfi˜ ª·ÚÙ˘Ú·˜

¶·ıÔÏÔÁÈÎfi˜ ª·ÚÙ˘Ú·˜

∞ÛıÂÓ‹˜

ªËÙ¤Ú·

∂ÈÎfiÓ· 3·. DGGE ·Ó¿Ï˘ÛË. ∏ ̤ıÔ‰Ô˜ ‚·Û›˙ÂÙ·È ÛÙË ‰ËÌÈÔ˘ÚÁ›· ÂÙÂÚÔ‰›ÎÏˆÓˆÓ ÙÌËÌ¿ÙˆÓ DNA, ÂÓfi˜ ÌÂÙ·ÏÏ·Á̤ÓÔ˘ Î·È ÂÓfi˜ Ê˘ÛÈÔÏÔÁÈÎÔ‡, ηıÒ˜ ÌÂÙ·Ó·ÛÙÂ‡Ô˘Ó ‰È·Ì¤ÛÔ˘ ÂÓfi˜ οıÂÙÔ˘ ËÎÙÒÌ·ÙÔ˜ ÔÏ˘·ÎÚ˘Ï·Ìȉ›Ô˘ Ì ·˘Í·ÓfiÌÂÓË ¯ËÌÈ΋ ÎÏ›ÛË ÂÓfi˜ ·ԉȷٷÎÙÈÎÔ‡. ∫·ıÒ˜ ÙÔ ÙÌ‹Ì· ÙÔ˘ DNA ÂÈÛ¤Ú¯ÂÙ·È ÛÙË Û˘ÁΤÓÙÚˆÛË ÂΛÓË ÙÔ˘ ·ԉȷٷÎÙÈÎÔ‡ ̤ÛÔ˘, fiÔ˘ Ë ÂÚÈÔ¯‹ ÙÔ˘ Ì ÙÔ ¯·ÌËÏfiÙÂÚÔ ÛËÌÂ›Ô Ù‹Í˘ ·Ú¯›˙ÂÈ Ó· ·ԉȷٿÛÛÂÙ·È, ÙÔ ÙÌ‹Ì· “·ÓÔ›ÁÂÈ” ‰ËÌÈÔ˘ÚÁÒÓÙ·˜ ¤Ó· ÌfiÚÈÔ DNA Ì ‰È·ÎÏ·‰ÈṲ̂ÓË ‰ÔÌ‹. ∆Ô ‰È·ÎÏ·‰ÈṲ̂ÓÔ ·˘Ùfi DNA ¤¯ÂÈ ÂÍ·ÈÚÂÙÈο ηı˘ÛÙÂÚË̤ÓË ÎÈÓËÙÈÎfiÙËÙ· ÛÙÔ ÛÙÚÒÌ· ÙÔ˘ ËÎÙÒÌ·ÙÔ˜. ∞Ó ¤Ó· ‰Â›ÁÌ· DNA ÂÚȤ¯ÂÈ ÌÈ· ÛËÌÂȷ΋ ÌÂÙ¿ÏÏ·ÍË ÛÙËÓ ÂÚÈÔ¯‹ ·˘Ù‹, ÙÔ ÛËÌÂ›Ô Ù‹Í˘ Ù˘ ÂÚÈÔ¯‹˜ ı· Â›Ó·È ‰È·ÊÔÚÂÙÈÎfi, ÔfiÙ ÙÔ ÌÂÙ·ÏÏ·Á̤ÓÔ ÌfiÚÈÔ ÙÔ˘ DNA ı· ˘ÔÛÙ› Ù‹ÍË Û ÂÏ·ÊÚ¿ ‰È·ÊÔÚÂÙÈ΋ ıÂÚÌÔÎÚ·Û›· Î·È Û˘ÓÂÒ˜ ı· ¤¯ÂÈ ‰È·ÊÔÚÂÙÈ΋ ÎÈÓËÙÈÎfiÙËÙ· ÛÙÔ ‹Îو̷ Û˘ÁÎÚÈÙÈο Ì ÙÔ DNA ÂϤÁ¯Ô˘. °È· ÙÔ Û¯Â‰È·ÛÌfi ÙˆÓ ÂÈÚ·Ì·ÙÈÎÒÓ Û˘ÓıËÎÒÓ ¯ÚËÛÈÌÔÔÈ‹ıËΠÙÔ ÚfiÁÚ·ÌÌ· Meltmap (21). ¶·È‰È·ÙÚÈ΋ 2008;71:38-47

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·42

42

™. æÒÓË Î·È Û˘Ó.

¶›Ó·Î·˜ 3. ™˘Óı‹Î˜ PCR Î·È DGGE ·Ó¿Ï˘Û˘ ÁÈ· ÙÔ ÂÍfiÓÈÔ 4 ÙÔ˘ MECP2 ÁÔÓȉ›Ô˘ ∆Ì‹Ì·

∞ÏÏËÏÔ˘¯›· ÂÎÎÈÓËÙÒÓ

ª‹ÎÔ˜ (bp) £. ·Ó·‰È¿Ù·Í˘ ∫Ï›ÛË ™˘ÁΤÓÙÚˆÛË £. Ú˘ıÌÈÛÙÈÎÔ‡ Û˘ÁΤÓÙÚˆÛ˘ ·ÎÚ˘Ï·Ì›‰Ë˜ ‰È·Ï‡Ì·ÙÔ˜ DNA (oC) ·ԉȷٷÎÙÈÎÔ‡ (%) Û˘Û΢‹˜ (%) DGGE (oC)

4.1

4.1F: 5ã-GC45-TGA CAT TGC TAT GGA GAG CC-3ã 4.1R:5ã-CGT TTG ATC ACC ATG ACC TG-3ã 4.2F:5ã-GC57-AGG GGG CAA GGC TGA GGG GG-3ã 4.2R:5ã-GGT GCT CCT TCT TGG GGG GT-3ã 4.3F:5ã-AGG ACT GAA GAC CTG TAA GAG C-3ã 4.3R: 5ã-GC45-CCC TTT GCT TTG CAA TCC GCT CC-3ã

430

60

20-60

6-12

60

410

60

20-80

6

60

488

56

40-70

6

63

4.2

4.3

*XÚfiÓÔ˜ ËÏÂÎÙÚÔÊfiÚËÛ˘: 18 ÒÚ˜, ∆¿ÛË: 65 Volts

·ÔÎÏÂÈÛÌÔ‡ Û˘ÓÔÏÈο 10 ·È‰ÈÒÓ ·ÔÙ¤ÏÂÛ·Ó: ·Ó·ÙÔÌÈΤ˜ ·ÓˆÌ·Ï›Â˜ ÂÁÎÂÊ¿ÏÔ˘, ·ıÔÏÔÁÈÎfi˜ ηڢfiÙ˘Ô˜, ‰˘ÛÌÔÚÊÈο ¯·Ú·ÎÙËÚÈÛÙÈο, ∞S Î·È ¤ÏÏÂÈ„Ë ÎÏÈÓÈÎÒÓ ÛÙÔȯ›ˆÓ. ∆· ˘fiÏÔÈ· 59 ·È‰È¿ ηÙËÁÔÚÈÔÔÈ‹ıËÎ·Ó ˆ˜ ÂÍ‹˜: ·. ÎÏ·ÛÈÎfi RS (n1=23 ÎÔÚ›ÙÛÈ·), ‚. ¿Ù˘Ô RS (n2=25 ÎÔÚ›ÙÛÈ·) Î·È Á. ·ÁfiÚÈ· Ì Èı·Ó¤˜ MECP2 ÌÂÙ·ÏÏ¿ÍÂȘ (n3=11). ∏ Ù·ÍÈÓfiÌËÛË Û ÎÏ·ÛÈÎfi ‹ ¿Ù˘Ô RS ¤ÁÈÓ ‚¿ÛÂÈ ‰È·ÁÓˆÛÙÈÎÒÓ ÎÚÈÙËÚ›ˆÓ (¶›Ó·Î˜ 1·, 1‚) (3). ™ÙȘ ÔÌ¿‰Â˜ ·-‚ Û˘ÌÏËÚÒıËΠÂÚˆÙËÌ·ÙÔÏfiÁÈÔ ÎÏÈÓÈ΋˜ ·ÍÈÔÏfiÁËÛ˘ (¶›Ó·Î·˜ 2) (20). √È ··ÓÙ‹ÛÂȘ ‚·ıÌÔÏÔÁ‹ıËÎ·Ó Ì 2-1-0. ™ÙËÓ ÔÌ¿‰· ÙˆÓ ·ÁÔÚÈÒÓ ‰ÂÓ ¯ÚËÛÈÌÔÔÈ‹ıËΠۇÛÙËÌ· ·ÍÈÔÏfiÁËÛ˘, ÏfiÁˆ Ù˘ ÌË Î·Ï¿ ÙÂÎÌËÚȈ̤Ó˘ Ê·ÈÓÔÙ˘È΋˜ ÂÈÎfiÓ·˜ Î·È Û·ÓÈfiÙËÙ·˜ ÙˆÓ ÂÚÈÛÙ·ÙÈÎÒÓ. ∞fi ÙÔ˘˜ ÂÈÏÂÁ̤ÓÔ˘˜ ·ÛıÂÓ›˜ Î·È Î·Ù¿ ÂÚ›ÙˆÛË ·fi ̤ÏË Ù˘ ÔÈÎÔÁ¤ÓÂÈ¿˜ ÙÔ˘˜, ÌÂÏÂÙ‹ıËΠ‰Â›ÁÌ· DNA ·fi ÂÚÈÊÂÚÈο ÏÂÌÊÔ·ÙÙ·Ú· ·›Ì·ÙÔ˜. ™ÙË Û˘Ó¤¯ÂÈ·, Ù· ÂÍfiÓÈ· 3 Î·È 4 Î·È ÔÈ ·Ú¿Ï¢Ú˜ Û˘Ó‰ÂÙÈΤ˜ ÂÚÈÔ¯¤˜ ÂÍÔÓ›ˆÓ-ÂÓ‰ÔÓ›ˆÓ ÂÓÈÛ¯‡ıËÎ·Ó Ì PCR, Ì ¯ÚËÛÈÌÔÔ›ËÛË ÂȉÈο ۯ‰ȷ-

R106W (397C>T)

ÛÌ¤ÓˆÓ ÂÎÎÈÓËÙÒÓ (¶›Ó·Î·˜ 3). ∆· ÚÔ˚fiÓÙ· ÂÓ›Û¯˘Û˘ ÙÔ˘ ÂÍÔÓ›Ô˘ 4 ˘Ô‚Ï‹ıËÎ·Ó Û ËÏÂÎÙÚÔÊfiÚËÛË Û ‹Îو̷ Ì ÎÏ›ÛË ·ԉȷٷÎÙÈÎÔ‡ (DGGE - Denaturant Gradient Gel Electrophoresis), Ë ÔÔ›· Â›Ó·È ÈÛ¯˘Ú‹ ̤ıÔ‰Ô˜ ‰È·ÏÔÁ‹˜, ηıÒ˜ ÂÈÙÚ¤ÂÈ ÙËÓ ÂͤٷÛË ÔÏÏÒÓ ‰ÂÈÁÌ¿ÙˆÓ Ù·˘Ùfi¯ÚÔÓ· Î·È ·ÓȯÓ‡ÂÈ ÛËÌÂȷΤ˜ ÌÂÙ·ÏÏ¿ÍÂȘ Û ÔÛÔÛÙfi ¤ˆ˜ Î·È 100% (∂ÈÎfiÓ· 3·) (21). ∆Ô ÂÍfiÓÈÔ 3 ‰ÂÓ ·Ó·Ï‡ıËΠ̠DGGE, ÏfiÁˆ Ù¯ÓÈÎÒÓ È‰ÈÔÌÔÚÊÈÒÓ (˘„ËÏ¿ ÛËÌ›· Ù‹Í˘), ηıÈÛÙÒÓÙ·˜ ‰‡ÛÎÔÏÔ ÙÔ Û¯Â‰È·ÛÌfi ÙˆÓ ÂÈÚ·Ì·ÙÈÎÒÓ Û˘ÓıËÎÒÓ. ™Â fiÛ· ÚÔ˚fiÓÙ· ·ÚÔ˘ÛÈ¿ÛıËΠ·ÓÒÌ·ÏÔ ÚfiÙ˘Ô ÌÂÙ·Ó¿ÛÙ¢Û˘ ÛÙË DGGE ·Ó¿Ï˘ÛË, ηıÒ˜ Î·È ÛÙ· ÚÔ˚fiÓÙ· PCR ÙÔ˘ ÂÍÔÓ›Ô˘ 3, ¤ÁÈÓ ¿ÌÂÛÔ˜ ÚÔÛ‰ÈÔÚÈÛÌfi˜ Ù˘ ·ÏÏËÏÔ˘¯›·˜ DNA (∂ÈÎfiÓ· 3‚). ™Ù· ·ÚÓËÙÈο ‰Â›ÁÌ·Ù· ÙˆÓ RS ·È‰ÈÒÓ (ÎÔÚ›ÙÛÈ· Ì ÎÏ·ÛÈÎfi ‹ ¿Ù˘Ô RS, ·ÁfiÚÈ·) ÂÊ·ÚÌfiÛıËÎÂ Ë Ì¤ıÔ‰Ô˜ GAP-PCR, ˆ˜ ÚÒÙË ÚÔÛ¿ıÂÈ· ·ÔÎ¿Ï˘„˘ ÌÂÁ¿ÏˆÓ ÁÔÓȉȷÎÒÓ ·Ó·Î·Ù·Ù¿ÍˆÓ, Ì ¯ÚËÛÈÌÔÔ›ËÛË 6 ˙¢ÁÒÓ ·ÏÏËÏÔÂÈÎ·Ï˘ÙfiÌÂÓˆÓ ÂÎÎÈÓËÙÒÓ ÁÈ· Ù· ÂÍfiÓÈ· 3-4.

R306C (916C>T)

del 806G (G269fs)

∂ÈÎfiÓ· 3‚. ¶ÚÔÛ‰ÈÔÚÈÛÌfi˜ ·ÏÏËÏÔ˘¯›·˜ DNA (sequencing). ÃÚËÛÈÌÔÔÈ‹ıËÎ·Ó ÂȉÈο ÛÂÛËÌ·Ṳ̂ÓÔÈ Ì ÊıÔÚ›˙Ô˘Û· ¯ÚˆÛÙÈ΋ M13 ÂÎÎÈÓËÙ¤˜ (forward Cy5.0: 5ã-GTAAAACGACGGCCAGT-3ã; reverse Cy5.5: 5ã-CAGGAAACAGCTATGAC-3ã) Î·È ÙÔ kit Ù˘ Visible Genetics. ∏ ·Ó¿Ï˘ÛË ¤ÁÈÓ ÛÙÔ ·˘ÙfiÌ·Ùo Û‡ÛÙËÌ· sequencing Opengeneì (Visible Genetics, Ontario, Canada).

Paediatriki 2008;71:38-47

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·43

43

∫ÏÈÓÈ΋ Î·È ÌÔÚȷ΋ ÌÂϤÙË ÙÔ˘ ÁÔÓȉ›Ô˘ MECP2

¶›Ó·Î·˜ 4. ∫ÏÈÓÈο ¯·Ú·ÎÙËÚÈÛÙÈο ·ÁÔÚÈÒÓ Ì Èı·Ó¤˜ ÌÂÙ·ÏÏ¿ÍÂȘ MECP2 (n=11) ∞ÛıÂÓ‹˜

∏ÏÈΛ·

∫ÏÈÓÈΤ˜ ÂΉËÏÒÛÂȘ

ªÂÙ¿ÏÏ·ÍË

1 2

R11 R18

11 ÂÙÒÓ 13 ÌËÓÒÓ

R106W -

3

R23

9 ÌËÓÒÓ

4 5

R29 R39

6 ÂÙÒÓ 14 ÌËÓÒÓ

æ∫∫ ·fi 18 ÌËÓÒÓ, ·˘ÙÈÛÙÈο ÛÙÔȯ›·, ÌÂÁ¿Ï˜ ۈ̷ÙÔÌÂÙÚÈΤ˜ ·Ú¿ÌÂÙÚÔÈ ¡ÂÔÁÓÈ΋ ÂÁÎÂÊ·ÏÔ¿ıÂÈ· (ηÏfi ÂÚÈÁÂÓÓËÙÈÎfi ÈÛÙÔÚÈÎfi, ‚·ÚËÎÔ˝·, ˘ÂÚÙÔÓ›· ¿ÎÚˆÓ, ·‡ÚÂÙÔÈ Û·ÛÌÔ› ·fi 8,5 ÌËÓÒÓ, æ∫∫, Â›ÎÙËÙË ÌÈÎÚÔÎÂÊ·Ï›·) ¡ÂÔÁÓÈ΋ ÂÁÎÂÊ·ÏÔ¿ıÂÈ· (IVF, ‰›‰˘ÌÔ, ÌÈÎÚÔÎÂÊ·Ï›·, ˘ÂÚÙÔÓ›· ¿ÎÚˆÓ˘ÔÙÔÓ›· ÎÔÚÌÔ‡, ÛÙÂÚÂÔÙ˘ÈΤ˜ ÎÈÓ‹ÛÂȘ ÛÙÔÓ ‡ÓÔ, ¤ÓÙÔÓË æ∫∫) ÀÔÙÔÓ›·, æ∫∫, ÛÙÂÚÂfiÙ˘˜ ÎÈÓ‹ÛÂȘ ¯ÂÚÈÒÓ ÚÔ˜ ÙÔ ÛÙfiÌ· ªÈÎÚÔÎÂÊ·Ï›·, ˘ÔÙÔÓ›· ÎÔÚÌÔ‡, ÛÙÂÚÂÔÙ˘›Â˜, ÎÈÓËÙÈ΋ ·ÓˆÚÈÌfiÙËÙ· ÛÙ· ¯¤ÚÈ·

6 7 8 9 10

R41 R53 R54 R56 R59

14 ÌËÓÒÓ 5 ÂÙÒÓ 4 ÂÙÒÓ

™‡Ó‰ÚÔÌÔ West, ÛÙÂÚÂÔÙ˘›Â˜, æ∫∫, ÙÚfiÌÔ˜ ÎÔÚÌÔ‡ æ∫∫, Û·ÛÌÔ›, ÌÈÎÚÔÎÂÊ·Ï›· æ∫∫, ∂∂G (+) ¯ˆÚ›˜ Û·ÛÌÔ‡˜, ÛÈÙÈÛÙÈο ÚÔ‚Ï‹Ì·Ù· ˆ˜ ÓÂÔÁÓfi-‚Ú¤ÊÔ˜ æ∫∫, ·˘ÙÈÛÙÈο ÛÙÔȯ›·

11

R65

14 ÌËÓÒÓ

∫Ú›ÛÂȘ ‘∂’, ÛÙÂÚÂÔÙ˘›Â˜, ·Ù·Í›·, æ∫∫, ·˘ÙÈÛÙÈο ÛÙÔȯ›·

ªÂÁ¿ÏË ÁÔÓȉȷ΋ ·Ó·Î·Ù¿Ù·ÍË ÛÙ· ÂÍfiÓÈ· 3, 4 -

∞ÔÙÂϤÛÌ·Ù· ∆· ·ÔÙÂϤÛÌ·Ù· Û˘ÁÎÚ›ıËÎ·Ó Ì ÙËÓ InterRett ËÏÂÎÙÚÔÓÈ΋ ‚¿ÛË MECP2 ÌÂÙ·ÏÏ¿ÍÂˆÓ (http:// mecp2.chw.edu.au/). ªÔÚȷ΋ ·Ó¿Ï˘ÛË ¤ÁÈÓÂ Û˘ÓÔÏÈο Û ¤ÓÙ ÔÌ¿‰Â˜ (n=221): 1. ∫Ï·ÛÈÎfi RS: µÚ¤ıËÎ·Ó ·ÏÏ·Á¤˜ Û 18/23 ÎÔÚ›ÙÛÈ· (78,3%). ™˘ÓÔÏÈο, fï˜, ‚Ú¤ıËÎ·Ó 19 ·ÏÏ·Á¤˜, ηıÒ˜ Ë ·ÛıÂÓ‹˜ R22 ¤ÊÂÚ ÙË ÌÂÙ¿ÏÏ·ÍË p.R168X Î·È ÙÔ ÛȈËÏfi ÔÏ˘ÌÔÚÊÈÛÌfi p.F142F. 12/19 ·ÏÏ·Á¤˜ ‹Ù·Ó ·ÚÂÚÌËÓ‡ÛÈ̘ (missense) (66,7%), 3 ·ÓÂÚÌËÓ‡ÛÈ̘ (nonsense) (16,7%) Î·È 3 Ï·ÈÛÈÔÙÚÔÔÔÈËÙÈΤ˜ (frameshift) (16,7%). ™ÙȘ missense ·ÏÏ·Á¤˜ ÂÚÈÏ‹ÊıËÎ·Ó 10 ÌÂÙ·ÏÏ¿ÍÂȘ Î·È 3 ÚÔ·Ó·ÊÂÚı¤ÓÙ˜ ηÏÔ‹ıÂȘ ÔÏ˘ÌÔÚÊÈÛÌÔ› Ô˘ ·Ú·ÙËÚ‹ıËÎ·Ó Î·È Û ·Û˘Ìو̷ÙÈο ̤ÏË ÙˆÓ ÔÈÎÔÁÂÓÂÈÒÓ. O ÔÏ˘ÌÔÚÊÈÛÌfi˜ p.T197M ·Ú·ÙËÚ‹ıËΠÛÙËÓ ·ÛıÂÓ‹ R67, Ô p.L328L ÛÙËÓ R58 Î·È Ô p.F142F ÛÙËÓ R22. E›Û˘, ÛÙËÓ ·ÛıÂÓ‹ R13 Ô˘ ¤·Û¯Â ·fi ‰È·ÁÓˆṲ̂ÓË ÎÏÈÓÈο Î·È ÙÂÎÌËÚȈ̤ÓË ÌÔÚȷο NˆÙÈ·›· ª˘˚΋ ∞ÙÚÔÊ›·, ·ÓȯÓ‡ıËÎÂ Ë p.R306C (22).

2. ÕÙ˘Ô RS: ™ÙËÓ ÔÌ¿‰· ·˘Ù‹ ÂÍÂÙ¿ÛıËÎ·Ó 25 ÎÔÚ›ÙÛÈ·. ∞ÏÏ·Á¤˜ ÛÙË ÓÔ˘ÎÏÂÔÙȉÈ΋ ·ÏÏËÏÔ˘¯›· ‚Ú¤ıËÎ·Ó ÛÙÔ 20% (5/25). ¢‡Ô ·ÏÏ·Á¤˜ ·Ó‹Î·Ó ÛÙȘ 8 ÈÔ Û˘¯Ó¤˜ ·ıÔÁfiÓ˜ ÌÂÙ·ÏÏ¿ÍÂȘ ÁÈ· ÙÔ ÎÏ·ÛÈÎfi RS (p.R106W, p.R306C). ∏ ÙÚ›ÙË ·ÏÏ·Á‹ ‹Ù·Ó Ô ÛȈËÏfi˜ ÔÏ˘ÌÔÚÊÈÛÌfi˜ p.T299T ÛÙËÓ ·ÛıÂÓ‹ R46 Î·È ÙÔÓ ·Ù¤Ú· Ù˘. ™ÙËÓ ÂÚ›ÙˆÛË ·˘Ù‹, Ë ÌÂÙ·‚ÔÏ‹ ÛÙË ÓÔ˘ÎÏÂÔÙȉÈ΋ ·ÏÏËÏÔ˘¯›· ‰ÂÓ Î·Ù¤ÏËÍ Û ÌÂÙ·‚ÔÏ‹ ÛÙËÓ ·Ï˘Û›‰· ÙˆÓ ·ÌÈÓÔͤˆÓ. ∏ ٤ٷÚÙË ·ÏÏ·Á‹ (R61) ‹Ù·Ó ÌÈ· Ó¤· Û‡ÓıÂÙË ÌÂÙ¿ÏÏ·ÍË (del318insA), ηٿ ÙËÓ ÔÔ›· ·Ú·ÙËÚ‹ıËΠٷ˘Ùfi¯ÚÔÓ· ¤ÏÏÂÈÌÌ· Î·È ¤ÓıÂÛË ‚¿ÛˆÓ. ∏ ·ÛıÂÓ‹˜ ·˘-

-

Ù‹ ·ÚÔ˘Û›·˙ Â›Û˘ ÙË ¯ÚˆÌÔÛˆÌÈ΋ ·ÓˆÌ·Ï›· 46,ÃXdel(13)(q11→pter), ÙËÓ ÔÔ›· ›¯Â ÎÏËÚÔÓÔÌ‹ÛÂÈ ·fi ÙÔÓ ·Ù¤Ú· Ù˘. ∏ ÙÂÏÂ˘Ù·›· ÂÚ›ÙˆÛË (R64) ÂÌÊ¿ÓÈÛ ·ıÔÏÔÁÈÎfi ·ÔÙ¤ÏÂÛÌ· ÛÙËÓ GAPPCR, ·Ú¤¯ÔÓÙ·˜ ÂӉ›ÍÂȘ ÁÈ· ÌÂÁ¿ÏË ·Ó·Î·Ù¿Ù·ÍË ÛÙ· ÂÍfiÓÈ· 3-4. ™‡Ìʈӷ Ì ÙËÓ ÔÛÔÙÈ΋ ·˘Ù‹ ̤ıÔ‰Ô ÔÏÏ·Ï·ÛÈ¿˙ÔÓÙ·È Î·È Û˘ÁÎÚ›ÓÔÓÙ·È ÌÂÁ¿Ï· ·ÏÏËÏÔÂÈÎ·Ï˘ÙfiÌÂÓ· ÙÌ‹Ì·Ù· ÙÔ˘ ÁÔÓȉ›Ô˘, ÔfiÙ ·ÔηχÙÔÓÙ·È ÂÏÏ›ÌÌ·Ù· Î·È ÂÓı¤ÛÂȘ Ô˘ ·ÊÔÚÔ‡Ó ·ÎfiÌË Î·È ÔÏfiÎÏËÚ· ÂÍfiÓÈ·.

3. ∞ÁfiÚÈ· Ì Èı·Ó¤˜ MECP2 ÌÂÙ·ÏÏ¿ÍÂȘ: ™ÙËÓ ÔÌ¿‰· ÙˆÓ ·ÁÔÚÈÒÓ ‚Ú¤ıËÎ·Ó ‰‡Ô ·ÏÏ·Á¤˜ (2/11, 18,1%). ∏ ÚÒÙË ·ÊÔÚÔ‡Û ·ÛıÂÓ‹ 11 ÂÙÒÓ (R11) Î·È ‹Ù·Ó Ù˘È΋ RS ÌÂÙ¿ÏÏ·ÍË (p.R106W). ∆Ô ‰Â‡ÙÂÚÔ ·ÁfiÚÈ (R59), ËÏÈΛ·˜ 4 ÂÙÒÓ, ·ÚÔ˘Û›·Û ·ıÔÏÔÁÈÎfi GAP-PCR (¶›Ó·Î·˜ 4).

4. AS-·ÚÓËÙÈο ‰Â›ÁÌ·Ù·: ∞fi Ù· 41 ‰Â›ÁÌ·Ù·, Â˘Ú‹Ì·Ù· ˘‹ÚÍ·Ó Û ÙÚ›· ÎÔÚ›ÙÛÈ· (7,3%). √È ‰‡Ô ÚÒÙ˜ (RA1, RA28) ›¯·Ó ÙȘ Ù˘ÈΤ˜ ÌÂÙ·ÏÏ¿ÍÂȘ p.R306C Î·È p.R133C, ·ÓÙ›ÛÙÔȯ·, ÂÓÒ Ë RA35 ÂÌÊ¿ÓÈÛ de novo ¤ÏÏÂÈÌÌ· 6 ‚¿ÛÂˆÓ ÛÙÔ Î·Ú‚Ô͢ÙÂÏÈÎfi ¿ÎÚÔ (c.1159del6).

5. FXS-·ÚÓËÙÈο ‰Â›ÁÌ·Ù·: ™Â 3/124 ‰Â›ÁÌ·Ù· (2,4%) ÛËÌÂÈÒıËÎ·Ó ·ÏÏ·Á¤˜. H ÚÒÙË ·ÊÔÚÔ‡Û ÔÈÎÔÁÂÓ‹ ÂÚ›ÙˆÛË æ∫∫. ™˘ÁÎÂÎÚÈ̤ӷ, ÂÚfiÎÂÈÙÔ ÁÈ· ‰‡Ô ·‰¤ÏÊÈ· (FR108), (·ÁfiÚÈ· 5 Î·È 3 ÂÙÒÓ, ·ÓÙ›ÛÙÔȯ·) Ì æ∫∫ Î·È Ó¢ÚÔÏÔÁÈο ÚÔ‚Ï‹Ì·Ù· Î·È ÙËÓ ·Û˘Ìو̷ÙÈ΋ ÌËÙ¤Ú· ÙÔ˘˜. ŸÏÔÈ ÂÌÊ¿ÓÈÛ·Ó de novo ¤ÏÏÂÈÌÌ· ÛÙÔ Î·Ú‚Ô͢ÙÂÏÈÎfi ¿ÎÚÔ (c.1140del86). ∏ ‰Â‡ÙÂÚË ÂÚ›ÙˆÛË ·ÊÔÚÔ‡Û ¤Ó· ·ÁfiÚÈ (FR120), Ì ÙËÓ p.∆203ª ·ÏÏ·Á‹, Ë ÔÔ›· ıˆÚÂ›Ù·È Î·ÏÔ‹ı˘ ÔÏ˘ÌÔÚÊÈÛÌfi˜. ∏ ÌËÙ¤Ú· ÙÔ˘, fï˜, ‹Ù·Ó Ê˘ÛÈÔÏÔÁÈ΋. ∏ ÙÚ›ÙË ÌÂÙ¿ÏÏ·ÍË ¶·È‰È·ÙÚÈ΋ 2008;71:38-47

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·44

44

™. æÒÓË Î·È Û˘Ó.

¶›Ó·Î·˜ 5. ™˘ÁÎÂÓÙÚˆÙÈο ·ÔÙÂϤÛÌ·Ù· Ù˘ ÌÂϤÙ˘. ªÂÙ·ÏÏ¿ÍÂȘ Î·È ·ÏÏ·Á¤˜ ·ÏÏËÏÔ˘¯›·˜ ηٿ ÛÂÈÚ¿ Û˘¯ÓfiÙËÙ·˜ ∞ÛıÂÓ›˜

∆‡Ô˜ ÌÂÙ¿ÏÏ·Í˘

To̤·˜

∂ÍfiÓÈÔ

¡Ô˘ÎÏÂÔÙȉÈ΋ ·ÏÏ·Á‹

∞ÏÏ·Á‹ ··

∫ÏÈÓÈο ÛÙÔȯ›· - ¶·Ú·ÙËÚ‹ÛÂȘ

R4 R5 R9 R11 R8 R12 R35 RA28 R21 R28 R36 R66 R2 R13

missense missense missense missense missense missense missense missense missense missense missense missense missense missense

MBD MBD MBD MBD MBD MBD MBD MBD MBD MBD MBD MBD TRD TRD

3 3 3 3 4 4 4 4 4 4 4 4 4 4

c.316C>T c.316C>T c.316C>T c.316C>T c.397C>T c.397C>T c.397C>T c.397C>T c.473C>T c.473C>T c.473C>T c.473C>T c.916C>T c.916C>T

R106W R106W R106W R106W R133C R133C R133C R133C T158M T158M T158M T158M R306C R306C

RA1

missense

TRD

4

c.916C>T

R306C

ÕÙ˘Ô RS, 21 ÌËÓÒÓ, ∫Ï·ÛÈÎfi RS, 7,5 ÂÙÒÓ, ∫Ï·ÛÈÎfi RS, 18 ÌËÓÒÓ, , 11 ÂÙÒÓ, ·˘ÙÈÛÙÈο ÛÙÔȯ›·, æ∫∫ ∫Ï·ÛÈÎfi RS, 3 ÂÙÒÓ, ∫Ï·ÛÈÎfi RS, 14 ÂÙÒÓ, ∫Ï·ÛÈÎfi RS, 3 ÂÙÒÓ, AS Ê·ÈÓfiÙ˘Ô˜, 2 ÂÙÒÓ, ∫Ï·ÛÈÎfi RS, 2,5 ÂÙÒÓ, ∫Ï·ÛÈÎfi RS, 11 ÂÙÒÓ, ∫Ï·ÛÈÎfi RS, 3 ÂÙÒÓ, ∫Ï·ÛÈÎfi RS, 11 ÂÙÒÓ, ∫Ï·ÛÈÎfi RS, 3 ÂÙÒÓ, ∫Ï·ÛÈÎfi RS, 8,5 ÂÙÒÓ, , ¿Û¯ÂÈ Î·È ·fi SMA II AS Ê·ÈÓfiÙ˘Ô˜, 2 ÂÙÒÓ,

R7

nonsense

4

c.502C>T

R168X

∫Ï·ÛÈÎfi RS, 7 ÂÙÒÓ,

R22

nonsense

4

c.502C>T

R168X

∫Ï·ÛÈÎfi RS, 19 ÌËÓÒÓ,

R1

nonsense

ªÂٷ͇ MBD-TRD ªÂٷ͇ MBD-TRD TRD

4

c.880C>T

R294X

∫Ï·ÛÈÎfi RS, 2 ÂÙÒÓ,

R61

frameshift

MBD

3

c.del318insA

R47 R3 R62

frameshift frameshift frameshift

TRD-NLS C-term.

C-term.

4 4 4

RA35 FR36

frameshift frameshift

C-term.

C-term.

4 4

c.806delG c.1117del87 c.1159insAGGGG TGGdel41 c.1159del6 c.1163del44

FR108 ·+‚

frameshift

C-term.

4

c.1140del86

R59 R64

ÕÙ˘Ô RS + ¯ÚˆÌÔÛˆÌÈ΋ ·ÓˆÌ·Ï›· ÎÏËÚÔÓÔÌË̤ÓË ·fi ÙÔÓ ·Ù¤Ú·, 4 ÂÙÒÓ, , Ó¤· ÌÂÙ¿ÏÏ·ÍË G269fs P387fs P387fs P388fs

ªÂÁ¿ÏË ÁÔÓȉȷ΋ ·Ó·Î·Ù¿Ù·ÍË ªÂÁ¿ÏË ÁÔÓȉȷ΋ ·Ó·Î·Ù¿Ù·ÍË

∫Ï·ÛÈÎfi RS, 19 ÌËÓÒÓ, ∫Ï·ÛÈÎfi RS, 22 ÌËÓÒÓ, , Ó¤· ÌÂÙ¿ÏÏ·ÍË ∫Ï·ÛÈÎfi RS, 16 ÂÙÒÓ, , ‚·Ú‡Ù·ÙË ÛÎÔÏ›ˆÛË, Ó¤· ÌÂÙ¿ÏÏ·ÍË ∞S Ê·ÈÓfiÙ˘Ô˜, 2 ÂÙÒÓ, , Ó¤· ÌÂÙ¿ÏÏ·ÍË FXS Ê·ÈÓfiÙ˘Ô˜, 5 ÂÙÒÓ, ÙÂÏÈÎfi˜ ÙÚfiÌÔ˜ ¿Óˆ ¿ÎÚˆÓ, , Ó¤· ÌÂÙ¿ÏÏ·ÍË XLMR, ·‰¤ÏÊÈ· , 5 Î·È 3 ÂÙÒÓ, ÌËÙ¤Ú· ·Û˘Ìو̷ÙÈ΋ ÊÔÚ¤·˜ æ∫∫, ·˘ÙÈÛÙÈο ÛÙÔȯ›· ∞Ù˘Ô RS, 2 ÂÙÒÓ,

R67

ÔÏ˘ÌÔÚÊÈÛÌfi˜

ªÂٷ͇ MBD-TRD

4

c.590C>T

T197M

∫Ï·ÛÈÎfi RS, 22 ÌËÓÒÓ, , ·Ù¤Ú·˜ ·Û˘Ìو̷ÙÈÎfi˜ ÊÔÚ¤·˜

FR120

ÔÏ˘ÌÔÚÊÈÛÌfi˜

ªÂٷ͇ MBD-TRD

4

c.608C>T

∆203ª

FXS Ê·ÈÓfiÙ˘Ô˜ (æ∫∫, ÚÔ‚Ï‹Ì·Ù· Û˘ÌÂÚÈÊÔÚ¿˜, Ì·ÎÚ‡ ÚfiÛˆÔ, ÚÔ¤¯ÔÓÙ· ·˘ÙÈ¿), 16 ÂÙÒÓ, , Ë ÌËÙ¤Ú· ‰ÂÓ Ê¤ÚÂÈ ÙËÓ ·ÏÏ·Á‹

R22

™ÈˆËÏfi˜ ÔÏ˘ÌÔÚÊÈÛÌfi˜ ™ÈˆËÏfi˜ ÔÏ˘ÌÔÚÊÈÛÌfi˜ ™ÈˆËÏfi˜ ÔÏ˘ÌÔÚÊÈÛÌfi˜

ªµD

4

c.426C>T

F142F

KÏ·ÛÈÎfi RS ÌÂ ÌÂÙ¿ÏÏ·ÍË R168X

TRD

4

c.897C>T

∆299∆

C-term.

4

c.984C>T

L328L

∞Ù˘Ô RS, 7 ÂÙÒÓ, , ·Ù¤Ú·˜ ·Û˘Ìو̷ÙÈÎfi˜ ÊÔÚ¤·˜ ∫Ï·ÛÈÎfi RS, , ÔÈ ÁÔÓ›˜ ‰ÂÓ ¤¯Ô˘Ó ÂÏÂÁ¯ı›

R46 R58

·Ú·ÙËÚ‹ıËΠ۠ÎÔÚ›ÙÛÈ (FR36) Î·È ‹Ù·Ó Î·È ·˘Ù‹ de novo ηڂÔ͢ÙÂÏÈÎfi ¤ÏÏÂÈÌÌ· (c.1163del44). ™˘ÓÔÏÈο, ÔÈ ·ÏÏ·Á¤˜ ÛÙÔ ÁÔÓ›‰ÈÔ MECP2 ‹Ù·Ó 32 (27 ÌÂÙ·ÏÏ¿ÍÂȘ, 5 ÔÏ˘ÌÔÚÊÈÛÌÔ›). 14/32 Paediatriki 2008;71:38-47

(43,75%) ·ÏÏ·Á¤˜ ÂÓÙÔ›˙ÔÓÙ·Ó ÂÓÙfi˜ ÙÔ˘ MBD, 5/32 (15,625%) ÂÓÙfi˜ ÙÔ˘ TRD, 4/32 (12,5%) ÛÙË MBD-TRD ÂÚÈÔ¯‹, 1/32 (3,125%) ÛÙË NLS, 6/32 (18,75%) ÛÙÔ Î·Ú‚Ô͢ÙÂÏÈÎfi ¿ÎÚÔ Î·È 2/32 (6,25%)

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·45

45

∫ÏÈÓÈ΋ Î·È ÌÔÚȷ΋ ÌÂϤÙË ÙÔ˘ ÁÔÓȉ›Ô˘ MECP2

·ÔÙÂÏÔ‡Û·Ó ÌÂÁ¿Ï˜ ·Ó·Î·Ù·Ù¿ÍÂȘ. 18/32 ·ÏÏ·Á¤˜ (56,25%) ·Ó‹Î·Ó ÛÙȘ ÔÎÙÒ Ù˘ÈÎfiÙÂÚ˜ ÌÂ Û˘¯ÓfiÙËÙ˜: p.T158M, p.R106W Î·È p.R133C (4/18, 22,2%), ·ÎÔÏÔ˘ıÔ‡ÌÂÓ˜ ·fi ÙȘ p.R168X Î·È p.R294X Ì ÔÛÔÛÙ¿ 13,7% Î·È 5,5%, ·ÓÙ›ÛÙÔȯ·. ∏ Û˘ÓÙÚÈÙÈ΋ ÏÂÈÔ„ËÊ›· ·Ú·ÙËÚ‹ıËΠÛÙÔ ÂÍfiÓÈÔ 4 (27/32, 84,375%) Î·È ÌfiÓÔ 5/32 (15,625%) ÛÙÔ ÂÍfiÓÈÔ 3 (¶›Ó·Î·˜ 5). ŒÁÈÓ ÚÔÛ¿ıÂÈ· ÁÈ· ÛÙ·ÙÈÛÙÈ΋ ·Ó¿Ï˘ÛË ÙˆÓ ·ÔÙÂÏÂÛÌ¿ÙˆÓ, ÒÛÙ ӷ ÂÍ·¯ıÔ‡Ó Û˘ÌÂÚ¿ÛÌ·Ù· ÁÈ· ÙË Û˘Û¯¤ÙÈÛË ÁÔÓÔÙ‡Ô˘-Ê·ÈÓÔÙ‡Ô˘. ™ÙËÓ ·Ó¿Ï˘ÛË ÂÚÈÏ‹ÊıËÎ·Ó ÌfiÓÔ ÎÔÚ›ÙÛÈ· fiÏˆÓ ÙˆÓ Ê·ÈÓÔÙ˘ÈÎÒÓ ÔÌ¿‰ˆÓ. ¢ËÌÈÔ˘ÚÁ‹ıËÎ·Ó 2 ÔÌ¿‰Â˜, Ë ÚÒÙË Ì ÎÔÚ›ÙÛÈ· Ì ÌÂÙ¿ÏÏ·ÍË (n=24) Î·È Ë ‰Â‡ÙÂÚË Ì ÎÔÚ›ÙÛÈ· Ì ÔÏ˘ÌÔÚÊÈÛÌÔ‡˜ ‹ ·ÚÓËÙÈÎfi ÌÔÚÈ·Îfi ¤ÏÂÁ¯Ô (n=28). √È ÔÌ¿‰Â˜ Û˘ÁÎÚ›ıËÎ·Ó ÌÂٷ͇ ÙÔ˘˜ ·) ˆ˜ ÚÔ˜ ÙËÓ Ù˘ÈÎfiÙËÙ· ÙÔ˘ Ê·ÈÓÔÙ‡Ô˘, Ë ÔÔ›· ÂÎÊÚ¿˙ÂÙ·È Ì ÙÔÓ ·ÚÈıÌfi ÙˆÓ ÌÂÈ˙fiÓˆÓ ÎÚÈÙËÚ›ˆÓ Ô˘ ÏËÚÔ‡ÓÙ·È (0 ¤ˆ˜ 6) Î·È ‚) ˆ˜ ÚÔ˜ ÙË ÛÔ‚·ÚfiÙËÙ· ÙÔ˘ Ê·ÈÓÔÙ‡Ô˘, fiˆ˜ ÂÎÊÚ¿˙ÂÙ·È ·fi ÙË ‚·ıÌÔÏÔÁ›· (0 ¤ˆ˜ 40) ÛÙËÓ Îϛ̷η ·ÍÈÔÏfiÁËÛ˘. ∏ ‰ÔÎÈÌ·Û›· t-test ÁÈ· ·ÓÂÍ¿ÚÙËÙ· ‰Â›ÁÌ·Ù· ¤‰ˆÛÂ Î·È ÛÙȘ ‰‡Ô ÂÚÈÙÒÛÂȘ ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈο ·ÔÙÂϤÛÌ·Ù· ÛÙÔ Â›Â‰Ô ÙÔ˘ 1% (ta=3,54, dfa=50, Pa=0,000438 Î·È tb=4,94, dfb=50, P<0,0001, ·ÓÙ›ÛÙÔȯ·). ™ÙË Û˘Ó¤¯ÂÈ·, ·Ó¿ÏÔÁ· Ì ÙËÓ ÎÏÈÓÈ΋ ÛÔ‚·ÚfiÙËÙ·, Ù· ıÂÙÈο ÎÔÚ›ÙÛÈ· (n=24) Ù·ÍÈÓÔÌ‹ıËÎ·Ó Û ¤¯Ô˘Û˜ ̤ÙÚÈ·˜ (score 0-19) Î·È ÌÂÁ¿Ï˘ ‚·Ú‡ÙËÙ·˜ Ê·ÈÓfiÙ˘Ô (score 20-40), ·ÓÙ›ÛÙÔȯ·. √È ÌÂÙ·ÏÏ¿ÍÂȘ ¯ˆÚ›ÛıËÎ·Ó Û ÙÚÂȘ ÔÌ¿‰Â˜: ∞. missense, µ. ÚÒÈÌ· ‰È·ÎfiÙÔ˘Û˜ ÙËÓ ÚˆÙ½ÓË (earlytruncating), ÂÓÙÔÈ˙fiÌÂÓ˜ ¤ˆ˜ Î·È ÙËÓ ÂÚÈÔ¯‹ TRD-NLS Î·È °. late-truncating, οوıÂÓ ÙÔ˘ TRD. ¢ÂÓ ‚Ú¤ıËΠÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈ΋ Û˘Û¯¤ÙÈÛË ÌÂٷ͇ ÙÔ˘ Ù‡Ô˘ Ù˘ ÌÂÙ¿ÏÏ·Í˘ Î·È Ù˘ ‚·Ú‡ÙËÙ·˜ ÙÔ˘ Ê·ÈÓÔÙ‡Ô˘, Û‡Ìʈӷ Ì ÙË ‰ÔÎÈÌ·Û›· Fisher-ExactTest ÁÈ· ÌÈÎÚfi ·ÚÈıÌfi ‰ÂÈÁÌ¿ÙˆÓ (Pa=0,3535, Pb=0,304). ∂›Û˘, Ë Û‡ÁÎÚÈÛË ÙˆÓ scores ÌÂٷ͇ ÙˆÓ missense Î·È ÙˆÓ nonsense-frameshift ÌÂÙ·ÏϿ͈Ó, Ì ÙË ‰ÔÎÈÌ·Û›· Wilcoxon-Mann-Whitney, ‰ÂÓ ¤‰ˆÛ ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈο ·ÔÙÂϤÛÌ·Ù· (U=31,5 Ì fiÚÈ· 15-53 ÛÙÔ Â›Â‰Ô ÙÔ˘ 5%). °È· ÙȘ ‰ÔÎÈ̷ۛ˜ ¯ÚËÛÈÌÔÔÈ‹ıËΠÙÔ ÏÔÁÈÛÌÈÎfi VassarStats (http:// faculty.vassar.edu/lowry/VassarStats.html).

™˘˙‹ÙËÛË ™ÙÔ ÎÏ·ÛÈÎfi RS, ÙÔ ÔÛÔÛÙfi ÌÂÙ·ÏÏ¿ÍÂˆÓ Î˘Ì·›ÓÂÙ·È ·fi 60 ¤ˆ˜ 95%. ∏ ‰È·Î‡Ì·ÓÛË ·˘Ù‹ ÔÊ›ÏÂÙ·È ÛÙȘ ·Ú·Ì¤ÙÚÔ˘˜ ÂÈÏÔÁ‹˜ ÙˆÓ ÂÍÂÙ·˙ÔÌ¤ÓˆÓ Î·È ÛÙȘ ¯ÚËÛÈÌÔÔÈÔ‡ÌÂÓ˜ ÌÔÚȷΤ˜ ÌÂıfi‰Ô˘˜. ¢È¿ÁÓˆÛË ÂÈÙ˘Á¯¿ÓÂÙ·È ÛÙÔ 95% Ì ÙËÓ ÂÊ·ÚÌÔÁ‹ ÔÛÔÙÈ΋˜ ÌÂıfi‰Ô˘ ÁÈ· ·Ó›¯Ó¢ÛË ÌÂÁ¿ÏˆÓ ·Ó·Î·Ù·-

Ù¿ÍÂˆÓ Ô˘ ÂÚÈÏ·Ì‚¿ÓÔ˘Ó ÔÏfiÎÏËÚ· ÂÍfiÓÈ· ‹ Î·È ÙÌ‹Ì·Ù· ·Ú·Î›ÌÂÓˆÓ ÁÔÓȉ›ˆÓ Î·È ÂͤٷÛË ÂÈϤÔÓ Î·È ÙÔ˘ ÂÍÔÓ›Ô˘ 1 (16,19). ™ÙËÓ ·ÚÔ‡Û· ÌÂϤÙË, ÙÔ ÔÛÔÛÙfi 78,3% Â›Ó·È ÛÙ· Ï·›ÛÈ· ÙÔ˘ Û˘Ó‹ıÔ˘˜ Ê¿ÛÌ·ÙÔ˜ (60-85%) (17). ™ÙÔ ¿Ù˘Ô RS, ÙÔ ÔÛÔÛÙfi ‹Ù·Ó ·ÚÎÂÙ¿ ¯·ÌËÏfi (20%) Û ۯ¤ÛË Ì ÙË ‚È‚ÏÈÔÁÚ·Ê›· (30-45%) (23), ÁÂÁÔÓfi˜ Ô˘ ÌÔÚ› Ó· ·Ô‰Ôı› ÛÙËÓ ÎÏÈÓÈ΋ ÂÙÂÚÔÁ¤ÓÂÈ· ÙÔ˘ ‰Â›ÁÌ·ÙÔ˜ Î·È ÛÙÔ ÁÂÁÔÓfi˜ fiÙÈ Î·È ¿ÏÏ· ÁÔÓ›‰È· ¢ı‡ÓÔÓÙ·È ÁÈ· ÙÔ RS, fiˆ˜ ÙÔ CDKL5, Û‡Ìʈӷ Ì ÚfiÛÊ·Ù· ‰Â‰Ô̤ӷ (24). ∞Ó ÛÙËÓ ÔÌ¿‰· ÙÔ˘ ¿Ù˘Ô˘ RS ÚÔÛÙ›ıÂÓÙÔ Î·È ÔÈ ÌÂÙ·ÏÏ¿ÍÂȘ ÙˆÓ ÎÔÚÈÙÛÈÒÓ ÙˆÓ ÔÌ¿‰ˆÓ AS-FXS, ÙÔ ÔÛÔÛÙfi ı· ·ÓÂÚ¯fiÙ·Ó ÛÙÔ 31% (9/29). ∏ ÏÂÈÔ„ËÊ›· ÙˆÓ ÌÂÙ·ÏÏ¿ÍÂˆÓ ÂÓÙÔ›ÛıËΠÛÙÔ ÂÍfiÓÈÔ 4, Û˘ÓÂÒ˜ ı· Ú¤ÂÈ Ó· ÌÂÏÂÙ¿Ù·È ÚÒÙÔ. ∆˘ÈΤ˜ ÌÂÙ·ÏÏ¿ÍÂȘ ‚Ú¤ıËÎ·Ó ÛÙÔ 56,25%, ÔÛÔÛÙfi Ô˘ ÚÔÛÂÁÁ›˙ÂÈ ˘¿Ú¯Ô˘Û˜ ÌÂϤÙ˜ (58-72%) (17). ∂ÓÙo‡ÙÔȘ, ‰ÂÓ ÂÎÚÔÛˆ‹ıËÎ·Ó Î·ıfiÏÔ˘ ÔÈ p.R255X Î·È p.R270X (NLS). ∞ÓÙ›ıÂÙ·, ·Ú·ÙËÚ‹ıËÎ·Ó ÔÏϤ˜ MBD ÌÂÙ·ÏÏ¿ÍÂȘ, ¯ˆÚ›˜ οÔÈ· Ó· ÚÔÂÍ¿Ú¯ÂÈ. ™Â ÌÂÁ¿Ï˜ ÏËı˘ÛÌȷΤ˜ ÌÂϤÙ˜ Û˘¯ÓfiÙÂÚ· ·Ó¢ڛÛÎÂÙ·È Ë p.R168X Î·È Ë p.∆158ª. 6/32 (18,75%) ÙˆÓ ·ÏÏ·ÁÒÓ ‹Ù·Ó de novo, fiˆ˜ Ë del318insA ÛÙÔ ÂÍfiÓÈÔ 3 Î·È Ù· ¤ÓÙ ηڂÔ͢ÙÂÏÈο ÂÏÏ›ÌÌ·Ù·, ÙˆÓ ÔÔ›ˆÓ Ë Û˘¯ÓfiÙËÙ· (5/32, 15,625%) Û˘Ì‚¿‰È˙ Ì ÙË ‚È‚ÏÈÔÁÚ·Ê›· (10-15%) (16,17). ∏ ÚÔÛ¿ıÂÈ· Û˘Û¯¤ÙÈÛ˘ ÁÔÓÔÙ‡Ô˘-Ê·ÈÓÔÙ‡Ô˘ ·ÚÔ˘Û›·Û ‰˘ÛÎÔϛ˜, ÏfiÁˆ ÙÔ˘ ÌÈÎÚÔ‡ ‰Â›ÁÌ·ÙÔ˜. ¶Ú¿ÁÌ·ÙÈ, ÔÏϤ˜ ÌÂϤÙ˜ Ì ÌÈÎÚ¤˜ ÛÂÈÚ¤˜ ·ÛıÂÓÒÓ ¤¯Ô˘Ó Ô‰ËÁËı› Û ·ÓÙÈÎÚÔ˘fiÌÂÓ· Û˘ÌÂÚ¿ÛÌ·Ù· Î·È ÌË ÛÙ·ÙÈÛÙÈÎÒ˜ ÛËÌ·ÓÙÈο ·ÔÙÂϤÛÌ·Ù·. ™ÙËÓ ·ÚÔ‡Û· ÌÂϤÙË ‚Ú¤ıËΠÛÙ·ÙÈÛÙÈÎÒ˜ ÈÛ¯˘Ú¿ ÛËÌ·ÓÙÈ΋ Û˘Û¯¤ÙÈÛË ÌÂٷ͇ Ù˘ Ù˘ÈÎfiÙËÙ·˜ Î·È Ù˘ ‚·Ú‡ÙËÙ·˜ ÙÔ˘ Ê·ÈÓÔÙ‡Ô˘ Ì ÙËÓ Èı·ÓfiÙËÙ· ÌÂÙ¿ÏÏ·Í˘. ∂›Ó·È ÚÔÊ·Ó¤˜ fiÙÈ Ú¤ÂÈ Ó· Á›ÓÂÙ·È ·ÍÈÔÏfiÁËÛË ÙˆÓ ·ÛıÂÓÒÓ ‚¿ÛÂÈ ÎÚÈÙËÚ›ˆÓ, ÚÔÙÔ‡ ·Ú·ÂÌÊıÔ‡Ó ÁÈ· DNA ·Ó¿Ï˘ÛË, ÒÛÙ ӷ ·˘Í¿ÓÔÓÙ·È ÔÈ Èı·ÓfiÙËÙ˜ ·Ó‡ÚÂÛ˘ ÌÂÙ¿ÏÏ·Í˘. ∏ Û‡ÁÎÚÈÛË ÙÔ˘ Ù‡Ô˘ ÙˆÓ ÌÂÙ·ÏÏ¿ÍÂˆÓ ÌÂٷ͇ ÙÔ˘˜ Î·È Û ۯ¤ÛË Ì ÙÔ ‚·ıÌfi Ê·ÈÓÔÙ˘È΋˜ ‚·Ú‡ÙËÙ·˜ ‰ÂÓ ¤‰ˆÛ ÛÙ·ÙÈÛÙÈÎÒ˜ ÛËÌ·ÓÙÈο ·ÔÙÂϤÛÌ·Ù·. ÕÏÏÔÈ ÙÚÔÔÔÈËÙ¤˜ Ù˘ ÁÔÓÔÙ˘È΋˜-Ê·ÈÓÔÙ˘È΋˜ Û˘Û¯¤ÙÈÛ˘ ›ӷÈ: 1. Ô ‚·ıÌfi˜ ·‰Ú·ÓÔÔ›ËÛ˘ ÙÔ˘ X ¯ÚˆÌÔÛÒÌ·ÙÔ˜, Ô ÔÔ›Ô˜ Â›Ó·È Û˘Ó‹ıˆ˜ Ù˘¯·›Ô˜ Ì ·ÔÙ¤ÏÂÛÌ· ÎÏÈÓÈ΋ ÂÙÂÚÔÁ¤ÓÂÈ·, 2. Ë ËÏÈΛ· ÂͤٷÛ˘, ηıÒ˜ Ô Ï‹Ú˘ Ê·ÈÓfiÙ˘Ô˜ ·ÔηχÙÂÙ·È ÌÂÙ¿ Ù· 3-4 ¤ÙË, 3. Ù· ÎÚÈÙ‹ÚÈ· Ô˘ ÂÈϤÁÔÓÙ·È ÁÈ· ÙË ‰ËÌÈÔ˘ÚÁ›· ÙˆÓ Ê·ÈÓÔÙ˘ÈÎÒÓ scores, 4. Ô ‚·ıÌfi˜ Ù˘ÈÎfiÙËÙ·˜ ÙÔ˘ Ê·ÈÓÔÙ‡Ô˘ Î·È 5. ¿ÁÓˆÛÙÔÈ ÂÈÁÂÓÂÙÈÎÔ› ·Ú¿ÁÔÓÙ˜ (25). øÛÙfiÛÔ, ÓÂfiÙÂÚ˜ ÌÂϤÙ˜ ηٷϋÁÔ˘Ó fiÙÈ ÌÂÙ·ÏÏ¿ÍÂȘ ÚÈÓ Î·È ÂÓÙfi˜ Ù˘ NLS ÂÚÈÔ¯‹˜, Ô‰ËÁÔ‡Ó Û ÛÔ‚·Úfi Ê·ÈÓfiÙ˘Ô, ‰ÈfiÙÈ ÂȉÚÔ‡Ó ÛÙËÓ ¶·È‰È·ÙÚÈ΋ 2008;71:38-47

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·46

46

™. æÒÓË Î·È Û˘Ó.

ÈηÓfiÙËÙ· Ù˘ ÚˆÙ½Ó˘ Ó· ÂÈÛ·¯ı› ÛÙÔÓ ˘Ú‹Ó· Î·È Ó· ÚÔÛ‰Âı› ÛÙÔ ÌÂı˘ÏȈ̤ÓÔ DNA (25,26). √È ÌÂÙ·ÏÏ¿ÍÂȘ ¤Ú· ·fi ÙÔ NLS Î·È Ù· ηڂÔ͢ÙÂÏÈο ÂÏÏ›ÌÌ·Ù· ¤¯Ô˘Ó ‹È·, ¿Ù˘Ë ¤ÎÊÚ·ÛË, ηıÒ˜ Ë ÚˆÙ½ÓË ·ÏÒ˜ ¯¿ÓÂÈ Î¿ÔÈ· ÈηÓfiÙËÙ· ÌÂÙ·ÁÚ·ÊÈ΋˜ ηٷÛÙÔÏ‹˜ (26). ∞fi ÙȘ ÎÏ·ÛÈΤ˜ ÌÂÙ·ÏÏ¿ÍÂȘ ÂӉȷʤÚÔÓ ·ÚÔ˘ÛÈ¿˙Ô˘Ó Ë p.R133C Î·È Ë p.R306C. ∏ ÚÒÙË Û¯ÂÙ›˙ÂÙ·È Ì ÌÈÎÚ‹ ‚·Ú‡ÙËÙ·, ÌÂÁ·Ï‡ÙÂÚË ËÏÈΛ· ¤Ó·Ú͢ ·ÏÈÓ‰ÚfiÌËÛ˘ Î·È ÎÏÈÓÈ΋ ÔÈÎÈÏÔÌÔÚÊ›· (25,26). ™Â Â›Â‰Ô ÚˆÙÂ˚ÓÈ΋˜ ¤ÎÊÚ·Û˘, ÌÈ· ÌÂϤÙË ¤‰ÂÈÍ in vitro ·ÚfiÌÔÈ· ÏÂÈÙÔ˘ÚÁÈÎfiÙËÙ· Ù˘ R133C Ì ÙË wild-type ÚˆÙ½ÓË (27). ∏ ‰Â‡ÙÂÚË ÂÓÙÔ›˙ÂÙ·È ÛÙÔ Ù¤ÏÔ˜ ÙÔ˘ TRD, ofiÙ ‰ÂÓ ·Ú·‚Ï¿ÙÂÈ ÛËÌ·ÓÙÈο ÙÔ˘˜ ÏÂÈÙÔ˘ÚÁÈÎÔ‡˜ ÙÔÌ›˜ Î·È ıˆÚÂ›Ù·È ‹È· (27). ™ÙË ÌÂϤÙË, Ë p.R133C Û˘ÁΤÓÙÚˆÛ ·Ú·‰fi͈˜ ˘„ËÏfi score ‚·Ú‡ÙËÙ·˜ (mean=23,55, SD=1,2714), ·ÏÏ¿ fiˆ˜ Î·È Ë p.R306C ·Ú·ÙËÚ‹ıËÎ·Ó Î·È ÛÙËÓ ¿Ù˘Ë AS-ÔÌ¿‰·. ∆· ·ÔÙÂϤÛÌ·Ù· ·fi ÙËÓ ¤Ú¢ӷ ÙÔ˘ MECP2 Û ¿ÏÏÔ˘˜ æ∫∫ Ê·ÈÓÔÙ‡Ô˘˜ ‹Ù·Ó ÂÓı·ÚÚ˘ÓÙÈο, ·Ó Î·È ‰ÂÓ ÂÈÙÚ¤Ô˘Ó ÙË Ì·˙È΋ ÂÊ·ÚÌÔÁ‹ ÂϤÁ¯Ô˘ Û fiÏ· Ù· ·È‰È¿ Ì æ∫∫. ∂›Ó·È ›Ûˆ˜ ÛÎfiÈÌÔ Ó· ÂϤÁ¯ÔÓÙ·È AS-·ÚÓËÙÈο ·È‰È¿, ÏfiÁˆ ÂÈÎ¿Ï˘„˘ Ì ÙÔ RS, fiˆ˜ Ê¿ÓËΠ·fi Ù· ·ÔÙÂϤÛÌ·Ù· Ù˘ AS-ÔÌ¿‰·˜. ™ÙËÓ FÃS-oÌ¿‰· ÂӉȷʤÚÔÓ ÚÔηÏ› Ë ÔÈÎÔÁÂÓÂȷ΋ ÂÚ›ÙˆÛË. Œ¯Ô˘Ó ‹‰Ë ·Ó·ÊÂÚı› ÂÚÈÛÙ·ÙÈο Ì ÎÏËÚÔÓÔÌÔ‡ÌÂÓË ÌÂÙ¿ÏÏ·ÍË ·fi ·Û˘Ìو̷ÙÈΤ˜ ÌËÙ¤Ú˜-ÊÔÚ›˜ Ì ÌÂÁ¿ÏÔ ‚·ıÌfi X ·‰Ú·ÓÔÔ›ËÛ˘ (28). ø˜ ÚÔ˜ ÙË ÛËÌ·Û›· Ù˘ ÌÂÙ·ÏÏ·Á‹˜ p.T203ª (·ÁfiÚÈ FR120 Ì ·ÚÓËÙÈ΋ ÌËÙ¤Ú·), ÌÂϤÙË Ì ÙÔ ÏÔÁÈÛÌÈÎfi PolyPhen (http://genetics. bwh.harvard.edu/pph/) ‰ÂÓ ÚÔ¤‚Ï„ ηÎÔ‹ıË Â›‰Ú·ÛË ÛÙËÓ ÚˆÙ½ÓË, ˆÛÙfiÛÔ ‰ÂÓ ÌÔÚ› Ó· ·ÔÎÏÂÈÛı› Ë Â›‰Ú·ÛË ÛÙÔ Ê·ÈÓfiÙ˘Ô. ªÂϤÙ˜ Ì FÃS-·ÚÓËÙÈÎÔ‡˜ ·ÛıÂÓ›˜ ‰›ÓÔ˘Ó ıÂÙÈο ·ÔÙÂϤÛÌ·Ù· Û 0,5-2%, ÔÛÔÛÙ¿ Û˘ÁÎÚ›ÛÈÌ· Ì ÙË ÌÂϤÙË Ì·˜ (12,29). ∞fi ÙËÓ ÔÌ¿‰· ÙˆÓ 11 ·ÁÔÚÈÒÓ, Ô R11 (p.R106W) ›Ûˆ˜ ·ÚÔ˘ÛÈ¿˙ÂÈ ÛˆÌ·ÙÈÎfi ̈۷˚ÎÈÛÌfi, ˘fiıÂÛË Û˘Ì‚·Ù‹ Ì ÙË Ê·ÈÓÔÙ˘È΋ ÙÔ˘ ÂÈÎfiÓ·, ηıÒ˜ ·Ó ¤ÊÂÚ ÙË ÌÂÙ¿ÏÏ·ÍË Û Ï‹ÚË ÌÔÚÊ‹ ı· ÂÌÊ¿ÓÈ˙ Èı·Ófiٷٷ ÓÂÔÁÓÈ΋ ÂÁÎÂÊ·ÏÔ¿ıÂÈ· Î·È ‰ÂÓ ı· ÂÈ‚›ˆÓÂ. ∏ ÌËÙ¤Ú· ‰ÂÓ ‹Ù·Ó ‰È·ı¤ÛÈÌË ÁÈ· ÂͤٷÛË. ™ÙË ‚È‚ÏÈÔÁÚ·Ê›· ¤¯ÂÈ ·Ó·ÊÂÚı› Ì›· ·ÎfiÌË ·ÚfiÌÔÈ· ÂÚ›ÙˆÛË (30). ∏ ÂÚ›ÙˆÛË Ì ÙÔ ÌÂÁ¿ÏÔ ¤ÏÏÂÈÌÌ· (R59) ¯Ú‹˙ÂÈ ‰ÈÂÚ‡ÓËÛ˘ Ì ÔÛÔÙÈ΋ ̤ıÔ‰Ô. ∞Ó·ÎÂÊ·Ï·ÈÒÓÔÓÙ·˜, ÙÔ RS ·ÔÙÂÏ› ÛËÌ·ÓÙÈ΋ Ó¢ÚÔ·Ó·Ù˘Íȷ΋ ‰È·Ù·Ú·¯‹ Ô˘ ÁÈ· ÚÒÙË ÊÔÚ¿ ÌÂÏÂÙ‹ıËΠÛÙÔÓ ÂÏÏËÓÈÎfi ÏËı˘ÛÌfi. ∏ ‰È¿ÎÚÈÛË Û ÎÏ·ÛÈ΋ Î·È ¿Ù˘Ë ÌÔÚÊ‹ Á›ÓÂÙ·È ‚¿ÛÂÈ ÎÚÈÙËÚ›ˆÓ ÂÈÙÚ¤ÔÓÙ·˜ ÙËÓ ·Ó›¯Ó¢ÛË ÌÂÙ·ÏÏ¿ÍÂˆÓ Û ÌÂÁ¿ÏÔ ÔÛÔÛÙfi. øÛÙfiÛÔ, Ë ÌË ÂÎÏ‹ÚˆÛË ÙˆÓ ÎÚÈÙËÚ›ˆÓ Paediatriki 2008;71:38-47

ÌÔÚ› Ó· ÂÁ›ÚÂÈ ˘Ô„›· RS, ÏfiÁˆ Ù˘ ÂÌÏÔ΋˜ ÙÔ˘ ˘‡ı˘ÓÔ˘ ÁÔÓȉ›Ô˘ Û ÏËıÒÚ· Ê·ÈÓÔÙ‡ˆÓ. ¶ÚÔÛÔ¯‹ Ú¤ÂÈ Ó· ‰Ôı› ÛÙ· ·È‰È¿ Ì AS Ê·ÈÓfiÙ˘Ô Î·È ÛÙ· ·È‰È¿ Ì ·‰È¢ÎÚ›ÓÈÛÙË æ∫∫, Ó¢ÚÔÏÔÁÈο ÚÔ‚Ï‹Ì·Ù· ¯ˆÚ›˜ ‰ÔÌÈΤ˜ ÂÁÎÂÊ·ÏÈΤ˜ ·ÓˆÌ·Ï›Â˜ Î·È ·Ô˘Û›· ‰˘ÛÌÔÚÊÈÎÒÓ ÛÙÔȯ›ˆÓ. ∂ȉÈÎÔ› Ê·ÈÓfiÙ˘ÔÈ ·ÁÔÚÈÒÓ Ô˘ Ú¤ÂÈ Ó· ·Ó·ÁÓˆÚ›˙ÔÓÙ·È Â›Ó·È ‚Ú¤ÊË Ì ÛÔ‚·Ú‹ ÓÂÔÁÓÈ΋ ÂÁÎÂÊ·ÏÔ¿ıÂÈ·, ·ÁfiÚÈ· Ì ÛËÌ›· RS, ÌË-ÂȉÈ΋, ÌË-ÂÍÂÏÈÛÛfiÌÂÓË æ∫∫, Û˘Óԉ¢fiÌÂÓË ·fi Ó¢ÚÔÏÔÁÈο ÚÔ‚Ï‹Ì·Ù· Î·È ÛÙ· Ï·›ÛÈ· ÔÈÎÔÁÂÓÔ‡˜ Ê˘ÏÔÛ‡Ó‰ÂÙ˘ æ∫∫. ∏ ÁÂÓÂÙÈ΋ Û˘Ì‚Ô˘Ï¢ÙÈ΋ Â›Ó·È ÔχÏÔÎË, ηıÒ˜ 99% ÙˆÓ ÎÔÚÈÙÛÈÒÓ ¤¯ÂÈ de novo ÌÂÙ·ÏÏ¿ÍÂȘ ÏfiÁˆ ̈۷˚ÎÈÛÌÔ‡ ÙˆÓ ÁÔÓ¿‰ˆÓ ÙÔ˘ ·Ù¤Ú· Î·È ÌfiÓÔ 1% Â›Ó·È ÔÈÎÔÁÂÓ›˜ ÂÚÈÙÒÛÂȘ. ™ÙȘ ÂÚÈÙÒÛÂȘ ıÂÙÈÎÒÓ ·ÁÔÚÈÒÓ, Ú¤ÂÈ Ó· ÂϤÁ¯ÂÙ·È Î·È Ë ÌËÙ¤Ú·, ‰ÈfiÙÈ Û˘Ó‹ıˆ˜ Â›Ó·È ·Û˘Ìو̷ÙÈÎfi˜ ÊÔÚ¤·˜. °È· ÙËÓ ÂÍ·ÛÊ¿ÏÈÛË Ù˘ ÔÈÎÔÁ¤ÓÂÈ·˜ Ì ¿Û¯ÔÓ Ì¤ÏÔ˜, Û˘ÓÈÛÙ¿Ù·È ¤ÏÂÁ¯Ô˜ Ù˘ ÌËÙ¤Ú·˜ Î·È ÚÔÁÂÓÓËÙÈÎfi˜ ¤ÏÂÁ¯Ô˜ Û ÌÂÏÏÔÓÙÈ΋ ·ËÛË. ∏ ·Ó·ÁÓÒÚÈÛË ÙÔ˘ RS Î·È ÙˆÓ ¿Ù˘ˆÓ ÌÔÚÊÒÓ Î·È Ë ¤Ú¢ӷ Û ÁÔÓȉȷÎfi Â›Â‰Ô Û˘Ì‚¿ÏÏÔ˘Ó ÛÙË ‰ÈÂÚ‡ÓËÛË ÙˆÓ ÌÔÚÊÒÓ Ù˘ ÓÔËÙÈ΋˜ ˘ÛÙ¤ÚËÛ˘ ÛÙÔÓ ·È‰ÈÎfi ÏËı˘ÛÌfi Î·È ÛÙË ÁÂÓÂÙÈ΋ ηıÔ‰‹ÁËÛË ÙˆÓ ÔÈÎÔÁÂÓÂÈÒÓ.

µÈ‚ÏÈÔÁÚ·Ê›·: 1. Kim IJ, Kim YJ, Son BH, Nam SO, Kang HC, Kim HD, et al. Diagnostic mutational analysis of MECP2 in Korean patients with Rett syndrome. Exp Mol Med 2006;38:119-125.

2. Hagberg B, Hagberg G. Rett syndrome: epidemiology and geographical variability. Eur Child Adolesc Psychiatry 1997;6 Suppl 1:5-7.

3. Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome.

Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Eur J Paediatr Neurol 2002;6:293-297.

4. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in Xlinked MECP2, encoding methyl-CpG-binding protein 2.

Nat Genet 1999;23:185-188.

5. Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ, et al. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet 2004;36:339-341.

6. Van den Veyver IB, Zoghbi HY. Methyl-CpG-binding protein 2 mutations in Rett syndrome. Curr Opin Genet Dev 2000;10:275-279.

7. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat Genet 2005;37:31-40.

8. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003;302: 890-893.

9. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: M∂CP2 levels display tissue-

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·47

47

∫ÏÈÓÈ΋ Î·È ÌÔÚȷ΋ ÌÂϤÙË ÙÔ˘ ÁÔÓȉ›Ô˘ MECP2

and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 2002;11:115-124.

10. Hagberg BA, Skjeldal OH. Rett variants: a suggested model for inclusion criteria. Pediatr Neurol 1994;11:5-11.

11. Hitchins MP, Rickard S, Dhalla F, Fairbrother UL, de Vries BB, Winter R, et al. Investigation of UBE3A and MECP2 in Angelman syndrome (AS) and patients with features of AS. Am J Med Genet A 2004;125:167-172.

12. Gomot M, Gendrot C, Verloes A, Raynaud M, David A, Yntema HG, et al. MECP2 gene mutations in non-syndromic X-linked mental retardation: phenotype-genotype correlation. Am J Med Genet A 2003;123:129-139.

13. Erlandson A, Hagberg B. MECP2 abnormality phenotypes: clinicopathologic area with broad variability. J Child Neurol 2005;20:727-732.

14. Moog U, Smeets EE, van Roozendaal KE, Schoenmakers S, Herbergs J, Schoonbrood-Lenssen AM, et al. Neurodevelopmental disorders in males related to the gene causing Rett syndrome in females (MECP2). Eur J Paediatr Neurol 2003;7:5-12.

15. Orrico A, Lam C, Galli L, Dotti MT, Hayek G, Tong SF, et al. MECP2 mutation in male patients with non-specific Xlinked mental retardation. FEBS Lett 2000;481:285-288.

16. Philippe C, Villard L, De Roux N, Raynaud M, Bonnefond JP, Pasquier L, et al. Spectrum and distribution of MECP2 mutations in 424 Rett syndrome patients: a molecular update. Eur J Med Genet 2006;49:9-18.

17. Miltenberger-Miltenyi G, Laccone F. Mutations and polymorphisms in the human methyl CpG-binding protein MECP2. Human Mutat 2003;22:107-115.

18. Lee SS, Wan M, Francke U. Spectrum of MECP2 mutations in Rett syndrome. Brain Dev 2001;23 Suppl 1:S138S143.

19. Laccone F, Jünemann I, Whatley S, Morgan R, Butler R, Huppke P, et al. Large deletions of the MECP2 gene detected by gene dosage analysis in patients with Rett syndrome.

Hum Mutat 2004;23:234-244.

20. Kerr AM, Nomura Y, Armstrong D, Anvret M, Belichenko PV, Budden S, et al. Guidelines for reporting clinical features in cases with MECP2 mutations. Brain Dev 2001;23: 208-211.

21. Myers RM, Maniatis T, Lerman LS. Detection and localization of single base changes by denaturing gradient gel electrophoresis. Methods Enzymol 1987;155:501-527.

22. Voutoufianakis S, Psoni S, Vorgia P, Tsekoura F, Kekou K, Traeger-Synodinos J, et al. Coinheritance of mutated SMN1 and MECP2 genes in a child with phenotypic features of spinal muscular atrophy (SMA) type II and Rett syndrome. Eur J Paediatr Neurol 2007;11:235-239.

23. Schanen C, Houwink EJ, Dorrani N, Lane J, Everett R, Feng A, et al. Phenotypic manifestations of MECP2 mutations in classical and atypical Rett syndrome. Am J Med Genet A 2004;126:129-140.

24. Mari F, Azimonti S, Bertani I, Bolognese F, Colombo E, Caselli R, et al. CDKL5 belongs to the same molecular pathway of MECP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet, 2005;14:1935-1946.

25. Charman T, Neilson TC, Mash V, Archer H, Gardiner MT, Knudsen GP, et al. Dimensional phenotypic analysis and functional categorisation of mutations reveal novel genotype-phenotype associations in Rett syndrome. Eur J Hum Genet 2005;13:1121-1130.

26. Ham AL, Kumar A, Deeter R, Schanen NC. Does genotype predict phenotype in Rett syndrome? J Child Neurol 2005;20:768-778.

27. Yusufzai TM, Wolffe AP. Functional consequences of Rett syndrome mutations on human MECP2. Nucleic Acids Res 2000;28:4172-4179.

28. Dayer AG, Bottani A, Bouchardy I, Fluss J, Antonarakis SE, Haenggeli CA, et al. MECP2 mutant allele in a boy with Rett syndrome and his unaffected heterozygous mother.

Brain Dev 2007;29:47-50.

29. Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C, et al. MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 2001;10:941-946.

30. Masuyama T, Matsuo M, Jing JJ, Tabara Y, Kitsuki K, Yamagata H, et al. Classic Rett syndrome in a boy with R133C mutation of MECP2. Brain Dev 2005;27:439-442.

¶·È‰È·ÙÚÈ΋ 2008;71:38-47

Pediatri Jan-Feb 08

15-02-08

48

11:00

™ÂÏ›‰·48

∂ƒ∂À¡∏∆π∫∏ ∂ƒ°∞™π∞

ORIGINAL ARTICLE

¢È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘ Û ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ 1 ¶·È‰ÔÓ¢ÚÔÏÔÁÈÎfi ∆Ì‹Ì·, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ¶¿ÙÚ·˜ “∫·Ú·Ì·Ó‰¿ÓÂÈÔ” 2 ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ¶¿ÙÚ·˜ “∫·Ú·Ì·Ó‰¿ÓÂÈÔ” 3 ∂ȉÈ΋ ¶·ıÔÏfiÁÔ˜ AÏÏËÏÔÁÚ·Ê›·: ¢Ú. πˆÛ‹Ê ∫·Ï¤ÁÈ·˜ Kaleyias@hotmail.com ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ¶¿ÙÚ·˜ “∫·Ú·Ì·Ó‰¿ÓÂÈÔ” ∂Ú˘ıÚÔ‡ ™Ù·˘ÚÔ‡ 40, ∆.∫. 263 31, ¶¿ÙÚ·

π. ∫·Ï¤ÁÈ·˜1, µ. ƒÔ‡ÏË2, ∞. ∫·Ú·Ù˙·Ê¤ÚË3, ∫. ¢·ÎÔÚÒÓÈ·˜2, ª. ¶··˚ˆ¿ÓÓÔ˘2, £. ¢·Ó›‰Ë1, √. ¢. ¶··ÁˆÚÁ›Ô˘2, ∫. ¶·Ô˘ÙÛ‹2, °. ∫ÚÔÎȉ¿˜2, ¡. ¢È·Ì·ÓÙfiÔ˘ÏÔ˜1 ¶ÂÚ›ÏË„Ë ™ÎÔfi˜: ™ÎÔfi˜ Ù˘ ·ÚÔ‡Û·˜ ÌÂϤÙ˘ ‹Ù·Ó Ë ‰ÈÂÚ‡ÓËÛË Ù˘ Â›ÙˆÛ˘ ÙˆÓ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘ Û ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ Î·È Ë Èı·Ó‹ Û˘Û¯¤ÙÈÛË ÙˆÓ ‰È·Ù·Ú·¯ÒÓ ·˘ÙÒÓ Ì ÔÈΛÏÔ˘˜ ÎÔÈÓˆÓÈÎÔ‡˜ Î·È ÂÚÈ‚·ÏÏÔÓÙÈÎÔ‡˜ ·Ú¿ÁÔÓÙ˜. ÀÏÈÎfi Î·È Ì¤ıÔ‰ÔÈ: ÃÔÚËÁ‹ıËÎÂ Ù˘ÔÔÈË̤ÓÔ ÂÚˆÙËÌ·ÙÔÏfiÁÈÔ Û 166 ÁÔÓ›˜ ·È‰ÈÒÓ ËÏÈΛ·˜ 6-12 ÂÙÒÓ Ô˘ ÂÈÛΤÊıËÎ·Ó ÙÔ ¡ÔÛÔÎÔÌ›Ô. ∞ÔÙÂϤÛÌ·Ù·: ∂·Ú΋˜ ‡ÓÔ˜ (≥10 ÒÚ˜) ÙȘ ηıËÌÂÚÈÓ¤˜ ·Ó·Ê¤ÚÂÙ·È ÛÙÔ 39% ÙˆÓ ·È‰ÈÒÓ 6-9 ÂÙÒÓ Î·È ÛÙÔ 9% ÙˆÓ ·È‰ÈÒÓ 10-12 ÂÙÒÓ (p=0,0001), ÂÓÒ Ù· ™·‚‚·ÙÔ·Úȷη ÛÙÔ 74% Î·È 57%, ·ÓÙ›ÛÙÔȯ· (p=0,025). ∆Ô 24,7% ÙˆÓ ·È‰ÈÒÓ ·ÚÔ˘Û›·˙·Ó Û˘ÓÔÏÈο ÙȘ ÂÍ‹˜ ‰È·Ù·Ú·¯¤˜ ‡ÓÔ˘: I. ¢˘Û˘ÓÈΤ˜ ‰È·Ù·Ú·¯¤˜ (dysomnias): ·ÓÙ›ÛÙ·ÛË Ó· ¿ÂÈ ÛÙÔ ÎÚ‚¿ÙÈ (31%), ·Ó¿ÁÎË ÁÈ· Û˘Óԉ›· ÁÈ· ‡ÓÔ (26%), ËÌÂÚ‹ÛÈ· ˘ÓËÏ›· (14%), Ó˘¯ÙÂÚÈÓ‹ ·Ê‡ÓÈÛË (9,6%), ‡ÓÔ ÛÙÔ ÎÚ‚¿ÙÈ ÙˆÓ ÁÔÓÈÒÓ (9%), ÚÔ¯·ÏËÙfi (7,2%) Î·È ‰˘ÛÎÔÏ›· Ó· ·ÔÎÔÈÌËı› (6,6%). ππ. ¶·Ú·¸ÓÈΤ˜ ‰È·Ù·Ú·¯¤˜ (parasomnia): ·Ú·ÌÈÏËÙfi (11,4%), ÙÚÈÛÌfi˜ ‰ÔÓÙÈÒÓ (10,2%), Û˘Á¯˘ÙÈΤ˜ ·Ê˘Ó›ÛÂȘ (7,2%), ÂÊÈ¿ÏÙ˜ (5%), Ú˘ıÌÈΤ˜ ÎÈÓ‹ÛÂȘ (3%), Ó˘¯ÙÂÚÈÓ‹ ÂÓÔ‡ÚËÛË (2,4%), Ó˘¯ÙÂÚÈÓfi˜ ÙÚfiÌÔ˜ (1,8%) Î·È ˘ÓÔ‚·Û›· (1,8%). ªfiÓÔ ÙÔ 10% ÙˆÓ ÁÔÓ¤ˆÓ ·Ó·ÁÓˆÚ›˙Ô˘Ó ÙËÓ ‡·ÚÍË ‰È·Ù·Ú·¯‹˜ ‡ÓÔ˘, ÂÓÒ ÌfiÏȘ ÔÈ ÌÈÛÔ› ·fi ·˘ÙÔ‡˜ ÈÛÙÂ‡Ô˘Ó fiÙÈ ·˘Ùfi ¤¯ÂÈ ‰˘ÛÌÂÓ‹ Â›‰Ú·ÛË ÛÙËÓ ÔÈÎÔÁ¤ÓÂÈ·, ηıÒ˜ Î·È ÛÙË Û¯ÔÏÈ΋ ·fi‰ÔÛË ÙÔ˘ ·È‰ÈÔ‡. ™˘ÌÂÚ¿ÛÌ·Ù·: ™ÙËÓ ·ÚÔ‡Û· ÛÂÈÚ¿ ·È‰ÈÒÓ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜, ÔÈ ‰È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘ ‹Ù·Ó Û˘¯Ó¤˜ (25%). ŸÌˆ˜, ÌfiÓÔ ÙÔ 10% ÙˆÓ ÁÔÓ¤ˆÓ ÈÛÙÂ‡Ô˘Ó fiÙÈ Ù· ·È‰È¿ ÙÔ˘˜ ¤¯Ô˘Ó οÔÈÔ Úfi‚ÏËÌ· ÛÙÔÓ ‡ÓÔ. ŒÙÛÈ, Ë ¯Ú‹ÛË Ù˘ÔÔÈË̤ÓÔ˘ ÂÚˆÙËÌ·ÙÔÏÔÁ›Ô˘ ı· ÌÔÚÔ‡Û ӷ ‰È¢ÎÔχÓÂÈ ÛÙÔÓ ÂÓÙÔÈÛÌfi ·È‰ÈÒÓ Ì ‰È·Ù·Ú·¯¤˜ ÛÙÔÓ ‡ÓÔ Î·È ÙËÓ ·Ú·ÔÌ‹ ÙÔ˘˜ ÁÈ· ÂÚ·ÈÙ¤Úˆ ·ÓÙÈÌÂÙÒÈÛË.

§¤ÍÂȘ ÎÏÂȉȿ: ¢È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘, ·È‰È¿, ÁÔÓ›˜, ÂÚˆÙËÌ·ÙÔÏfiÁÈÔ.

Sleep problems in school-age children 1 Paediatric Neurology Department, “Karamandanion” Children’s Hospital of Patras, Patras, Greece 2 Paediatric Department, “Karamandanion” Children’s Hospital of Patras, Patras, Greece 3 Internist Correspondence: J. Kaleyias Kaleyias@hotmail.com “Karamandanion” Children’s Hospital of Patras 40, Erythrou Stavrou St., 263 31, Patras, Greece

J. Kaleyias1, V. Rouli2, A. Karatzaferi3, K. Dakoronias2, M. Papaioannou2, T. Danidi2, U. D. Papageorgiou2, K. Papoutsi2, G. Krokidas2, N. Diamantopoulos1 Abstract Objectives: To survey the prevalence of sleep problems in school-age children and to explore the association between sleep disorders and various social and environmental factors.

Methods: Sleep questionnaires were administrated to the parents of 166 children aged between 6 and 12 years.

Results: Sufficient sleep (≥10 hours) was reported during the week for 39% of children aged 6-9 years and 9% of those aged 10-12 years (p=0.0001), while at the weekends the corresponding percentages were 74% and 57% respectively (p=0.025). The overall prevalence of sleep problems was 24.7%, and specifically: I. Dysomnia-related sleep-wake behaviour: bedtime resistance (31%), needing to be accompanied by someone (26%), daytime sleepiness (14%), night waking (9.6%), coming to parents’ bed (9%), snoring (7.2%), and difficulty in falling asleep (6.6%).

II. Parasomnia-related sleep behaviour: talking in the sleep (11.4%), teeth grinding (10.2%), confused arousals (7.2%), nightmares (5%), rhythmical movements (3%), bed wetting (2.4%), night terrors (1.8%), and sleepwalking (1.8%). Ten percent of parents admitted that their child had a sleep problem, of which only 50% considered that this was a burden for the family.

Conclusions: Sleep problems are common among school-age children, with an overall incidence of 25%, although only 10% of the parents reported that their children might have a sleep problem. The sleep questionnaire could help for the identification of children with sleep problems.

Key words: Sleep problems, children, parents, questionnaire.

Paediatriki 2008;71:48-54

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·49

49

¢È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘

∂ÈÛ·ÁˆÁ‹ √ ‡ÓÔ˜ Â›Ó·È ÎÔÈÓ¿ ·Ô‰ÂÎÙfi fiÙÈ Û˘Ì‚¿ÏÏÂÈ ÛÙËÓ Â˘ÂÍ›· ÙˆÓ ·È‰ÈÒÓ Î·È ·ÔÙÂÏ› ÛËÌ·ÓÙÈÎfi ‰Â›ÎÙË “ηϋ˜ ˘Á›·˜”, fiˆ˜ ›¯Â ‰È·Ù˘ÒÛÂÈ Î·È Ô πÔÎÚ¿Ù˘ (1). ∆· ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ ¯ÚÂÈ¿˙ÔÓÙ·È Û˘ÓÔÏÈο 10-11 ÒÚ˜ ‡ÓÔ ÙËÓ Ë̤ڷ (2). ∞ÓÂ·Ú΋˜ Û ‰È¿ÚÎÂÈ· ‡ÓÔ˜ Û˘Û¯ÂÙÈ˙fiÌÂÓÔ˜ Ì ˘ÓËÏ›· ηٿ ÙË ‰È¿ÚÎÂÈ· Ù˘ Ë̤ڷ˜ (daytime sleepiness) ·ÔÙÂÏ› ¤Ó· Û˘¯Ófi ‡ÚËÌ· Û ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ Î·È ¤¯ÂÈ Û˘Û¯ÂÙÈÛÙ› Ì ‰˘ÛÌÂÓ›˜ ÂÈÙÒÛÂȘ ÛÙȘ ÓÔËÙÈΤ˜ ÏÂÈÙÔ˘ÚÁ›Â˜, ÙË Ê˘ÛÈ΋ Î·È Û˘Ó·ÈÛıËÌ·ÙÈ΋ ˘Á›·, ηıÒ˜ Â›Û˘ Ì ÚÔ‚Ï‹Ì·Ù· ÂÈÎÔÈÓˆÓ›·˜ Î·È Î·Ù¿¯ÚËÛË Ô˘ÛÈÒÓ (1,3). √È ‰È·Ù·Ú·¯¤˜ ÛÙÔÓ ‡ÓÔ Â›Ó·È Û˘¯Ó¤˜ ηı’ fiÏË ÙË ‰È¿ÚÎÂÈ· Ù˘ ˙ˆ‹˜, ·Ó Î·È Ë Â›ÙˆÛË ÙˆÓ Û˘ÁÎÂÎÚÈÌ¤ÓˆÓ ‰È·Ù·Ú·¯ÒÓ ÂÍ·ÚÙ¿Ù·È ·fi ÙËÓ ËÏÈΛ· (1). °È· ·Ú¿‰ÂÈÁÌ·, Ù· ·È‰È¿ ÓËȷ΋˜ ËÏÈΛ·˜ ·ÚÔ˘ÛÈ¿˙Ô˘Ó Û˘¯Ó¿ ·ÓÙ›ÛÙ·ÛË ÁÈ· Ó· ¿Ó ÛÙÔ ÎÚ‚¿ÙÈ ÙÔ˘˜ ÙËÓ ÒÚ· ÙÔ˘ ‡ÓÔ˘, ÂÓÒ Ù· ·È‰È¿ Ù˘ ÚÔÂÊË‚È΋˜ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ ¤¯Ô˘Ó Û˘¯ÓfiÙÂÚ· ‰È·Ù·Ú·¯¤˜ ‡ÓÔ˘, fiˆ˜ ˘ÓÔ‚·Û›·, ÂÊÈ¿ÏÙ˜ Î·È ÙÚÈÛÌfi ÙˆÓ ‰ÔÓÙÈÒÓ (4). √È ¤ÊË‚ÔÈ Î·È ÔÈ ÂÓ‹ÏÈΘ ·ÚÔ˘ÛÈ¿˙Ô˘Ó Û˘¯ÓfiÙÂÚ· ÚÔ‚Ï‹Ì·Ù·, fiˆ˜ ·¸Ó›· Î·È ˘ÓËÏ›· ηٿ ÙË ‰È¿ÚÎÂÈ· Ù˘ Ë̤ڷ˜ (5). √È ‰È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘ ÛÙËÓ ·È‰È΋ ËÏÈΛ· ·ÔÙÂÏÔ‡Ó ÛËÌ·ÓÙÈÎfi ‰›Ô ÌÂϤÙ˘, ·ÊÔ‡ Ù· ˘¿Ú¯ÔÓÙ· ‚È‚ÏÈÔÁÚ·ÊÈο ‰Â‰Ô̤ӷ Â›Ó·È ·ÓÂ·Ú΋. ∆· ·È‰È¿, Û ·ÓÙ›ıÂÛË Ì ÙÔ˘˜ ÂÓ‹ÏÈΘ, Û¿ÓÈ· ·ÈÙÈÒÓÙ·È ÁÈ· ÚÔ‚Ï‹Ì·Ù· ÛÙÔÓ ‡ÓÔ Î·È ÔÈ ÁÔÓ›˜, Ô˘ Â›Ó·È Î·È ÔÈ ÌÔÓ·‰ÈÎÔ› “·Ú·ÙËÚËÙ¤˜” ÙÔ˘ ‡ÓÔ˘ ÙˆÓ ·È‰ÈÒÓ, Â›Ó·È ÔÈ ÌfiÓÔÈ Ô˘ ÌÔÚÔ‡Ó Ó· ‰ÒÛÔ˘Ó ÈηÓÔÔÈËÙÈΤ˜ ÏËÚÔÊÔڛ˜ (6). ∆· ÚÔ‚Ï‹Ì·Ù· ÙÔ˘ ‡ÓÔ˘ ÌÔÚ› Ó· Â›Ó·È ·ÔÙ¤ÏÂÛÌ· ÛËÌ·ÓÙÈÎÒÓ È·ÙÚÈÎÒÓ ÚÔ‚ÏËÌ¿ÙˆÓ, fiˆ˜ ÂÈÏË„›·, ‰È¿¯˘ÙË ·Ó·Ù˘Íȷ΋ ‰È·Ù·Ú·¯‹, ¿ÓÔÈ·, Ï‹„Ë Ê·ÚÌ¿ÎˆÓ (5). ¶ÚfiÛÊ·Ù·, ÔÈ ∫·Ï¤ÁÈ·˜ Î·È Û˘Ó.

(7) ¤‰ÂÈÍ·Ó fiÙÈ Ë ·¸Ó›· ÌÔÚ› Ó· Â›Ó·È ÂΉ‹ÏˆÛË ‰È¿¯˘ÙˆÓ ·Ó·Ù˘ÍÈ·ÎÒÓ ‰È·Ù·Ú·¯ÒÓ. ¶ÈÔ Û˘ÁÎÂÎÚÈ̤ӷ, Û ÌÈ· ÛÂÈÚ¿ 48 ·ÛıÂÓÒÓ ËÏÈΛ·˜ 1,5-18 ÂÙÒÓ Ô˘ ·ÍÈÔÏÔÁ‹ıËÎ·Ó ÏfiÁˆ Û˘ÌÙˆÌ¿ÙˆÓ ·¸Ó›·˜ Û ·È‰È·ÙÚÈÎfi ΤÓÙÚÔ ‡ÓÔ˘ ÛÙȘ ∏¶∞, ÔÈ 9 (19%) ›¯·Ó ·˘ÙÈÛÌfi Ô˘ ‰È¤Ï·ı Ù˘ ‰È¿ÁÓˆÛ˘. ∞‰È·ÌÊÈÛ‚‹ÙËÙ·, Ù· ÚÔ‚Ï‹Ì·Ù· ÙÔ˘ ‡ÓÔ˘ Â¿ÁÔÓÙ·È ‹ ÂËÚ¿˙ÔÓÙ·È ·fi ÂÚÈ‚·ÏÏÔÓÙÈÎÔ‡˜ ·Ú¿ÁÔÓÙ˜, fiˆ˜ Ë ·Ô˘Û›· ÚÔÁÚ¿ÌÌ·ÙÔ˜ ÛÙËÓ ÔÈÎÔÁ¤ÓÂÈ· Î·È Ë ÌË ÂÊ·ÚÌÔÁ‹ ÙˆÓ Î·ÓfiÓˆÓ ˘ÁÈÂÈÓ‹˜ ÙÔ˘ ‡ÓÔ˘. ªÈ· Û˘¯Ó‹ Ù·ÍÈÓfiÌËÛË ÙˆÓ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘ Â›Ó·È Û ‰˘Û˘ÓÈΤ˜ (dysomnias) Î·È ·Ú·¸ÓÈΤ˜ (parainsomnias) (8). ¢˘Û˘ÓÈΤ˜ ÔÓÔÌ¿˙ÔÓÙ·È ÔÈ ‰È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘ Ô˘ ¯·Ú·ÎÙËÚ›˙ÔÓÙ·È ·fi ·ÓÂÈÙ˘¯‹, ·ÓÂ·Ú΋, ‹ ˘ÂÚ‚ÔÏÈ΋˜ ‰È¿ÚÎÂÈ·˜ ‡ÓÔ, fiˆ˜ Ë ·¸Ó›· (‰˘ÛÎÔÏ›· ÛÙËÓ Â¤Ï¢ÛË ÙÔ˘

‡ÓÔ˘) ‹/Î·È Ë Ó˘¯ÙÂÚÈÓ‹ ·Ê‡ÓÈÛË (·¸Ó›·insomnia) (9). √È ·Ú·¸ÓÈΤ˜ ‰È·Ù·Ú·¯¤˜ Ô˘ Ï·Ì‚¿ÓÔ˘Ó ¯ÒÚ· ηٿ ÙË ‰È¿ÚÎÂÈ· ÙÔ˘ ‡ÓÔ˘ Â›Ó·È ÔÈ Ó˘¯ÙÂÚÈÓÔ› ÂÊÈ¿ÏÙ˜, Ô Ó˘¯ÙÂÚÈÓfi˜ ÙÚfiÌÔ˜, Ë Ó˘¯ÙÂÚÈÓ‹ ÂÓÔ‡ÚËÛË, Î.¿. ∂ȉËÌÈÔÏÔÁÈΤ˜ ÌÂϤÙ˜ ¤¯Ô˘Ó ηٷ‰Â›ÍÂÈ fiÙÈ ÙfiÛÔ ÔÈ ‰˘Û˘ÓÈΤ˜, fiÛÔ Î·È ÔÈ ·Ú·¸ÓÈΤ˜ ‰È·Ù·Ú·¯¤˜, Â›Ó·È Û˘¯Ó¤˜ ÛÙËÓ ·È‰È΋ ËÏÈΛ· (8,10,11).

H ̤ıÔ‰Ô˜ ÂÎÏÔÁ‹˜ (gold standard) ÁÈ· ÙËÓ ·ÍÈÔÏfiÁËÛË ÙˆÓ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘ Â›Ó·È Ë ÔÏ˘¸ÓÔÁÚ·ÊÈ΋ ÌÂϤÙË (overnight polysomnography PSG) (12). ∏ ÌÂϤÙË ‡ÓÔ˘ ·ÓÙÈÎÂÈÌÂÓÔÔÈ› Ù· Â˘Ú‹Ì·Ù·, ··ÈÙ› fï˜ ¤Ó· ¿ÚÙÈ· ÔÚÁ·ÓˆÌ¤ÓÔ Î¤ÓÙÚÔ ·È‰È·ÙÚÈ΋˜ ÎÏÈÓÈ΋˜ ‡ÓÔ˘. √ ·ÚÈÔ˜ ÏfiÁÔ˜, ÁÈ· ÙÔÓ ÔÔ›Ô Ë ÔÏ˘¸ÓÔÁÚ·ÊÈ΋ ÌÂϤÙË ‰ÂÓ ÂÊ·ÚÌfi˙ÂÙ·È ÛÙËÓ Ú¿ÍË ‹ ÛÙË ‰ÈÂÚ‡ÓËÛË Ù˘ ·¸Ó›·˜ ÙˆÓ ·È‰ÈÒÓ, Â›Ó·È ÁÈ·Ù› ··ÈÙ› Û˘Óı‹Î˜ ÓÔÛÔÎÔÌ›Ԣ Î·È Û‡Ó‰ÂÛË ÙÔ˘ ·È‰ÈÔ‡ Ì ÔÏÏ·Ï¿ ËÏÂÎÙÚfi‰È·. ø˜ ÂÎ ÙÔ‡ÙÔ˘, ˘¿Ú¯ÂÈ ·‰˘Ó·Ì›· Â›Ù¢Í˘ ȉ·ÓÈÎÒÓ Û˘ÓıËÎÒÓ ÁÈ· ÙË ÌÂϤÙË Ù˘ ·¸Ó›·˜ (12) Î·È ÂӉ›ÎÓ˘Ù·È ÌfiÓÔ Û ÂÚÈÙÒÛÂȘ, fiÔ˘ ˘Ô„È·˙fiÌ·ÛÙ ·ÔÊÚ·ÎÙÈΤ˜ ¿ÓÔȘ (Obstructive Sleep Apnea Syndrome - OSAS), ÂÚÈÔ‰ÈΤ˜ ÎÈÓ‹ÛÂȘ ÛÙÔÓ ‡ÓÔ (periodic leg movements - PLMs), ‰È·Ù·Ú·¯¤˜ Ù˘ Ê¿Û˘ REM, ·Ó Ë ‰È¿ÁÓˆÛË Ù˘ ·¸Ó›·˜ ·ÌÊÈÛ‚ËÙÂ›Ù·È ‹ ·Ó Ë ıÂÚ·›· ·ÔÙ‡¯ÂÈ (13). ∂›Û˘, ·ÔÙÂÏ› ÛËÌ·ÓÙÈÎfi ÂÚ¢ÓËÙÈÎfi ÂÚÁ·ÏÂ›Ô ÛÙË ÌÂϤÙË ÙˆÓ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘, fiˆ˜ ÚfiÛÊ·Ù· ¤‰ÂÈÍ·Ó ÔÈ ∫·Ï¤ÁÈ·˜ Î·È Û˘Ó. (14), fiÙ·Ó ‰ÈÂÚ‡ÓËÛ·Ó ÙȘ Ó˘¯ÙÂÚÈÓ¤˜ ·Ê˘Ó›ÛÂȘ Û ·È‰È¿, Ì ÙË ¯Ú‹ÛË ÂÈÚfiÛıÂÙˆÓ ÌÂÙˆÈ·›ˆÓ ËÏÂÎÙÚÔ‰›ˆÓ ÂÎÙfi˜ ÙˆÓ Û˘Ì‚·ÙÈÎÒÓ ÎÂÓÙÚÈÎÒÓ, ÚÔÎÂÈ̤ÓÔ˘ Ó· ‰È¢ÎÚÈÓÈÛıÔ‡Ó ÔÈ Ì˯·ÓÈÛÌÔ› Ù˘ ·Ê‡ÓÈÛ˘ Û ·È‰È¿ Ì ‰È·Ù·Ú·¯¤˜ ÛÙÔÓ ‡ÓÔ. √È ÁÔÓ›˜, ˆ˜ ·ÚÈÔÈ Ì¿ÚÙ˘Ú˜ ÙÔ˘ ·È‰ÈÎÔ‡ ‡ÓÔ˘, ÌÔÚ› Ó· Û˘Ì‚¿ÏÏÔ˘Ó ÛËÌ·ÓÙÈο ÛÙË ÌÂϤÙË ÙˆÓ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘ ÛÙ· ·È‰È¿ ̤ۈ Ù˘ÔÔÈË̤ÓÔ˘ ÂÚˆÙËÌ·ÙÔÏÔÁ›Ô˘, Ì ÛËÌ·ÓÙÈÎÔ‡˜ fï˜ ÂÚÈÔÚÈÛÌÔ‡˜, ·ÊÔ‡ ÛÙËÚ›˙ÂÙ·È ÛÙËÓ ˘ÔÎÂÈÌÂÓÈÎfiÙËÙ¿ ÙÔ˘˜ (6,15). ™ÎÔfi˜ Ù˘ ·ÚÔ‡Û·˜ ÌÂϤÙ˘ ‹Ù·Ó Ë ‰ÈÂÚ‡ÓËÛË ÙˆÓ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘ Û ˘ÁÈ‹ ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ (6-12 ÂÙÒÓ) Ì ÙË ¯ÔÚ‹ÁËÛË Ù˘ÔÔÈË̤ÓÔ˘ ÂÚˆÙËÌ·ÙÔÏÔÁ›Ô˘ ÛÙÔ˘˜ ÁÔÓ›˜ ÙÔ˘˜ Î·È Ë Û˘Û¯¤ÙÈÛË ÙˆÓ ÚÔ‚ÏËÌ¿ÙˆÓ ·˘ÙÒÓ Ì ÔÈΛÏÔ˘˜ ·Ú¿ÁÔÓÙ˜ (ÎÔÈÓˆÓÈÎÔ‡˜, Û˘Óı‹Î˜ ‰È·‚›ˆÛ˘ Î·È Û˘Ó‹ıÂȘ) Ô˘ ·ÏÏ¿˙Ô˘Ó ÛËÌ·ÓÙÈο Ì ÙËÓ ¿ÚÔ‰Ô ÙÔ˘ ¯ÚfiÓÔ˘ ÛÙËÓ ÂÏÏËÓÈ΋ ÎÔÈÓˆÓ›· Î·È ÂËÚ¿˙Ô˘Ó ÙÔÓ ‡ÓÔ ÙˆÓ ·È‰ÈÒÓ ÛÙË ¯ÒÚ· Ì·˜ ¯ˆÚ›˜ Ó· ˘¿Ú¯Ô˘Ó Â·Ú΋ ·Ó¿ÏÔÁ· ‚È‚ÏÈÔÁÚ·ÊÈο ‰Â‰Ô̤ӷ (16). ∂›Û˘, Û˘Û¯ÂÙ›Û·Ì ÙȘ ‰È·Ù·Ú·¯¤˜ ·˘Ù¤˜ Ì ÙË ÛÊ·ÈÚÈ΋ ¿Ô„Ë ÙˆÓ ÁÔÓ¤ˆÓ Û¯ÂÙÈο Ì ÙËÓ ‡·ÚÍË ÚÔ‚Ï‹Ì·ÙÔ˜ ‡ÓÔ˘ ÛÙ· ·È‰È¿ ÙÔ˘˜. ¶·È‰È·ÙÚÈ΋ 2008;71:48-54

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·50

50

π. ∫·Ï¤ÁÈ·˜ Î·È Û˘Ó.

¶›Ó·Î·˜ 1. ÷ڷÎÙËÚÈÛÙÈο ·È‰ÈÒÓ Ã·Ú·ÎÙËÚÈÛÙÈο º‡ÏÔ ∏ÏÈΛ· ¶ÚfiˆÚ· (<37 ‚‰ÔÌ¿‰ˆÓ) BMI ¶·¯˘Û·ÚΛ· (>95Ë ∂£) ∆Ô ·È‰› ¤¯ÂÈ ‰ÈÎfi ÙÔ˘ ˘ÓÔ‰ˆÌ¿ÙÈÔ ªÔÓÔηÙÔÈΛ· ¢È·ÌÔÓ‹ Û ÚÔ¿ÛÙÈÔ £fiÚ˘‚Ô˜ ÙË Ó‡¯Ù· ªÔÚʈÙÈÎfi Â›Â‰Ô ÌËÙ¤Ú·˜

ªÔÚʈÙÈÎfi Â›Â‰Ô ·Ù¤Ú·

ÀÏÈÎfi Î·È Ì¤ıÔ‰ÔÈ π. ÀÏÈÎfi ™ÙË ÌÂϤÙË Û˘ÌÂÚÈÂÏ‹ÊıËÛ·Ó 166 ·È‰È¿. ∫ÚÈÙ‹ÚÈ· ÂÈÏÔÁ‹˜ ‹Ù·Ó: 1. ∏ÏÈΛ· 6-12 ÂÙÒÓ.

2. ∂ÏÏËÓÈ΋ ηٷÁˆÁ‹. ∂ÓÒ ÎÚÈÙ‹ÚÈ· ·ÔÎÏÂÈÛÌÔ‡ ‹Ù·Ó: 1. ∏ ‡·ÚÍË ÛÔ‚·ÚÔ‡ Ó¢ÚÔÏÔÁÈÎÔ‡ ÚÔ‚Ï‹Ì·ÙÔ˜ (ÂÁÎÂÊ·ÏÈ΋ ·Ú¿Ï˘ÛË, ÓÔËÙÈ΋ ˘ÛÙ¤ÚËÛË, ‰È¿¯˘ÙË ·Ó·Ù˘Íȷ΋ ‰È·Ù·Ú·¯‹, ‰È¿Û·ÛË ÚÔÛÔ¯‹˜-˘ÂÚÎÈÓËÙÈÎfiÙËÙ·, ÂÈÏË„›· ˘fi ·ÁˆÁ‹).

2. ∏ Ï‹„Ë ÔÔÈ·Û‰‹ÔÙ ̷ÎÚÔ¯ÚfiÓÈ·˜ ·ÁˆÁ‹˜. ∏ ÂÈÏÔÁ‹ ÙˆÓ ·È‰ÈÒÓ ‰ÈÂÓÂÚÁ‹ıËΠÛÙ· Ù·ÎÙÈο Â͈ÙÂÚÈο È·ÙÚ›· Ù˘ ∫ÏÈÓÈ΋˜. ππ. ∂ÚˆÙËÌ·ÙÔÏfiÁÈÔ ∆Ô ÂÚˆÙËÌ·ÙÔÏfiÁÈÔ ·˘Ùfi ›¯Â ¯ÔÚËÁËı› ÛÙÔ ·ÚÂÏıfiÓ ·fi ÙÔ˘˜ Smedje et al. (15) Û ·È‰È¿ ËÏÈΛ·˜ 5-7 ÂÙÒÓ ÛÙË ™Ô˘Ë‰›·. ∆Ô ÂÚˆÙËÌ·ÙÔÏfiÁÈÔ Â›¯Â 4 ̤ÚË: 1. ™ÙÔ ÚÒÙÔ Ì¤ÚÔ˜ Û˘ÌÂÚÈÂÏ‹ÊıËÛ·Ó ÏËÚÔÊÔڛ˜ Ô˘ ·ÊÔÚÔ‡Û·Ó ÙÔ ·È‰› (ʇÏÔ, ËÏÈΛ·, ÚÔˆÚfiÙËÙ·, ‰Â›ÎÙ˘ Ì¿˙·˜ ÛÒÌ·ÙÔ˜, ·¯˘Û·ÚΛ·), ÙȘ Û˘Óı‹Î˜ ‰È·‚›ˆÛ˘ (fiÛ· ¿ÙÔÌ· ̤ÓÔ˘Ó ÛÙÔ ›‰ÈÔ Û›ÙÈ, ·Ó ÙÔ ·È‰› ¤¯ÂÈ ‰ÈÎfi ÙÔ˘ ˘ÓÔ‰ˆÌ¿ÙÈÔ, ·Ó fi¯È Ì fiÛ· ¿ÙÔÌ· ÙÔ ÌÔÈÚ¿˙ÂÙ·È, ·Ó ̤ÓÔ˘Ó Û ÌÔÓÔηÙÔÈΛ· ‹ ÔÏ˘Î·ÙÔÈΛ·, ·Ó Â›Ó·È Û ΤÓÙÚÔ ‹ Û ÚÔ¿ÛÙÈÔ, ·Ó ˘¿Ú¯ÂÈ Ê·Û·Ú›· ÙË Ó‡¯Ù· ‹ fi¯È), ÙÔ˘˜ ÁÔÓ›˜ (ÌÔÚʈÙÈÎfi Â›‰Ô, Â¿ÁÁÂÏÌ·) Î·È ÙÔ ·ÙÔÌÈÎfi ·Ó·ÌÓËÛÙÈÎfi ÙÔ˘ ·È‰ÈÔ‡.

2. ™ÙÔ ‰Â‡ÙÂÚÔ Ì¤ÚÔ˜ Û˘ÌÂÚÈÂÏ‹ÊıËÛ·Ó ÁÂÓÈΤ˜ ÏËÚÔÊÔڛ˜ ÁÈ· ÙÔÓ ‡ÓÔ ÙÔ˘ ·È‰ÈÔ‡ (ÙÈ ÒÚ· ËÁ·›ÓÂÈ ÁÈ· ‡ÓÔ ÙȘ ηıËÌÂÚÈÓ¤˜ Î·È Ù· ™·‚‚·ÙÔ·Úȷη, ÙÈ ÒÚ· ͢Ó¿ÂÈ ÙȘ ηıËÌÂÚÈÓ¤˜ Î·È Ù· ™·‚‚·ÙÔ·Úȷη, fiÛ˜ ÒÚ˜ ÈÛÙÂ‡Ô˘Ó fiÙÈ ÎÔÈÌ¿Ù·È Û˘ÓÔÏÈο ÙȘ ηıËÌÂÚÈÓ¤˜ Î·È Ù· ™·‚‚·ÙÔ·Úȷη, ·Ó ËÁ·›ÓÂÈ ÁÈ· ‡ÓÔ ÌÂÙ¿ ÙȘ 11 ÙÔ ‚Ú¿‰˘, ·Ó ¤¯ÂÈ ÙËÏÂfiÚ·ÛË ÛÙÔ ‰ˆÌ¿ÙÈÔ ÙÔ˘, ·Ó ÎÔÈÌ¿Ù·È ÙÔ ÌÂÛË̤ÚÈ).

3. ™ÙÔ ÙÚ›ÙÔ Ì¤ÚÔ˜ Û˘ÌÂÚÈÂÏ‹ÊıËÛ·Ó 21 ÂÚˆÙ‹ÛÂȘ Ô˘ ·ÊÔÚÔ‡Û·Ó ÙË Û˘ÌÂÚÈÊÔÚ¿ ÙÔ˘ ·È‰ÈÔ‡ ˆ˜ ÚÔ˜ ÙËÓ ÂÁÚ‹Paediatriki 2008;71:48-54

∞ÁfiÚÈ· ¡ (%) ∫ÔÚ›ÙÛÈ· ¡ (%) ª¤ÛË ÙÈÌ‹ ± SD (¤ÙË) (min-max) ¡ (%) (̤ÛË ± SD) (25Ë-75Ë ∂£) ¡ (%) ¡ (%) ¡ (%) ¡ (%) ¡ (%) π ππ πππ π ππ πππ

74 (44,5%) 92 (55,5%) 9±2 (6-12) 9 (5,4%) 19,1±3,8 (16-22) 23 (13,9%) 92 (55,4%) 110 (66%) 115 (69%) 21 (17,5%) 24 (14,5%) 83 (50%) 59 (35,5%) 22 (13,3%) 82 (49,4%) 62 (37,3%)

ÁÔÚÛË Î·È ÙÔÓ ‡ÓÔ. √È ÂÚˆÙ‹ÛÂȘ ·˘Ù¤˜ ·ÓȯÓÂ‡Ô˘Ó ‰˘Û˘ÓÈΤ˜ (∂1-∂12) Î·È ·Ú·¸ÓÈΤ˜ (∂13-∂21) ‰È·Ù·Ú·¯¤˜ Î·È ‚·ıÌÔÏÔÁÔ‡ÓÙ·È ·fi 1 ¤ˆ˜ Î·È 5 (ÔÙ¤, ÂÚÈÛÙ·Ûȷο, 1-2 ÊÔÚ¤˜ ÙËÓ Â‚‰ÔÌ¿‰·, 3-4 ÊÔÚ¤˜ ÙËÓ Â‚‰ÔÌ¿‰·, ÂÚÈÛÛfiÙÂÚÔ ·fi ¤ÓÙ ÊÔÚ¤˜ ÙËÓ Â‚‰ÔÌ¿‰·). ∏ οı ÂÚÒÙËÛË ‚·ıÌÔÏÔÁ‹ıËΠͯˆÚÈÛÙ¿ Î·È ÙÔ ·È‰› ‚·ıÌÔÏÔÁ‹ıËΠ̠‚¿ÛË fiϘ ÙȘ ··ÓÙ‹ÛÂȘ (score: 21-105).

4. ∆Ô Ù¤Ù·ÚÙÔ Ì¤ÚÔ˜ ·ÔÙÂÏ›ÙÔ ·fi 4 ÂÚˆÙ‹ÛÂȘ Ì ÛÎÔfi ÙËÓ ·ÔÙ‡ˆÛË Ù˘ ÛÊ·ÈÚÈ΋˜ ¿Ԅ˘ (global aspect) ÙˆÓ ÁÔÓ¤ˆÓ ÁÈ· ÙËÓ ‡·ÚÍË ‹ fi¯È ÔÔÈÔ˘‰‹ÔÙ ÚÔ‚Ï‹Ì·ÙÔ˜ ÛÙÔÓ ‡ÓÔ. ∏ ÚÒÙË ‹Ù·Ó ÛÊ·ÈÚÈ΋ ÂÚÒÙËÛË Û¯ÂÙÈο Ì ÙÔ ·Ó ÈÛÙÂ‡Ô˘Ó fiÙÈ ÙÔ ·È‰› ÙÔ˘˜ ¤¯ÂÈ ‰È·Ù·Ú·¯‹ ÛÙÔÓ ‡ÓÔ ‹ fi¯È. ŸÙ·Ó ··ÓÙÔ‡Û·Ó Î·Ù·Ê·ÙÈο, Û˘Ó¤¯È˙·Ó ÛÙȘ ¿ÏϘ ÙÚÂȘ ÂÚˆÙ‹ÛÂȘ Ô˘ ·ÊÔÚÔ‡Û·Ó ÙËÓ Â›ÙˆÛË ÙÔ˘ ÚÔ‚Ï‹Ì·ÙÔ˜ ·˘ÙÔ‡ ÛÙÔ ›‰ÈÔ ÙÔ ·È‰›, ÛÙË Û¯ÔÏÈ΋ ÙÔ˘ ·fi‰ÔÛË Î·È Ù¤ÏÔ˜ ÛÙËÓ ›‰È· ÙËÓ ÔÈÎÔÁ¤ÓÂÈ·. ∏ Û˘ÌÏ‹ÚˆÛË ÙÔ˘ ÂÚˆÙËÌ·ÙÔÏÔÁ›Ô˘ ‰ÈÂÓÂÚÁ‹ıËΠ·fi ÙÔ˘˜ Û˘ÌÌÂÙ¤¯ÔÓÙ˜ ÛÙË ÌÂϤÙË È·ÙÚÔ‡˜ Ì ‚¿ÛË ÙȘ ··ÓÙ‹ÛÂȘ Ô˘ ¤‰ÈÓ·Ó ÔÈ ÁÔÓ›˜. πππ. ™Ù·ÙÈÛÙÈ΋ ·Ó¿Ï˘ÛË ∆· ÔÈÔÙÈο ¯·Ú·ÎÙËÚÈÛÙÈο ÂÎÊÚ¿ÛÙËÎ·Ó Û ·fiÏ˘ÙÔ ·ÚÈıÌfi (¡) Î·È ÂηÙÔÛÙÈ·›Ô ÔÛÔÛÙfi (%), ÂÓÒ Ù· ÔÛÔÙÈο ¯·Ú·ÎÙËÚÈÛÙÈο Û ̤ÛË ÙÈÌ‹ (SD). ¢ÈÂÓÂÚÁ‹ıËΠÌÔÓÔ·Ú·ÁÔÓÙÈ΋ ·Ó¿Ï˘ÛË (‰ÔÎÈÌ·Û›· χ2 Î·È student t-test). ÃÚËÛÈÌÔÔÈ‹ıËΠÙÔ ÛÙ·ÙÈÛÙÈÎfi ÚfiÁÚ·ÌÌ· SPSS (version 12).

∞ÔÙÂϤÛÌ·Ù· π. ÷ڷÎÙËÚÈÛÙÈο ÙˆÓ ·È‰ÈÒÓ (¶›Ó·Î·˜ 1) ™˘ÌÏËÚÒıËÎ·Ó Ù· 166 (92%) ÂÚˆÙËÌ·ÙÔÏfiÁÈ· ·fi Ù· 180 Ô˘ ¯ÔÚËÁ‹ıËηÓ. ππ. ™˘Ó‹ıÂȘ ÂÁÚ‹ÁÔÚÛ˘-‡ÓÔ˘ ∆Ô Û‡ÓÔÏÔ ÙˆÓ ·È‰ÈÒÓ ÙȘ ηıËÌÂÚÈÓ¤˜ ÎÔÈÌ¿Ù·È ÓˆÚ›ÙÂÚ· (10±0,8) Û ۯ¤ÛË Ì ٷ ™·‚‚·ÙÔ·Úȷη (11±0,8) (p=0,01). ªÂÙ¿ ÙȘ 11:00 Ì.Ì. ÙȘ ηıËÌÂÚÈÓ¤˜ ÎÔÈÌ¿Ù·È ÙÔ 24% ÙˆÓ ·È‰ÈÒÓ Î·È Ù· ™·‚‚·ÙÔ·Úȷη ÙÔ 68%.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·51

51

¢È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘

¶›Ó·Î·˜ 2. ¢È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘ ™‡ÓÔÏÔ ¡=186

6-9 ÂÙÒÓ ¡=80

10-12 ÂÙÒÓ ¡=86

p-value

¢˘Û˘ÓÈΤ˜ ‰È·Ù·Ú·¯¤˜ ¢˘ÛÎÔÏ›· Ó· ·ÔÎÔÈÌËı› ¡˘¯ÙÂÚÈÓ‹ ·Ê‡ÓÈÛË ∞Ó‹Û˘¯Ô Î·È ÎÔ˘ÓÈ¤Ù·È ÛÙÔÓ ‡ÓÔ ÙÔ˘ ¶fiÓÔÈ ÛÙ· fi‰È· ‹ Ù· ÎÔ˘Ó¿ÂÈ Î·È Í˘Ó¿ÂÈ ƒÔ¯·Ï›˙ÂÈ ¢˘ÛÎÔÏ›· ÛÙËÓ ·Ó·ÓÔ‹ ÙÔ˘ ¡˘ÛÙ¿˙ÂÈ ÙËÓ Ë̤ڷ ∞ÓÙ›ÛÙ·ÛË Ó· ¿ÂÈ ÛÙÔ ÎÚ‚¿ÙÈ ÙÔ˘ ÙËÓ ÒÚ· ÙÔ˘ ‡ÓÔ˘ ¡Â˘ÚÈÎfi ‹ ·Ó‹Û˘¯Ô ÙËÓ ÒÚ· ÙÔ˘ ‡ÓÔ˘ ™˘Óԉ‡ÂÙ·È ·fi οÔÈÔÓ ÁÈ· Ó· ¿ÂÈ ÛÙÔ ÎÚ‚¿ÙÈ ∫ÔÈÌ¿Ù·È Ì¤ÚÔ˜ ÙÔ˘ ‡ÓÔ˘ Ì ÙÔ˘˜ ÁÔÓ›˜ ÃÚÂÈ¿˙ÂÙ·È ÊÒÙ· ηٿ ÙË ‰È¿ÚÎÂÈ· Ù˘ Ó‡¯Ù·˜

6,6% 9,6% 17,4% 3% 7,3% 4,2% 14% 31% 15,6% 26,5% 9% 36%

10% 15% 24% 5% 10% 6,2% 15% 34% 25% 36,2% 16,2% 49%

3,5% 4,6% 11,6% 0,1% 4,7% 2,3% 12,7% 29% 7% 17,4% 2,3% 24%

0,04 0,024 0,039 0,19 0,18 0,26 0,67 0,51 0,002 0,006 0,002 0,01

¶·Ú·¸ÓÈΤ˜ ‰È·Ù·Ú·¯¤˜ ƒ˘ıÌÈΤ˜ ÎÈÓ‹ÛÂȘ ¡˘¯ÙÂÚÈÓ‹ ÂÓÔ‡ÚËÛË ∆ÚÈÛÌfi˜ ‰ÔÓÙÈÒÓ ªÈÏ¿ÂÈ ÛÙÔÓ ‡ÓÔ ÙÔ˘ ÀÓÔ‚·Û›· ™˘Á¯˘ÙÈΤ˜ ·Ê˘Ó›ÛÂȘ ¡˘¯ÙÂÚÈÓfi˜ ÙÚfiÌÔ˜ ∂ÊÈ¿ÏÙ˜

3% 2,4% 10,2% 11,4% 1,8% 7,2% 1,8% 5%

2,5% 3,7% 11,2% 12,5% 1,2% 10% 2,5% 7,5%

3,5% 1,2% 9,3% 10,5% 2,3% 4,6% 1,2% 2,3%

0,72 0,48 0,67 0,69 0,85 0,04 0,86 0,15

∆· ·È‰È¿ ËÏÈΛ·˜ 6-9 ÂÙÒÓ ÎÔÈÌÔ‡ÓÙ·È ÌÂÙ¿ ÙȘ 11:00 Ì.Ì. ÙȘ ηıËÌÂÚÈÓ¤˜ ÏÈÁfiÙÂÚÔ Û˘¯Ó¿ Û ۯ¤ÛË Ì ٷ ÌÂÁ·Ï‡ÙÂÚ· (11% Î·È 36% ·ÓÙ›ÛÙÔȯ·, p<0,0001). ¶·ÚfiÌÔÈ·, Ù· ™·‚‚·ÙÔ·Úȷη ÎÔÈÌ¿Ù·È ÌÂÙ¿ ÙȘ 11:00 Ì.Ì. ÙÔ 53% Î·È 81% ÙˆÓ ·È‰ÈÒÓ ·ÓÙ›ÛÙÔȯ· (p<0,0001). ∆Ô 75% ÙˆÓ ·È‰ÈÒÓ ÎÔÈÌ¿Ù·È Û˘ÓÔÏÈο ÏÈÁfiÙÂÚÔ ·fi 10 ÒÚ˜ ηıËÌÂÚÈÓ¿, ÂÓÒ Ù· ™·‚‚·ÙÔ·Úȷη ÙÔ 33% ÎÔÈÌ¿Ù·È ÏÈÁfiÙÂÚÔ ·fi 10 ÒÚ˜. ∏ ÏÂÈÔÓfiÙËÙ· ÙˆÓ ÌÂÁ¿ÏˆÓ ·È‰ÈÒÓ ‰ÂÓ ÎÔÈÌ¿Ù·È ÂÚÈÛÛfiÙÂÚÔ ·fi 10 ÒÚ˜ (90%) ÙȘ ηıËÌÂÚÈÓ¤˜, ÂÓÒ ÙÔ 60% ÙˆÓ ·È‰ÈÒÓ 6-9 ÂÙÒÓ ÎÔÈÌÔ‡ÓÙ·È ÏÈÁfiÙÂÚÔ ·fi 10 ÒÚ˜ ÙȘ ηıËÌÂÚÈÓ¤˜ (p<0,0001). ∏ ‰È·ÊÔÚ¿ ·˘Ù‹ ÂÍ·ÎÔÏÔ˘ı› Ó· ˘Ê›ÛÙ·Ù·È Ù· ™·‚‚·ÙÔ·Úȷη, ·ÏÏ¿ Â›Ó·È ·ÛıÂÓ¤ÛÙÂÚË (25% 6-9 ÂÙÒÓ Î·È 42% 10-12 ÂÙÒÓ, p=0,02). ªÔÓÔ·Ú·ÁÔÓÙÈ΋ Û˘Û¯¤ÙÈÛË Ù˘ ̤Û˘ ‰È¿ÚÎÂÈ·˜ ‡ÓÔ˘, ÙfiÛÔ ÙȘ ηıËÌÂÚÈÓ¤˜ fiÛÔ Î·È Ù· ™·‚‚·ÙÔ·Úȷη, ‰ÂÓ ·Ó¤‰ÂÈÍÂ Û˘Û¯¤ÙÈÛË Ì ÙÔ Ê‡ÏÔ (p=0,55), ÙËÓ ÚÔˆÚfiÙËÙ· (p=0,89),ÙËÓ ‡·ÚÍË ‰ÈÎÔ‡ ÙÔ˘ ‰ˆÌ·Ù›Ô˘ (p=0,96), ÙË ‰È·ÌÔÓ‹ ÛÙÔ Î¤ÓÙÚÔ (p=0,48), ÙËÓ ·Ó·ÊÔÚ¿ ıÔÚ‡‚Ô˘ ÛÙË Î·ÙÔÈΛ· (p=0,56), ÙËÓ ‡·ÚÍË ÙËÏÂfiÚ·Û˘ ÛÙÔ ˘ÓÔ‰ˆÌ¿ÙÈÔ (p=0,84) Î·È ÙË ÌfiÚʈÛË Ù˘ ÌËÙ¤Ú·˜ (p=0,19) Î·È ÙÔ˘ ·Ù¤Ú· (p=0,13). ∆· ·¯‡Û·Úη ·È‰È¿ ÎÔÈÌfiÓÙÔ˘Û·Ó ÏÈÁfiÙÂÚÔ ·fi Ù· ÌË-·¯‡Û·Úη, ¯ˆÚ›˜ fï˜ Ë ‰È·ÊÔÚ¿ ·˘Ù‹ Ó· Â›Ó·È ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈ΋ (p=0,09, Ù¿ÛË).

πππ. ∂ȉÈΤ˜ ‰È·Ù·Ú·¯¤˜ ‡ÓÔ˘ ∏ Â›ÙˆÛË ÙˆÓ ÂÈ̤ÚÔ˘˜ ‰È·Ù·Ú·¯ÒÓ ‡ÓÔ˘ Ì ‚¿ÛË ÙȘ ··ÓÙ‹ÛÂȘ ÙˆÓ ÁÔÓ¤ˆÓ ηٷÁÚ¿ÊÂÙ·È ÛÙÔÓ ¶›Ó·Î· 2. πV. ∫ϛ̷η ‰È·Ù·Ú·¯ÒÓ ‡ÓÔ˘ (¶›Ó·Î·˜ 3) ∏ ̤ÛË ÙÈÌ‹ (± SD) Ù˘ Îϛ̷η˜ ‹Ù·Ó 31,1 (±8,8) [25Ë ∂£ 27% Î·È 75Ë ∂£ 37%]. ¢ÈÂÓÂÚÁ‹ıËÎÂ Û˘Û¯¤ÙÈÛË (ÌÔÓÔ·Ú·ÁÔÓÙÈ΋) Ù˘ Îϛ̷η˜ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘ Ì ‰È¿ÊÔÚ˜ ÌÂÙ·‚ÏËÙ¤˜. ¢È·ÈÛÙÒıËÎÂ Û˘Û¯¤ÙÈÛË Ì ÙËÓ ·Ó·ÊÔÚ¿ ıÔÚ‡‚Ô˘ ÙË Ó‡¯Ù· ÛÙÔ Û›ÙÈ (p=0,018), ÙËÓ ·ÚÔ˘Û›· ÙËÏÂfiÚ·Û˘ ÛÙÔ ˘ÓÔ‰ˆÌ¿ÙÈÔ ÙÔ˘ ·È‰ÈÔ‡ (p=0,001) Î·È ÙËÓ ËÏÈΛ· (p=0,001). ¢ÂÓ ‰È·ÈÛÙÒıËÎÂ Û˘Û¯¤ÙÈÛË Ì ÙÔ Ê‡ÏÔ, ÙËÓ ÚÔˆÚfiÙËÙ·, ÙËÓ ·¯˘Û·ÚΛ·, ÙË ‰È·ÌÔÓ‹, ÙÔ ÌÔÚʈÙÈÎfi Â›Â‰Ô ÌËÙ¤Ú·˜ Î·È ·Ù¤Ú· ‹ Ì ÙÔ ·Ó ÙÔ ·È‰› ›¯Â ‰ÈÎfi ÙÔ˘ ˘ÓÔ‰ˆÌ¿ÙÈÔ.

V. ™Ê·ÈÚÈ΋ ¿Ô„Ë ÙˆÓ ÁÔÓ¤ˆÓ ÁÈ· ÙËÓ ‡·ÚÍË ‰È·Ù·Ú·¯ÒÓ ‡ÓÔ˘ ™ÙËÓ ÂÚÒÙËÛË “ÈÛÙ‡ÂÙ fiÙÈ ÙÔ ·È‰› Û·˜ ÙÔ˘˜ ÙÂÏÂ˘Ù·›Ô˘˜ 6 Ì‹Ó˜ ·ÚÔ˘ÛÈ¿˙ÂÈ Î¿ÔÈ· ‰È·Ù·Ú·¯‹ ÛÙÔÓ ‡ÓÔ” ÙÔ 10% ÙˆÓ ÁÔÓ¤ˆÓ ·¿ÓÙËÛ ηٷʷÙÈο. ∏ ̤ÛË ‚·ıÌÔÏÔÁ›· ‰È·Ù·Ú·¯ÒÓ ‡ÓÔ˘ ÙˆÓ ·È‰ÈÒÓ, ÔÈ ÁÔÓ›˜ ÙˆÓ ÔÔ›ˆÓ ·Ó·Ê¤ÚÔ˘Ó fiÙÈ ¤¯Ô˘Ó Úfi‚ÏËÌ·, Â›Ó·È ÛËÌ·ÓÙÈο ˘„ËÏfiÙÂÚË Û ۯ¤ÛË Ì ·˘Ù‹ ÙˆÓ ·È‰ÈÒÓ, ÙˆÓ ÔÔ›ˆÓ ÔÈ ÁÔÓ›˜ ÈÛÙÂ‡Ô˘Ó fiÙÈ ‰ÂÓ ¤¯Ô˘Ó Úfi‚ÏËÌ· (45±11 ¤Ó·ÓÙÈ 31,7±7,4, p<0,0001). ¶·È‰È·ÙÚÈ΋ 2008;71:48-54

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·52

52

π. ∫·Ï¤ÁÈ·˜ Î·È Û˘Ó.

¶›Ó·Î·˜ 3. ªÔÓÔ·Ú·ÁÔÓÙÈ΋ Û˘Û¯¤ÙÈÛË Ù˘ ‚·ıÌÔÏÔÁ›·˜ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘ Ì ÔÈΛÏÔ˘˜ ·Ú¿ÁÔÓÙ˜ ¶·Ú¿ÁÔÓÙ˜

µ·ıÌÔÏÔÁ›· (score) (̤ÛË ÙÈÌ‹ ± SD)

p-value

º‡ÏÔ

∞ÁfiÚÈ· ∫ÔÚ›ÙÛÈ· ¡·È Ÿ¯È ¡·È Ÿ¯È ∫¤ÓÙÚÔ ¶ÚÔ¿ÛÙÈÔ ¡·È Ÿ¯È ∫·ÙÒÙÂÚÔ/̤ÛÔ ∞ÓÒÙÂÚÔ ∫·ÙÒÙÂÚÔ/̤ÛÔ ∞ÓÒÙÂÚÔ ¡·È Ÿ¯È ¡·È Ÿ¯È 6-9 ÂÙÒÓ 10-12 ÂÙÒÓ ¡·È Ÿ¯È

0,61

¶ÚÔˆÚfiÙËÙ· ¶·¯˘Û·ÚΛ· ¢È·ÌÔÓ‹ £fiÚ˘‚Ô˜ ªÔÚʈÙÈÎfi Â›Â‰Ô ÌËÙ¤Ú·˜ ªÔÚʈÙÈÎfi Â›Â‰Ô ·Ù¤Ú· ∆Ô ·È‰› ¤¯ÂÈ ‰ÈÎfi ÙÔ˘ ˘ÓÔ‰ˆÌ¿ÙÈÔ ¶·ÚÔ˘Û›· ÙËÏÂfiÚ·Û˘ ÛÙÔ ˘ÓÔ‰ˆÌ¿ÙÈÔ ∏ÏÈΛ· ÙÔ˘ ·È‰ÈÔ‡ ™Ê·ÈÚÈ΋ ¿Ô„Ë ÙˆÓ ÁÔÓ¤ˆÓ ÁÈ· ÙËÓ ‡·ÚÍË ‰È·Ù·Ú·¯ÒÓ

∆Ô 41% ÙˆÓ ÁÔÓ¤ˆÓ Ô˘ ÈÛÙÂ‡Ô˘Ó fiÙÈ ÙÔ ·È‰› ÙÔ˘˜ ¤¯ÂÈ ‰È·Ù·Ú·¯‹ ‡ÓÔ˘ ıˆÚ› fiÙÈ ÙÔ Úfi‚ÏËÌ· ·˘Ùfi ÂËÚ¿˙ÂÈ ‰˘ÛÌÂÓÒ˜ ÙÔ ·È‰›, ÙÔ 53% fiÙÈ ÙÔ Úfi‚ÏËÌ· ·˘Ùfi ÂËÚ¿˙ÂÈ ÙËÓ Î·ıËÌÂÚÈÓ‹ ÙÔ˘ ‰Ú·ÛÙËÚÈfiÙËÙ· ÛÙÔ Û¯ÔÏÂ›Ô Î·È ÙÔ 53% fiÙÈ ÙÔ Úfi‚ÏËÌ· ·˘Ùfi ÂËÚ¿˙ÂÈ fiÏË ÙËÓ ÔÈÎÔÁ¤ÓÂÈ·.

™˘˙‹ÙËÛË ∏ ·ÚÔ‡Û· ÌÂϤÙË Û˘Ì‚¿ÏÏÂÈ ÛÙË ÁÓÒÛË Ì·˜ ÁÈ· ÙËÓ ¿Ô„Ë ÙˆÓ ÁÔÓ¤ˆÓ fiÛÔÓ ·ÊÔÚ¿ ÙȘ ‰È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘ Ô˘ ·ÚÔ˘ÛÈ¿˙Ô˘Ó Ù· ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜. ∏ ÛÊ·ÈÚÈ΋ ¿Ô„Ë ÙˆÓ ÁÔÓ¤ˆÓ Ô˘ ·¿ÓÙËÛ·Ó ÛÙË ÌÂϤÙË ·˘Ù‹ ÁÈ· ÙËÓ ‡·ÚÍË ‰È·Ù·Ú·¯ÒÓ ÛÙÔÓ ‡ÓÔ ÛÙ· ·È‰È¿ ÙÔ˘˜ ‰Â›¯ÓÂÈ fiÙÈ ÙÔ 10% ÈÛÙ‡ÂÈ fiÙÈ ÙÔ ·È‰› ÙÔ˘˜ ·ÚÔ˘ÛÈ¿˙ÂÈ Î¿ÔÈ· ‰È·Ù·Ú·¯‹ ÛÙÔÓ ‡ÓÔ. ¶ÂÚÈÛÛfiÙÂÚÔ ·fi ÙÔ ¤Ó· ¤ÌÙÔ ÙˆÓ ·È‰ÈÒÓ ÛÙËÓ ·ÚÔ‡Û· ÛÂÈÚ¿ Ê·›ÓÂÙ·È Ó· ·ÚÔ˘ÛÈ¿˙ÂÈ Î¿ÔÈ· ‰È·Ù·Ú·¯‹ ÙÔ˘Ï¿¯ÈÛÙÔÓ Ì›· ÊÔÚ¿ ÙËÓ Â‚‰ÔÌ¿‰·, Ô˘ ÂÌ›ÙÂÈ Î˘Ú›ˆ˜ ÛÙËÓ Î·ÙËÁÔÚ›· ÙˆÓ ‰˘Û˘ÓÈÎÒÓ ‰È·Ù·Ú·¯ÒÓ (fiˆ˜ ·ÓÙ›ÛÙ·ÛË ÙËÓ ÒÚ· ÙÔ˘ ‡ÓÔ˘ Î·È ·¸Ó›·) Î·È ÏÈÁfiÙÂÚÔ Û˘¯Ó¿ Û ÂΛÓË ÙˆÓ ·Ú·¸ÓÈÎÒÓ ‰È·Ù·Ú·¯ÒÓ. ∂ÈÚfiÛıÂÙ·, Ë ·ÚÔ‡Û· ÌÂϤÙË ·Ó·‰ÂÈÎÓ‡ÂÈ ÙË ÛËÌ·ÓÙÈ΋ ÛÙ¤ÚËÛË ÙˆÓ ·È‰ÈÒÓ Ù˘ ¯ÒÚ·˜ Ì·˜, ËÏÈΛ·˜ ΢ڛˆ˜ 10-12 ÂÙÒÓ, Û Â·Ú΋ ‡ÓÔ, ΢ڛˆ˜ ÙȘ ηıËÌÂÚÈÓ¤˜, Î·È ÙÔ ÛËÌ·ÓÙÈÎfi ÔÛÔÛÙfi ·È‰ÈÒÓ Ô˘ ·ÚÔ˘ÛÈ¿˙Ô˘Ó ˘ÓËÏ›· ηٿ ÙË ‰È¿ÚÎÂÈ· Ù˘ Ë̤ڷ˜ Ì ÙȘ ÁÓˆÛÙ¤˜ ÂÈÙÒÛÂȘ ÛÙË Û¯ÔÏÈ΋ ·fi‰ÔÛË. √È Owens Î·È Û˘Ó. (17) ¤‰ÂÈÍ·Ó fiÙÈ ÙfiÛÔ ÎÔÈÓˆÓÈPaediatriki 2008;71:48-54

33,5±7,9 32,8±9,4 32,6±11 33,2±8,7 33,5±8,5 33,3±8,8 34,7±8,8 32,3±8,7 36,6±9,3 32,4±8,5 32,5±8,8 34,2±8,6 32,6±9,1 34±8,2 33,3±8,8 32,9±7,8 39±7,8 33,5±9,2 35,4±9,6 31±7,5 45±11 31,7±7,4

0,86 0,91 0,086 0,018 0,23 0,33 0,73 0,001 0,001 <0,0001

ÎÔ› ·Ú¿ÁÔÓÙ˜ (ÊÔÚو̤ÓÔ ÚfiÁÚ·ÌÌ· ÙˆÓ ·È‰ÈÒÓ, ÙËÏÂı¤·ÛË, stress Ù˘ ÔÈÎÔÁ¤ÓÂÈ·˜), fiÛÔ Î·È È·ÙÚÈÎÔ› ÚԉȷıÂÛÈÎÔ› ·Ú¿ÁÔÓÙ˜ (¿ÛıÌ·, ÏÔÈÌÒÍÂȘ ·ÓÒÙÂÚÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡) ÌÔÚ› Ó· Û˘Ì‚¿ÏÏÔ˘Ó ÛÙËÓ ·ÔÛÙ¤ÚËÛË ‡ÓÔ˘, ·ÏÏ¿ Î·È Û ¿ÏϘ ‰È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘. ™ÙËÓ ·ÚÔ‡Û· ÌÂϤÙË Ê·›ÓÂÙ·È fiÙÈ Ù· ·È‰È¿ ËÏÈΛ·˜ 10-12 ÂÙÒÓ ·ÚÔ˘ÛÈ¿˙Ô˘Ó ÛËÌ·ÓÙÈ΋ ÛÙ¤ÚËÛË ‡ÓÔ˘ ÙȘ ηıËÌÂÚÈÓ¤˜. ∂›Û˘, Ë ·ÚÔ˘Û›· ÙËÏÂfiÚ·Û˘ ÛÙÔ ˘ÓÔ‰ˆÌ¿ÙÈÔ Û˘Û¯ÂÙ›ÛÙËΠ̠ÙËÓ ·˘ÍË̤ÓË Îϛ̷η ‰È·Ù·Ú·¯ÒÓ ÛÙÔÓ ‡ÓÔ. √È Ú·ÎÙÈΤ˜ ÛÙÔÓ ‡ÓÔ, fiˆ˜ ÎÔÈÓfi ˘ÓÔ‰ˆÌ¿ÙÈÔ, ı· ÌÔÚÔ‡Û·Ó Ó· ÂËÚ¿ÛÔ˘Ó Ù· ÚÔ‚Ï‹Ì·Ù· ‡ÓÔ˘, fï˜, ÛÙËÓ ·ÚÔ‡Û· ÌÂϤÙË ‰ÂÓ ÚԤ΢„Â Û˘Û¯¤ÙÈÛË ÎÔÈÓÔ‡ ˘ÓÔ‰ˆÌ·Ù›Ô˘ Î·È ‰È·Ù·Ú·¯ÒÓ ‡ÓÔ˘. π‰È·›ÙÂÚÔ ÂӉȷʤÚÔÓ ·ÚÔ˘ÛÈ¿˙ÂÈ ÙÔ Â‡ÚËÌ· fiÙÈ ÔÈ ‰˘Û˘ÓÈΤ˜ ‰È·Ù·Ú·¯¤˜ Ê·›ÓÂÙ·È Ó· ÂÍ·ÚÙÒÓÙ·È ·fi ÙËÓ ËÏÈΛ· Û ·ÓÙ›ıÂÛË Ì ÙȘ ·Ú·¸ÓÈΤ˜. ™Â ·ÚfiÌÔÈ· ·ÔÙÂϤÛÌ·Ù· η٤ÏËÍ·Ó ÔÈ Owens Î·È Û˘Ó. (17), ÔÈ ÔÔ›ÔÈ ÌÂϤÙËÛ·Ó ÙȘ ‰È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘ Û ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜. ª›· ‡ÏÔÁË ÂÍ‹ÁËÛË ÌÔÚ› Ó· Â›Ó·È fiÙÈ ÌÂÁ·Ï‡ÙÂÚÔ ÔÛÔÛÙfi ÙˆÓ ÌÈÎÚÒÓ ·È‰ÈÒÓ (16% Û ۯ¤ÛË Ì 2%) ÎÔÈÌÔ‡ÓÙ·È Ì·˙› Ì ÙÔ˘˜ ÁÔÓ›˜ ÙÔ˘˜, ÁÂÁÔÓfi˜ Ô˘ οÓÂÈ ÙȘ ‰˘Û˘ÓÈΤ˜ ‰È·Ù·Ú·¯¤˜ ÈÔ Â‡ÎÔÏ· ·ÓȯÓ‡ÛÈ̘. ∏ ·¸Ó›· (insomnia) ·ÔÙÂÏ› ¤Ó· ·fi Ù· ϤÔÓ ÛËÌ·ÓÙÈο ÚÔ‚Ï‹Ì·Ù· ‡ÓÔ˘ ÛÙËÓ ÂÓ‹ÏÈÎË ˙ˆ‹, Ë ÔÔ›· fï˜ ¤¯ÂÈ ÏËÌÌÂÏÒ˜ ÌÂÏÂÙËı› ÛÙËÓ ·È‰È΋ ËÏÈΛ· (18). √È ÂÈÙÒÛÂȘ Ù˘ ·¸Ó›·˜ ÌÔÚ›

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·53

53

¢È·Ù·Ú·¯¤˜ ÙÔ˘ ‡ÓÔ˘

Ó· Â›Ó·È ‰Ú·Ì·ÙÈΤ˜ ÁÈ· ÙËÓ ·fi‰ÔÛË ÙÔ˘ ·È‰ÈÔ‡. ∂ÈÚfiÛıÂÙ·, ‰È·›ÛÙˆÛË ·¸Ó›·˜ Û ·È‰È¿ ÌÔÚ› Ó· ÂÈ‚¿ÏÏÂÈ ¤ÏÂÁ¯Ô ¿ÏÏˆÓ ‰È·Ù·Ú·¯ÒÓ, fiˆ˜ Û˘Ó‰ÚfiÌÔ˘ ‰È¿Û·Û˘ ÚÔÛÔ¯‹˜-˘ÂÚÎÈÓËÙÈÎfiÙËÙ·˜ ‹ ‰È¿¯˘ÙˆÓ ·Ó·Ù˘ÍÈ·ÎÒÓ ‰È·Ù·Ú·¯ÒÓ (7). ¶ÚfiÛÊ·Ù·, ÔÈ Ivanenko Î·È Û˘Ó. (19) ÌÂϤÙËÛ·Ó ÙÔ „˘¯È·ÙÚÈÎfi ˘fiÛÙڈ̷ Î·È Ù· ÎÏÈÓÈο ¯·Ú·ÎÙËÚÈÛÙÈο 46 ·È‰ÈÒÓ Ô˘ ·ÍÈÔÏÔÁ‹ıËÎ·Ó Û ·È‰È·ÙÚÈÎfi ΤÓÙÚÔ ‰È·Ù·Ú·¯ÒÓ ‡ÓÔ˘ Ì ·ÚÈ· ‰È·Ù·Ú·¯‹ ÙËÓ ·¸Ó›·, Ë ÔÔ›· ÔÚ›˙ÂÙ·È ˆ˜ ‰˘ÛÎÔÏ›· Ó· ·ÔÎÔÈÌËı› ÙÔ ·È‰› ‹/Î·È Ó· ‰È·ÙËÚ‹ÛÂÈ ÙÔÓ ‡ÓÔ ÙÔ˘. ™˘ÓÔÏÈο, ÙÔ 50% ÙˆÓ ·È‰ÈÒÓ Â›¯·Ó Û˘ÁÎÂÎÚÈ̤ÓÔ ˘fiÛÙڈ̷. ∞Ó¿ÌÂÛ· Û ·˘Ù¿, ÙÔ 61% ›¯Â Û‡Ó‰ÚÔÌÔ ‰È¿Û·Û˘ ÚÔÛÔ¯‹˜ Î·È ˘ÂÚÎÈÓËÙÈÎfiÙËÙ· ‹/Î·È „˘¯È·ÙÚÈÎfi ˘fiÛÙڈ̷, fiˆ˜ ηٿıÏÈ„Ë (30%) Î·È ·Á¯Ò‰Ë ‰È·Ù·Ú·¯‹ (65%). ∂Ô̤ӈ˜, Ë ¯ÚfiÓÈ· ·¸Ó›· ÌÔÚ› Ó· ·ÔÙÂÏ› ÂΉ‹ÏˆÛË ˘ÔΛÌÂÓ˘ „˘¯È·ÙÚÈ΋˜ ‰È·Ù·Ú·¯‹˜ (18). π‰È·›ÙÂÚË ·ÍÈÔÏfiÁËÛË ¯ÚÂÈ¿˙ÂÙ·È ÙÔ ·È‰› Ô˘ ·ÚÁ› Ó· ·ÔÎÔÈÌËı›, ·ÊÔ‡ Û ·˘Ùfi ÌÔÚ› Ó· Û˘Ì‚¿ÏÏÔ˘Ó ·Ú¿ÁÔÓÙ˜ Â͈ÁÂÓ›˜, fiˆ˜ ·Ô˘Û›· ¯ÚÔÓÈÎÒÓ ÔÚ›ˆÓ, ÂÚÈ‚·ÏÏÔÓÙÈο ·›ÙÈ·, Û˘Ó‹ıÂȘ ‡ÓÔ˘, „˘¯ÔÏÔÁÈο ·›ÙÈ· ‹ ·ÎfiÌ· Î·È ¯ÚfiÓȘ ‹ ÔÍ›˜ È·ÙÚÈΤ˜ ηٷÛÙ¿ÛÂȘ ‹ Î·È Ê¿Ú̷η. ™ÙËÓ ·ÚÔ‡Û· ÌÂϤÙË, ÙÔ 7% ÙˆÓ ·È‰ÈÒÓ ÚÔ¯·Ï›˙ÂÈ Î·È ÙÔ 14% Ó˘ÛÙ¿˙ÂÈ ÙËÓ Ë̤ڷ. ∆Ô ÚÔ¯·ÏËÙfi Û˘Ì‚¿ÏÏÂÈ ÛÙËÓ ËÌÂÚ‹ÛÈ· ˘ÓËÏ›·, Û˘Û¯ÂÙ›˙ÂÙ·È Ì ÙËÓ ·ÔÊÚ·ÎÙÈ΋ ¿ÓÔÈ· ÛÙÔÓ ‡ÓÔ Î·È Û˘¯Ó¿ ÔÊ›ÏÂÙ·È Û ˘ÂÚÙÔÊ›· ÙˆÓ ·‰ÂÓÔÂȉÒÓ Â΂ϷÛÙ‹ÛˆÓ. ŸÙ·Ó ÙÔ ·È‰› ÚÔ¯·Ï›˙ÂÈ, ··ÈÙÂ›Ù·È ·ÍÈÔÏfiÁËÛË, ÚÔÎÂÈ̤ÓÔ˘ Ó· ‰È·ÊÔÚԉȷÁÓˆÛÙ› ÙÔ ÚˆÙÔ·ı¤˜ ÚÔ¯·ÏËÙfi (primary snoring) ·fi ÙÔ Û‡Ó‰ÚÔÌÔ ·ÔÊÚ·ÎÙÈ΋˜ ¿ÓÔÈ·˜ ÛÙÔÓ ‡ÓÔ (obstructive sleep apnea syndrome). ∞Ó ‰È·ÁÓˆÛÙ› ÙÔ Û‡Ó‰ÚÔÌÔ Ù˘ ·ÔÊÚ·ÎÙÈ΋˜ ¿ÓÔÈ·˜ ÛÙÔÓ ‡ÓÔ, ÙfiÙÂ Ë ·ÓÙÈÌÂÙÒÈÛË ·˘ÙÔ‡ (CPAP ‹ ·‰ÂÓÔÂȉÂÎÙÔÌ‹) ÌÔÚ› Ó· Û˘Ì‚¿ÏÏÂÈ ÛËÌ·ÓÙÈο ÛÙË ‚ÂÏÙ›ˆÛË Ù˘ ËÌÂÚ‹ÛÈ·˜ ÂÁÚ‹ÁÔÚÛ˘ ÙÔ˘ ·È‰ÈÔ‡ (20). ∏ ·ÚÔ‡Û· ÌÂϤÙË ·ÚÔ˘ÛÈ¿˙ÂÈ ÂÚÈÔÚÈÛÌÔ‡˜ Ô˘ Ú¤ÂÈ Ó· ÏËÊıÔ‡Ó ˘fi„Ë Î·Ù¿ ÙËÓ ÂÚÌËÓ›· ÙˆÓ ·ÔÙÂÏÂÛÌ¿ÙˆÓ. ŸÛÔÓ ·ÊÔÚ¿ ÙÔÓ ·ÚÈıÌfi ÙÔ˘ ‰Â›ÁÌ·ÙÔ˜, Ù· ·ÔÙÂϤÛÌ·Ù· ·ÚÔ˘ÛÈ¿˙Ô˘Ó ÛÙ·ÙÈÛÙÈ΋ ÛËÌ·ÓÙÈÎfiÙËÙ·, ˆÛÙfiÛÔ ··ÈÙÂ›Ù·È ÛËÌ·ÓÙÈο ÌÂÁ·Ï‡ÙÂÚÔ˜ ·ÚÈıÌfi˜ ·È‰ÈÒÓ. ∂ÈϤÔÓ, Û˘ÌÌÂÙÔ¯‹ ·È‰ÈÒÓ ·fi ‰È·ÊÔÚÂÙÈΤ˜ ÂÚÈÔ¯¤˜ Ù˘ ¯ÒÚ·˜ Ì·˜ ı· ÌÔÚÔ‡Û ӷ Û˘Ì‚¿ÏÏÂÈ Û ÛÊ·ÈÚÈÎfiÙÂÚË ·ÍÈÔÏfiÁËÛË ÙˆÓ ÚÔ‚ÏËÌ¿ÙˆÓ ÙÔ˘ ‡ÓÔ˘. ∞Í›˙ÂÈ, fï˜, Ó· ÛËÌÂȈı› fiÙÈ ÛÙÔ Û˘ÁÎÂÎÚÈ̤ÓÔ ‰›Ô ˘¿Ú¯ÂÈ ·Ô˘Û›· ‰Â‰ÔÌ¤ÓˆÓ Î·È ¤ÙÛÈ, Ë ·ÚÔ‡Û· ÌÂϤÙË ı· ÌÔÚÔ‡Û ӷ ÂÎÏËÊı› ˆ˜ ÌÈ· ÚÒÙË ÚÔÛ¿ıÂÈ· ‰ÈÂÚ‡ÓËÛ˘ ÙˆÓ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘ ÛÙËÓ ·È‰È΋ ËÏÈΛ·. √ ‰Â‡ÙÂÚÔ˜ ÂÚÈÔÚÈÛÌfi˜ ÚÔ·ÙÂÈ ·fi ÙË ÌÂ-

ıÔ‰ÔÏÔÁ›· Ù˘ ÌÂϤÙ˘. ∏ ¯Ú‹ÛË ÂÚˆÙËÌ·ÙÔÏÔÁ›Ô˘ Ô˘ ·¢ı‡ÓÂÙ·È Û ÁÔÓ›˜ ·ÔÙÂÏ› ˘ÔÎÂÈÌÂÓÈ΋ ̤ıÔ‰Ô Ô˘ ¤¯ÂÈ fï˜ ¯ÚËÛÈÌÔÔÈËı› ¢ڤˆ˜ Î·È ·fi ¿ÏÏÔ˘˜ ÂÚ¢ÓËÙ¤˜ (15,16). ∫·Ù¿ Û˘Ó¤ÂÈ·, Ë ·ÚÔ‡Û· ÌÂϤÙË Ú¤ÂÈ Ó· ÂÎÏËÊı› ˆ˜ ·ÍÈÔÏfiÁËÛË Ù˘ ·ÓÙ›Ï˄˘ ÙˆÓ ÁÔÓ¤ˆÓ ÁÈ· Ù· ÚÔ‚Ï‹Ì·Ù· ‡ÓÔ˘ ÙˆÓ ·È‰ÈÒÓ ÙÔ˘˜, ·Ú¿ ˆ˜ ·ÓÙÈÎÂÈÌÂÓÈ΋ ·ÍÈÔÏfiÁËÛË ÙˆÓ ‰È·Ù·Ú·¯ÒÓ ‡ÓÔ˘. ¶·ÚfiÏ· Ù·‡Ù·, ÔÈ ·Ó·ÊÔÚ¤˜ ÙˆÓ ÁÔÓ¤ˆÓ ÌÔÚ› Ó· ÂÎÏËÊıÔ‡Ó ˆ˜ ·ÍÈÔÔÈ‹ÛÈ̘, ·ÊÔ‡ ÔÈ ÁÔÓ›˜ Â›Ó·È ÔÈ ÌfiÓÔÈ Ì¿ÚÙ˘Ú˜ ÙÔ˘ ‡ÓÔ˘ ÙˆÓ ·È‰ÈÒÓ Î·È È‰È·›ÙÂÚ· ÛÙË ¯ÒÚ· Ì·˜, fiÔ˘ ·Ô˘ÛÈ¿˙Ô˘Ó Î¤ÓÙÚ· ·È‰È·ÙÚÈÎÒÓ ‰È·Ù·Ú·¯ÒÓ ‡ÓÔ˘ Ì ‰˘Ó·ÙfiÙËÙ˜ ÔÏ˘¸ÓÔÁÚ·ÊÈÎÒÓ ÌÂÏÂÙÒÓ. ∫·Ù·Ï‹ÁÔÓÙ·˜, Ì ÙËÓ ·ÚÔ‡Û· ÌÂϤÙË ı· ı¤Ï·Ì ӷ ÙÔÓ›ÛÔ˘Ì ÌÂÚÈÎÔ‡˜ ÛËÌ·ÓÙÈÎÔ‡˜ ÏfiÁÔ˘˜, ÁÈ· ÙÔ˘˜ ÔÔ›Ô˘˜ Ô ·È‰›·ÙÚÔ˜ ÔÊ›ÏÂÈ Ó· ÚˆÙ‹ÛÂÈ ÁÈ· ÙÔÓ ‡ÓÔ ÙˆÓ ·È‰ÈÒÓ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜. ∞Ó¿ÌÂÛ· Û ·˘ÙÔ‡˜ ÙÔ˘˜ ÏfiÁÔ˘˜ Â›Ó·È Ë ÛËÌ·ÓÙÈ΋ Â›ÙˆÛË ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘ Û ·˘Ùfi ÙÔ ËÏÈÎÈ·Îfi Ê¿ÛÌ·, Ë Èı·ÓfiÙËÙ· ·Ó‡ÚÂÛ˘ ıÂÚ·‡ÛÈÌÔ˘ ·ÈÙ›Ô˘, fiˆ˜ ¿ÓÔÈ·˜ ‹ ÂÓÔ‡ÚËÛ˘, Î·È ÙÔ ÁÂÁÔÓfi˜ fiÙÈ Ù· ÚÔ‚Ï‹Ì·Ù· ‡ÓÔ˘ Û˘Û¯ÂÙ›˙ÔÓÙ·È ÈÛ¯˘Ú¿ Ì ¿ÏÏ· „˘¯ÔÏÔÁÈο Î·È È·ÙÚÈο ÚÔ‚Ï‹Ì·Ù·, fiˆ˜ Ù˘ ηٿıÏȄ˘, ÙÔ˘ Û˘Ó‰ÚfiÌÔ˘ ‰È¿Û·Û˘ Ù˘ ÚÔÛÔ¯‹˜ Î·È ˘ÂÚÎÈÓËÙÈÎfiÙËÙ·˜ Î·È Ù˘ ÓÔËÙÈ΋˜ ˘ÛÙ¤ÚËÛ˘ (21-28). ŒÙÛÈ, ·Ó·˙ËÙÒÓÙ·˜ Ù˘¯fiÓ ‰È·Ù·Ú·¯¤˜ ÛÙÔÓ ‡ÓÔ, ÌÔÚ› Ó· ·Ó·‰ÂȯıÔ‡Ó ÛËÌ·ÓÙÈΤ˜ ÏËÚÔÊÔڛ˜ Û˘ÌÂÚÈÊÔÚ¿˜ (ÌË Û˘ÌÌfiÚʈÛ˘), Û˘Ó·ÈÛıËÌ·ÙÈΤ˜ Î·È „˘¯È·ÙÚÈΤ˜ ‰È·Ù·Ú·¯¤˜ (ÊÔ‚›Â˜, ηٿıÏÈ„Ë, ·˘ÙÈÛÌfi˜) ‹ È·ÙÚÈο ÚÔ‚Ï‹Ì·Ù· (¿ÛıÌ·) Ô˘ Û˘Ó˘¿Ú¯Ô˘Ó Ì ·˘Ù¤˜. §·Ì‚¿ÓÔÓÙ·˜ ˘fi„Ë ÙÔ ÁÂÁÔÓfi˜ fiÙÈ ÂÏ¿¯ÈÛÙÔÈ ·fi ÙÔ˘˜ ÁÔÓ›˜ Ô˘ ÈÛÙÂ‡Ô˘Ó fiÙÈ ÙÔ ·È‰› ÙÔ˘˜ ¤¯ÂÈ Î¿ÔÈ· ‰È·Ù·Ú·¯‹ ÛÙÔÓ ‡ÓÔ Û˘˙ËÙÔ‡Ó ÙÔ ı¤Ì· ·˘Ùfi Ì ÙÔÓ ·È‰›·ÙÚÔ, ·Ó·‰ÂÈÎÓ‡ÂÙ·È ·ÎfiÌ· ÂÚÈÛÛfiÙÂÚÔ Ë ÂÈÙ·ÎÙÈ΋ ·Ó¿ÁÎË ÁÈ· ÌÂÁ·Ï‡ÙÂÚË Â˘·ÈÛıËÙÔÔ›ËÛË ÙÔ˘ ıÂÚ¿ÔÓÙ· È·ÙÚÔ‡ ¿Óˆ Û ·˘Ù¿ Ù· ÚÔ‚Ï‹Ì·Ù·. ∏ Û˘˙‹ÙËÛË ÙˆÓ ÚÔ‚ÏËÌ¿ÙˆÓ ÙÔ˘ ‡ÓÔ˘ Î·È Ù˘ Û˘ÌÂÚÈÊÔÚ¿˜ Ì ÙÔ˘˜ ÁÔÓ›˜, ·ÏÏ¿ Î·È Ì ÙÔ ·È‰›, ÌÔÚ› Ó· Ì·˜ ‰ÒÛÂÈ ÙË ‰˘Ó·ÙfiÙËÙ· Ó· ηٷÓÔ‹ÛÔ˘Ì ηχÙÂÚ· ÙÔ ·È‰› Î·È ÙËÓ ÔÈÎÔÁ¤ÓÂÈ·, Ó· ·ÍÈÔÏÔÁ‹ÛÔ˘Ì ÙÔ ÂÚÈ‚¿ÏÏÔÓ Î·È Ó· ÂÎ·È‰Â‡ÛÔ˘Ì ÙÔ˘˜ ÁÔÓ›˜ Û ٷÎÙÈΤ˜ ˘ÁÈÂÈÓ‹˜ ÙÔ˘ ‡ÓÔ˘, Ì ·ÒÙÂÚÔ ÛÙfi¯Ô ÙËÓ ÚfiÏË„Ë ÛËÌ·ÓÙÈÎfiÙÂÚˆÓ ‹/Î·È ¯ÚfiÓÈˆÓ ‰È·Ù·Ú·¯ÒÓ ÙÔ˘ ‡ÓÔ˘.

µÈ‚ÏÈÔÁÚ·Ê›· 1. Sateia MJ, Nowell PD. Insomnia. Lancet 2004;364:19591973.

2. Meltzer LJ, Mindell JA. Sleep and sleep disorders in children and adolescents. Psychiatr Clin North Am 2006;29:1059-1076.

3. Johnson EO, Roth T, Schultz L, Breslau N. Epidemiology of ¶·È‰È·ÙÚÈ΋ 2008;71:48-54

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·54

54

π. ∫·Ï¤ÁÈ·˜ Î·È Û˘Ó.

DSM-IV insomnia in adolescents: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics 2006;117:e247-e256.

4. Rosen G, Mahowald M, Ferber R. Sleepwalking, confusional arousals, and sleep terrors in the child. In: Ferber R, Kryger M, eds. Principles and Practice of Sleep Medicine in the Child. New York: WB Saunders; 1995. p. 99-106.

5. Ohayon MM, Roberts RE, Zulley J, Smirne S, Priest RG. Prevalence and patterns of problematic sleep among older adolescents. J Am Acad Child Adolesc Psychiatry 2000;39: 1549-1556.

6. Couturier JL, Speechley KN, Steele M, Norman R, Stringer B, Nicolson R. Parental perception of sleep problems in children of normal intelligence with pervasive developmental disorders: prevalence, severity, and pattern. J Am Acad Child Adolesc Psychiatry 2005;44:815-822.

7. Kaleyias J, Adams R, Legido A, Kothare SV. Insomnia as a presenting manifestation of autistic spectrum disorders in children. Proceedings of the 35th Annual Meeting of the Child Neurology Society; 2006 October 18-21. Pittsburgh: Child Neurology Society; 2006. p. 36.

8. Mindell JA. Sleep disorders in children. Health Psychol 1993;12:151-162.

9. Glaze DG, Rosen CL, Owens JA. Towards a practical definition of pediatric insomnia. Curr Ther Res Clin Exp 2002;63:4-17.

10. Anders TF, Eiben LA. Pediatric sleep disorders: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1997;36:9-20.

11. Pollock JI. Night-waking at five years of age: predictors and prognosis. J Child Psychol Psychiatry 1994;35:699-708.

12. Standards of Practice Committee of the American Sleep Disorders Association. Practice parameters for the use of polysomnography in the evaluation of insomnia. Sleep 1995;18:55-57.

13. Buysee DJ, Reynolds CF 3rd, Kupfer DJ, Thorpy MJ, Bixler E, Manfredi R, et al. Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV Field Trial. Sleep 1994;17:630-637.

14. Kaleyias J, Grant M, Darbari F, Ajagbe O, Cepelowicz-Rajter J, Kothare SV. Detection of cortical arousals in children using frontal EEG leads in addition to conventional central leads. J Clin Sleep Med 2006;2:305-308.

15. Smedje H, Broman JE, Hetta J. Parents’ reports of disturbed sleep in 5-7-year-old Swedish children. Acta Paediatr 1999;88:858-865.

Paediatriki 2008;71:48-54

16. Ottaviano S, Giannotti F, Cortesi F, Bruno O, Ottaviano C. Sleep characteristics in healthy children from birth to 6 years of age in the urban area of Rome. Sleep 1996;19:1-3.

17. Owens JA, Spirito A, McGuinn M, Nobile C. Sleep habits and sleep disturbance in elementary school-aged children.

J Dev Behav Pediatr 2000;21:27-36.

18. The National Institutes of Health Consensus Development Program. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Available at http://consensus.nih.gov/ 2005/ 2005InsomniaSOS026html.htm.

19. Ivanenko A, Barnes ME, Crabtree VM, Gozal D. Psychiatric symptoms in children with insomnia referred to a pediatric sleep medicine center. Sleep Med 2004;5:253-259.

20. Stradling JR, Thomas G, Warley AR, Williams P, Freeland A. Effects of adenotonsillectomy on nocturnal hypoxaemia, sleep disturbance, and symptoms in snoring children. Lancet 1990;335:249-253.

21. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-1484.

22. Kaplan BJ, McNicol J, Conte RA, Moghadam HK. Sleep disturbance in preschool-aged hyperactive and nonhyperactive children. Pediatrics 1987;80:839-844.

23. Stores G. Sleep studies in children with a mental handicap.

J Child Psychol Psychiatry 1992;33:1303-1317.

24. Sadeh A, McGuire JP, Sachs H, Seifer R, Tremblay A, Civita R, et al. Sleep and psychological characteristics of children on a psychiatric inpatient unit. J Am Acad Child Adolesc Psychiatry 1995;34:813-819.

25. Johnson CR. Sleep problems in children with mental retardation and autism. Child Adolesc Psychiatr Clin North Am 1996;5:673-683.

26. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006;15:210-215.

27. Abad VC, Guilleminault C. Sleep and psychiatry. Dialogues Clin Neurosci 2005;7:291-303.

28. Malow BA, McGrew SG, Harvey M, Henderson LM, Stone WL. Impact of treating sleep apnea in a child with autism spectrum disorder. Pediatr Neurol 2006;34: 325-328.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·55

∂ƒ∂À¡∏∆π∫∏ ∂ƒ°∞™π∞

ORIGINAL ARTICLE

55

√È Û˘Ó¤ÂȘ Ù˘ ÁÚ›˘ ÛÙ· ·È‰È¿ ÛÙËÓ ÎÔÈÓfiÙËÙ· ª. ∆ÛÔÏÈ¿1, π. §ÔÁÔı¤ÙË1, N. ¶··‰fiÔ˘ÏÔ˜1, M. ª·˘Ú›ÎÔ˘2, N. ™˘Ú›‰Ë˜1, ¶. ¢ÚÔÛ¿ÙÔ˘3, ¢. ∫·ÊÂÙ˙‹˜1, ∞. ∫ˆÓÛÙ·ÓÙfiÔ˘ÏÔ˜1 Î·È Ë ÔÌ¿‰· ÌÂϤÙ˘ Ù˘ ÁÚ›˘ ÛÙËÓ ÎÔÈÓfiÙËÙ·* ¶ÂÚ›ÏË„Ë ∂ÈÛ·ÁˆÁ‹: ∏ Ï‹„Ë Ù˘ ·fiÊ·Û˘ ÁÈ· ÂÌ‚ÔÏÈ·ÛÌfi ÙˆÓ ˘ÁÈÒÓ ·È‰ÈÒÓ Î·Ù¿ Ù˘ ÁÚ›˘ ÚÔ¸Ôı¤ÙÂÈ ÙÔÓ ·ÎÚÈ‚‹ ÚÔÛ‰ÈÔÚÈÛÌfi Ù˘ ÓÔÛËÚfiÙËÙ·˜. ∏ ÚÔÔÙÈ΋ ·˘Ù‹ ÌÂϤÙË ¤¯ÂÈ ÛÙfi¯Ô ÙËÓ ÂÎÙ›ÌËÛË Ù˘ ÂÚÁ·ÛÙËÚȷο ÂȂ‚·ÈˆÌ¤Ó˘ ÁÚ›˘ Î·È ÙˆÓ ÂÈÏÔÎÒÓ Ù˘ Û ˘ÁÈ‹ ·È‰È¿ ÛÙËÓ ÎÔÈÓfiÙËÙ·. ÀÏÈÎfi Î·È Ì¤ıÔ‰ÔÈ: ªÂÏÂÙ‹ıËÎ·Ó 1.462 ·È‰È¿ ËÏÈΛ·˜ ≥6 ÌËÓÒÓ ¤ˆ˜ <14 ÂÙÒÓ Ô˘ ÂÍÂÙ¿ÛıËÎ·Ó ÛÙ· Â͈ÙÂÚÈο È·ÙÚ›· ÙÔ˘ ÓÔÛÔÎÔÌ›Ԣ ‹ Û ȉȈÙÈο ·È‰È·ÙÚÈο È·ÙÚ›·, ÏfiÁˆ ˘ÚÂÙÔ‡ Î·È Ïԛ̈͢ ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ ηٿ ÙËÓ ÂÔ¯‹ Ù˘ ÂÙ‹ÛÈ·˜ ÂȉËÌÈ΋˜ ¤Í·ÚÛ˘ Ù˘ ÁÚ›˘ ÁÈ· ‰‡Ô ¯ÚfiÓÈ·. ∞ÔÙÂϤÛÌ·Ù·: ∏ ÂȉËÌÈ΋ ¤Í·ÚÛË Ù˘ ÁÚ›˘ ‰È‹ÚÎÂÛ οı ¯ÚfiÓÔ 13-14 ‚‰ÔÌ¿‰Â˜. §Ô›ÌˆÍË ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ ‰È·ÈÛÙÒıËΠÛÙÔ˘˜ 573/1.462 (39%) ÙˆÓ ÂÍÂÙ·Ûı¤ÓÙˆÓ Ô˘ ·ÓÙÈÛÙÔȯ› ÛÙÔ 13,5% ÙÔ˘ Û˘ÓfiÏÔ˘ ÙˆÓ ·È‰ÈÒÓ Ô˘ ÂÈÛΤÊıËÎ·Ó Ù· ·È‰È·ÙÚÈο È·ÙÚ›· ηٿ ÙËÓ ÂÚ›Ô‰Ô ·˘Ù‹. ∏ ÔÍ›· ̤ÛË ˆÙ›Ùȉ· ‹Ù·Ó Ë ÈÔ Û˘¯Ó‹ ÂÈÏÔ΋ (18,5%). ∞ÓÙÈ‚ÈÔÙÈο Û˘ÓÙ·ÁÔÁÚ·Ê‹ıËÎ·Ó ÛÙÔ 40% ÙˆÓ ·ÛıÂÓÒÓ Ì ÁÚ›Ë. √Í›· ̤ÛË ˆÙ›Ùȉ· Î·È Ï‹„Ë ·ÓÙÈ‚ÈÔÙÈÎÒÓ ‹Ù·Ó Û˘¯ÓfiÙÂÚ˜ ÛÙ· ·È‰È¿ ËÏÈΛ·˜ οو ÙˆÓ 5 ÂÙÒÓ Ô˘ ·ÔÙÂÏÔ‡Û·Ó ÙÔ 58% ÙÔ˘ Û˘ÓfiÏÔ˘ ÙˆÓ ·ÛıÂÓÒÓ Ù˘ ÌÂϤÙ˘. °È· οı ¿ÚÚˆÛÙÔ ·È‰›, ÔÈ ÁÔÓ›˜ ¤¯·Û·Ó 1,34 Ë̤Ú˜ ÂÚÁ·Û›·˜. ™ÙȘ ÔÈÎÔÁ¤ÓÂȘ ÙˆÓ ·È‰ÈÒÓ Ì ÁÚ›Ë Î·Ù·ÁÚ¿ÊËΠÌÂÁ·Ï‡ÙÂÚË Û˘¯ÓfiÙËÙ· ÂÌÊ¿ÓÈÛ˘ Î·È ‰Â‡ÙÂÚÔ˘ ÂÚÈÛÙ·ÙÈÎÔ‡ ·Ó·Ó¢ÛÙÈ΋˜ Ïԛ̈͢, ÂÈÛΤ„ÂˆÓ Û ȷÙÚfi Î·È ¯Ú‹Û˘ ·ÓÙÈ‚ÈÔÙÈÎÒÓ. ™˘ÌÂÚ¿ÛÌ·Ù·: H ÁÚ›Ë ÚÔηÏ› ÛËÌ·ÓÙÈ΋ ÓÔÛËÚfiÙËÙ· ÛÙ· ·È‰È¿ ÛÙËÓ ÎÔÈÓfiÙËÙ·. √È Û˘Ó¤ÂȤ˜ Ù˘ ı· ÌÔÚÔ‡Û·Ó Ó· ÂÚÈÔÚÈÛıÔ‡Ó Ì ÙÔÓ Î·ıÔÏÈÎfi ÂÌ‚ÔÏÈ·ÛÌfi ÙˆÓ ·È‰ÈÒÓ ËÏÈΛ·˜ <5 ÂÙÒÓ.

1 µ’ ¶·È‰È·ÙÚÈ΋ ¶·ÓÂÈÛÙËÌȷ΋ ∫ÏÈÓÈ΋ 2 ∞’ ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ “¶. & ∞. ∫˘ÚÈ·ÎÔ‡”, ∞ı‹Ó· 3 µ’ ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ “¶. & ∞. ∫˘ÚÈ·ÎÔ‡”, ∞ı‹Ó· AÏÏËÏÔÁÚ·Ê›·: πˆ¿ÓÓ· §ÔÁÔı¤ÙË giannalogotheti@yahoo.gr µ’ ¶·È‰È·ÙÚÈ΋ ¶·ÓÂÈÛÙËÌȷ΋ ∫ÏÈÓÈ΋, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ∞ıËÓÒÓ “¶. & ∞. ∫˘ÚÈ·ÎÔ‡” £Ë‚ÒÓ Î·È §Â‚·‰Â›·˜, ∆.∫. 115 27, ∞ı‹Ó·

§¤ÍÂȘ ÎÏÂȉȿ: °Ú›Ë, ·È‰È¿, Â͈ÙÂÚÈÎÔ› ·ÛıÂÓ›˜, ÎÔÈÓfiÙËÙ·.

The impact of influenza in children on the community M. Tsolia1, I. Logotheti1, N. Papadopoulos1, M. Mavrikou2, N. Spyridis1, P. Drossatou3, D. Kafetzis1, A. Konstantopoulos1 and the outpatient flu study group* Abstract Background: Decisions regarding the introduction of influenza immunization of healthy children require an accurate evaluation of the influenza disease burden not only in the inpatient but also in the outpatient setting.

Methods: A prospective study was made of the impact of virologically confirmed influenza on 1,462 outpatient children (≥6 months to <14 years) and on their families, during two consecutive influenza seasons.

Results: Influenza was documented in 573/1,462 (39%) outpatients with febrile respiratory illness and it accounted for 13.5% of all outpatient visits during the 14 weeks of each season. Acute otitis media (AOM) was the most common complication (18.5%) and about 40% of influenza positive patients received antibiotics. AOM and antibiotic use were more common in children aged younger than 5 years, who accounted for 58% of all patients in the study. For each sick child with influenza, a mean of 1.34 workdays were lost by the parents. Family members of influenza positive children were more likely to develop a secondary respiratory illness and to require medical consultations and antibiotic prescription.

Conclusions: Influenza is associated with a heavy burden of morbidity in the community that could be reduced considerably with the implementation of influenza immunization of children in the under 5 years age group.

1 2nd Department of Paediatrics, School of Medicine, University of Athens 2 1st Department of Paediatrics, “P. & A. Kyriakou” Children’s Hospital, Athens 3 2nd Department of Paediatrics, “P. & A. Kyriakou” Children’s Hospital, Athens Correspondence: Ioanna Logotheti giannalogotheti@yahoo.gr 2nd Department of Paediatrics, School of Medicine, University of Athens, “P. & A. Kyriakou” Children’s Hospital Thivon & Levadias St., 115 27, Athens, Greece

Key words: Influenza, children, outpatients, community.

*√Ì¿‰· ÌÂϤÙ˘ Ù˘ ÁÚ›˘ ÛÙËÓ ÎÔÈÓfiÙËÙ· º. ™ÙÚÈ¤ÏË, °. ∆ÛfiÏ·˜, ª. ¶ÂÙÚ¿ÎË, ¶. ™˘Ú›‰Ë˜, ¢. ÃÔϤ‚·˜, Ã. ¶ÂÙÚÔÁÈ·ÓÓÔÔ‡ÏÔ˘, ∫. ™È·Î·‚¤Ï·˜, ¡. ª˘ÚÈÔÎÂÊ·ÏÈÙ¿Î˘ *Outpatient flu study group F. Stripeli, G. Tsolas, M. Petraki, P. Spyridis, D. Cholevas, C. Petroyannopoulou, K. Siakavellas, N. Myriokefalitakis ¶·È‰È·ÙÚÈ΋ 2008;71:55-61

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·56

56

ª. ∆ÛÔÏÈ¿ Î·È Û˘Ó.

™˘ÓÙÔÌÔÁڷʛ˜ RSV ∆∂¶ ™∞

Respiratory Syncytial Virus ∆Ì‹Ì· ∂ÂÈÁfiÓÙˆÓ ¶ÂÚÈÛÙ·ÙÈÎÒÓ ™Ù·ıÂÚ‹ ∞fiÎÏÈÛË

∂ÈÛ·ÁˆÁ‹ ¶ÚfiÛÊ·Ù˜ ÂȉËÌÈÔÏÔÁÈΤ˜ ÌÂϤÙ˜ ¤¯Ô˘Ó ‰Â›ÍÂÈ fiÙÈ Ë Û˘¯ÓfiÙËÙ· ÂÈÛ·ÁˆÁ‹˜ ÛÙÔ ÓÔÛÔÎÔÌ›Ô, ÏfiÁˆ ÁÚ›˘ ÙˆÓ ˘ÁÈÒÓ ·È‰ÈÒÓ ÌÈÎÚ‹˜ ËÏÈΛ·˜, Â›Ó·È Û˘ÁÎÚ›ÛÈÌË Ì ·˘Ù‹ ÙˆÓ ·ÙfiÌˆÓ Ô˘ ·Ó‹ÎÔ˘Ó Û ÔÌ¿‰Â˜ ·˘ÍË̤ÓÔ˘ ÎÈÓ‰‡ÓÔ˘ (1,2). øÛÙfiÛÔ, Ë ·ÎÚÈ‚‹˜ ·ÍÈÔÏfiÁËÛË ÙˆÓ Â˘ÚËÌ¿ÙˆÓ ·˘ÙÒÓ ÂËÚ¿˙ÂÙ·È ·fi ÙÔ ÁÂÁÔÓfi˜ fiÙÈ Î·Ù¿ ÙÔ˘˜ ¯ÂÈÌÂÚÈÓÔ‡˜ Ì‹Ó˜ Ë ÂȉËÌÈ΋ ¤Í·ÚÛË Ù˘ ÁÚ›˘ Û˘Ì›ÙÂÈ Ì ·˘Ù‹Ó Ô˘ ÚÔηÏÂ›Ù·È ·fi ¿ÏÏÔ˘˜ ÈÔ‡˜, fiˆ˜ Â›Ó·È Î·Ù¿ ·ÚÈÔ ÏfiÁÔ Ô ·Ó·Ó¢ÛÙÈÎfi˜ Û˘Á΢ÙÈ·Îfi˜ Èfi˜ (respiratory syncytial virus - RSV). ÕÏϘ ÌÂϤÙ˜, ‚·ÛÈṲ̂Ó˜ Û ÂȉËÌÈÔÏÔÁÈ΋ ÂÈÙ‹ÚËÛË, Âȯ›ÚËÛ·Ó Ó· ‰È·¯ˆÚ›ÛÔ˘Ó ÙËÓ Â›‰Ú·ÛË ÙÔ˘ RSV Î·È ÙÔ˘ ÈÔ‡ Ù˘ ÁÚ›˘ ÛÙË Û˘¯ÓfiÙËÙ· ÂÈÛ·ÁˆÁ‹˜ ÙˆÓ ˘ÁÈÒÓ ·È‰ÈÒÓ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô (3,4). ∆· ·ÔÙÂϤÛÌ·Ù¿ ÙÔ˘˜ ÂȂ‚·›ˆÛ·Ó fiÙÈ Ù· ˘ÁÈ‹ ·È‰È¿ <2 ÂÙÒÓ, Î·È Èı·ÓfiÓ Î·È ÂΛӷ ÌÂٷ͇ 2 Î·È 4 ÂÙÒÓ, ·ÚÔ˘ÛÈ¿˙Ô˘Ó ·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ Ó· ÓÔÛËÏ¢ıÔ‡Ó ÏfiÁˆ Ù˘ ÁÚ›˘, Û ۇÁÎÚÈÛË Ì ٷ ÌÂÁ·Ï‡ÙÂÚ· ·È‰È¿. ¶ÈÔ ÚfiÛÊ·Ù˜ ÌÂϤÙ˜ Ô˘ ‚·Û›ÛÙËÎ·Ó Û ηÏÏȤÚÁÂȘ ÙÔ˘ ÈÔ‡ ÂȂ‚·›ˆÛ·Ó ÙËÓ ·˘ÍË̤ÓË Û˘¯ÓfiÙËÙ· ÂÈÛ·ÁˆÁ‹˜ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô ÙˆÓ ·È‰ÈÒÓ ÌÈÎÚ‹˜ ËÏÈΛ·˜ (5). µ¿ÛÂÈ ·˘ÙÒÓ ÙˆÓ ÛÙÔȯ›ˆÓ Û˘ÛÙ‹ÓÂÙ·È ÛÙȘ ∏¶∞ ·fi ÙÔ 2003 Ô Î·ıÔÏÈÎfi˜ ÂÌ‚ÔÏÈ·ÛÌfi˜ ηٿ Ù˘ ÁÚ›˘ ÙˆÓ ·È‰ÈÒÓ ËÏÈΛ·˜ 6-23 ÌËÓÒÓ (6). ¶·ÚfiÏÔ Ô˘ ÔÈ Û˘ÛÙ¿ÛÂȘ ÁÈ· ÂÌ‚ÔÏÈ·ÛÌfi ‚·Û›ÛÙËÎ·Ó ÛÙÔÓ ·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ ÂÈÛ·ÁˆÁ‹˜ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô ÙˆÓ ÌÈÎÚfiÙÂÚˆÓ ·È‰ÈÒÓ, ˘¿Ú¯Ô˘Ó ÂӉ›ÍÂȘ fiÙÈ Ë Ïԛ̈ÍË ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ ÚÔηÏ› ÛËÌ·ÓÙÈ΋ ÓÔÛËÚfiÙËÙ· ÛÙ· ·È‰È¿ Î·È ÙËÓ ÎÔÈÓfiÙËÙ· (3). ÀÔÏÔÁ›˙ÂÙ·È fiÙÈ ÂÚ›Ô˘ ÙÔ 30-40% ÙˆÓ ·È‰ÈÒÓ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ ÓÔÛÔ‡Ó ·fi ÁÚ›Ë Î¿ı ¯ÚfiÓÔ Î·È ·ÔÙÂÏÔ‡Ó ÙËÓ Î‡ÚÈ· ËÁ‹ ÌÂÙ¿‰ÔÛ˘ Ù˘ ÓfiÛÔ˘ Û ÂÓËÏ›ÎÔ˘˜, ·È‰È¿ Î·È ¿ÙÔÌ· Ô˘ ·Ó‹ÎÔ˘Ó Û ÔÌ¿‰Â˜ ·˘ÍË̤ÓÔ˘ ÎÈÓ‰‡ÓÔ˘ (7-12). ∞fi Ù· ·È‰È¿ Ô˘ ·Ó·Ù‡ÛÛÔ˘Ó Û˘Ìو̷ÙÈ΋ Ïԛ̈ÍË, ÌfiÓÔ ¤Ó· ÌÈÎÚfi ÔÛÔÛÙfi ÓÔÛËχÂÙ·È, Ì ·ÔÙ¤ÏÂÛÌ· Ë ÂÈÛ·ÁˆÁ‹ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô Ó· ·ÓÙÈÚÔÛˆ‡ÂÈ ¤Ó· ÌÈÎÚfi ̤ÚÔ˜ Ù˘ Û˘ÓÔÏÈ΋˜ ÓÔÛËÚfiÙËÙ·˜ Ù˘ ÁÚ›˘ (13,14). ∏ ÙÂÏÈ΋ ·fiÊ·ÛË ÁÈ· ÙË Û‡ÛÙ·ÛË ÂÌ‚ÔÏÈ·ÛÌÔ‡ Û ˘ÁÈ‹ ·È‰È¿ ··ÈÙ› ÚÔÛÂÎÙÈ΋ ÂÎÙ›ÌËÛË ÙˆÓ ÂÈÙÒÛÂˆÓ Ù˘ ÁÚ›˘ ÙfiÛÔ ÛÙÔ˘˜ ÓÔÛËÏ¢fiÌÂÓÔ˘˜ fiÛÔ Î·È ÛÙÔ˘˜ Â͈ÙÂÚÈÎÔ‡˜ ·ÛıÂÓ›˜, ηıÒ˜ Â›Û˘ Î·È ÙˆÓ ÎÔÈÓˆÓÈÎÔÔÈÎÔÓÔÌÈÎÒÓ Û˘ÓÂÂÈÒÓ Ù˘ Ïԛ̈͢ ÛÙËÓ ÎÔÈÓfiÙËÙ·. ™ÎÔfi˜ Ù˘ ÌÂϤÙ˘ ·˘Ù‹˜ ‹Ù·Ó Ë ÂÎÙ›ÌËÛË ÙˆÓ Û˘ÓÂÂÈÒÓ Ù˘ ÂÚÁ·ÛÙËPaediatriki 2008;71:55-61

Úȷο ÂȂ‚·ÈˆÌ¤Ó˘ ÁÚ›˘ Û ˘ÁÈ‹ ·È‰È¿ Î·È ÙȘ ÔÈÎÔÁ¤ÓÂȤ˜ ÙÔ˘˜ ÛÙËÓ ÎÔÈÓfiÙËÙ·.

ÀÏÈÎfi Î·È Ì¤ıÔ‰ÔÈ ¶ÚfiÎÂÈÙ·È ÁÈ· ÚÔÔÙÈ΋ ÌÂϤÙË Ô˘ ¤Ï·‚ ¯ÒÚ· ηٿ ÙË ‰È¿ÚÎÂÈ· ‰‡Ô Û˘Ó¯fiÌÂÓˆÓ ÂÙÒÓ 2003-2004 Î·È 2004-2005. ø˜ ÂÚ›Ô‰Ô˜ ÂȉËÌÈ΋˜ ¤Í·ÚÛ˘ ÁÚ›˘ ÔÚ›ÛÙËΠοı ¯ÚfiÓÔ ·˘Ù‹ Ô˘ ÔÚÈÔıÂÙÔ‡ÓÙ·Ó ·fi ÙÔ ÚÒÙÔ ¤ˆ˜ Î·È ÙÔ ÙÂÏÂ˘Ù·›Ô ıÂÙÈÎfi ‰Â›ÁÌ· ÁÈ· ÙÔÓ Èfi Ù˘ ÁÚ›˘, Ô˘ ηٷÁÚ¿ÊËΠÛÙÔ ÓÔÛÔÎÔÌÂ›Ô ·›‰ˆÓ “¶. & ∞. ∫˘ÚÈ·ÎÔ‡” ηٿ ÙË ‰È¿ÚÎÂÈ· Ù˘ ÂÈÙ‹ÚËÛ˘. ∏ ÂÈÙ‹ÚËÛË ‰ÈÂÍ‹¯ıË ÛÙÔ ÙÌ‹Ì· ÂÂÈÁfiÓÙˆÓ ÂÚÈÛÙ·ÙÈÎÒÓ (∆∂¶) ÙÔ˘ ÓÔÛÔÎÔÌ›Ԣ ·fi ÙËÓ 1Ë ¢ÂÎÂÌ‚Ú›Ô˘ οı ¯ÚfiÓÔ˘ Î·È Û˘Ó¯›ÛÙËΠ̤¯ÚÈ ÙËÓ Î·Ù·ÁÚ·Ê‹ ·ÚÓËÙÈÎÒÓ ÌfiÓÔ ·ÔÙÂÏÂÛÌ¿ÙˆÓ ÁÈ· ‰‡Ô Û˘Ó¯fiÌÂÓ˜ ‚‰ÔÌ¿‰Â˜. ∆Ô ‰Â‡ÙÂÚÔ ¤ÙÔ˜ Û˘ÌÂÚÈÏ‹ÊıËÎ·Ó ÛÙË ÌÂϤÙË Î·È ·ÛıÂÓ›˜ Ô˘ ÂÍÂÙ¿˙ÔÓÙ·Ó Û ÂÙ¿ ȉȈÙÈο ·È‰È·ÙÚÈο È·ÙÚ›·. ∆Ô ÚˆÙfiÎÔÏÏÔ Ù˘ ÌÂϤÙ˘ ÂÁÎÚ›ıËΠ·fi ÙËÓ ∂ÈÙÚÔ‹ ∏ıÈ΋˜ Î·È ¢ÂÔÓÙÔÏÔÁ›·˜ ÙÔ˘ ÓÔÛÔÎÔÌ›Ԣ. √È ÁÔÓ›˜ ÂÓËÌÂÚÒÓÔÓÙ·Ó ÚÔÊÔÚÈο Î·È ¤‰ÈÓ·Ó ÙË Û˘ÁηٿıÂÛ‹ ÙÔ˘˜ ÁÈ· ÙË Û˘ÌÌÂÙÔ¯‹ ÙˆÓ ·È‰ÈÒÓ ÛÙË ÌÂϤÙË. ™ÙË ÌÂϤÙË Û˘ÌÂÚÈÏ‹ÊıËÎ·Ó ·È‰È¿ ËÏÈΛ·˜ 6 ÌËÓÒÓ ¤ˆ˜ 14 ÂÙÒÓ Ì ˘ÚÂÙfi (ıÂÚÌÔÎÚ·Û›· Ì·Û¯¿Ï˘ ≥37,8oC) Î·È ÂÓfi˜ ÙÔ˘Ï¿¯ÈÛÙÔÓ Û˘ÌÙÒÌ·ÙÔ˜ ‹ ÛËÌ›Ԣ Ïԛ̈͢ ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜. ∂Í·ÈÚ¤ıËÎ·Ó ·fi ÙË ÌÂϤÙË ·È‰È¿ Ì ¯ÚfiÓÈ· ÓÔÛ‹Ì·Ù· ηıÒ˜ Î·È ‚Ú¤ÊË <1 ¤ÙÔ˘˜ Ì ÈÛÙÔÚÈÎfi ÚÔˆÚfiÙËÙ·˜. °È· οı ·ÛıÂÓ‹ Û˘ÌÏËÚÒıËΠÂȉÈÎfi ÂÚˆÙËÌ·ÙÔÏfiÁÈÔ Ô˘ ÂÚÈ›¯Â ‰ËÌÔÁÚ·ÊÈο ÛÙÔȯ›·, Û‡ÓÙÔÌÔ ÈÛÙÔÚÈÎfi, Û˘ÌÙÒÌ·Ù· Î·È ÛËÌ›· ·fi ÙË Ê˘ÛÈ΋ ÂͤٷÛË, ·ÔÙÂϤÛÌ·Ù· ·fi ÂÚÁ·ÛÙËÚȷΤ˜ ÂÍÂÙ¿ÛÂȘ (Â¿Ó ¤ÁÈÓ·Ó), ÙÂÏÈ΋ ‰È¿ÁÓˆÛË, Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹, ÂÈÏÔΤ˜ Î·È ¤Î‚·ÛË. ∂›Û˘, Û˘ÏϤ¯ıËÎ·Ó ÛÙÔȯ›· Ô˘ ·ÊÔÚÔ‡Û·Ó ÙÔÓ ·ÚÈıÌfi ÙˆÓ ·‰ÂÏÊÒÓ, ÙËÓ ¤ÎıÂÛË Û οÓÈÛÌ·, ÙË Û˘ÌÌÂÙÔ¯‹ ‹ fi¯È Û ·È‰ÈÎfi ÛÙ·ıÌfi, ÙËÓ ÂÚÁ·Ûȷ΋ ηٿÛÙ·ÛË ÙˆÓ ÁÔÓÈÒÓ Î·È ÙË ¯Ú‹ÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ. ¢‡Ô ¤ˆ˜ ÙÚÂȘ ‚‰ÔÌ¿‰Â˜ ÌÂÙ¿ ÙËÓ ·Ú¯È΋ ÂͤٷÛË, ηÙfiÈÓ ÙËÏÂʈÓÈ΋˜ ÂÈÎÔÈÓˆÓ›·˜ Ì ÙÔ˘˜ ÁÔÓ›˜, ηٷÁÚ¿ÊÔÓÙ·Ó ‰Â‰Ô̤ӷ Ô˘ ·ÊÔÚÔ‡Û·Ó ÙËÓ ÔÚ›· Ù˘ ÓfiÛÔ˘, ÙË ‰È¿ÚÎÂÈ· ÙˆÓ Û˘Ìو̿وÓ, ÙÔ Û˘ÓÔÏÈÎfi ·ÚÈıÌfi ÙˆÓ È·ÙÚÈÎÒÓ ÂÈÛΤ„ˆÓ, ÙËÓ ÙÂÏÈ΋ ‰È¿ÁÓˆÛË (Â¿Ó ‹Ù·Ó ‰È·ÊÔÚÂÙÈ΋ ·fi ÙËÓ ·Ú¯È΋), ÙË ÏËÊı›۷ ıÂÚ·›·, ÙËÓ Èı·Ó‹ ÂÈÛ·ÁˆÁ‹ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô Î·È ÙË ‰È¿ÚÎÂÈ· ·Ô˘Û›·˜ ·fi ÙÔ Û¯ÔÏÂ›Ô ‹ ÙÔÓ ·È‰ÈÎfi ÛÙ·ıÌfi. ∂›Û˘, ηٷÁÚ¿ÊÔÓÙ·Ó Ë ÂΉ‹ÏˆÛË Ïԛ̈͢ ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ Û ¿ÏÏ· ̤ÏË Ù˘ ÔÈÎÔÁ¤ÓÂÈ·˜, Ë ·Ó·ÁηÈfiÙËÙ· È·ÙÚÈ΋˜ ÂͤٷÛ˘ ÁÈ’ ·˘Ù¿, Ë ¯Ú‹ÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ, Ë ·Ô˘Û›· ·fi ÙËÓ ÂÚÁ·Û›· ÙÔ˘˜ Î·È Ë Ù˘¯fiÓ ÂÈÛ·ÁˆÁ‹ ÛÙÔ ÓÔÛÔÎÔÌ›Ô. ∏ ‰È¿ÁÓˆÛË Ù˘ Ó¢ÌÔÓ›·˜ ‚·Û›ÛÙËΠ۠·ÂÈÎÔÓÈÛÙÈ΋ ÂȂ‚·›ˆÛË. ∏ ‰È¿ÁÓˆÛË Ïԛ̈͢ ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ ¤ÁÈÓ Ì ·Ó›¯ÓÂ˘Û‹ ÙÔ˘ Û ÚÈÓÈÎfi Â›¯ÚÈÛÌ· Ô˘ ÂÏ‹ÊıË ·fi οı ·ÛıÂÓ‹. °È· ÙËÓ ·Ó›¯Ó¢ÛË ÙÔ˘ ÈÔ‡ ¯ÚËÛÈÌÔÔÈ‹ıËΠ‰ÔÎÈÌ·Û›· Ù·¯Â›·˜ ·Ó›¯Ó¢Û˘ ·ÓÙÈÁfiÓÔ˘ [QuickVue Influenza Test (Quidel, San Diego, Ca)]. ªÂ ·˘Ù‹ ÙË ‰ÔÎÈÌ·Û›· ·Ó›¯Ó¢Û˘ ÙÔ˘ ÈÔ‡ Ù˘ ÁÚ›˘, ‰ÂÓ ‹Ù·Ó ‰˘Ó·Ùfi˜ Ô ÚÔÛ‰ÈÔÚÈÛÌfi˜ ˘ÔÙ‡ˆÓ ÁÚ›˘. ŒÁÈÓ·Ó Û˘ÁÎÚ›ÛÂȘ ÌÂٷ͇ ıÂÙÈÎÒÓ Î·È ·ÚÓËÙÈÎÒÓ ÁÈ· ÁÚ›Ë ·ÛıÂÓÒÓ. √È ıÂÙÈÎÔ› ÁÈ· ÁÚ›Ë ·ÛıÂÓ›˜ ‰È·¯ˆÚ›ÛÙËÎ·Ó Î·È Û˘ÁÎÚ›ıËÎ·Ó Î·È Î·Ù¿ ËÏÈΛ· (≥6 ÌËÓÒÓ ¤ˆ˜ <2 ÂÙÒÓ, ≥2 ¤ˆ˜ <5 ÂÙÒÓ Î·È ≥5 ¤ˆ˜ <14 ÂÙÒÓ), ηٿ ÂÍÂÙ·ÛÙÈÎfi ΤÓÙÚÔ (∆∂¶ ‹ ȉȈÙÈο ·È‰È·ÙÚÈο È·ÙÚ›·) Î·È ¤ÙÔ˜ ¤ÓÙ·Í˘ ÛÙË ÌÂϤÙË. ∆Ô χ2 ‹ ÙÔ 2-tailed Fisher’s ÙÂÛÙ Î·È ÙÔ one-way ANOVA ÙÂÛÙ ¯ÚËÛÈÌÔÔÈ‹ıËÎ·Ó ÁÈ· ÙË Û‡ÁÎÚÈÛË

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·57

57

√È Û˘Ó¤ÂȘ Ù˘ ÁÚ›˘

ÙˆÓ Î·ÙËÁÔÚÈÎÒÓ Î·È Û˘Ó¯ÒÓ ÌÂÙ·‚ÏËÙÒÓ, ·ÓÙ›ÛÙÔȯ·. ø˜ Â›Â‰Ô ÛËÌ·ÓÙÈÎfiÙËÙ·˜ ηıÔÚ›ÛÙËΠÙÔ ·=5%. ∏ ÛÙ·ÙÈÛÙÈ΋ ·Ó¿Ï˘ÛË ¤ÁÈÓ ¯ÚËÛÈÌÔÔÈÒÓÙ·˜ ÙÔ ÚfiÁÚ·ÌÌ· SPSS 11.5.

¶›Ó·Î·˜ 1. ÷ڷÎÙËÚÈÛÙÈο ·ÛıÂÓÒÓ ¢ËÌÔÁÚ·ÊÈο ÛÙÔȯ›·

°Ú›Ë (+) °Ú›Ë (-) N=573 N=888

∞ÔÙÂϤÛÌ·Ù· ∏ ‰È¿ÚÎÂÈ· Ù˘ ÂȉËÌÈ΋˜ ¤Í·ÚÛ˘ Ù˘ ÁÚ›˘ ‹Ù·Ó 13 Î·È 14 ‚‰ÔÌ¿‰Â˜, ·ÓÙ›ÛÙÔȯ·, ÁÈ· Ù· ‰‡Ô Û˘Ó¯fiÌÂÓ· ¤ÙË. ∆ÔÓ ÚÒÙÔ ¯ÚfiÓÔ, Ë ÂÔ¯‹ Ù˘ ÁÚ›˘ ¿Ú¯ÈÛ ÙË ‰Â‡ÙÂÚË Â‚‰ÔÌ¿‰· ÙÔ˘ ºÂ‚ÚÔ˘·Ú›Ô˘ ÂÓÒ ÙÔ ‰Â‡ÙÂÚÔ ·Ú¯¤˜ ¢ÂÎÂÌ‚Ú›Ô˘. ∞fi 1.462 ·È‰È¿ ËÏÈΛ·˜ 6 ÌËÓÒÓ-14 ÂÙÒÓ Ô˘ ÂÍÂÙ¿ÛÙËÎ·Ó Ì ˘ÚÂÙfi Î·È Ïԛ̈ÍË ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜, 573 (39,2%) ‹Ù·Ó ıÂÙÈο ÁÈ· ÁÚ›Ë. ∆ËÓ ÂÚ›Ô‰Ô ·È¯Ì‹˜, Ô˘ Î·È ÙȘ ‰‡Ô ¯ÚÔÓȤ˜ ‰È‹ÚÎÂÛ ÂÚ›Ô˘ Ù¤ÛÛÂÚȘ ‚‰ÔÌ¿‰Â˜, >50% ÙˆÓ ·ÛıÂÓÒÓ ‹Ù·Ó ıÂÙÈÎÔ› (∂ÈÎfiÓ· 1). ∆ÔÓ ÚÒÙÔ ¯ÚfiÓÔ (2002-2003) Î·È ÙÔ ‰Â‡ÙÂÚÔ (2003-2004) ÂÍÂÙ¿ÛÙËÎ·Ó Ì Ô͇ Úfi‚ÏËÌ· 2.553 ·È‰È¿ Î·È 2.359, ·ÓÙ›ÛÙÔȯ·, Î·È ·fi ·˘Ù¿ 759 (29,7%) Î·È 946 (40%), ·ÓÙ›ÛÙÔȯ·, ÏËÚÔ‡Û·Ó Ù· ÎÚÈÙ‹ÚÈ· ¤ÓÙ·Í˘ ÛÙË ÌÂϤÙË. ¢ÔÎÈÌ·Û›· ÁÈ· ·Ó›¯Ó¢ÛË ÙÔ˘ ÈÔ‡ Ù˘ ÁÚ›˘ ¤ÁÈÓ Û 608 (80%) Î·È 854 (90%) Î·È ·fi ·˘ÙÔ‡˜ 254/608 (41,8%) Î·È 319/854 (37,3%), ·ÓÙ›ÛÙÔȯ·, ‹Ù·Ó ıÂÙÈÎÔ›. ¢ÂÓ ˘‹ÚÍ ÛËÌ·ÓÙÈ΋ ‰È·ÊÔÚ¿ ÛÙÔ ÔÛÔÛÙfi Ïԛ̈͢ Ù· ‰‡Ô Û˘Ó¯fiÌÂÓ· ¤ÙË (p=0,088). ∆Ô 13,5% ÙÔ˘ Û˘ÓfiÏÔ˘ ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ÚÔÛ‹Ïı·Ó ÛÙ· ∆∂¶ ÙÔ˘ ÓÔÛÔÎÔÌ›Ԣ ηٿ Ù· ‰‡Ô ¯ÚfiÓÈ· Ô˘ ‰È‹ÚÎÂÛÂ Ë ÌÂϤÙË Î·È ÙÔ 16,1% ·˘ÙÒÓ Ô˘ ÂÈÛΤÊÙËÎ·Ó ÙÔ˘˜ ȉÈÒÙ˜ ·È‰È¿ÙÚÔ˘˜ Ô˘ Û˘ÌÌÂÙ›¯·Ó ›¯Â Ïԛ̈ÍË ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘. ∏ Û˘¯ÓfiÙËÙ· Ïԛ̈͢ ·fi ÁÚ›Ë ‹Ù·Ó ¯·ÌËÏfiÙÂÚË ÛÙ· ·È‰È¿ <2 ÂÙÒÓ (30,9%) Û˘ÁÎÚÈÓfiÌÂÓË Ì ·˘Ù¿ ËÏÈΛ·˜ ≥2 Î·È ≤5 (42%) Î·È ÂΛӷ ≥5 ÂÙÒÓ (41,5%) (p=0,004). ∆· ¯·Ú·ÎÙËÚÈÛÙÈο ÙˆÓ ·ÛıÂÓÒÓ ÌÂ Î·È ¯ˆÚ›˜ Ïԛ̈ÍË ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ Ê·›ÓÔÓÙ·È ÛÙÔÓ ¶›-

∏ÏÈΛ·, ̤ÛË ± ™∞ (Ì‹Ó˜) ∞ÁfiÚÈ·/∫ÔÚ›ÙÛÈ· πÛÙÔÚÈÎfi ‚ÚÔÁ¯ÈÎÔ‡ ¿ÛıÌ·ÙÔ˜ ¶·ıËÙÈÎfi οÓÈÛÌ· ™¯ÔÏ›Ô/·È‰ÈÎfi˜ ÛÙ·ıÌfi˜ ¶·È‰ÈÎfi˜ ÛÙ·ıÌfi˜ ¶·Ú·ÌÔÓ‹ ÛÙÔ Û›ÙÈ ™¯ÔÏÂ›Ô ª¤ÁÂıÔ˜ ÔÈÎÔÁ¤ÓÂÈ·˜, ̤ÛË ± ™∞ ∞‰¤ÏÊÈ·, ̤ÛË ± ™∞

62±43 1,4

55,8±43,6 0,008 1,2 0,411

97 (17)· 261 (46) 355 (61,5) 180 (31,5) 217 (38) 175 (30,5)

162 (18) 439 (50) 482 (55) 245 (28) 402 (45) 237 (27)

0,514 0,138 0,004 0,116 0,005 0,110

3,7±0,77 0,7±0,83

3,7±0,76 0,7±0,76

0,530 0,619

P

·

√È ·ÚÈıÌÔ› ÛÙËÓ ·Ú¤ÓıÂÛË ·ÓÙÈÛÙÔÈ¯Ô‡Ó Û ÔÛÔÛÙ¿ % ™∞ ÛÙ·ıÂÚ‹ ·fiÎÏÈÛË

ӷη 1. ∏ Ïԛ̈ÍË ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ ‹Ù·Ó Û˘¯ÓfiÙÂÚË ÛÙ· ·È‰È¿ Ô˘ ·Ú·ÎÔÏÔ˘ıÔ‡Û·Ó ·È‰ÈÎfi ÛÙ·ıÌfi ‹ Û¯ÔÏ›Ô. ¶ÂÚ›Ô˘ ÙÔ 60% ÙˆÓ ·È‰ÈÒÓ Ì ÁÚ›Ë ‹Ù·Ó οو ÙˆÓ 5 ÂÙÒÓ. ∏ ËÏÈÎȷ΋ ηٷÓÔÌ‹ ÙˆÓ ·ÛıÂÓÒÓ Ì ÁÚ›Ë Ê·›ÓÂÙ·È ÛÙËÓ ∂ÈÎfiÓ· 2. ∏ ÔÍ›· ̤ÛË ˆÙ›Ùȉ· ‹Ù·Ó Ë ÈÔ Û˘¯Ó‹ ÂÈÏÔ΋. ∫·Ù·ÁÚ¿ÊËΠÛÙÔ 15% ÙˆÓ ıÂÙÈÎÒÓ ÁÈ· ÁÚ›Ë ·ÛıÂÓÒÓ Î·Ù¿ ÙËÓ ·Ú¯È΋ ÂͤٷÛË Î·È ÛÙÔ 18,5% ÛÙÔ follow-up (∂ÈÎfiÓ· 3). µÚÔÁ¯ÈÔÏ›Ùȉ·, ‚ÚÔÁ¯ÈÎfi ¿ÛıÌ· Î·È Ó¢ÌÔÓ›· ‹Ù·Ó ÏÈÁfiÙÂÚÔ Û˘¯Ó¤˜ ÂÈÏÔΤ˜ ÛÙÔ˘˜ ıÂÙÈÎÔ‡˜ ·ÛıÂÓ›˜. ∞Ó¿Ï˘ÛË ÙˆÓ ·ÔÙÂÏÂÛÌ¿ÙˆÓ Ì ‚¿ÛË ÙËÓ ËÏÈÎȷ΋ ηٷÓÔÌ‹ ÙˆÓ ıÂÙÈÎÒÓ ·ÛıÂÓÒÓ ¤‰ÂÈÍ fiÙÈ ÔÍ›· ̤ÛË ˆÙ›Ùȉ· ‰È·ÁÓÒÛÙËΠÙÂÏÈο ÈÔ Û˘¯Ó¿ ÛÙ· ·È‰È¿ οو ÙˆÓ 2 ÂÙÒÓ Î·È Û ·˘Ù¿ ËÏÈΛ·˜ ≥2 ¤ˆ˜ <5 ÂÙÒÓ Û ۇÁÎÚÈÛË Ì ٷ ÌÂÁ·Ï‡ÙÂÚ· ≥5 ¤ˆ˜

90 ∆∂¶

80

π‰ÈˆÙÈο π·ÙÚ›·

£ÂÙÈÎÔ› ·ÛıÂÓ›˜ %

70 60 50 40 30 20 10 11

9

7

5

3

1

51

20

18

16

14

12

10

8

6

0 2003 ∂‚‰ÔÌ¿‰Â˜ 2004 ∂ÈÎfiÓ· 1. ∫·Ù·ÓÔÌ‹ ÙˆÓ ÂÚÈÙÒÛÂˆÓ ÁÚ›˘ Û ·È‰È¿ Ì ÂÌ‡ÚÂÙË Ïԛ̈ÍË ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Ô˘ ÂÍÂÙ¿ÛÙËÎ·Ó ÛÙ· Â͈ÙÂÚÈο ·È‰È·ÙÚÈο È·ÙÚ›· ‹ Û ȉȈÙÈο ·È‰È·ÙÚÈο È·ÙÚ›· ηٿ ÙË ‰È¿ÚÎÂÈ· ÙˆÓ ‰‡Ô ÂȉËÌÈÒÓ ÁÚ›˘ Ù˘ ÌÂϤÙ˘ (2002-2004). ¶·È‰È·ÙÚÈ΋ 2008;71:55-61

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·58

58

ª. ∆ÛÔÏÈ¿ Î·È Û˘Ó.

¶›Ó·Î·˜ 2. ¶·Ú·ÎÔÏÔ‡ıËÛË ·ÛıÂÓÒÓ Ì ÁÚ›Ë

80

÷ڷÎÙËÚÈÛÙÈο

60 40

13-<14

12-<13

11-<12

9-<10

10-<11

8-<9

7-<8

6-<7

5-<6

4-<5

3-<4

2-<3

0

1-<2

20 0,5-<1

∞ÚÈıÌfi˜ ·ÛıÂÓÒÓ

100

∏ÏÈΛ· (¤ÙË) ∂ÈÎfiÓ· 2. ∏ÏÈÎȷ΋ ηٷÓÔÌ‹ ÙˆÓ ıÂÙÈÎÒÓ ÁÈ· ÁÚ›Ë ·ÛıÂÓÒÓ.

<14 ÂÙÒÓ (p=0,001) (¶›Ó·Î·˜ 3). §·Ú˘ÁÁ›Ùȉ· (croup) ÛÙȘ ·Ú·¿Óˆ ÔÌ¿‰Â˜ ÂΉËÏÒıËÎÂ Û˘¯ÓfiÙÂÚ· ÛÙ· ÌÈÎÚfiÙÂÚ· ·È‰È¿ (p=0,002) (¶›Ó·Î·˜ 3). ∞Ó¿Ï˘ÛË ÙˆÓ ·ÔÙÂÏÂÛÌ¿ÙˆÓ Ì ‚¿ÛË ÙÔÓ ÙfiÔ ÂͤٷÛ˘ ÙˆÓ ·ÛıÂÓÒÓ ¤‰ÂÈÍ fiÙÈ ÙÔ ‚ÚÔÁ¯ÈÎfi ¿ÛıÌ· ‹Ù·Ó Û˘¯ÓfiÙÂÚÔ ÛÙÔ˘˜ ıÂÙÈÎÔ‡˜ ·ÛıÂÓ›˜ Ô˘ ÂÍÂÙ¿ÛÙËÎ·Ó ÛÙ· ȉȈÙÈο ·È‰È·ÙÚÈο È·ÙÚ›· (14/90, 15,5%), Û ۇÁÎÚÈÛË Ì ٷ ∆∂¶ ÙÔ˘ ÓÔÛÔÎÔÌ›Ԣ (32/483, 6,6%) (p=0,004). ¢ÂÓ ˘‹ÚÍ·Ó ¿ÏϘ ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈΤ˜ ‰È·ÊÔÚ¤˜ ÛÙËÓ ·Ó¿Ï˘ÛË ÙˆÓ ·ÔÙÂÏÂÛÌ¿ÙˆÓ Î·Ù¿ ËÏÈΛ·, ¤ÙÔ˜ Î·È ÙfiÔ ÂͤٷÛ˘ ÙÔ˘ ·ÛıÂÓÔ‡˜. ∏ ̤ÛË ‰È¿ÚÎÂÈ· ÙˆÓ Û˘ÌÙˆÌ¿ÙˆÓ ÙˆÓ ·ÛıÂÓÒÓ Ì ÁÚ›Ë ‹Ù·Ó 8,4 Ë̤Ú˜ Î·È ‹Ù·Ó ÛËÌ·ÓÙÈο ÌÂÁ·Ï‡ÙÂÚË Ù˘ ·ÓÙ›ÛÙÔȯ˘ ÙˆÓ ·ÚÓËÙÈÎÒÓ ÁÈ· ÁÚ›Ë ·ÛıÂÓÒÓ. ¢ÂÓ ˘‹ÚÍ ÛËÌ·ÓÙÈ΋ ‰È·ÊÔÚ¿ ÛÙË Ì¤ÛË ‰È¿ÚÎÂÈ· ·Ô˘Û›·˜ ·fi ÙÔ Û¯ÔÏÂ›Ô Î·È ÙÔÓ ·È‰ÈÎfi ÛÙ·ıÌfi ÛÙȘ ‰‡Ô ÔÌ¿‰Â˜ ÙˆÓ ·ÛıÂÓÒÓ. √È ıÂÙÈÎÔ› ÁÈ· ÁÚ›Ë ·ÛıÂÓ›˜ ÂÈÛΤÊÙËÎ·Ó ÙÔÓ È·ÙÚfi 1,36 ÊÔÚ¤˜ ηٿ ÙË ‰È¿ÚÎÂÈ· Ù˘ ·Ûı¤ÓÂÈ¿˜ ÙÔ˘˜. ∂ÈÛ·ÁˆÁ‹ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô ‹Ù·Ó ··Ú·›ÙËÙË ÁÈ· ÙÔ 5,4% ÙˆÓ ·ÛıÂÓÒÓ Ì ÁÚ›Ë Î·È ÁÈ· ÙÔ 7,7% ÙˆÓ ·ÛıÂÓÒÓ Ì ¿ÏϘ ÏÔÈÌÒÍÂȘ (p=0,165) (¶›Ó·Î·˜ 2). ∫·Ù¿ ÙËÓ ·Ú¯È΋ ÂͤٷÛË ÙˆÓ ·ÛıÂÓÒÓ, ·ÓÙÈ‚ÈÔÙÈο ¯ÔÚËÁ‹-

µÚÔÁ¯ÔÏ›Ùȉ·

(P=0,005)

∞Ì˘Á‰·Ï›Ùȉ·

(P=0,002)

ª˘ÔÛ›Ùȉ·

∞ÚÓËÙÈÎÔ› £ÂÙÈÎÔ›

(P=0,13)

¶·Ú·ÚÚÈÓÔÎÔÏ›Ùȉ·

(P=0,579)

Croup

(P=0,203)

¶Ó¢ÌÔÓ›·

(P=0,002) (P=0,001)

µÚÔÁ¯ÈÎfi ¿ÛıÌ·

(P=0,005)

√ªø 0

5

10

15

20

25

30

∂ÈÎfiÓ· 3. ∂ÈÏÔΤ˜ Û ıÂÙÈÎÔ‡˜ Î·È ·ÚÓËÙÈÎÔ‡˜ ÁÈ· ÁÚ›Ë ·ÛıÂÓ›˜.

Paediatriki 2008;71:55-61

¢È¿ÚÎÂÈ· Û˘Ìو̿وÓ, ̤ÛË ± ™∞, Ë̤Ú˜ ∞Ô˘Û›· ·fi Û¯ÔÏ›Ô, ̤ÛË ± ™∞, Ë̤Ú˜ ∞Ô˘Û›· ·fi ·È‰ÈÎfi ÛÙ·ıÌfi, ̤ÛË ± ™∞, Ë̤Ú˜ ¡Ô È·ÙÚÈÎÒÓ ÂÈÛΤ„ÂˆÓ ∂ÈÛ·ÁˆÁ‹ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô ∞ÓÙÈ‚ÈÔÙÈο µÚÔÁ¯Ô‰È·ÛÙ·ÏÙÈο ∂ÈÛÓÂfiÌÂÓ· ÎÔÚÙÈÎÔÛÙÂÚÈÓÔÂȉ‹ ™˘ÛÙËÌ·ÙÈο ÎÔÚÙÈÎÔÛÙÂÚÈÓÔÂȉ‹ ∞ÓÙȂ˯Èο

°Ú›Ë (+) °Ú›Ë (-) N=392 N=452

P

8,4±5,7

7,3±4,4

0,002

5,2±5,5

5,9±5,1

0,302

9,2±8,19 1,4±0,96 21 (5,4)· 153 (39,5) 52 (13,3)

7,6±6,2 1,3±0,52 35 (7,7) 260 (57,6) 120 (26,5)

0,069 0,078 0,165 <0,0001 <0,0001

21 (5,4)

68 (15)

<0,0001

8 (2) 8 (1,8) 0,772 216 (55,4) 295 (65,3) 0,003

·

√È ·ÚÈıÌÔ› ÛÙËÓ ·Ú¤ÓıÂÛË ·ÓÙÈÛÙÔÈ¯Ô‡Ó Û ÔÛÔÛÙ¿ % ™∞ ÛÙ·ıÂÚ‹ ·fiÎÏÈÛË

ıËÎ·Ó ÛÙÔ 18,5% ÙˆÓ ıÂÙÈÎÒÓ ÁÈ· ÁÚ›Ë ·ÛıÂÓÒÓ, ΢ڛˆ˜ ÏfiÁˆ ÔÍ›·˜ ̤Û˘ ˆÙ›Ùȉ·˜. ∫·Ù¿ ÙËÓ ·Ú·ÎÔÏÔ‡ıËÛË ‰È·ÈÛÙÒıËΠfiÙÈ ·ÓÙÈ‚ÈÔÙÈο ¤Ï·‚ ÙÂÏÈο ÂÚ›Ô˘ ÙÔ 40% ÙˆÓ ·ÛıÂÓÒÓ. ∞ÓÙÈ‚ÈÔÙÈο, ‚ÚÔÁ¯Ô‰È·ÛÙ·ÏÙÈο Î·È ÂÈÛÓÂfiÌÂÓ· ÎÔÚÙÈÎÔÛÙÂÚÈÓÔÂȉ‹ ¤Ï·‚·Ó Û˘¯ÓfiÙÂÚ· ÔÈ ·ÚÓËÙÈÎÔ› ÁÈ· ÁÚ›Ë ·ÛıÂÓ›˜ (¶›Ó·Î·˜ 2). ∞Ó¿Ï˘ÛË ÙˆÓ ·ÔÙÂÏÂÛÌ¿ÙˆÓ Ì ‚¿ÛË ÙËÓ ËÏÈΛ· ÙˆÓ ·ÛıÂÓÒÓ ¤‰ÂÈÍ fiÙÈ ·ÓÙÈ‚ÈÔÙÈο Û˘ÓÙ·ÁÔÁÚ·Ê‹ıËÎ·Ó Û˘¯ÓfiÙÂÚ· ÛÙ· ·È‰È¿ οو ÙˆÓ 2 ÂÙÒÓ Ì ÁÚ›Ë, Û ۇÁÎÚÈÛË Ì ٷ ÌÂÁ·Ï‡ÙÂÚ· ·È‰È¿ (p=0,027) (¶›Ó·Î·˜ 3). ∞ÓÙȂ˯Èο ÛÈÚfiÈ· ‰fiıËÎ·Ó ÏÈÁfiÙÂÚÔ Û˘¯Ó¿ ÛÙ· ÌÈÎÚfiÙÂÚ· ·È‰È¿ Û ۇÁÎÚÈÛË Ì ÂΛӷ ËÏÈΛ·˜ ≥2 ¤ˆ˜ <5 ÂÙÒÓ Î·È Ù· ÌÂÁ·Ï‡ÙÂÚ· (p=0,017) (¶›Ó·Î·˜ 3). µÚÔÁ¯Ô‰È·ÛÙ·ÏÙÈο, ÂÈÛÓÂfiÌÂÓ· ÎÔÚÙÈÎÔÛÙÂÚÈÓÔÂȉ‹ Î·È ·ÓÙȂ˯Èο Ê¿Ú̷η Û˘ÓÙ·ÁÔÁÚ·Ê‹ıËÎ·Ó ÂÚÈÛÛfiÙÂÚÔ ·fi ÙÔ˘˜ ȉÈÒÙ˜ ·È‰È¿ÙÚÔ˘˜. ∫·Ó¤Ó·˜ ·fi ÙÔ˘˜ 90 ıÂÙÈÎÔ‡˜ ÁÈ· ÁÚ›Ë ·ÛıÂÓ›˜ Ô˘ ÂÍÂÙ¿ÛÙËÎ·Ó ÛÙ· ȉȈÙÈο ·È‰È·ÙÚÈο È·ÙÚ›· ‰ÂÓ ÂÈÛ‹¯ıË ÛÙÔ ÓÔÛÔÎÔÌ›Ô, ÂÓÒ 21/302 (6,8%) Ô˘ ÂÍÂÙ¿ÛÙËÎ·Ó ÛÙ· Â›ÁÔÓÙ· Â͈ÙÂÚÈο È·ÙÚ›· ÂÈÛ‹¯ıËÛ·Ó ÛÙÔ ÓÔÛÔÎÔÌ›Ô. √È ÁÔÓ›˜ ¤¯·Û·Ó ηٿ ̤ÛÔ fiÚÔ 1,34 ÂÚÁ¿ÛÈ̘ Ë̤Ú˜ ÁÈ· ÙË ÊÚÔÓÙ›‰· ÙÔ˘ οı ¿ÚÚˆÛÙÔ˘ ·È‰ÈÔ‡. ∏ ‰È¿ÚÎÂÈ· ·Ô˘Û›·˜ ·fi ÙËÓ ÂÚÁ·Û›· ‹Ù·Ó ›‰È· ÁÈ· ÙÔ˘˜ ÁÔÓ›˜ ÙˆÓ ıÂÙÈÎÒÓ Î·È ÙˆÓ ·ÚÓËÙÈÎÒÓ ÁÈ· ÁÚ›Ë ·ÛıÂÓÒÓ. ¢Â˘ÙÂÚÔÁÂÓ‹˜ Ïԛ̈ÍË ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ ‹Ù·Ó Û˘¯ÓfiÙÂÚË ÛÙ· ̤ÏË ÙˆÓ ÔÈÎÔÁÂÓÂÈÒÓ ÙˆÓ ıÂÙÈÎÒÓ ÁÈ· ÁÚ›Ë ·ÛıÂÓÒÓ (58,2% ¤Ó·ÓÙÈ 40%, p<0,001). √È ‰È·ÊÔÚ¤˜ ‹Ù·Ó ÛËÌ·ÓÙÈΤ˜ ÁÈ· ÙÔ˘˜ ÁÔÓ›˜ (·Ù¤Ú·˜ 21,9% ¤Ó·ÓÙÈ 11,8%, p<0,001, ÌËÙ¤Ú· 27,2% ¤Ó·ÓÙÈ 14,4, p<0,001) ¿ÏÏ· fi¯È ÁÈ· Ù·

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·59

59

√È Û˘Ó¤ÂȘ Ù˘ ÁÚ›˘

¶›Ó·Î·˜ 3. ™˘ÁÎÚÈÙÈο ·ÔÙÂϤÛÌ·Ù· ÌÂٷ͇ ËÏÈÎÈ·ÎÒÓ ÔÌ¿‰ˆÓ ÙˆÓ ıÂÙÈÎÒÓ ÁÈ· ÁÚ›Ë ·È‰ÈÒÓ

>6-23 ÌËÓÒÓ 24-59 ÌËÓÒÓ >59 ÌËÓÒÓ P

√Í›· ̤ÛË ˆÙ›Ùȉ·

§·Ú˘ÁÁ›Ùȉ·

∞ÓÙÈ‚ÈÔÙÈο

∞ÓÙȂ˯Èο

20 (27,8%) 35 (22,6%) 3. 17 (10,5%) 0,001

6 (8,3%) 3 (1,9%) 1 (0,6%) 0,002

35 (48,6%) 66 (42,9%) 52 (32,5%) 0,027

22 (30,6%) 69 (44,5%) 83 (51,2%) 0,017

·‰¤ÏÊÈ· (35,3% ¤Ó·ÓÙÈ 34%, p=0,734). ™ÙȘ ÔÈÎÔÁ¤ÓÂȘ ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ‹Ù·Ó ıÂÙÈÎÔ› ÁÈ· ÁÚ›Ë, Ë ·Ó¿ÁÎË È·ÙÚÈ΋˜ Â›Û΄˘ Î·È ¯ÔÚ‹ÁËÛ˘ ·ÓÙÈ‚ÈÔÙÈÎÒÓ ‹Ù·Ó Û˘¯ÓfiÙÂÚË. ∂›Û˘, Ïԛ̈ÍË ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ ÂÌÊ¿ÓÈÛ·Ó Û˘¯ÓfiÙÂÚ· Ù· ·‰¤ÏÊÈ· ÙˆÓ ıÂÙÈÎÒÓ ·ÛıÂÓÒÓ Ô˘ ‹Ù·Ó ÌÈÎÚfiÙÂÚ· ·fi 5 ÂÙÒÓ (44/141 ·‰¤ÏÊÈ·, 31,2%) Û ۇÁÎÚÈÛË Ì ٷ ÌÂÁ·Ï‡ÙÂÚ· (24/128, 18,8%) (p=0,003).

™˘˙‹ÙËÛË ™ÙËÓ ÚÔÔÙÈ΋ ·˘Ù‹ ÌÂϤÙË, Ô˘ ‚·Û›ÛÙËΠÛÙËÓ ÂÚÁ·ÛÙËÚȷ΋ ÂȂ‚·›ˆÛË Ù˘ ÁÚ›˘, ·ÂÈÎÔÓ›˙ÂÙ·È Ë Â›‰Ú·ÛË Ù˘ Ïԛ̈͢ ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ ÛÙ· ·È‰È¿ Î·È ÙȘ ÔÈÎÔÁ¤ÓÂȤ˜ ÙÔ˘˜ ÛÙËÓ ÎÔÈÓfiÙËÙ·, ηıÒ˜ Î·È Ë ÂÈ‚¿Ú˘ÓÛË ÙÔ˘ Û˘ÛÙ‹Ì·ÙÔ˜ ˘Á›·˜ ·fi ·˘Ù‹. ™ÙËÓ ¤Ú¢ӷ ·˘Ù‹ ¤Ï·‚ ̤ÚÔ˜ ¤Ó·˜ ÌÂÁ¿ÏÔ˜ ·ÚÈıÌfi˜ ·ÛıÂÓÒÓ, ÔÈ ÔÔ›ÔÈ ÂÍÂÙ¿ÛÙËÎ·Ó ÛÙ· Â›ÁÔÓÙ· Â͈ÙÂÚÈο È·ÙÚ›· ÙÔ˘ ÓÔÛÔÎÔÌ›Ԣ ‹ Û ȉȈÙÈο ·È‰È·ÙÚÈο È·ÙÚ›·, Î·È Ë ÌÂϤÙË Û˘Ó¯›ÛÙËΠÁÈ· ‰‡Ô ‰È·‰Ô¯Èο ¤ÙË. ¢È·ÈÛÙÒıËΠfiÙÈ Ë ÁÚ›Ë ÚÔηÏ› ÛËÌ·ÓÙÈ΋ ÓÔÛËÚfiÙËÙ· ÛÙ· ·È‰È¿ Î·È ÙȘ ÔÈÎÔÁ¤ÓÂȤ˜ ÙÔ˘˜ ÛÙËÓ ÎÔÈÓfiÙËÙ· οı ¯ÚfiÓÔ. ∏ ‰È¿ÚÎÂÈ· Ù˘ ÂȉËÌÈ΋˜ ¤Í·ÚÛ˘ Ù˘ ÁÚ›˘ ‹Ù·Ó 13-14 ‚‰ÔÌ¿‰Â˜ Î·È fi¯È 4-6 ‚‰ÔÌ¿‰Â˜, fiˆ˜ ‹Ù·Ó ÁÓˆÛÙfi ̤¯ÚÈ ÚfiÛÊ·Ù·. ∫·Ù¿ ÙÔ ‰È¿ÛÙËÌ· ·˘Ùfi, Ë ÓfiÛÔ˜ ÚÔοÏÂÛ ÙÔ 40% ÙˆÓ ÂÈÛΤ„ÂˆÓ ÁÈ· Ïԛ̈ÍË ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ Ì ˘ÚÂÙfi Î·È ÙÔ 13,5% ÙÔ˘ Û˘ÓfiÏÔ˘ ÙˆÓ ÂÈÛΤ„ÂˆÓ ÛÙ· Â›ÁÔÓÙ· ·È‰È·ÙÚÈο È·ÙÚ›· ÙÔ˘ ÓÔÛÔÎÔÌ›Ԣ ÙˆÓ ·È‰ÈÒÓ ËÏÈΛ·˜ 6 ÌËÓÒÓ ¤ˆ˜ 14 ÂÙÒÓ. ∆Ô Ì‹Ó· ̤ÁÈÛÙ˘ ‰Ú·ÛÙËÚÈfiÙËÙ·˜ Ù˘ ÓfiÛÔ˘, Ô Èfi˜ Ù˘ ÁÚ›˘ ¢ı˘ÓfiÙ·Ó ÁÈ· ÔÛÔÛÙfi >50% fiÏˆÓ ÙˆÓ ·Ó·Ó¢ÛÙÈÎÒÓ ÏÔÈÌÒÍÂˆÓ Ô˘ Û˘Óԉ‡ÔÓÙ·È ·fi ˘ÚÂÙfi, ηıÒ˜ Î·È ÁÈ· ÙÔ 25% ÙÔ˘ Û˘ÓfiÏÔ˘ ÙˆÓ ÂÈÛΤ„ÂˆÓ ÛÙ· ·È‰È·ÙÚÈο È·ÙÚ›· ÙÔ˘ ∆∂¶. ™Â ÚÔËÁÔ‡ÌÂÓË ÌÂϤÙË ‚·ÛÈṲ̂ÓË Û ÂȉËÌÈÔÏÔÁÈο ‰Â‰Ô̤ӷ, ÙÔ ÔÛÔÛÙfi ÁÚ›˘ Û ·È‰È¿ οو ÙˆÓ 3 ÂÙÒÓ ‹Ù·Ó Ù˘ ٿ͈˜ ÙÔ˘ 24% ¤ˆ˜ 35% ηٿ ÙË ‰È¿ÚÎÂÈ· ÙÔ˘ ¯ÂÈÌÒÓ· (3). ∞ÎfiÌË Î·È ·Ó ¿ÏÏÔÈ ÈÔ› ΢ÎÏÔÊÔÚÔ‡Ó Ù·˘Ùfi¯ÚÔÓ· ηٿ ÙÔ˘˜ ¯ÂÈÌÂÚÈÓÔ‡˜ Ì‹Ó˜, Ê·›ÓÂÙ·È fiÙÈ Ë ÁÚ›Ë ˘ÂÚ¤¯ÂÈ Î·È Â›Ó·È Ë Î‡ÚÈ· ·ÈÙ›· Ïԛ̈͢ ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜, ÙÔ˘Ï¿¯ÈÛÙÔÓ Î·Ù¿ ÙȘ Ù¤ÛÛÂÚȘ ‚‰ÔÌ¿‰Â˜ Ù˘ ·È¯Ì‹˜ Ù˘ ÓfiÛÔ˘. ªfiÓÔ ¤Ó· ÌÈÎÚfi ÔÛÔÛÙfi (5%) ÙˆÓ ·ÛıÂÓÒÓ Ì ÁÚ›Ë Ô˘ ÂÍÂÙ¿ÛÙËÎ·Ó ÙÂÏÈ-

ο ÓÔÛËχÙËÎ·Ó Î·È ·˘Ùfi ˘ÔÁÚ·ÌÌ›˙ÂÈ ÙÔ ÁÂÁÔÓfi˜ fiÙÈ ÙÔ ÌÂÁ·Ï‡ÙÂÚÔ Ì¤ÚÔ˜ Ù˘ ÓÔÛËÚfiÙËÙ·˜ Ô˘ ÚÔηÏÂ›Ù·È ·fi ÙË ÓfiÛÔ ·ÊÔÚ¿ ÙÔ˘˜ Â͈ÙÂÚÈÎÔ‡˜ ·ÛıÂÓ›˜. ∏ Ú·ÁÌ·ÙÈ΋ Â›‰Ú·ÛË Ù˘ ÁÚ›˘ ÛÙËÓ ÎÔÈÓfiÙËÙ· Èı·ÓÒ˜ Ó· ¤¯ÂÈ ˘ÔÂÎÙÈÌËı› Û ·˘Ù‹ ÙË ÌÂϤÙË. ™ÙË ÌÂϤÙË, Û˘ÌÂÚÈÏ‹ÊıËÎ·Ó ÌfiÓÔ ·ÛıÂÓ›˜ Ì Ïԛ̈ÍË ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Î·È ˘ÚÂÙfi (14). ∏ ·Ó›¯Ó¢ÛË ÙÔ˘ ·ÓÙÈÁfiÓÔ˘ ÂÍ·ÚÙ¿Ù·È ·fi ÙËÓ Â˘·ÈÛıËÛ›· Ù˘ ¯ÚËÛÈÌÔÔÈÔ‡ÌÂÓ˘ ÌÂıfi‰Ô˘ (15,16). ∞ÎfiÌË, Ô Èfi˜ ÙË ÁÚ›˘ ÌÔÚ› Ó· ÌËÓ Â›Ó·È ·ÓȯÓ‡ÛÈÌÔ˜ ÛÙÔÓ ÚÈÓÔÊ¿Ú˘ÁÁ·, Â¿Ó ¤¯Ô˘Ó ÂÚ¿ÛÂÈ ·ÚÎÂÙ¤˜ Ë̤Ú˜ ·fi ÙËÓ ¤Ó·ÚÍË ÙˆÓ Û˘ÌÙˆÌ¿ÙˆÓ Î·È Ô ·ÛıÂÓ‹˜ ÚÔÛ¤Ú¯ÂÙ·È Ì ÂÈÏÔΤ˜ Ù˘ ÓfiÛÔ˘ (17). ∆¤ÏÔ˜, Èı·Ófiٷٷ Ó· ›¯·Ì ¤Ó· ÌÂÁ·Ï‡ÙÂÚÔ ÔÛÔÛÙfi ıÂÙÈÎÒÓ ÁÈ· ÁÚ›Ë ‰ÂÈÁÌ¿ÙˆÓ, Â¿Ó ·ÓÙ› ÁÈ· ÚÈÓÈÎfi Â›¯ÚÈÛÌ· ›¯Â ¯ÚËÛÈÌÔÔÈËı› ÚÈÓÔÊ·Ú˘ÁÁÈÎfi ¤ÎÏ˘Ì· Î·È ·Ó ›¯Â ÂÊ·ÚÌÔÛı› ̤ıÔ‰Ô˜ ·Ï˘ÛȉˆÙ‹˜ ·ÓÙ›‰Ú·Û˘ ÔÏ˘ÌÂÚ¿Û˘ (PCR). √È ·ÛıÂÓ›˜ Ô˘ ÂÌÊ¿ÓÈÛ·Ó ÁÚ›Ë ‹Ù·Ó ËÏÈÎȷο ÌÂÁ·Ï‡ÙÂÚÔÈ ·fi ·˘ÙÔ‡˜ Ô˘ ‹Ù·Ó ·ÚÓËÙÈÎÔ› Î·È ·Ú·ÎÔÏÔ˘ıÔ‡Û·Ó Û˘¯ÓfiÙÂÚ· ·È‰ÈÎfi ÛÙ·ıÌfi ‹ Û¯ÔÏ›Ô, ÏfiÁˆ Û˘Á¯ÚˆÙÈÛÌÔ‡. ¶ÔÛÔÛÙfi ÂÚ›Ô˘ 60% ÙˆÓ ·ÛıÂÓÒÓ Ì ÁÚ›Ë ‹Ù·Ó οو ÙˆÓ 5 ÂÙÒÓ. ∏ ÈÔ Û˘¯Ó‹ ÂÈÏÔ΋ Ù˘ ÁÚ›˘ ‹Ù·Ó Ë ÔÍ›· ̤ÛË ˆÙ›Ùȉ· Î·È ÙÔ ‚ÚÔÁ¯ÈÎfi ¿ÛıÌ·. ∆· ÛÙÔȯ›· ·˘Ù¿ Û˘ÌʈÓÔ‡Ó Ì ÂΛӷ ÚfiÛÊ·ÙˆÓ ÌÂÏÂÙÒÓ (13,14). ™ËÌÂÈÒÓÂÙ·È, Â›Û˘, fiÙÈ ÔÍ›· ̤ÛË ˆÙ›Ùȉ·, ‚ÚÔÁ¯ÈÔÏ›Ùȉ· Î·È Ó¢ÌÔÓ›· ‹Ù·Ó ÈÔ Û˘¯Ó¤˜ ÛÙÔ˘˜ ·ÚÓËÙÈÎÔ‡˜ ÁÈ· ÁÚ›Ë ·ÛıÂÓ›˜. ¶·ÚfiÏ· ·˘Ù¿, ‰È·ÈÛÙÒıËΠfiÙÈ Ë ÁÚ›Ë ÚÔηÏ› ÙÔ 33% ÙˆÓ ÂÚÈÙÒÛÂˆÓ ÔÍ›·˜ ̤Û˘ ˆÙ›Ùȉ·˜, ÙÔ 40% ÙˆÓ ÂÚÈÙÒÛÂˆÓ Ï·Ú˘ÁÁÔÙÚ·¯ÂÈÔ‚ÚÔÁ¯›Ùȉ·˜, ÙÔ 25% ÙˆÓ ÂÂÈÛÔ‰›ˆÓ ‚ÚÔÁ¯ÈÎÔ‡ ¿ÛıÌ·ÙÔ˜ Î·È ÙÔ 17% ÙˆÓ ÂÚÈÙÒÛÂˆÓ Ó¢ÌÔÓ›·˜ ÛÙÔ˘˜ Â͈ÙÂÚÈÎÔ‡˜ ·ÛıÂÓ›˜ ηٿ ÙË ‰È¿ÚÎÂÈ· ÙˆÓ 13-14 ‚‰ÔÌ¿‰ˆÓ ÂȉËÌÈ΋˜ ¤Í·ÚÛ˘ Ù˘ ÁÚ›˘ ÁÈ· ‰‡Ô Û˘Ó¯fiÌÂÓ· ¤ÙË. ™Â Û˘Ìʈӛ· Ì ٷ ˆ˜ ¿Óˆ Â˘Ú‹Ì·Ù· Â›Ó·È Î·È ·˘Ù¿ ÚÔËÁÔ‡ÌÂÓˆÓ ÌÂÏÂÙÒÓ, ÛÙȘ Ôԛ˜ ‰È·ÈÛÙÒıËΠfiÙÈ Ì ÙÔÓ ÂÌ‚ÔÏÈ·ÛÌfi ηٿ Ù˘ ÁÚ›˘ Ë Û˘¯ÓfiÙËÙ· Ù˘ ÔÍ›·˜ ̤Û˘ ˆÙ›Ùȉ·˜ ÌÂÈÒÓÂÙ·È Î·Ù¿ 30%-36% (18,19,20). ∆· ÂÚÈÛÛfiÙÂÚ· ÂÂÈÛfi‰È· ÔÍ›·˜ ̤Û˘ ˆÙ›Ùȉ·˜ (76%) Î·È 9/10 ÂÚÈÙÒÛÂȘ Ï·Ú˘ÁÁÔÙÚ·¯ÂÈÔ‚ÚÔÁ¯›Ùȉ·˜ ÂÌÊ·Ó›ÛÙËÎ·Ó Û ·È‰È¿ ËÏÈΛ·˜ οو ÙˆÓ 5 ÂÙÒÓ. ¶·È‰È·ÙÚÈ΋ 2008;71:55-61

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·60

60

ª. ∆ÛÔÏÈ¿ Î·È Û˘Ó.

∏ Ïԛ̈ÍË ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ Û˘Ó‰¤ÂÙ·È Ì ·ÏfiÁÈÛÙË ¯Ú‹ÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ. ¢È·ÈÛÙÒıËΠfiÙÈ ÂÚ›Ô˘ 40% ÙˆÓ ·ÛıÂÓÒÓ ¤Ï·‚ ·ÓÙÈ‚ÈÔÙÈο ηٿ ÙË ‰È¿ÚÎÂÈ· Ù˘ ÓfiÛÔ˘ ÌÂ Û˘¯ÓfiÙÂÚÔ ·›ÙÈÔ ÙËÓ ÔÍ›· ̤ÛË ˆÙ›Ùȉ·. ∞˘Ù¿ Ù· ÛÙÔȯ›· Û˘ÌʈÓÔ‡Ó Ì ÛÙÔȯ›· ·fi ÚÔËÁÔ‡ÌÂÓ˜ ÌÂϤÙ˜ (3,13,14). ¶Èı·Ófiٷٷ, Ë ¯Ú‹ÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ Ó· ‹Ù·Ó ·ÎfiÌË ÌÂÁ·Ï‡ÙÂÚË, Â¿Ó ÙÔ ·ÔÙ¤ÏÂÛÌ· Ù˘ ‰ÔÎÈÌ·Û›·˜ Ù·¯Â›·˜ ‰È¿ÁÓˆÛ˘ ‰ÂÓ ÁÈÓfiÙ·Ó ÁÓˆÛÙfi (21). ∏ Ïԛ̈ÍË ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ ¤¯ÂÈ ÛËÌ·ÓÙÈ΋ Â›ÙˆÛË Î·È ÛÙȘ ÔÈÎÔÁ¤ÓÂȘ ÙˆÓ ·ÛıÂÓÒÓ. ∆Ô ÔÛÔÛÙfi ‰Â‡ÙÂÚÔ˘ ÂÂÈÛÔ‰›Ô˘ ÛÙËÓ ÔÈÎÔÁ¤ÓÂÈ·, Ô˘ ÂÎÙÈÌ¿Ù·È Û 17%, Â›Ó·È Û‡ÌʈÓÔ Ì ÚÔËÁÔ‡ÌÂÓ˜ ÌÂϤÙ˜ (11,22,23) Î·È Â›Ó·È ÌÂÁ·Ï‡ÙÂÚÔ Û ۇÁÎÚÈÛË Ì ÙÔ˘˜ ·ÚÓËÙÈÎÔ‡˜ ÁÈ· ÁÚ›Ë ·ÛıÂÓ›˜. ∆· Â˘Ú‹Ì·Ù· ·˘Ù¿ ˘Ô‰ËÏÒÓÔ˘Ó ˘„ËÏfiÙÂÚÔ ÔÛÔÛÙfi ÂÓ‰ÔÔÈÎÔÁÂÓÂȷ΋˜ ÌÂÙ¿‰ÔÛ˘ Ù˘ ÁÚ›˘, Û ۇÁÎÚÈÛË Ì ¿ÏϘ ÏÔÈÌÒÍÂȘ ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡. °È· οı ·ÛıÂÓ‹ Ì ÁÚ›Ë, ¯¿ıËΠ·fi ÙÔ˘˜ ÁÔÓ›˜ ·ÚÎÂÙfi˜ ¯ÚfiÓÔ˜ ·fi ÙËÓ ÂÚÁ·Û›· ÙÔ˘˜ ÁÈ· ÙË ÊÚÔÓÙ›‰· ÙˆÓ ·È‰ÈÒÓ ·ÏÏ¿ Î·È ÏfiÁˆ ·Ûı¤ÓÂÈ·˜ ÙˆÓ ›‰ÈˆÓ. ™˘ÌÂÚ·ÛÌ·ÙÈο, Ë Ïԛ̈ÍË ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ Â›Ó·È Ë Î‡ÚÈ· ·ÈÙ›· ÂÌ‡ÚÂÙ˘ Ïԛ̈͢ ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ ÛÙ· ·È‰È¿ ÛÙËÓ ÎÔÈÓfiÙËÙ·, ÙÔ˘Ï¿¯ÈÛÙÔÓ Î·Ù¿ ÙË ‰È¿ÚÎÂÈ· ·È¯Ì‹˜ Ù˘ ÂÙ‹ÛÈ·˜ ÂȉËÌ›·˜ ÁÚ›˘ Î·È Â›Ó·È ¿ÌÂÛ· Û˘Ó‰Â‰Â̤ÓË Ì ÛËÌ·ÓÙÈ΋ ÓÔÛËÚfiÙËÙ· Î·È ˘ÂÚ‚ÔÏÈ΋, ÔÏϤ˜ ÊÔÚ¤˜ ·ÏfiÁÈÛÙË, ¯Ú‹ÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ. ªfiÓÔ ÌÈÎÚfi ÔÛÔÛÙfi ·È‰ÈÒÓ Ì ÁÚ›Ë ÓÔÛËχÂÙ·È ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô Î·È ·˘Ùfi Ô‰ËÁ› ÛÙÔ Û˘Ì¤Ú·ÛÌ· fiÙÈ ÙÔ ÌÂÁ·Ï‡ÙÂÚÔ ÊÔÚÙ›Ô Ù˘ ÓfiÛÔ˘ ·ÊÔÚ¿ ÙÔ˘˜ Â͈ÙÂÚÈÎÔ‡˜ ·ÛıÂÓ›˜. ∏ Ïԛ̈ÍË ·fi ÙË ÁÚ›Ë ¤¯ÂÈ ÛËÌ·ÓÙÈ΋ Â›‰Ú·ÛË Î·È ÛÙ· ¿ÏÏ· ̤ÏË ÙˆÓ ÔÈÎÔÁÂÓÂÈÒÓ ÙˆÓ ·È‰ÈÒÓ Ô˘ ÚÔÛ‚¿ÏÏÔÓÙ·È ÚÔηÏÒÓÙ·˜ ÓfiÛÔ, È·ÙÚÈΤ˜ ÂÈÛΤ„ÂȘ, ¯Ú‹ÛË ·ÓÙÈ‚ÈÔÙÈÎÒÓ Î·È ·ÒÏÂÈ· ˆÚÒÓ ÂÚÁ·Û›·˜. ∆Ô 50% ÙˆÓ ÂÚÈÙÒÛÂˆÓ ÁÚ›˘ Î·È ÙÔ ÌÂÁ·Ï‡ÙÂÚÔ ÔÛÔÛÙfi ÙˆÓ ÂÈÏÔÎÒÓ ·ÊÔÚ¿ ·È‰È¿ ËÏÈΛ·˜ οو ÙˆÓ 5 ÂÙÒÓ, ÂÔ̤ӈ˜, Ë ÂÊ·ÚÌÔÁ‹ ηıÔÏÈÎÔ‡ ÂÌ‚ÔÏÈ·ÛÌÔ‡ Ûã ·˘Ù‹Ó ÙËÓ ËÏÈÎȷ΋ ÔÌ¿‰· ı· ÌÔÚÔ‡Û ӷ ÌÂÈÒÛÂÈ ÙËÓ Â›ÙˆÛË Ù˘ ÁÚ›˘ ÛÙËÓ ÎÔÈÓfiÙËÙ· Î·È ÙȘ Û˘Ó¤ÂȤ˜ Ù˘ ÛÙÔ Û‡ÛÙËÌ· ˘Á›·˜.

∂˘¯·ÚÈÛٛ˜ £ÂṲ́˜ ¢¯·ÚÈÛٛ˜ ÛÙËÓ Î˘Ú›· ŒÏÂÓ· ∫ÚÈÙÛ¤ÏË ÁÈ· ÙË ‚Ô‹ıÂÈ¿ Ù˘ ÛÙË ÛÙ·ÙÈÛÙÈ΋ ÂÂÍÂÚÁ·Û›· ÙˆÓ ‰ÈÔÚıÒÛÂˆÓ ÙÔ˘ ÎÂÈ̤ÓÔ˘.

µÈ‚ÏÈÔÁÚ·Ê›· 1. Mullooly JP, Barker WH. Impact of type A influenza on children: a retrospective study. Am J Public Health 1982;72:1008-1016.

2. Glezen WP, Decker M, Joseph SW, Mercready RG Jr. Acute respiratory disease associated with influenza epiPaediatriki 2008;71:55-61

demics in Houston, 1981-1983. J Infect Dis 1987;155:11191126.

3. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin M. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225-231.

4. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-239.

5. Neuzil KM, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002;185:147-152.

6. Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA; Advisory Committee on Immunization Practices. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52(RR-8):1-34.

7. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr Infect Dis J 1997;16:1065-1068.

8. Hurwitz ES, Haber M, Chang A, Shope T, Teo ST, Giesick JS, et al. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis 2000;182:1218-1221.

9. Hurwitz ES, Haber M, Chang A, Shope T, Teo S, Ginsberg M, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000;284:1677-1682.

10. Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. Am J Epidemiol 1982;115:736-751.

11. Frank AL, Taber LH, Glezen WP, Geyer EA, McIlwain S, Paredes A. Influenza B virus infections in the community and the family. The epidemics of 1976-1977 and 1979-1980 in Houston, Texas. Am J Epidemiol 1983;118:313-325.

12. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001;344: 889-896.

13. Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, et al. Burden of influenza in children in the community. J Infect Dis 2004;190:1369-1373.

14. Principi N, Esposito S, Gasparini R, Marchisio P, Crovari P; Flu-Flu Study Group. Burden of influenza in healthy children and their households. Arch Dis Child 2004;89:1002-1007.

15. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003;22:164177.

16. Zambon M, Hays J, Webster A, Newman R, Keene O. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med 2001;161:2116-2122.

17. Neuzil KM, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002;185:147-152.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·61

61

√È Û˘Ó¤ÂȘ Ù˘ ÁÚ›˘

18. Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 1991;145: 445-448.

19. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30month-old children in day care. Arch Pediatr Adolesc Med 1995;149:1113-1117.

20. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

N Engl J Med 1998;338:1405-1412.

21. Noyola DE, Demmler GJ. Effect of rapid diagnosis on management of influenza A infections. Pediatr Infect Dis J 2000;19:303-307.

22. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989;321:1696-1702.

23. White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 1999;103:e73.

™ˆÛÙ¤˜ ··ÓÙ‹ÛÂȘ ÙÔ˘ Quiz ÁÈ· ÙÔ ¿ÚıÚÔ “ƒÂ˘Ì·ÙÈÎfi˜ ˘ÚÂÙfi˜: Â›Ó·È ·ÎfiÌ· ‰Ò!”

1. ∏ ˘„ËÏfiÙÂÚË Â›ÙˆÛË ÙÔ˘ ƒ¶ ·Ú·ÙËÚ›ٷÈ: ·. ™Ù· ·È‰È¿ ÚÈÓ ·fi ÙËÓ ÂÊ˂›· 2. √ ÂÈÔÏ·ÛÌfi˜ Ù˘ ƒ∫ Â›Ó·È ÌÂÁ·Ï‡ÙÂÚÔ˜: Á. ™ÙÔ˘˜ ÂÓ‹ÏÈΘ 3. ∏ ‰È¿ÚÎÂÈ· ıÂÚ·›·˜ Ù˘ ÛÙÚÂÙÔÎÔÎÎÈ΋˜ Ê·Ú˘ÁÁ›Ùȉ·˜ ›ӷÈ: ·. 10 Ë̤Ú˜ 4. ŒÊË‚Ô˜ 17 ÂÙÒÓ Ì ‹È· ·ÓÂ¿ÚÎÂÈ· ÌÈÙÚÔÂȉԇ˜, ÏfiÁˆ ÔͤԘ ƒ¶, ÂÊfiÛÔÓ ‰ÂÓ ·ÚÔ˘ÛÈ¿ÛÂÈ ¿ÏÏÔ ÂÂÈÛfi‰ÈÔ, ı· Ú¤ÂÈ Ó· ¿ÚÂÈ ÚfiÏË„Ë: Á. ø˜ ÙÔ 25Ô ¤ÙÔ˜ 5. ¶ÔÈÔ˜ ·fi ÙÔ˘˜ ·Ú·Î¿Ùˆ ¤¯ÂÈ ÙÂÎÌËÚȈ̤ÓÔ ƒ¶: Á. ∫·È ÔÈ ‰‡Ô 6. 10¯ÚÔÓÔ˜ Ì ˘ÚÂÙfi, ·ÚıÚ·ÏÁ›·, Û˘Ìو̷ÙÔÏÔÁ›· ηډȷ΋˜ ·ÓÂ¿ÚÎÂÈ·˜ Î·È Û˘ÛÙÔÏÈÎfi ʇÛËÌ· 3/6 ÛÙËÓ ÎÔÚ˘Ê‹ Ì Â¤ÎÙ·ÛË ÛÙË Ì·Û¯¿ÏË ¤¯ÂÈ ÙÂÎÌËÚȈ̤ӷ ƒ¶, ÂÊfiÛÔÓ Û˘Ó˘¿Ú¯ÂÈ: ‚. ™ÙÚÂÙÔÎÔÎÎÈ΋ Ê·Ú˘ÁÁ›Ùȉ· ÚÔ 2-3 ‚‰ÔÌ¿‰ˆÓ

¶·È‰È·ÙÚÈ΋ 2008;71:55-61

Pediatri Jan-Feb 08

15-02-08

62

11:00

™ÂÏ›‰·62

¶ƒ∞∫∆π∫√ £∂ª∞

PRACTICAL ISSUE

™˘ÁÎÔÙÈο ÂÂÈÛfi‰È· ÛÙËÓ ·È‰È΋ Î·È ÂÊË‚È΋ ËÏÈΛ·: ‰È¿ÁÓˆÛË - ·ÓÙÈÌÂÙÒÈÛË ∫·Ú‰ÈÔÏÔÁÈÎfi ∆Ì‹Ì· ¡ÔÛÔÎÔÌ›Ԣ ¶·›‰ˆÓ ∞ıËÓÒÓ “¶. & ∞. ∫˘ÚÈ·ÎÔ‡”

¢. π. °ÂˆÚÁ·ÎfiÔ˘ÏÔ˜

AÏÏËÏÔÁÚ·Ê›·: ¢ËÌ‹ÙÚÈÔ˜ π. °ÂˆÚÁ·ÎfiÔ˘ÏÔ˜ geodim4@hotmail.com ∫·Ú‰ÈÔÏÔÁÈÎfi ∆Ì‹Ì·, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ∞ıËÓÒÓ “¶. & ∞. ∫˘ÚÈ·ÎÔ‡” £Ë‚ÒÓ Î·È §Â‚·‰Â›·˜, ∆.∫. 115 27, ∞ı‹Ó·

ÙÂÚÔ ·›ÙÈÔ Û˘ÁÎÔÙÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ Â›Ó·È Ë Ó¢ÚÔηډÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹, Ë ÔÔ›· Â›Ó·È ÌÈ· ηÏÔ‹ı˘ ηٿÛÙ·ÛË, Ì Ôχ ηϋ ÚfiÁÓˆÛË ÛÙË ÌÂÁ¿ÏË ÏÂÈÔÓfiÙËÙ· ÙˆÓ ÂÚÈÙÒÛˆÓ. ∏ ‰È¿ÁÓˆÛ‹ Ù˘ ‚·Û›˙ÂÙ·È ÛÙÔ ÏÂÙÔÌÂÚ¤˜ ÔÈÎÔÁÂÓÂÈ·Îfi Î·È ·ÙÔÌÈÎfi ÈÛÙÔÚÈÎfi Î·È ÛÙËÓ ÚÔÛÂÎÙÈ΋ ÎÏÈÓÈ΋ ÂͤٷÛË. ∞fi ÙÔ ÈÛÙÔÚÈÎfi ·Ó·˙ËÙ¿Ù·È È‰È·›ÙÂÚ· Ë ‡·ÚÍË ÂÂÈÛÔ‰›Ô˘ ·ÈÊÓȉ›Ô˘ ı·Ó¿ÙÔ˘ ÛÂ Û˘ÁÁÂÓÈÎfi ¿ÙÔÌÔ Ó·ڋ˜ ËÏÈΛ·˜, Ë ·ÚÔ˘Û›· ÛÙÔÓ ·ÛıÂÓ‹ ÁÓˆÛÙ‹˜ ηډȷ΋˜ ÓfiÛÔ˘, ÂÓÒ ‰ÈÂÚ¢ÓÒÓÙ·È Î·È ÔÈ ·ÎÚȂ›˜ Û˘Óı‹Î˜ ÙÔ˘ ÂÂÈÛÔ‰›Ô˘ Î·È Ë Î·Ù¿ÛÙ·ÛË ÙÔ˘ ·ÛıÂÓÔ‡˜ ηٿ ÙË ‰È¿ÚÎÂÈ¿ ÙÔ˘ Î·È ·Ì¤Ûˆ˜ ÌÂÙ¿. ∏ ÎÏÈÓÈ΋ ÂͤٷÛË ÂÈÎÂÓÙÚÒÓÂÙ·È ÛÙÔ Î˘ÎÏÔÊÔÚÈÎfi Î·È ÛÙÔ Ó¢ÚÈÎfi Û‡ÛÙËÌ·, ·Ó·˙ËÙÒÓÙ·˜ ÛËÌ›· ηډȷ΋˜ ‹ Ó¢ÚÔÏÔÁÈ΋˜ ·ı‹Ûˆ˜. ∞fi ÙȘ ·Ú·ÎÏÈÓÈΤ˜ ÂÍÂÙ¿ÛÂȘ, ··Ú·›ÙËÙÔ ÎÚ›ÓÂÙ·È ÙÔ ∏∫°, ÂÓÒ ÔÈ ˘fiÏÔÈ˜ ·ÔÊ·Û›˙ÔÓÙ·È Ì ‚¿ÛË Ù· ÎÏÈÓÈο Â˘Ú‹Ì·Ù·. π‰È·›ÙÂÚË ÚÔÛÔ¯‹ ¯ÚÂÈ¿˙ÂÙ·È ÛÙËÓ ·Ó›¯Ó¢ÛË ÙˆÓ Û¿ÓÈˆÓ ÂÚÈÙÒÛÂˆÓ Î·Ú‰ÈÔÁÂÓÔ‡˜ Û˘ÁÎÔ‹˜ Î·È ÛÙË ‰È·ÊÔÚÈ΋ ‰È¿ÁÓˆÛË ·fi Ù· ÂÂÈÛfi‰È· Û·ÛÌÒÓ. ∏ ·ÓÙÈÌÂÙÒÈÛË Ù˘ Ó¢ÚÔηډÈÔÁÂÓÔ‡˜ Û˘ÁÎÔ‹˜ Á›ÓÂÙ·È Û˘Ó‹ıˆ˜ Ì ÂÊ·ÚÌÔÁ‹ ·ÏÒÓ Ì¤ÙÚˆÓ ÚfiÏ˄˘. ∫·ıÔÚÈÛÙÈÎfi˜ ·Ú¿ÁÔÓÙ·˜ Â›Ó·È Ô Î·ıËÛ˘¯·ÛÌfi˜ ÙÔ˘ ·ÛıÂÓÔ‡˜ Î·È Ë ÂÎ·›‰Â˘Û‹ ÙÔ˘ ÛÙËÓ ·Ó·ÁÓÒÚÈÛË Î·È ¤ÁηÈÚË ·ÓÙÈÌÂÙÒÈÛË ÙˆÓ ÂÂÈÛÔ‰›ˆÓ.

¶ÂÚ›ÏË„Ë: ∆· Û˘ÁÎÔÙÈο ÂÂÈÛfi‰È· Â›Ó·È Ôχ Û˘¯Ó¿ ηٿ ÙËÓ ·È‰È΋ Î·È ÂÊË‚È΋ ËÏÈΛ·. ∆Ô Û˘¯Ófi-

§¤ÍÂȘ ÎÏÂȉȿ: ™˘ÁÎÔ‹, ·ÒÏÂÈ· Ù˘ Û˘Ó›‰ËÛ˘, Ó¢ÚÔηډÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹.

Syncopal episodes in childhood and adolescence: diagnosis - management Cardiology Department, “P. & A. Kyriakou” Children’s Hospital, Athens, Greece Correspondence: Dimitrios π. Georgakopoulos geodim4@hotmail.com Cardiology Department, “P. & A. Kyriakou” Children’s Hospital Thivon & Levadias St., 115 27, Athens, Greece

D. π. Georgakopoulos Abstract: Syncopal episodes are very frequent during childhood and adolescence. The most frequent form is the common faint or neurocardiogenic syncope, which is a benign situation with excellent prognosis in the majority of cases. The diagnosis of neurocardiogenic syncope is based on the history and the physical examination. From the history, it is elicited, among other information, whether there has ever been a sudden death in a family member at a young age and whether the patient suffers from a known heart disease. An effort is made to elucidate the exact circumstances of the episode and the condition of the patient during and immediately after the syncope. Physical examination is concentrated on the circulatory and nervous systems, to detect possible signs of a cardiac or neurological disease. An ECG is considered necessary in all cases, with other laboratory examinations according to the clinical findings. Special care must be given to the detection of the rare but potentially dangerous episodes of cardiogenic syncope. The vast majority of patients are treated with simple measures aimed at avoidance of potential triggers. The patients must be reassured and taught how to recognize the premonitory signs and what to do to avoid evolution to full syncope.

Key words: Syncope, loss of consciousness, cardiogenic syncope.

∂ÈÛ·ÁˆÁ‹ ∆· Û˘ÁÎÔÙÈο ÂÂÈÛfi‰È· Â›Ó·È ÂÍ·ÈÚÂÙÈο Û˘¯Ó¿ ÛÙ· ·È‰È¿ Î·È ÙÔ˘˜ ÂÊ‹‚Ô˘˜. ø˜ Û˘ÁÎÔ‹ ÔÚ›˙ÂÙ·È Ë ·ÈÊÓ›‰È· Î·È ‚Ú·¯Â›·˜ ‰È¿ÚÎÂÈ·˜ ·ÒÏÂÈ· Ù˘ Û˘Ó›‰ËÛ˘ Î·È ÙÔ˘ Ì˘˚ÎÔ‡ ÙfiÓÔ˘ Ô˘ ÔÊ›ÏÂÙ·È Û ·ÓÂ·Ú΋ ·ÚÔ¯‹ ·›Ì·ÙÔ˜ ÛÙÔÓ ÂÁΤʷÏÔ, Ù˘ ÔÔ›·˜ Û˘Ó‹ıˆ˜ ÚÔËÁÔ‡ÓÙ·È Úfi‰ÚÔÌ· Û˘ÌÙÒÌ·Ù· Ôχ Û‡ÓÙÔÌ˘ ‰È¿ÚÎÂÈ·˜ Î·È Ù˘ ÔÔ›·˜ ¤ÂÙ·È ·˘ÙfiÌ·ÙË, Ù·¯Â›· Î·È Ï‹Ú˘ ·ÔηٿÛÙ·ÛË (1). ™ÙÔ ¿ÚıÚÔ Paediatriki 2008;71:62-67

·Ó·Ê¤ÚÂÙ·È Ë ÂȉËÌÈÔÏÔÁ›·, Ë ·ıÔÊ˘ÛÈÔÏÔÁ›·, Ë ÂÚÈÁÚ·Ê‹ ÙˆÓ ·ÈÙ›ˆÓ, Ë ‰È·ÁÓˆÛÙÈ΋ ÚÔÛ¤ÁÁÈÛË Î·È Ë ·ÓÙÈÌÂÙÒÈÛ‹ ÙÔ˘˜.

∂ȉËÌÈÔÏÔÁ›· ∆· Û˘ÁÎÔÙÈο ÂÂÈÛfi‰È· Â›Ó·È Û˘¯Ó¿ ÛÙËÓ ·È‰È΋ Î·È ÂÊË‚È΋ ËÏÈΛ·, Ì ÙËÓ Â›ÙˆÛ‹ ÙÔ˘˜ Ó· ·ÚÔ˘ÛÈ¿˙ÂÈ Ì›· ·È¯Ì‹ ÂÚ› ÙËÓ ËÏÈΛ· ÙˆÓ 15 ÂÙÒÓ Î·È Ó· Â›Ó·È ‰‡Ô ÊÔÚ¤˜ Û˘¯ÓfiÙÂÚË ÛÙ· ÎÔÚ›ÙÛÈ· Û ۯ¤ÛË Ì ٷ

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·63

63

™˘ÁÎÔÙÈο ÂÂÈÛfi‰È· ÛÙ· ·È‰È¿

¶›Ó·Î·˜ 1. ∞›ÙÈ· Û˘ÁÎÔÙÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ

¶›Ó·Î·˜ 2. ∞›ÙÈ· ηډÈÔÁÂÓÔ‡˜ Û˘ÁÎÔ‹˜

ñ ¡Â˘ÚÔηډÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹ ñ ∫·Ú‰ÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹ ñ ∫Ú¿ÙËÌ· ·Ó·ÓÔ‹˜ ñ æ˘¯ÔÁÂÓ‹˜ Û˘ÁÎÔ‹ ñ √ÚıÔÛÙ·ÙÈ΋ ˘fiÙ·ÛË ñ ™‡Ó‰ÚÔÌÔ ÔÚıÔÛÙ·ÙÈ΋˜ Ù·¯˘Î·Ú‰›·˜ ñ ∞ÓÙ·Ó·ÎÏ·ÛÙÈ΋ Û˘ÁÎÔ‹ (‚‹¯·˜, Ô‡ÚËÛË, ·Êfi‰Â˘ÛË) ñ ∞Ó·ÈÌ›· ñ §‹„Ë Ô˘ÛÈÒÓ

ñ ∆·¯˘·ÚÚ˘ı̛˜ ñ µÚ·‰˘·ÚÚ˘ı̛˜ ñ ™Ù¤ÓˆÛË ·ÔÚÙ‹˜ ñ ÀÂÚÙÚÔÊÈ΋ Ì˘ÔηډÈÔ¿ıÂÈ· ñ ∆ÂÙÚ·ÏÔÁ›· Fallot ñ ™Ù¤ÓˆÛË Ó¢ÌÔÓÈ΋˜ ñ ¶Ó¢ÌÔÓÈ΋ ˘¤ÚÙ·ÛË ñ ™ÙÂÊ·ÓÈ·›· ÓfiÛÔ˜ (Kawasaki, Û˘ÁÁÂÓ›˜ ·ÓˆÌ·Ï›Â˜ ·ÚÙËÚÈÒÓ) ñ ¢È·Ù·ÙÈ΋ Ì˘ÔηډÈÔ¿ıÂÈ· ñ ª˘Ôηډ›Ùȉ·

·ÁfiÚÈ·. ∏ Â›ÙˆÛ‹ Ù˘ ÛÙÔ ÁÂÓÈÎfi ·È‰È·ÙÚÈÎfi Î·È ÂÊË‚ÈÎfi ÏËı˘ÛÌfi ÂÎÙÈÌ¿Ù·È ÛÙÔ 0,05% ¤ˆ˜ 0,3% (2), ·Ó ÏËÊıÔ‡Ó ˘fi„Ë Ù· ÂÂÈÛfi‰È·, Ù· ÔÔ›· ηٷϋÁÔ˘Ó ÛÙ· Â͈ÙÂÚÈο È·ÙÚ›· ÙˆÓ ÓÔÛÔÎÔÌ›ˆÓ. ™ÙËÓ Ú·ÁÌ·ÙÈÎfiÙËÙ· fï˜, Ë Û˘¯ÓfiÙËÙ¿ ÙÔ˘˜ Â›Ó·È Ôχ ÌÂÁ·Ï‡ÙÂÚË ·Ó Û˘Ó˘ÔÏÔÁÈÛıÔ‡Ó Ù· ÂÂÈÛfi‰È· ÂΛӷ, Ù· ÔÔ›· ‰ÂÓ Êı¿ÓÔ˘Ó Ì¤¯ÚÈ ÙÔ˘ ÛËÌ›Ԣ Ó· ·Ó·˙ËÙ‹ÛÔ˘Ó È·ÙÚÈ΋ ‚Ô‹ıÂÈ·. Ÿˆ˜ Ê·›ÓÂÙ·È ·fi ÚfiÛÊ·Ù˜ ÌÂϤÙ˜ Û ÊÔÈÙËÙ¤˜ ËÏÈΛ·˜ 20 ÂÙÒÓ, ÙÔ 20% ÙˆÓ ·Ó‰ÚÒÓ Î·È ÙÔ 50% ÙˆÓ Á˘Ó·ÈÎÒÓ ·Ó·Ê¤ÚÔ˘Ó fiÙÈ ¤¯Ô˘Ó ÙËÓ ÂÌÂÈÚ›· ÂÓfi˜ ÙÔ˘Ï¿¯ÈÛÙÔÓ Û˘ÁÎÔÙÈÎÔ‡ ÂÂÈÛÔ‰›Ô˘ (3). ™˘ÁÎÚÈÙÈο, Ó· ÛËÌÂȈı› fiÙÈ Ë Â›ÙˆÛË ÙˆÓ ÂÂÈÛÔ‰›ˆÓ Û·ÛÌÒÓ Û ·ÚfiÌÔȘ ËÏÈ˘ Î˘Ì·›ÓÂÙ·È ÂÚ› ÙÔ 0,5% (4). ∞Ó Î·È Ù· Û˘ÁÎÔÙÈο ÂÂÈÛfi‰È· ÛÙËÓ ÏÂÈÔÓfiÙËÙ¿ ÙÔ˘˜ Â›Ó·È Î·ÏÔ‹ıË Î·È ·Î›Ó‰˘Ó·, ¯ÚÂÈ¿˙ÂÙ·È Ó· ‰Ôı› ȉȷ›ÙÂÚË ÚÔÛÔ¯‹, ÒÛÙ ӷ ÌËÓ ‰È·Ê‡ÁÔ˘Ó ÔÈ Û¿ÓȘ, ·ÏÏ¿ ‰˘ÓËÙÈο ÂÈΛӉ˘Ó˜, ÂÚÈÙÒÛÂȘ, Ô˘ ÔÊ›ÏÔÓÙ·È Û ηډȷο ·›ÙÈ·.

∞ÈÙÈÔÏÔÁ›· - ¶·ıÔÊ˘ÛÈÔÏÔÁ›· ∆· Û˘ÁÎÔÙÈο ÂÂÈÛfi‰È· ·ÔÙÂÏÔ‡Ó Ì¤ÚÔ˜ ÙˆÓ ÂÂÈÛÔ‰›ˆÓ ·ÒÏÂÈ·˜ Ù˘ Û˘Ó›‰ËÛ˘. TÔ Û˘¯ÓfiÙÂÚÔ ·›ÙÈÔ Û˘ÁÎÔ‹˜ ÛÙ· ·È‰È¿ Î·È ÙÔ˘˜ ÂÊ‹‚Ô˘˜, Î·È Ì¿ÏÈÛÙ· Ì ÌÂÁ¿ÏË ‰È·ÊÔÚ¿ ·fi Ù· ˘fiÏÔÈ·, Â›Ó·È Ë Ó¢ÚÔηډÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹ (¡∫™), ÁÓˆÛÙ‹ Î·È ˆ˜ ÎÔÈÓ‹ ÏÈÔı˘Ì›· (5). ÕÏÏ· ·›ÙÈ· Â›Ó·È Ë Î·Ú‰ÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹, ÙÔ ÎÚ¿ÙËÌ· Ù˘ ·Ó·ÓÔ‹˜, Ë „˘¯ÔÁÂÓ‹˜ Û˘ÁÎÔ‹, Ë ÔÚıÔÛÙ·ÙÈ΋ ˘fiÙ·ÛË Î·È ÙÔ Û‡Ó‰ÚÔÌÔ ÔÚıÔÛÙ·ÙÈ΋˜ Ù·¯˘Î·Ú‰›·˜ (¶›Ó·Î·˜ 1). ∆· ·›ÙÈ· Ù˘ ηډÈÔÁÂÓÔ‡˜ Û˘ÁÎÔ‹˜, Ù· ÔÔ›·, ·Ó Î·È Û¿ÓÈ· ÛÙ· ·È‰È¿, ÂÓ‰¤¯ÂÙ·È Ó· Â›Ó·È ÂÈΛӉ˘Ó·, Ê·›ÓÔÓÙ·È ÛÙÔÓ ¶›Ó·Î· 2. ∏ ·ıÔÊ˘ÛÈÔÏÔÁ›· Ù˘ ¡∫™ ‰ÂÓ ¤¯ÂÈ Ï‹Úˆ˜ ·ÔÛ·ÊËÓÈÛı›. °ÂÓÈο, Ê˘ÛÈÔÏÔÁÈÎfi Â›Â‰Ô Û˘Ó›‰ËÛ˘ ‰È·ÙËÚÂ›Ù·È fiÙ·Ó ÂÍ·ÛÊ·Ï›˙ÂÙ·È ¤Ó· ··Ú·›ÙËÙÔ Â›Â‰Ô Ì¤Û˘ ·ÚÙËÚȷ΋˜ ›ÂÛ˘, ‰Â‰Ô̤ÓÔ˘ fiÙÈ Ì¤Ûˆ ·˘Ù‹˜ ΢ڛˆ˜ ÂϤÁ¯ÂÙ·È Ë ÂÁÎÂÊ·ÏÈ΋ ÚÔ‹ ·›Ì·ÙÔ˜ (1). ∏ Ú‡ıÌÈÛË Ù˘ ·ÚÙËÚȷ΋˜ ›ÂÛ˘ Î·È Î·Ù¿ Û˘Ó¤ÂÈ· Î·È Ù˘ ÂÁÎÂÊ·ÏÈ΋˜ ·ÚÔ¯‹˜ ÂÈÙ˘Á¯¿ÓÂÙ·È ·fi ÙÔ ·˘ÙfiÓÔÌÔ Ó¢ÚÈÎfi Û‡ÛÙËÌ·, ̤ۈ ÂÓfi˜ ÔχÏÔÎÔ˘ Î·È ·ÔÙÂÏÂÛÌ·ÙÈÎÔ‡ ·ÓÙ·-

Ó·ÎÏ·ÛÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜. ∆Ô Û‡ÛÙËÌ· ·˘Ùfi ÂÚÈÏ·Ì‚¿ÓÂÈ ÙÔ˘˜ Ù·ÛÂÔ¸ԉԯ›˜ Ô˘ ‚Ú›ÛÎÔÓÙ·È ÛÙÔ ÙÔ›¯ˆÌ· ÌÂÁ¿ÏˆÓ ·ÁÁ›ˆÓ (Ó¢ÌÔÓÈ΋ ·ÚÙËÚ›·, ·ÓÈÔ‡Û· ·ÔÚÙ‹, ¤Ûˆ ηڈٛ‰Â˜) Î·È ÙÔ˘˜ Ì˯·ÓÔ¸ԉԯ›˜ Ô˘ ‚Ú›ÛÎÔÓÙ·È ÛÙÔ ÙÔ›¯ˆÌ· ÙˆÓ ÎÔÈÏÈÒÓ Ù˘ ηډȿ˜. ∏ ÈÔ ·Ô‰ÂÎÙ‹ ıˆڛ· Â›Ó·È fiÙÈ Ë ¡∫™ ¤¯ÂÈ ˆ˜ ·ÊÂÙËÚ›· ÙËÓ ÂÏ¿ÙÙˆÛË ÙÔ˘ fiÁÎÔ˘ ·›Ì·ÙÔ˜ Ô˘ ÂÈÛÙÚ¤ÊÂÈ ÛÙË ‰ÂÍÈ¿ Î·È ÙËÓ ·ÚÈÛÙÂÚ‹ ÎÔÈÏ›·. ∏ ÂÏ¿ÙÙˆÛË ·˘Ù‹ ÙÔ˘ fiÁÎÔ˘ ·›Ì·ÙÔ˜ ÌÔÚ› Ó· Â›Ó·È ·fiÙÔÎÔ˜ ·Ê˘‰¿ÙˆÛ˘ ‹ ÌÂÙ·‚ÔÏÒÓ Ù˘ ı¤Ûˆ˜ ÙÔ˘ ÛÒÌ·ÙÔ˜ (.¯. ·fi ηıÈÛÙ‹ Û fiÚıÈ· ı¤ÛË). ∏ ηډȿ ·ÓÙȉڿ ·˘Í¿ÓÔÓÙ·˜ ÙË Û˘ÛÙ·ÏÙÈÎfiÙËÙ¿ Ù˘ Î·È ·ÔÛÙ¤ÏÏÔÓÙ·˜ ̤ۈ ÙˆÓ Ì˯·ÓÔ¸Ô‰Ô¯¤ˆÓ Î·È ÙˆÓ ÚÔÛ·ÁˆÁÒÓ ÈÓÒÓ C ÌËӇ̷ٷ ÛÙÔÓ ÂÁΤʷÏÔ, Ô ÔÔ›Ô˜ ·ÓÙ·ÔÎÚ›ÓÂÙ·È Ì ÙË ÛÂÈÚ¿ ÙÔ˘ Î·È ÛÙ¤ÏÓÂÈ ··ÁˆÁ¿ ÂÚÂı›ÛÌ·Ù· ÛÙËÓ Î·Ú‰È¿ Î·È ÛÙ· ·ÁÁ›· ̤ۈ ÙÔ˘ ·˘ÙfiÓÔÌÔ˘ Ó¢ÚÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜. ∆· ÂÚÂı›ÛÌ·Ù· ·˘Ù¿ ÂÏ·ÙÙÒÓÔ˘Ó ÙÔÓ ÙfiÓÔ ÙÔ˘ Û˘Ì·ıËÙÈÎÔ‡ Î·È ·˘Í¿ÓÔ˘Ó ÙÔÓ ÙfiÓÔ ÙÔ˘ ·Ú·Û˘Ì·ıËÙÈÎÔ‡, Ì ·ÔÙ¤ÏÂÛÌ· ÙËÓ ˘fiÙ·ÛË Î·È ÙË ‚Ú·‰˘Î·Ú‰›·. ŸÙ·Ó Ë ·¿ÓÙËÛË ·˘ÙÔ‡ ÙÔ˘ Ù‡Ô˘ Â›Ó·È ˘¤ÚÌÂÙÚË Î·È ˘Âڂ› οÔÈÔ fiÚÈÔ, ÙfiÙ ÂΉËÏÒÓÂÙ·È Û˘ÁÎÔÙÈÎfi ÂÂÈÛfi‰ÈÔ. ™ÙË Û˘Ó¤¯ÂÈ·, ÌfiÏȘ Ô ·ÛıÂÓ‹˜ ¤ÛÂÈ ÛÙÔ ¤‰·ÊÔ˜, ·˘Í¿ÓÂÙ·È Ë ÊÏ‚È΋ ÂÈÛÙÚÔÊ‹ ÛÙËÓ Î·Ú‰È¿, Ô ·ÓÙ·Ó·ÎÏ·ÛÙÈÎfi˜ Ì˯·ÓÈÛÌfi˜ ‰È·ÎfiÙÂÙ·È Î·È ÙÔ Â›Â‰Ô Û˘Ó›‰ËÛ˘ ·Ôηı›ÛٷٷÈ.

∫ÏÈÓÈο ¯·Ú·ÎÙËÚÈÛÙÈο Ó¢ÚÔηډÈÔÁÂÓÔ‡˜ Û˘ÁÎÔ‹˜ ∏ Ó¢ÚÔηډÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹, fiˆ˜ ÚԷӷʤÚıËÎÂ, Â›Ó·È Û˘¯ÓfiÙÂÚË ÛÙÔ˘˜ ÂÊ‹‚Ô˘˜ Î·È ÂȉÈο ÛÙ· ÎÔÚ›ÙÛÈ·. ™˘Ó‹ıË ÂÚÂı›ÛÌ·Ù· Â›Ó·È Ë ·fiÙÔÌË ·ÏÏ·Á‹ ı¤Ûˆ˜ (·fi ηıÈÛÙ‹ ‹ Í·ψ̤ÓË Û fiÚıÈ·), Ë ·Ú·ÙÂٷ̤ÓË ÔÚıÔÛÙ·Û›· Î·È Î·Ù·ÛÙ¿ÛÂȘ Ô˘ ÚÔηÏÔ‡Ó ¤ÓÙÔÓÔ Êfi‚Ô ‹ fiÓÔ (.¯. ·ÈÌÔÏË„›·, ı¤· ·›Ì·ÙÔ˜). ™˘¯Ó¿, ÛÙÔ ›‰ÈÔ ¿ÙÔÌÔ, Ù· ÂÂÈÛfi‰È· ÚÔηÏÔ‡ÓÙ·È ¿ÏÏÔÙ Ì ÙÔ ¤Ó· Î·È ¿ÏÏÔÙ Ì ÙÔ ¿ÏÏÔ ÂÚ¤ıÈÛÌ·. ¶ÚԉȷıÂÛÈÎÔ› ·Ú¿ÁÔÓÙ˜ ÁÈ· ÙËÓ ÂΉ‹ÏˆÛË ÙˆÓ ÂÂÈÛÔ‰›ˆÓ Â›Ó·È Ë ·Ê˘‰¿ÙˆÛË, Ë ¶·È‰È·ÙÚÈ΋ 2008;71:62-67

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·64

64

¢. π. °ÂˆÚÁ·ÎfiÔ˘ÏÔ˜

˙¤ÛÙË, Ô Û˘ÓˆÛÙÈÛÌfi˜, ÙÔ ¿Á¯Ô˜, Ë ·‰È·ıÂÛ›· Î·È Ë ·Ó·ÈÌ›·. ∆· ÂÂÈÛfi‰È· Â›Ó·È ‰˘Ó·Ùfi Ó· Û˘Ì‚Ô‡Ó Î·È ¯ˆÚ›˜ Ó· ˘¿Ú¯ÂÈ ·ÓȯÓ‡ÛÈÌÔ˜ ÂÎÏ˘ÙÈÎfi˜ ·Ú¿ÁÔÓÙ·˜ ‹ Î·È Ì ÙÔÓ ·ÛıÂÓ‹ Û ηıÈÛÙ‹ ı¤ÛË. ∂ÂÈÛfi‰È· ·ÒÏÂÈ·˜ Ù˘ Û˘Ó›‰ËÛ˘ Ô˘ Â¤Ú¯ÔÓÙ·È Û ηٷÎÂÎÏÈÌ̤ÓË ı¤ÛË Î·È ¯ˆÚ›˜ Ó· ¤¯ÂÈ ÚÔËÁËı› οÔÈÔ Û˘Ó·ÈÛıËÌ·ÙÈÎfi ÂÚ¤ıÈÛÌ· Â›Ó·È ·›ı·ÓÔ Ó· ÔÊ›ÏÔÓÙ·È Û ¡∫™. ™˘Ó‹ıˆ˜ ‰È·ÎÚ›ÓÔÓÙ·È ÙÚ›· ÛÙ¿‰È·: ·) ¶ÚÔÛ˘ÁÎÔÙÈ΋ Ê¿ÛË. ∏ ¤Ó·ÚÍË Â›Ó·È ·fiÙÔÌË. √ ·ÛıÂÓ‹˜ ÂÓ‰¤¯ÂÙ·È Ó· ·ÈÛı·Óı› ·‰˘Ó·Ì›·, ˙¿ÏË, ‰È·Ù·Ú·¯¤˜ Ù˘ ÔÚ¿Ûˆ˜, ÎÂÊ·Ï·ÏÁ›·, ÛÈÂÏfiÚÚÔÈ· Î·È Ó·˘Ù›·, Ô˘ ÌÔÚ› Ó· ηٷϋÍÂÈ Î·È Û ÂÌÂÙfi. ∂›Û˘ ·Ú·ÙËÚÔ‡ÓÙ·È ˆ¯ÚfiÙËÙ·, ÂÊ›‰ÚˆÛË, ˘ÂÚ·ÂÚÈÛÌfi˜, ·Ó·ÛÙÂÓ·ÁÌÔ›, ¯·ÛÌÔ˘ÚËÙ¿, ‚Ú·‰˘Î·Ú‰›· Î·È ˘fiÙ·ÛË. ∏ ‰È¿ÚÎÂÈ· Ù˘ ÂÚÈfi‰Ô˘ ·˘Ù‹˜ Â›Ó·È Û‡ÓÙÔÌË, Û˘Ó‹ıˆ˜ ·fi 10 ̤¯ÚÈ 20 ‰Â˘ÙÂÚfiÏÂÙ·. ‚) ™˘ÁÎÔ‹. √ ·ÛıÂÓ‹˜ ÎÂ›Ù·È ·Ó·›ÛıËÙÔ˜, ¯·Ï·Úfi˜, ˆ¯Úfi˜, Ì ÙȘ ÎfiÚ˜ Û ‰È·ÛÙÔÏ‹. ∆Ô ‰¤ÚÌ· Â›Ó·È ÎÚ‡Ô Î·È Î¿ıȉÚÔ, ÂÓÒ Ô ÛÊ˘ÁÌfi˜ Â›Ó·È ‚Ú·‰‡˜ Î·È ·ÛıÂÓÈÎfi˜. ™¿ÓÈ· ÂÓ‰¤¯ÂÙ·È Ó· ·Ú·ÙËÚËıÔ‡Ó ·ÒÏÂÈ· Ô‡ÚˆÓ Î·È ÙÔÓÈΤ˜-ÎÏÔÓÈΤ˜ ÎÈÓ‹ÛÂȘ ÙˆÓ ¿ÎÚˆÓ. ¢È·ÚΛ ÙÔ Ôχ Ï›Á· ÏÂÙ¿. Á) ªÂÙ·Û˘ÁÎÔÙÈ΋ Ê¿ÛË. √ ·ÛıÂÓ‹˜ ÓÔÈÒıÂÈ ·‰‡Ó·ÌÔ˜, ˙·ÏÈṲ̂ÓÔ˜, Ì ٿÛË ÁÈ· ÂÌÂÙfi Î·È ÂÏ·ÊÚÈ¿ ÎÂÊ·Ï·ÏÁ›·. ∏ Ï‹Ú˘ Â·Ó·ÊÔÚ¿ Â›Ó·È ÁÚ‹ÁÔÚË, Û˘Ó‹ıˆ˜ ̤۷ Û ÌÈÛ‹ ÒÚ·.

¢È·ÊÔÚÈ΋ ‰È¿ÁÓˆÛË Û˘ÁÎÔÙÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ ∏ ‰È·ÊÔÚÈ΋ ‰È¿ÁÓˆÛË Ù˘ ¡∫™ Ú¤ÂÈ Ó· Á›ÓÂÙ·È ·fi Ù· ˘fiÏÔÈ· ·›ÙÈ· ÙˆÓ Û˘ÁÎÔÙÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ Î·È ÙˆÓ ÂÂÈÛÔ‰›ˆÓ ·ÒÏÂÈ·˜ Ù˘ Û˘Ó›‰ËÛ˘, Û˘¯ÓfiÙÂÚÔ ÙˆÓ ÔÔ›ˆÓ Â›Ó·È ÔÈ Û·ÛÌÔ›. π‰È·›ÙÂÚË ÚÔÛÔ¯‹ Ú¤ÂÈ Ó· ‰›‰ÂÙ·È ÛÙÔÓ ·ÔÎÏÂÈÛÌfi ·ıÔÏÔÁÈÎÒÓ Î·Ú‰ÈÔÏÔÁÈÎÒÓ Î·Ù·ÛÙ¿ÛˆÓ, (ηډÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹), ÔÈ Ôԛ˜ ÂÓ‰¤¯ÂÙ·È Ó· Â›Ó·È ·ÂÈÏËÙÈΤ˜ ·ÎfiÌ· Î·È ÁÈ· ÙË ˙ˆ‹ ÙÔ˘ ·ÛıÂÓÔ‡˜. ∫·Ú‰ÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹ ∏ ηډÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹ Â¤Ú¯ÂÙ·È fiÙ·Ó Ë Î·Ú‰È¿, ÁÈ· ÔÈΛÏÔ˘˜ ÏfiÁÔ˘˜, ·‰˘Ó·Ù› Ó· ηχ„ÂÈ ÙȘ ··ÈÙ‹ÛÂȘ ÙÔ˘ ÔÚÁ·ÓÈÛÌÔ‡ Û √2, ÂȉÈο ηٿ ÙË ÛˆÌ·ÙÈ΋ ¿ÛÎËÛË. ŸÏ˜ ÔÈ Î·Ú‰È·Î¤˜ ·ı‹ÛÂȘ Â›Ó·È ‰˘Ó·Ùfi οو ·fi ÔÚÈṲ̂Ó˜ Û˘Óı‹Î˜ Ó· ÚÔηϤÛÔ˘Ó Û˘ÁÎÔÙÈÎfi ÂÂÈÛfi‰ÈÔ, Û˘¯ÓfiÙÂÚ· fï˜ ·˘Ùfi ÌÔÚ› Ó· ·Ú·ÙËÚËı› Û ‰È·Ù·Ú·¯¤˜ ÙÔ˘ Ú˘ıÌÔ‡, ·ÔÊÚ·ÎÙÈΤ˜ ·ı‹ÛÂȘ ÙÔ˘ ¯ÒÚÔ˘ ÂÍfi‰Ô˘ Ù˘ ·ÚÈÛÙÂÚ‹˜ ÎÔÈÏ›·˜, ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ, ‰È·Ù·ÙÈ΋ Ì˘ÔηډÈÔ¿ıÂÈ·-Ì˘Ôηډ›Ùȉ·, Ó¢ÌÔÓÈ΋ ˘¤ÚÙ·ÛË. ™ÙÔȯ›·, Ù· ÔÔ›· ı· ÛÙÚ¤„Ô˘Ó ÙËÓ ÚÔÛÔ¯‹ Ì·˜ ÚÔ˜ ÙÔ Î˘ÎÏÔÊÔÚÈÎfi Û‡ÛÙËÌ·, Â›Ó·È Ë ‡·ÚÍË ÁÓˆÛÙÔ‡ ηډȷÎÔ‡ ÚÔ‚Ï‹Ì·ÙÔ˜ ÙÔ˘ ·ÛıÂÓÔ‡˜, Ô ·ÈÊÓ›‰ÈÔ˜ Î·È ·ÓÂÍ‹ÁËÙÔ˜ ı¿Ó·ÙÔ˜ Ó·ÚÔ‡ Û˘ÁÁÂÓÈÎÔ‡ ÚÔPaediatriki 2008;71:62-67

¶›Ó·Î·˜ 3. ∂Ӊ›ÍÂȘ ηډȷ΋˜ ÚÔ¤Ï¢Û˘ Û˘ÁÎÔÙÈÎÔ‡ ÂÂÈÛÔ‰›Ô˘ ñ √ÈÎÔÁÂÓÂÈ·Îfi ÈÛÙÔÚÈÎfi ·ÈÊÓȉ›Ô˘ ı·Ó¿ÙÔ˘ (<40 ÂÙÒÓ) ñ ⁄·ÚÍË ÁÓˆÛÙÔ‡ ηډȷÎÔ‡ ÚÔ‚Ï‹Ì·ÙÔ˜ ñ ¶·ÚÔ˘Û›· ÔÚÁ·ÓÈÎÔ‡ Ê˘Û‹Ì·ÙÔ˜ ñ ∞Ô˘Û›· Úfi‰ÚÔÌˆÓ Û˘ÌÙˆÌ¿ÙˆÓ ñ ∞›ÛıËÌ· ÚÔÎ¿Ú‰ÈˆÓ ·ÏÌÒÓ ÚÈÓ ·fi ÙÔ ÂÂÈÛfi‰ÈÔ ñ ∂Ή‹ÏˆÛË Î·Ù¿ ÙËÓ ¿ÛÎËÛË ‹ ·Ì¤Ûˆ˜ ÌÂÙ¿

ÛÒÔ˘ (<40 ÂÙÒÓ), Ë ‡·ÚÍË ÔÚÁ·ÓÈÎÔ‡ Ê˘Û‹Ì·ÙÔ˜ ÛÙËÓ ·ÎÚfi·ÛË Ù˘ ηډȿ˜, Ë ·›ÛıËÛË ÚÔÎ¿Ú‰ÈˆÓ ·ÏÌÒÓ ÚÈÓ ·fi ÙÔ ÂÂÈÛfi‰ÈÔ, Ë Ôχ ÌÈÎÚ‹ ‰È¿ÚÎÂÈ· (<5 ‰Â˘ÙÂÚfiÏÂÙ·) ‹ Î·È Ï‹Ú˘ ·Ô˘Û›· Ù˘ Úfi‰ÚÔÌ˘ Ê¿Û˘ Î·È Ê˘ÛÈο Ë Â¤Ï¢ÛË ÙÔ˘ ÂÂÈÛÔ‰›Ô˘ ηٿ ÙËÓ ¿ÛÎËÛË ‹ ·Ì¤Ûˆ˜ ÌÂÙ¿ (¶›Ó·Î·˜ 3). ∫Ú¿ÙËÌ· ·Ó·ÓÔ‹˜ ∆· ÂÂÈÛfi‰È· ÎÚ·Ù‹Ì·ÙÔ˜ ·Ó·ÓÔ‹˜ (breathholding spells) Â›Ó·È ·ÚÎÂÙ¿ Û˘¯Ó¿ ÛÙȘ ÌÈÎÚ¤˜ ËÏÈ˘ Î·È È‰È·›ÙÂÚ· ÛÙ· ·È‰È¿ 2-3 ÂÙÒÓ (6,7). ∏ ¤Ó·ÚÍË ÙˆÓ ÂÂÈÛÔ‰›ˆÓ Á›ÓÂÙ·È Û˘Ó‹ıˆ˜ Û ËÏÈΛ· ÌÂٷ͇ 6 ÌËÓÒÓ Î·È 2 ÂÙÒÓ Î·È Ù· ÂÚÈÛÛfiÙÂÚ· ÛÙ·Ì·ÙÔ‡Ó ÌÂÙ¿ ÙËÓ ËÏÈΛ· ÙˆÓ 4 ÂÙÒÓ. ¢È·ÎÚ›ÓÔÓÙ·È ‰‡Ô ÌÔÚʤ˜ Ù˘, Ë Î˘·ÓˆÙÈ΋ Î·È Ë ˆ¯Ú¿, Ô˘ Î·È ÔÈ ‰‡Ô ıˆÚÂ›Ù·È fiÙÈ ·Ó‹ÎÔ˘Ó ÛÙËÓ Î·ÙËÁÔÚ›· ÙˆÓ ·Ú·Û˘Ì·ıËÙÈÎÒÓ Û˘ÁÎÔÙÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ. ∏ ΢·ÓˆÙÈ΋ ÌÔÚÊ‹ Â›Ó·È Ë ÈÔ Û˘¯Ó‹, ¯·Ú·ÎÙËÚ›˙ÂÙ·È ·fi ÂÂÈÛfi‰ÈÔ ¤ÓÙÔÓÔ˘ ÎÏ¿Ì·ÙÔ˜, ÙÔ ÔÔ›Ô ·ÎÔÏÔ˘ıÂ›Ù·È ·fi ¿ÓÔÈ·, ΢¿ÓˆÛË Î·È Û‡ÓÙÔÌË ÂÚ›Ô‰Ô ·ÒÏÂÈ·˜ Ù˘ Û˘Ó›‰ËÛ˘ Î·È ÔÊ›ÏÂÙ·È ÛÙËÓ ·Ú·ÙÂٷ̤ÓË ÂÎÓÔ‹ Ì ÎÏÂÈÛÙ‹ ÙË ÁψÙÙ›‰·. ∏ ˆ¯Ú¿ ÌÔÚÊ‹ ¯·Ú·ÎÙËÚ›˙ÂÙ·È ·fi ÙËÓ ‡·ÚÍË ÂÓfi˜ ·Ú¯ÈÎÔ‡ Û˘Ì‚¿Ì·ÙÔ˜, fiˆ˜ ÙÚ·˘Ì·ÙÈÛÌÔ‡ ‹ ¤ÓÙÔÓÔ˘ Î·È Í·ÊÓÈÎÔ‡ Êfi‚Ô˘, Ô˘ ·ÎÔÏÔ˘ıÂ›Ù·È ·fi ·Û˘ÛÙÔÏ›· Î·È ·fiÙÔÌË ·ÒÏÂÈ· Ù˘ Û˘Ó›‰ËÛ˘, Ë ÔÔ›· Û˘Óԉ‡ÂÙ·È ·fi ˆ¯ÚfiÙËÙ·. ¶ÈÛÙ‡ÂÙ·È fiÙÈ Ë ÌÔÚÊ‹ ·˘Ù‹ ÎÚ·Ù‹Ì·ÙÔ˜ Ù˘ ·Ó·ÓÔ‹˜ ÔÊ›ÏÂÙ·È Û ‰˘ÛÏÂÈÙÔ˘ÚÁ›· ÙÔ˘ ·˘ÙfiÓÔÌÔ˘ Ó¢ÚÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ Î·È fiÙÈ Ù· ·È‰È¿ ·˘Ù¿ ¤¯Ô˘Ó ·˘ÍË̤Ó˜ Èı·ÓfiÙËÙ˜ Ó· ÂÌÊ·Ó›ÛÔ˘Ó ·ÚÁfiÙÂÚ· ηٿ ÙËÓ ÂÊ˂›· ÂÂÈÛfi‰È· Ó¢ÚÔηډÈÔÁÂÓÔ‡˜ Û˘ÁÎÔ‹˜. æ˘¯ÔÁÂÓ‹˜ Û˘ÁÎÔ‹ ∆· „˘¯ÔÁÂÓ‹ ÂÂÈÛfi‰È· ‰È·ÎÚ›ÓÔÓÙ·È ÛÙȘ ÎÚ›ÛÂȘ ·ÓÈÎÔ‡ Î·È ÛÙȘ ˘ÛÙÂÚÈΤ˜ ÎÚ›ÛÂȘ. ™ÙËÓ ÚÒÙË ÂÚ›ÙˆÛË ·Ú·ÙËÚ›ٷÈ, ÏfiÁˆ οÔÈÔ˘ Â͈ÙÂÚÈÎÔ‡ ÁÂÁÔÓfiÙÔ˜, ¤ÓÙÔÓÔ˜ ·ÓÈÎfi˜ Ì ˘ÂÚ·ÂÚÈÛÌfi Î·È ·›ÛıËÌ· ‚¿ÚÔ˘˜ Î·È ›ÂÛ˘ ÛÙÔ ÛÙ‹ıÔ˜. ∏ ˘ÛÙÂÚÈ΋ ÎÚ›ÛË ·Ú·ÙËÚÂ›Ù·È Û˘Ó‹ıˆ˜ Û ÂÊ‹‚Ô˘˜, ¿ÓÙ· ·ÚÔ˘Û›· ¿ÏÏˆÓ ÚÔÛÒˆÓ, ‰ÂÓ Û˘Ó‰˘¿˙ÂÙ·È Ì ˆ¯ÚfiÙËÙ· ‹ ‚Ú·‰˘Î·Ú‰›·, Ù· ÂÂÈÛfi‰È· Â›Ó·È Ôχ Û˘¯Ó¿ (̤¯ÚÈ Î·È ÔÏϤ˜ ÊÔÚ¤˜ ÙÔ ›‰ÈÔ 24ˆÚÔ) Î·È Ë ‰È¿ÚÎÂÈ¿ Ù˘ Â›Ó·È ·ÚÎÂÙ¿ ÌÂÁ¿ÏË. ÷ڷÎÙËÚÈÛÙÈÎfi

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·65

65

™˘ÁÎÔÙÈο ÂÂÈÛfi‰È· ÛÙ· ·È‰È¿

¶›Ó·Î·˜ 4. ¢È¿ÎÚÈÛË Û˘ÁÎÔ‹˜ ·fi ÂÂÈÛfi‰È· Û·ÛÌÒÓ ™˘ÁÎÔ‹

™·ÛÌÔ›

ñ ∞Ú¯›˙ÂÈ ÌÂÙ¿ ÙËÓ ÙÒÛË ñ ™˘Ó‹ıˆ˜ ˆ¯ÚfiÙ˘ ñ ªÈÎÚ‹˜ ‰È¿ÚÎÂÈ·˜ (1-2 ÏÂÙ¿) ñ ∞ÒÏÂÈ· Ô‡ÚˆÓ: Û¿ÓÈ· ñ Ÿ¯È ‰¿ÁΈ̷ ÁÏÒÛÛ·˜ ñ ◊È· ÌÂÙ·Û˘ÁÎÔÙÈ΋ Û˘Á¯˘ÙÈ΋ Ê¿ÛË

ñ ∞Ú¯›˙Ô˘Ó ·fi ÙËÓ fiÚıÈ· ı¤ÛË ñ ¶Èı·Ó‹ ΢¿ÓˆÛË ñ ªÂÁ·Ï‡ÙÂÚ˘ ‰È¿ÚÎÂÈ·˜ (>5 ÏÂÙ¿) ñ ∞ÒÏÂÈ· Ô‡ÚˆÓ: Û˘¯Ó‹ ñ ¢¿ÁΈ̷ ÁÏÒÛÛ·˜: 25% ñ ŒÓÙÔÓË Î·È ·Ú·ÙÂٷ̤ÓË Û˘Á¯˘ÙÈ΋ Ê¿ÛË ÌÂÙ¿ ÙÔ ÂÂÈÛfi‰ÈÔ

ÙˆÓ ÂÂÈÛÔ‰›ˆÓ ·˘ÙÒÓ Â›Ó·È fiÙÈ Ô ·ÛıÂÓ‹˜ ¤ÊÙÂÈ ¿ÓÙ· Ì οÔÈ· ¯¿ÚË Î·È ı·ÙÚÈÎfiÙËÙ· Î·È ˘¿Ú¯ÂÈ ÚfiÓÔÈ· ·ÔÊ˘Á‹˜ ÙÚ·˘Ì·ÙÈÛÌÔ‡. ∂›Û˘, fiÙ·Ó ÂÚÈÁÚ¿ÊÂÈ ÙÔ ÂÂÈÛfi‰ÈÔ Â›Ó·È ÂÍ·ÈÚÂÙÈο ‹ÚÂÌÔ˜ Î·È „‡¯Ú·ÈÌÔ˜. ∞Ú¯È΋ ÔÚıÔÛÙ·ÙÈ΋ ˘fiÙ·ÛË ™˘ÁÎÔ‹ ‹ Û˘¯ÓfiÙÂÚ· ÂÓԯϋ̷ٷ Ù˘ ÚÔÛ˘ÁÎÔÙÈ΋˜ Ê¿Û˘ Â›Ó·È Ôχ Û˘¯Ó¿ ηٿ ÙËÓ ·Ú¯È΋ Ê¿ÛË Ù˘ ¤ÁÂÚÛ˘ ÛÙËÓ fiÚıÈ· ı¤ÛË, ÂȉÈο ÛÙËÓ ÂÊË‚È΋ ËÏÈΛ· (8). ™¯Â‰fiÓ fiÏÔÈ ÔÈ ¤ÊË‚ÔÈ ·Ó·Ê¤ÚÔ˘Ó ÂÂÈÛfi‰È· ˙¿Ï˘ ηٿ ÙËÓ ·fiÙÔÌË ¤ÁÂÚÛË, ÂȉÈο ÌÂÙ¿ ·fi ·Ú·ÙÂٷ̤ÓË Î·Ù¿ÎÏÈÛË. ∆· ÂÓԯϋ̷ٷ ÂÌÊ·Ó›˙ÔÓÙ·È ÂÓÙfi˜ ‰Â˘ÙÂÚÔϤÙˆÓ ·fi ÙËÓ ¤ÁÂÚÛË Î·È ‰È·ÚÎÔ‡Ó Ï›ÁÔ (30 ‰Â˘ÙÂÚfiÏÂÙ·). ™‡Ó‰ÚÔÌÔ ÔÚıÔÛÙ·ÙÈ΋˜ Ù·¯˘Î·Ú‰›·˜ (postural orthostatic tachycardia syndrome) ÷ڷÎÙËÚ›˙ÂÙ·È ·fi Û˘ÌÙÒÌ·Ù· ·ÓÂ·ÚÎÔ‡˜ ·ÈÌ¿ÙˆÛ˘ ÙÔ˘ ÂÁÎÂÊ¿ÏÔ˘ Î·È ÙÔ˘ ·ÌÊÈ‚ÏËÛÙÚÔÂȉԇ˜ (˙¿ÏË, ·›ÛıËÌ· ÎfiˆÛ˘, ·‰˘Ó·Ì›·, ıfiψÛË Ù˘ ÔÚ¿Ûˆ˜) ÛÂ Û˘Ó‰˘·ÛÌfi Ì ·˘ÍË̤ÓË Î·Ú‰È·Î‹ Û˘¯ÓfiÙËÙ· ÛÙËÓ fiÚıÈ· ı¤ÛË, ÂÓÒ Ë ·ÚÙËÚȷ΋ ›ÂÛË ·Ú·Ì¤ÓÂÈ ÛÙ· ηÙÒÙÂÚ· Ê˘ÛÈÔÏÔÁÈο fiÚÈ· (9). ª›· ·‡ÍËÛË Ù˘ ηډȷ΋˜ Û˘¯ÓfiÙËÙ·˜ ηٿ 35% ‹ ηډȷ΋ Û˘¯ÓfiÙËÙ· ¿Óˆ ÙˆÓ 120/ÏÂÙfi ÌÂÙ¿ ·fi ‰‡Ô ÏÂÙ¿ ÔÚıÔÛÙ·Û›·˜ ıˆÚÂ›Ù·È ·ıÔÏÔÁÈ΋. ∆Ô Û‡Ó‰ÚÔÌÔ Â›Ó·È Û·ÊÒ˜ Û˘¯ÓfiÙÂÚÔ ÛÙ· ÎÔÚ›ÙÛÈ· (4:1), ·Ó Î·È Ë ·ÎÚÈ‚‹˜ ‰È¿ÁÓˆÛ‹ ÙÔ˘ ··ÈÙ› Û˘Ó‹ıˆ˜ ÙË ‚Ô‹ıÂÈ· ÂÍÂȉÈÎÂ˘Ì¤ÓÔ˘ ΤÓÙÚÔ˘. ∂ÂÈÛfi‰È· Û·ÛÌÒÓ ∏ ‰È¿ÎÚÈÛË ·fi Ù· ÂÂÈÛfi‰È· Û·ÛÌÒÓ ‰ÂÓ Â›Ó·È ¿ÓÙ· ‡ÎÔÏË (10). ™ÙÔȯ›· Ô˘ Û˘ÓËÁÔÚÔ‡Ó ˘¤Ú ÙˆÓ ÂÂÈÛÔ‰›ˆÓ Û·ÛÌÒÓ Â›Ó·È Ë ·ÚÔ˘Û›· ·ÊÚÒÓ ÛÙÔ ÛÙfiÌ·, ÙÔ ‰¿ÁΈ̷ Ù˘ ÁÏÒÛÛ·˜, Ë ÛÙÚÔÊ‹ Ù˘ ÎÂÊ·Ï‹˜, Ë ·ÒÏÂÈ· ÎÔÚ¿ÓˆÓ, Ë ‰È¿ÚÎÂÈ· ¿Óˆ ÙˆÓ ¤ÓÙ ÏÂÙÒÓ, Ë ·Ú·ÙÂٷ̤ÓË Î·È ¿Ù˘Ë ÌÂÙ·Û˘ÁÎÔÙÈ΋ Ê¿ÛË Ô˘ Û˘Óԉ‡ÂÙ·È ·fi ·ÒÏÂÈ· ÙÔ˘ ÚÔÛ·Ó·ÙÔÏÈÛÌÔ‡, ÛÔ‚·Ú‹ ÎÂÊ·Ï·ÏÁ›· Î·È ·ÒÏÂÈ· Ù˘ ÌÓ‹Ì˘ Î·È Ë ‡·ÚÍË ÂÛÙÈ·ÎÒÓ Ó¢ÚÔÏÔÁÈÎÒÓ Â˘ÚËÌ¿ÙˆÓ (¶›Ó·Î·˜ 4). ∆· ˘fiÏÔÈ· ·›ÙÈ· ÂÂÈÛÔ‰›ˆÓ ·ÒÏÂÈ·˜ Ù˘

Û˘Ó›‰ËÛ˘, fiˆ˜ Ë ·Ó·ÈÌ›·, Ë ˘ÔÁÏ˘Î·ÈÌ›·, Ë Ô‡ÚËÛË, Ô ‚‹¯·˜ Î·È Ë ·Êfi‰Â˘ÛË Â›Ó·È ÂÍ·ÈÚÂÙÈο Û¿ÓÈ· ÛÙ· ·È‰È¿. ∂ΛÓÔ, ÙÔ ÔÔ›Ô Â›Ó·È ÌÂÓ ·ÎfiÌ· Û¿ÓÈÔ, ·ÏÏ¿ ÚÔԉ¢ÙÈο ·˘Í¿ÓÂÙ·È Î·È Ú¤ÂÈ Ó· Û˘Óԉ¢Ù› Î·È ·fi ·Ó¿ÏÔÁË ·‡ÍËÛË ÙÔ˘ ‚·ıÌÔ‡ ÂÁÚ‹ÁÔÚÛ‹˜ Ì·˜, Â›Ó·È Ë ¯Ú‹ÛË „˘¯ÔÙÚfiˆÓ Ô˘ÛÈÒÓ.

¢È·ÁÓˆÛÙÈ΋ ÚÔÛ¤Ï·ÛË ∏ ÌÂÁ¿ÏË ÏÂÈÔÓfiÙËÙ· ÙˆÓ Û˘ÁÎÔÙÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ ÔÊ›ÏÂÙ·È Û ηÏÔ‹ıË ·›ÙÈ· Î·È Ë ÚfiÁÓˆÛ‹ ÙÔ˘˜ Â›Ó·È Ôχ ηϋ. ∏ ·ÎÚÈ‚‹˜ fï˜ ‰È¿ÁÓˆÛË Ù˘ ·ÈÙÈÔÏÔÁ›·˜ ¤¯ÂÈ ÌÂÁ¿ÏË ÛËÌ·Û›·, ·ÊÂÓfi˜ ÌÂÓ ÁÈ· ÙÔÓ ·ÔÎÏÂÈÛÌfi ÙˆÓ Û¿ÓÈˆÓ ·ÏÏ¿ ÂÈΛӉ˘ÓˆÓ ÂÚÈÙÒÛÂˆÓ Î·Ú‰ÈÔÁÂÓÔ‡˜ Û˘ÁÎÔ‹˜, ·ÊÂÙ¤ÚÔ˘ ‰Â ÏfiÁˆ ÙˆÓ ÛÔ‚·ÚÒÓ ÂÈÙÒÛÂˆÓ Ô˘ ¤¯Ô˘Ó Ù· ÂÂÈÛfi‰È· ·˘Ù¿ ÛÙËÓ ÔÈfiÙËÙ· ˙ˆ‹˜ Î·È ÙËÓ ÎÔÈÓˆÓÈ΋ ˙ˆ‹ ÙˆÓ ·ÛıÂÓÒÓ Î·È ÙˆÓ ÁÔÓ¤ˆÓ ÙÔ˘˜ (11). ∆Ô ÛËÌ·ÓÙÈÎfiÙÂÚÔ ÛÙÔÈ¯Â›Ô Ù˘ ‰È·ÁÓˆÛÙÈ΋˜ ‰È·‰Èηۛ·˜ Â›Ó·È ·Ó·ÌÊ›‚ÔÏ· ÙÔ ÈÛÙÔÚÈÎfi Î·È Ë ÎÏÈÓÈ΋ ÂͤٷÛË. ∞fi ÙÔ ÈÛÙÔÚÈÎfi ‰ÈÂÚ¢ÓÒÓÙ·È ·Ú¯Èο ÔÈ Û˘Óı‹Î˜ οو ·fi ÙȘ Ôԛ˜ ¤ÁÈÓ ÙÔ ÂÂÈÛfi‰ÈÔ. √ ·ÛıÂÓ‹˜ ‹Ù·Ó Í·ψ̤ÓÔ˜; ¶ÚÔËÁ‹ıËΠοÔÈÔ ¤ÓÙÔÓÔ Û˘ÁÎÈÓËÛÈ·Îfi ÂÚ¤ıÈÛÌ·; ™ËÎÒıËΠ·fiÙÔÌ· ·fi ÙËÓ Î·ıÈÛÙ‹ ÛÙËÓ fiÚıÈ· ı¤ÛË; ◊Ù·Ó ÁÈ· ÌÂÁ¿ÏÔ ‰È¿ÛÙËÌ· fiÚıÈÔ˜ Î·È Ì¿ÏÈÛÙ· Û ÎÏÂÈÛÙfi, ˙ÂÛÙfi ¯ÒÚÔ, Ì ÌÂÁ¿ÏÔ Û˘ÓˆÛÙÈÛÌfi; ∆Ô ÂÂÈÛfi‰ÈÔ Û˘Ó¤‚Ë Î·Ù¿ ÙËÓ ¿ÛÎËÛË ‹ ·Ì¤Ûˆ˜ ÌÂÙ¿; ™ÙË Û˘Ó¤¯ÂÈ·, Á›ÓÂÙ·È ÚÔÛ¿ıÂÈ· Ó· ‰È¢ÎÚÈÓÈÛı› ÔÈ· ‹Ù·Ó Ë Î·Ù¿ÛÙ·ÛË ÙÔ˘ ·ÛıÂÓÔ‡˜ ηٿ ÙÔ ÂÂÈÛfi‰ÈÔ. ¶ÚÔËÁ‹ıËÎ·Ó Úfi‰ÚÔÌ· Û˘ÌÙÒÌ·Ù·; À‹ÚÍ ·›ÛıËÌ· ÚÔηډ›ˆÓ ·ÏÌÒÓ; À‹ÚÍ ·ÒÏÂÈ· Ù˘ Û˘Ó›‰ËÛ˘ ‹ ÙÔ ÂÂÈÛfi‰ÈÔ ÂÚÈÔÚ›ÛıËΠÌfiÓÔ ÛÙ· Úfi‰ÚÔÌ· ÛËÌ›·; À‹ÚÍ·Ó Û·ÛÌÔ›; √ ·ÛıÂÓ‹˜ ‹Ù·Ó ˆ¯Úfi˜ Î·È ¯·Ï·Úfi˜ ‹ Û ۇÛ·ÛË; À‹ÚÍ ·ÒÏÂÈ· Ô‡ÚˆÓ ‹ Î·È ÎÔÚ¿ÓˆÓ; À‹ÚÍ ÙÚ·˘Ì·ÙÈÛÌfi˜ ·fi ÙËÓ ÙÒÛË; ¶fiÛË ÒÚ· ‰È‹ÚÎÂÛ ÙÔ ÂÂÈÛfi‰ÈÔ; ªÂÙ¿ ÙËÓ ·ÔηٿÛÙ·ÛË ÙÔ˘ ÂÈ¤‰Ô˘ Û˘Ó›‰ËÛ˘, Ô ·ÛıÂÓ‹˜ ‹Ù·Ó Û˘Á¯˘ÙÈÎfi˜ Î·È ÁÈ· fiÛÔ ‰È¿ÛÙËÌ·; ∂Âȉ‹ ÔÏϤ˜ ÊÔÚ¤˜ Ô ·ÛıÂÓ‹˜ ‰ÂÓ Â›Ó·È Û ı¤ÛË Ó· Ì·˜ ‰ÒÛÂÈ ÈηÓÔÔÈËÙÈΤ˜ ÏËÚÔÊÔڛ˜, Ë Û˘Ó‰ÚÔÌ‹ ÙˆÓ ·ÚÈÛÙ·Ì¤ÓˆÓ ÛÙÔ ÂÂÈÛfi‰ÈÔ Â›Ó·È ÔχÙÈÌË. ∞fi ÙÔ ÔÈÎÔÁÂÓÂÈ·Îfi ÈÛÙÔÚÈÎfi ¤¯ÂÈ ·Í›· Ë ‡·ÚÍË ¶·È‰È·ÙÚÈ΋ 2008;71:62-67

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·66

66

¢. π. °ÂˆÚÁ·ÎfiÔ˘ÏÔ˜

·ÈÊÓȉ›Ô˘ ı·Ó¿ÙÔ˘, ·‰È¢ÎÚ›ÓÈÛÙ˘ ·ÈÙÈÔÏÔÁ›·˜, ÛÂ Û˘ÁÁÂÓÈÎfi ÚfiÛˆÔ ËÏÈΛ·˜ οو ÙˆÓ 40 ÂÙÒÓ. ∞fi ÙÔ ·ÙÔÌÈÎfi ·Ó·ÌÓËÛÙÈÎfi ·ÍÈÔÏÔÁÂ›Ù·È Ë ·ÚÔ˘Û›· ÁÓˆÛÙ‹˜ ηډÈÔ¿ıÂÈ·˜ ‹ ¿ÏÏ˘ ·ıÔÏÔÁÈ΋˜ ηٿÛÙ·Û˘ (.¯. Ó¢ÚÔÏÔÁÈ΋ Û˘Ó‰ÚÔÌ‹), ηıÒ˜ Â›Û˘ Î·È Ë Û˘¯ÓfiÙËÙ· ÙˆÓ ÂÂÈÛÔ‰›ˆÓ. ∏ ÎÏÈÓÈ΋ ÂͤٷÛË ÂÚÈÏ·Ì‚¿ÓÂÈ Ê˘ÛÈο fiÏ· Ù· Û˘ÛÙ‹Ì·Ù·, ÂÈÎÂÓÙÚÒÓÂÙ·È fï˜ ÛÙÔ Î˘ÎÏÔÊÔÚÈÎfi Î·È ÙÔ Ó¢ÚÔÏÔÁÈÎfi. ∞fi ÙÔ Î˘ÎÏÔÊÔÚÈÎfi Á›ÓÂÙ·È ÚÔÛÂÎÙÈ΋ ·ÎÚfi·ÛË ÙÔ˘ ÚÔηډ›Ô˘ Û ηٷÎÂÎÏÈÌ̤ÓË Î·È fiÚıÈ· ı¤ÛË, „ËÏ¿ÊËÛË ÙˆÓ ÂÚÈÊÂÚÈÎÒÓ Ûʇ͈Ó, ̤ÙÚËÛË Ù˘ ηډȷ΋˜ Û˘¯ÓfiÙËÙ·˜ Î·È Ù˘ ·ÚÙËÚȷ΋˜ ›ÂÛ˘ Û ηٷÎÂÎÏÈÌ̤ÓË Î·È Û fiÚıÈ· ı¤ÛË, ‰‡Ô ÏÂÙ¿ ÌÂÙ¿ ÙËÓ ¤ÁÂÚÛË. ∞fi ÙÔ Ó¢ÚÔÏÔÁÈÎfi Á›ÓÂÙ·È ÌÈ· ·‰Ú‹ ÂÎÙ›ÌËÛË ·Ó·˙ËÙÒÓÙ·˜ ÂÛÙȷ΋ ÛËÌÂÈÔÏÔÁ›·. ∞fi ÙȘ ÂÚÁ·ÛÙËÚȷΤ˜ ÂÍÂÙ¿ÛÂȘ, Û˘ÓÈÛÙ¿Ù·È Ó· Á›ÓÂÙ·È ∏∫° Û fiÏÔ˘˜ ÙÔ˘˜ ·ÛıÂÓ›˜ ÚÔ˜ ·ÔÎÏÂÈÛÌfi ÔÚÈÛÌ¤ÓˆÓ Î·Ù·ÛÙ¿ÛÂˆÓ ‹ ·ı‹ÛˆÓ, fiˆ˜ Ë ˘ÂÚÙÚÔÊ›· ÙˆÓ ÎÔÈÏÈÒÓ, Ô ÎÔÏÔÎÔÈÏÈ·Îfi˜ ·ÔÎÏÂÈÛÌfi˜, ÙÔ Û‡Ó‰ÚÔÌÔ Ì·ÎÚÔ‡ QT, ÙÔ Û‡Ó‰ÚÔÌÔ Wolff-Parkinson-White ‹ ÙÔ Û‡Ó‰ÚÔÌÔ Brugada. ∂›Û˘, ÙÔ ∏∫° ÌÔÚ› Ó· ‚ÔËı‹ÛÂÈ ÛÙË ‰È¿ÁÓˆÛË Ù˘ ˘ÂÚÙÚÔÊÈ΋˜ Ì˘ÔηډÈÔ¿ıÂÈ·˜ Î·È Ù˘ ·ÚÚ˘ıÌÈÔÁfiÓÔ˘ ‰˘ÛÏ·Û›·˜ Ù˘ ‰ÂÍÈ¿˜ ÎÔÈÏ›·˜. ŸÙ·Ó ·fi ÙÔ ÈÛÙÔÚÈÎfi ‹ ·fi Ù· Â˘Ú‹Ì·Ù· Ù˘ ÎÏÈÓÈ΋˜ ÂͤٷÛ˘ Î·È ÙÔ˘ ∏∫° ÚÔ·ÙÔ˘Ó ÛÙÔȯ›· ÁÈ· Èı·Ó‹ ηډȷ΋ ÚԤϢÛË ÙˆÓ ÂÂÈÛÔ‰›ˆÓ, ÙfiÙÂ Ô ·ÛıÂÓ‹˜ Ú¤ÂÈ Ó· ·Ú·¤ÌÂÙ·È Û ηډÈÔÏfiÁÔ ÁÈ· ÂÚ·ÈÙ¤Úˆ ¤ÏÂÁ¯Ô. °ÂÓÈ΋ ·›Ì·ÙÔ˜ Î·È ‚ÈÔ¯ËÌÈÎfi˜ ¤ÏÂÁ¯Ô˜ Á›ÓÔÓÙ·È fiÙ·Ó ˘¿Ú¯ÂÈ ˘Ô„›· ÁÈ· ·Ó·ÈÌ›· ‹ ˘ÔÁÏ˘Î·ÈÌ›·. ∂›Û˘, ÂÁÎÂÊ·ÏÔÁÚ¿ÊËÌ· Á›ÓÂÙ·È ÌÂÙ¿ ·fi ÂÎÙ›ÌËÛË ·fi Ó¢ÚÔÏfiÁÔ, fiÙ·Ó ˘¿Ú¯ÂÈ ¤Ó‰ÂÈÍË ÁÈ· Ó¢ÚÔÏÔÁÈ΋ ÚԤϢÛË ÙÔ˘ ÂÂÈÛÔ‰›Ô˘. ∏ ‰ÔÎÈÌ·Û›· ·Ó·ÎÏÈÓÒÌÂÓ˘ ÙÚ·¤˙˘ (tilt test) ‰ÂÓ ¤¯ÂÈ ¤Ó‰ÂÈÍË ÌÂÙ¿ ·fi ¤Ó· Ù˘ÈÎfi, ÌÂÌÔӈ̤ÓÔ ÂÂÈÛfi‰ÈÔ. À¿Ú¯Ô˘Ó ÔÏÏ¿ ÚˆÙfiÎÔÏÏ· Ú·ÁÌ·ÙÔÔ›ËÛ˘ Ù˘ ‰ÔÎÈÌ·Û›·˜, fiÏ· fï˜ ÂÚÈÏ·Ì‚¿ÓÔ˘Ó ÌÈ· ·Ú¯È΋ Ê¿ÛË Î·Ù¿ÎÏÈÛ˘ Û ÔÚÈ˙fiÓÙÈ· ı¤ÛË ÁÈ· 20-30 ÏÂÙ¿ Î·È ÛÙË Û˘Ó¤¯ÂÈ· ¤ÁÂÚÛË ÛÙËÓ fiÚıÈ· ı¤ÛË ‹ Û ÎÏ›ÛË 60-70 ÌÔÈÚÒÓ Î·È ·Ú·ÌÔÓ‹ ÛÙË ı¤ÛË ·˘Ù‹ ÁÈ· 15-20 ÏÂÙ¿ ‹ ̤¯ÚÈ ÚÔÎÏ‹Ûˆ˜ ÙÔ˘ ÂÂÈÛÔ‰›Ô˘. ™Â ÔÚÈṲ̂ӷ ÚˆÙfiÎÔÏÏ·, ·Ó Ë ·Ú¯È΋ ·˘Ù‹ Ê¿ÛË Â›Ó·È ·ÚÓËÙÈ΋, ÙfiÙ ·ÎÔÏÔ˘ı› Ì›· ‰Â‡ÙÂÚË, Ì Ӥ· ηٿÎÏÈÛË ÁÈ· 20-30 ÏÂÙ¿ Î·È ÛÙË Û˘Ó¤¯ÂÈ· ¤ÁÂÚÛË Ì ٷ˘Ùfi¯ÚÔÓË ¯ÔÚ‹ÁËÛË ÈÛÔÚÔÙÂÚÂÓfiÏ˘. ¢È·ÎÚ›ÓÔ˘Ì ÙÚÂȘ ‰È·ÊÔÚÂÙÈÎÔ‡˜ Ù‡Ô˘˜ ·¿ÓÙËÛ˘ Û ÂÚ›ÙˆÛË ıÂÙÈ΋˜ ‰ÔÎÈÌ·Û›·˜, ·Ó¿ÏÔÁ· Ì ÙÔ ·Ó ΢Úȷگ› Ë ‚Ú·‰˘Î·Ú‰›· (ηډÈÔ·Ó·ÛÙ·ÏÙÈ΋), Ë ˘fiÙ·ÛË (·ÁÁÂÈÔηٷÛÙ·ÏÙÈ΋) ‹ Î·È Ù· ‰‡Ô (ÌÈÎÙ‹), Ô˘ Â›Ó·È Î·È Ô Û˘¯ÓfiÙÂÚÔ˜. ∆Ô ÛËÌ·ÓÙÈÎfiÙÂÚÔ ÌÂÈÔÓ¤ÎÙËÌ· Ù˘ ‰ÔÎÈÌ·Û›·˜ Â›Ó·È ÙÔ Ôχ ˘„ËÏfi ÔÛÔÛÙfi „¢‰Ò˜ ·ÚÓËÙÈÎÒÓ ··ÓÙ‹Paediatriki 2008;71:62-67

ÛÂˆÓ (12), Ô˘ ÌÔÚ› Ó· Êı¿ÛÂÈ ÙÔ 50% Û‡Ìʈӷ Ì ÔÚÈṲ̂Ó˜ ÌÂϤÙ˜ (13). ∂›Û˘, Ë ıÂÙÈ΋ ·¿ÓÙËÛË ÛÙË ‰ÔÎÈÌ·Û›· ‰ÂÓ ·ÔÙÂÏ› ηÏfi ÚÔÁÓˆÛÙÈÎfi ‰Â›ÎÙË ÁÈ· ÙÔÓ Î›Ó‰˘ÓÔ ÂÌÊ¿ÓÈÛ˘ ˘ÔÙÚÔÒÓ (14). ª¿ÏÈÛÙ·, fiˆ˜ Ê¿ÓËΠ·fi ÙËÓ ›‰È· ÌÂϤÙË, Ô Î·Ï‡ÙÂÚÔ˜ ÚÔÁÓˆÛÙÈÎfi˜ ·Ú¿ÁÔÓÙ·˜ ‹Ù·Ó Ô ·ÚÈıÌfi˜ ÙˆÓ ÚÔËÁËı¤ÓÙˆÓ Û˘ÁÎÔÙÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ. ªÂ ‚¿ÛË Ù· ·ÓˆÙ¤Úˆ, Ë ‰ÔÎÈÌ·Û›· ·Ó·ÎÏÈÓÒÌÂÓ˘ ÙÚ·¤˙˘ ‰ÂÓ ·ÔÙÂÏ› ÙÔ Î·Ï‡ÙÂÚÔ ‰È·ÁÓˆÛÙÈÎfi ÂÚÁ·ÏÂ›Ô ÁÈ· ÙËÓ ·Ú¯È΋ ‰È¿ÁÓˆÛË ÙˆÓ Û˘ÁÎÔÙÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ. ªÔÚ› Ó· ¯ÚËÛÈÌÔÔÈËı› Û ·ÛıÂÓ›˜ ÌÂ Û˘¯Ó¿, ÌË Ù˘Èο ÂÂÈÛfi‰È·, Ù· ÔÔ›· ‰ÂÓ ·ÓÙ·ÔÎÚ›ÓÔÓÙ·È ÛÙ· ÚÔÏËÙÈο ̤ÙÚ· Ô˘ ÂÚÈÁÚ¿ÊÔÓÙ·È ·Ú·Î¿Ùˆ, ηıÒ˜ Â›Û˘ Î·È fiÙ·Ó Â›Ó·È ÂÈı˘ÌËÙfi Ó· ηıËÛ˘¯¿ÛÔ˘Ì ÙÔÓ ·ÛıÂÓ‹ Î·È Ó· ÙÔÓ ÂÎ·È‰Â‡ÛÔ˘ÌÂ, ÒÛÙ ӷ ·Ó·ÁÓˆÚ›˙ÂÈ Ù· Úfi‰ÚÔÌ· ÛËÌ›· Î·È Ó· ÌÔÚ› Ó· Ù· ÚÔÏ·Ì‚¿ÓÂÈ (15).

∞ÓÙÈÌÂÙÒÈÛË ∏ ·ÓÙÈÌÂÙÒÈÛË ÙˆÓ Û˘ÁÎÔÙÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ Â›Ó·È ·ÈÙÈÔÏÔÁÈ΋. ™ÙÔ ·ÚfiÓ ¿ÚıÚÔ ı· ·Ó·ÊÂÚıԇ̠ÛÙËÓ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ¡∫™, Ô˘ Â›Ó·È Î·È Ë Û˘¯ÓfiÙÂÚË ÌÔÚÊ‹ ÙÔ˘˜. ∏ ·ÓÙÈÌÂÙÒÈÛË ÙˆÓ Î·Ú‰È·ÎÒÓ ·ÈÙ›ˆÓ Û˘ÁÎÔ‹˜ Î·È ÙˆÓ ÂÂÈÛÔ‰›ˆÓ Û·ÛÌÒÓ ÍÂʇÁÂÈ ·fi ÙÔ Ï·›ÛÈÔ Ù˘ ·ÚÔ‡Û·˜ ·Ó·ÛÎfiËÛ˘. ∏ ÚfiÏË„Ë Î·È Ë ·ÓÙÈÌÂÙÒÈÛË Ù˘ Ó¢ÚÔηډÈÔÁÂÓÔ‡˜ Û˘ÁÎÔ‹˜ Û˘Ó‹ıˆ˜ ÂÈÙ˘Á¯¿ÓÂÙ·È Ì ‰È¿ÊÔÚ· ·ÓÒ‰˘Ó· Î·È Â‡ÎÔÏ· ÂÊ·ÚÌfiÛÈÌ· ̤ÙÚ· Î·È ÌfiÓÔ Û·Ó›ˆ˜ ··ÈÙÂ›Ù·È Ê·Ú̷΢ÙÈ΋ ıÂÚ·›·. ∂ΛÓÔ, ÙÔ ÔÔ›Ô ··ÈÙ›ٷÈ, Â›Ó·È Ó· ηıËÛ˘¯·Ûı› Ô ·ÛıÂÓ‹˜ Î·È ÔÈ ÁÔÓ›˜ ÙÔ˘, Ó· ÂÍËÁËı› Ô Ì˯·ÓÈÛÌfi˜ ÚfiÎÏËÛ˘ ÙÔ˘ ÂÂÈÛÔ‰›Ô˘, Ó· Ì¿ıÂÈ Ô ·ÛıÂÓ‹˜ Ó· ·Ó·ÁÓˆÚ›˙ÂÈ Ù· Úfi‰ÚÔÌ· Û˘ÌÙÒÌ·Ù· Î·È Ó· ÂÎ·È‰Â˘ı› ÛÙÔ˘˜ ÙÚfiÔ˘˜ ·ÓÙ›‰Ú·Û˘, ÒÛÙ ӷ ·Ó·ÛÙ›ÏÂÈ ÙËÓ ÂͤÏÈÍË ÙÔ˘ ÂÂÈÛÔ‰›Ô˘ Î·È Ó· ·ÔʇÁÂÈ ÙËÓ ·ÒÏÂÈ· Ù˘ Û˘Ó›‰ËÛ˘. ∆· ÚÔÏËÙÈο ̤ÙÚ·, Ù· ÔÔ›· ÚÔÙ›ÓÔÓÙ·È ÁÈ· ·ÔÊ˘Á‹ ˘ÔÙÚÔ‹˜ ÙÔ˘ ÂÂÈÛÔ‰›Ô˘, Â›Ó·È Ù· ÂÍ‹˜: 1. ·ÔÊ˘Á‹ ·Ê˘‰¿ÙˆÛ˘, ÂȉÈο ÙÔ˘˜ ηÏÔηÈÚÈÓÔ‡˜ Ì‹Ó˜, Ì ÙË Ï‹„Ë ÙÔ˘Ï¿¯ÈÛÙÔÓ 6-8 ÔÙËÚÈÒÓ ÓÂÚÔ‡ ËÌÂÚËÛ›ˆ˜ (Ù· Ô‡Ú· Ú¤ÂÈ Ó· Â›Ó·È ·ÓÔȯÙfi¯ÚˆÌ· Î·È Ë Û˘¯ÓfiÙËÙ· Ô‡ÚËÛ˘ ÙÔ˘Ï¿¯ÈÛÙÔÓ ‰‡Ô ÊÔÚ¤˜ ÙÔ Úˆ› Î·È ‰‡Ô ÙÔ ·fiÁÂ˘Ì·). ¡· ·ÔʇÁÔÓÙ·È ÔÈ ¯˘ÌÔ›, ÂȉÈο ÔÈ ÂÌÊȷψ̤ÓÔÈ, ‰ÈfiÙÈ ÚÔηÏÔ‡Ó ÔÛ̈ÙÈ΋ ‰ÈÔ‡ÚËÛË, 2. ·ÔÊ˘Á‹ Ï‹„˘ ηʤ, 3. ¯Ú‹ÛË ÚfiÛıÂÙÔ˘ ·Ï·ÙÈÔ‡ ÛÙÔ Ê·ÁËÙfi, 4. ·ÔÊ˘Á‹ ¯ÒÚˆÓ ÌÂ Û˘ÓˆÛÙÈÛÌfi Î·È ˙¤ÛÙË, 5. ·ÔÊ˘Á‹ ·fiÙÔÌ˘ ¤ÁÂÚÛ˘ (Ó· ÚÔËÁÔ‡ÓÙ·È ÎÈÓ‹ÛÂȘ ÙˆÓ Ô‰ÈÒÓ ÚÈÓ ·fi ÙËÓ ¤ÁÂÚÛË, Ó· οıÂÙ·È ÁÈ· Ï›ÁÔ Î·ıÈÛÙfi˜ ÛÙËÓ ¿ÎÚË ÙÔ˘ ÎÚ‚·ÙÈÔ‡), 6. ·ÔÊ˘Á‹ ·Ú·ÙÂٷ̤Ó˘ ÔÚıÔÛÙ·Û›·˜, ÂȉÈο Û ˙ÂÛÙÔ‡˜ ¯ÒÚÔ˘˜ ÌÂ Û˘ÓˆÛÙÈÛÌfi ηÈ, fiÙ·Ó ·˘Ùfi

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·67

67

™˘ÁÎÔÙÈο ÂÂÈÛfi‰È· ÛÙ· ·È‰È¿

Â›Ó·È ·Ó·fiÊ¢ÎÙÔ, Ó· Á›ÓÔÓÙ·È Û˘Ó¯›˜ ÎÈÓ‹ÛÂȘ ÙˆÓ Ô‰ÈÒÓ ÂÈÙfiÔ˘. ŸÙ·Ó, ·ÚfiÏ· ·˘Ù¿, ÂΉËψıÔ‡Ó Ù· Úfi‰ÚÔÌ· Û˘ÌÙÒÌ·Ù·, Ô ·ÛıÂÓ‹˜ Ú¤ÂÈ Ó· ·ÓÙȉڿÛÂÈ „‡¯Ú·ÈÌ· Î·È ¤ÁηÈÚ· οÓÔÓÙ·˜ ¤Ó· ·fi Ù· ·Ú·Î¿Ùˆ: Ó· Í·ÏÒÛÂÈ ·Ó ·˘Ùfi Â›Ó·È ‰˘Ó·Ùfi, Ó· ηı›ÛÂÈ ÔÎÏ·‰fiÓ, Ó· Û˘Û¿ÛÂÈ ÙÔ˘˜ ÎÔÈÏÈ·ÎÔ‡˜ ̇˜ ‹ Ó· ‚¿ÏÂÈ ÙÔ ¤Ó· fi‰È ¿Óˆ Û οÔÈ· ηڤÎÏ· ‹ ÛηÏÔ¿ÙÈ. √È ÂÚÈÛÛfiÙÂÚÔÈ ·ÛıÂÓ›˜ ¤¯Ô˘Ó ηϋ ·ÓÙ·fiÎÚÈÛË Ì ÙËÓ ÂÊ·ÚÌÔÁ‹ ÙˆÓ ·Ú·¿Óˆ ̤ÙÚˆÓ, ·Ó Î·È ÙÔ ÔÛÔÛÙfi ˘ÔÙÚÔÒÓ ·Ú·Ì¤ÓÂÈ ˘„ËÏfi (ÂÚ›Ô˘ 32%), ¯ˆÚ›˜ Ó· ˘¿Ú¯ÂÈ Î¿ÔÈÔ˜ ·ÍÈfiÈÛÙÔ˜ ÚÔ‚ÏÂÙÈÎfi˜ ‰Â›ÎÙ˘. ŸÙ·Ó Ù· ÂÂÈÛfi‰È· Â·Ó·Ï·Ì‚¿ÓÔÓÙ·È Û˘¯Ó¿, Â›Ó·È ‰˘Ó·Ùfi Ó· ÚÔÛʇÁÔ˘Ì ÛÙË ¯Ú‹ÛË Ê·Ú̷΢ÙÈÎÒÓ Ô˘ÛÈÒÓ, fiˆ˜ Ë ÊÏÔ˘ÔÚÔÎÔÚÙÈ˙fiÓË (‰Ú· ·˘Í¿ÓÔÓÙ·˜ ÙÔÓ ÂÓ‰Ô·ÁÁÂÈ·Îfi fiÁÎÔ), ÔÈ ‚-·Ó·ÛÙÔÏ›˜ (ÂÏ·ÙÙÒÓÔ˘Ó ÙËÓ ¤ÓÙ·ÛË Ù˘ ηډȷ΋˜ Û˘ÛÙÔÏ‹˜ Î·È ÂӉ¯Ô̤ӈ˜ ·Ó·ÛÙ¤ÏÏÔ˘Ó ÙËÓ ·ÓÙ·Ó·ÎÏ·ÛÙÈ΋ Ô‰fi Ô˘ ηٷϋÁÂÈ ÛÙË ‰È¤ÁÂÚÛË ÙÔ˘ ·Ú·Û˘Ì·ıËÙÈÎÔ‡) Î·È Ë „¢‰ÔÂʉڛÓË (·-‰ÈÂÁ¤ÚÙ˘, ÚÔηÏ› ÂÚÈÊÂÚÈ΋ ·ÁÁÂÈÔÛ‡Û·ÛË, ·ÏÏ¿ ¤¯ÂÈ ÔÏϤ˜ ·ÚÂÓ¤ÚÁÂȘ). ∆Ô Úfi‚ÏËÌ· Ì ÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ Â›Ó·È fiÙÈ ·ÊÂÓfi˜ ÌÂÓ Ê·›ÓÂÙ·È Ó· ÌËÓ ÂÏ·ÙÙÒÓÂÈ ÙË Û˘¯ÓfiÙËÙ· ˘ÔÙÚÔÒÓ (14), ·ÊÂÙ¤ÚÔ˘ ‰Â ·Ú·Ì¤ÓÂÈ ¿ÁÓˆÛÙÔ ÁÈ· fiÛÔ ¯ÚÔÓÈÎfi ‰È¿ÛÙËÌ· Ú¤ÂÈ Ó· ¯ÔÚËÁ›ٷÈ. ∏ ÙÔÔı¤ÙËÛË ÌfiÓÈÌÔ˘ ‚ËÌ·ÙÔ‰fiÙË ÂȉÈο ÛÙ· ·È‰È¿ Ú¤ÂÈ Ó· Á›ÓÂÙ·È Ì ÔÏÏ‹ ÊÂÈ‰Ò Î·È ÂÚ›Û΄Ë. ª¤¯ÚÈ Û‹ÌÂÚ· (16), ¤¯ÂÈ Á›ÓÂÈ Û ÂÏ¿¯ÈÛÙ˜ ÂÚÈÙÒÛÂȘ ·ÛıÂÓÒÓ Ì Â·Ó·Ï·Ì‚·ÓfiÌÂÓ·, ÛÔ‚·Ú¿ ÂÂÈÛfi‰È·, ηٿ ÙË ‰È¿ÚÎÂÈ· ÙˆÓ ÔÔ›ˆÓ ›¯Â ÙÂÎÌËÚȈı› Ë ‡·ÚÍË ·Ú·ÙÂٷ̤Ó˘ ηډȷ΋˜ ·‡Ï·˜ (>4 ‰Â˘ÙÂÚfiÏÂÙ·). Ÿˆ˜ Ê¿ÓËÎÂ Î·È ·fi ÙË ÌÂϤÙË VPSII (17), Ë ÌfiÓÈÌË ‚ËÌ·ÙÔ‰fiÙËÛË ‰ÂÓ ÚÔÛʤÚÂÈ Î¿ÔÈÔ Û˘ÁÎÚÈÙÈÎfi ÏÂÔÓ¤ÎÙËÌ· ÛÙË ÌÂÁ¿ÏË ÏÂÈÔÓfiÙËÙ· ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ‰ÂÓ ÂÌÊ·Ó›˙Ô˘Ó ¤ÓÙÔÓË ·Û˘ÛÙÔÏ›· ηٿ Ù· ÂÂÈÛfi‰È· Ó¢ÚÔηډÈÔÁÂÓÔ‡˜ Û˘ÁÎÔ‹˜.

™˘ÌÂÚ¿ÛÌ·Ù· ∆· Û˘ÁÎÔÙÈο ÂÂÈÛfi‰È· ÛÙËÓ ·È‰È΋ Î·È ÂÊË‚È΋ ËÏÈΛ· ÔÊ›ÏÔÓÙ·È Û˘Ó‹ıˆ˜ Û ηÏÔ‹ıÂȘ ηٷÛÙ¿ÛÂȘ, ÂÎ ÙˆÓ ÔÔ›ˆÓ Û˘¯ÓfiÙÂÚË Â›Ó·È Ë Ó¢ÚÔηډÈÔÁÂÓ‹˜ Û˘ÁÎÔ‹. ∏ ÚfiÏË„Ë Î·È Ë ·ÓÙÈÌÂÙÒÈÛ‹ ÙÔ˘˜ ÂÈÙ˘Á¯¿ÓÂÙ·È Ì ·Ï¿ ̤ÙÚ· Î·È Û·Ó›ˆ˜ ··ÈÙÂ›Ù·È Ê·Ú̷΢ÙÈ΋ ‹ ¿ÏÏË ·ÁˆÁ‹. ∏ ‰È¿ÁÓˆÛ‹ ÙÔ˘˜ ‚·Û›˙ÂÙ·È ÛÙÔ ÏÂÙÔÌÂÚ¤˜ ÈÛÙÔÚÈÎfi Î·È ÙËÓ ÂÓ‰Âϯ‹ ÎÏÈÓÈ΋ ÂͤٷÛË, ÒÛÙ ӷ ÌË ‰È·Ê‡ÁÔ˘Ó Ù· Û¿ÓÈ· ·ÏÏ¿ ÂÈΛӉ˘Ó· ·›ÙÈ· ηډȷ΋˜ ÚÔ¤Ï¢Û˘. ∆Ô ∏∫°, Ï·Ì‚¿ÓÔÓÙ·˜ ˘fi„Ë ÙÔ˘˜ ÂÚÈÔÚÈÛÌÔ‡˜ ÙÔ˘, ÎÚ›ÓÂÙ·È ··Ú·›ÙËÙÔ Û fiϘ ÙȘ ÂÚÈÙÒÛÂȘ, ‰ÈfiÙÈ ÌÔÚ› Ó· ·Ôηχ„ÂÈ ‰˘ÓËÙÈο ÂÈΛӉ˘Ó˜ ηٷÛÙ¿ÛÂȘ (Û‡Ó‰ÚÔÌÔ Ì·ÎÚÔ‡ QT, Û‡Ó‰ÚÔÌÔ Wolff-

Parkinson-White, ‰È·Ù·Ú·¯¤˜ Ù˘ ·ÁˆÁÈÌfiÙËÙ·˜). √ ˘fiÏÔÈÔ˜ ÂÚÁ·ÛÙËÚÈ·Îfi˜ ¤ÏÂÁ¯Ô˜, ·ÈÌ·ÙÔÏÔÁÈÎfi˜, ηډÈÔÏÔÁÈÎfi˜ ‹ Ó¢ÚÔÏÔÁÈÎfi˜, ÚÔÁÚ·ÌÌ·Ù›˙ÂÙ·È ·Ó¿ÏÔÁ· Ì ٷ ÎÏÈÓÈο Â˘Ú‹Ì·Ù·.

µÈ‚ÏÈÔÁÚ·Ê›· 1. Johnsrude CL. Current approach to pediatric syncope. Pediatr Cardiol 2000;21:522-531.

2. Driscoll DJ, Jacobsen SJ, Porter CJ, Wollan PC. Syncope in children and adolescents. J Am Coll Cardiol 1997;29:10391045.

3. Ganzeboom KS, Colman N, Reitsma JB, Shen WK, Wieling W. Prevalence and triggers of syncope in medical students.

Am J Cardiol 2003;91:1006-1008.

4. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998;352:1970-1973.

5. Sapin SO. Autonomic syncope in pediatrics: a practice-oriented approach to classification, pathophysiology, diagnosis and management. Clin Pediatr (Phila) 2004;43:17-23.

6. Lombroso CT, Lerman P. Breathholding spells (cyanotic and pallid infantile syncope). Pediatrics 1967;39:563-581.

7. Saul JP. Syncope: etiology, management, and when to refer. J S C Med Assoc 1999;95:385-387.

8. Tanaka H, Yamaguchi H, Matushima R, Tamai H. Instantaneous orthostatic hypotension in children and adolescents: a new entity of orthostatic intolerance. Pediatr Res 1999;46:691-696.

9. Low PA, Sandroni P, Singer W, et al. Postural tachycardia syndrome - an update. Clin Autonom Res 2002;12:107-109.

10. Hoefnagels WA, Padberg GW, Overweg J, van der Velde EA, Roos RA. Transient loss of consciousness: the value of the history for distinguishing seizure from syncope. J Neurol 1991;238:39-43.

11. Linzer M, Pontinen M, Gold DT, Divine GW, Felder A, Brooks WB. Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol 1991;44: 1037-1043.

12. Levine MM. Neurally mediated syncope in children: results of tilt testing, treatment, and long-term follow-up.

Pediatr Cardiol 1999;20:331-335.

13. De Jong-de Vos Steenwijk CC, Wieling W, Johannes JM, Harms MP, Kuis W, Wesseling KH. Incidence and hemodynamic characteristics of near-fainting in healthy 6- to 16year old subjects. J Am Coll Cardiol 1995;25:1615-1621.

14. Kouakam C, Vaksmann G, Pachy E, Lacroix D, Rey C, Kacet S. Long-term follow-up of children and adolescents with syncope; predictor of syncope recurrence. Eur Heart J 2001;22:1618-1625.

15. Kenny RA, O’Shea D, Parry SW. The Newcastle protocols for head-up tilt table testing in the diagnosis of vasovagal syncope, carotid sinus hypersensitivity, and related disorders. Heart 2000;83:564-569.

16. McLeod KA, Wilson N, Hewitt J, Norrie J, Stephenson JB. Cardiac pacing for severe childhood neurally mediated syncope with reflex anoxic seizures. Heart 1999;82:721-725.

17. Connolly SJ, Sheldon R, Thorpe KE, Roberts RS, Ellenbogen KA, Wilkoff BL, et al. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA. 2003;289:2224-2229. ¶·È‰È·ÙÚÈ΋ 2008;71:62-67

Pediatri Jan-Feb 08

15-02-08

68

11:00

™ÂÏ›‰·68

∂¡¢π∞º∂ƒ√À™∞ ¶∂ƒπ¶∆ø™∏

CASE REPORT

µÚ¤ÊÔ˜ Ì ˈÛÈÓÔÊÈÏÈ΋ ÂÓÙÂÚ›Ùȉ· 1 ∞’ ¶·È‰È·ÙÚÈÎfi ∆Ì‹Ì·, °ÂÓÈÎfi ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ¶ÂÓÙ¤Ï˘ 2 ∞’ ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋ ¶·ÓÂÈÛÙËÌ›Ô˘ ∞ıËÓÒÓ, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ “∞Á›· ™ÔÊ›·” 3 ¶·ıÔÏÔÁÔ·Ó·ÙÔÌÈÎfi ∆Ì‹Ì·, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ “∞Á›· ™ÔÊ›·” AÏÏËÏÔÁÚ·Ê›·: ÃÚ˘Û‹ ∫Ô˘ÙÛ·˘Ù›ÎË kochrysa@yahoo.com ∞’ ¶·È‰È·ÙÚÈÎfi ∆Ì‹Ì·, °ÂÓÈÎfi ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ¶ÂÓÙ¤Ï˘ ∆.∫. 152 36, ¶. ¶ÂÓÙ¤ÏË

Ã. ∫Ô˘ÙÛ·˘Ù›ÎË1, ∂. ª¿ÓÙ˙ÈÔ˘1, ¢. ÷Ù˙‹˜2, ∫. ¶··ÓÙ˙›Ì·˜1, ∫. ™ÙÂÊ·Ó¿ÎË3, ¡. ª˘ÚÈÔÎÂÊ·ÏÈÙ¿Î˘1, ∂. ƒÒÌ·-°È·ÓÓ›ÎÔ˘2 ¶ÂÚ›ÏË„Ë: ∏ ˈÛÈÓÔÊÈÏÈ΋ Á·ÛÙÚÂÓÙÂÚ›Ùȉ· Â›Ó·È Û¿ÓÈ· ÓÔÛÔÏÔÁÈ΋ ÔÓÙfiÙËÙ·, Ë ÔÔ›· ÂÚÈÁÚ¿ÊËΠÁÈ· ÚÒÙË ÊÔÚ¿ ÙÔ 1937 ·fi ÙÔÓ Kaijser. ∂›Ó·È ΢ڛˆ˜ ÓfiÛÔ˜ ÙˆÓ ÂÓËϛΈÓ, ·ÊÔ‡ ··ÓÙ¿Ù·È Û ¿ÙÔÌ· ËÏÈΛ·˜ ÌÂٷ͇ ‰Â‡ÙÂÚ˘ Î·È ¤ÎÙ˘ ‰ÂηÂÙ›·˜ Ù˘ ˙ˆ‹˜, Ì ÌÈÎÚ‹ ˘ÂÚÔ¯‹ ÛÙÔ˘˜ ¿Ó‰Ú˜, ÂÓÒ ÙÂÏÂ˘Ù·›· ÏËı·›ÓÔ˘Ó ÔÈ ·Ó·ÊÔÚ¤˜ Û ÂÚÈÙÒÛÂȘ ·È‰ÈÒÓ Ì ˈÛÈÓÔÊÈÏÈ΋ Á·ÛÙÚÂÓÙÂÚ›Ùȉ· Î·È ·ÎfiÌË Û·ÓÈfiÙÂÚ· ‚ÚÂÊÒÓ. ∞·Ú·›ÙËÙ· ÛÙÔȯ›· ÁÈ· ÙËÓ ÙÂÎÌËÚ›ˆÛË Ù˘ ‰È¿ÁÓˆÛ˘ ›ӷÈ: 1) ™˘ÌÙÒÌ·Ù· ·fi ÙÔ ÂÙÈÎfi Û‡ÛÙËÌ·, fiˆ˜ ÎÔÈÏÈ·Îfi ¿ÏÁÔ˜, ¤ÌÂÙÔÈ, Á·ÛÙÚÂÓÙÂÚÈ΋ ÚˆÙÂ˚ÓfiÚÚÔÈ· Î.Ù.Ï. 2) ¢È‹ıËÛË ÙÔ˘ Á·ÛÙÚÂÓÙÂÚÈÎÔ‡ ۈϋӷ (°∂™) ·fi ˈÛÈÓfiÊÈÏ· >20 ∏PF Û ˘ÏÈÎfi ‚ÈÔ„›·˜ ‰È·ÊfiÚˆÓ ÙÌËÌ¿ÙˆÓ ÙÔ˘, Û˘Ó‹ıˆ˜ ÛÙÔÌ¿¯Ô˘ Î·È ÏÂÙÔ‡ ÂÓÙ¤ÚÔ˘. ™Ù· ‚Ú¤ÊË Â›Ó·È Û˘¯Ó‹ Ë ‰È‹ıËÛË ÙÔ˘ ÔÈÛÔÊ¿ÁÔ˘ (ˈÛÈÓÔÊÈÏÈ΋ ÔÈÛÔÊ·Á›Ùȉ·). 3) √ ·ÔÎÏÂÈÛÌfi˜ ¿ÏÏ˘ ·ÈÙ›·˜ ˈÛÈÓÔÊÈÏ›·˜ ÂÚÈÊÂÚÈÎÔ‡ ·›Ì·ÙÔ˜, ‰Â‰Ô̤ÓÔ˘ fiÙÈ >80% ÙˆÓ ÂÚÈÙÒÛÂˆÓ ÂÌÊ·Ó›˙Ô˘Ó ÛÔ‚·ÚÔ‡ ‚·ıÌÔ‡ ˈÛÈÓÔÊÈÏ›· ÂÚÈÊÂÚÈÎÔ‡ ·›Ì·ÙÔ˜. 4) ∏ ·ÓÙ·fiÎÚÈÛË Î·È Ë ‚ÂÏÙ›ˆÛË ÙˆÓ Û˘ÌÙˆÌ¿ÙˆÓ ÌÂÙ¿ ÙË ıÂÚ·›·. ∏ ˈÛÈÓÔÊÈÏÈ΋ ÔÈÛÔÊ·Á›Ùȉ· ÔÌÔÈ¿˙ÂÈ ·ÚÎÂÙ¿ Ì ÙË Á·ÛÙÚÔÔÈÛÔÊ·ÁÈ΋ ·ÏÈÓ‰ÚfiÌËÛË (°√¶) Î·È ı· Ú¤ÂÈ Ó· Èı·ÓÔÏÔÁÂ›Ù·È ˆ˜ ‰È¿ÁÓˆÛË Î·È Ó· Á›ÓÂÙ·È ÂÓ‰ÔÛÎfiËÛË ÛÙȘ ÂÚÈÙÒÛÂȘ Ô˘ ‰ÂÓ ·ÓÙ·ÔÎÚ›ÓÔÓÙ·È ÛÙË Û˘Ó‹ıË ıÂÚ·›·. ∞Ó¿ÏÔÁ· Ì ÙÔ ÙÌ‹Ì· ÙÔ˘ ÙÔȯÒÌ·ÙÔ˜ ÙÔ˘ ÂÙÈÎÔ‡ ۈϋӷ Ô˘ ¤¯ÂÈ ˘ÔÛÙ› ÙËÓ ËˆÛÈÓÔÊÈÏÈ΋ ‰È‹ıËÛË (‚ÏÂÓÓÔÁfiÓÔ˜, Ì˘˚Îfi˜ ¯ÈÙÒÓ·˜, ÔÚÔÁfiÓÔ˜, fiÏÔ ÙÔ ÙÔ›¯ˆÌ·) ‰È·ÎÚ›ÓÂÙ·È Û 4 ÈÛÙÔÏÔÁÈÎÔ‡˜ Ù‡Ô˘˜ ‰›ÓÔÓÙ·˜ Î·È ·ÓÙ›ÛÙÔÈ¯Ë Û˘Ìو̷ÙÔÏÔÁ›·. ø˜ ̤ÙÚÔ ·ÓÙÈÌÂÙÒÈÛ˘ ·ÎÔÏÔ˘ıÂ›Ù·È ·Ú¯Èο ˘Ô·ÏÏÂÚÁÈ΋-ÛÙÔȯÂȷ΋ ‰›·ÈÙ· ηÈ, Â› ·ÔÙ˘¯›·˜ ·˘Ù‹˜, ¯ÔÚËÁÔ‡ÓÙ·È Î˘Ú›ˆ˜ Ù· ÎÔÚÙÈÎÔÛÙÂÚÔÂȉ‹ Î·È ‰Â˘ÙÂÚ¢fiÓÙˆ˜ Ë ÌÔÓÙÂÏÔ˘Î¿ÛÙË, ÙÔ ¯ÚˆÌÔÁÏ˘ÎÈÎfi Ó¿ÙÚÈÔ Î·È ¿ÏÏ·. ¶ÂÚÈÁÚ¿ÊÂÙ·È Ë ÂÚ›ÙˆÛË ‚Ú¤ÊÔ˘˜ Ì ˈÛÈÓÔÊÈÏÈ΋ Á·ÛÙÚÂÓÙÂÚ›Ùȉ· Ô˘ ‰ÈÂÚ¢ӋıËΠÏfiÁˆ ÌÂȈ̤Ó˘ ÚfiÛÏ˄˘ ‚¿ÚÔ˘˜, ÂÌ¤ÙˆÓ Î·È ÂÎÛÂÛËÌ·Ṳ̂Ó˘ ˈÛÈÓÔÊÈÏ›·˜ ÙÔ˘ ÂÚÈÊÂÚÈÎÔ‡ ·›Ì·ÙÔ˜. §¤ÍÂȘ ÎÏÂȉȿ: ∏ˆÛÈÓÔÊÈÏÈ΋ ÂÓÙÂÚ›Ùȉ·, ˈÛÈÓÔÊÈÏ›·, ¤ÌÂÙÔÈ, ‚Ú¤ÊÔ˜.

An infant with eosinophilic enteritis 1 1st Paediatric Department, General Children’s Hospital of Penteli 2 1st Paediatric Clinic, University of Athens, Children’s Hospital “Aghia Sophia” 3 Pathology Department, Children’s Hospital “Aghia Sophia” Correspondence: Chrysie Koutsaftiki kochrysa@yahoo.com 1st Paediatric Department, General Children’s Hospital of Penteli 152 36, P. Penteli, Greece

C. Koutsaftiki1, E. Mantziou1, D. Hatzis2, K. Papantzimas1, ∫. Stefanaki3, N. Myriokefalitakis1, E. Roma-Giannikou2 Abstract: Eosinophilic gastroenteritis is a rare disease, which was first described by Kaijser in 1937. It is a disease mainly of adults, encountered in people between the second and sixth decades of life, predominantly men, but recently there has been an increase in case reports of children, and more rarely of infants, with eosinophilic gastroenteritis. The diagnostic criteria are: 1) Gastrointestinal system symptoms, such as abdominal pain, vomiting, protein loss, etc. 2) Infiltration of the gastrointestinal tract by eosinophils (>20 HPF in biopsies), mainly found in the stomach and small intestine. In infants the oesophagus is most often infiltrated (eosinophilic oesophagitis). 3) Exclusion of other causes of eosinophilia, since in >80% of cases pronounced eosinophilia is reported. 4) Relief or improvement of the symptoms after initiation of treatment. The symptoms of eosinophilic oesophagitis resemble those of gastrooesophageal reflux, so it should be considered as possible diagnosis and biopsy must be taken in those cases where there is no improvement with the usual treatment. According to the layer of the enteric wall that is infiltrated (mucosa, muscle layer, serosa, the whole enteric wall), 4 histological types are described, with related symptoms in each type. To treat the disease, an elimination-hypoallergenic diet is introduced, and if that fails, oral corticosteroids are the main treatment, and in some cases montelucast, sodium cromoglycate or other drugs have been proposed. The case is described of an infant that was investigated due to weight loss, vomiting and marked eosinophilia, and found to have eosinophilic gastroenteritis.

Key words: Eosinophilic enteritis, eosinophilia, vomiting, infant.

Paediatriki 2008;71:68-73

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·69

69

µÚ¤ÊÔ˜ Ì ˈÛÈÓÔÊÈÏÈ΋ ÂÓÙÂÚ›Ùȉ·

∂ÈÛ·ÁˆÁ‹ ∏ ˈÛÈÓÔÊÈÏÈ΋ Á·ÛÙÚÂÓÙÂÚ›Ùȉ· ıˆÚÂ›Ù·È Û¯ÂÙÈο Û¿ÓÈ· ÓfiÛÔ˜, ·Ó Î·È ÂÚÈÁÚ¿ÊÂÙ·È ÛÙË ‚È‚ÏÈÔÁÚ·Ê›· ÂÚÈÛÛfiÙÂÚÔ ·fi 30 ¯ÚfiÓÈ· (1). ∂›Ó·È ÓfiÛÔ˜ ȉÈÔ·ı‹˜, Ô˘ ÚÔ‚¿ÏÏÂÈ Ì ¢ڇ Ê¿ÛÌ· Û˘ÌÙˆÌ¿ÙˆÓ ·fi ÙÔ ÂÙÈÎfi Û‡ÛÙËÌ· (¶›Ó·Î·˜ 1). ™ËÌ·ÓÙÈÎfi ÚfiÏÔ ·›˙ÂÈ Ë ‡·ÚÍË ·ÙÔ›·˜ ÛÙÔ ÔÈÎÔÁÂÓÂÈ·Îfi-·ÙÔÌÈÎfi ÈÛÙÔÚÈÎfi. ¢È·ÎÚ›ÓÂÙ·È Û 4 Ù‡Ô˘˜, Ì ‚¿ÛË ÙËÓ ËˆÛÈÓÔÊÈÏÈ΋ ‰È‹ıËÛË ÙÔ˘ ÙÔȯÒÌ·ÙÔ˜ ÙÔ˘ ÂÓÙ¤ÚÔ˘: 1) ¶ÚÔÛ‚ÔÏ‹ ÙÔ˘ ‚ÏÂÓÓÔÁfiÓÔ˘ (Û˘ÓËı¤ÛÙÂÚÔ˜ Ù‡Ô˜), ÌÂ Û˘ÌÙÒÌ·Ù· fiˆ˜ ¤ÌÂÙÔÈ, ÎÔÈÏÈ·Îfi ¿ÏÁÔ˜ (ÌÈÌÂ›Ù·È ÔÍ›· ÎÔÈÏ›·), ‰È¿ÚÚÔȘ, ·ÒÏÂÈ· ·›Ì·ÙÔ˜ ÛÙ· ÎfiÚ·Ó·, ÛȉËÚÔÂÓÈ΋ ·Ó·ÈÌ›·, ‰˘Û·ÔÚÚfiÊËÛË, ÚˆÙÂ˚ÓfiÚÚÔÈ·, ·Ó·ÛÙÔÏ‹ ·‡ÍËÛ˘ Î.¿. 2) ¶ÚÔÛ‚ÔÏ‹ ÙÔ˘ Ì˘˚ÎÔ‡ ¯ÈÙÒÓ·, fiÔ˘ ·¯‡ÓÂÙ·È ÙÔ ÂÓÙÂÚÈÎfi ÙÔ›¯ˆÌ· Î·È ÚÔÂÍ¿Ú¯Ô˘Ó Î·Ù¿ Û˘Ó¤ÂÈ· ·ÔÊÚ·ÎÙÈο Û˘ÌÙÒÌ·Ù· (ÌÈÌÂ›Ù·È ˘ÏˆÚÈ΋ ÛÙ¤ÓˆÛË). 3) ¶ÚÔÛ‚ÔÏ‹ ÙÔ˘ ÔÚÔÁfiÓÔ˘ (Û·ÓÈfiÙÂÚÔ˜ Ù‡Ô˜), Ì ·ÚÈÔ Û‡Ìو̷ ÙÔÓ ·ÛΛÙË (¤¯ÂÈ ÙÔÓ ÌÂÁ·Ï‡ÙÂÚÔ ·ÚÈıÌfi ˈÛÈÓÔÊ›ÏˆÓ ÛÙËÓ ÂÚÈʤÚÂÈ·). 4) ¶ÚÔÛ‚ÔÏ‹ fiÏÔ˘ ÙÔ˘ ÙÔȯÒÌ·ÙÔ˜, Ì ÔÈΛÏË Û˘Ìو̷ÙÔÏÔÁ›· (1-4). ∆· ıÂÚ·¢ÙÈο ̤ÙÚ·, Ô˘ ηٿ ·ÚÈÔ ÏfiÁÔ ÂÊ·ÚÌfi˙ÔÓÙ·È, Â›Ó·È Ë ÛÙÔȯÂȷ΋ ‰›·ÈÙ·, ·Ú¯Èο, ȉȷ›ÙÂÚ· ÛÙȘ ÂÚÈÙÒÛÂȘ ÂΛӘ fiÔ˘ ˘¿Ú¯ÂÈ Û·Ê‹˜ Û˘Û¯¤ÙÈÛË Ì ÙÚÔʤ˜ (ÛÙÔȯ›· ·fi ÈÛÙÔÚÈÎfi, prick tests, patch tests, RAST tests) Î·È Â› ·ÔÙ˘¯›·˜ Ë ¯ÔÚ‹ÁËÛË ·fi ÙÔ˘ ÛÙfiÌ·ÙÔ˜ ÎÔÚÙÈÎÔÛÙÂÚÔÂȉÒÓ (Ú‰ÓÈ˙fiÓË) Û ‰fiÛË 0,5-2mg/kg/ 24ˆÚÔ, Ì ÛÙfi¯Ô ÙË Ì›ˆÛ‹ ÙÔ˘˜ ‹ Î·È ÙËÓ Ï‹ÚË ‰È·ÎÔ‹ ÙÔ˘˜ Û fiÛÔ ÙÔ ‰˘Ó·ÙfiÓ Û˘ÓÙÔÌfiÙÂÚÔ ¯ÚÔÓÈÎfi ‰È¿ÛÙËÌ·. ™Â ÂÈÚ·Ì·ÙÈÎfi ÛÙ¿‰ÈÔ ‚Ú›ÛÎÂÙ·È Ë ¯ÔÚ‹ÁËÛË Î·È ¿ÏÏˆÓ Ô˘ÛÈÒÓ, fiˆ˜ ÙÔ ¯ÚˆÌÔÁÏ˘ÎÈÎfi Ó¿ÙÚÈÔ, Ë ÌÔÓÙÂÏÔ˘Î¿ÛÙË, Ë ÎÂÙÔÙÈÊ·›ÓË Î·È, Û ȉȷ›ÙÂÚ· ·ÓıÂÎÙÈΤ˜ ÛÙË ıÂÚ·›· ÌÔÚʤ˜, Ë Î˘ÎÏÔÛÔÚ›ÓË ‹ ¿ÏÏ· ·ÓÔÛÔÙÚÔÔÔÈËÙÈο Ê¿Ú̷η, Ì ¿ÏÏÔÙ ¿ÏÏ· ·ÔÙÂϤÛÌ·Ù· (2-5,11). ¢˘ÛÙ˘¯Ò˜, ÛÙË ‚È‚ÏÈÔÁÚ·Ê›· ‰ÂÓ ·Ó¢ڛÛÎÔÓÙ·È ÛÙÔȯ›· ·fi ÛˆÛÙ¿ ÚÔÁÚ·ÌÌ·ÙÈṲ̂Ó˜ ÌÂϤÙ˜ ÁÈ· ÙËÓ ·ÈÙÈÔ·ıÔÁ¤ÓÂÈ·, ÙËÓ ·ÓÙÈÌÂÙÒÈÛË Î·È ÙËÓ ÂȉËÌÈÔÏÔÁ›·, ·ÏÏ¿ ÌÂÌÔӈ̤Ó˜ ·ÚÔ˘ÛÈ¿ÛÂȘ ÂÚÈÛÙ·ÙÈÎÒÓ, Ù· ÂÚÈÛÛfiÙÂÚ· ·fi Ù· ÔÔ›· ·ÊÔÚÔ‡Ó ÂÓËÏ›ÎÔ˘˜. ¶·Ú¿ Ù·‡Ù·, ¤¯ÂÈ ÂÚÈÁÚ·Ê› Î·È ÂÚ›ÙˆÛË ÓÂÔÁÓÔ‡ Ì ˈÛÈÓÔÊÈÏÈ΋ Á·ÛÙÚÂÓÙÂÚ›Ùȉ· Ô˘ ÂΉËÏÒıËΠ·fi ÙËÓ ÚÒÙË Ë̤ڷ ˙ˆ‹˜ Î·È Ì¿ÏÈÛÙ· Ì ·Û˘Ó‹ıÂȘ ÂÈÏÔΤ˜, fiˆ˜ ‰È¿ÙÚËÛË ÛÙÔÌ¿¯Ô˘ Î·È ÂÁÎÔÏ·ÛÌfi˜ (12). ÿÛˆ˜, ÙÂÏÈο, Ë ÓfiÛÔ˜ ·˘Ù‹ Ó· ÌËÓ Â›Ó·È ÙfiÛÔ Û¿ÓÈ· (3). ∞Ó Î·È ‰ÂÓ Â›Ó·È Ï›Á˜ ÔÈ ·Ó·ÊÔÚ¤˜ ÂÚÈÙÒÛÂˆÓ Ì ȉȷ›ÙÂÚ· ıÔÚ˘‚Ò‰Ë Û˘Ìو̷ÙÔÏÔÁ›· ηÈ, ÔÏϤ˜ ÊÔÚ¤˜, Ì ÌÔÈÚ·›· ηٿÏËÍË, Ë ÚfiÁÓˆÛË Ù˘ ÓfiÛÔ˘ ıˆÚÂ›Ù·È ÁÂÓÈο ηϋ. ¶·Ú·ÙËÚÔ‡ÓÙ·È ˘Ê¤ÛÂȘ Î·È ÂÍ¿ÚÛÂȘ, Ì ÚÔÛ‚ÔÏ‹ Û˘¯Ó¿ ‰È·ÊÔÚÂÙÈÎÒÓ ÙÌËÌ¿ÙˆÓ ÙÔ˘ Á·ÛÙÚÂÓÙÂÚÈÎÔ‡.

¶›Ó·Î·˜ 1. ™˘ÌÙÒÌ·Ù· Î·È ÛËÌ›· Ù˘ ˈÛÈÓÔÊÈÏÈ΋˜ Á·ÛÙÚÂÓÙÂÚ›Ùȉ·˜ ·fi ÙÔ ÂÙÈÎfi (4) ™˘ÌÙÒÌ·Ù·

™ËÌ›·

∫ÔÈÏÈ·Îfi ¿ÏÁÔ˜ ∞ÓÔÚÂÍ›· ªÂÙˆÚÈÛÌfi˜ ¢È¿ÚÚÔÈ· ¢˘ÛÊ·Á›· ªÂȈ̤ÓË ·Ó¿Ù˘ÍË ª¤Ï·ÈÓ˜ ÎÂÓÒÛÂȘ ŒÌÂÙÔÈ ∞ÒÏÂÈ· ‚¿ÚÔ˘˜

∞ÛΛÙ˘ ∫ÔÏ›Ùȉ· °·ÛÙÚÂÓÙÂÚÈ΋ ÚˆÙÂ˚ÓfiÚÚÔÈ· √›‰ËÌ· √ÈÛÔÊ·Á›Ùȉ· ™˘Ú›ÁÁÈÔ ÂÓÙ¤ÚÔ˘ ¶ÂÙÈÎfi ¤ÏÎÔ˜ ÀÔÚˆÙÂ˚Ó·ÈÌ›· ∂ÈϽÙȉ· ¢˘Û·ÔÚÚfiÊËÛË ∞fiÊÚ·ÍË ÂÓÙ¤ÚÔ˘ ¢È¿ÙÚËÛË ÂÓÙ¤ÚÔ˘ £¿Ó·ÙÔ˜

¶ÂÚÈÁÚ·Ê‹ ÂÚ›ÙˆÛ˘ µÚ¤ÊÔ˜ ¿ÚÚÂÓ ËÏÈΛ·˜ 7 1/2 ÌËÓÒÓ ÂÈÛ‹¯ıË ÛÙËÓ ÎÏÈÓÈ΋, ÏfiÁˆ ÌÂȈ̤Ó˘ ÚfiÛÏ˄˘ ‚¿ÚÔ˘˜ ·fi ‰ÈÌ‹ÓÔ˘ Î·È ¤ÓÙÔÓÔ Úfi‚ÏËÌ· ÂÌ¤ÙˆÓ ·fi ÓÂÔÁÓÈ΋˜ ËÏÈΛ·˜, Û˘Ó‹ıˆ˜ ÌÈÛ‹ ÒÚ· ‹ Î·È ·ÚÁfiÙÂÚ· ÌÂÙ¿ ÙË Û›ÙÈÛË, Ô˘ ÂȉÂÈÓÒıËΠȉȷ›ÙÂÚ· Ì ÙËÓ ÂÈÛ·ÁˆÁ‹ ÛÙÔ ‰È·ÈÙÔÏfiÁÈfi ÙÔ˘ ÛÙÂÚÂÒÓ ÙÚÔÊÒÓ Û ËÏÈΛ· 5 ÌËÓÒÓ. ∆Ô ·È‰› ·ÓÙÈÌÂÙˆÈ˙fiÙ·Ó Ì ۛÙÈÛË Ì ·ÓÙÈ·Ó·ÁˆÁÈο Á¿Ï·Ù·, ˆ˜ ̤ÙÚÔ ¤Ó·ÓÙÈ Èı·Ó‹˜ Á·ÛÙÚÔÔÈÛÔÊ·ÁÈ΋˜ ·ÏÈÓ‰ÚfiÌËÛ˘, ·Ó·ÔÙÂÏÂÛÌ·ÙÈÎÒ˜ fï˜. ◊Ù·Ó ÙÔ ÚÒÙÔ Î·È ÌÔÓ·‰ÈÎfi ·È‰› Ù˘ ÔÈÎÔÁ¤ÓÂÈ·˜, ηÏÔ‡ ÎÔÈÓˆÓÈÎÔÔÈÎÔÓÔÌÈÎÔ‡ ÂÈ¤‰Ô˘, Ì ¤ÓÙÔÓË ·ÙÔÈ΋ ÚԉȿıÂÛË. √ ·Ù¤Ú·˜ ¿Û¯ÂÈ ·fi ‚ÚÔÁ¯ÈÎfi ¿ÛıÌ· Î·È Â·ÚÈÓ‹ ÚÈÓÔÂÈÂÊ˘Î›Ùȉ· Î·È Ë ÌËÙ¤Ú· ·fi ·ÏÏÂÚÁÈ΋ ÚÈÓ›Ùȉ·. ∆Ô ÂÚÈÁÂÓÓËÙÈÎfi ÈÛÙÔÚÈÎfi ÙÔ˘ ·È‰ÈÔ‡ ‹Ù·Ó ÂχıÂÚÔ, ÂÓÒ ·fi ËÏÈΛ·˜ 5 ÌËÓÒÓ Ì¤¯ÚÈ ÙËÓ ËÏÈΛ· Ù˘

∂ÈÎfiÓ· 1. ¢È‹ıËÛË ÙÔ˘ ¯ÔÚ›Ô˘, ÙˆÓ ÎÚ˘ÙÒÓ Î·È ÂÛÙ›· ÙÔ˘ ÂÈÊ·ÓÂÈ·ÎÔ‡ ÂÈıËÏ›Ô˘ ÙÂÌ·¯›Ô˘ ‰ˆ‰Âη‰·ÎÙ‡ÏÔ˘ ·fi ˈÛÈÓfiÊÈÏ· (·ÈÌ·ÙÔÍ˘Ï›ÓË-ˈۛÓË x200). ¶·È‰È·ÙÚÈ΋ 2008;71:68-73

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·70

70

Ã. ∫Ô˘ÙÛ·˘Ù›ÎË Î·È Û˘Ó.

¶›Ó·Î·˜ 2. ∂ÚÁ·ÛÙËÚÈ·Îfi˜ ŒÏÂÁ¯Ô˜ ∞Ú¯ÈÎfi˜ ¤ÏÂÁ¯Ô˜ °ÂÓÈ΋ ·›Ì·ÙÔ˜ §Â˘Î¿ ·ÈÌÔÛÊ·›ÚÈ·: 26.800 K/ÌL (¶=6%, §=42%, ª=2%, ∏=50% ·fiÏ˘ÙÔ˜ ·ÚÈıÌfi˜: 13.400) ∞ÈÌÔÛÊ·ÈÚ›ÓË = 11,1 g/dl ∞ÈÌ·ÙÔÎÚ›Ù˘ = 33,6% ∞ÈÌÔÂÙ¿ÏÈ· = 530.000 K/ÌL ∆∫∂ = 14 mmHg/1Ë ÒÚ· CRP = (-) √ÏÈο Ï¢ÎÒÌ·Ù· = 5,2 g/dl §Â˘ÎˆÌ·Ù›Ó˜ = 3,2 g/dl ™Ê·ÈÚ›Ó˜ = 2 g/dl §ÔÈfi˜ ‚ÈÔ¯ËÌÈÎfi˜ ¤ÏÂÁ¯Ô˜: º˘ÛÈÔÏÔÁÈÎfi˜ ∞ÓÔÛÔÛÊ·ÈÚ›Ó˜: IgG=206 mg/dl ↓ IgM=26 mg/dl ↓ IgA=11,8 mg/dl IgG1=85 mg/dl ↓ IgG2=84 mg/dl IgG3=5 mg/dl ↓ IgE=130 iu/ml ↑ IgG4=43 mg/dl RAST: °¿Ï· = ∆¿ÍË 1 ∞˘Áfi-™ÈÙËÚ¿-¶ÔÚÙÔοÏÈ = 0 ∫˘ÙÙ·ÚÈ΋ ·ÓÔÛ›·: º˘ÛÈÔÏÔÁÈÎÔ› ÏÂÌÊÔ΢ÙÙ·ÚÈÎÔ› ÏËı˘ÛÌÔ› ÁÈ· ÙËÓ ËÏÈΛ·. º˘ÛÈÔÏÔÁÈ΋ ÔÍÂȉˆÙÈ΋ ·Ó·Ó¢ÛÙÈ΋ ÈηÓfiÙËÙ· ÔÏ˘ÌÔÚÊÔ˘Ú‹ÓˆÓ. ∫·Ú‰ÈÔÏÔÁÈ΋ ÂÎÙ›ÌËÛË: º˘ÛÈÔÏÔÁÈ΋ ‰ÔÌ‹ Î·È ÏÂÈÙÔ˘ÚÁ›· Ù˘ ηډȿ˜.

RÖ ıÒÚ·ÎÔ˜: º˘ÛÈÔÏÔÁÈ΋ U/S ÎÔÈÏ›·˜: ◊·Ú-ÛÏËÓ Ê˘ÛÈÔÏÔÁÈο. ¢ÂÓ ·Ú·ÙËÚÂ›Ù·È Û·Ê‹˜ ¿¯˘ÓÛË ÙÔ˘ ÙÔȯÒÌ·ÙÔ˜ ÙˆÓ ÂÓÙÂÚÈÎÒÓ ÂϛΈÓ. ¶·Ú·ÛÈÙÔÏÔÁÈ΋ ÎÔÚ¿ÓˆÓ: ∞ÚÓËÙÈ΋ ∫·ÏÏȤÚÁÂȘ ÎÔÚ¿ÓˆÓ: º˘ÛÈÔÏÔÁÈ΋ ¯ÏˆÚ›‰· Mayer ÎÔÚ¿ÓˆÓ: £ÂÙÈ΋ ∞ÔÙÂϤÛÌ·Ù· ÂÓ‰ÔÛÎfiËÛ˘ Á·ÛÙÚÂÓÙÂÚÈÎÔ‡: ∞Ó·ÁÚ¿ÊÔÓÙ·È ÛÙÔ Î›ÌÂÓÔ. ŒÏÂÁ¯Ô˜ ÌÂÙ¿ ÙËÓ ¤Ó·ÚÍË Ù˘ Ú‰ÓÈ˙fiÓ˘ °ÂÓÈ΋ ·›Ì·ÙÔ˜ §Â˘Î¿ ·ÈÌÔÛÊ·›ÚÈ·: 10.600 K/ÌL (¶=18%, §=72%, ª=10%, ∏=2% ·fiÏ˘ÙÔ˜ ·ÚÈıÌfi˜:212) ∞ÈÌÔÛÊ·ÈÚ›ÓË = 14 g/dl ∞ÈÌ·ÙÔÎÚ›Ù˘ = 43,2% ∞ÈÌÔÂÙ¿ÏÈ· = 362.000 K/ÌL ∆∫∂ = 5 mmHg/1Ë ÒÚ· CRP = (-) √ÏÈο Ï¢ÎÒÌ·Ù· = 5,9 g/dl §Â˘ÎˆÌ·Ù›Ó˜ = 4,2 g/dl ™Ê·ÈÚ›Ó˜ = 1,7 g/dl ↓ §ÔÈfi˜ ‚ÈÔ¯ËÌÈÎfi˜ ¤ÏÂÁ¯Ô˜: º˘ÛÈÔÏÔÁÈÎfi˜ ∞ÓÔÛÔÛÊ·ÈÚ›Ó˜: IgG=231 mg/dl ↓ IgM=60,4 mg/dl IgA=19,1 mg/dl Mayer ÎÔÚ¿ÓˆÓ: ∞ÚÓËÙÈΤ˜

ÂÈÛ·ÁˆÁ‹˜ ÙÔ˘ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô Â›¯Â ÓÔÛ‹ÛÂÈ ÂÚÈÛÛfiÙÂÚÔ ·fi ‰‡Ô ÊÔÚ¤˜ Ì ‚ÚÔÁ¯ÈÔÏ›Ùȉ· Î·È ÔÍ›· ̤ÛË ˆÙ›Ùȉ·. ¢ÂÓ ·Ó·ÊÂÚfiÙ·Ó ¯Ú‹ÛË Ê·Ú̷΢ÙÈÎÒÓ Ô˘ÛÈÒÓ ¤Ú·Ó Ù˘ ·ÌÈÎÈÏÏ›Ó˘ ÁÈ· ÙËÓ ·ÓÙÈÌÂÙÒÈÛË ÙˆÓ ÂÂÈÛÔ‰›ˆÓ Ù˘ ˆÙ›Ùȉ·˜ Î·È Ù˘ Û·Ï‚Ô˘Ù·ÌfiÏ˘

∂ÈÎfiÓ· 2. ∫Ú˘ÙÈ΋ ‰È‹ıËÛË ÙÂÌ·¯È‰›Ô˘ ‰ˆ‰Âη‰·ÎÙ‡ÏÔ˘ ·fi ˈÛÈÓfiÊÈÏ· x400.

Paediatriki 2008;71:68-73

IgE=<5,0 iu/ml

Î·È Ù˘ ÊÏÔ˘ÙÈη˙fiÓ˘ Ì ÙË ÌÔÚÊ‹ ÂÈÛÓÔÒÓ, ÁÈ· ‰È¿ÛÙËÌ· 15 ËÌÂÚÒÓ Û˘ÓÔÏÈο . ∆Ô ‚¿ÚÔ˜ ÛÒÌ·ÙÔ˜ ‹Ù·Ó ÌÂٷ͇ 3˘-10˘ ÂηÙÔÛÙÈ·›·˜ ı¤Û˘ (∂£), ÂÓÒ Ë ÂÚ›ÌÂÙÚÔ˜ ÎÂÊ·Ï‹˜ Î·È ÙÔ Ì‹ÎÔ˜ ÛÒÌ·ÙÔ˜ ¿Óˆ ·fi ÙËÓ 50Ë ∂£. ™ÙËÓ Î·Ì‡ÏË ·Ó¿Ù˘Í˘ ÙÔ˘ ‚¿ÚÔ˘˜ ÙÔ˘ ·È‰ÈÔ‡, ·Ú·ÙËÚÔ‡ÓÙ·Ó ÙÒÛË ·fi ÙËÓ ËÏÈΛ· ÙˆÓ 5 ÌËÓÒÓ. ∂›¯Â ÂÈÎfiÓ· ‹È·˜ Ïԛ̈͢ ÙÔ˘ ·ÓÒÙÂÚÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡, ¯ˆÚ›˜ ¿ÏÏ· Â˘Ú‹Ì·Ù· ·fi Ù· ÏÔÈ¿ Û˘ÛÙ‹Ì·Ù·. √ ÂÚÁ·ÛÙËÚÈ·Îfi˜ ¤ÏÂÁ¯Ô˜ ¤‰ÂÈÍ ÌÂÁ¿ÏË ·‡ÍËÛË ÙˆÓ ËˆÛÈÓÔÊ›ÏˆÓ ÙÔ˘ ÂÚÈÊÂÚÈÎÔ‡ ·›Ì·ÙÔ˜, Ô˘ ·Ú¯Èο ‹Ù·Ó 4.680/mm3 ηٿ ·fiÏ˘ÙÔ ·ÚÈıÌfi, ÂÓÒ ÙËÓ ÙÚ›ÙË Ì¤Ú· ÓÔÛËÏ›·˜ ÍÂ¤Ú·Û ÙȘ 13.400/mm3 (50% ÙˆÓ Ï¢ÎÒÓ ·ÈÌÔÛÊ·ÈÚ›ˆÓ) (¶›Ó·Î·˜ 2). ¢ÂÓ ·ÚÔ˘Û›·˙ ·Ó·ÈÌ›· ‹ ·ıÔÏÔÁÈÎfi ·ÚÈıÌfi ·ÈÌÔÂÙ·Ï›ˆÓ. ¶·ıÔÏÔÁÈ΋ ‹Ù·Ó ·ÎfiÌË Ë ÙÈÌ‹ ÙˆÓ ÏÂ˘ÎˆÌ¿ÙˆÓ Î·È ÈÔ Û˘ÁÎÂÎÚÈ̤ӷ ÙÔ˘ Û˘ÓfiÏÔ˘ ÙˆÓ ÛÊ·ÈÚÈÓÒÓ Î·È ·ÚÁfiÙÂÚ· Î·È Ù˘ ÏÂ˘ÎˆÌ·Ù›Ó˘. √ ¤ÏÂÁ¯Ô˜ ÙˆÓ ÎÔÚ¿ÓˆÓ ‹Ù·Ó ·ÚÓËÙÈÎfi˜ ÁÈ· ‡·ÚÍË ·Ú·Û›ÙˆÓ ‹ ÌÈÎÚÔ‚›ˆÓ, ·ÏÏ¿ ıÂÙÈÎfi˜ ÁÈ· ·ÚÔ˘Û›· ·›Ì·ÙÔ˜ Û ÔÏÏ·Ï¿ ‰Â›ÁÌ·Ù·, ¯ˆÚ›˜ Ì·ÎÚÔÛÎÔÈ΋ ÂȂ‚·›ˆÛË. √ ¤ÏÂÁ¯Ô˜ ÙˆÓ ·ÓÔÛÔÛÊ·ÈÚÈÓÒÓ ·Ú¯Èο

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·71

71

µÚ¤ÊÔ˜ Ì ˈÛÈÓÔÊÈÏÈ΋ ÂÓÙÂÚ›Ùȉ·

¶›Ó·Î·˜ 3. ¢ÈÂÚ‡ÓËÛË ËˆÛÈÓÔÊÈÏ›·˜ (7) ∞ÏÏÂÚÁÈΤ˜ ηٷÛÙ¿ÛÂȘ ∞ÏÏÂÚÁÈ΋ ÚÈÓ›Ùȉ· ÕÛıÌ· √Í›· ÎÓ›‰ˆÛË ∞ÓÙ›‰Ú·ÛË ˘ÂÚ¢·ÈÛıËÛ›·˜ Û ʿÚ̷η §ÔÈÌÒ‰ÂȘ ·Ú¿ÁÔÓÙ˜ ∂ÏÌÈÓıÈ¿ÛÂȘ ∆Úȯ›ÓˆÛË ∆ÔÍÔηڛ·ÛË ™ÙÚÔÁÁ˘ÏÔ›‰ˆÛË ∞Ûηڛ·ÛË ºÈÏ·Ú›·ÛË ™¯ÈÛÙÔۈ̛·ÛË ∂¯ÈÓÔÎÔÎΛˆÛË ¶Ó¢ÌÔÓÔ·ÛÙË carinii ∆ÔÍÔÏ¿Û̈ÛË ∞ÌÔÈ‚¿‰ˆÛË ∂ÏÔÓÔÛ›· µÚÔÁ¯ÔÓ¢ÌÔÓÈ΋ ·ÛÂÚÁ›ÏψÛË ∫ÔÎÎȉÈÔÂȉÔ̇ΈÛË

∫·ÎÔ‹ıÂȘ ŸÁÎÔÈ ÂÁÎÂÊ¿ÏÔ˘ ¡fiÛÔ˜ Hodgkin - §ÂÌÊÒÌ·Ù· ∆ √Í›· Ì˘ÂÏÔÁÂÓ‹˜ Ï¢¯·ÈÌ›· °·ÛÙÚÂÓÙÂÚÈΤ˜ ·ı‹ÛÂȘ ºÏÂÁÌÔÓ҉˘ ÓfiÛÔ˜ ÙÔ˘ ÂÓÙ¤ÚÔ˘ ∏ˆÛÈÓÔÊÈÏÈ΋ Á·ÛÙÚÂÓÙÂÚ›Ùȉ· ∞ÓÔÛÔ·ÓÂ¿ÚÎÂȘ ™‡Ó‰ÚÔÌÔ ˘ÂÚ IgE ™‡Ó‰ÚÔÌÔ Wiskott-Aldrich ∞ÓÙ›‰Ú·ÛË Î·Ù¿ ÌÔۯ‡̷ÙÔ˜ ¶Ó¢ÌÔÓÈΤ˜ ·ı‹ÛÂȘ ™‡Ó‰ÚÔÌÔ Löffler ∏ˆÛÈÓÔÊÈÏÈ΋ Ï¢¯·ÈÌ›· ¶Ó¢ÌÔӛ˜ ˘ÂÚ¢·ÈÛıËÛ›·˜ ÕÏϘ ηٷÛÙ¿ÛÂȘ £ÚÔÌ‚Ô΢ÙÙ·ÚÔÂÓ›· Ì ·Ô˘Û›· ÎÂÚΛ‰·˜ ∞ÁÁÂÈ›Ùȉ· ªÂÙ¿ ·ÎÙÈÓÔ‚ÔÏ›· ÎÔÈÏȷ΋˜ ¯ÒÚ·˜ πÛÙÈÔ΢ÙÙ¿ÚˆÛË ÌÂ Û˘ÌÌÂÙÔ¯‹ ·fi ÙÔ ‰¤ÚÌ·

·Ó¤‰ÂÈÍ ·˘ÍË̤ÓË ÙÈÌ‹ Ù˘ πgE, ·ÏÏ¿ ÌÂȈ̤ÓË Ù˘ IgG Î·È Î¿ÔȘ ·fi ÙȘ ˘ÔÙ¿ÍÂȘ Ù˘, ηıÒ˜ Î·È ÂÏ·Ùو̤ÓË Ù˘ IgM. √ ¤ÏÂÁ¯Ô˜ Ù˘ ΢ÙÙ·ÚÈ΋˜ ·ÓÔÛ›·˜ ¤‰ÂÈÍ ÏÂÌÊÔ΢ÙÙ·ÚÈÎÔ‡˜ ÏËı˘ÛÌÔ‡˜ ÂÓÙfi˜ ÙˆÓ ÚÔ‚ÏÂfiÌÂÓˆÓ ÁÈ· ÙËÓ ËÏÈΛ· ÙÔ˘ ÔÚ›ˆÓ. ∏ ·ÎÙÈÓÔÁÚ·Ê›· ıÒÚ·ÎÔ˜ ‰ÂÓ ·Ó¤‰ÂÈÍ ÂÓÂÚÁfi Ó¢ÌÔÓÈ΋ ·ÏÏÔ›ˆÛË Î·È ÙÔ ˘ÂÚ˯ÔÁÚ¿ÊËÌ· ¿Óˆ Î·È Î¿Ùˆ ÎÔÈÏ›·˜ ‹Ù·Ó ¯ˆÚ›˜ ȉȷ›ÙÂÚ· ·ıÔÏÔÁÈο Â˘Ú‹Ì·Ù·. ∏ ‰È·ÁÓˆÛÙÈ΋ ÛΤ„Ë Î·Ù¢ı‡ÓıËΠ۠ÓÔÛÔÏÔÁÈΤ˜ ÔÓÙfiÙËÙ˜, fiˆ˜ Ë ·ÏÏÂÚÁ›· ÛÙÔ Á¿Ï· ·ÁÂÏ¿‰·˜, ÔÈ ÙÚÔÊÈΤ˜ ·ÏÏÂÚÁ›Â˜ ÁÂÓÈÎfiÙÂÚ·, Ë ·ÏÏÂÚÁÈ΋ Á·ÛÙÚÂÓÙÂÚ›Ùȉ·, ÔÈ ÊÏÂÁÌÔÓÒ‰ÂȘ ÓfiÛÔÈ ÙÔ˘ ÂÓÙ¤ÚÔ˘, ÔÈ ·Ú·ÛÈÙÒÛÂȘ-ÏÔÈÌÒÍÂȘ, Ù· ·ÈÌ·ÙÔÏÔÁÈο ÓÔÛ‹Ì·Ù· Î.¿., ·ı‹ÛÂȘ Ô˘ ÚÔÎÂÈ̤ÓÔ˘ Ó· ‰È·ÁÓˆÛıÔ‡Ó ¯ÚÂÈ¿˙ÔÓÙ·È ÂÓ‰ÔÛÎÔÈÎfi ¤ÏÂÁ¯Ô (¶›Ó·Î·˜ 3). ªÂ ‚¿ÛË ÙÔ ÔÈÎÔÁÂÓÂÈ·Îfi ÈÛÙÔÚÈÎfi Î·È ÙË ÌÈÎÚ‹

ËÏÈΛ· ÙÔ˘ ·ÛıÂÓÔ‡˜, ıˆڋıËΠˆ˜ Èı·ÓfiÙÂÚÔ˜ ·ÈÙÈÔ·ıÔÁÂÓÂÙÈÎfi˜ Ì˯·ÓÈÛÌfi˜ οÔÈ· ·ÏÏÂÚÁÈ΋ ηٿÛÙ·ÛË Î·È ÂÊ·ÚÌfiÛÙËΠ‰›·ÈÙ· Ì ÛÙÔȯÂÈ·Îfi Á¿Ï·, Ï‹Ú˘ ·Ô¯‹ ·fi ÚÔ˚fiÓÙ· ·ÁÂÏ¿‰·˜ Î·È ·fi ¿ÏϘ ‰˘ÓËÙÈο ·ÏÏÂÚÁÈÔÁfiÓ˜ ÙÚÔʤ˜. ∏ ÁÂÓÈ΋ ηٿÛÙ·ÛË ÙÔ˘ ·È‰ÈÔ‡ ‚ÂÏÙÈÒıËÎÂ, ÛÙ·Ì¿ÙËÛ·Ó ÔÈ ¤ÌÂÙÔÈ Î·È ¿Ú¯ÈÛ ӷ ÚÔÛÏ·Ì‚¿ÓÂÈ ‚¿ÚÔ˜ ÈηÓÔÔÈËÙÈο. ŸÌˆ˜, ·Ú¿ ÙËÓ Î¿ÔÈÔ˘ ‚·ıÌÔ‡ ÂÏ¿ÙÙˆÛË ÙˆÓ ËˆÛÈÓÔʛψÓ, ‰È·ÈÛÙÒıËΠÂÈϤÔÓ ÙÒÛË ÙˆÓ ÏÂ˘ÎˆÌ·ÙÈÓÒÓ Î·È ÙˆÓ ÛÊ·ÈÚÈÓÒÓ (ȉ›ˆ˜ Ù˘ IgG) Î·È Û˘Ó¯‹˜ ·Ó›¯Ó¢ÛË ·ÈÌÔÛÊ·ÈÚ›Ó˘ ÛÙ· ÎfiÚ·Ó·. ∆Ô ‚Ú¤ÊÔ˜ ˘Ô‚Ï‹ıËΠ۠ÂÓ‰ÔÛÎÔÈÎfi ¤ÏÂÁ¯Ô ÙÔ˘ ÂÙÈÎÔ‡, Ô˘ ¤‰ÂÈÍÂ Ê˘ÛÈÔÏÔÁÈο Â˘Ú‹Ì·Ù· ·fi ÙÔ ·ÓÒÙÂÚÔ ÂÙÈÎfi Î·È ÏÂ˘Îˆfi Â›¯ÚÈÛÌ· ÛÙÔ ÔÚıfi Î·È ÙÔ ÛÈÁÌÔÂȉ¤˜. ªÂ ÙËÓ ÈÛÙÔÏÔÁÈ΋ ÂͤٷÛË ‰È·ÈÛÙÒıËÎ·Ó ‹È· ¯ÚfiÓÈ· ÔÈÛÔÊ·Á›Ùȉ· Î·È ‹È· ÌË ÂȉÈ΋ Á·ÛÙÚ›Ùȉ·, Ì ·ÚÎÂÙ¿ ˈÛÈÓfiÊÈÏ·, 4-13 HPF. √ ‚ÏÂÓÓÔÁfiÓÔ˜ ÙÔ˘ ‰ˆ‰Âη‰·ÎÙ‡ÏÔ˘ ›¯Â Ê˘ÛÈÔÏÔÁÈΤ˜ Ï¿¯Ó˜, ̤ÙÚÈ· ¯ÚfiÓÈ· 12Ï›Ùȉ· Î·È Û·ÊÒ˜ ·˘ÍË̤ӷ ˈÛÈÓfiÊÈÏ·, 20-39 HPF, Ì ʷÈÓfiÌÂÓ· ·ÔÎÔÎΛˆÛ˘ Î·È ÛÙÔȯ›· ÂÓ‰ÔÂÈıËÏȷ΋˜ ÌÂÙ·Ó·ÛÙ‡Ûˆ˜. ™ÙÔ ÔÚıÔÛÈÁÌÔÂȉ¤˜ ‰È·ÈÛÙÒıËΠÌÈÎÚÔ‡ ‚·ıÌÔ‡ ‰È·Ù·Ú·¯‹ Ù˘ ·Ú¯ÈÙÂÎÙÔÓÈ΋˜ ÙˆÓ ·‰ÂÓÈÎÒÓ ÛÙÔȯ›ˆÓ ÙÔ˘ ‚ÏÂÓÓÔÁfiÓÔ˘, ·‡ÍËÛË ÏÂÌÊÔ΢ÙÙ¿ÚˆÓ Î·È Ï·ÛÌ·ÙÔ΢ÙÙ¿ÚˆÓ, ÂÓÒ Ù· ˈÛÈÓfiÊÈÏ· ‹Ù·Ó ÌÂÙÚ›ˆ˜ ·˘ÍË̤ӷ, 12-20 HPF, Ì ¤ÓÙÔÓ· Ê·ÈÓfiÌÂÓ· ·ÔÎÔÎΛˆÛ˘. √ ¤ÏÂÁ¯Ô˜ ÁÈ· ∏. pylori Î·È Ï¿Ì‚ÏȘ ‹Ù·Ó ·ÚÓËÙÈÎfi˜. ™˘ÌÂÚ·ÛÌ·ÙÈο, Ë ÂÈÎfiÓ· ‹Ù·Ó Û˘Ì‚·Ù‹ Ì ·ÏÏÂÚÁÈ΋ ÂÍÂÚÁ·Û›· ÛÙÔ ·ÓÒÙÂÚÔ ÂÙÈÎfi Î·È ‹È· ˆ˜ ̤ÙÚÈ· ¯ÚfiÓÈ· ÊÏÂÁÌÔÓ‹, Ì ̤ÙÚÈ· ˈÛÈÓÔÊÈÏ›· ÛÙÔ Î·ÙÒÙÂÚÔ ÂÙÈÎfi.

∂ÈÎfiÓ· 3. ∆ÂÌ·¯›‰ÈÔ ‚ÏÂÓÓÔÁfiÓÔ˘ ·¯¤Ô˜ ÂÓÙ¤ÚÔ˘ Ì ·˘ÍË̤ӷ ˈÛÈÓfiÊÈÏ· Ì ÂÓ Ùˆ ‚¿ıÂÈ Î·Ù·ÓÔÌ‹ Î·È ÎÚ˘ÙÈ΋ ‰È‹ıËÛË x400.

¶·È‰È·ÙÚÈ΋ 2008;71:68-73

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·72

72

Ã. ∫Ô˘ÙÛ·˘Ù›ÎË Î·È Û˘Ó.

∏ ÙÂÏÈ΋ ‰È¿ÁÓˆÛË ‹Ù·Ó ÂΛÓË Ù˘ ˈÛÈÓÔÊÈÏÈ΋˜ ÂÓÙÂÚ›Ùȉ·˜. ∂Âȉ‹ οÔÈ· ·fi Ù· Û˘ÌÙÒÌ·Ù·, fiˆ˜ Ë ÚˆÙÂ˚ÓfiÚÚÔÈ· Î·È ÔÈ ·ÈÌÔÚÚ·ÁÈΤ˜ ÎÂÓÒÛÂȘ, Â¤ÌÂÓ·Ó, ·Ú¿ ÙË ‰›·ÈÙ· Ô˘ ¤ÁÈÓ ·ÎfiÌ· ÈÔ Û˘ÁÎÂÎÚÈ̤ÓË ‡ÛÙÂÚ· ·fi ‰ÂÚÌ·ÙÈΤ˜ ‰ÔÎÈ̷ۛ˜ (patch tests), ·ÔÊ·Û›ÛÙËÎÂ Ë ¯ÔÚ‹ÁËÛË Ú‰ÓÈ˙fiÓ˘ ·fi ÙÔ ÛÙfiÌ·, ·Ú¯Èο Û ‰fiÛË 1,5 mg/kg/ 24ˆÚÔ. √ ÚÒÙÔ˜ Â·Ó¤ÏÂÁ¯Ô˜, 7 ̤Ú˜ ÌÂÙ¿, ·Ó¤‰ÂÈÍ ·ÚÈıÌfi ˈÛÈÓÔÊ›ÏˆÓ <800/mm3, Ê˘ÛÈÔÏÔÁÈ΋ ÙÈÌ‹ πgE, Mayer ÎÔÚ¿ÓˆÓ ·ÚÓËÙÈ΋, ·ÏÏ¿ ¯·ÌËϤ˜ ÙÈ̤˜ ÏÂ˘ÎˆÌ·Ù›Ó˘ Î·È IgG, ÂÓÒ ÔÈ ÙÈ̤˜ ÙˆÓ IgM Î·È IgA ‹Ù·Ó Ê˘ÛÈÔÏÔÁÈΤ˜. ŒÎÙÔÙÂ, ÙÔ ·È‰› ·Ú·ÎÔÏÔ˘ıÂ›Ù·È Ù·ÎÙÈο ·fi ÔÌ¿‰· ÁÈ·ÙÚÒÓ (ÂȉÈÎfi Á·ÛÙÚÂÓÙÂÚÔÏfiÁÔ, ·ÏÏÂÚÁÈÔÏfiÁÔ Î·È ·È‰›·ÙÚÔ). ∏ Ú‰ÓÈ˙fiÓË ‰È·ÎfiÙÂÙ·È ÛÙ·‰È·Î¿, ¯ˆÚ›˜ ˘ÔÙÚÔ‹ ÙˆÓ Û˘ÌÙˆÌ¿ÙˆÓ (¯ÚÔÓÈÎfi ‰È¿ÛÙËÌ· ·Ú·ÎÔÏÔ‡ıËÛ˘ 7 Ì‹Ó˜). ∏ ·Ó¿Ù˘Í‹ ÙÔ˘ Î·È Ë ÁÂÓÈ΋ ÙÔ˘ ‰È¿ıÂÛË Â›Ó·È ¿ÚÈÛÙË, Ë ÚfiÛÏË„Ë ‚¿ÚÔ˘˜ ÈηÓÔÔÈËÙÈ΋ ÁÈ· ÙËÓ ËÏÈΛ· ÙÔ˘, Ì ·ÔÙ¤ÏÂÛÌ· Ó· ‚Ú›ÛÎÂÙ·È Û‹ÌÂÚ· ÌÂٷ͇ 25˘-50˘ ÂηÙÔÛÙÈ·›·˜ ı¤Û˘.

™˘˙‹ÙËÛË ∏ ÂÈÛ·ÁˆÁ‹ ‚ÚÂÊÒÓ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô ÁÈ· ÙË ‰ÈÂÚ‡ÓËÛË ÌÂȈ̤Ó˘ ÚfiÛÏ˄˘ ‚¿ÚÔ˘˜, Ô˘ Û˘¯Ó¿ Û˘Óԉ‡ÂÙ·È Î·È ·fi ¿ÏÏ· Û˘ÌÙÒÌ·Ù· ·fi ÙÔ ÂÙÈÎfi Û‡ÛÙËÌ·, Â›Ó·È Û¯ÂÙÈο Û˘ÓËıÈṲ̂ÓË Î·Ù¿ÛÙ·ÛË. ∏ ‡·ÚÍË, fï˜, ˈÛÈÓÔÊÈÏ›·˜ ÛÙÔ ÂÚÈÊÂÚÈÎfi ·›Ì· Î·È Ì¿ÏÈÛÙ· ȉȷ›ÙÂÚ· ÛÔ‚·Ú‹˜ Â›Ó·È ·Û˘Ó‹ıÈÛÙË Î·È ÚÔ‚ÏËÌ·Ù›˙ÂÈ È‰È·›ÙÂÚ· ÙÔÓ ÎÏÈÓÈÎfi È·ÙÚfi. ∏ ·ÏÏÂÚÁ›· ÛÙÔ Á¿Ï· ·ÁÂÏ¿‰·˜ Î·È ÁÂÓÈÎfiÙÂÚ· ÛÙȘ ÙÚÔʤ˜ ÌÔÚ› Ó· ÚÔ‚¿ÏÏÂÈ ˆ˜ ·ÒÏÂÈ· ‚¿ÚÔ˘˜, Û˘Ìو̷ÙÔÏÔÁ›· Á·ÛÙÚÔÔÈÛÔÊ·ÁÈ΋˜ ·ÏÈÓ‰ÚfiÌËÛ˘, ·ÈÌÔÚÚ·ÁÈΤ˜ ÎÂÓÒÛÂȘ Î·È ÂÓ›ÔÙÂ Û˘Óԉ‡ÂÙ·È ·fi ‚ÚÔÁ¯ÈÔÏ›Ùȉ· Î·È Û˘¯Ó¿ ÂÂÈÛfi‰È· ˆÙ›Ùȉ·˜. ™ÙÔ˘˜ ·ıÔÁÂÓÂÙÈÎÔ‡˜ Ì˯·ÓÈÛÌÔ‡˜ Ï·Ì‚¿ÓÂÈ Ì¤ÚÔ˜ Ë πgE (πgE-mediated), ·ÏÏ¿ Î·È ¿ÏÏÔÈ Ì˯·ÓÈÛÌÔ› (non IgE-mediated). ™ÙËÓ ÔÍ›· Ê¿ÛË Ù˘ ÙÚÔÊÈ΋˜ ·ÏÏÂÚÁ›·˜ ÌÔÚ› Ó· ·Ú·ÙËÚËı› ¤ˆ˜ Î·È Ï¢¯·ÈÌÔÂȉ‹˜ ·ÓÙ›‰Ú·ÛË ÛÙ· ˈÛÈÓfiÊÈÏ· ·ÙÙ·Ú·, Ì ·ÚÈıÌfi Ô˘ ÌÔÚ› Ó· Â›Ó·È >20.000/mm3, ·ÏÏ¿ Û ʿÛË ¯ÚÔÓÈfiÙËÙ·˜ Û¿ÓÈ· ÍÂÂÚÓ¿ Ù· 2.000/mm3 (6). ™ÙËÓ ÂÚ›ÙˆÛË ÙÔ˘ Û˘ÁÎÂÎÚÈ̤ÓÔ˘ ·ÛıÂÓ‹ ‰ÂÓ ÂÚfiÎÂÈÙÔ ÁÈ· ÔÍ›· ηٿÛÙ·ÛË, ¿Ú· ‰ÂÓ Â˘ÛÙ·ı› ˆ˜ Èı·Ó‹ Ë ‰È¿ÁÓˆÛË ·˘Ù‹. √È ·Ú·ÛÈÙÈΤ˜ ÓfiÛÔÈ Î·È ÏÔÈÌÔÁfiÓÔÈ ·Ú¿ÁÔÓÙ˜ ÁÂÓÈÎfiÙÂÚ· (∆oxocara canis, Strongyloides sp, H. pylori, Echinococcus, Î.¿.) ÌÔÚÔ‡Ó Ó· ÚÔηϤÛÔ˘Ó ÂÎÛÂÛËÌ·Ṳ̂ÓË ËˆÛÈÓÔÊÈÏ›·, ÙfiÛÔ ÛÙÔ ÂÚÈÊÂÚÈÎfi ·›Ì·, fiÛÔ Î·È ÙÔÈο ÛÙÔ˘˜ ÈÛÙÔ‡˜. ™ÙÔÓ ·ÛıÂÓ‹ Ì·˜ Ô ¤ÏÂÁ¯Ô˜ ÙˆÓ ÎÔÚ¿ÓˆÓ ‹Ù·Ó ¿ÓÙ· ·ÚÓËÙÈÎfi˜, fiˆ˜ Î·È Ô ¤ÏÂÁ¯Ô˜ ÙˆÓ ÈÛÙÔÙÂÌ·¯›ˆÓ ÙÔ˘ ÂÙÈÎÔ‡ (6,7). ∂Í¿ÏÏÔ˘, Ë ÌÈÎÚ‹ ËÏÈΛ· ÙÔ˘ ·ÛıÂÓÔ‡˜ Î·È ÙÔ Paediatriki 2008;71:68-73

ηÏfi ÎÔÈÓˆÓÈÎÔÔÈÎÔÓÔÌÈÎfi ÂÚÈ‚¿ÏÏÔÓ Î·ıÈÛÙÔ‡Û·Ó Ï›ÁÔ ·›ı·ÓË ÙËÓ Â·Ê‹ ÙÔ˘ Ì οÔÈÔÓ ·fi ÙÔ˘˜ ·Ú¿ÁÔÓÙ˜ ·˘ÙÔ‡˜. ∏ ȉÈÔ·ı‹˜ ÊÏÂÁÌÔÓ҉˘ ÓfiÛÔ˜ ÙÔ˘ ÂÓÙ¤ÚÔ˘, Î·È È‰È·›ÙÂÚ· Ë ÌÔÚÊ‹ Ù˘ ÓfiÛÔ˘ Crohn, Ôχ Û¿ÓÈ· ÌÔÚ› Ó· ÚÔÛ‚¿ÏÏÂÈ Ù· ‚Ú¤ÊË ÌÈÎÚ‹˜ ËÏÈΛ·˜ Î·È Ì¿ÏÈÛÙ· Ì ÌfiÓÔ Û‡Ìو̷ ÙËÓ Î·ı˘ÛÙ¤ÚËÛË ÛÙË ÛˆÌ·ÙÈ΋ ·Ó¿Ù˘ÍË Î·È ÙËÓ ˘ÔıÚ„›·. ¶·Ú¿ ÙÔ ÁÂÁÔÓfi˜, Â›Û˘, fiÙÈ ÚÔηÏÔ‡Ó Î¿ÔÈÔ˘ ‚·ıÌÔ‡ ˈÛÈÓÔÊÈÏ›· ·›Ì·ÙÔ˜ Î·È ÙˆÓ ÈÛÙÒÓ ÙÔ˘ °∂™, ÔÙ¤ ·˘Ù‹ ‰ÂÓ Â›Ó·È ÛÔ‚·ÚÔ‡ ‚·ıÌÔ‡ (·fiÏ˘ÙÔ˜ ·ÚÈıÌfi˜ ˈÛÈÓÔÊ›ÏˆÓ ·›Ì·ÙÔ˜ <1.500/mm3 Î·È ÈÛÙÒÓ <20 HPF ÛÙË ‚ÈÔ„›·) (3,6,8). ∆· ·ÈÌ·ÙÔÏÔÁÈο ÓÔÛ‹Ì·Ù· Î·È ÁÂÓÈÎfiÙÂÚ· ÔÈ Î·ÎÔ‹ıÂȘ (ˈÛÈÓÔÊÈÏÈ΋ Ï¢¯·ÈÌ›·, ÏÂÌÊÒÌ·Ù· ÌË Hodgkin, Î.¿.), Û˘Ó‹ıˆ˜ ·ÊÔÚÔ‡Ó ·È‰È¿ ËÏÈΛ·˜ >2 ÂÙÒÓ, ÂÓÒ Û˘Ó˘¿Ú¯Ô˘Ó Î·È ¿ÏÏ· Â˘Ú‹Ì·Ù· ÛÙË ÁÂÓÈ΋ ·›Ì·ÙÔ˜ (.¯. ıÚÔÌ‚Ô΢ÙÙ·ÚÔÂÓ›·) (6,9). ∏ Èı·ÓfiÙËÙ· ÙÔ˘ ˘ÂÚˈÛÈÓÔÊÈÏÈÎÔ‡ Û˘Ó‰ÚfiÌÔ˘ ·ÔÎÏ›ÛÙËÎÂ, ηıÒ˜ ‰ÂÓ ÏËÚÔ‡Û ηӤӷ ·fi Ù· 3 ··Ú·›ÙËÙ· ÎÚÈÙ‹ÚÈ· ÁÈ· ÙË ‰È¿ÁÓˆÛ‹ ÙÔ˘: ·) ∏ˆÛÈÓÔÊÈÏ›· ÂÚÈÊÂÚÈÎÔ‡ ·›Ì·ÙÔ˜ >1.500/mm3 ÁÈ· ÂÚÈÛÛfiÙÂÚÔ ·fi 6 Ì‹Ó˜. ‚) ªË ·Ó‡ÚÂÛË ¿ÏÏÔ˘ ·ÈÙÈÔÏÔÁÈÎÔ‡ ·Ú¿ÁÔÓÙ· ˈÛÈÓÔÊÈÏ›·˜. Á) ⁄·ÚÍË Û˘ÌÙˆÌ¿ÙˆÓ Î·È ÛËÌ›ˆÓ ÛÔ‚·Ú‹˜ ‰˘ÛÏÂÈÙÔ˘ÚÁ›·˜ ‰È·ÊfiÚˆÓ ÔÚÁ¿ÓˆÓ (Ó¢ÌfiÓˆÓ, ÎÂÓÙÚÈÎÔ‡ Î·È ÂÚÈÊÂÚÈÎÔ‡ Ó¢ÚÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜, ηډȿ˜, ÔÊı·ÏÌÒÓ, ‰¤ÚÌ·ÙÔ˜) (6). ∆¤ÏÔ˜, Ë ‰È¿ÁÓˆÛË Ù˘ ÔÈÎÔÁÂÓÔ‡˜ ˈÛÈÓÔÊÈÏ›·˜ Ù›ıÂÙ·È Î·ÙfiÈÓ ·ÔÎÏÂÈÛÌÔ‡ ¿ÏÏˆÓ ·ı‹ÛÂˆÓ Î·È ÂÊfiÛÔÓ ˘¿Ú¯ÂÈ ÛÙÔ ¿ÌÂÛÔ ÔÈÎÔÁÂÓÂÈ·Îfi ÂÚÈ‚¿ÏÏÔÓ ¿ÏÏÔ ¿ÙÔÌÔ Ì ·Û˘Ìو̷ÙÈ΋ ˈÛÈÓÔÊÈÏ›· (10). √ ·ÛıÂÓ‹˜ Ì·˜ ÏËÚÔ‡Û fiÏ· Ù· ‰È·ÁÓˆÛÙÈο ÎÚÈÙ‹ÚÈ· Ù˘ ˈÛÈÓÔÊÈÏÈ΋˜ ÂÓÙÂÚ›Ùȉ·˜ Î·È Î·Ù¿ Û˘Ó¤ÂÈ· ·˘Ù‹ Ë ‰È¿ÁÓˆÛË ‹Ù·Ó Î·È Ë ÙÂÏÈ΋. Œ¯ÂÈ ·ÓÙÈÌÂÙˆÈÛÙ› Ì ÂÈÙ˘¯›· ˆ˜ ÙÒÚ· Ì ‰È·ÈÙËÙÈο ̤ÙÚ· Î·È ¯ÔÚ‹ÁËÛË Ú‰ÓÈ˙fiÓ˘, ÂÓÒ 7 Ì‹Ó˜ ÌÂÙ¿ ÙË ‰È¿ÁÓˆÛË, Ë ‰fiÛË Û˘ÓÙ‹ÚËÛ˘ ÙÔ˘ ÛÙÂÚÔÂȉԇ˜ Â›Ó·È ÂÏ¿¯ÈÛÙË Î·È ¤¯ÂÈ ·Ú¯›ÛÂÈ Ë ÂÈÙ˘¯‹˜ ÛÙ·‰È·Î‹ ÂÈÛ·ÁˆÁ‹ ÙÚÔÊÒÓ ÛÙË ‰È·ÙÚÔÊ‹ ÙÔ˘. ¶ÚÔ‚ÏËÌ·Ù›˙ÂÈ Ë Â›ÌÔÓ· ¯·ÌËÏ‹ ÙÈÌ‹ Ù˘ IgG, Ë ÔÔ›· ·˘Í¿ÓÂÙ·È ·ÚÁ¿, ÂÓÒ ÔÈ ÙÈ̤˜ ÙˆÓ ˘fiÏÔÈˆÓ ·ÓÔÛÔÛÊ·ÈÚÈÓÒÓ Â›Ó·È Ê˘ÛÈÔÏÔÁÈΤ˜. ∆Ô ÙÂÏÂ˘Ù·›Ô, ηıÒ˜ Î·È ÙÔ ÁÂÁÔÓfi˜ fiÙÈ ÙÔ ·È‰› ‰ÂÓ ¤¯ÂÈ ·ÚÔ˘ÛÈ¿ÛÂÈ ÏÔÈÌÒÍÂȘ, οÓÂÈ Èı·Ó‹ ÙËÓ ·ÚÔ‰È΋ ˘ÔÁ·ÌÌ·ÛÊ·ÈÚÈÓ·ÈÌ›· Ù˘ ‚ÚÂÊÈ΋˜ ËÏÈΛ·˜. ∆Ô ·È‰› ı· Â·Ó˘Ô‚ÏËı› Û ÂÓ‰ÔÛÎÔÈÎfi ¤ÏÂÁ¯Ô ÚÔÎÂÈ̤ÓÔ˘ Ó· ÂÏÂÁ¯ı› Î·È ÈÛÙÔÏÔÁÈο Ë ·ÓÙ·fiÎÚÈÛË ÛÙËÓ ·ÁˆÁ‹. ™˘ÌÂÚ·ÛÌ·ÙÈο, ÛÙ· ·È‰È¿ Î·È È‰È·›ÙÂÚ· ÛÙ· ‚Ú¤ÊË, ÔÈ ÂÂÌ‚·ÙÈΤ˜ ÂÍÂÙ¿ÛÂȘ, fiˆ˜ Ë ÂÓ‰ÔÛÎfiËÛË ÙÔ˘ ÂÙÈÎÔ‡, Á›ÓÔÓÙ·È Ì ÊÂȉÒ. £· Ú¤ÂÈ Ó· ·ÔÊ·Û›˙ÂÙ·È fï˜, ÚÔÎÂÈ̤ÓÔ˘ Ó· ‰È·ÈÛÙˆı›

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·73

73

µÚ¤ÊÔ˜ Ì ˈÛÈÓÔÊÈÏÈ΋ ÂÓÙÂÚ›Ùȉ·

Ë ËˆÛÈÓÔÊÈÏÈ΋ ‰È‹ıËÛË ÙÔ˘ °∂™ ÛÙȘ ÂÚÈÙÒÛÂȘ ÂΛӘ Ô˘ ˘¿Ú¯ÂÈ Û˘Ìو̷ÙÔÏÔÁ›· ·fi ÙÔ ÂÙÈÎfi Ô˘ ÔÈ Û˘Ó‹ıÂȘ ÎÏÈÓÈΤ˜ ÔÓÙfiÙËÙ˜ (°√¶, ·ÏÏÂÚÁ›· ÛÙÔ Á¿Ï· ·ÁÂÏ¿‰Ô˜, ÙÚÔÊÈ΋ ·ÏÏÂÚÁ›·) Î·È Ë ·ÓÙ›ÛÙÔÈ¯Ë ·ÓÙÈÌÂÙÒÈÛ‹ ÙÔ˘˜ ‰ÂÓ ÂÚÌËÓÂ‡Ô˘Ó Â·ÚÎÒ˜ (¶›Ó·Î·˜ 1). ¢ÂÓ Ú¤ÂÈ Ó· ÏËÛÌÔÓÂ›Ù·È fiÙÈ Ë ÛÔ‚·ÚÔ‡ ‚·ıÌÔ‡ ÂÚÈÊÂÚÈ΋ ˈÛÈÓÔÊÈÏ›· Ô˘ ηÙ¢ı‡ÓÂÈ ÛÙË ‰È¿ÁÓˆÛË ÌÔÚ› Ó· ·Ô˘ÛÈ¿˙ÂÈ ÛÙÔ 20% ÙˆÓ ÂÚÈÙÒÛˆÓ, ÙÔ˘Ï¿¯ÈÛÙÔÓ (4). ¶Èı·ÓÒ˜, ÛÙÔ Ì¤ÏÏÔÓ Ó· ÌÂÏÂÙËı› ÏËÚ¤ÛÙÂÚ· Ë Û¿ÓÈ· ·˘Ù‹ ÔÓÙfiÙËÙ·, Ó· ηٷÁÚ·Ê› Ë ·ÎÚÈ‚‹˜ Û˘¯ÓfiÙËÙ¿ Ù˘ Î·È Ó· Á›ÓÔ˘Ó Î·Ù·ÓÔËÙÔ› ÔÈ ·ÈÙÈÔ·ıÔÁÂÓÂÙÈÎÔ› Ì˯·ÓÈÛÌÔ› Ù˘, ÚÔÎÂÈ̤ÓÔ˘ Ó· ·ÓÙÈÌÂÙˆÈÛÙ› Ì ÂÈÙ˘¯›·.

µÈ‚ÏÈÔÁÚ·Ê›· 1. Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine (Baltimore) 1970; 49:299-319.

2. Khan S, Orenstein SR. Eosinophilic gastroenteritis: epidemiology, diagnosis and management. Paediatr Drugs 2002;4:563-570.

3. Kelly KJ. Eosinophilic gastroenteritis. J Pediatr Gastroenterol Nutr 2000;30 Suppl:S28-35.

4. Liacouras CA. Eosinophilic esophagitis in children and adults. J Pediatr Gastroenterol Nutr 2003;37 Suppl 1:S23-28.

5. Quack I, Sellin L, Buchner NJ, Theegarten D, Rump LC, Henning BF. Eosinophilic gastroenteritis in a young girl-long term remission under Montelucast. BMC Gastroenterol 2005;5:24.

6. Boxer LA. Eosinophils: diseases associated with eosinophilia. In: Behrman RE, Kliegman RM, Jenson HB, editors.

Nelson Textbook of Pediatrics. 17th ed. Saunders; 2004. p. 709-710.

7. Brigden ML. A practical workup for eosinophilia. You can investigate the most likely causes right in your office. Postgrad Med 1999;105:193-194, 199-202, 207-210.

8. Bischoff SC. Mucosal allergy: role of mast cells and eosinophil granulocytes in the gut. Baillieres Clin Gastroenterol 1996;10:443-459.

9. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103:2879-2891.

10. Curnutte JT. Disorder of granulocyte function and granulopoiesis. In: Nathan DG, Oski FA, editors. Hematology of infancy and childhood. 4th ed. Philadelphia: WB Saunders Co; 1993. p. 953-957.

11. Daikh BE, Ryan CK, Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann Allergy Asthma Immunol 2003;90:23-27.

12. Siahanidou T, Mandyla H, Salavoura K, Dimitriadis D, Van-Vliet C, Anagnostakis D. Eosinophilic gastroenteritis in a neonate. Paediatriki 2000;63:534-537.

¶·È‰È·ÙÚÈ΋ 2008;71:68-73

Pediatri Jan-Feb 08

15-02-08

74

11:00

™ÂÏ›‰·74

∂¡¢π∞º∂ƒ√À™∞ ¶∂ƒπ¶∆ø™∏

CASE REPORT

ƒ·‚‰ÔÌ˘fiÏ˘ÛË ÌÂÙ¿ ·fi Ïԛ̈ÍË ·fi influenza ∞ ªÈÎÚÔ‚ÈÔÏÔÁÈÎfi ∆Ì‹Ì·, ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋, °ÂÓÈÎfi ¡ÔÛÔÎÔÌÂ›Ô “∞ÛÎÏËÈÂ›Ô µÔ‡Ï·˜” AÏÏËÏÔÁÚ·Ê›·: ŸÏÁ· ºÈÏ›Ô˘ filiolga@hotmail.com ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋, °ÂÓÈÎfi ¡ÔÛÔÎÔÌÂ›Ô “∞ÛÎÏËÈÂ›Ô µÔ‡Ï·˜”

O. ºÈÏ›Ô˘, M. ¢ÔÏÈ·Ó›ÙË, K. ¢ÈÁ·Ï¿ÎË-£¤ÌÂÏË, M. ∑‹‚·-¶ÂÙÚÔÔ‡ÏÔ˘, ™. ¶··‰¿ÎÔ˘-§·ÁÔÁÈ¿ÓÓË ¶ÂÚ›ÏË„Ë: ¶ÂÚÈÁÚ¿ÊÂÙ·È Ë ÂÚ›ÙˆÛË ·ÁÔÚÈÔ‡ 9 ¯ÚÔÓÒÓ Ì ڷ‚‰ÔÌ˘fiÏ˘ÛË. √ ·ÛıÂÓ‹˜ ÚÔÛ‹Ïı ÏfiÁˆ ·‰˘Ó·Ì›·˜ ‚¿‰ÈÛ˘ Î·È ¿ÏÁÔ˘˜ ÛÙȘ Á·ÛÙÚÔÎÓË̛˜ ·fi ˆÚÒÓ, ÂÓÒ ·fi ÂÓıË̤ÚÔ˘ ·ÚÔ˘Û›·˙Â Û˘ÌÙÒÌ·Ù· ÈÔÁÂÓÔ‡˜ Û˘Ó‰ÚÔÌ‹˜ ÙÔ˘ ·ÓÒÙÂÚÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡. ∞fi ÙÔÓ ÂÚÁ·ÛÙËÚÈ·Îfi ¤ÏÂÁ¯Ô ‰È·ÈÛÙÒıËΠfiÙÈ Ô Èfi˜ Ù˘ ÁÚ›˘ Ù‡Ô˘ A ‹Ù·Ó Ô ÏÔÈÌ҉˘ ·ÈÙÈÔÏÔÁÈÎfi˜ ·Ú¿ÁÔÓÙ·˜ Ô˘ ÚÔοÏÂÛ ÙËÓ ÂÌÊ¿ÓÈÛË ÙÔ˘ ÎÏÈÓÈÎÔÂÚÁ·ÛÙËÚÈ·ÎÔ‡ Û˘Ó‰ÚfiÌÔ˘ Ù˘ Ú·‚‰ÔÌ˘fiÏ˘Û˘. ¶ÚfiÎÂÈÙ·È ÁÈ· Û¿ÓÈ· ÂÈÏÔ΋ Ù˘ Ïԛ̈͢ ·fi influenza A, ·ÊÔ‡ ÌfiÓÔ ÛÔÚ·‰ÈΤ˜ ÂÚÈÙÒÛÂȘ ¤¯Ô˘Ó ÂÚÈÁÚ·Ê› ̤¯ÚÈ Û‹ÌÂÚ· ÛÙË ‰ÈÂıÓ‹ ‚È‚ÏÈÔÁÚ·Ê›· ÁÈ· ·È‰È¿. √ ·ÛıÂÓ‹˜ ηٿ ÙË ‰È¿ÚÎÂÈ· Ù˘ ÓÔÛËÏ›·˜ ÙÔ˘ ‰ÂÓ ·ÚÔ˘Û›·Û ÂÈÏÔΤ˜ Î·È ·ÓÙ·ÔÎÚ›ıËΠÈηÓÔÔÈËÙÈο ÛÙËÓ Î·Ù¿ÏÏËÏË ˘ÔÛÙËÚÈÎÙÈ΋ ·ÁˆÁ‹. §fiÁˆ Ù˘ ¿Ù˘˘ ÎÏÈÓÈ΋˜ ÂÈÎfiÓ·˜, ··ÈÙÂ›Ù·È ˘„ËÏÔ‡ ‚·ıÌÔ‡ ˘Ô„›· ÁÈ· Ó· ÙÂı› Ë ‰È¿ÁÓˆÛË.

§¤ÍÂȘ ÎÏÂȉȿ: ƒ·‚‰ÔÌ˘fiÏ˘ÛË, Ì˘·ÏÁ›Â˜, influenza A.

Rhabdomyolysis following influenza A infection Microbiological Department, Paediatric Clinic, “Asklipieio Voulas” General Hospital Correspondence: Olga Filippou filiolga@hotmail.com Paediatric Clinic, “Asklipieio Voulas” General Hospital

√. Filippou, ª. Dolianiti, ∫. Digalaki-Themeli, ª. Ziva-Petropoulou, S. Papadakou-Lagogianni Abstract: The case of a 9 year-old boy with rhabdomyolysis is described. The patient presented muscular weakness and myalgia of the calves following an upper respiratory tract infection of 5 days duration. The laboratory findings showed that influenza A was the viral agent responsible for the development of rhabdomyolysis. This is a remarkably rare complication of influenza A infection, since only occasional cases have been reported. This patient had a good response to supportive therapy and an uneventful recovery.

A high index of suspicion is required in order to make this diagnosis, because of the subtle clinical presentation.

Key words: Rhabdomyolysis, myalgia, influenza A.

™˘ÓÙÔÌÔÁڷʛ˜ IFA DAF £.™. ∞.¶.

Immunofluorescence Assay Direct Assay Fluorescence £ÂÚÌÔÎÚ·Û›· ™ÒÌ·ÙÔ˜ ∞ÚÙËÚȷ΋ ¶›ÂÛË

∂ÈÛ·ÁˆÁ‹ ∏ Ïԛ̈ÍË ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ (Ù‡ÔÈ ∞, µ Î·È C) ·ÊÔÚ¿ fiϘ ÙȘ ËÏÈÎȷΤ˜ ÔÌ¿‰Â˜ Î·È ÂΉËÏÒÓÂÙ·È Î˘Ú›ˆ˜ ˆ˜ ·Ó·Ó¢ÛÙÈ΋ ÓfiÛÔ˜ ÙÔ˘˜ „˘¯ÚÔ‡˜ Ì‹Ó˜ ÙÔ˘ ¤ÙÔ˘˜. ∞fi ÙÔ˘˜ ÙÚÂȘ Ù‡Ô˘˜, ÔÈ ∞ Î·È µ Â›Ó·È ÔÈ Î˘Ú›ˆ˜ ·ıÔÁfiÓÔÈ, ÂÓÒ Ô C ·ÔÙÂÏ› ÛÔÚ·‰ÈÎfi ·›ÙÈÔ ÏÔÈÌÒÍÂˆÓ ÙÔ˘ ·ÓÒÙÂÚÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡. √ Èfi˜ ÌÔÚ› Ó· ÂÓÙÔ›˙ÂÙ·È ÛÙÔ ·ÓÒÙÂÚÔ ‹ ηÙÒÙÂÚÔ ·Ó·Ó¢ÛÙÈÎfi ÚÔηÏÒÓÙ·˜ ÂÌ‡ÚÂÙË ÓfiÛÔ ÙˆÓ ·ÓÒÙÂÚˆÓ ·ÂÚ·ÁˆÁÒÓ, Ï·Ú˘ÁÁ›Ùȉ·, ÙÚ·¯ÂÈÔ‚ÚÔÁ¯›Ùȉ·, ‚ÚÔÁ¯ÈÔÏ›Ùȉ· ‹ Ó¢ÌÔÓ›·. ∏ Ïԛ̈ÍË ·fi ÈÓÊÏÔ˘¤ÓÙ˙· ÚÔηÏ› ÔÈÎÈÏ›· ÎÏÈÓÈÎÒÓ ÂΉËÏÒÛÂˆÓ Ì ÛËÌ·ÓÙÈ΋ ÓÔÛËÚfiÙËÙ· ÛÙ· ·È‰È¿, ÂÓÒ ÔÈ Û˘¯ÓfiÙÂÚ˜ ÂÈÏÔΤ˜ Ô˘ ÂÚÈÁÚ¿ÊÔÓÙ·È Â›Ó·È Ë ÔÍÂÈ¿ ̤ÛË ˆÙ›Ùȉ· Î·È Ë ‚·ÎÙËÚȷ΋ Ó¢ÌÔÓ›·. øÛÙfiÛÔ, ¤¯Ô˘Ó ·Ó·ÊÂÚPaediatriki 2008;71:74-78

ı› Î·È ÏÈÁfiÙÂÚÔ Û˘¯Ó¤˜, fiˆ˜ Ë Ì˘Ôηډ›Ùȉ·, Ë ÌËÓÈÁÁÔÂÁÎÂÊ·Ï›Ùȉ·, ÙÔ Û‡Ó‰ÚÔÌÔ Reye, Ë Ì˘ÔÛ›Ùȉ· Î·È Ë Ú·‚‰ÔÌ˘fiÏ˘ÛË. ¶ÂÚÈÁÚ¿ÊÂÙ·È Ë ÂÚ›ÙˆÛË ÂÓfi˜ ·ÁÔÚÈÔ‡ Ô˘ ÂΉ‹ÏˆÛ ڷ‚‰ÔÌ˘fiÏ˘ÛË ÛÙËÓ ÔÚ›· Ïԛ̈͢ ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡ ·fi influenza A. ∞ÎfiÌË, Á›ÓÂÙ·È ·Ó·ÛÎfiËÛË Ù˘ ‚È‚ÏÈÔÁÚ·Ê›·˜ Î·È ·Ó·Ê¤ÚÔÓÙ·È ÔÈ Û‡Á¯ÚÔÓ˜ ·fi„ÂȘ ·Ó·ÊÔÚÈο Ì ÙËÓ ·ÈÙÈÔ·ıÔÁ¤ÓÂÈ·, ÙËÓ ÎÏÈÓÈ΋ ÚÔ‚ÔÏ‹ Î·È ÙËÓ ·ÓÙÈÌÂÙÒÈÛ‹ Ù˘.

¶ÂÚÈÁÚ·Ê‹ ÂÚ›ÙˆÛ˘ ∞ÁfiÚÈ ËÏÈΛ·˜ 9 ¯ÚÔÓÒÓ ÂÈÛ‹¯ıË ÛÙËÓ ÎÏÈÓÈ΋ Ì·˜ Ì ˘ÚÂÙfi ¤ˆ˜ 39ÆC ÌÂ Û˘ÓÔ‰fi Ê·Ú˘ÁÁ·ÏÁ›· Î·È ÚÈÓÈ΋ ηٷÚÚÔ‹ ·fi ÂÓıË̤ÚÔ˘ Î·È ¿ÏÁÔ˜ ÛÙȘ Á·ÛÙÚÔÎÓË̛˜ ·fi 48ÒÚÔ˘, Ô˘ ÂȉÂÈÓÒıËΠÌÂÙ¿ ·fi ¯·ÌËÏ‹˜ ¤ÓÙ·Û˘ ¿ÛÎËÛË. ∆Ô ·ÙÔÌÈÎfi Î·È ÔÈÎÔÁÂÓÂÈ·Îfi ÈÛÙÔÚÈÎfi ·Ó·Ê¤ÚÔÓÙ·È ÂχıÂÚ·. √ ·ÛıÂÓ‹˜ ‹Ù·Ó Û ηϋ ÁÂÓÈ΋ ηٿÛÙ·ÛË Î·È ·fi ÙËÓ ·ÓÙÈÎÂÈÌÂÓÈ΋ ÂͤٷÛË Î·Ù¿ ÙËÓ ÂÈÛ·ÁˆÁ‹ ÚԤ΢„·Ó Ù· ·ÎfiÏÔ˘ı·: ıÂÚÌÔÎÚ·Û›·: 37,6ÆC, ∞.¶.: 85/46 mmHg, ÛʇÍÂȘ: 90/min, ·ÚÈıÌfi˜ ·Ó·ÓÔÒÓ: 23/min,

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·75

75

ƒ·‚‰ÔÌ˘fiÏ˘ÛË ÌÂÙ¿ ·fi influenza ∞

·Ú›ÛıÌÈ· ÂÓÙfiÓˆ˜ ÂͤڢıÚ· Î·È Ú›Ó· Û˘ÌÊÔÚË̤ÓË. ∞fi ÙËÓ ·ÎÚfi·ÛË ÙÔ˘ ıÒڷη ‰È·ÈÛÙÒıËÎ·Ó ·¯Â›˜ ˘ÁÚÔ› ÚfiÁ¯ÔÈ ‰È¿Û·ÚÙÔÈ Î·È ÛÙ· ‰‡Ô Ó¢ÌÔÓÈο ‰›·, ÂÓÒ Î·Ù¿ ÙËÓ ÂͤٷÛË Ù˘ ÎÔÈÏ›·˜ ÙÔ ‹·Ú ‹Ù·Ó „ËÏ·ÊËÙfi ÂÚ›Ô˘ 3 cm, ¯ˆÚ›˜ ¢·ÈÛıËÛ›·, Ì ÔÌ·Ïfi ¯Â›ÏÔ˜ Î·È Ì·Ï·Î‹ Û‡ÛÙ·ÛË Î·È ‰ÂÓ ‹Ù·Ó „ËÏ·ÊËÙfi˜ Ô ÛÏ‹Ó·˜. √ ·ÛıÂÓ‹˜ ·ÚÔ˘Û›·˙ ·‰˘Ó·Ì›· ‚¿‰ÈÛ˘, ¢·ÈÛıËÛ›· ηٿ ÙËÓ „ËÏ¿ÊËÛË ÛÙȘ Á·ÛÙÚÔÎÓË̛˜ ¿Ìʈ Î·È ÌÂȈ̤ÓÔ Ì˘˚Îfi ÙfiÓÔ ÛÙ· οو ¿ÎÚ·. ∆· ÙÂÓfiÓÙÈ· ·ÓÙ·Ó·ÎÏ·ÛÙÈο Î·È Ë ·ÈÛıËÙÈÎfiÙËÙ· (ÂÈÔÏ‹˜ Î·È ÂÓ Ùˆ ‚¿ıÂÈ) ÂϤÁ¯ıËÎ·Ó Ê˘ÛÈÔÏÔÁÈο. ∞fi Ù· ˘fiÏÔÈ· Û˘ÛÙ‹Ì·Ù· ‰ÂÓ ‚Ú¤ıËÎ·Ó ·ıÔÏÔÁÈο Â˘Ú‹Ì·Ù·. √ ÂÚÁ·ÛÙËÚÈ·Îfi˜ ¤ÏÂÁ¯Ô˜ ÂÈÛfi‰Ô˘ ¤‰ÂÈÍÂ: ÏÂ˘Î¿ ·ÈÌÔÛÊ·›ÚÈ·: 1.800/mm3, (ÔÏ˘ÌÔÚÊÔ‡ÚËÓ·: 37% ·fiÏ˘ÙÔ˜ ·ÚÈıÌfi˜: 666, ÏÂÌÊÔ·ÙÙ·Ú·: 48%, ÌÔÓÔ·ÙÙ·Ú·: 8%, ˈÛÈÓfiÊÈÏ·: 2%), Hb: 11,8 g/dl, Ht: 38,6%, ·ÈÌÔÂÙ¿ÏÈ·: 173.000/mm3, ∆∫∂: 9 mm/1Ë ÒÚ·, CRP<3,13 mg/dl, SGOT: 203 U/L, SGPT: 61 U/L, LDH: 942 U/L, ÔÏÈο Ï¢ÎÒÌ·Ù·: 7 g/dl, ÏÂ˘ÎˆÌ·Ù›ÓË: 4 g/dl, ÔÏÈ΋/¿ÌÂÛË ¯ÔÏÂÚ˘ıÚ›ÓË: 0,3/0,1 mg/dl, ÁGT: 9 U/L, ALP: 200 U/L, CPK: 4.767 U/L (º∆: 15-105 U/L ÁÈ· ÙËÓ ËÏÈΛ· ÙÔ˘), CPK-MB: 2 U/L <5% Ù˘ ÔÏÈ΋˜ CPK, Glu: 98 mg/dl, Ô˘Ú›·: 23 mg/dl, ÎÚ·ÙÈÓ›ÓË: 0,6 mg/dl, Na+: 137 mEq/L, K+: 3,8 mEq/L, Ca++: 8,5 mg/dl, P: 4,7 mg/dl, ÁÂÓÈ΋ Ô‡ÚˆÓ: ÎÊ. ∏ ·/· ıÒڷη ‹Ù·Ó Ê˘ÛÈÔÏÔÁÈ΋ Î·È Ë ‰ÂÚÌÔ·ÓÙ›‰Ú·ÛË ªantoux ·ÚÓËÙÈ΋. ™ÙÔÓ ·ÛıÂÓ‹ Ù¤ıËÎÂ Ë ‰È¿ÁÓˆÛË Ù˘ Ú·‚‰ÔÌ˘fiÏ˘Û˘, ÌÂ Û˘ÓÔ‰¿ Â˘Ú‹Ì·Ù·, Ï¢ÎÔÂÓ›· Î·È Ô˘‰ÂÙÂÚÔÂÓ›·, Û ¤‰·ÊÔ˜ Èı·Ó‹˜ ÈÔÁÂÓÔ‡˜ Ïԛ̈͢, Î·È Ô ¤ÏÂÁ¯Ô˜ Û˘ÌÏËÚÒıËΠ̠·Ï‰ÔÏ¿ÛË ÔÚÔ‡: 7 U/L (º∆: 1,2-8,8 U/L ÁÈ· ÙËÓ ËÏÈΛ· ÙÔ˘), Ì˘ÔÛÊ·ÈÚ›ÓË ÔÚÔ‡: 54 Ìg/L (º∆: 0-70 Ìg/L), Ì˘ÔÛÊ·ÈÚ›ÓË Ô‡ÚˆÓ: 154 Ìg/L (º∆: 0 Ìg/L), Ô˘ÚÈÎfi Ô͇: 7 mg/dl, ·¤ÚÈ· ·›Ì·ÙÔ˜: ÎÊ, PT: 11 sec, APTT: 31 sec, INR: 1, ÈÓˆ‰ÔÁfiÓÔ: 2,75 mg/dl. EÏ‹ÊıËÛ·Ó Î·ÏÏȤÚÁÂȘ ·›Ì·ÙÔ˜, ÔÈ Ôԛ˜ ‹Ù·Ó ÛÙ›Ú˜, Î·È ÔÚÔÏÔÁÈÎfi˜ ¤ÏÂÁ¯Ô˜ ÁÈ· ·Ó‡ÚÂÛË ·ÓÙÈÛˆÌ¿ÙˆÓ ¤Ó·ÓÙÈ ÙˆÓ ÈÒÓ influenza A-B, parainfluenza 12-3, EBV, CMV, adenovirus, coxsackie, echo fiˆ˜ Â›Û˘ Î·È ÁÈ· mycoplasma. ∞fi ÙÔÓ ÈÔÏÔÁÈÎfi ¤ÏÂÁ¯Ô ‰È·ÈÛÙÒıËÎ·Ó ·ÓÙÈÁfiÓ· ÁÈ· influenza A ıÂÙÈο ÛÙÔ ÚÈÓÔÊ·Ú˘ÁÁÈÎfi Â›¯ÚÈÛÌ·, Ù· ÔÔ›· ·Ó·˙ËÙ‹ıËÎ·Ó Ì ÙË Ì¤ıÔ‰Ô DAF, Î·È ·ÓÙÈÛÒÌ·Ù· Ù¿Í˘ IgM ıÂÙÈο Û ٛÙÏÔ 1/160 ¤Ó·ÓÙÈ ÙÔ˘ ÈÔ‡ Ù˘ influenza A Ô˘ ·ÓȯÓ‡ÙËÎ·Ó ÙËÓ 3Ë Ì¤Ú· ÓfiÛÔ˘. ªÂÙ¿ ·fi ‰‡Ô ‚‰ÔÌ¿‰Â˜ (17Ë Ì¤Ú· ÓfiÛÔ˘), ·ÓȯÓ‡ÙËÎ·Ó ·ÓÙÈÛÒÌ·Ù· Ù¿Í˘ IgG ıÂÙÈο Û ٛÙÏÔ 1/160 ¤Ó·ÓÙÈ ÙÔ˘ ›‰ÈÔ˘ ÈÔ‡ (ÔÚÔÌÂÙ·ÛÙÚÔÊ‹) Ì ÙË Ì¤ıÔ‰Ô πFA. √ ·ÓÙ›ÛÙÔȯԘ ¤ÏÂÁ¯Ô˜ ÁÈ· influenza B ‹Ù·Ó ·ÚÓËÙÈÎfi˜. √ ·ÛıÂÓ‹˜ Ù¤ıËΠ۠·˘ÍË̤ÓË ÂÓ˘‰¿ÙˆÛË

¶›Ó·Î·˜ 1. ∂ÚÁ·ÛÙËÚȷο Â˘Ú‹Ì·Ù· ·ÛıÂÓÔ‡˜ 24ˆÚÔ ÓfiÛÔ˘

1Ô

2Ô

§Â˘Î¿ ·ÈÌÔÛÊ·›ÚÈ·/ÌL 1.800 1.800 ¶ÔÏ˘ÌÔÚÊÔ‡ÚËÓ· 37% 18% (666) (288) CPK (U/L) 4.767 2.247 SGOT (U/L) 203 187 SGPT (U/L) 61 70 LDH (U/L) 942 333 ª˘ÔÛÊ·ÈÚ›ÓË Ô‡ÚˆÓ 154 60 (Ìg/L)

3Ô

5Ô

8Ô

2.700 34% (618) 1.085 98 74 323 7,8

4.050 47% (1.900) 275 70 65

5.550 37% (2.035) 100 40 35 290

(¤Ï·‚ ˘ÁÚ¿ 1,5 ÊÔÚ¿ ÙȘ Ê˘ÛÈÔÏÔÁÈΤ˜ ÁÈ· ÙËÓ ËÏÈΛ· ÙÔ˘ ·Ó¿ÁΘ) Î·È ¯ÔÚ‹ÁËÛË ÂÓ‰ÔÊϤ‚È·˜ ÊÔ˘ÚÔÛÂÌ›‰Ë˜ (‰fiÛË = 1 mg/kg/24ˆÚÔ) Â› ÙÚÈË̤ÚÔ˘. °ÈÓfiÙ·Ó Î·Ù·ÁÚ·Ê‹ ÙˆÓ ˙ˆÙÈÎÒÓ ÛËÌ›ˆÓ (·Ó¿ 1 ÒÚ· ÙÔ 1Ô 24ˆÚÔ ÓÔÛËÏ›·˜ Î·È ·Ó¿ 4 ÒÚ˜ Ù· ÂfiÌÂÓ· 24ˆÚ·), Ù˘ ˆÚÈ·›·˜ ‰ÈÔ‡ÚËÛ˘ Î·È ÙÔ˘ ÈÛÔ˙˘Á›Ô˘ ÚÔÛÏ·Ì‚·ÓÔ̤ӈÓ-·Ô‚·ÏÏÔÌ¤ÓˆÓ ˘ÁÚÒÓ. ¶Ú·ÁÌ·ÙÔÔÈÔ‡ÓÙ·Ó Î·ıËÌÂÚÈÓfi˜ ÂÚÁ·ÛÙËÚÈ·Îfi˜ ¤ÏÂÁ¯Ô˜ ÌÂ: ÁÂÓÈ΋ ·›Ì·ÙÔ˜, ·¤ÚÈ· ·›Ì·ÙÔ˜, Ô˘Ú›·, ÎÚ·ÙÈÓ›ÓË, Ì˘ÔÛÊ·ÈÚ›ÓË ·›Ì·ÙÔ˜ Î·È Ô‡ÚˆÓ, ·Ï‰ÔÏ¿ÛË, CPK, LDH, SGOT, SGPT, Ô˘ÚÈÎfi Ô͇, Na+, K+, Ca++, P Î·È ÁÂÓÈ΋ Ô‡ÚˆÓ (¶›Ó·Î·˜ 1). ∆Ô ·È‰› ·Ú¤ÌÂÈÓ ηٷÎÂÎÏÈ̤ÓÔ Î·È Û ·ÔÌfiÓˆÛË. √ ·ÛıÂÓ‹˜ ‹Ù·Ó ·‡ÚÂÙÔ˜ Î·È Û ηϋ ÁÂÓÈ΋ ηٿÛÙ·ÛË Î·ıfiÏË ÙË ‰È¿ÚÎÂÈ· Ù˘ ÂÓı‹ÌÂÚ˘ ÓÔÛËÏ›·˜ ÙÔ˘. ¶·ÚÔ˘Û›·Û ÚÔԉ¢ÙÈ΋ ‚ÂÏÙ›ˆÛË Ù˘ Ì˘˚΋˜ ÈÛ¯‡Ô˜ Î·È ‡ÊÂÛË ÙÔ˘ ¿ÏÁÔ˘˜ Ì Ï‹ÚË ˘Ô¯ÒÚËÛË Ì¤¯ÚÈ ÙËÓ ¤ÍÔ‰Ô. ¢ÂÓ ÂÌÊ¿ÓÈÛ ‰È·Ù·Ú·¯‹ Ù˘ ÔÍÂÔ‚·ÛÈ΋˜ ÈÛÔÚÚÔ›·˜ Î·È Ù˘ ÓÂÊÚÈ΋˜ ÏÂÈÙÔ˘ÚÁ›·˜, ÂÓÒ ·Ú·ÙËÚ‹ıËΠÚÔԉ¢ÙÈ΋ ·ÔηٿÛÙ·ÛË ÛÙÔ Ê˘ÛÈÔÏÔÁÈÎfi fiÏˆÓ ÙˆÓ ·ıÔÏÔÁÈÎÒÓ ÂÚÁ·ÛÙËÚÈ·ÎÒÓ Â˘ÚËÌ¿ÙˆÓ.

™˘˙‹ÙËÛË ∏ Ú·‚‰ÔÌ˘fiÏ˘ÛË ·ÔÙÂÏ› ¤Ó· Û¯ÂÙÈο Û¿ÓÈÔ ÓfiÛËÌ· ÛÙ· ·È‰È¿ Î·È ÔÈ ‚È‚ÏÈÔÁÚ·ÊÈΤ˜ ·Ó·ÊÔÚ¤˜ Ô˘ ˘¿Ú¯Ô˘Ó Â›Ó·È ÂÚÈÔÚÈṲ̂Ó˜. ¶ÚfiÎÂÈÙ·È ÁÈ· ¤Ó· ÎÏÈÓÈÎÔÂÚÁ·ÛÙËÚÈ·Îfi Û‡Ó‰ÚÔÌÔ Ô˘ ÂΉËÏÒÓÂÙ·È ÌÂÙ¿ ·fi ηٷÛÙÚÔÊ‹ ÙˆÓ ÁÚ·Ì̈ÙÒÓ Ì˘ÒÓ Î·È ·ÂÏ¢ı¤ÚˆÛË ÛÙËÓ Î˘ÎÏÔÊÔÚ›· ÙÔÍÈÎÒÓ Î˘ÙÙ·ÚÈÎÒÓ ÚÔ˚fiÓÙˆÓ. ∆Ô ÎÂÓÙÚÈÎfi ÁÂÁÔÓfi˜ ÛÙËÓ ·ıÔÁ¤ÓÂÈ· ÙÔ˘ Û˘Ó‰ÚfiÌÔ˘ Â›Ó·È Ë ·‡ÍËÛË Ù˘ Û˘ÁΤÓÙÚˆÛ˘ ÙÔ˘ ÂÓ‰Ô΢ÙÙ¿ÚÈÔ˘ Ca++, Ë ÔÔ›· ÔÊ›ÏÂÙ·È Û ÙÚ·˘Ì·ÙÈÛÌfi Ù˘ ÌÂÌ‚Ú¿Ó˘ ÙÔ˘ Ì˘˚ÎÔ‡ ΢ÙÙ¿ÚÔ˘, ‹/Î·È Û ÂÍ¿ÓÙÏËÛË ÙˆÓ ÂÓ‰Ô΢ÙÙ¿ÚÈˆÓ ·ÔıÂÌ¿ÙˆÓ ∞∆ƒ. √ ηٷÚÚ¿ÎÙ˘ ÙˆÓ ÁÂÁÔÓfiÙˆÓ Ô˘ ·ÎÔÏÔ˘ıÔ‡Ó ¤¯ÂÈ ˆ˜ ·ÔÙ¤ÏÂÛÌ· ÙËÓ ·Ú·ÁˆÁ‹ ÚˆÙÂÔÏ˘ÙÈÎÒÓ ÂÓ˙‡ÌˆÓ Î·È ÂÏ¢ı¤ÚˆÓ ÚÈ˙ÒÓ, Ô˘ ÚÔ¿ÁÔ˘Ó ÙË Û˘Ó¯È˙fiÌÂÓË Î·Ù·ÛÙÚÔÊ‹ ÙˆÓ Ì˘ÈÎÒÓ Î˘ÙÙ¿ÚˆÓ. ∆· ·›ÙÈ· Ù˘ Ú·‚‰ÔÌ˘fiÏ˘Û˘ ‰È·ÎÚ›ÓÔÓÙ·È ·‰Ú¿ ÛÂ Û˘ÁÁÂÓ‹ Î·È Â›ÎÙËÙ· (¶›Ó·Î·˜ 2) (1-3). ∞fi Ù· ¶·È‰È·ÙÚÈ΋ 2008;71:74-78

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·76

76

O. ºÈÏ›Ô˘ Î·È Û˘Ó.

¶›Ó·Î·˜ 2. ∞›ÙÈ· Ú·‚‰ÔÌ˘fiÏ˘Û˘ ™˘ÁÁÂÓ‹ ªÂÙ·‚ÔÏÈο ÓÔÛ‹Ì·Ù·: ·. ∞ÓÂ¿ÚÎÂȘ ÁÏ˘ÎÔÏ˘ÙÈÎÒÓ ÂÓ˙‡ÌˆÓ ‚. ¢È·Ù·Ú·¯¤˜ ÌÂÙ·‚ÔÏÈÛÌÔ‡ ÏÈȉ›ˆÓ ª˘˚Τ˜ ‰˘ÛÙÚÔʛ˜ ÕÏÏ· (ηÎÔ‹ı˘ ˘ÂÚıÂÚÌ›·) ∂›ÎÙËÙ· 1. §ÔÈÌÒÍÂȘ πÔ›: Influenza A-B, Parainfluenza 1-2-3, HIV, Coxsackie, ECHO, EBV, CMV, VZV, HSV µ·ÎÙËÚ›‰È·: Staphylococcus, Streptococcus, E.coli, Shigella, Salmonella spp, Mycoplasma, Legionella, Brucella ª‡ÎËÙ˜: Candida, Aspergillus 2. ∞˘ÍË̤ÓË Ì˘˚΋ ‰Ú·ÛÙËÚÈfiÙËÙ· (¿ıÏËÛË, status epilepticus, Î.¿.)

3. ∞˘ÍË̤ÓË Ì˘˚΋ ηٷÛÙÚÔÊ‹ (ÂÁη‡Ì·Ù·, crush syndrome) 4. ªÂÙ·‚ÔÏÈΤ˜ Î·È ËÏÂÎÙÚÔÏ˘ÙÈΤ˜ ‰È·Ù·Ú·¯¤˜ 5. ™·Î¯·Ú҉˘ ‰È·‚‹Ù˘, ÌË ÎÂÙˆÙÈÎfi ˘ÂÚˆÛ̈ÙÈÎfi ÎÒÌ·, Ì˘ÍÔ›‰ËÌ·, ˘ÔÓ·ÙÚÈ·ÈÌ›·, ˘ÔηÏÈ·ÈÌ›·, ˘ÔʈÛÊ·Ù·ÈÌ›· 6. º¿Ú̷η, ÙÔÍÈΤ˜ Î·È Ó·ÚΈÙÈΤ˜ Ô˘Û›Â˜ (·ÓÙÈÈÛÙ·ÌÈÓÈο, ·Ó·ÈÛıËÙÈο, ·ÏÎÔfiÏ, ‰‹ÁÌ·Ù· ÊȉÈÒÓ, ËÚˆ›ÓË, ·ÌÊÂٷ̛Ә) 7. πÛ¯·ÈÌ›· Ì˘˚ÎÒÓ Î˘ÙÙ¿ÚˆÓ (ıÚÔÌ‚ÒÛÂȘ, ‰ÚÂ·ÓÔ΢ÙÙ·ÚÈ΋ ÎÚ›ÛË) 8. ºÏÂÁÌÔÓÒ‰ÂȘ Ì˘Ô¿ıÂȘ (ÔÏ˘ÔÌ˘ÔÛ›Ùȉ·, ‰ÂÚÌ·ÙÔÌ˘ÔÛ›Ùȉ·)

Û˘ÁÁÂÓ‹ ·›ÙÈ· Ù· ÛËÌ·ÓÙÈÎfiÙÂÚ· Â›Ó·È Ù· ÌÂÙ·‚ÔÏÈο ÓÔÛ‹Ì·Ù· Î·È Ë Î·ÎÔ‹ı˘ ˘ÂÚıÂÚÌ›·. ∞fi Ù· Â›ÎÙËÙ·, ÙË ÛÔ˘‰·ÈfiÙÂÚË ı¤ÛË ÛÙËÓ ·È‰È΋ ËÏÈΛ· η٤¯Ô˘Ó ÔÈ ÏÔÈÌÒÍÂȘ Î·È ·ÎÔÏÔ˘ıÔ‡Ó Î·Ù·ÛÙ¿ÛÂȘ ·˘ÍË̤Ó˘ Ì˘˚΋˜ ‰Ú·ÛÙËÚÈfiÙËÙ·˜ Î·È Ì˘˚΋˜ ηٷÛÙÚÔÊ‹˜, Ù· ÂÁη‡Ì·Ù·, ÌÂÙ·‚ÔÏÈΤ˜ Î·È ËÏÂÎÙÚÔÏ˘ÙÈΤ˜ ‰È·Ù·Ú·¯¤˜, Ë ¯Ú‹ÛË ÙÔÍÈÎÒÓ Ô˘ÛÈÒÓ Î·È Ê·ÚÌ¿ÎˆÓ Î·È ÔÈ ÊÏÂÁÌÔÓÒ‰ÂȘ Ì˘Ô¿ıÂȘ. ∞Ó·ÊÔÚÈο Ì ÙÔ˘˜ ÏÔÈÌÒ‰ÂȘ ·Ú¿ÁÔÓÙ˜, ¤Ó· Ï‹ıÔ˜ ÈÔÁÂÓÒÓ, ÌÈÎÚÔ‚È·ÎÒÓ Î·È Ì˘ÎËÙÈ·ÛÈÎÒÓ ·Ú·ÁfiÓÙˆÓ ÌÔÚÔ‡Ó Ó· ÏÂÈÙÔ˘ÚÁ‹ÛÔ˘Ó ˆ˜ ·ÈÙÈÔÏÔÁÈÎfi ˘fiÛÙڈ̷, Ì ÙȘ ÈÔÁÂÓ›˜ ÏÔÈÌÒÍÂȘ Ó· ·ÔÙÂÏÔ‡Ó ÙÔ Û˘¯ÓfiÙÂÚÔ ·›ÙÈÔ (¶›Ó·Î·˜ 2) (1,2,4,5,8). ™ÙË ÌÂÁ·Ï‡ÙÂÚË ·Ó·‰ÚÔÌÈ΋ ÌÂϤÙË Ô˘ ¤¯ÂÈ ‰ËÌÔÛÈ¢Ù› ̤¯ÚÈ Û‹ÌÂÚ·, ‰È·ÈÛÙÒıËΠfiÙÈ ˘¿Ú¯ÂÈ ‰ÈÎfiÚ˘ÊË Î·Ù·ÓÔÌ‹ ÙˆÓ ·ÈÙ›ˆÓ Ú·‚‰ÔÌ˘fiÏ˘Û˘ ÛÙËÓ ·È‰È΋ ËÏÈΛ· (3). ∂ȉÈÎfiÙÂÚ·, ÔÈ ÈÔ› ·ÔÙÂÏÔ‡Ó ÙÔ ÚˆÙ·Ú¯ÈÎfi ·›ÙÈÔ ÛÙȘ ËÏÈ˘ 0-9 ¯ÚÔÓÒÓ, ÂÓÒ Û ÌÂÁ·Ï‡ÙÂÚ· ·È‰È¿ Ù· ÙÚ·‡Ì·Ù· Î·È Ë ¯Ú‹ÛË ÙÔÍÈÎÒÓ Ô˘ÛÈÒÓ Â›Ó·È Ù· Û˘ÓËı¤ÛÙÂÚ· ·›ÙÈ·. ∆· ‰Â‰Ô̤ӷ Ô˘ ˘¿Ú¯Ô˘Ó Û¯ÂÙÈο Ì ÙË Û˘¯ÓfiÙËÙ· ÂΉ‹ÏˆÛ˘ Ú·‚‰ÔÌ˘fiÏ˘Û˘ ÛÙËÓ ÔÚ›· Ïԛ̈͢ ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ ÛÙ· ·È‰È¿ Â›Ó·È ÂÚÈÔÚÈṲ̂ӷ. ∞ӷʤÚÂÙ·È fiÙÈ ÙÔ 42% ÙˆÓ ÈÔÁÂÓÒÓ ·ÈÙ›ˆÓ Ú·‚‰ÔÌ˘fiÏ˘Û˘ Û ÂÓ‹ÏÈΘ ÔÊ›ÏÂÙ·È ÛÙÔÓ Èfi Paediatriki 2008;71:74-78

Ù˘ ÁÚ›˘, ÂÓÒ Ë Û˘ÌÌÂÙÔ¯‹ ÙÔ˘ ÛÙËÓ ·È‰È΋ ËÏÈΛ· ·ÔÙÂÏ› ÙÔÓ ·ÈÙÈÔÏÔÁÈÎfi ·Ú¿ÁÔÓÙ· ÌfiÓÔ ÛÙÔ 8% (2,3). ™Â ÂÚÁ·Û›· ÙˆÓ Agyeman Î·È Û˘Ó., Ô˘ ·ÊÔÚÔ‡Û 311 ·È‰È¿ ÌÂ Ì˘ÔÛ›Ùȉ· ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘, ‰È·ÈÛÙÒıËΠfiÙÈ ÌfiÏȘ ÙÔ 3% ÂΉ‹ÏˆÛ ڷ‚‰ÔÌ˘fiÏ˘ÛË (6). º·›ÓÂÙ·È, ÏÔÈfiÓ, fiÙÈ ÛÙ· ·È‰È¿ Ë ÂÌÊ¿ÓÈÛË Ú·‚‰ÔÌ˘fiÏ˘Û˘ ÛÙ· Ï·›ÛÈ· ÁÚÈÒ‰Ô˘˜ Û˘Ó‰ÚÔÌ‹˜ Â›Ó·È Û·ÓÈfiÙÂÚË Û˘ÁÎÚÈÙÈο Ì ÙÔ˘˜ ÂÓ‹ÏÈΘ, ÂÓÒ ÛÙËÓ ÎÏÈÓÈ΋ ÔÚ›· Ù˘ ÓfiÛÔ˘ Û˘Ì‚¿ÏÏÂÈ Î·È Ë Ê‡ÛË ÙˆÓ Î˘ÎÏÔÊÔÚÔ‡ÓÙˆÓ ÛÙÂϯÒÓ ÙÔ˘ ÈÔ‡ ηٿ ÙË ‰È¿ÚÎÂÈ· ÌÈ·˜ ÂȉËÌ›·˜. √ Ù‡Ô˜ ∞ ÙÔ˘ ÈÔ‡ ÚÔηÏ› Û˘¯ÓfiÙÂÚ· Ú·‚‰ÔÌ˘fiÏ˘ÛË, ÂÓÒ Ô Ù‡Ô˜ µ Ì˘ÔÛ›Ùȉ· (6,7). ∏ Ú·‚‰ÔÌ˘fiÏ˘ÛË ÂÌÊ·Ó›˙ÂÙ·È Û˘Ó‹ıˆ˜ Û ·È‰È¿ Û¯ÔÏÈ΋˜ ËÏÈΛ·˜ Î·È ÌÔÚ› Ó· ÂΉËψı› Ì ÙËÓ ¤Ó·ÚÍË ÙˆÓ Û˘ÌÙˆÌ¿ÙˆÓ Ù˘ ÁÚ›˘, ÛÙËÓ ÔÚ›· Ù˘ ‹ ·ÎfiÌË Î·È ÌÂÙ¿ ÙËÓ ·Ô‰ÚÔÌ‹ Ù˘ (8). ™ÙËÓ ÂÚ›ÙˆÛË Ô˘ ÂÚÈÁÚ¿ÊÂÙ·È, Ô ·ÛıÂÓ‹˜ ÓfiÛËÛ ÛÙË Ì¤ÛË ÙÔ˘ ¯ÂÈÌÒÓ·, ÂÔ¯‹ Ô˘ ‹‰Ë ›¯Â ·Ú¯›ÛÂÈ Ë ÂȉËÌÈ΋ ¤Í·ÚÛË Ù˘ ÓfiÛÔ˘ Î·È ·ÚÔ˘Û›·ÛÂ Ì˘·ÏÁ›Â˜ ÙËÓ ÙÚ›ÙË Ë̤ڷ ÂÌÊ¿ÓÈÛ˘ Ù˘ ÁÚÈÒ‰Ô˘˜ Û˘Ó‰ÚÔÌ‹˜. ¶ÚÔÛ‚¿ÏÏÔÓÙ·È Ôχ Û˘¯Ó¿ ÔÈ Á·ÛÙÚÔÎÓ‹ÌÈÔÈ Ì‡Â˜ (70%) Î·È ·ÎÔÏÔ˘ıÔ‡Ó ÔÈ Ì‡Â˜ Ù˘ ˆÌÈ΋˜ ˙ÒÓ˘ Î·È ÙˆÓ ¿Óˆ ¿ÎÚˆÓ (20%) Î·È ÔÈ ÔÛÊ˘˚ÎÔ› (5%) (6). ∂ÎÙfi˜ ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘ Ô˘ ·ÔÙÂÏ› ÙÔ Û˘¯ÓfiÙÂÚÔ ·›ÙÈÔ ÌÂÙ·ÏÔÈÌÒ‰Ô˘˜ Ú·‚‰ÔÌ˘fiÏ˘Û˘ ÛÙ· ·È‰È¿, ˘¿Ú¯ÂÈ ÛÙË ‚È‚ÏÈÔÁÚ·Ê›· ÛÔÚ·‰È΋ ηٷÁÚ·Ê‹ ÂÚÈÛÙ·ÙÈÎÒÓ Ú·‚‰ÔÌ˘fiÏ˘Û˘ Î·È ·fi ¿ÏÏ· ÏÔÈÌÒ‰Ë ·›ÙÈ· (¶›Ó·Î·˜ 2). ™˘¯ÓfiÙÂÚ· ·Ó·Ê¤ÚÔÓÙ·È Ô Èfi˜ Ù˘ ·Ú·ÁÚ›˘, Ô Coxsackie B, Ô VZV, Ô HIV, o EBV, Ô Èfi˜ ROTA Î·È ÙÔ Ì˘ÎfiÏ·ÛÌ·. ∞ÓÂÍ¿ÚÙËÙ· ·fi ÙÔ ·›ÙÈÔ Ô˘ ÙËÓ ÚÔοÏÂÛÂ, Ë Ú·‚‰ÔÌ˘fiÏ˘ÛË ÌÔÚ› Ó· ÂΉËψı› ÎÏÈÓÈο ›Ù Ì ÙËÓ “ÎÏ·ÛÈ΋ ÙÚÈ¿‰·” Û˘ÌÙˆÌ¿ÙˆÓ (Ì˘·ÏÁ›Â˜, Ì˘˚΋ ·‰˘Ó·Ì›·, ίڈṲ̂ӷ Ô‡Ú·), Ô˘ fï˜ Ë Û˘¯ÓfiÙËÙ· ÂÌÊ¿ÓÈÛ‹˜ Ù˘ Â›Ó·È Ôχ ÌÈÎÚ‹ (ÌfiÏȘ 0,5%), ›Ù Ì ¿Ù˘Ë Î·È ·Ì‚Ï˯ڋ Û˘Ìو̷ÙÔÏÔÁ›·. ∂ȉÈÎfiÙÂÚ·, Ë ÓfiÛÔ˜ ÌÔÚ› Ó· ÚÔ‚¿ÏÏÂÈ ÙfiÛÔ Ì ÙÔÈο Û˘ÌÙÒÌ·Ù· Î·È ÛËÌ›·, fiˆ˜ Ì˘˚Τ˜ Û˘Û¿ÛÂȘ, ÌÂȈ̤ӷ ‹ ηٷÚÁË̤ӷ ÙÂÓfiÓÙÈ· ·ÓÙ·Ó·ÎÏ·ÛÙÈο, fiÛÔ Î·È ÌÂ Û˘ÛÙËÌ·ÙÈο, fiˆ˜ ˘ÚÂÙfi, ηÎÔ˘¯›·, Ó·˘Ù›·, Â̤ÙÔ˘˜. √È ÌÂϤÙ˜ ÂȂ‚·ÈÒÓÔ˘Ó fiÙÈ Ì˘·ÏÁ›Â˜ ÂÌÊ·Ó›˙ÂÈ ÂÚ›Ô˘ ÙÔ 45% ÙˆÓ ·ÛıÂÓÒÓ, Ì˘˚΋ ·‰˘Ó·Ì›· ÙÔ 38%, ÂÓÒ ˘¤Ú¯ÚÔ· Ô‡Ú· ‰È·ÈÛÙÒÓÔÓÙ·È ÌfiÏȘ ÛÙÔ 3,6% (3). ∂Ô̤ӈ˜, ··ÈÙÂ›Ù·È ˘„ËÏÔ‡ ‚·ıÌÔ‡ ˘Ô„›· ÁÈ· Ó· ÙÂı› Ë ‰È¿ÁÓˆÛË. ∂ÚÁ·ÛÙËÚȷο, Ë Ú·‚‰ÔÌ˘fiÏ˘ÛË ÔÚ›˙ÂÙ·È ˆ˜ ·‡ÍËÛË Ù˘ ÙÈÌ‹˜ Ù˘ CPK (ÎÚ·ÙÈÓÔʈÛÊÔÎÈÓ¿ÛË) ¿Óˆ ·fi ÙÔ 5Ï¿ÛÈÔ Ù˘ Ê˘ÛÈÔÏÔÁÈ΋˜ ÁÈ· ÙËÓ ËÏÈΛ· ÙÔ˘ ·ÛıÂÓÔ‡˜ ÙÈÌ‹˜, ÂÓÒ ÙÔ ÎÏ¿ÛÌ· CPK-MB Ú¤ÂÈ Ó· Â›Ó·È <5% Ù˘ ÔÏÈ΋˜ ÙÈÌ‹˜. ∞˘ÍË̤Ó˜,

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·77

77

ƒ·‚‰ÔÌ˘fiÏ˘ÛË ÌÂÙ¿ ·fi influenza ∞

·ÏÏ¿ ηÙÒÙÂÚ˜ ·fi ÙÔ ÚÔ·Ó·ÊÂÚı¤Ó fiÚÈÔ, ÙÈ̤˜, Ì ›‰È· ‹ ·ÚfiÌÔÈ· ÎÏÈÓÈ΋ ÂÈÎfiÓ·, Û˘ÓÈÛÙÔ‡Ó Ì˘ÔÛ›Ùȉ· (3,14). ∏ CPK ·ÔÙÂÏ› ¤Ó· ÁÚ‹ÁÔÚÔ Î·È ·ÍÈfiÈÛÙÔ ‰Â›ÎÙË ÙfiÛÔ ÁÈ· ÙË ‰È¿ÁÓˆÛË Ù˘ ÓfiÛÔ˘ (¢·ÈÛıËÛ›· 100%), fiÛÔ Î·È ÁÈ· ÙËÓ ·Ú·ÎÔÏÔ‡ıËÛË Ù˘ ÔÚ›·˜ Ù˘. ™˘Ó‹ıˆ˜, ÊÙ¿ÓÂÈ ÙË Ì¤ÁÈÛÙË ÙÈÌ‹ Ù˘ ÛÙÔ ÚÒÙÔ 24ˆÚÔ ·fi ÙËÓ ¤Ó·ÚÍË ÙˆÓ Û˘ÌÙˆÌ¿ÙˆÓ Î·È ÌÂÈÒÓÂÙ·È Î·ıËÌÂÚÈÓ¿ ηٿ 40% ÂÚ›Ô˘. ¢È·Ù‹ÚËÛË ‹ ·‡ÍËÛË ÙˆÓ ÂÈ¤‰ˆÓ Ù˘ ÛÙÔÓ ÔÚfi ‰ËÏÒÓÂÈ Û˘Ó¯È˙fiÌÂÓË Ì˘˚΋ ηٷÛÙÚÔÊ‹ ‹ Û‡Ó‰ÚÔÌÔ ‰È·ÌÂÚÈÛÌ·ÙÔÔ›ËÛ˘ (ÌÂÈÒÓÂÙ·È Ë ›ÂÛË ¿Ú‰Â˘Û˘ ÙˆÓ Ì˘ÈÎÒÓ ÈÓÒÓ, Ì ·ÔÙ¤ÏÂÛÌ· ˘ÔÍ·ÈÌ›· Î·È ÈÛÙÈ΋ Ó¤ÎÚˆÛË). ∆· Û˘ÓÔ‰¿ Û˘ÌÙÒÌ·Ù· Ô˘ ‰È·ÈÛÙÒÓÔÓÙ·È ·ÊÔÚÔ‡Ó: Ì˘ÔÛÊ·ÈÚÈÓÔ˘Ú›· Î·È Ì˘ÔÛÊ·ÈÚÈÓ·ÈÌ›·, ·‡ÍËÛË Ù˘ ·Ï‰ÔÏ¿Û˘, Ù˘ LDH Î·È ÙˆÓ ÙÚ·ÓÛ·ÌÈÓ·ÛÒÓ, ˘ÂÚÔ˘Úȯ·ÈÌ›·, ˘ÂÚηÏÈ·ÈÌ›· Î·È ·‡ÍËÛË Ù˘ Ô˘Ú›·˜ Î·È Ù˘ ÎÚ·ÙÈÓ›Ó˘. ∞ÎfiÌË, ÌÔÚ› Ó· ÚÔÎÏËıÔ‡Ó ˘·Û‚ÂÛÙÈ·ÈÌ›· Î·È ˘ÂÚʈÛÊ·Ù·ÈÌ›·, ÔÈ Ôԛ˜ ‰ÂÓ ¯Ú‹˙Ô˘Ó ‰ÈfiÚıˆÛ˘, ·Ú¿ ÌfiÓÔ Â› Û˘Ìو̿وÓ. ™ÙË ÁÂÓÈ΋ Ô‡ÚˆÓ ·ÓȯÓ‡ÂÙ·È ·ÈÌÔÛÊ·ÈÚ›ÓË ¯ˆÚ›˜ ÂÚ˘ıÚ¿ ·ÈÌÔÛÊ·›ÚÈ·, ÂÓÒ ÔÏϤ˜ ÊÔÚ¤˜ ÛÙÔ ›˙ËÌ· ÙˆÓ Ô‡ÚˆÓ ÂÚȤ¯ÔÓÙ·È ÔÈ ¯·Ú·ÎÙËÚÈÛÙÈÎÔ› ηʤ Ï·ÛÒ‰ÂȘ ·ÏÈÓ‰ÚÔÈ (muddy brown casts). ∏ ÔÚ›· Ù˘ ÌÂÙ·ÏÔÈÌÒ‰Ô˘˜ Ú·‚‰ÔÌ˘fiÏ˘Û˘ Â›Ó·È Û˘Ó‹ıˆ˜ ηÏÔ‹ı˘, Â¿Ó ·ÓÙÈÌÂÙˆÈÛÙ› ¤ÁηÈÚ· Î·È ÂÈıÂÙÈο, Î·È Ë ·ÔηٿÛÙ·ÛË ÛÙÔ Ê˘ÛÈÔÏÔÁÈÎfi ÌÔÚ› Ó· Á›ÓÂÈ ÂÓÙfi˜ ÔÏ›ÁˆÓ ËÌÂÚÒÓ, fiˆ˜ Û˘Ó¤‚Ë ÛÙÔÓ ·ÛıÂÓ‹ Ô˘ ÂÚÈÁÚ¿ÊÂÙ·È, ·ÏÏ¿ ÌÔÚ› Ó· ÎÚ·Ù‹ÛÂÈ Î·È ¤ˆ˜ 6 ‚‰ÔÌ¿‰Â˜ (8). ™ÙȘ ÂÈÏÔΤ˜ ÂÚÈÏ·Ì‚¿ÓÔÓÙ·È Ë ÔÍ›· ÓÂÊÚÈ΋ ·ÓÂ¿ÚÎÂÈ·, Ô˘ Â›Ó·È Ë ÛÔ‚·ÚfiÙÂÚË Î·È ÈÔ ÂÈΛӉ˘ÓË, Ë ˘ÔÔÁηÈÌ›·, Ë ÌÂÙ·‚ÔÏÈ΋ ÔͤˆÛË, ÔÈ ËÏÂÎÙÚÔηډÈÔÁÚ·ÊÈΤ˜ ·ÏÏÔÈÒÛÂȘ, Ë ‰È¿¯˘ÙË ÂÓ‰·ÁÁÂȷ΋ ‹ÍË Î·È ÙÔ Û‡Ó‰ÚÔÌÔ ‰È·ÌÂÚÈÛÌ·ÙÔÔ›ËÛ˘. ∏ Ú·‚‰ÔÌ˘fiÏ˘ÛË Ô˘ ÔÊ›ÏÂÙ·È ÛÙÔÓ Èfi Ù˘ ÁÚ›˘ Â›Ó·È ‰˘Ó·ÙfiÓ Ó· ÂÈϷΛ ·fi ÔÍ›· ÓÂÊÚÈ΋ ·ÓÂ¿ÚÎÂÈ·, Û ÔÛÔÛÙfi Ô˘ Î˘Ì·›ÓÂÙ·È ÛÙȘ ‰È¿ÊÔÚ˜ ÌÂϤÙ˜ ·fi 2,2% ¤ˆ˜ 80% (6). ŸÌˆ˜, Ë ÂÈÏÔ΋ ·˘Ù‹ ۯ‰fiÓ ÔÙ¤ ‰ÂÓ ÌÂÙ·›ÙÂÈ Û ¯ÚÔÓÈfiÙËÙ· (11,12). ∏ ‰È·Ù·Ú·¯‹ Ù˘ ÓÂÊÚÈ΋˜ ÏÂÈÙÔ˘ÚÁ›·˜ Û˘Ì‚·›ÓÂÈ Î˘Ú›ˆ˜ Û ·ÛıÂÓ›˜ Ô˘ ÛÙËÓ ÔÚ›· Ù˘ Ïԛ̈͢ ÂΉËÏÒÓÔ˘Ó Û‹„Ë ‹ Û‡Ó‰ÚÔÌÔ ¤ÎÙˆÛ˘ ÔÏÏ·ÏÒÓ ÔÚÁ¿ÓˆÓ, ÂÓÒ ‰ÂÓ Ê·›ÓÂÙ·È Ó· ˘¿Ú¯ÂÈ ·¢ı›·˜ ÚÔÛ‚ÔÏ‹ ÙÔ˘ ÓÂÊÚÈÎÔ‡ ΢ÙÙ¿ÚÔ˘ ·fi ÙÔÓ Èfi (11). ∏ ıÂÚ·›· Ù˘ Ú·‚‰ÔÌ˘fiÏ˘Û˘, ·ÓÂÍ¿ÚÙËÙ· ·fi ÙËÓ ·ÈÙÈÔÏÔÁ›· Ù˘, ÛÙËÚ›˙ÂÙ·È ÛÙËÓ ÂÈıÂÙÈ΋ ÂÓ˘‰¿ÙˆÛË ˘fi Û˘Ó¯‹ ·Ú·ÎÔÏÔ‡ıËÛË ÙˆÓ ˙ˆÙÈÎÒÓ ÛËÌ›ˆÓ Î·È ÛÙËÓ ·˘ÍË̤ÓË ‰ÈÔ‡ÚËÛË, Ì ÛÙfi¯Ô ÙË ‰È·Ù‹ÚËÛË ÈηÓÔÔÈËÙÈ΋˜ ÓÂÊÚÈ΋˜ ÏÂÈÙÔ˘ÚÁ›·˜. ÃÔÚËÁÔ‡ÓÙ·È ÈÛfiÙÔÓ· ‰È·Ï‡Ì·Ù· ¯ÏˆÚÈÔ‡¯Ô˘ Ó·ÙÚ›Ô˘ Û ÔÛfiÙËÙ· ‰ÈÏ¿ÛÈ· ‹/Î·È ÙÚÈÏ¿ÛÈ· ÙˆÓ

ËÌÂÚ‹ÛÈˆÓ ·Ó·ÁÎÒÓ ÙÔ˘ ·ÛıÂÓÔ‡˜, ÒÛÙ ӷ ÂÈÙ¢¯ı› ÈηÓÔÔÈËÙÈ΋ ¤ÎÙ˘ÍË ÙÔ˘ ÂÍˆÎ˘ÙÙ¿ÚÈÔ˘ ¯ÒÚÔ˘. ∞·Ú·›ÙËÙË Â›Ó·È, Â›Û˘, Ë Ù·ÎÙÈ΋ (·Ó¿ 2 ÒÚ˜) ·Ú·ÎÔÏÔ‡ıËÛË ÙˆÓ ËÏÂÎÙÚÔÏ˘ÙÒÓ, ÙÔ˘ pH Î·È ÙˆÓ ‰ÈÙÙ·ÓıÚ·ÎÈÎÒÓ ÙÔ˘ ·›Ì·ÙÔ˜, ηıÒ˜ Î·È ÙÔ˘ pH ÙˆÓ Ô‡ÚˆÓ, fiˆ˜ Î·È Ë ÙÔÔı¤ÙËÛË Ô˘ÚÔηıÂÙ‹Ú·, Ì ÛÙfi¯Ô ÙËÓ Î·Ù·ÁÚ·Ê‹ Ù˘ ˆÚÈ·›·˜ ‰ÈÔ‡ÚËÛ˘. ™Â Û˘Ó˘¿Ú¯Ô˘Û· ÌÂÙ·‚ÔÏÈ΋ ÔͤˆÛË, ¯ÔÚËÁÔ‡ÓÙ·È Ì ÚÔÛÔ¯‹ i.v. ‰ÈÙÙ·ÓıÚ·ÎÈο, ÂÓÒ ÚÔÙ›ÓÂÙ·È Î·È ·ÏηÏÔÔ›ËÛË ÙˆÓ Ô‡ÚˆÓ (ÛÙfi¯Ô˜ pH Ô‡ÚˆÓ >6,5), ÂÓÒ Â› ÔÏÈÁÔ˘Ú›·˜, ¯ÔÚËÁÂ›Ù·È ÊÔ˘ÚÔÛÂÌ›‰Ë. ™Â ÂÚ›ÙˆÛË ÂÌÊ¿ÓÈÛ˘ ÔÍ›·˜ ÓÂÊÚÈ΋˜ ·ÓÂ¿ÚÎÂÈ·˜ Ô˘ ‰ÂÓ ·ÓÙ·ÔÎÚ›ÓÂÙ·È ÛÙ· ‰ÈÔ˘ÚËÙÈο, Â›ÌÔÓ˘ ˘ÂÚηÏÈ·ÈÌ›·˜ ‹/Î·È ÌÂÙ·‚ÔÏÈ΋˜ ÔͤˆÛ˘, Ó¢ÌÔÓÈÎÔ‡ Ôȉ‹Ì·ÙÔ˜ ‹ Û˘ÌÊÔÚËÙÈ΋˜ ηډȷ΋˜ ·ÓÂ¿ÚÎÂÈ·˜, Ô ·ÛıÂÓ‹˜ ˘Ô‚¿ÏÏÂÙ·È Û ıÂÚ·›· ÓÂÊÚÈ΋˜ ˘ÔηٿÛÙ·Û˘ Ì ‰È¿ÊÔÚ˜ ÌÂıfi‰Ô˘˜ Â͈ÓÂÊÚÈ΋˜ οı·ÚÛ˘, ·Ó¿ÏÔÁ· Ì ÙËÓ ËÏÈΛ· Î·È ÙËÓ ÎÏÈÓÈ΋ ÙÔ˘ ÂÈÎfiÓ· (ÂÚÈÙÔÓ·˚΋ οı·ÚÛË, Û˘Ó¯‹ ·ÈÌԉȋıËÛË, ·ÈÌÔοı·ÚÛË) (9,13). ™˘ÌÂÚ·ÛÌ·ÙÈο, Ë Ú·‚‰ÔÌ˘fiÏ˘ÛË Â›Ó·È ÌÈ· Û¯ÂÙÈο Û¿ÓÈ· ÂÈÏÔ΋ Ù˘ Ïԛ̈͢ ·fi ÙÔÓ Èfi Ù˘ ÁÚ›˘, Ë ÔÔ›· fï˜ ··ÈÙ› ˘„ËÏÔ‡ ‚·ıÌÔ‡ ˘Ô„›· ÏfiÁˆ Ù˘ ¿Ù˘˘ ÎÏÈÓÈ΋˜ ÚÔ‚ÔÏ‹˜. ∏ ÓfiÛÔ˜ ¤¯ÂÈ Û˘Ó‹ıˆ˜ ηÏÔ‹ıË ÔÚ›· ÛÙ· ·È‰È¿, ·ÏÏ¿ ÌÔÚ› Ó· ÚÔηϤÛÂÈ ÛÔ‚·Ú¤˜ Î·È Û οÔȘ ÂÚÈÙÒÛÂȘ ı·Ó·ÙËÊfiÚ˜ ÂÈÏÔΤ˜, fiˆ˜ ÔÍ›· ÓÂÊÚÈ΋ ·ÓÂ¿ÚÎÂÈ· Î·È ‰È¿¯˘ÙË ÂÓ‰·ÁÁÂȷ΋ ‹ÍË.

µÈ‚ÏÈÔÁÚ·Ê›· 1. Poels PJ, Gabreëls FJ. Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 1993;95:175-192.

2. Singh U, Scheld WM. Infectious etiologies of rhabdomyolysis: three case reports and review. Clin Infect Dis 1996;22:642-649.

3. Mannix R, Tan ML, Wright R, Baskin M. Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics 2006;118:2119-2125.

4. Watemberg N, Leshner RL, Armstrong BA, Lerman-Sagie T. Acute pediatric rhabdomyolysis. J Child Neurol 2000;15:222-227.

5. Hue V, Martinot A, Fourier C, Cremer R, Leteurtre S, Leclerc F. Acute rhabdomyolysis in the child. Arch Pediatr 1998;5:887-895.

6. Agyeman P, Duppenthaler A, Heininger U, Aebi C. Influenza-associated myositis in children. Infection 2004;32:199-203.

7. Hu JJ, Kao CL, Lee PI, Chen CM, Lee CY, Lu CY, Huang LM. Clinical features of influenza A and B in children and association with myositis. J Microbiol Immunol Infect 2004;37:95-98.

8. Mackay MT, Kornberg AJ, Shield LK, Dennett X. Benign acute childhood myositis: laboratory and clinical features.

Neurology 1999;53:2127-2131.

9. Berger RP, Wadowksy RM. Rhabdomyolysis associated with infection by Mycoplasma pneumoniae: a case report.

Pediatrics 2000;105:433-436. ¶·È‰È·ÙÚÈ΋ 2008;71:74-78

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·78

78

O. ºÈÏ›Ô˘ Î·È Û˘Ó.

10. Watanabe T. Rhabdomyolysis and acute renal failure in children. Pediatr Nephrol 2001;16:1072-1075.

11. Watanabe T, Yoshikawa H, Abe Y, Yamazaki S, Uehara Y, Abe T. Renal involvement in children with influenza A virus infection. Pediatr Nephrol 2003;18:541-544.

12. ∞be M, Higuchi T, Okada K, Kaizu K, Matsumoto K. Clinical study of influenza-associated rhabdomyolysis with acute renal failure. Clin Nephrol 2006;66:166-170.

Dariusz Tulik, 15 ÂÙÒÓ, ¶Ôψӛ· ¶·È‰› Ì ÌÂÚÈ΋ fiÚ·ÛË “∆· Ù˘ÊÏ¿ ·È‰È¿ ˙ˆÁÚ·Ê›˙Ô˘Ó”, ÕÓÓ· §·Ô˘Ù¿ÚË°ÎÚÈÙ˙¿Ï·, ∞ı‹Ó· 2006

Dariusz Tulik, 15 years old, Poland Partially blind child “Blind children paint”, Anna Laoutari-Gritzala, Athens 2006

Paediatriki 2008;71:74-78

13. Wakabayashi Y, Nakano T, Kikuno T, Ohwada T, Kikawada R. Massive rhabdomyolysis associated with influenza A infection. Internal Med 1994;33:450-453.

14. Muscal E, de Guzman MM, Wilson R, Shah BR. Rhabdomyolysis. eMedicine [Internet]. 2007 Apr: Webpage: http://www.emedicine.com/ped/topic2003.htm.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·79

∫§π¡π∫√ ∫√Àπ∑

79

∞. ™·‚‚›‰Ô˘1, °. ªÚÈ·ÛÔ‡Ï˘2, ª. ƒ·˚Û¿ÎË3, Õ. ª. ™·Ó¿ÎË2, ¡. º˘ÙÚÔÏ¿ÎË2, ∂. °·Ï·Ó¿Î˘1, ª. ∫·ÏÌ·ÓÙ‹1 ∞ÁfiÚÈ 7 ÂÙÒÓ ‰È·ÎÔÌ›ÛıËΠÛÙË ªÔÓ¿‰· ∂ÓÙ·ÙÈ΋˜ £ÂÚ·›·˜ Ì ˘ÚÂÙfi, ÎÂÊ·Ï·ÏÁ›· Î·È Â̤ÙÔ˘˜ ·fi 12ÒÚÔ˘. ∫·Ù¿ ÙËÓ ·ÓÙÈÎÂÈÌÂÓÈ΋ ÂͤٷÛË ÂÈÛfi‰Ô˘, ÙÔ ·È‰› ‹Ù·Ó ÏËı·ÚÁÈÎfi, Ì Îϛ̷η °Ï·ÛÎ҂˘ 9/15 Î·È Ì ·˘¯ÂÓÈ΋ ‰˘Ûη̄›·. √ ÂÚÁ·ÛÙËÚÈ·Îfi˜ ¤ÏÂÁ¯Ô˜ ÂÈÛfi‰Ô˘ ¤‰ÂÈÍ ÏÂ˘Î¿ ·ÈÌÔÛÊ·›ÚÈ· 23.000/Ìl Ì 92% ÔÏ˘ÌÔÚÊÔ‡ÚËÓ·, ·ÈÌÔÛÊ·ÈÚ›ÓË 13,3 gr/dl, ·ÈÌÔÂÙ¿ÏÈ· 154.000/Ìl, C ·ÓÙȉÚÒÛ· ÚˆÙÂ˚ÓË 18 mg/dl, ¯ˆÚ›˜ ËÏÂÎÙÚÔÏ˘ÙÈΤ˜ ‰È·Ù·Ú·¯¤˜ Î·È ¯ˆÚ›˜ ‰È·Ù·Ú·¯¤˜ ·fi ÙË ÓÂÊÚÈ΋ Î·È Ë·ÙÈ΋ ÏÂÈÙÔ˘ÚÁ›·. ∏ ÔÛÊ˘ÔÓˆÙÈ·›· ·Ú·Î¤ÓÙËÛË ¤‰ÂÈÍ 900 ·ÙÙ·Ú·/Ìl (51% Ô˘‰ÂÙÂÚfiÊÈÏ· Î·È 15% ÏÂÌÊÔ·ÙÙ·Ú· Î·È Ù· ˘fiÏÔÈ· ‹Ù·Ó ÌÔÓÔ‡ÚËÓ· ‹ ÌË ·Ó·ÁÓˆÚ›ÛÈÌ·), ÚˆÙ½ÓË 128 mg/dl Î·È ÁÏ˘Îfi˙Ë 67 mg/dl. √ ·ÛıÂÓ‹˜ ‰È·ÛˆÏËÓÒıËÎÂ

A

B

Î·È Ù¤ıËΠ۠ÂÌÂÈÚÈ΋ ·ÁˆÁ‹ Ì ÎÂÊÙÚÈ·ÍfiÓË, ‚·ÓÎÔÌ˘Î›ÓË, ·Î˘ÎÏÔ‚›ÚË Î·È ‰ÂÍ·ÌÂı·˙fiÓË. ŒÁÈÓ ̷ÁÓËÙÈ΋ ÙÔÌÔÁÚ·Ê›· Ì ·ÎÔÏÔ˘ı›Â˜ ‰È¿¯˘Û˘ (∂ÈÎfiÓ˜ 1∞, 1µ, 1°) Î·È Ì ‚¿ÛË Ù· Â˘Ú‹Ì·Ù¿ Ù˘ ·ÎÔÏÔ‡ıËÛÂ Î·È Ì·ÁÓËÙÈ΋ ÊÏ‚ÔÁÚ·Ê›· (∂ÈÎfiÓ· 2).

1 ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋ 2 ªÔÓ¿‰· ∂ÓÙ·ÙÈ΋˜ £ÂÚ·›·˜ ¶·›‰ˆÓ 3 ∂ÚÁ·ÛÙ‹ÚÈÔ π·ÙÚÈ΋˜ ∞ÂÈÎfiÓÈÛ˘, ¶·ÓÂÈÛÙËÌÈ·Îfi °ÂÓÈÎfi ¡ÔÛÔÎÔÌÂ›Ô ∏Ú·ÎÏ›Ԣ AÏÏËÏÔÁÚ·Ê›·: ∂. °·Ï·Ó¿Î˘ egalanak@med.uoc.gr ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋, ¶·ÓÂÈÛÙËÌÈ·Îfi °ÂÓÈÎfi ¡ÔÛÔÎÔÌÂ›Ô ∏Ú·ÎÏ›Ԣ

¶Èı·Ó¤˜ ‰È·ÁÓÒÛÂȘ: 1. ∂ÚËÙÈ΋ ÂÁÎÂÊ·Ï›Ùȉ· 2. ∞ÁÁÂÈ›Ùȉ· ·fi Û˘ÛÙËÌ·ÙÈÎfi ÂÚ˘ıËÌ·ÙÒ‰Ë Ï‡ÎÔ 3. µ·ÎÙËÚȷ΋ ÌËÓÈÁÁ›Ùȉ· Ì ıÚfiÌ‚ˆÛË ÂÁηÚÛ›Ô˘ ÎfiÏÔ˘ 4. ªËÓÈÁÁÈÙȉÔÎÔÎÎÈ΋ ÓfiÛÔ˜ Ì ‰È¿¯˘ÙË ÂÓ‰Ô·ÁÁÂȷ΋ ‹ÍË 5. ∂ÁÎÂÊ·Ï›Ùȉ· ·fi ÚÈΤÙÛÈ·

°

∂ÈÎfiÓ· 1. ∞. ∞ÎÔÏÔ˘ı›· ‰È¿¯˘Û˘: ÔÏÏ·Ϥ˜ ÌÈÎÚ¤˜ ÂÚÈÔ¯¤˜ Ì ÂÚÈÔÚÈṲ̂ÓË ‰È¿¯˘ÛË (‚¤ÏË) ÛÙËÓ ˘ÔÊÏÔÈÒ‰Ë Ï¢΋ Ô˘Û›· ÙˆÓ ‚ÚÂÁÌ·ÙÈÎÒÓ ÏÔ‚ÒÓ. µ. ∞ÎÔÏÔ˘ı›· ADC ¯¿ÚÙÔ˘ ÛÙÔ ›‰ÈÔ Â›‰Ô: ÔÈ ‚Ï¿‚˜ ·Ô‰›‰Ô˘Ó ¯·ÌËÏ‹˜ ¤ÓÙ·Û˘ Û‹Ì· (‚¤ÏË), ‡ÚËÌ· ÂÓ‰ÂÈÎÙÈÎfi ÈÛ¯·ÈÌÈÎÒÓ ·ÏÏÔÈÒÛÂˆÓ Û ÔÍ›· Ê¿ÛË. °. ™ÙË Û˘Ì‚·ÙÈ΋ ·ÎÔÏÔ˘ı›· ∆2 ÚÔÛ·Ó·ÙÔÏÈÛÌÔ‡, ÔÈ ‚Ï¿‚˜ Â›Ó·È ÌfiÏȘ ˘ÔÛËÌ·ÈÓfiÌÂÓ˜.

∏ ·¿ÓÙËÛË ·ÎÔÏÔ˘ı› ÛÙË ÛÂÏ›‰· 86

∂ÈÎfiÓ· 2. ª·ÁÓËÙÈ΋ ÊÏ‚ÔÁÚ·Ê›·: ÂÏ·Ùو̤ÓË ¤ˆ˜ ·Ô‡Û· ÚÔ‹ ÛÙÔ ÌÂÁ·Ï‡ÙÂÚÔ Ì‹ÎÔ˜ ÙÔ˘ ‰ÂÍÈÔ‡ ÂÁηÚÛ›Ô˘ ÎfiÏÔ˘ (‚¤ÏË). ¶·È‰È·ÙÚÈ΋ 2008;71:79,86

Pediatri Jan-Feb 08

15-02-08

80

11:00

™ÂÏ›‰·80

™À¡∆√ª∞ ¶∞π¢π∞∆ƒπ∫∞ ¡∂∞

∂ÏÏËÓÈ΋ ·È‰È·ÙÚÈ΋ ¤Ú¢ӷ Û ‰ÈÂıÓ‹ ÂÚÈÔ‰Èο, 2007 ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋ ¶·ÓÂÈÛÙ‹ÌÈÔ ∫Ú‹Ù˘ AÏÏËÏÔÁÚ·Ê›·: ∂ÌÌ·ÓÔ˘‹Ï °·Ï·Ó¿Î˘ egalanak@med.uoc.gr ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋ ¶·ÓÂÈÛÙËÌ›Ô˘ ∫Ú‹Ù˘

∂. °·Ï·Ó¿Î˘ ∆Ô 2007, ηٷ¯ˆÚ‹ıËÎ·Ó 483 ÂÚÁ·Û›Â˜ ·fi ÙËÓ ∂ÏÏ¿‰· ÁÈ· ÙÔ ·È‰› Û 284 ‰ÈÂıÓ‹ ÂÚÈÔ‰Èο (·Ó·˙‹ÙËÛË ÛÙË ‚¿ÛË ISI, 31 ¢ÂÎÂÌ‚Ú›Ô˘ 2007, ϤÍÂȘ-ÎÏÂȉȿ: “child*” ÁÈ· ÙÔ ·ÓÙÈΛÌÂÓÔ Î·È “Greece” ÁÈ· ÙÔ Î¤ÓÙÚÔ ÚÔ¤Ï¢Û˘). ∏ ‰ËÌÔÛÈÂ˘Ì¤ÓË ¤Ú¢ӷ Î¿Ï˘Ù fiÏ· Ù· ‰›·, ·fi ÙÔ ÂÚÁ·ÛÙËÚÈ·Îfi ˆ˜ ÙÔ ÎÏÈÓÈÎfi Î·È ÙÔ ÎÔÈÓˆÓÈÎfi, Î·È fiϘ ÙȘ ËÏÈ˘, ·fi ÙÔ ÓÂÔÁÓfi Î·È ÙÔ ‚Ú¤ÊÔ˜ ˆ˜ ÙÔ ·È‰› Î·È ÙÔÓ ¤ÊË‚Ô. ∞ÎÔÏÔ˘ıÔ‡Ó, Ôχ ÂÈÁÚ·ÌÌ·ÙÈο, ·ÔÙÂϤÛÌ·Ù· ¢ڇÙÂÚÔ˘ ÂӉȷʤÚÔÓÙÔ˜ Ï›ÁˆÓ ·fi ·˘Ù¤˜ ÙȘ ÂÚÁ·Û›Â˜.

Greek paediatric research in international journals, 2007 Department of Paediatrics, University of Crete

E. Galanakis

Correspondence: Emmanouil Galanakis egalanak@med.uoc.gr Department of Paediatrics, University of Crete

In 2007, 483 studies from Greece focusing on child health were recorded in 284 international journals (search in the ISI; December 31, 2007; terms “child*” for topic and “Greece” for address). The reported studies extended from laboratory to clinical and social fields and from the neonatal age through infancy and childhood to adolescence. A handful of the results of these studies that are of general interest are presented here in brief.

√È ÂÚÁ·˙fiÌÂÓ˜ ÌËÙ¤Ú˜ ıËÏ¿˙Ô˘Ó ÂÚÈÛÛfiÙÂÚÔ. ∞fi 3.734 ÌËÙ¤Ú˜ Ô˘ Á¤ÓÓËÛ·Ó ÙÔ 2000 Î·È ·ÓÙ·ÔÎÚ›ıËÎ·Ó (77%) Û ÂÚˆÙËÌ·ÙÔÏfiÁÈÔ 8-12 Ì‹Ó˜ ÌÂÙ¿ ÙÔÓ ÙÔÎÂÙfi: ÛÙÔ˘˜ ÚÒÙÔ˘˜ 3 Î·È 6 Ì‹Ó˜ ı‹Ï·˙·Ó 52% Î·È 24% (·ÔÎÏÂÈÛÙÈÎfi˜ ıËÏ·ÛÌfi˜ 37% Î·È 17%, ·ÓÙ›ÛÙÔȯ·). ¶ÂÚÈÛÛfiÙÂÚÔ ı‹Ï·Û·Ó ÔÈ ÂÚÁ·˙fiÌÂÓ˜ ÌËÙ¤Ú˜, fiˆ˜ Î·È fiÛ˜ ›¯·Ó Í·Ó·ıËÏ¿ÛÂÈ (Bakoula C, et al. Acta Pediatr 2007;96: 510-515). ∏ ¯ÔÚ‹ÁËÛË ÁÏ˘ÎÔÎÔÚÙÈÎÔÂȉÒÓ ÛÙËÓ ¤ÁÎ˘Ô ÂËÚ¿˙ÂÈ ÙËÓ ÂÌ‚Ú˘È΋ ÔÛÙÂÔÁ¤ÓÂÛË (¯·ÌËÏ¿ Â›‰· ÚÔÂÙȉ›Ô˘ ÙÔ˘ ÚÔÎÔÏÏ·ÁfiÓÔ˘ Ù‡Ô˘ π ÛÙÔ ÓÂÔÁÓfi), ˆÛÙfiÛÔ, ·˘Ù‹ Ë Â›ÙˆÛË ¤¯ÂÈ ÚÔÛˆÚÈÓfi Î·È ·Ó·ÛÙÚ¤„ÈÌÔ ¯·Ú·ÎÙ‹Ú· ‹‰Ë ÛÙȘ ÚÒÙ˜ Ë̤Ú˜ ˙ˆ‹˜ (Korakaki E, et al. J Bone Miner Metab 2007;25:172-178).

Paediatriki 2008;71:80-82

¶·Ú¿ÁÔÓÙ˜ ÎÈÓ‰‡ÓÔ˘ ÂÁÎÂÊ·ÏÈ΋˜ ·Ú¿Ï˘Û˘. 15ÂÙ‹˜ (1989-2003) ÌÂϤÙË fiÏˆÓ ÙˆÓ ÓÂÔÁÓÒÓ Ì ÓÔÛËÏ›· ÛÙË ª∂¡¡ πˆ·ÓÓ›ÓˆÓ Î·È ÌÂÙ¤ÂÈÙ· ÂÁÎÂÊ·ÏÈ΋ ·Ú¿Ï˘ÛË Î·Ù¤ÏËÍ fiÙÈ ÔÈ Î‡ÚÈÔÈ ·Ú¿ÁÔÓÙ˜ ÎÈÓ‰‡ÓÔ˘ ‹Û·Ó, ÁÈ· ÌÂÓ Ù· ÓÂÔÁÓ¿ <34 ‚‰ÔÌ¿‰ˆÓ ËÏÈΛ·˜ ·ËÛ˘ Ë ÂÚÈÎÔÈÏȷ΋ Ï¢ÎÔ̷ϷΛ·, Ë ·Ú·ÙÂٷ̤ÓË Ú‹ÍË ÙˆÓ ÂÌ‚Ú˘ÈÎÒÓ ˘Ì¤ÓˆÓ Î·È Ë ·Ú·ÌÔÓ‹ ·ÓÔÈÎÙÔ‡ ·ÚÙËÚÈ·ÎÔ‡ fiÚÔ˘, ÁÈ· ‰Â Ù· ÓÂÔÁÓ¿ >34 ‚‰ÔÌ¿‰ˆÓ ÙÔ ÌÈÎÚfi ‚¿ÚÔ˜ ÁÈ· ÙËÓ ËÏÈΛ· ·ËÛ˘, Ë ÌÂÙ·ÊÔÚ¿ ÙÔ˘ ÓÂÔÁÓÔ‡ Î·È Ë ÛË„·ÈÌ›·-ÌËÓÈÁÁ›Ùȉ· (Drougia A, et al. Early Hum Dev 2007;83:541-547). ∞ÓÙÔ¯‹ Ô˘ÚÔ·ıÔÁfiÓˆÓ ÛÙ· ·ÓÙÈ‚ÈÔÙÈο ÚÒÙ˘ ÁÚ·ÌÌ‹˜. ªÂϤÙË ÂÓÙ·ÂÙ›·˜ (20002004) ÙˆÓ Ô˘ÚÔ·ıÔÁfiÓˆÓ Û 262 ·È‰È¿ Ì ÚÒÙÔ ÂÂÈÛfi‰ÈÔ Ô˘ÚÔÏԛ̈͢ ÛÙËÓ ∫Ú‹ÙË ¤‰ÂÈÍ ·ÓÙÔ¯‹ Û ·ÌÈÎÈÏÏ›ÓË, ÙÚÈÌÂıÔÚ›ÌË-

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·81

PAEDIATRIC NEWS IN BRIEF ÛÔ˘ÏÊ·ÌÂıÔÍ·˙fiÏË Î·È ÎÂÊ·ÎÏfiÚË Û 61%, 28%, Î·È 27%, ·ÓÙ›ÛÙÔȯ· (Anatoliotaki M, et al. Scand J Infect Dis 2007;39:671-675). ªËÓÈÁÁ›Ùȉ·: Ì·ÎÚÔ¯ÚfiÓȘ Ù¿ÛÂȘ. ∞Ó·ÛÎfiËÛË 2.477 ÎÚÔ˘ÛÌ¿ÙˆÓ ‚·ÎÙËÚȷ΋˜ ÌËÓÈÁÁ›Ùȉ·˜ (32 ¤ÙË, 1974-2005) ÛÙÔ “∞Á›· ™ÔÊ›·”: Ô ÌËÓÈÁÁÈÙȉfiÎÔÎÎÔ˜ ‹Ù·Ó ÛÙ·ıÂÚ¿ ÙÔ ÚÒÙÔ ·›ÙÈÔ ÁÈ· fiϘ ÙȘ ËÏÈ˘, Ì 10ÂÙ‹ ΢ÎÏÈÎfiÙËÙ·. √ ·ÈÌfiÊÈÏÔ˜ ‹Ù·Ó ·Ú¯Èο ‰Â‡ÙÂÚÔ ·›ÙÈÔ, ·ÏÏ¿ Ë Â›ÙˆÛ‹ ÙÔ˘ ˘ÔÂÍ·Ï·ÛÈ¿ÛÙËΠÌÂÙ¿ ÙÔ ÂÌ‚fiÏÈÔ. √ Ó¢ÌÔÓÈfiÎÔÎÎÔ˜ ›¯Â ÌÈ· ÛÙ·ıÂÚ‹ ·ÚÔ˘Û›·. ∏ ÁÂÓÈ΋ ıÓËÙfiÙËÙ· ‹Ù·Ó 3,8% (Theodoridou MN, et al. BMC Infect Dis 2007;7:101). ™¯‹Ì· ÂÌ‚ÔÏÈ·ÛÌÔ‡ ÁÈ· ÌËÓÈÁÁÈÙȉfiÎÔÎÎÔ. ∞fi 348 ·È‰›·ÙÚÔ˘˜ ·fi fiÏË ÙË ¯ÒÚ·, 72% ÚÔÙÈÌÔ‡Ó Û¯‹Ì· ÌÈ·˜ ÌfiÓÔ ‰fiÛ˘ ÌËÓÈÁÁÈÙȉÔÎÔÎÎÈÎÔ‡ ÂÌ‚ÔÏ›Ô˘ C ÌÂÙ¿ ÙËÓ ËÏÈΛ· ÙˆÓ 12 ÌËÓÒÓ. ∏ Î¿Ï˘„Ë Ì ÌÈ· ÙÔ˘Ï¿¯ÈÛÙÔÓ ‰fiÛË Â›Ó·È Û¯Â‰fiÓ 100% ÁÈ· Ù· ·È‰È¿ ¤ˆ˜ 2 ÂÙÒÓ Î·È 51% ÁÈ· ÙÔ Û‡ÓÔÏÔ ≤15 ÂÙÒÓ. ∏ ΢ÎÏÔÊÔÚ›· (2001) ÙÔ˘ Û˘ÓÂ˙¢Á̤ÓÔ˘ ÂÌ‚ÔÏ›Ô˘ Û˘Óԉ‡ıËΠ·fi ‰Ú·Ì·ÙÈ΋ Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ Ù˘ ÔÚÔÔÌ¿‰·˜ C (Kafetzis DA, et al. Clin Microbiol Infect 2007;13:550-552). ∞ÓÙÔ¯‹ ÙÔ˘ Ó¢ÌÔÓÈÔÎfiÎÎÔ˘. ¶·ÓÂÏÏ‹ÓÈ· ÌÂϤÙË 780 ÛÙÂϯÒÓ S. pneumoniae ·fi ÙÔ ÚÈÓÔÊ¿Ú˘ÁÁ· ·È‰ÈÒÓ ·fi ‚ÚÂÊÔÓËÈ·ÎÔ‡˜ ÛÙ·ıÌÔ‡˜ ÛÙÔ ‰È¿ÛÙËÌ· 2004-6 ¤‰ÂÈÍ ÌË-¢·ÈÛıËÛ›· Û ÂÓÈÎÈÏÏ›ÓË, ÎÂÊÔ˘ÚÔÍ›ÌË, ÎÂÊÙÚÈ·ÍfiÓË, ÂÚ˘ıÚÔÌ˘Î›ÓË, ÙÂÙڷ΢ÎÏ›ÓË Î·È ÙÚÈÌÂıÔÚ›ÌË-ÛÔ˘ÏÊ·ÌÂıÔÍ·˙fiÏË ÛÙÔ 35%, 25%, 1%, 34%, 26% Î·È 44%. ∆Ô 7‰‡Ó·ÌÔ Û˘ÓÂ˙¢Á̤ÓÔ Ó¢ÌÔÓÈÔÎÔÎÎÈÎfi ÂÌ‚fiÏÈÔ ı· ÂÎ¿Ï˘Ù ÙÔ 72% ÙˆÓ ÛÙÂϯÒÓ (Poulakou G, et al. Int J Antimicrob Agents 2007;30:87-92). º˘Ì·Ù›ˆÛË: ·ÓÙÔ¯‹ ÛÙ· ·ÓÙÈÊ˘Ì·ÙÈο. ∞fi 77 ÛÙÂϤ¯Ë M. tuberculosis ·fi ÈÛ¿ÚÈıÌ· ·È‰È¿ (42% ËÏÈΛ·˜ <2 ÂÙÒÓ, 87% ∂ÏÏËÓfiÔ˘Ï·), 1994-2004, 21% ‹Û·Ó ·ÓıÂÎÙÈο Û 1 ÙÔ˘Ï¿¯ÈÛÙÔÓ ·ÓÙÈÊ˘Ì·ÙÈÎfi Î·È 4% ÔÏ˘·ÓıÂÎÙÈο (ÙÔ˘Ï¿¯ÈÛÙÔÓ Û ÈÛÔÓÈ·˙›‰Ë Î·È ÚÈÊ·ÌÈΛÓË). ∏ ·ÓÙÔ¯‹ ÛÙË ÛÙÚÂÙÔÌ˘Î›ÓË ‹Ù·Ó ÈÔ Û˘¯Ó‹ ÛÙ· ·È‰È¿ ·Ú¿ ÛÙÔ˘˜ ÂÓ‹ÏÈΘ (p<0,001). ∆· ÛÙÂϤ¯Ë ·ÔÌÔÓÒıËÎ·Ó Î·Ù¿ 87% ·fi Á·ÛÙÚÈÎfi ˘ÁÚfi (Kanavaki S, et al. Int J Tuberc Lung Dis 2007;11:424-428). º˘Ì·Ù›ˆÛË: ‚Ú·¯‡ÙÂÚ· Û¯‹Ì·Ù·. ∂Ó‰ÂηÂÙ‹˜ ÌÂϤÙË (1995-2005) Û 926 ·È‰È¿ Ì ϷÓı¿ÓÔ˘Û· Ê˘Ì·Ù›ˆÛË Û˘Ó¤ÎÚÈÓ ÙË ¯ÔÚ‹ÁËÛË ÈÛÔÓÈ·˙›‰Ë˜ Â› 9 Ì‹Ó˜ Ì ÙÔ Û˘Ó‰˘·ÛÌfi ÈÛÔÓÈ·˙›‰Ë˜ Î·È ÚÈÊ·ÌÈΛÓ˘ Â› 3 ‹ 4 Ì‹Ó˜. ∏ Û˘ÌÌfiÚʈÛË ‹Ù·Ó ηχÙÂÚË ÛÙ· ‚Ú·¯¤· Û¯‹Ì·Ù·. ™ÙËÓ 3ÂÙ‹ ÙÔ˘Ï¿¯ÈÛÙÔÓ ·-

81

Ú·ÎÔÏÔ‡ıËÛË, ηӤӷ ·È‰› ‰ÂÓ ·Ó¤Ù˘Í ÎÏÈÓÈ΋ ÓfiÛÔ Î·È Ó¤· ·ÎÙÈÓÔÏÔÁÈο Â˘Ú‹Ì·Ù· ÂÓ‰ÂÈÎÙÈο ÂÓÂÚÁÔ‡ ÓfiÛÔ˘ ‹Ù·Ó Û·ÓÈfiÙÂÚ· ÛÙ· ·È‰È¿ Ì ٷ ‚Ú·¯¤· Û¯‹Ì·Ù· (Spyridis NP, et al. Clin Infect Dis 2007;45:715-722). °·ÛÙÚÂÓÙÂÚ›Ùȉ· Î·È Èfi˜ ÚfiÙ·. ªÂϤÙË ·fi Ù· ÓÔÛÔÎÔÌ›· 4 fiÏÂˆÓ Î·È 50 ·È‰È¿ÙÚÔ˘˜ Û fiÏË ÙË ¯ÒÚ·, π·ÓÔ˘¿ÚÈÔ˜-∞Ú›ÏÈÔ˜ 2006: ·fi 706 ·È‰È¿ Ì ÔÍ›· Á·ÛÙÚÂÓÙÂÚ›Ùȉ·, 29% ›¯·Ó Ïԛ̈ÍË ·fi Èfi ÚfiÙ·, ÎÈ ·fi ·˘Ù¿ Ù· 72% ›¯·Ó ËÏÈΛ· 6 ÌËÓÒÓ-3 ÂÙÒÓ. √ Èfi˜ ÚfiÙ· Û˘Ó‰˘¿ÛıËΠ̠‚·Ú‡ÙÂÚË ÎÏÈÓÈ΋ ÂÈÎfiÓ· (p<0,01), ÂÚÈÛÛfiÙÂÚ˜ ÂÈÛ·ÁˆÁ¤˜ (p<0,01) Î·È Ì·ÎÚ‡ÙÂÚÔ ¯ÚfiÓÔ ÓÔÛËÏ›·˜ (p<0,05) ·fi Ù· ¿ÏÏ· ·›ÙÈ· (Kavaliotis I, et al. Eur J Pediatr 2007;Epub ahead of print). ∏ ‚ÚԢΤÏψÛË ÂÈ̤ÓÂÈ. ∞Ó·‰ÚÔÌÈ΋ 14ÂÙ‹˜ ÌÂϤÙË ·fi ÙË §·ÎˆÓ›· Ì 144 ÎÚÔ‡ÛÌ·Ù· ‚ÚԢΤÏψÛ˘ (·È‰È¿ Î·È ÂÓ‹ÏÈΘ): ÔÈ Î·ÏÏȤÚÁÂȘ ·›Ì·ÙÔ˜ ‹Û·Ó ıÂÙÈΤ˜ ÛÙÔ 82% Î·È Ë ·ÓÙ·fiÎÚÈÛË ÛÙË ıÂÚ·›· (ÛÙÚÂÙÔÌ˘Î›ÓË Î·È ‰Ô͢΢ÎÏ›ÓË) 97%. √È 4 ˘ÔÙÚÔ¤˜ ·ÊÔÚÔ‡Û·Ó ·ÛıÂÓ›˜ Ô˘ ‰ÂÓ Â›¯·Ó Û˘ÌÌÔÚʈı› ÛÙËÓ ·ÁˆÁ‹ (Andriopoulos P, et al. Int J Infect Dis 2007;11:52-57). °ÂÓÂÙÈ΋ ÙˆÓ Û˘ÁÁÂÓÒÓ ·ÓˆÌ·ÏÈÒÓ ÙÔ˘ Ô˘ÚÔÔÈËÙÈÎÔ‡. ªÂϤÙË ·fi Ù· πˆ¿ÓÓÈÓ· Ì 275 ·È‰È¿ ÌÂ Û˘ÁÁÂÓ›˜ ·ÓˆÌ·Ï›Â˜ Ô˘ÚÔÔÈËÙÈÎÔ‡ ‰ÂÓ ÂȂ‚·›ˆÛÂ Û˘Û¯¤ÙÈÛË ÙÔ˘ ÔÏ˘ÌÔÚÊÈÛÌÔ‡ ∞-1332G ÛÙÔ ÁÔÓ›‰ÈÔ ÙÔ˘ ˘Ô‰Ô¯¤· Ù‡Ô˘ 2 Ù˘ ·ÁÁÂÈÔÙÂÓÛ›Ó˘ ππ ÌÂ Û˘ÁÁÂÓ›˜ Ô˘ÚÔ¿ıÂȘ (Siomou E, et al.

Pediatr Res 2007;62:83-87). ∂›‰· ¯·ÏÎÔ‡ Î·È „¢‰·ÚÁ‡ÚÔ˘ Û ˘ÁÈ‹ ·È‰È¿. ™Â ÌÈ· ÚÒÙË ÁÈ· ÙËÓ ∂ÏÏ¿‰· ÌÂϤÙË, ÚÔÛ‰ÈÔÚ›ÛıËÎ·Ó ¯·ÏÎfi˜ Î·È „¢‰¿ÚÁ˘ÚÔ˜ ÛÙÔÓ ÔÚfi 105 ˘ÁÈÒÓ ·È‰ÈÒÓ ÛÙË £Ú¿ÎË Î·È ‰È·ÈÛÙÒıËÎ·Ó Û˘Û¯ÂÙ›ÛÂȘ Ì ËÏÈΛ·, ‡„Ô˜, ‰Â›ÎÙË Ì¿˙·˜ ÛÒÌ·ÙÔ˜ Î·È ‰È·ÈÙËÙÈΤ˜ Û˘Ó‹ıÂȘ (Arvanitidou V, et al. Biol Trace Elem Res 2007;115:1-12). ¶·¯˘Û·ÚΛ· Î·È ‰È·Ù·Ú·¯¤˜ ‡ÓÔ˘. ªÂϤÙË ·fi ÙË §¿ÚÈÛ· Û ·È‰È¿ Ì ÚÔ¯·ÏËÙfi η٤ÏËÍ fiÙÈ Ë ·¯˘Û·ÚΛ· ‰ÂÓ ·ÔÙÂÏ› ÚÔÁÓˆÛÙÈÎfi ‰Â›ÎÙË Ù˘ ‚·Ú‡ÙËÙ·˜ ÙˆÓ ·ÔÊÚ·ÎÙÈÎÒÓ ‰È·Ù·Ú·¯ÒÓ Ù˘ ·Ó·ÓÔ‹˜ ηٿ ÙÔÓ ‡ÓÔ ÛÙ· ÌÈÎÚ¿ ·È‰È¿, ·Ó Î·È ÂӉ¯Ô̤ӈ˜ Ó· ¤¯ÂÈ ÈÔ ÛËÌ·ÓÙÈ΋ Û˘Ì‚ÔÏ‹ ÛÙȘ ‰È·Ù·Ú·¯¤˜ Û ÌÂÁ·Ï‡ÙÂÚ· ·È‰È¿ (Kaditis AG, et al. Sleep Breath 2007; [Epub ahead of print]). ¶·¯˘Û·ÚΛ· ·È‰ÈÒÓ Î·È ÂÊ‹‚ˆÓ. ™Â ‰Â›ÁÌ· 6.448 Ì·ıËÙÒÓ ËÏÈΛ·˜ 6-17 ÂÙÒÓ, ·fi fiÏË ÙËÓ ¶·È‰È·ÙÚÈ΋ 2008;71:80-82

Pediatri Jan-Feb 08

82

15-02-08

11:00

™ÂÏ›‰·82

™À¡∆√ª∞ ¶∞π¢π∞∆ƒπ∫∞ ¡∂∞ ∂ÏÏ¿‰· (1990-1991), 17% ÙˆÓ ·ÁÔÚÈÒÓ Î·È 18% ÙˆÓ ÎÔÚÈÙÛÈÒÓ ‹Û·Ó ˘¤Ú‚·Ú·, Î·È 3,8% ÙˆÓ ·ÁÔÚÈÒÓ Î·È 3,3% ÙˆÓ ÎÔÚÈÙÛÈÒÓ ‹Û·Ó ·¯‡Û·Úη. ∆· ÔÛÔÛÙ¿ ·˘Ù¿ ‹Ù·Ó ·Ó¿ÏÔÁ· ¿ÏÏˆÓ ∂˘Úˆ·˚ÎÒÓ ¯ˆÚÒÓ (Georgiadis G, et al. Eur J Clin Nutr 2007;61:1072-1074). ∂Ê˂›· Î·È ¿Á¯Ô˜. ™‡Ìʈӷ Ì fiÛ· ·¿ÓÙËÛ·Ó 3.373 ŒÏÏËÓ˜ ¤ÊË‚ÔÈ ËÏÈΛ·˜ 18 ÂÙÒÓ Î·È 7.039 ºÈÓÏ·Ó‰Ô› ¤ÊË‚ÔÈ ËÏÈΛ·˜ 15-16 ÂÙÒÓ, ÔÈ ¤ÊË‚ÔÈ ÛÙËÓ ∂ÏÏ¿‰· ›¯·Ó ÈÔ Û˘¯Ó¿ ¿Á¯Ô˜ Î·È Î·Ù¿ıÏÈ„Ë (Kapi A, et al. Acta Paediatr 2007;96:1174-1179). ∂Ê˂›· Î·È ·ÏÎÔfiÏ. ™Â ÌÂϤÙË 1.185 ÂÊ‹‚ˆÓ ·fi 15 Û¯ÔÏ›· Ù˘ £ÂÛÛ·ÏÔӛ΢, 57% ÙˆÓ ·ÁÔÚÈÒÓ Î·È 48% ÙˆÓ ÎÔÚÈÙÛÈÒÓ ·Ó¤ÊÂÚ·Ó Î·Ù·Ó¿ÏˆÛË ·ÏÎÔfiÏ, Ì ¤Ó·ÚÍË ÛÙ· 13 ÂÚ›Ô˘ ¤ÙË. ¶ÂÚÈÛÛfiÙÂÚÔ ¤ÈÓ·Ó ÔÈ ¤ÊË‚ÔÈ Ì ÁÔÓ›˜ ¯·ÌËÏÔ‡ ÌÔÚʈÙÈÎÔ‡ ÂÈ¤‰Ô˘, ¤ÏÏÂÈ„Ë ÛˆÌ·ÙÈ΋˜ ¿ÛÎËÛ˘ Î·È Û˘¯Ó‹ ¯Ú‹ÛË Î·Ê¤ Î·È Î·ÓÔ‡. ∏ ¯Ú‹ÛË ·ÏÎÔfiÏ Ê·›ÓÂÙ·È Ó· ÌÂÈÒÓÂÙ·È, ˆÛÙfiÛÔ, ·Ú·Ì¤ÓÂÈ ·Ó¿ÌÂÛ· ÛÙȘ ˘„ËÏfiÙÂÚ˜ Â˘Úˆ·˚Τ˜ (Arvanitidou M, et al. Am J Drug Alcohol Abuse 2007;33:411-417). ∂Ê˂›· Î·È Î¿ÓÈÛÌ·. ∞fi ·ÓÂÏÏ‹ÓÈÔ ‰Â›ÁÌ· ÂÊ‹‚ˆÓ ËÏÈΛ·˜ 13-15 ÂÙÒÓ, 32% ›¯·Ó ‰ÔÎÈÌ¿ÛÂÈ ÙÛÈÁ¿ÚÔ Î·È 16% οÓÈ˙·Ó ηٿ ÙÔÓ ¯ÚfiÓÔ Ù˘ ÌÂϤÙ˘. ŒÓ·˜ ÛÙÔ˘˜ 4 Ì ·Ó·ÌÓËÛÙÈÎfi ηÓ›ÛÌ·ÙÔ˜ ¿Ú¯ÈÛ ÚÈÓ ·fi Ù· 10 ¤ÙË. 90% ÙˆÓ ÂÊ‹‚ˆÓ ›¯·Ó ¤ÎıÂÛË Û ηÓfi ÛÙÔ Û›ÙÈ Î·È 95% ·Ó¤ÊÂÚ·Ó fiÙÈ ÌÔÚÔ‡Û·Ó Ó· ·ÁÔÚ¿ÛÔ˘Ó fiÛ· ÙÛÈÁ¿Ú· ‹ıÂÏ·Ó Ì ‰Èο ÙÔ˘˜ ¯Ú‹Ì·Ù· (Kyrlesi A, et al. BMC Public Health 2007;7:3). ¶·ıËÙÈÎfi οÓÈÛÌ· ÓË›ˆÓ. ∞fi 2.809 ÁÔÓ›˜ Ì ·È‰› Û ‚ÚÂÊÔÓËÈ·Îfi ÛÙ·ıÌfi ÛÙË ¢˘ÙÈ΋ ∫Ú‹ÙË (2004-2005), 52% ÙˆÓ ·Ù¤ÚˆÓ Î·È 36% ÙˆÓ ÌËÙ¤ÚˆÓ Î¿ÓÈ˙·Ó, ÛÙÔ 63% ÙˆÓ ÔÈÎÔÁÂÓÂÈÒÓ Î¿ÓÈ˙ ÙÔ˘Ï¿¯ÈÛÙÔÓ Ô ¤Ó·˜ Î·È ÛÙÔ 26% οÓÈ˙·Ó Î·È ÔÈ ‰˘Ô ÁÔÓ›˜ (Vardavas CI, et al. BMC Public Health 2007;7:112). ÕÛıÌ·: Ì·ÎÚÔ¯ÚfiÓȘ Ù¿ÛÂȘ. √ ÂÈÔÏ·ÛÌfi˜ ÙÔ˘ ¿ÛıÌ·ÙÔ˜/‚ÚÔÁ¯fiÛ·ÛÌÔ˘ Û 11.221

Paediatriki 2008;71:80-82

·È‰È¿ ËÏÈΛ·˜ 8-10 ÂÙÒÓ ÛÙËÓ ¶¿ÙÚ· ÌÂÏÂÙ‹ıËΠ̠ÛÙ·ıÂÚ‹ ÌÂıÔ‰ÔÏÔÁ›· ÛÙË ‰È·‰ÚÔÌ‹ ÌÈ·˜ 25ÂÙ›·˜ (1978, 1991, 1998 Î·È 2003) Î·È ‚Ú¤ıËΠ1,5%, 4,6%, 6% Î·È 6,9%, ·ÓÙ›ÛÙÔȯ·, Ì ÛÙ·ıÂÚ‹ ‰ËÏ·‰‹ ·‡ÍËÛË, ·Ó Î·È Ì ٿÛË ÂÈ¤‰ˆÛ˘ ÛÙ· ÙÂÏÂ˘Ù·›· ¤ÙË (Anthracopoulos MB, et al. Arch Dis Child 2007; 92: 209-212). ¢ˆÚ¿ ÔÚÁ¿ÓˆÓ ·fi ·È‰È¿. ∞Ó·ÛÎfiËÛË ÙˆÓ ‚ÈˆÌ¿ÙˆÓ 22 ÁÔÓ¤ˆÓ 14 ·È‰ÈÒÓ Ì ÂÁÎÂÊ·ÏÈÎfi ı¿Ó·ÙÔ Û 2 ·È‰È·ÙÚÈΤ˜ ª∂£ ÛÙËÓ ∞ı‹Ó· Î·È Ù˘ ·fiÊ·Û‹˜ ÙÔ˘˜ Ó· ‰ˆÚËıÔ‡Ó fiÚÁ·Ó· Î·È ÈÛÙÔ› ÙˆÓ ·È‰ÈÒÓ ÙÔ˘˜ (Bellali T, et al. Soc Sci Med 2007;64:439-450). ŒÎıÂÛË ÛÙÔÓ ‹ÏÈÔ Î·È ÏÂÌÊÒÌ·Ù·. ªÂÏÂÙ‹ıËÎ·Ó ÔÈ Û˘Ó‹ıÂȘ ¤ÎıÂÛ˘ ÛÙÔÓ ‹ÏÈÔ 71 ·È‰ÈÒÓ Ì ϤÌʈ̷ Hodgin, 87 Ì ϤÌʈ̷ ÌË Hodgin Î·È 164 ·È‰ÈÒÓ ÔÌ¿‰·˜ ÂϤÁ¯Ô˘. ∏ ·˘ÍË̤ÓË ¤ÎıÂÛË ÛÙÔÓ ‹ÏÈÔ ‚Ú¤ıËΠӷ Û¯ÂÙ›˙ÂÙ·È Ì ÂÏ¿ÙÙˆÛË ÙÔ˘ ÎÈÓ‰‡ÓÔ˘ ÁÈ· ϤÌʈ̷ ÌË Hodgin (Petridou ET, et al. Cancer Causes Control 2007;18:1031-1037). ªÂÛÔÁÂȷ΋ ‰›·ÈÙ·. ªÂϤÙË 690 ·È‰ÈÒÓ Î·È ÂÊ‹‚ˆÓ ËÏÈΛ·˜ 7-18 ÂÙÒÓ ÛÙËÓ ·ÁÚÔÙÈ΋ ∫Ú‹ÙË ¤‰ÂÈÍ fiÙÈ Ë ‰È·ÙÚÔÊ‹ Ì ÛٷʇÏÈ·, ÔÚÙÔοÏÈ·, Ì‹Ï· Î·È ÓÙÔÌ¿Ù˜ ÚÔÛٷهÂÈ ·fi ‚ÚÔÁ¯fiÛ·ÛÌÔ Î·È ÚÈÓ›Ùȉ· Î·È Ë ÌÂÁ¿ÏË Î·Ù·Ó¿ÏˆÛË ÍËÚÒÓ Î·ÚÒÓ ·fi ‚ÚÔÁ¯fiÛ·ÛÌÔ. ∏ ·ÏÏÂÚÁÈ΋ ÚÈÓ›Ùȉ· ‹Ù·Ó ÈÔ Û˘¯Ó‹ Ì ÙËÓ Î·Ù·Ó¿ÏˆÛË Ì·ÚÁ·Ú›Ó˘ (fiˆ˜ Î·È Ô ‚ÚÔÁ¯fiÛ·ÛÌÔ˜) Î·È ÈÔ Û¿ÓÈ· Ì ÙË ÌÂÛÔÁÂȷ΋ ‰›·ÈÙ· (Chatzi L, et al. Thorax 2007;62:677-683). ¢ÔÛÔÏÔÁ›· ÎÏ·ÚÈıÚÔÌ˘Î›Ó˘. ∞fi 343 ·È‰È¿ Ì Ïԛ̈ÍË ·Ó·Ó¢ÛÙÈÎÔ‡ Î·È ·ÁˆÁ‹ ·fi 29 ·È‰È¿ÙÚÔ˘˜ Ù˘ ∞ı‹Ó·˜, 78% ‹Ú·Ó ËÌÂÚ‹ÛÈ· ‰fiÛË ÌÂÁ·Ï‡ÙÂÚË Ù˘ Û˘ÓÈÛÙÒÌÂÓ˘ (15 mg/kg) Î·È 26% ËÌÂÚ‹ÛÈ· ‰fiÛË ≥30 mg/kg. ∫·Î‹ ·ÓÔ¯‹ ·Ó·Ê¤ÚıËΠÛÙÔ 4% Î·È ·ÚÂÓ¤ÚÁÂȘ (΢ڛˆ˜ Á·ÛÙÚÂÓÙÂÚÈΤ˜) ÛÙÔ 18%. ∏ ·˘ÍË̤ÓË ‰fiÛË ‰ÂÓ Û˘Û¯ÂÙ›ÛıËΠ̠ÙËÓ ·ÓÔ¯‹ ‹ ÙȘ ·ÚÂÓ¤ÚÁÂȘ (Kafetzis DA, et al. Eur J Clin Microbiol Infect Dis 2007;26:99-103).

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·83

¡∂∞ ∞¶√ ∆√ ¢π∞¢π∫∆À√

83

πÛÙÔÛÂÏ›‰Â˜ ÁÈ· ÙËÓ ∞ÏÏÂÚÁÈÔÏÔÁ›· ÃÚ˘Û¿ÓıË ™Î¢¿ÎË

µ’ ¶·È‰È·ÙÚÈ΋ ¶·ÓÂÈÛÙËÌȷ΋ ∫ÏÈÓÈ΋, ¡ÔÛÔÎÔÌÂ›Ô ¶·›‰ˆÓ ∞ıËÓÒÓ «¶. & ∞. ∫˘ÚÈ·ÎÔ‡»

πÛÙÔÛÂÏ›‰· Ù˘ ∂˘Úˆ·˚΋˜ ∞η‰ËÌ›·˜ ∞ÏÏÂÚÁÈÔÏÔÁ›·˜ Î·È ∫ÏÈÓÈ΋˜ ∞ÓÔÛÔÏÔÁ›·˜ http://www.eaaci.net

AÏÏËÏÔÁÚ·Ê›·: ÃÚ˘Û¿ÓıË ™Î¢¿ÎË cskevaki@allergy.gr

H ÈÛÙÔÛÂÏ›‰· www.eaaci.net ·ÔÙÂÏ› ÙÔÓ Â›ÛËÌÔ ‰È·‰ÈÎÙ˘·Îfi ÙfiÔ Ù˘ ∂˘Úˆ·˚΋˜ ∞η‰ËÌ›·˜ ∞ÏÏÂÚÁÈÔÏÔÁ›·˜ Î·È ∫ÏÈÓÈ΋˜ ∞ÓÔÛÔÏÔÁ›·˜, Ë ÔÔ›· ȉڇıËΠÙÔ 1956 ÛÙË ºÏˆÚÂÓÙ›· Î·È ·ÚÈıÌ› ̤¯ÚÈ Û‹ÌÂÚ· 40 ∂˘Úˆ·˚Τ˜ ∂ıÓÈΤ˜ ∂ÓÒÛÂȘ (National Societies) Î·È ÂÚÈÛÛfiÙÂÚ· ·fi 5.500 ̤ÏË, ÚÔÂÚ¯fiÌÂÓ· ·fi ÙËÓ ·Î·‰ËÌ·˚΋ Î·È ÂÚ¢ÓËÙÈ΋ È·ÙÚÈ΋ ÎÔÈÓfiÙËÙ·. ™Ùfi¯Ô˜ Ù˘ ∞η‰ËÌ›·˜ Â›Ó·È Ë ÚÔÒıËÛË Ù˘ ‚·ÛÈ΋˜ Î·È ÎÏÈÓÈ΋˜ ¤Ú¢ӷ˜ ÛÙÔ ‰›Ô Ù˘ ·ÏÏÂÚÁÈÔÏÔÁ›·˜ Î·È ÎÏÈÓÈ΋˜ ·ÓÔÛÔÏÔÁ›·˜, Ë Û˘ÏÏÔÁ‹, ηٷÁÚ·Ê‹, ·ÍÈÔÏfiÁËÛË Î·È ‰È¿‰ÔÛË Ù˘ ÂÈÛÙËÌÔÓÈ΋˜ ÏËÚÔÊfiÚËÛ˘, Ë ÏÂÈÙÔ˘ÚÁ›· ˆ˜ ΤÓÙÚÔ˘ ·Ó·ÊÔÚ¿˜ ÁÈ· ÂÈÛÙËÌÔÓÈο fiÚÁ·Ó· Î·È ÔÏÈÙÈΤ˜ ‰Ô̤˜ ÁÈ· ÙË Ï‹„Ë ·ÔÊ¿ÛÂˆÓ Û ·ÓÂ˘Úˆ·˚Îfi Â›‰Ô, Ë ÂÓı¿ÚÚ˘ÓÛË Î·È ÚÔÛÊÔÚ¿ Û˘Ó¯È˙fiÌÂÓ˘ È·ÙÚÈ΋˜ ÂÎ·›‰Â˘Û˘ Î·È Ë ÚÔÛÊÔÚ¿ ˘ËÚÂÛÈÒÓ ÂÓË̤ڈÛ˘ Û ·ÛıÂÓ›˜ Ì ·ÏÏÂÚÁ›Â˜ Î·È ¿ÛıÌ·. ™ÙȘ ‰Ú¿ÛÂȘ Ù˘ ∞η‰ËÌ›·˜ ÂÚÈÏ·Ì‚¿ÓÔÓÙ·È Û˘ÓÂÚÁ·Û›Â˜ Ì ·ÓÙ›ÛÙÔȯ˜ ·ÁÎfiÛÌȘ ÔÚÁ·ÓÒÛÂȘ, Û˘ÌÌÂÙÔ¯‹ Û ÂÚ¢ÓËÙÈο ÚÔÁÚ¿ÌÌ·Ù· Î·È ‰ÈÂıÓ›˜ Û˘Ó·ÓÙ‹ÛÂȘ, Ì ·ÔÎÔڇʈ̷ ÙÔ ÂÙ‹ÛÈÔ ‰ÈÂıÓ¤˜ Û˘Ó¤‰ÚÈÔ ·ÏÏÂÚÁÈÔÏÔÁ›·˜ Î·È ÎÏÈÓÈ΋˜ ·ÓÔÛÔÏÔÁ›·˜. ™ÙËÓ Î·ÙËÁÔÚ›· ¡¤· ˘¿Ú¯ÂÈ ÏËÚÔÊfiÚËÛË ÂÈÛÙËÌÔÓÈÎÔ‡ Î·È ÂȉËÛÂÔÁÚ·ÊÈÎÔ‡ ÂÚȯÔ̤ÓÔ˘ Û¯ÂÙÈο Ì ÙȘ ·ÏÏÂÚÁ›Â˜ Î·È ÙÔ ¿ÛıÌ·. ∂ÈϤÔÓ, ÛÙËÓ ˘ÔηÙËÁÔÚ›· ¶ÚÔÊ›Ï, Á›ÓÂÙ·È ·ÚÔ˘Û›·ÛË ÂÈÏÂÁÌ¤ÓˆÓ ÚÔÛˆÈÎÔÙ‹ÙˆÓ Ì¤Û· ·fi ÙËÓ ∞η‰ËÌ›·, Ì ¤ÓÙÔÓË ‰Ú¿ÛË Î·È ÂÈÛÙËÌÔÓÈÎfi ÚÔÊ›Ï. ∆¤ÏÔ˜, ÛÙËÓ ÂÓfiÙËÙ· ·˘Ù‹ Á›ÓÂÙ·È ·Ó·ÊÔÚ¿ Î·È Û Ӥ˜ ÂΉfiÛÂȘ Î·È ‚È‚Ï›· ·fi ÙÔ ¯ÒÚÔ Ù˘ ·ÏÏÂÚÁÈÔÏÔÁ›·˜. ™ÙËÓ Î·ÙËÁÔÚ›· ¢Ú·ÛÙËÚÈfiÙËÙ˜, ÂÎÙfi˜ ·fi ÙËÓ Ù·ÎÙÈ΋ ÂÙ‹ÛÈ· Û˘Ó¿ÓÙËÛË Ù˘ ∞η‰ËÌ›·˜, ˘¿Ú¯Ô˘Ó ÏËÚÔÊÔڛ˜ ÁÈ· Ù· ıÂÚÈÓ¿ Î·È ¯ÂÈÌÂÚÈÓ¿ Û¯ÔÏ›· Ì ÂÎ·È‰Â˘ÙÈÎfi ¯·Ú·ÎÙ‹Ú·, ÂÈÛÙËÌÔÓÈΤ˜ Û˘Ó·ÓÙ‹ÛÂȘ, ·ÏÏ¿ Î·È ÁÂÓÈÎfiÙÂÚË ÏËÚÔÊfiÚËÛË ÁÈ· ·ÚÂÌÊÂÚÔ‡˜ ¯·Ú·ÎÙ‹Ú· ÁÂÁÔÓfiÙ· Û ·ÁÎfiÛÌÈÔ Â›‰Ô. ∆· ÂÈ̤ÚÔ˘˜ ÂÚ¢ÓËÙÈο Î·È ÂÈÛÙËÌÔÓÈο ‰›· ÛÙÔ ¯ÒÚÔ Ù˘ ·ÏÏÂÚÁÈÔÏÔÁ›·˜ Î·È ÎÏÈÓÈ΋˜ ·ÓÔÛÔÏÔÁ›·˜ ÂÚÈÁÚ¿ÊÔÓÙ·È ·Ó·Ï˘ÙÈο ÛÙËÓ Î·ÙËÁÔÚ›· ∂ÓfiÙËÙ˜/√Ì¿‰Â˜ ∂ӉȷʤÚÔÓÙÔ˜, ÂÓÒ ÁÈ· Ù· Ó·ڿ ̤ÏË Ù˘ ∞η‰ËÌ›·˜ (¤ˆ˜ 35 ÂÙÒÓ) ˘¿Ú¯ÂÈ Í¯ˆÚÈÛÙ‹ ηÙËÁÔÚ›· Ì ÏËÚÔÊÔڛ˜ Î·È Ó¤· Ô˘ ·¢ı‡ÓÔÓÙ·È ÛÙÔ˘˜ Ó¤Ô˘˜ ÂÈÛÙ‹ÌÔÓ˜ ÙÔ˘ ¯ÒÚÔ˘. ¶·Ú¿ÏÏËÏ·, ˘¿Ú¯ÂÈ Î·È Ë ÂȉÈ΋ ÂÓfiÙËÙ· °È· Ù· ª¤ÏË ªfiÓÔ, ÛÙËÓ ÔÔ›· ÂÈÙÚ¤ÂÙ·È Ë ÚfiÛ‚·ÛË ‚¿ÛÂÈ Îˆ‰ÈÎÔ‡ ηıÒ˜ ÚÔÛʤÚÂÈ ÂÍ·ÙÔÌÈÎÂ˘Ì¤ÓË ÏËÚÔÊfiÚËÛË. π‰È·›ÙÂÚÔ ÂӉȷʤÚÔÓ ·ÚÔ˘ÛÈ¿˙ÂÈ Ë ÂÓfiÙËÙ· ¶ËÁ¤˜, Ô˘ ÚÔÛʤÚÂÈ ÂÚÁ·Ï›· ËÏÂÎÙÚÔÓÈ΋˜ ÂÎ·›‰Â˘Û˘ (e-learning) Ì ‰È·‰Ú·ÛÙÈ΋ Û˘ÌÌÂÙÔ¯‹ ÙÔ˘ ¯Ú‹ÛÙË (webcasts), ·‰ËÌÔÛ›Â˘Ù˜ ÂÈÛÙËÌÔÓÈΤ˜ ¤Ú¢Ó˜ Î·È case-studies, ÏÔ‡ÛÈÔ ÊˆÙÔÁÚ·ÊÈÎfi ˘ÏÈÎfi Î·È ÏËÚÔÊfiÚËÛË ÁÈ· ı¤ÛÂȘ ¤Ú¢ӷ˜ Î·È ÂÚÁ·Û›·˜. ∆¤ÏÔ˜, Ë ÈÛÙÔÛÂÏ›‰· ÙÔ˘ www.eaaci.net ÚÔÛʤÚÂÈ ÚfiÛ‚·ÛË ÛÙȘ Â›ÛË̘ ÂΉfiÛÂȘ Ù˘ ∞η‰ËÌ›·˜ (Allergy, Pediatric Allergy and Immunology, Newsletter) ηıÒ˜ Î·È ËÏÂÎÙÚÔÓÈΤ˜ Û˘Ó‰¤ÛÂȘ Ì ·ÁÎfiÛÌȘ ÂÈÛÙËÌÔÓÈΤ˜ Î·È È·ÙÚÈΤ˜ ÔÚÁ·ÓÒÛÂȘ.

¶·È‰È·ÙÚÈ΋ 2008;71:83-85

Pediatri Jan-Feb 08

84

15-02-08

11:00

™ÂÏ›‰·84

¡∂∞ ∞¶√ ∆√ ¢π∞¢π∫∆À√ πÛÙÔÛÂÏ›‰· ÙÔ˘ ¶·ÁÎfiÛÌÈÔ˘ √ÚÁ·ÓÈÛÌÔ‡ ∞ÏÏÂÚÁ›·˜ http://www.worldallergy. org/index.php ∏ ·Ó·Óˆ̤ÓË ÈÛÙÔÛÂÏ›‰· www.worldallergy.org ·ÔÙÂÏ› ÙÔÓ Â›ÛËÌÔ ‰È·‰ÈÎÙ˘·Îfi ÙfiÔ ÙÔ˘ ¶·ÁÎfiÛÌÈÔ˘ √ÚÁ·ÓÈÛÌÔ‡ ∞ÏÏÂÚÁ›·˜ (WAO), Ô ÔÔ›Ô˜ ·ÓÙÈÚÔÛˆ‡ÂÈ ¤Ó· ‰ÈÂıÓ¤˜ ‰›ÎÙ˘Ô ·fi 74 ÂıÓÈΤ˜ Î·È ÂÚÈÊÂÚÂȷΤ˜ ÂÙ·ÈÚ›˜ ·ÏÏÂÚÁÈÔÏÔÁ›·˜ Î·È ÎÏÈÓÈ΋˜ ·ÓÔÛÔÏÔÁ›·˜ ·fi fiÏÔ ÙÔÓ ÎfiÛÌÔ. ™Ùfi¯Ô˜ ÙÔ˘ WAO Â›Ó·È Ó· ·ÔÙÂϤÛÂÈ ¤Ó· ·ÁÎfiÛÌÈÔ Î¤ÓÙÚÔ ÂÈÛÙËÌÔÓÈ΋˜ ÏËÚÔÊfiÚËÛ˘ ÁÈ· ÙËÓ ÎÏÈÓÈ΋ Ú·ÎÙÈ΋, ÙËÓ ¤Ú¢ӷ, ÙËÓ ÂÎ·›‰Â˘ÛË Î·È ÙË ‰È· ‚›Ô˘ ηٿÚÙÈÛË, ̤۷ ·fi ‰ÈÔÚÁ·ÓÒÛÂȘ, ÂÈÛÙËÌÔÓÈο Û˘ÌfiÛÈ·, ÂÎ·È‰Â˘ÙÈο ÚÔÁÚ¿ÌÌ·Ù· Î·È ÂÎ·È‰Â˘ÙÈÎfi ˘ÏÈÎfi, Ì ¤ÌÊ·ÛË ÛÙȘ ·Ó·Ù˘ÛÛfiÌÂÓ˜ ΢ڛˆ˜ ¯ÒÚ˜. √ ¶·ÁÎfiÛÌÈÔ˜ √ÚÁ·ÓÈÛÌfi˜ ∞ÏÏÂÚÁ›·˜ ȉڇıËΠÙÔ 1951 Û˘ÓÂÓÒÓÔÓÙ·˜ ÙËÓ ÂÚ¢ÓËÙÈ΋, ·Î·‰ËÌ·˚΋ Î·È È·ÙÚÈ΋ ÎÔÈÓfiÙËÙ· ·fi ÙÔ ¯ÒÚÔ Ù˘ ·ÏÏÂÚÁÈÔÏÔÁ›·˜, ÂÓÒ Û˘ÓÂÚÁ¿˙ÂÙ·È Â›Û˘ ÛÙÂÓ¿ Î·È Ì ÙÔÓ ¶·ÁÎfiÛÌÈÔ √ÚÁ·ÓÈÛÌfi ÀÁ›·˜ (WHO).

H ÈÛÙÔÛÂÏ›‰· ÙÔ˘ ÔÚÁ·ÓÈÛÌÔ‡, Ì ÚfiÛÊ·ÙÔ, ·Ó·Óˆ̤ÓÔ ÚÔÊ›Ï, ¤¯ÂÈ ÌÔÓÙ¤ÚÓÔ Û¯Â‰È·ÛÌfi Î·È Â‡ÎÔÏË ÏÔ‹ÁËÛË. ∏ ηÙËÁÔÚ›· ∂Î·›‰Â˘ÛË ÛÙËÓ ∞ÏÏÂÚÁ›· ÂÚÈÏ·Ì‚¿ÓÂÈ ÏËÚÔÊÔڛ˜ ÁÈ· Ù· ÂÎ·È‰Â˘ÙÈο ÚÔÁÚ¿ÌÌ·Ù· ÙÔ˘ ÔÚÁ·ÓÈÛÌÔ‡, ÛÂÌÈÓ¿ÚÈ· Î·È ˘ÔÙÚÔʛ˜. ∏ ηÙËÁÔÚ›· ŒÚ¢ӷ ÛÙËÓ ∞ÏÏÂÚÁ›· ÂÚÈÏ·Ì‚¿ÓÂÈ ÏËÚÔÊÔڛ˜ ÁÈ· ÂÚ¢ÓËÙÈο ÚÔÁÚ¿ÌÌ·Ù·, ÂÈÛÙËÌÔÓÈΤ˜ Û˘Ó·ÓÙ‹ÛÂȘ, Ì·ı‹Ì·Ù· Î·È ÈÛÙÔÔÈËÙÈο ÁÓÒÛ˘ Á‡Úˆ ·fi ÙËÓ ·ÏÏÂÚÁ›· Î·È ÙËÓ ÎÏÈÓÈ΋ ·ÓÔÛÔÏÔÁ›·. π‰È·›ÙÂÚÔ ÂӉȷʤÚÔÓ ·ÚÔ˘ÛÈ¿˙ÂÈ Ë ÂÓfiÙËÙ· ∫ÚÈÙÈΤ˜, fiÔ˘ ·Ó·Ê¤ÚÂÙ·È Û ÎÚÈÙÈΤ˜ ‚È‚Ï›ˆÓ, ÂÚÈÔ‰ÈÎÒÓ Î·È ¿ÏÏˆÓ ÂÈÛÙËÌÔÓÈÎÒÓ ÂΉfiÛÂˆÓ Ì ·ÓÙÈΛÌÂÓÔ ÙËÓ ·ÏÏÂÚÁ›·. ∏ ÈÛÙÔÛÂÏ›‰· ÏÂÈÙÔ˘ÚÁ›, Â›Û˘, ˆ˜ ̤ÛÔ ÂÈÎÔÈÓˆÓ›·˜ Ì ٷ ̤ÏË ÙÔ˘ ÔÚÁ·ÓÈÛÌÔ‡ ̤۷ ·fi Ì›· ͯˆÚÈÛÙ‹ ηÙËÁÔÚ›· (°È· Ù· ª¤ÏË ªfiÓÔ), Ë ÔÔ›· ‰›ÓÂÈ ÙË ‰˘Ó·ÙfiÙËÙ· ˘Ô‚ÔÏ‹˜ ÂÚˆÙËÌ¿ÙˆÓ Û ÂȉÈÎÔ‡˜ ·fi ÙÔ ¯ÒÚÔ Ù˘ ·ÏÏÂÚÁÈÔÏÔÁ›·˜. ∆¤ÏÔ˜, Ë ÈÛÙÔÛÂÏ›‰· ÚÔÛʤÚÂÈ ÏËÚÔÊfiÚËÛË ÁÈ· Ù· ÂÂÚ¯fiÌÂÓ· Û˘Ó¤‰ÚÈ· ÙÔ˘ ÔÚÁ·ÓÈÛÌÔ‡, ηıÒ˜ Î·È ËÏÂÎÙÚÔÓÈΤ˜ Û˘Ó‰¤ÛÂȘ Ì ·ÚÂÌÊÂÚ›˜ ÔÚÁ·ÓÈÛÌÔ‡˜ Î·È ÂÓÒÛÂȘ.

πÛÙÔÛÂÏ›‰· Ù˘ ∂˘Úˆ·˚΋˜ √ÌÔÛÔÓ‰›·˜ ÁÈ· ÙȘ ∂ÓÒÛÂȘ ∞ÛıÂÓÒÓ Ì ∞ÏÏÂÚÁ›· Î·È ¶·ı‹ÛÂȘ ÙÔ˘ ∞Ó·Ó¢ÛÙÈÎÔ‡ (EFA) - http://www.efanet.org/ ∏ ÈÛÙÔÛÂÏ›‰· www.efanet.org ·ÔÙÂÏ› ÙÔÓ Â›ÛËÌÔ ‰È·‰ÈÎÙ˘·Îfi ÙfiÔ Ù˘ ∂˘Úˆ·˚΋˜ √ÌÔÛÔÓ‰›·˜ ÁÈ· ÙȘ ∂ÓÒÛÂȘ ∞ÛıÂÓÒÓ Ì ∞ÏÏÂÚÁ›· Î·È ¶·ı‹ÛÂȘ ÙÔ˘ ∞Ó·Ó¢ÛÙÈÎÔ‡, EFA, Ë ÔÔ›· ȉڇıËΠÙÔ 1991 ÛÙË ™Ô˘Ë‰›·. ™Ùfi¯Ô˜ ‹Ù·Ó Ó· Û˘ÓÂÓÒÛÂÈ fiϘ ÙȘ ÂÓÒÛÂȘ ·ÛıÂÓÒÓ Ì ·ÏÏÂÚÁ›Â˜ Î·È ¿ÛıÌ· ÛÙËÓ ∂˘ÚÒË ÁÈ· Ó· ÈηÓÔÔÈ‹ÛÂÈ ÙȘ ·Ó¿ÁΘ ÙÔ˘˜ Î·È Ó· ÚÔ·Û›ÛÂÈ Ù· ‰ÈηÈÒÌ·Ù¿ ÙÔ˘˜, ·ÔÛÎÔÒÓÙ·˜ ÛÙË ‚ÂÏÙ›ˆÛË Ù˘ ˘Á›·˜ ÙÔ˘˜ Î·È ÂÓ Á¤ÓÂÈ Ù˘ ÔÈfiÙËÙ·˜ Ù˘ ˙ˆ‹˜ ÙÔ˘˜. ™ÙÔ Ï·›ÛÈÔ ·˘Ùfi, ÚÔÛʤÚÂÈ ˘ËÚÂۛ˜ ÂȉËÛÂÔÁÚ·ÊÈ΋˜ ÂÓË̤ڈÛ˘ Î·È ÂÌÂÚÈÛٷو̤Ó˘ ÂÈÛÙËÌÔÓÈ΋˜ ÏËÚÔÊfiÚËÛ˘, ηıÒ˜ Î·È Û˘Ó·Ê¤˜ ÂÎ·È‰Â˘ÙÈÎfi ˘ÏÈÎfi. ª¤¯ÚÈ Û‹ÌÂÚ·, ÙÔ ‰›ÎÙ˘Ô Ù˘ EFA ÂÚÈÏ·Ì‚¿ÓÂÈ 14 ÂıÓÈΤ˜ ÂÓÒÛÂȘ Ì ۇÓÔÏÔ ÌÂÏÒÓ ¿Óˆ ÙˆÓ 400.000 Û fiÏË ÙËÓ ∂˘ÚÒË. ∏ ηÙËÁÔÚ›· ¢Ú·ÛÙËÚÈfiÙËÙ˜ ÂÚÈÏ·Ì‚¿ÓÂÈ ÏËÚÔÊÔڛ˜ ÁÈ· ÙȘ Ù·ÎÙÈΤ˜ Î·È ¤ÎÙ·ÎÙ˜ ÂΉfiÛÂȘ ÙÔ˘ ÔÚÁ·ÓÈÛÌÔ‡, ÁÂÁÔÓfiÙ· Î·È ÂΉËÏÒÛÂȘ, ‰Ú¿ÛÂȘ Î·È ÚˆÙÔ‚Ô˘Ï›Â˜ Ù˘ ∂∂ Î·È ÂÎ·È‰Â˘ÙÈο Î·È ÂÚ¢ÓËÙÈο ÚÔÁÚ¿ÌÌ·Ù· ÛÂ Û˘ÓÂÚÁ·Û›· Ì ·ÚÂÌÊÂÚ›˜ Â˘Úˆ·˚ÎÔ‡˜ ÊÔÚ›˜. ∂ÈϤÔÓ, ˘¿Ú¯ÂÈ ÂÎÙÂٷ̤ÓË ·Ó·ÊÔÚ¿ Û ¤ÁÁÚ·Ê· ÔÏÈÙÈ΋˜, fiˆ˜ Â˘Úˆ·˚Τ˜ Û˘Óı‹Î˜ Î·È Û˘ÛÙ¿ÛÂȘ, ı¤Ì·Ù·

Paediatriki 2008;71:83-85

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·85

NEWS FROM THE INTERNET

85

ηٷӷψÙÈÎÔ‡ ÂӉȷʤÚÔÓÙÔ˜ Î·È ˘ÁÂÈÔÓÔÌÈ΋˜ ÂÚ›ı·Ï„˘, ÂÚÈ‚·ÏÏÔÓÙÔÏÔÁÈο ı¤Ì·Ù·, Û˘Ó‰ÂfiÌÂÓ· Ì ÙȘ ·ÏÏÂÚÁ›Â˜ Î·È ÙȘ ·ı‹ÛÂȘ ÙÔ˘ ·Ó·Ó¢ÛÙÈÎÔ‡, ˙ËÙ‹Ì·Ù· ‰È·ÙÚÔÊ‹˜ Î·È Û‹Ì·ÓÛ˘ ÙˆÓ ÙÚÔÊÒÓ, ηıÒ˜ Î·È ˙ËÙ‹Ì·Ù· È·ÙÚÔÊ·Ú̷΢ÙÈ΋˜ ÂÚ›ı·Ï„˘. ∏ ηÙËÁÔÚ›· ¡¤· ·fi ÙËÓ EFA ÂÚÈÏ·Ì‚¿ÓÂÈ Âȉ‹ÛÂȘ ·fi ÙÔÓ ∆‡Ô Û¯ÂÙÈο Ì ÙȘ ·ÏÏÂÚÁ›Â˜ Î·È ÙÔ ¿ÛıÌ·, ÙËÓ ËÏÂÎÙÚÔÓÈ΋ ¤Î‰ÔÛË ÙÔ˘ ÔÚÁ·ÓÈÛÌÔ‡, ηıÒ˜ Î·È Âȉ‹ÛÂȘ ·fi ÙÔ ‰È·‰›ÎÙ˘Ô. ∂ÎÙfi˜ ·fi ÙȘ ͯˆÚÈÛÙ¤˜ ηÙËÁÔڛ˜ ÂÓË̤ڈÛ˘ ∞ÏÏÂÚÁ›· Î·È ÕÛıÌ·, Ô˘ ÂÚȤ¯Ô˘Ó ÏËÚÔÊÔڛ˜ Û¯ÂÙÈο Ì ÙË Ê‡ÛË, ÙËÓ ÔÚÔÏÔÁ›·, ÙË ÏÂÈÙÔ˘ÚÁ›· Î·È ÙËÓ ÂͤÏÈÍË ÙˆÓ ·ı‹ÛÂˆÓ ·˘ÙÒÓ, Ë ÈÛÙÔÛÂÏ›‰· ÂÚÈÏ·Ì‚¿ÓÂÈ Î·È ÂȉÈ΋ ηÙËÁÔÚ›· ÁÈ· ÙË ÃÚfiÓÈ· ∞ÔÊÚ·ÎÙÈ΋ ¶Ó¢ÌÔÓÔ¿ıÂÈ·. ™ÙËÓ ÂÓ ÏfiÁˆ ηÙËÁÔÚ›·, ÚÔÛʤÚÂÙ·È ÏËÚÔÊfiÚËÛË Û¯ÂÙÈο Ì ÙËÓ ·Ó·ÁÓÒÚÈÛË Ù˘ Û˘ÁÎÂÎÚÈ̤Ó˘ ¿ıËÛ˘, Ù· ̤ÙÚ· ÚfiÏ˄˘, ÙËÓ ·ÓÙÈÌÂÙÒÈÛË Î·È ÙË ‚ÂÏÙ›ˆÛË Ù˘ ÔÈfiÙËÙ·˜ ˙ˆ‹˜ ÙÔ˘ ¿Û¯ÔÓÙÔ˜. ∆¤ÏÔ˜, ÛÙËÓ Î·ÙËÁÔÚ›· ÃÚ‹ÛÈ̘ ™˘Ó‰¤ÛÂȘ, Ë ÈÛÙÔÛÂÏ›‰· ÚÔÛʤÚÂÈ ÏËıÒÚ· ËÁÒÓ Î·È Û˘Ó‰¤ÛÌˆÓ Ì ·ÓÙ›ÛÙÔÈ¯Ô˘˜ ÊÔÚ›˜ Î·È ÔÚÁ·ÓÒÛÂȘ ·fi ÙÔ ¯ÒÚÔ Ù˘ ˘Á›·˜ Î·È Ù˘ ¤Ú¢ӷ˜.

¶·È‰È·ÙÚÈ΋ 2008;71:83-85

Pediatri Jan-Feb 08

86

15-02-08

11:00

™ÂÏ›‰·86

∫§π¡π∫√ ∫√Àπ∑

∫ÏÈÓÈÎfi QUIZ ∞¶∞¡∆∏™∏ ∏ ‰È¿ÁÓˆÛË ‹Ù·Ó ‚·ÎÙËÚȷ΋ ÌËÓÈÁÁ›Ùȉ· Ì ıÚfiÌ‚ˆÛË ÂÁηÚÛ›Ô˘ ÎfiÏÔ˘. ∏ PCR ÙÔ˘ ÂÁÎÂÊ·ÏÔÓˆÙÈ·›Ô˘ ˘ÁÚÔ‡ ‹Ù·Ó ıÂÙÈ΋ ÁÈ· ÙÔÓ ÔÚfiÙ˘Ô 6 ÙÔ˘ S. pneumoniae. ∏ ÂÈÎfiÓ· ıÚfiÌ‚ˆÛ˘ ÙÔ˘ ‰ÂÍÈÔ‡ ÂÁοÚÛÈÔ˘ ÎfiÏÔ˘ Î·È ÔÈ ÔÏÏ·Ϥ˜ ÌÈÎÚ¤˜ ‚Ï¿‚˜ ÛÙË Ï¢΋ Ô˘Û›· ÙˆÓ ‚ÚÂÁÌ·ÙÈÎÒÓ ÏÔ‚ÒÓ ı· ÌÔÚÔ‡Û·Ó Ó· ·Ô‰ÔıÔ‡Ó Û ÌÈÎÚ¤˜ ÂÚÈÔ¯¤˜ ÈÛ¯·ÈÌ›·˜, ·fiÚÚÔÈ· Ù˘ ıÚfiÌ‚ˆÛ˘ ÙˆÓ ÊÏ‚ˆ‰ÒÓ ÎfiÏˆÓ ‹/Î·È ·fiÚÚÔÈ· ·ÁÁÂÈ›Ùȉ·˜ ÛÙ· Ï·›ÛÈ· ÂÁÎÂÊ·Ï›Ùȉ·˜. ∆Ô ·È‰› Ù¤ıËΠ۠˘Ô‰fiÚÈ· ¯ÔÚ‹ÁËÛË ÂÓÔÍ··Ú›Ó˘ Î·È ·Ú¤ÌÂÈÓ ‰È·ÛˆÏËӈ̤ÓÔ ÁÈ· 6 24ˆÚ·. ∆Ë 2Ë Â‚‰ÔÌ¿‰· Ù˘ ÓfiÛÔ˘, ¤ÁÈÓ ̷ÁÓËÙÈ΋ ÙÔÌÔÁÚ·Ê›· Ô˘ ¤‰ÂÈÍ ‚ÂÏÙ›ˆÛË ÙˆÓ ·ÂÈÎÔÓÈÛÙÈÎÒÓ Â˘ÚËÌ¿ÙˆÓ ıÚfiÌ‚ˆÛ˘. √È ‚Ï¿‚˜ Ù˘ Ï¢΋˜ Ô˘Û›·˜ ¤ÁÈÓ·Ó ÂÌÊ·Ó¤ÛÙÂÚ˜ ÛÙȘ Û˘Ì‚·ÙÈΤ˜ ·ÎÔÏÔ˘ı›Â˜, ‰ÂÓ ÂÌÊ¿ÓÈ˙·Ó ÂÚÈÔÚÈÛÌfi Ù˘ ‰È¿¯˘Û˘ ÛÙÔ ÛÙ¿‰ÈÔ ·˘Ùfi Î·È ÂÌÏÔ˘Ù›˙ÔÓÙ·Ó Ì ÛÎÈ·ÁÚ·ÊÈ΋ Ô˘Û›·, Â˘Ú‹Ì·Ù· ÂÓ‰ÂÈÎÙÈο ÈÛ¯·ÈÌÈÎÒÓ ·ÏÏÔÈÒÛÂˆÓ Û ˘ÔÍ›· Ê¿ÛË ·ÈÌ¿ÙˆÛ˘. ™ÙËÓ Â·ÓÂͤٷÛË ÌÂÙ¿ ·fi 1 Ì‹Ó·, Ë Ì·ÁÓËÙÈ΋ ÙÔÌÔÁÚ·Ê›· ·Ó¤‰ÂÈÍ ˘ÊÔÏÈ΋ χÛË Ù˘ ıÚfiÌ‚ˆÛ˘ ÙÔ˘ ÂÁηÚÛ›Ô˘ ÊÏÂ‚Ò‰Ô˘˜ ÎfiÏÔ˘ Î·È ˘ÔÏÂÈÌÌ·ÙÈΤ˜ ÌÈÎÚÔ·ÏÏÔÈÒÛÂȘ ÁÏÔ›ˆÛ˘ Ï¢΋˜ Ô˘Û›·˜. √ ¤ÏÂÁ¯Ô˜ ËÎÙÈÎfiÙËÙ·˜ ‹Ù·Ó Ê˘ÛÈÔÏÔÁÈÎfi˜ (ÔÌÔ΢ÛÙ½ÓË, ·Ú¿ÁÔÓÙ·˜ Leyden, ÚˆÙ½ÓË S, ÚˆÙ½ÓË C, ·ÓÙÈıÚÔÌ‚›ÓË πππ, ·ÓÙÈʈÛÊÔÏÈȉÈο ·ÓÙÈÛÒÌ·Ù·). √ Ó¢ÌÔÓÈfiÎÔÎÎÔ˜ Â›Ó·È ÎÔÈÓfi ·›ÙÈÔ ‚·ÎÙËÚȷ΋˜ ÌËÓÈÁÁ›Ùȉ·˜, ‰Â‡ÙÂÚÔ ÛÂ Û˘¯ÓfiÙËÙ·, ÌÂÙ¿ ÙÔ ÌËÓÈÁÁÈÙȉfiÎÔÎÎÔ, Û ·È‰ÈÎÔ‡˜ ÏËı˘ÛÌÔ‡˜ Ô˘ ¤¯Ô˘Ó ÂÌ‚ÔÏÈ·Ûı› ÁÈ· ·ÈÌfiÊÈÏÔ Ù˘ ÁÚ›˘ Ù‡Ô˘ b (1). H ıÓËÙfiÙËÙ· Ù˘ Ó¢ÌÔÓÈÔÎÔÎÎÈ΋˜ ÌËÓÈÁÁ›Ùȉ·˜ ‰ÂÓ Â›Ó·È ·ÌÂÏËÙ¤· Î·È ÔÈ Ì·ÎÚÔ¯ÚfiÓȘ ÂÈÏÔΤ˜ Â›Ó·È ·ÚÎÂÙ¿ Û˘¯Ó¤˜. ∏ ÚfiÛÊ·ÙË ÂÈÛ·ÁˆÁ‹ ÙÔ˘ ÂÌ‚ÔÏ›Ô˘ ¤¯ÂÈ ÔˆÛ‰‹ÔÙÂ Û˘Ì‚¿ÏÏÂÈ ÛÙË Ì¿¯Ë ηٿ Ù˘ Ófi-

Paediatriki 2008;71:79,86

ÛÔ˘, ·fi ÙËÓ ¿ÏÏË fï˜ Ë ·Ó¿‰˘ÛË ÛÙÂϯÒÓ ·ÓıÂÎÙÈÎÒÓ ÛÙȘ ÎÂÊ·ÏÔÛÔÚ›Ó˜ Áã ÁÂÓ¿˜ ¤¯ÂÈ ÂÈ‚¿ÏÏÂÈ ÙËÓ ÚÔÛı‹ÎË Ù˘ ‚·ÓÎÔÌ˘Î›Ó˘ ÛÙÔ ÂÌÂÈÚÈÎfi ·ÓÙÈ‚ÈÔÙÈÎfi Û¯‹Ì· Ù˘ ÎÂÊ·ÏÔÛÔÚ›Ó˘ Áã ÁÂÓ¿˜ (2,3). ∏ ‰ÂÍ·ÌÂı·˙fiÓË ÚÔÛÙ›ıÂÙ·È Û˘¯Ó¿ ÛÙË ıÂÚ·›·, ·Ó Î·È Ë ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ¿ Ù˘ Â›Ó·È Û˘˙ËÙ‹ÛÈÌË. ∏ ıÚfiÌ‚ˆÛË ÊÏ‚ˆ‰ÒÓ ÎfiÏˆÓ ÌÂÙ¿ ·fi Ó¢ÌÔÓÈÔÎÔÎÎÈ΋ ÌËÓÈÁÁ›Ùȉ· ¤¯ÂÈ ·Ó·ÊÂÚı› Û ÂÍ·ÈÚÂÙÈο Û¿ÓȘ ÂÚÈÙÒÛÂȘ (4,5). ¶ÚԉȷıÂÛÈÎfi˜ ·Ú¿ÁÔÓÙ·˜ ÁÈ· ıÚfiÌ‚ˆÛË ÊÏ‚ˆ‰ÒÓ ÎfiÏˆÓ ·ÔÙÂÏ› Ë ·Ê˘‰¿ÙˆÛË, Ë ÔÔ›· Èı·ÓfiÓ, ÏfiÁˆ ÚÔËÁËı¤ÓÙˆÓ Â̤وÓ, Ó· Û˘ÓÙ¤ÏÂÛ ÛÙË ‰ËÌÈÔ˘ÚÁ›· ıÚfiÌ‚ˆÛ˘ ÛÙÔÓ ·ÛıÂÓ‹ Ì·˜.

µÈ‚ÏÈÔÁÚ·Ê›· 1. Theodoridou MN, Vasilopoulou VA, Atsali EE, Pangalis AM, Mostrou GJ, Syriopoulou VP, et al. Meningitis registry of hospitalized cases in children: epidemiological patterns of acute bacterial meningitis throughout a 32-year period. BMC Infect Dis 2007;7:101.

2. Poulakou G, Katsarolis I, Matthaiopoulou I, Tsiodras S, Kanavaki S, et al; Hellenic Study Group for the Susceptibility of Streptococcus pneumoniae. Nationwide surveillance of Streptococcus pneumoniae in Greece: patterns of resistance and serotype epidemiology. Int J Antimicrob Agents 2007;30:87-92.

3. Levidiotou S, Vrioni G, Tzanakaki G, Pappa C, Gesouli H, Gartzonika C, et al. Serotype distribution of Streptococcus pneumoniae in north-western Greece and implications for a vaccination programme. FEMS Immunol Med Microbiol 2006;48:179-182.

4. Jorens PG, Parizel PM, Wojciechowski M, Laridon A, De Weerdt A, Mertens G, et al. Streptococcus pneumoniae meningoencephalitis with unusual and widespread white matter lesions. Eur J Paediatr Neurol 2007 [Epub ahead of print].

5. Chatterjee T, Gowardman JR, Goh TD. Pneumococcal meningitis masquerading as subarachnoid haemorrhage. Med J Aust 2003;178:505-507.

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·87

¶ƒ√™∂Ã∏ ™À¡∂¢ƒπ∞

xix

15-16 ºÂ‚ÚÔ˘·Ú›Ô˘ 2008 ∂ÓÙ·ÙÈ΋ ∂Î·›‰Â˘ÛË: 11Ô˜ ∫‡ÎÏÔ˜ “¶·È‰ÔÂÓ‰ÔÎÚÈÓÔÏÔÁ›·” ¶ÏËÚÔÊÔڛ˜: ∂ÏÏËÓÈ΋ ∂Ó‰ÔÎÚÈÓÔÏÔÁÈ΋ ∂Ù·ÈÚ›· ¶·ÓÂÏÏ‹ÓÈ· ŒÓˆÛË ∂Ó‰ÔÎÚÈÓÔÏfiÁˆÓ TËÏ.: 0030-210-7774370, 7474046 Fax: 0030-210-7701552 E-mail: info@endo.gr Website: www.endo.gr

∞ı‹Ó·

15-16 ºÂ‚ÚÔ˘·Ú›Ô˘ 2008 Primer Simposio Internacional de Nutricion Neonatal Contact: Meeting Organiser Tel.: 57-63-354-923 E-mail: theobeltran@yahoo.com

Bogota, Colombia

23-24 ºÂ‚ÚÔ˘·Ú›Ô˘ 2008 Caribean ASCLEPIOS - IXth Congress about Mother & Child Health Contact: Kamel Bargaoui Tel.: 33-607-686-118 Fax: 33-143-839-985 E-mail: Kamel@medicom-international.com

Cancun, Mexico

28 ºÂ‚ÚÔ˘·Ú›Ô˘ 2008

Child Protect: Current Issues in Child Abuse and Neglect II Contact: Dr Desaline Joseph Simon Tel./Fax: 44-0-8-700-416-215 E-mail: info@medupdate.co.ul

Leicester, United Kingdom

1 ª·ÚÙ›Ô˘ 2008

17Ô ∂ÓËÌÂÚˆÙÈÎfi ™ÂÌÈÓ¿ÚÈÔ “∂›Î·ÈÚ· ¶·È‰È·ÙÚÈο £¤Ì·Ù·” ¢ÈÔÚÁ¿ÓˆÛË: ¢ã ¶·È‰È·ÙÚÈ΋ ∫ÏÈÓÈ΋ °¡£ “°. ¶··ÁˆÚÁ›Ô˘” ¶ÏËÚÔÊÔڛ˜: Triaena Tours & Congress TËÏ.: 0030-2310-256194/5 Fax: 0030-2310-256196 E-mail: salonica@triaenatours.gr Website: www.triaenatours.gr

∞›ıÔ˘Û· ∆ÂÏÂÙÒÓ ∞.¶.£., £ÂÛÛ·ÏÔÓ›ÎË

8-9 ª·ÚÙ›Ô˘ 2008

5Ô ¶·ÓÂÏÏ‹ÓÈÔ ™˘Ó¤‰ÚÈÔ ÀÔÂȉÈÎÔÙ‹ÙˆÓ ¶·È‰È·ÙÚÈ΋˜ •ÂÓÔ‰Ô¯Â›Ô ¶ÏËÚÔÊÔڛ˜: AC&C International “Hilton”, ∞ı‹Ó· TËÏ.: 0030-210-6889130 Fax: 0030-210-6844777 E-mail: ped-subspec@acnc.gr Website: www.ped-subspec.gr

10-14 ª·ÚÙ›Ô˘ 2008

Gynaecology, Neonatology, Paediatrics: Deepening and Comparing Contact: Tivigest Sagl Tel.: 41-818-375-830 Fax: 41-818-375-831 E-mail: info@neonatologia.net

St. Moritz, Switzerland

27-30 ª·ÚÙ›Ô˘ 2008

PCICS Europe 2008 - European Symposium of the Pediatric Cardiac Intensive Care Society Contact: Secretariat Tel.: 41-229-080-488 ext 275 Fax: 41-227-322-850 E-mail: pcics@kenes.com

Monte Carlo, Monaco

Pediatri Jan-Feb 08

15-02-08

11:00

™ÂÏ›‰·88

xx

4-6 ∞ÚÈÏ›Ô˘ 2008

2Ô ¶·ÓÂÏÏ‹ÓÈÔ ™˘Ó¤‰ÚÈÔ ¡ÂÔÁÓÔÏÔÁ›·˜ ¢ÈÔÚÁ¿ÓˆÛË: ∂ÏÏËÓÈ΋ ¡ÂÔÁÓÔÏÔÁÈ΋ ∂Ù·ÈÚ›· Î·È ∂ÏÏËÓÈ΋ ∂Ù·ÈÚ›· ¶ÂÚÈÁÂÓÓËÙÈ΋˜ π·ÙÚÈ΋˜ ¶ÏËÚÔÊÔڛ˜: Triaena Tours & Congress ∆ËÏ.: 0030-210-7499300 Fax: 0030-210-7705752 E-mail: info@neonatology2008.gr Website: http://www.neonatology2008.gr

∞›ÁÏË ∑·›Ԣ, ∞ı‹Ó·

5 ∞ÚÈÏ›Ô˘ 2008

ªÂÙÂÎ·È‰Â˘ÙÈ΋ ∏ÌÂÚ›‰· ¶·È‰È·ÙÚÈο ∂›ÁÔÓÙ· & µ·ÛÈ΋ YÔÛÙ‹ÚÈÍË ∑ˆ‹˜ ¢ÈÔÚÁ¿ÓˆÛË: π·ÙÚÈÎfi˜ ™‡ÏÏÔÁÔ˜ ∞ıËÓÒÓ Î·È ∂ÏÏËÓÈ΋ ¶·È‰È·ÙÚÈ΋ ∂Ù·ÈÚ›· ¶ÏËÚÔÊÔڛ˜: ∞Ó·ÛÙ¿ÛÈÔ˜ ¢. ÷Ù˙‹˜ ∆ËÏ.: 0030-210-7488686 Website: www.isathens.gr

∞›ıÔ˘Û· ∂ΉËÏÒÛÂˆÓ π·ÙÚÈÎÔ‡ ™˘ÏÏfiÁÔ˘ ∞ıËÓÒÓ, ∞ı‹Ó·

19 ∞ÚÈÏ›Ô˘ 2008

6Ë ∂ÈÛÙËÌÔÓÈ΋ ∏ÌÂÚ›‰· ∂˘ÚˆÎÏÈÓÈ΋˜ ¶·›‰ˆÓ “™‡Á¯ÚÔÓ· ¶·È‰È·ÙÚÈο £¤Ì·Ù·” ¶ÏËÚÔÊÔڛ˜: Firstevent TËÏ.: 0030-210-8228950 Fax: 0030-210-8228901 E-mail: info@firstevent.gr

•ÂÓÔ‰Ô¯Â›Ô “Royal Olympic”, ∞ı‹Ó·

5-11 ª·˝Ô˘ 2008

XXIth European Society of Pediatric Neurosurgery (ESPN) Meeting Contact: Meeting Organiser E-mail: info@espn2008.org

Montreux, Switzerland

9-11 ª·˝Ô˘ 2008

13Ô ¶·ÓÂÏÏ‹ÓÈÔ ™˘ÌfiÛÈÔ √ÚıÔ·È‰È΋˜ ¶·›‰ˆÓ ¢ÈÔÚÁ¿ÓˆÛË: ∂ÏÏËÓÈ΋ ∂Ù·ÈÚ›· ÃÂÈÚÔ˘ÚÁÈ΋˜ √ÚıÔ·È‰È΋˜ & ∆Ú·˘Ì·ÙÔÏÔÁ›·˜ ∆Ì‹Ì· √ÚıÔ·È‰È΋˜ ·›‰ˆÓ ¶ÏËÚÔÊÔڛ˜: ∫∂°ª ∆Ô˘ÚÈÛÙÈΤ˜ & ™˘Ó‰ÚȷΤ˜ ∂ȯÂÈÚ‹ÛÂȘ ∞∂ - Congress World - ª. ¶···Ó·ÁÈÒÙÔ˘ TËÏ.: 0030-210-7210052, 7210001 Fax: 0030-210-7210051 E-mail: info@congress@goldair.gr

•ÂÓÔ‰Ô¯Â›Ô “Olympian Village Aldemar”, ™Î·Êȉȿ

15-17 ª·˝Ô˘ 2008

9th Congress of the European Society for Pediatric Dermatology ¶ÏËÚÔÊÔڛ˜: Erasmus, η ¶ËÓÂÏfiË ªËÙÚÔÁÈ¿ÓÓË Tel.: 0030-210-7257693 Fax: 0030-210-7257532 E-mail: info@espd2008.com

∞ı‹Ó·

2-4 πÔ˘Ó›Ô˘ 2008

Perinatal Medicine 2008 Contact: Kate Melton Tel.: 02-0-89-798-300 Fax: 02-0-89-796-700 E-mail: kmelton@hamptonmedical.com

Harrogate, England, United Kingdom

13-15 πÔ˘Ó›Ô˘ 2008

46Ô ¶·ÓÂÏÏ‹ÓÈÔ ¶·È‰È·ÙÚÈÎfi ™˘Ó¤‰ÚÈÔ ¶ÏËÚÔÊÔڛ˜: AC&C International ∆ËÏ.: 0030-210-6889130 Fax: 0030-210-6844777 E-mail: pedcongress@acnc.gr Website:www.pediatric-congress.gr

COREXPO ∂ÎıÂÛÈ·Îfi ∫¤ÓÙÚÔ ∫¤Ú΢ڷ˜, ∫¤Ú΢ڷ